<SEC-DOCUMENT>0001193125-17-298083.txt : 20170929
<SEC-HEADER>0001193125-17-298083.hdr.sgml : 20170929
<ACCEPTANCE-DATETIME>20170928184356
ACCESSION NUMBER:		0001193125-17-298083
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		19
FILED AS OF DATE:		20170929
DATE AS OF CHANGE:		20170928

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NuCana plc
		CENTRAL INDEX KEY:			0001709626
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-220321
		FILM NUMBER:		171108666

	BUSINESS ADDRESS:	
		STREET 1:		3 LOCHSIDE WAY
		CITY:			EDINBURGH
		STATE:			X0
		ZIP:			EH12 9DT
		BUSINESS PHONE:		44-0-131-248-3660

	MAIL ADDRESS:	
		STREET 1:		3 LOCHSIDE WAY
		CITY:			EDINBURGH
		STATE:			X0
		ZIP:			EH12 9DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NuCana BioMed Ltd
		DATE OF NAME CHANGE:	20170619
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d393013d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Filed Pursuant to Rule 424(b)(4) <BR> Registration No. 333-220321<BR><BR> </B></FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>6,667,000 American Depositary Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g18b14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Representing 6,667,000 Ordinary Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>$15.00 per American Depositary Share </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This is the initial public offering of our American
Depositary Shares, or ADSs. We are selling 6,667,000 of our ADSs in this offering. Each ADS will represent one ordinary share, nominal value &pound;0.04 per share. The ADSs may be evidenced by American Depositary Receipts, or ADRs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The initial public offering price is $15.00 per ADS. No
public market has previously existed for our ADSs or ordinary shares. We have received approval to list our ADSs on the Nasdaq Global Select Market under the symbol &#147;NCNA.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an &#147;emerging growth company&#148; as such term is used in the Jumpstart Our Business Startups Act
of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in our ADSs involves a high degree of risk. See &#147;<A HREF="#toc393013_4">Risk Factors</A>&#148; beginning on
page&nbsp;11. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither the U.S. Securities
and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;ADS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public Offering Price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,005,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting Discounts and Commissions</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,000,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds to NuCana (before expenses)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,004,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We refer you to &#147;Underwriting&#148; beginning on page&nbsp;189 for additional information regarding underwriting compensation. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain of our existing shareholders have agreed to purchase
an aggregate of 933,332 ADSs in this offering at the initial public offering price. See &#147;Prospectus Summary&#151;The Offering.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters have an option to purchase up to&nbsp;1,000,050 additional ADSs from us at the public offering price, less the
underwriting discounts and commissions payable by us, for 30 days after the date of this prospectus to cover over-allotments, if any. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delivery of the ADSs will be made against payment in New York, New York on or about October&nbsp;2, 2017. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><I>Joint Book-Running Managers </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Jefferies</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Cowen</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><I><FONT STYLE="white-space:nowrap">Co-Manager</FONT>
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>William Blair </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;27, 2017 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>You should rely only on the information contained in this prospectus and any related
free-writing prospectus that we authorize to be distributed to you. We have not, and the underwriters have not, authorized any person to provide you with information different from that contained in this prospectus or any related free-writing
prospectus that we authorize to be distributed to you. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any jurisdiction where the offer or sale is not permitted. The information in this prospectus
speaks only as of the date of this prospectus unless the information specifically indicates that another date applies, regardless of the time of delivery of this prospectus or of any sale of the securities offered hereby. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_1">About This Prospectus</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_2">Presentation of Financial Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_3">Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_4">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_5">Special Note Regarding Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_6">Exchange Rates</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_7">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_8">Dividends and Dividend Policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_9">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_10">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_11">Selected Consolidated Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_12">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_13">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_14">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">131</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_15">Related Party Transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_16">Principal Shareholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_17">Description of Share Capital</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_18">Description of American Depositary Shares</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_19">Shares and ADSs Eligible for Future Sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_20">Taxation</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_21">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">189</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_22">Expenses of the Offering</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_23">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_24">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_25">Service of Process and Enforcement of Judgments</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_26">Where You Can Find More Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc393013_27">Index to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:15%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>No action is being taken in any jurisdiction outside the
United States to permit a public offering of the ADSs or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform
themselves about and to observe any restrictions as to this offering and the distribution of the prospectus applicable to that jurisdiction. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are incorporated under the laws of England and Wales and a majority of our outstanding securities are owned by <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> residents. Under the rules of the U.S. Securities and Exchange Commission, or the SEC, we are currently eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we will
not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_1"></A>ABOUT THIS PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August 29, 2017, we
<FONT STYLE="white-space:nowrap">re-registered</FONT> NuCana BioMed Limited as a public limited company and changed our name from NuCana BioMed Limited to NuCana plc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated or the context otherwise requires,
in this prospectus, &#147;NuCana,&#148; &#147;NuCana BioMed Limited,&#148; &#147;NuCana plc,&#148; the &#147;Group,&#148; the &#147;company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to (i)&nbsp;NuCana BioMed Limited and its
consolidated subsidiaries prior to the <FONT STYLE="white-space:nowrap">re-registration</FONT> of NuCana BioMed Limited as a public limited company and (ii)&nbsp;NuCana plc and its consolidated subsidiaries after the
<FONT STYLE="white-space:nowrap">re-registration</FONT> of NuCana BioMed Limited as a public limited company. See &#147;Description of Share Capital.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_2"></A>PRESENTATION OF FINANCIAL INFORMATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We report under International Financial Reporting Standards,
or IFRS, as issued by the International Accounting Standards Board, or IASB. None of the financial statements were prepared in accordance with generally accepted accounting principles in the United States. We present our financial statements in
pounds sterling and in accordance with IFRS. All references in this prospectus to &#147;$&#148; are to U.S. dollars and all references to &#147;&pound;&#148; are to pounds sterling. Unless otherwise indicated, certain U.S. dollar amounts contained
in this prospectus have been translated into pounds sterling at the rate on June 30, 2017 of &pound;1.00 to $1.2995. These translations should not be considered representations that any such amounts have been, could have been or could be converted
into pounds sterling at that or any other exchange rate as of that or any other date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have made rounding adjustments to some of the figures included in this prospectus. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that
preceded them. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_3"></A>SUMMARY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights information contained elsewhere in
this prospectus. It may not contain all of the information that may be important to you. Before investing in our ADSs, you should read this entire prospectus carefully for a more complete understanding of our business and this offering, including
our consolidated financial statements and the notes thereto, and the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included in this prospectus.
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage
biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our
ProTide<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs,
into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated.
Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide
candidates, Acelarin<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine
and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in three clinical trials across several solid tumor indications, including ovarian cancer, biliary cancer and pancreatic cancer. NUC-3373 is
currently in a Phase 1 trial for the potential treatment of a wide range of advanced solid tumor cancers. We have retained worldwide rights to these lead product candidates as well as our preclinical product candidates, all of which we refer to as
ProTides. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acelarin, our most advanced product
candidate, is a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> ProTide that has been evaluated in over 140 patients. Acelarin is a ProTide transformation of gemcitabine that we believe could
replace gemcitabine in certain cancer indications and have utility across a range of other cancers. In a Phase 1 dose-ranging trial in 49 evaluable patients with advanced metastatic solid tumors, Acelarin was well tolerated, achieved a 78% disease
control rate and was associated with intracellular levels of active anti-cancer metabolite over 200 times higher than those reported for gemcitabine. A subset of 14 evaluable patients with relapsed/refractory gynecological cancers achieved a 93%
disease control rate. In a Phase 1b dose-ranging trial in 23&nbsp;evaluable patients with recurrent ovarian cancer, Acelarin was combined with carboplatin and achieved a 96% disease control rate. Based on these disease control rates and the
tolerability profile, we have begun a Phase 2 trial of Acelarin in patients with platinum-resistant ovarian cancer, for which we expect to report interim data in 2018.&nbsp;Acelarin is also being evaluated in another Phase 1b trial in patients with
biliary cancer to determine its optimal dose in combination with cisplatin. We expect to report data from this trial in 2018, after which we plan to commence a multi-national Phase 3 trial.&nbsp;In addition, the National Cancer Research Institute in
the United Kingdom is facilitating a Phase 3 trial of Acelarin for the treatment of patients with pancreatic cancer. The disease control rates referred to above include complete responses, partial responses and stable disease, measured by
radiographic assessment to determine changes in tumor size, and evaluated using the standard scoring system known as Response Evaluation Criteria in Solid Tumors, or RECIST. The disease control rates are based on investigator assessment of tumor
response in a limited number of patients and may not be predictive of or consistent with the results of later trials. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">NUC-3373,</FONT> our second product candidate, is a ProTide transformation of the active anti-cancer
metabolite of <FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> or <FONT STYLE="white-space:nowrap">5-FU,</FONT> which we believe has the potential to replace <FONT STYLE="white-space:nowrap">5-FU</FONT> as the standard of care in the
treatment of a wide range of cancers. In preclinical studies, we observed that <FONT STYLE="white-space:nowrap">NUC-3373</FONT> overcame the key resistance mechanisms associated with <FONT STYLE="white-space:nowrap">5-FU</FONT> and generated
intracellular levels of active anti-cancer metabolite over 300 times higher than that of 5-FU. <FONT STYLE="white-space:nowrap">NUC-3373</FONT> is currently being evaluated in a Phase 1 clinical trial of
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
patients with advanced solid tumors for which we reported interim data in September 2017. We expect to report final data from this trial in 2018. Contingent on regulatory guidance and other
factors, we plan to initiate a number of clinical trials in 2018: a Phase 1b trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in patients with colorectal cancer together with </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">other agents routinely used in <FONT STYLE="white-space:nowrap">5-FU</FONT> combination regimens; a Phase 3 trial in patients with advanced colorectal cancer; and a Phase 2 trial in patients with advanced
breast cancer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">NUC-7738,</FONT> our third product candidate, is a ProTide transformation of cordycepin, a novel
nucleoside analog that has shown potent anti-cancer activity in preclinical studies. We are evaluating <FONT STYLE="white-space:nowrap">NUC-7738</FONT> in preclinical studies and we expect to initiate a Phase 1 clinical trial in 2018. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite the widespread use of nucleoside analogs, their
efficacy is severely limited by cancer cell resistance mechanisms and they are often poorly tolerated. Harnessing the power of phosphoramidate chemistry, we convert nucleoside analogs into activated nucleotide analogs with the addition of a
phosphate group, which is protected by specific combinations of aryl, ester and amino acid groupings. By adding and protecting this phosphate group, we design our ProTides to avoid or overcome key cancer resistance mechanisms in the uptake,
activation and breakdown of nucleoside analogs. As a result, we believe our ProTides have the potential to generate hundreds of times higher concentrations of the active anti-cancer metabolites inside tumor cells, potentially making our ProTides
more effective than the current standards of care. Because our ProTides resist breakdown, and are thus more stable, we believe they are also able to reduce or eliminate the generation of toxic byproducts that can result from the breakdown of
nucleoside analogs like gemcitabine and <FONT STYLE="white-space:nowrap">5-FU.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our proprietary ProTide technology was invented in the Cardiff University laboratory of our late Chief Scientific Officer, Professor Christopher McGuigan, who conceived of, and filed the original
composition of matter patents for our initial ProTides. The unique feature of his discovery was the specific combination of aryl, ester and amino acid groupings that protect the activated, or phosphorylated, nucleoside analog. This phosphoramidate
chemistry approach is the key to the ProTide technology. Every ProTide grouping is distinct, and Professor McGuigan and his team synthesized and tested thousands of compounds in order to identify the optimal ProTide grouping for each underlying
nucleoside analog. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We have
licensed what we believe to be the foundational patent estate for the application of phosphoramidate chemistry in oncology. We have granted patents in key markets, including the United States, Europe and Japan, protecting the composition of matter
of Acelarin, NUC-3373 and other of our product candidates. Professor McGuigan&#146;s work preceded and helped lead to the development of several FDA-approved anti-viral drugs containing nucleotide analogs, including: sofosbuvir, or Sovaldi<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, which is also a key component of Harvoni<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>; and tenofovir alafenamide fumarate, or TAF, which is a key component of Genvoya<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, Descovy<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Odefsey<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are led by Hugh&nbsp;S. Griffith, our founder and Chief Executive Officer, who brings over 25 years of experience in the
biopharmaceutical industry, including at Abbott Laboratories (now AbbVie Inc.) and Parke-Davis Warner Lambert (now Pfizer Inc.). Before founding NuCana, he led the operations of Bioenvision, Inc. from <FONT STYLE="white-space:nowrap">start-up</FONT>
through its acquisition by Genzyme Corporation. While at Bioenvision, he was instrumental in developing and commercializing clofarabine, a nucleoside analog for the treatment of pediatric leukemia. We are backed by leading life sciences investors,
including Sofinnova Partners, Sofinnova Ventures, Morningside Group and Scottish Enterprise. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our goal is to transform standards of care and improve
survival for patients across a wide range of cancer indications. Our strategy includes the following key components: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rapidly develop Acelarin as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> nucleotide analog for
the treatment of patients with cancer</B>. We believe that Acelarin has the potential to replace the core chemotherapy component of treatment regimens for patients with various cancers, including: </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Platinum-resistant ovarian cancer. </I>We expect to report data from a Phase 2 trial of Acelarin in 2018. We also intend to explore the use of
Acelarin in combination with Avastin, a widely used agent in the treatment of several cancers, and expect to report data from this trial in 2018. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Platinum-sensitive ovarian cancer. </I>Contingent on regulatory guidance and other factors, we expect to commence a Phase 3 trial of Acelarin in
combination with carboplatin for this indication in 2018. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Biliary cancer. </I>We expect to report data from a Phase 1b trial of Acelarin in combination with cisplatin in 2018. Contingent on regulatory
guidance and other factors, we plan to commence a Phase 3 trial of Acelarin in combination with cisplatin as a first-line treatment in 2018. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pancreatic cancer. </I>The National Cancer Research Institute in the United Kingdom is facilitating a Phase 3 trial of Acelarin as a first-line
treatment compared to gemcitabine. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#149;</B></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rapidly develop <FONT STYLE="white-space:nowrap">NUC-3373</FONT> to replace <FONT STYLE="white-space:nowrap">5-FU</FONT> as the standard of care for
the treatment of patients with various cancers. </B></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Advanced solid tumors</I>. We expect to report final data from a Phase 1 trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in patients with
advanced solid tumors in 2018. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Colorectal cancer</I>. We plan to establish the optimal dose of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in combination with other agents in
a Phase 1b trial in 2018. Contingent on regulatory guidance and other factors, we also intend to initiate a Phase 3 trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> monotherapy in 2018. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Breast cancer</I>. We intend to conduct a Phase 2 trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> compared to capecitabine, the oral
version of <FONT STYLE="white-space:nowrap">5-FU,</FONT> in patients with recurrent breast cancer and anticipate reporting interim data from this trial in 2018. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rapidly advance <FONT STYLE="white-space:nowrap">NUC-7738</FONT> into clinical trials</B>.<B> </B><FONT STYLE="white-space:nowrap">NUC-7738,</FONT>
a ProTide based on a novel nucleoside analog, is currently undergoing preclinical studies and we expect to initiate a Phase 1 trial in 2018 for solid tumors. In addition, we plan to develop <FONT STYLE="white-space:nowrap">NUC-7738</FONT> for the
treatment of hematological malignancies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Leverage our proprietary ProTide technology platform to develop additional product candidates</B>. We are pursuing both the transformation of
well-established and widely used nucleoside analogs as well as novel nucleoside analogs, which we believe have the potential to address additional areas of unmet medical need in oncology. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Continue to strengthen our intellectual property position</B>. We own or have exclusive rights to the core technologies underlying our ProTide
technology platform. We have granted patents in key markets, including the United States, Europe and Japan, protecting the composition of matter of Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and other of our product candidates. We
intend to further expand and enhance our intellectual property position. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Build a focused commercial organization</B>. We have worldwide rights to all product candidates that we are developing. We believe that many of the
cancers we are initially targeting with our ProTides can be addressed by a focused sales and marketing team. We plan to commercialize any product candidates for which we receive regulatory marketing approval using a specialized sales force in the
United States and Europe. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Pipeline </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We take a scientifically driven approach to designing
ProTides, which we believe have the potential to result in highly efficacious cancer therapies with improved tolerability. Our pipeline of product candidates is summarized below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g80f34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Information
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NuCana was incorporated under the laws of
England and Wales in 1997 under the name Biomed (UK) Limited, and commenced operations in 2008. On April&nbsp;28, 2008, we changed our name to NuCana BioMed Limited. On August 29, 2017, we <FONT STYLE="white-space:nowrap">re-registered</FONT> as a
public limited company and changed our name to NuCana plc. Our registered office is 77/78 Cannon Street, London EC4N 6AF, United Kingdom. Our principal executive offices are located at 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom, our general
telephone number is +44 (0)131 248 3660 and our internet address is http://www.nucana.com. Our website and the information contained on or accessible through our website are not part of this prospectus. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">NuCana, the NuCana logo and other
trademarks or service marks of NuCana plc appearing in this prospectus are the property of NuCana plc. Trade names, trademarks and service marks of other companies appearing in this prospectus are the property of their respective owners. Solely for
convenience, the trademarks, service marks and trade names referred to in this prospectus may be without the <FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>
and &#153; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights to these trademarks, service marks and trade names. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risk Factors </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is subject to numerous risks that could prevent
us from successfully implementing our business strategy. These and other risks are discussed more fully in &#147;Risk Factors&#148; immediately following this prospectus summary and include the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have incurred significant operating losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or
maintain profitability. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We depend heavily on the success of our product candidates, Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT
STYLE="white-space:nowrap">NUC-7738.</FONT> We cannot give any assurance that these product candidates will receive regulatory approval for any indication, which is necessary before any of them can be commercialized. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lack of any approved products and our limited operating history may make it difficult for you to evaluate the success of our business to date and
to assess our future viability. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing,
or ultimately be unable to complete, the development, and may experience delays in obtaining, or ultimately be unable to obtain, the approval, of our product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial success in early-stage clinical trials may not be indicative of results obtained in later-stage trials, and the results of our clinical trials
may not meet the level of statistical significance required by the Food and Drug Administration, or FDA, or comparable foreign regulatory authorities for marketing approval. In addition, the data from the Phase 1b trial are interim and may change as
the data are further examined, more patient data become available and the final clinical study report is prepared and issued. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be successful in our efforts to use and expand our technology platform to build a pipeline of additional ProTide candidates.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an
approved label or result in significant negative consequences following marketing approval, if any. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely on, and expect to continue to rely on, third parties to conduct our clinical trials for our product candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We contract with third parties for the manufacture and shipment of our product candidates for preclinical studies and clinical trials and expect to
continue to do so for commercialization. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into, and may in the future enter into, collaborations with third parties to discover or develop product candidates. If these
collaborations are not successful, our business could be adversely affected. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully
than we do. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to obtain and maintain intellectual property protection for our technology and products, or if the scope of the intellectual property
protection obtained is not sufficiently broad, our competitors could commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. In addition, if we
infringe the valid patent rights of others, we may be prevented from making, using or selling our products or may be subject to damages or penalties. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have a limited number of employees, and our future success depends on our ability to retain key executives and to attract, retain and
motivate qualified personnel. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Implications of Being an Emerging Growth Company and a Foreign Private Issuer </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We qualify as an &#147;emerging growth company,&#148; or EGC,
as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we may take advantage of specified reduced reporting requirements and are relieved of certain other significant requirements that are otherwise generally
applicable to public companies in the United States. These provisions include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to include only two years of audited financial statements and only two years of related Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations disclosure; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley
Act of 2002. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may take
advantage of these provisions for up to five years or such earlier time that we are no longer an EGC. We would cease to be an EGC if we have more than $1.07&nbsp;billion in total annual gross revenue, have more than $700&nbsp;million in market value
of our ordinary shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> or issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the completion of this offering, we will report under
the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company with foreign private issuer status. Even if we no longer qualify as an EGC, as long as we qualify as a foreign
private issuer under the Exchange Act we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the
Exchange Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities, and liability for insiders
who profit from trades made in a short period of time; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT>
containing unaudited financial and other specified information, or current reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> upon the occurrence of specified significant events. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both foreign private issuers and EGCs are also exempt from
certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an EGC, but remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures required of companies
that are neither an EGC nor a foreign private issuer. As a consequence, we do not know if some investors will find our ADSs less attractive, which may result in a less active trading market for our ADSs or more volatility in the price of our ADSs.
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE OFFERING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADSs offered by us </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">6,667,000 ADSs, each representing one ordinary share. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over-allotment option </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase up to 1,000,050 additional ADSs from us to cover over-allotments, if any.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ordinary shares to be outstanding immediately after this offering </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2"><BR>30,881,641 ordinary shares (or 31,881,691 ordinary shares if the underwriters exercise in full their over-allotment option to purchase an additional 1,000,050&nbsp;ADSs).
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">American Depositary Shares </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">Each ADS represents one ordinary share, nominal value &pound;0.04 per share. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary or its custodian, or a nominee of either, will hold the ordinary shares underlying your ADSs. As an ADS holder you will not be treated as one of our
shareholders and you will not have shareholder rights. You will have rights as provided in the deposit agreement. You may cancel your ADSs and withdraw the underlying ordinary shares as provided in the deposit agreement. We may amend or terminate
the deposit agreement without your consent. If you continue to hold your ADSs following an amendment, you agree to be bound by the terms of the deposit agreement then in effect. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To better understand the terms of the ADSs, you should carefully read &#147;Description of American Depositary Shares&#148; in this prospectus. You should also read the
deposit agreement, which is an exhibit to the registration statement that includes this prospectus. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depositary </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">Citibank, N.A. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shareholder approval of offering </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">Under English law, certain steps necessary for the completion of this offering require the approval of our shareholders by way of ordinary resolutions approved by more than 50% of all voting
rights and special resolutions approved by at least 75% of all voting rights. We will receive all such required approvals prior to the completion of this offering. See &#147;Description of Share Capital&#148; in this prospectus.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of proceeds </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to receive total estimated net proceeds from this offering of approximately $90.7 million (or approximately $104.7 million if the underwriters exercise in full their over-allotment
option to purchase an additional 1,000,050 ADSs) after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds of this offering, together with our existing cash and cash
equivalents, to fund our planned development of Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT STYLE="white-space:nowrap">NUC-7738,</FONT> other research and development activities and for working capital and other general
corporate purposes. See &#147;Use of Proceeds&#148; in this prospectus. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk factors </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">You should carefully read the information set forth under &#147;Risk Factors&#148; beginning on page&nbsp;11 of this prospectus before investing in our ADSs. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nasdaq Global Select Market<BR> Symbol </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2"><BR>&#147;NCNA&#148; </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The number of our ordinary shares to be outstanding immediately after this offering is calculated by reference to our entire issued share capital of 24,214,641 shares as of August 31, 2017 and gives
effect to the automatic conversion, immediately prior to the completion of this offering, of all issued series A convertible participating shares, series B convertible participating shares (after giving effect to the series B conversion adjustment
as described in &#147;Description of Share Capital&#151;Conversion of Series B Shares into Ordinary Shares&#148;), founder ordinary 1 shares and founder ordinary 2 shares into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, and excludes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,233,937 ordinary shares issuable upon exercise of outstanding options under our equity incentive plans as of August 31, 2017 at a weighted average
exercise price of &pound;0.71 per share; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,261,783 ordinary shares issuable upon exercise of outstanding options under our equity incentive plans that were granted after August 31, 2017 at a
weighted average exercise price of &pound;1.09 per share; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">215,782 ordinary shares issuable upon exercise of options approved for grant under our equity incentive plans as of and in connection with the pricing
of this offering to be issued at an exercise price equal to the initial public offering price per ADS in this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,545,409 ordinary shares authorized for issuance pursuant to future awards under our equity incentive plans. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, all information in this
prospectus, including information relating to the number of ordinary shares to be outstanding immediately after the completion of this offering: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">gives effect to a one-for-four reverse stock split of our ordinary shares that was effected on September 14, 2017; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">assumes no exercise by the underwriters of their option to purchase up to&nbsp;1,000,050 additional ADSs to cover over-allotments, if any.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Participation in the Offering
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain of our existing shareholders have
agreed to purchase an aggregate of 933,332 ADSs in this offering at the initial public offering price. The underwriters will receive the same underwriting discount on any securities purchased by these investors as they will on any other securities
sold to the public in this offering. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables summarize our consolidated financial
data as of the dates and for the periods indicated. The consolidated financial data as of and for the years ended December&nbsp;31, 2015 and 2016 have been derived from our consolidated financial statements, which have been prepared in accordance
with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standard Board, or IASB, and audited in accordance with the standards of the Public Company Accounting Oversight Board (United States), and included
elsewhere in this prospectus. The consolidated financial data as of and for the six months ended June&nbsp;30, 2016 and 2017 have been derived from our unaudited consolidated interim financial statements included elsewhere in this prospectus. The
unaudited consolidated interim financial statements have been prepared on the same basis as our audited consolidated financial statements and include all adjustments, consisting only of normal recurring adjustments, that we consider necessary for a
fair statement of our financial position and operating results as of the dates and for the periods presented. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our historical results are not necessarily indicative of the results that may be expected in the future and our results for the six months
ended June 30, 2017 are not necessarily indicative of our results to be expected for the full year 2017. The following summary consolidated financial data should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; and our consolidated financial statements included elsewhere in this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated statement of comprehensive loss data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial public offering related expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange (losses) gains </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive (expense) income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that may be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange differences on translation of foreign operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents
our consolidated statement of financial position data as of June&nbsp;30, 2017 on: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a pro forma basis to give effect to the automatic conversion, immediately prior to the completion of this offering, of all issued series A convertible
participating shares, series B convertible participating shares, founder ordinary 1 shares and founder ordinary 2 shares into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis; and
</FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a pro forma as adjusted basis to give further effect to the sale by us of 6,667,000 ADSs in this offering at the initial public offering price of
$15.00 per ADS after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June 30, 2017 </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro<BR>Forma </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro Forma<BR>as&nbsp;Adjusted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands) </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated statement of financial position data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share premium</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(28,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital reserve(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity attributable to equity holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The capital reserve balance arose from the impact of the reduction of our share premium account and corresponding increase to our capital reserve account reflected as
of June&nbsp;30, 2017 in connection with our re-registration as a public limited company, as further described in footnote&nbsp;10 to the unaudited consolidated interim financial statements. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_4"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Investing in the ADSs involves a high degree of risk. You
should carefully consider the following risk factors and all other information contained in this prospectus, including our consolidated financial statements and the related notes, before investing in the ADSs. The risks and uncertainties described
below are those significant risk factors, currently known and specific to us, that we believe are relevant to an investment in the ADSs. If any of these risks materialize, our business, results of operations or financial condition could suffer, the
price of the ADSs could decline and you could lose part or all of your investment. Additional risks and uncertainties not currently known to us or that we now deem immaterial may also harm us and adversely affect your investment in the ADSs.
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Business and Industry </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have incurred significant operating losses since
our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have incurred significant operating losses since our inception. We incurred net losses of &pound;5.3&nbsp;million for the year ended
December&nbsp;31, 2015, &pound;6.0&nbsp;million for the year ended December&nbsp;31, 2016 and &pound;4.4&nbsp;million for the six months ended June&nbsp;30, 2017. As of December&nbsp;31, 2016, we had an accumulated deficit of
&pound;22.3&nbsp;million and, as of June 30, 2017, we had an accumulated deficit of &pound;26.6&nbsp;million. Our most advanced product candidate, Acelarin, is currently being evaluated in four clinical trials: two Phase 1b trials, one Phase 2
trial, and one multi-year investigator-sponsored Phase 3 trial. Our other clinical-stage product candidate, <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> is currently in a Phase 1 trial. It may be several years, if ever, before we have a product
candidate ready for commercialization. To date, we have financed our operations primarily through private placements of our equity securities. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable
future. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that our expenses will increase substantially if and as we: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">continue development of our ProTides, including initiating additional clinical trials of Acelarin and <FONT STYLE="white-space:nowrap">NUC-3373;</FONT>
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">complete preclinical studies and potentially initiate clinical trials of our preclinical-stage product candidates, including our product candidate <FONT
STYLE="white-space:nowrap">NUC-7738;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identify and develop new product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish a robust supply chain for the manufacture of our product candidates in accordance with current good manufacturing practice, or cGMP;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">seek marketing approvals for our product candidates that successfully complete clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish a sales, marketing and distribution infrastructure to commercialize any products for which we obtain marketing approval;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pursue market acceptance of our product candidates in the medical community and with third-party payors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain, expand and protect our intellectual property portfolio; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expand our headcount by recruiting personnel to drive our clinical development programs and effectively manage
<FONT STYLE="white-space:nowrap">out-sourced</FONT> development activities; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into collaboration arrangements, if any, for the development of our product candidates or <FONT STYLE="white-space:nowrap">in-license</FONT>
other products and technologies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">achieve milestones which will trigger payments under our license agreements; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future
commercialization efforts; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">incur increased administrative and other costs as a result of operating as a public company. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the numerous risks and uncertainties associated with developing new
pharmaceutical drugs, we are unable to predict the extent of any future losses or when we will become profitable, if at all. In addition, our expenses could increase beyond expectations if we are required by the European Medicines Agency, or EMA,
the Food and Drug Administration, or FDA, or other foreign regulatory agencies, to perform studies and clinical trials in addition to those that we currently anticipate, or if there are any delays in the completion of planned clinical trials or the
development of any of our ProTides. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To become and
remain profitable, we must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">completing clinical trials of our product candidates that achieve their clinical endpoints; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtaining marketing approval for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">manufacturing, marketing and selling those products for which we may obtain marketing approval; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">achieving market acceptance of our product candidates in the medical community and with third-party payors. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may never succeed in these activities and, even if we do,
may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain
profitable would decrease the value of the company and could impair our ability to raise capital, maintain our discovery and preclinical development efforts, expand our business or continue our operations and may require us to raise additional
capital that may dilute your ownership interest. A decline in the value of our company could also cause you to lose all or part of your investment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We depend heavily on the success of our product candidates, Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT
STYLE="white-space:nowrap">NUC-7738.</FONT> We cannot give any assurance that these product candidates will receive regulatory approval for any indication, which is necessary before any of them can be commercialized. If we, and any collaborators
with whom we may enter into agreements for the development and commercialization of any of these product candidates, are unable to commercialize them, or experience significant delays in doing so, our ability to generate revenue and our financial
condition will be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
do not currently generate any revenues from sales of any products, and we may never be able to develop or commercialize a marketable product. We have invested substantially all of our efforts and financial resources to date in the development of
Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT STYLE="white-space:nowrap">NUC-7738.</FONT> Our ability to generate product revenues, which we do not expect will occur for at least the next several years, if ever, will depend
heavily on the successful development and eventual commercialization of these product candidates, if approved, which may never occur. Each of Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and
<FONT STYLE="white-space:nowrap">NUC-7738</FONT> will require additional clinical development, management of clinical, preclinical and manufacturing activities, regulatory approval in multiple jurisdictions, procurement of manufacturing supply,
commercialization, substantial additional investment and significant marketing efforts before we generate any revenues from product sales, if at all. We are not permitted to market or promote any product candidates in the United States, Europe or
other countries before we receive regulatory approval from the FDA, the EMA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> or <FONT
STYLE="white-space:nowrap">NUC-7738</FONT> or any future product candidate. We have not submitted a New Drug Application, or NDA, to the FDA, a Marketing Authorization Application, or MAA, to the EMA or comparable applications to other regulatory
authorities for any of our product candidates and do not expect to be in a position to do so in the foreseeable future. The success of our product candidates will depend on many factors, including the following with respect to each of Acelarin, <FONT
STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT STYLE="white-space:nowrap">NUC-7738,</FONT> specifically: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be able to demonstrate that the product candidate is safe and effective as a treatment for our targeted indications to the satisfaction of
the applicable regulatory authorities; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicable regulatory authorities may require additional preclinical or clinical trials of the product candidate, including additional toxicology
trials, which would increase our costs and prolong our development; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results of clinical trials of our product candidates may not meet the level of statistical or clinical significance required by the applicable
regulatory authorities for marketing approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicable regulatory authorities may disagree with the number, design, size, conduct or implementation of our planned clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the contract research organizations, or CROs, that we retain to conduct clinical trials may take actions outside of our control that adversely impact
our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicable regulatory authorities may not find the data from preclinical studies and clinical trials sufficient to demonstrate that the clinical
and other benefits of the product candidate outweigh its safety risks; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicable regulatory authorities may disagree with our interpretation of data from preclinical studies and clinical trials or may require that we
conduct additional studies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicable regulatory authorities may not accept data generated at our clinical trial sites; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if we submit an NDA to the FDA or an MAA to the EMA, and it is reviewed by an advisory committee, the advisory committee may recommend against approval
of our application or may recommend that the FDA or the EMA require, as a condition of approval, additional preclinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicable regulatory authorities may require development of a risk evaluation and mitigation strategy, or REMS, as a condition of approval;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicable regulatory authorities may change its approval policies or adopt new regulations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the applicable regulatory authorities may identify deficiencies in our formulation and manufacturing processes or facilities of our third-party
manufacturers; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may face delays in our formulation and manufacturing process as a result of having not yet optimized formulations or due to lack of availability of
starting materials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be unable to scale up the manufacture process for some of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may face challenges on the safe and appropriate administration of our drugs in the clinic, including with respect to the conversion of our product
candidates from a dry powder formulation to a liquid formulation prior to intravenous, or IV, administration, precipitation or other blockages in IV infusion lines, and the handling and storage of the IV infusion bags containing our product
candidates, any of which may result in the need to carry out additional studies on the administration and compatibility of our product candidates with infusion sets and pumps; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be faced with challenges from third parties on our right to use certain processes used in the formulation and process development of our product
candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may have to defend our patents against infringement by third parties; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may unknowingly infringe third-party patents; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may face a &#147;freedom to operate&#148; issue; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we will be dependent on the efforts of third parties in completing clinical trials of, receiving regulatory approval for and commercializing, any
product candidate we license to such third parties; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">through our clinical trials, we may discover factors that limit the commercial viability of the product candidate or make their commercialization
unfeasible; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be successful in completing preclinical studies and clinical trials of, receiving marketing approvals for, establishing commercial
manufacturing capabilities for and commercializing, any product candidate to which we retain rights under a collaboration agreement; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be successful in gaining acceptance of any product candidate by patients, the medical community and third-party payors, effectively
competing with other therapies, maintaining a continued acceptable safety profile following approval and qualifying for, maintaining, enforcing and defending our intellectual property rights and claims. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to each of Acelarin, <FONT
STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT STYLE="white-space:nowrap">NUC-7738,</FONT> if we or our suppliers, as applicable, do not overcome one or more of these factors in a timely manner or at all, we could experience significant delays
or an inability to successfully commercialize that product candidate. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We cannot be certain that Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> or <FONT STYLE="white-space:nowrap">NUC-7738</FONT> or any future product candidates will be successful in clinical
trials or receive regulatory approval. Further, Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> or <FONT STYLE="white-space:nowrap">NUC-7738</FONT> or any future product candidates may not receive regulatory approval even if they are
successful in clinical trials. If we do not receive regulatory approvals for Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> or <FONT STYLE="white-space:nowrap">NUC-7738</FONT> or any future product candidates, we may not be able to
continue our operations. Even if we successfully obtain regulatory approvals to manufacture and market Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> or <FONT STYLE="white-space:nowrap">NUC-7738</FONT> or any future product candidates,
our revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patient groups that we are targeting are not as significant as we estimate,
we may not generate significant revenues from sales of such products, if approved. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We plan to seek regulatory approval to commercialize Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT STYLE="white-space:nowrap">NUC-7738</FONT> in the United States and the European
Union, and potentially in additional foreign countries. While the scope of regulatory approval is similar in many countries, to obtain separate regulatory approval in multiple countries requires us to comply with the numerous and varying regulatory
requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials, commercial sales, pricing and distribution of Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT
STYLE="white-space:nowrap">NUC-7738,</FONT> and we cannot predict success in these jurisdictions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our lack of any approved products and our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biopharmaceutical drug development is a
highly speculative undertaking and involves a substantial degree of risk. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential product
candidates, undertaking preclinical studies, and conducting early-stage, non-comparative clinical trials of Acelarin and <FONT STYLE="white-space:nowrap">NUC-3373.</FONT> We have not yet demonstrated our ability to successfully complete large-scale,
randomized, pivotal clinical trials compared to standards of care, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for
successful product commercialization. Typically, it takes several years to develop one new drug from the time it is discovered to when it is available for treating patients. In addition, we may encounter unforeseen expenses, difficulties,
complications, delays and other known and unknown factors. We will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will require substantial additional
funding which may not be available to us on acceptable terms, or at all. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates or continue our development programs.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The development of pharmaceutical drugs
is capital-intensive. We expect our expenses to increase with our ongoing activities, particularly as we conduct larger-scale clinical trials of, and seek marketing approval for, our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing,
manufacturing and distribution. We may also need to raise additional funds sooner if we choose to pursue additional indications or geographies for our product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore,
upon the closing of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June 30, 2017, we had &pound;15.9&nbsp;million in cash
and cash equivalents. We believe, based upon our current operating plan, that, our cash and cash equivalents on hand, together with the anticipated net proceeds from this offering, will be sufficient to fund our anticipated operations at least
through the first quarter of 2020. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and
ongoing research and development and other corporate activities. Because the length of time and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate the actual funds
we will require for development and any approved marketing and commercialization activities. In addition, our future capital requirements will depend on many factors, and could increase significantly as a result of many factors, including:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, prioritization and number of our research and development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs, timing and outcome of regulatory review of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which we enter into <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> jointly funded clinical research collaboration arrangements,
if any, for the development of our product candidates in combination with other companies&#146; products; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to establish collaboration arrangements for the development of our product candidates on favorable terms, if at all;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the achievement of milestones or occurrence of other developments that trigger payments under our license agreements and any collaboration agreements
into which we may enter, if any; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> product candidates and technologies, and the terms of such <FONT
STYLE="white-space:nowrap">in-licenses;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates
for which we receive marketing approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending
intellectual property-related claims. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that can take years to complete, and we may never generate the necessary data or results required to
obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that may not be commercially available
for several years, if ever. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any additional fundraising efforts may divert our management from their
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop and commercialize our product candidates. Volatility in the financial
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
markets has generally made equity and debt financing more difficult to obtain, and may compromise our ability to meet our fundraising needs. We cannot guarantee that future financing will be
available in sufficient amounts or on terms acceptable to us, if at all. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any
product candidate or be unable to expand our operations or otherwise capitalize on our business opportunities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Raising additional capital may cause dilution to our shareholders, including purchasers of ADSs in this offering, restrict our
operations or require us to relinquish rights to our technologies or product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity and debt financings. The sale of additional equity or
convertible debt securities would dilute all of our shareholders, including purchasers of ADSs in this offering. The incurrence of indebtedness could result in increased fixed payment obligations, and we may be required to agree to certain
restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights, limitations on declaring dividends and other operating restrictions that could
adversely impact our ability to conduct our business. Moreover, the terms of any financing may adversely affect the holdings or the rights of our shareholders and the issuance of additional securities, whether equity or debt, by us, or the
possibility of such issuance, may cause the market price of our ADSs to decline. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We could decide to seek funds through collaborations, strategic alliances or licensing arrangements with third parties, and we could be required to do so at an earlier stage than otherwise would be
desirable. In connection with any such collaborations, strategic alliances or licensing arrangements, we may be required to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates,
grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves, or otherwise agree to terms unfavorable to us. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to use net operating loss and tax
credit carryforwards and certain <FONT STYLE="white-space:nowrap">built-in</FONT> losses to reduce future tax payments or benefit from favorable United Kingdom tax legislation. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a United Kingdom resident company, we are subject to U.K. corporate taxation. We have generated losses since
inception. As of June&nbsp;30, 2017, we had cumulative carry forward tax losses of &pound;8.5&nbsp;million. Subject to any relevant restrictions, we expect these to be available to carry forward and offset against future operating profits. As a
company that carries out extensive research and development activities, we benefit from the United Kingdom research and development tax credit regime for small and <FONT STYLE="white-space:nowrap">medium-sized</FONT> companies, whereby we are able
to surrender the trading losses that arise from our qualifying research and development activities for a payable tax credit of up to 33.35% of eligible research and development expenditures. Qualifying expenditures largely comprise employment costs
for research staff, consumables and subcontract costs incurred as part of research projects. Certain subcontracted qualifying research expenditures are eligible for a cash rebate of up to 21.68%. The majority of our pipeline research, clinical
trials management and manufacturing development activities are eligible for inclusion within these tax credit cash rebate claims. We may not be able to continue to claim payable research and development tax credits in the future as we become a
public company because we may no longer qualify as a small or <FONT STYLE="white-space:nowrap">medium-sized</FONT> company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may benefit in the future from the United Kingdom&#146;s &#147;patent box&#148; regime, which allows certain profits attributable to
revenues from patented products to be taxed at an effective rate of 10%. As we have many different patents covering our products, future upfront fees, milestone fees, product revenues and royalties could be taxed at this favorably low tax rate. When
taken in combination with the enhanced relief available on our research and development expenditures, we expect a long-term lower rate of corporation tax to apply to us. If, however, there are unexpected adverse changes to the United Kingdom
research and development tax credit </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
regime or the &#147;patent box&#148; regime, or for any reason we are unable to qualify for such advantageous tax legislation, or we are unable to use net operating loss and tax credit
carryforwards and certain <FONT STYLE="white-space:nowrap">built-in</FONT> losses to reduce future tax payments then our business, results of operations and financial condition may be adversely affected. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business may become subject to economic, political,
regulatory and other risks associated with international operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a company based in the United Kingdom, our business is subject to risks associated with conducting business internationally. Many of our suppliers and collaborative and clinical trial relationships are
located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic weakness, including inflation, or political instability in particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing and changing regulatory requirements for drug approvals in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potentially reduced protection for intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties in compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations and customs, tariffs and trade barriers; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange rates of the pound sterling, the euro and currency controls;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in a specific country&#146;s or region&#146;s political or economic environment, including the implications of the 2016 decision of the
eligible members of the U.K. electorate for the United Kingdom to withdraw from the European Union or any potential future referendum regarding the independence of Scotland; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing reimbursement regimes and price controls in certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> markets; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative consequences from changes in tax laws; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">workforce uncertainty in countries where labor unrest is more common than in the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties associated with staffing and managing international operations, including differing labor relations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and terrorism, or natural disasters
including earthquakes, typhoons, floods and fires. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Exchange rate fluctuations may adversely affect our results of operations and financial condition. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Owing to the international scope of our operations, fluctuations in exchange rates, particularly between the pound sterling and the U.S.
dollar, may adversely affect us. Since the vote of a majority of the eligible members of the electorate in the United Kingdom to withdraw from the European Union in a national referendum held on June&nbsp;23, 2016, referred to as &#147;BREXIT,&#148;
there has been a significant increase in the volatility of the exchange rate between the pound sterling and the U.S. dollar and an overall weakening of the pound sterling. Although we are based in the United Kingdom, we source our active
pharmaceutical ingredient, or API, and other raw </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
materials and our research and development, manufacturing, consulting and other services worldwide, including from the United States, the European Union and India. Any weakening of the pound
sterling against the currencies of such other jurisdictions makes the purchase of such goods and services more expensive for us. Further, potential future revenue may be derived from abroad, particularly from the United States. As a result, our
business and the price of our ADSs may be affected by fluctuations in foreign exchange rates not only between the pound sterling and the U.S. dollar, but also the currencies of other countries, which may have a significant impact on our results of
operations and cash flows from period to period. Currently, we do not have any exchange rate hedging arrangements in place. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Development of Our Product Candidates </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Initial success in the completed and ongoing early-stage clinical trials may not be indicative of results obtained when these trials
are completed or in later stage trials. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acelarin is currently being evaluated in three clinical trials across numerous solid tumor indications: one Phase 1b trial in combination
with cisplatin in patients with biliary cancer, one Phase 2 trial in patients with recurrent ovarian cancer, and one multi-year investigator-sponsored Phase 3 trial in patients with pancreatic cancer. While Acelarin has shown high disease control
rates and a favorable tolerability profile in early-stage trials, including in two first-in-human dose-ranging Phase 1 trials, we may not see such favorable data in future clinical trials involving Acelarin. Similarly, favorable results obtained
from preclinical studies of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and in the ongoing Phase 1 trial in patients with advanced solid tumors may not be replicated in any future clinical trials. In addition, data generated in these early
stage Phase 1 trials are not the basis on which marketing approval by the FDA or a comparable foreign regulatory authority would be sought. Furthermore, the results of our clinical trials may not meet the level of statistical significance required
by the FDA or comparable foreign regulatory authorities for marketing approval. Statistical significance means that an effect is unlikely to have occurred by chance. Clinical trial results are considered statistically significant when the
probability of the results occurring by chance, rather than from the efficacy of the product candidate, is sufficiently low. There can be no assurance that any of our clinical trials will ultimately be successful or support further clinical
development of any of our product candidates. There is a high failure rate for drugs proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical
development even after achieving promising results in earlier studies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Preliminary and interim data from our clinical trials may change as patient enrollment continues, patient data are further examined and more patient data become available. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary or interim data from our clinical trials,
including those from the Phase 1b trial of Acelarin in combination with cisplatin in patients with biliary cancer, the Phase 2 trial of Acelarin in patients with recurrent ovarian cancer, the multi-year investigator-sponsored Phase 3 trial of
Acelarin in patients with pancreatic cancer, the Phase&nbsp;1 trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in patients with advanced solid tumors, and any future clinical trials of any of product candidates, are not necessarily
predictive of final results and may change. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues, patient data are further examined, more patient data
become available, and we prepare and issue our final clinical study report. As a result, preliminary and interim data should be viewed with caution until the final data are available. Material adverse changes in the final data compared to the
preliminary or interim data could significantly harm our business prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are very early in our development efforts. If we are unable to successfully develop and commercialize our product candidates or experience significant delays in doing so, our business will be
harmed. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently do not have any
products that have gained marketing approval. We have invested substantially all of our efforts and financial resources identifying and developing our ProTides, such as Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT
STYLE="white-space:nowrap">NUC-7738.</FONT> Our ability to generate product revenues, which may not occur for several years, if ever, will </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
depend on the successful development and eventual commercialization of Acelarin, for which one Phase&nbsp;1b trial, one Phase&nbsp;2 trial and one multi-year investigator-sponsored Phase 3 trial
are ongoing, <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> for which one Phase&nbsp;1 trial is ongoing, and <FONT STYLE="white-space:nowrap">NUC-7738,</FONT> which is currently in preclinical development. We currently do not generate any
revenues from sales of any products, and we may never be able to develop or commercialize a marketable drug. Each of our product candidates will require development, management of development and manufacturing activities, marketing approval in
multiple jurisdictions, obtaining manufacturing supply, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenues from drug sales. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not yet demonstrated an ability to successfully
overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to execute our business plan, we will need to successfully: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">execute development activities for our product candidates, including successful enrollment in and completion of clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">manage our spending as costs and expenses increase due to preclinical development, clinical trials, marketing approvals and commercialization;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain required marketing approvals for the development and commercialization of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain and maintain patent and trade secret protection and regulatory exclusivity for our product candidates and ensure that we do not infringe the
valid patent rights of third parties; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">protect, leverage and expand our intellectual property portfolio; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish and maintain clinical and commercial manufacturing capabilities or make arrangements with third-party manufacturers for clinical and
commercial manufacturing; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">build and maintain robust sales, distribution and marketing capabilities, either on our own or in collaboration with strategic partners, if our product
candidates are approved; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">gain acceptance for our product candidates, if approved, by patients, the medical community and third-party payors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">compete effectively with other therapies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain and maintain healthcare coverage and adequate reimbursement; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">maintain a continued acceptable safety profile for our product candidates following approval, if approved; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">develop and maintain any strategic relationships we elect to enter into, if any. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we do not achieve one or more of these factors in a timely
manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would harm our business. If we do not receive marketing approvals for our product candidates, we may not be able to
continue our operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we experience
delays or difficulties in the enrollment of patients in clinical trials, development of our product candidates may be delayed or prevented. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Identifying and qualifying patients to participate in clinical trials for our product candidates is critical to our success. We may not be
able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials. Patient enrollment may be affected by many factors including:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the severity of the disease under investigation; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the size of the patient population for a product indication; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the eligibility criteria for the clinical trial in question; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the perceived risks and benefits of the product candidate under study; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the efforts to facilitate timely enrollment in clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the patient referral practices of physicians; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of competing therapies and clinical trials; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the proximity and availability of clinical trial sites for prospective patients. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we experience delays or difficulties in the enrollment of
patients in clinical trials, our clinical trials may be delayed or terminated. Any delays in completing our clinical trials will increase our costs, delay or prevent our product candidate development and approval process, and jeopardize our ability
to commence product sales and generate revenue. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or
experience delays in completing, or ultimately be unable to complete, the development and may experience delays in obtaining, or ultimately be unable to obtain, the approval of our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The risk of failure in drug development is high. Acelarin is
currently being studied in one Phase&nbsp;1b trial, one Phase&nbsp;2 trial and one multi-year investigator-sponsored Phase 3 trial, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> is currently being studied in one Phase&nbsp;1 trial, and <FONT
STYLE="white-space:nowrap">NUC-7738</FONT> is in preclinical development. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and conduct extensive clinical
trials to demonstrate the safety and efficacy of our product candidates in patients. Clinical trials are expensive, difficult to design and implement and can take several years to complete, and their outcome is inherently uncertain. Failure can
occur at any time during the clinical trial process. Further, the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, and interim results of a
clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily
in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing
approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may experience numerous unforeseen
events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates. Clinical trials may be delayed, suspended or prematurely terminated because costs are
greater than we anticipate or for a variety of reasons, such as: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure in reaching agreement with the FDA, the EMA or a comparable foreign regulatory authority on a trial design that we are able to
execute; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the
scope or design of a clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in reaching, or failure to reach, agreement on acceptable terms with prospective trial sites and prospective CROs, the terms of which can be
subject to extensive negotiation and may vary significantly among different CROs and trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability, delay, or failure in identifying and maintaining a sufficient number of trial sites, many of which may already be engaged in other clinical
programs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure in recruiting and enrolling suitable subjects to participate in a trial; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure in having subjects complete a trial or return for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT>
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical sites and investigators deviating from the clinical protocol, failing to conduct the trial in accordance with regulatory requirements, or
dropping out of a trial; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to initiate or delay of or failure to complete a clinical trial as a result of an Investigational New Drug Application, or IND, being placed on
clinical hold by the FDA, or for other reasons; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of adequate funding to continue a clinical trial, including unforeseen costs due to enrollment delays, requirements to conduct additional clinical
trials and increased expenses associated with the services of our CROs and other third parties; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct
additional clinical trials or abandon product development programs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may
be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulators, or a Data Safety Monitoring Board, or DSMB, if one is used for our clinical trials, may require that we suspend or terminate our clinical
trials for various reasons, including noncompliance with regulatory requirements, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, or a finding that the participants are being exposed to
unacceptable health risks; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the FDA or other regulatory authorities may require us to submit additional data or impose other requirements before permitting us to initiate a
clinical trial; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">there may be changes in governmental regulations or administrative actions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may
also ultimately lead to the denial of marketing approval for our product candidates. The FDA may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after it
has reviewed and commented on the design for our clinical trials. Even though Acelarin and <FONT STYLE="white-space:nowrap">NUC-3373</FONT> are transformations of chemotherapeutic agents that have been widely used for many years and there is a clear
unmet medical need in each of the indications that we are currently pursuing in the clinic, there can be no assurance that the FDA will permit us to move more quickly to the initiation of pivotal clinical trials in large patient populations.
Furthermore, <FONT STYLE="white-space:nowrap">NUC-7738</FONT> is a transformation of cordycepin, a nucleoside analog that has never been successfully developed or approved as a chemotherapy, which may result in the need for more preclinical studies
or clinical trials than would be the case for transformations of approved chemotherapeutic agents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we are required to conduct additional clinical trials or other studies of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of
our product candidates or other studies, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">be delayed in obtaining marketing approval for our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">not obtain marketing approval for our product candidates at all; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain approval for indications or patient populations that are not as broad as intended or desired; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings that would reduce the potential market for
our products or inhibit our ability to successfully commercialize our products; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">be subject to additional post-marketing restrictions or requirements, including confirmatory trials; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">have the product removed from the market after obtaining marketing approval. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product development costs will also increase if we experience delays in preclinical and clinical
development or receiving the requisite marketing approvals. We do not know whether any of our preclinical studies or clinical trials will need to be restructured or will be completed on schedule, or at all. Significant preclinical or clinical trial
delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our
product candidates and may harm our business and results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Due to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain ProTide candidates over other potential candidates. These decisions
may prove to have been wrong and may adversely affect our performance. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Because we have limited resources and access to capital to fund our operations, we must decide which ProTides to pursue and the amount of resources to allocate to each. Our decisions concerning the
allocation of research, collaboration, management and financial resources toward particular ProTides or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities.
Similarly, our decisions to delay, terminate or collaborate with third parties in respect of product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations
regarding the market potential of our ProTides or misread trends in the biopharmaceutical industry, in particular for our lead ProTides, then our business may be adversely affected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be successful in our efforts to use and expand our technology platform to build a pipeline of
additional ProTide candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A key
element of our strategy is to use and expand our proprietary ProTide technology to build a pipeline of additional ProTide candidates and progress these ProTide candidates through clinical development for the treatment of cancer. Although our
research and development efforts to date have resulted in a pipeline of ProTide candidates directed at the treatment of many solid tumors and hematological malignancies, we may not be able to develop ProTide candidates that are safe and effective.
Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics
that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Marketing Approval of Our Product Candidates </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are not able to obtain, or if there are delays
in obtaining, required marketing approvals, we will not be able to commercialize our product candidates and our ability to generate revenue will be impaired. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product candidates and the activities associated with
their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive
regulation by the FDA and other regulatory agencies in the United States and by comparable authorities in other countries. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements,
current good manufacturing practice, or cGMP, requirements relating to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by FDA and other regulatory authorities, requirements
regarding the distribution of samples to physicians and recordkeeping. Before we can commercialize any of our product candidates, each such product candidate must be approved by the FDA pursuant to an NDA in the United States, by the EMA pursuant to
a MAA in the European Union, and by similar regulatory authorities outside the United States prior to commercialization. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and takes several years, if approval is
obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent us from
commercializing the product candidate. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have limited experience in planning and conducting the clinical trials required for
marketing approvals, and we expect to rely on third-party contract research organizations, or CROs, to assist us in this process. Obtaining marketing approval requires the submission of extensive preclinical and clinical data and supporting
information to regulatory authorities for each therapeutic indication to establish the product candidate&#146;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process, and
in many cases the inspection of manufacturing facilities by the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other
characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Because a number of our clinical trials will be in combination with other approved therapies, there may also be undesirable or unintended side
effects, toxicities or other characteristics resulting from the other therapy or from its combination with our product candidate. In addition, because our product candidates are transformations of nucleoside analogs, including those that are
approved chemotherapeutic agents and those that have never been approved as chemotherapeutic agents, our product candidates could be negatively impacted by the identification of any new undesirable or unintended side effects, toxicities or other
characteristics in such existing nuceloside analogs, in particular in those that have never been approved as chemotherapeutic agents. Although we use the proprietary name Acelarin for our product candidate
<FONT STYLE="white-space:nowrap">NUC-1031,</FONT> we have not obtained any conditional approval of this proprietary name and any goodwill or recognition that we accrue during development of the product candidate may be lost if we are required to
select a different proprietary name in the course of obtaining regulatory approval, if such approval occurs at all. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our
data are insufficient for approval and require additional preclinical studies or clinical trials. Our product candidates could be delayed in receiving, or fail to receive, marketing approval for many reasons, including the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials or require that we perform
additional clinical trials, including toxicology trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and
effective for its proposed indication; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results of our clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities
for marketing approval; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission to
obtain marketing approval in the United States or elsewhere; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third-party manufacturers or our clinical or commercial product candidates may be unable to meet the FDA&#146;s cGMP requirements or similar
requirements of foreign regulatory authorities; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the approval requirements or policies of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our
clinical data insufficient for approval. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, even if we were to obtain approval, regulatory authorities may approve our product candidates for fewer or more limited indications than we request, may grant approval contingent on the
performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the
foregoing scenarios could harm the commercial prospects for our product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate
revenues will be impaired. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our product
candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Undesirable side effects caused by our
product candidates could cause us or the FDA or other regulatory authorities to interrupt, delay or halt our clinical trials and could result in more restrictive labels or the delay or denial of marketing approval by the FDA or other regulatory
authorities of our product candidates. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials could be suspended or terminated and the FDA or
comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could also affect patient recruitment or the
ability of enrolled patients to complete the trial or result in potential product liability claims. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of our product candidates may only be
uncovered with a significantly larger number of patients exposed to the product candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates or any other similar
drugs after such approval, a number of potentially significant negative consequences could result, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may withdraw or limit their approval of such product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require the addition of labeling statements, such as a &#147;boxed&#148; warning or a contraindication;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to change the way such product candidates are distributed or administered, conduct additional clinical trials or change the labeling
of the product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require a REMS plan to mitigate risks, which could include medication guides, physician communication plans, or elements to
assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to regulatory investigations and government enforcement actions; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may decide to remove such product candidates from the marketplace after they are approved; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our reputation may suffer. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the patient profile in the indications for which we are currently developing
our product candidates, with many patients already seriously ill at the time of initiation of treatment, may result in an increased risk of claims that undesirable side effects or poor prognoses or outcomes are related to our product candidates.
Regardless of whether or not such side effects or prognoses or outcomes are ultimately determined to be related to our product candidates, the claims themselves could result in some or all of the foregoing negative consequences. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that any of these events could prevent us from
achieving or maintaining market acceptance of the affected product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our
product candidates and generate revenues. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A
Fast Track Designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive
marketing approval. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not currently
have Fast Track Designation for any of our product candidates but may seek such designation. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs
for this condition, the drug sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion whether to grant this designation. Even if we believe a particular product candidate is eligible for this designation, we cannot assure you
that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it
believes that the designation is no longer supported by data from our clinical development program. Many drugs that have received Fast Track Designation have failed to obtain drug approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to obtain orphan drug designation from the FDA for any of our product candidates, and
even if we do obtain such designations, we may be unable to obtain or maintain the benefits associated with orphan drug designation, including the potential for orphan drug exclusivity. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Orphan Drug Act, the FDA may designate a product
as an orphan drug if it is intended to treat a rare disease or condition, defined as one occurring in a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is
no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA&#146;s Committee for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the
development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is
granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be
sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to
those affected by the condition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United
States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax credits for qualified clinical testing and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers.
In addition, if a product receives the first FDA approval of that drug for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market
the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure the availability of
sufficient quantities of the orphan drug to meet the needs of patients with the rare disease or condition. Under the FDA&#146;s regulations, the FDA will deny orphan drug exclusivity to a designated drug upon approval if the FDA has already approved
another drug with the same </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
active ingredient for the same indication, unless the drug is demonstrated to be clinically superior to the previously approved drug. In the European Union, orphan drug designation entitles a
party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is
shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We do not currently have orphan drug designation for any of our product candidates but may seek such designation. Even if we are able to obtain orphan designation for one or more of our product candidates
in the United States or the European Union, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products, which could prevent us from marketing
such product candidate if another company is able to obtain orphan drug exclusivity before we do. In addition, exclusive marketing rights in the United States may be unavailable if we seek approval for an indication broader than the
orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease
or condition following approval. Further, even if we obtain orphan drug exclusivity for one or more of our ProTides, that exclusivity may not effectively protect them from competition because different drugs with different active moieties can be
approved for the same condition. In addition, the FDA or the EMA can subsequently approve products with the same active moiety for the same condition if the FDA or the EMA concludes that the later drug is safer, more effective, or makes a major
contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek orphan drug
designation for one or more of our product candidates, we may never receive such designations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There have been legal challenges to aspects of the FDA&#146;s regulations and policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges could lead to changes that affect
the protections afforded our products in ways that are difficult to predict. In 2014, a U.S. district court invalidated the FDA&#146;s denial of orphan exclusivity to an orphan designated drug, which the FDA had based on its determination that the
drug was not proven to be clinically superior to a previously approved &#147;same drug.&#148; In response to the decision, the FDA released a policy statement stating that the court&#146;s decision is limited just to the facts of that particular
case and that the FDA will continue to deny orphan drug exclusivity to a designated drug upon approval if the drug is the &#147;same&#148; as a previously approved drug, unless the drug is demonstrated to be clinically superior to that previously
approved drug. In April 2016, another similar legal challenge was initiated against the FDA for its denial of orphan drug exclusivity to another designated drug. In the future, there is the potential for additional legal challenges to the FDA&#146;s
orphan drug regulations and policies, and it is uncertain how ongoing and future challenges might affect our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and
could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them
are approved. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the FDA or a comparable
foreign regulatory authority approves any of our product candidates, activities such as the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will
be subject to extensive and ongoing regulatory requirements. The FDA or a comparable foreign regulatory authority may also impose requirements for costly post-marketing preclinical studies or clinical trials and surveillance to monitor the safety or
efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes
stringent restrictions on manufacturers&#146; communications regarding use of their products, and if we promote our products beyond their approved indications, we may be subject to enforcement actions or prosecution arising from that <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and
abuse and other laws, as well as state consumer protection laws. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, later discovery of previously unknown adverse events or other problems with our
products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on such products, manufacturers or manufacturing processes; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on the labeling or marketing of a product; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on product distribution or use; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">requirements to conduct post-marketing studies or clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">warning or untitled letters; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">withdrawal of the products from the market; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusal to approve pending applications or supplements to approved applications that we submit; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">recall of products; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fines, restitution or disgorgement of profits or revenues; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension or withdrawal of marketing approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusal to permit the import or export of our products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product seizure; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injunctions or the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-compliance</FONT> with
European Union requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with the European Union&#146;s requirements regarding the protection of personal
information can also lead to significant penalties and sanctions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The FDA&#146;s policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of our product candidates. If we are slow or unable to adapt
to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our relationships with customers and third-party payors
will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we do not currently have any
drugs on the market, once we begin commercializing our product candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the U.S. federal and state governments and the foreign governments in the
jurisdictions in which we conduct our business. Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future
arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market,
sell and distribute any products for which we obtain marketing approval. Restrictions under applicable U.S. federal and state healthcare laws and regulations include the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or paying
remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under a federal
healthcare program such as Medicare and Medicaid; a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal false claims laws, including, without limitation, the civil False Claims Act (which can be enforced by private citizens through qui tam
actions), impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid,
decrease or conceal an obligation to pay money to the federal government; in addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the False Claims Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to
defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or
services; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal physician payment transparency requirements under the Physician Payments Sunshine Act, created under the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, require manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s
Health Insurance Program to report to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to payments and other transfers of value to physicians and teaching hospitals and the ownership and investment interests of
physicians and their immediate family members in such manufacturers; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, which also imposes
obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health
information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">some state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the
relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">state and foreign laws that govern the privacy and security of health information in certain circumstances, many of which differ from each other in
significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing
arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws
and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or
other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties,
damages, fines, disgorgement, imprisonment, exclusion of our products from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement
or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, reputational harm, and the curtailment or restructuring of our operations. In addition, if any of the physicians or other
healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare
programs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current and future legislation may increase the difficulty and cost for us to obtain
marketing approval of and commercialize our product candidates and affect the prices we may obtain. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing
approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, the Medicare
Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and certain disabled people
by establishing the Medicare Part D Program and introduced a reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this law provided authority for Medicare Part D plans to limit the number of drugs
covered in any therapeutic class. Cost reduction initiatives and other provisions of this law and future laws could decrease the coverage and price that we will receive for any approved products. While the MMA only applies to drug benefits for
Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Therefore, any limitations in reimbursement that results from the MMA may result in reductions in payments from
private payors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2010, the ACA became
law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance
industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our potential product candidates are the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of healthcare fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative
powers, and enhanced penalties for noncompliance; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">extension of manufacturers&#146; Medicaid rebate liability; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of eligibility criteria for Medicaid programs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of the entities eligible for discounts under the Public Health Service Act&#146;s pharmaceutical pricing program;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">new requirements to report financial arrangements with physicians and teaching hospitals; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along
with funding for such research. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The current administration supports a repeal of the ACA and an Executive Order has been signed commanding federal agencies to try to waive
or delay requirements of the ACA that impose economic or regulatory burdens on states, families, the health-care industry and others. The Executive Order also declares that the administration will seek the &#147;prompt repeal&#148; of the law and
that the government should prepare to &#147;afford the States more flexibility and control to create a more free and open healthcare market.&#148; In addition, following the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
passage of the budget resolution for fiscal year 2017, the U.S. House of Representatives passed legislation known as the American Health Care Act, which, if enacted, would have amended or
repealed significant portions of the ACA. More recently, the Senate Republicans introduced and then updated a bill to replace the ACA known as the Better Care Reconciliation Act of 2017. The Senate Republicans also introduced legislation to repeal
the ACA without companion legislation to replace it, and a &#147;skinny&#148; version of the Better Care Reconciliation Act of 2017. Each of these measures was rejected by the full Senate. Congress will likely consider other legislation to replace
elements of the ACA. At this time, we cannot know how any legislation that may be passed to amend or replace the ACA will impact our business in the United States. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, other legislative changes have been proposed and
adopted since the ACA was enacted. These new laws may result in additional reductions in Medicare and other healthcare funding. For example, as a result of the Budget Control Act of 2011, providers are subject to Medicare payment reductions of 2%
per fiscal year through 2025 unless additional Congressional action is taken. In addition, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to
recover overpayments from providers from three to five years. Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional
inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to product pricing, contain the cost of drugs, review the relationship between pricing and manufacturer patient programs, and reform
government program reimbursement methodologies for products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that
we will receive for any approved product. Any reduction in payments from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to generate revenue, attain profitability, or commercialize any of our products for which we receive marketing approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for
pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed or what the impact of such changes on the marketing approvals, if any, of
our product candidates, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and
post-marketing conditions and other requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional
regulatory burdens and other risks and uncertainties. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our future profitability may depend, in part, on our ability to commercialize our product candidates in foreign markets. In order to market and sell our products in the European Union and many other
jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and economic areas and can involve additional
testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In
addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory
authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does
not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. Additionally, a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in
others. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional
preclinical studies or clinical trials. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our
products in certain countries. If we fail to comply with the regulatory requirements in international markets or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our
product candidates will be harmed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be
able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we
would be subject to additional risks and uncertainties, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our customers&#146; ability to obtain reimbursement for our product candidates in foreign markets; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to directly control commercial activities because we are relying on third parties; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">import or export licensing requirements; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">longer accounts receivable collection times; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">longer lead times for shipping; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">language barriers for technical training; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduced or no protection on pharmaceutical products or their use in some foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the unwillingness of courts in some foreign jurisdictions to enforce patents even when valid and infringed in that country;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility of <FONT STYLE="white-space:nowrap">pre-grant</FONT> or post-grant review proceedings in certain foreign countries that allow a
petitioner to hold up patent rights for an extended period or permanently by challenging the patent filing at the patent office of that country; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility of a compulsory license issued by a foreign country that allows a third-party entity or a government to manufacture, use or sell our
products with a <FONT STYLE="white-space:nowrap">government-set</FONT> low royalty to us; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the existence of additional potentially relevant third-party intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">foreign currency exchange rate fluctuations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an increase in restrictions on trade or other protectionist measures; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign sales of our product candidates could also be
adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some countries, particularly the
countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing
approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our financial results would suffer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are subject to numerous environmental, health and safety
laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals
and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In
the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and the amount of the liability could exceed our resources. We also could incur significant costs associated with
civil or criminal fines and penalties for failure to comply with such laws and regulations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may
not provide adequate coverage against other potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or
radioactive materials. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we may incur
substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our discovery, preclinical development or production efforts. Our failure to
comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Dependence on Third Parties </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We rely on, and expect to continue to rely on, third parties to conduct our clinical trials for our product candidates. If these
third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize our product candidates, and our business could
be substantially harmed. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have
the ability to independently conduct clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or otherwise support clinical trials for our product candidates.
We expect to rely heavily on these parties for performance of clinical trials for our product candidates. Nevertheless, we will be responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol,
legal and regulatory requirements and scientific standards. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We, our investigators, and our CROs will be required to comply with regulations, including good clinical practice, or GCP, and other related requirements for conducting, monitoring, recording and
reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights
are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for any drugs in clinical development. The FDA enforces GCPs through
periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our investigators or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be called into question and
the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before considering our marketing applications for approval. We cannot assure you that, upon inspection, the FDA will determine that any of our
future clinical trials will comply with GCPs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our clinical trials must be conducted with product candidates produced under
cGMPs. Our failure or the failure of our investigators or CROs to comply with these requirements may require us to repeat clinical trials, which would delay the marketing approval process and could also subject us to enforcement action. We also are
required to register certain clinical trials and post the results of such completed clinical trials involving product candidates for which we receive marketing approval on a government-sponsored database, ClinicalTrials.gov, within certain
timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we intend to design the clinical trials for our product candidates, CROs will administer all of the clinical trials. As a result,
many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct future clinical trials will also result in less direct control over the
management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in
coordinating activities. Outside parties may: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">have staffing difficulties; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fail to comply with contractual obligations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">experience regulatory compliance issues; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">undergo changes in priorities or become financially distressed; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">make errors in the design, management or retention of our data or data systems; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">form relationships with other entities, some of which may be our competitors. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These factors may adversely affect the willingness or ability
of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with
regulatory requirements, the development, marketing approval and commercialization of our product candidates may be delayed, we may not be able to obtain marketing approval and commercialize our product candidates, or our development program may be
irreversibly harmed. If we are unable to rely on clinical data collected by our CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization
and require significantly greater expenditures. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs. If
CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our
clinical protocols, regulatory requirements or for other reasons, any clinical trials such CROs are associated with may be extended, delayed or terminated and we may not be able to obtain marketing approval for or successfully commercialize our
product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We contract with third parties for the
manufacture and shipment of our product candidates for preclinical studies and clinical trials and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of
our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not currently own or operate, nor do we have any plans
to establish in the future, any manufacturing facilities or personnel. We rely, and expect to continue to rely, on third parties for the manufacture and shipment of our product candidates for preclinical studies and clinical trials, as well as for
the commercial manufacture of our drugs if any of our product candidates receive marketing approval. This reliance on third parties increases the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or
commercialization efforts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The facilities used to
manufacture our product candidates must be evaluated by the FDA pursuant to inspections that will be conducted after we submit our marketing applications to the FDA to ensure compliance with cGMP. We do not control the manufacturing and shipment
process of, and will be completely dependent on, our contract manufacturers for compliance with cGMPs in connection with the manufacture and shipment of our product candidates. If our contract manufacturers cannot successfully manufacture and ship
material that conforms to our specifications and the regulatory requirements of the FDA or others, we will not be able to use the products produced at their manufacturing facilities. In addition, we have no control over the ability of our contract
manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds that these facilities do not comply with cGMP, we may need to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Further, our failure, or the failure of our third-party manufacturers, to comply with these or other
applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or
drugs, if approved, operating restrictions and criminal prosecutions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may be unable to establish any agreements with third-party manufacturers or do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on
third-party manufacturers entails additional risks, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reliance on the third party for regulatory compliance and quality assurance; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possible breach of the manufacturing agreement by the third party; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possible misappropriation of our proprietary information, including our trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product candidates and any
other drugs that we may develop may compete with other product candidates and approved drugs for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of
manufacturing for us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any performance failure on
the part of our existing or future manufacturers could delay clinical development or marketing approval. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there
are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current and anticipated future dependence upon others for the manufacture and shipment of our product
candidates or drugs may adversely affect our future profit margins and our ability to commercialize any drugs that receive marketing approval on a timely and competitive basis. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We, or our third-party manufacturers, may be unable to
successfully <FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products,
if any. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to conduct large-scale
clinical trials of our product candidates, we will need to manufacture them in large quantities. We, or any of our manufacturing partners, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a
timely or cost-effective manner, or at all. In </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
addition, quality issues may arise during <FONT STYLE="white-space:nowrap">scale-up</FONT> activities. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of
our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or
not obtained, which could significantly harm our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The third parties upon which we rely for the supply of the active pharmaceutical ingredients, formulations, and drug products are our sole sources of supply and have limited capacity, and the loss
of any of these suppliers could harm our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The API, formulations and drug products for our product candidates are supplied to us from single-source suppliers with limited capacity. Our ability to successfully develop our product candidates, and to
ultimately supply our commercial drugs in quantities sufficient to meet the market demand, depends in part on our ability to obtain the API, formulations and drug products in accordance with cGMP requirements and in sufficient quantities for
commercialization and clinical trials. We do not currently have arrangements in place for a redundant or second-source supply of any such API, formulation or drug product in the event any of our current suppliers cease their operations for any
reason. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not know whether our suppliers will
be able to meet our demand, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their
ability to timely meet our demand in the future based on past performance. While our suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For all of our product candidates, we intend to
identify and qualify additional manufacturers to provide API, formulations and drug products prior to submission of an NDA to the FDA or an MAA to the EMA. Establishing additional or replacement suppliers for the API, formulations and drug products
for our product candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified, or we may have to perform comparative studies comparing the drug product
from a new manufacturer to the product used in any completed clinical trials. All of this may require additional marketing approval, which could result in further delay. While we seek to maintain adequate inventory of the API, formulations and drug
products for our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API, formulation and drug product from alternate sources at acceptable prices in a timely manner could impede,
delay, limit or prevent our development efforts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have entered into, and may in the future enter into, collaborations with third parties to discover or develop product candidates.
If these collaborations are not successful, our business could be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into a research, collaboration and license agreement with Cardiff University and University College Cardiff Consultants Ltd., or Cardiff Consultants, for the design, synthesis,
characterization and evaluation of ProTides, with the results of such research assigned to us and other intellectual property of Cardiff University and Cardiff Consultants exclusively licensed to us for use for all purposes related to selected
ProTides and the nucleoside family of the selected ProTides. We are significantly reliant on this collaboration for the generation of additional potential product candidates and on the scientists employed by Cardiff University and Cardiff
Consultants to perform such research. We have limited control over the amount and timing of resources that our collaborators dedicate to the development of ProTides and our ability to generate potential additional ProTides from these arrangements
will depend on our and our collaborators&#146; abilities to successfully perform the functions assigned to each of us in these arrangements. In addition, our collaborators have the ability to abandon research or development projects and terminate
applicable agreements. If we breach any of our obligations under this agreement, Cardiff University and Cardiff Consultants may have the right to terminate the agreement, which would result in a significant reduction in our ability to develop
additional ProTides, and in our being unable to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
develop, manufacture and sell products that are covered by the licensed intellectual property, or in a competitor&#146;s gaining access to the licensed intellectual property. Our agreement will
expire at the end of 2017. Although we anticipate extending the agreement beyond its expiration, there can be no assurance that we will be successful in doing so. Any expiration of this agreement could also result in a significant reduction in our
ability to develop additional ProTides. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may
potentially enter into additional collaborations with third parties in the future. Our collaboration with Cardiff University and Cardiff Consultants, and any future collaborations we enter into in the future, may pose several risks, including the
following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not perform their obligations as expected; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the clinical trials conducted as part of, or as a result of, these collaborations may not be successful; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not pursue development or commercialization of any product candidates that achieve regulatory approval or may elect not to continue
or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding or external factors, such as an acquisition, that divert resources or create competing
priorities; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may delay clinical trials, provide insufficient funding for clinical trials, stop a clinical trial or abandon a product candidate, repeat
or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized
under a collaboration and, consequently, may have limited ability to inform our shareholders about the status of such product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if
the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product candidates developed in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products,
which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit
sufficient resources to the marketing and distribution of any such product candidate; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development of
any product candidates, may cause delays or termination of the research, development or commercialization of such product candidates, may lead to additional responsibilities for us with respect to such product candidates or may result in litigation
or arbitration, any of which would be time-consuming and expensive; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue
further development or commercialization of the applicable product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If our collaborations do not result in the successful development and commercialization of products, or if one of our collaborators terminates its agreement with us, we may not receive any future research
funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed and we may need additional resources to develop our product
candidates. In addition, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of us in the business and financial communities could be adversely affected. All of
the risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of our collaborators. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may in the future decide to collaborate with
pharmaceutical and biotechnology companies and other organizations for the development and potential commercialization of our product candidates. These relationships, or those like them, may require us to incur
<FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing shareholders or disrupt our management and business. In addition, we could face
significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the
collaborator&#146;s resources and expertise and the terms and conditions of the proposed collaboration. If we license rights to product candidates, we may not be able to realize the benefit of such transactions if we are unable to successfully
integrate them with our existing operations and strategy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to comply with our obligations under our license and collaboration agreement with Cardiff ProTides Ltd., we could lose rights to licensed and assigned intellectual property that are
necessary for developing and commercializing Acelarin and other potential product candidates. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We entered into an exclusive, worldwide assignment, license and collaboration agreement with Cardiff ProTides Ltd., or Cardiff ProTides,
for certain of the patents related to Acelarin and other potential ProTides. This agreement imposes various development, commercialization, royalty payment, diligence and other obligations on us. Among other obligations, we are specifically required
to: pay Cardiff ProTides potential milestone payments; pay Cardiff ProTides royalties equal to mid- to high-single digit percentages of sales of such products, including sales by sublicensees; use commercially reasonable efforts to bring products to
market; provide development and financial reports to Cardiff ProTides; file, prosecute, defend and maintain patent rights; indemnify Cardiff ProTides against certain claims and maintain insurance coverage; and direct future medicinal chemistry work
related to certain compounds to Cardiff ProTides on a preferential basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we breach any of these obligations, Cardiff ProTides may have the right to terminate the license and require us to assign back to Cardiff ProTides the intellectual property which was assigned to us
under this agreement, which would result in our being unable to develop, manufacture and sell products that are covered by the licensed intellectual property or the assigned intellectual property, including Acelarin, or in a competitor&#146;s
gaining access to the licensed intellectual property or the assigned intellectual property. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to the Commercialization of Our Product Candidates </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by
physicians, patients, third-party payors and others in the medical community necessary for commercial success. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians,
patients, third-party payors and others in the medical community. If our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our
product candidates, if approved for commercial sale, will depend on a number of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing of our receipt of any marketing approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms of any approvals and the countries in which approvals are obtained; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the efficacy and safety and potential advantages and disadvantages compared to alternative treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the prevalence and severity of any side effects associated with our products or with any product that is used in combination with our product;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the indications for which our products are approved; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse publicity about our products or favorable publicity about competing products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the approval of other products for the same indications as our products; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to offer our products for sale at competitive prices; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the convenience and ease of administration compared to alternative treatments; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the success of our physician education programs; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the strength of our marketing and distribution; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of third-party coverage and adequate reimbursement, including patient cost-sharing programs such as copays and deductibles; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any restrictions on the use of our products together with other medications. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We face substantial competition, which may result in others discovering, developing or commercializing
competing products before or more successfully than we do. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product
candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology
companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing our product candidates. Some of these competitive products and therapies are based
on scientific approaches that are the same as, or similar to, our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research
organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specifically, there are a large number of companies
developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. If Acelarin is approved, it would compete with (a)&nbsp;existing chemotherapies, including gemcitabine, (b) existing targeted therapies
or immunotherapies and, if approved, targeted therapies or immunotherapies in clinical trials for the treatment of patients with cancer and (c)&nbsp;multiple approved drugs or drugs that may be approved in the future for indications for which we may
develop Acelarin. If <FONT STYLE="white-space:nowrap">NUC-3373</FONT> is approved, it would compete with (a)&nbsp;existing chemotherapies, including 5-FU, (b) existing targeted therapies or immunotherapies and, if approved, targeted therapies or
immunotherapies in clinical trials for the treatment of patients with cancer and (c)&nbsp;multiple approved drugs or drugs that may be approved in the future for indications for which we may develop <FONT STYLE="white-space:nowrap">NUC-3373.</FONT>
If <FONT STYLE="white-space:nowrap">NUC-7738</FONT> is approved, it would </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
compete with existing chemotherapies and multiple approved drugs or drugs that may be approved in the future for indications for which we may develop
<FONT STYLE="white-space:nowrap">NUC-7738.</FONT> Existing chemotherapies with which we may compete, including gemcitabine and <FONT STYLE="white-space:nowrap">5-FU,</FONT> are no longer under patent and are produced by numerous generic
pharmaceutical manufacturers. As a result, these chemotherapies are and will continue to be substantially less expensive to patients than many other potential therapies, including our ProTide candidates, if approved. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial opportunity could be reduced or eliminated if
our competitors develop and commercialize products that are safer, more effective, more convenient or less expensive or have fewer or less severe side effects than any products that we may develop. Our competitors also may obtain FDA or other
marketing approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or slow our marketing approval. Some of the
important competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price and the availability of reimbursement from government and other third-party payors.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of the companies against which we are
competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical studies, conducting clinical trials, obtaining marketing approvals and
marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and early-stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and in
establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we are able to commercialize any product
candidates, such drugs may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some
countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject
to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country but then be subject to price regulations that delay our commercial launch of
the product candidate, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product candidate in that country. Adverse pricing limitations may hinder our ability to recoup our investment
in one or more product candidates, even if our product candidates obtain marketing approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize any product candidates, if approved, successfully will depend in part on the extent to which coverage and adequate reimbursement for these product candidates and related
treatments will be available from government authorities, private health insurers and other organizations. In the United States, the principal decisions about coverage and reimbursement for new medicines under Medicare are made by CMS, an agency
within the U.S. Department of Health and Human Services. Private payors ultimately determine which drugs they will cover and the amount of reimbursement they will provide for a covered drug. While there is no uniform system among payors for making
coverage and reimbursement decisions, private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement. Reimbursement agencies in Europe may be more conservative than CMS. For
example, a number of cancer drugs are generally covered and paid for in the United States, but have not been approved for reimbursement in certain European countries. A primary trend in the U.S. healthcare industry and elsewhere is cost containment.
Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of payments for particular drugs. Increasingly, third-party payors are requiring that drug companies provide them with predetermined
discounts from list prices and are challenging the prices charged for drugs. We </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
may also need to conduct expensive pharmacoeconomic studies, in addition to the costly studies required to obtain FDA or other comparable regulatory approvals, in order to demonstrate the medical
necessity and cost-effectiveness of the product in order to secure coverage and reimbursement. We cannot be sure that coverage will be available for any product candidate that we commercialize and, if coverage is available, the level of payments.
Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any
product candidate for which we obtain marketing approval. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to CMS and private payors, professional organizations such as the National Comprehensive Cancer Network and the American Society of Clinical Oncology can influence decisions about
reimbursement for new medicines by determining standards of care. In addition, many private payors contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for,
certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our products. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There may be significant delays in obtaining reimbursement
for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that any drug
will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may
not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments
for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where
they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could compromise our operating
results, our ability to raise capital needed to commercialize drugs and our overall financial condition. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently have no marketing capability or sales force. If we are unable to establish effective sales or marketing capabilities or
enter into agreements with third parties to sell or market our product candidates, we may not be able to effectively sell or market our product candidates, if approved, or generate product revenues. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no marketing capability or sales force,
but we plan to commercialize any product candidates for which we receive regulatory marketing approval using a specialized sales force in the United States and Europe. To achieve commercial success for any approved product candidate for which we
retain sales and marketing responsibilities, we must build our sales, marketing, managerial and other <FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities or make arrangements with third parties to perform these services. There are
risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could
delay any drug launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these
commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Factors that may inhibit our efforts to commercialize our product candidates on our own include: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our inability to recruit and retain adequate numbers of effective sales and marketing personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more
extensive product lines; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we enter into arrangements with third parties to perform
sales, marketing and distribution services, our drug revenues or the profitability of these drug revenues to us are likely to be lower than if we were to market and sell any product candidates that we develop ourselves. In addition, we may not be
successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so when needed or on terms that are favorable to us. We likely will have little control over such third parties, and any of
them may fail to devote the necessary resources and attention to sell and market our product candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we
will not be successful in commercializing our product candidates that receive marketing approval or any such commercialization may experience delays or limitations. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Product liability lawsuits against us could cause us to
incur substantial liabilities and to limit commercialization of any products that we may develop. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face an inherent risk of product liability exposure related to the evaluation of our product candidates in human clinical trials and
will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities.
Regardless of merit or eventual outcome, liability claims may result in: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">decreased demand for any product candidates or products that we may develop; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injury to our reputation and significant negative media attention; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant costs to defend the related litigation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">substantial monetary awards to trial participants or patients; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">loss of revenue; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduced resources of our management to pursue our business strategy; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability to successfully commercialize any products that we may develop. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product liability insurance may not be adequate to cover
all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to
maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Intellectual Property </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to obtain and maintain intellectual property protection for our technology and products, or if the scope of the intellectual property protection obtained is not sufficiently broad,
our competitors could commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. In addition, if we infringe the valid patent rights of others, we
may be prevented from making, using or selling our products or may be subject to damages or penalties. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success depends in large part on our ability to obtain and maintain patents in the United States and other countries that adequately
protect our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and in foreign countries that cover our novel product candidates and their uses, pharmaceutical
formulations and dosages, and processes for the manufacture of them. Our patent portfolio currently includes both patents and patent applications. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent prosecution process is expensive and time-consuming. We may not be able to file
and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may choose not to seek patent protection for certain innovations and may choose not to pursue patent protection in certain jurisdictions.
Under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope. It is also possible that we will fail to identify patentable aspects of our research and development before it is too late
to obtain patent protection. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently solely
own or exclusively license our patents and patent applications and we have the right to control the prosecution of the <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications. In the future, we may choose to <FONT
STYLE="white-space:nowrap">in-license</FONT> additional patents or patent applications from third parties that we conclude are useful or necessary for our business goals. We may not have the right to control the preparation, filing, prosecution or
maintenance of such patent applications. Therefore, if we do license additional patents or patent applications in the future, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our
business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent position of biotechnology
and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. Publications of discoveries in the scientific literature often lag behind the
actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to
make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value
of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing
competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recent patent reform legislation could increase the
uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September&nbsp;16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The
Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The U.S. Patent and Trademark Office, or USPTO,
recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, became
effective on March&nbsp;16, 2013. The Leahy-Smith Act also created certain new administrative adversarial proceedings, discussed below. It is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the
Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The U.S. Supreme Court has issued opinions in patent cases in the last few years that many consider may weaken
patent protection in the United States, either by narrowing the scope of patent protection available in certain circumstances, holding that certain kinds of innovations are not patentable or generally otherwise making it easier to invalidate patents
in court. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our
ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant <FONT STYLE="white-space:nowrap">law-making</FONT> bodies in other countries, the laws and regulations
governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if our patent applications issue as patents, they may not issue in a form that
will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or
alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents
may be challenged in the courts or patent offices in the United States and in other countries. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could
limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In particular, third parties, such as generics companies, may
seek to develop or acquire intellectual property rights proximate to our patents, including with respect to formulation and process matters, and may be able to do so in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner. Additionally,
given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and
licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Likewise, a court could uphold and enforce a third-party patent that it rules we have infringed, which
would subject us to damages or prevent us from making, using or selling our products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During patent prosecution in the United States and in most foreign countries, a third party can submit prior art or arguments to the reviewing patent office to attempt to prevent the issuance of a
competitor&#146;s patent. For example, our pending patent applications may be subject to a third-party preissuance submission of prior art to the USPTO or an Observation in Europe. Such submission may convince the receiving patent office not to
issue the patent. In addition, if the breadth or strength of protection provided by our patents and patent applications is reduced by such third-party submission, it could affect the value of our resulting patent or dissuade companies from
collaborating with us to license, develop or commercialize current or future product candidates. We may also seek to have issued patents re-issued for purposes of strengthening our patent position; however, such requests for reissuance may not
result in the issuance of the new patent and could result in loss of the originally issued patent. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The risks described here pertaining to our patents and other intellectual property rights also apply to any intellectual property rights that we currently license or may license in the future. In some
cases we may not have control over the prosecution, maintenance or enforcement of the patents that we license, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain and enforce the
licensed patents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may become involved in
administrative adversarial proceedings in the USPTO or in the patent offices of foreign countries brought by a third party to attempt to cancel or invalidate our patent rights, which could be expensive, time consuming and cause a loss of patent
rights. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Leahy-Smith Act created for
the first time new procedures to challenge issued patents in the United States, including post-grant review and inter partes review proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued
patents of competitors. For a patent with a priority date of March&nbsp;16, 2013 or later, a petition for post-grant review can be filed by a third party in a nine-month window from issuance of the patent. A petition for inter partes review can be
filed immediately following the issuance of a patent if the patent was filed prior to March&nbsp;16, 2013. A petition for inter partes review can be filed after the nine-month period for filing a post-grant review petition has expired for a patent
with a priority date of March&nbsp;16, 2013 or later. Post-grant review proceedings can be brought on any ground of challenge, whereas inter partes review proceedings can only be brought to raise a challenge based on published prior art. These
administrative adversarial actions at the USPTO review patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal courts, use a lower burden of proof than used by U.S. federal courts and interpret patent
claims using a &#147;broadest reasonable construction&#148; instead of &#147;plain and ordinary </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
meaning,&#148; which is used in court litigation. Because of these differences between U.S. administrative and judicial adversarial patent proceedings, it is generally considered easier for a
competitor or third party to have a U.S. patent cancelled in a patent office post-grant review or inter partes review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents are challenged by a third party in such
a U.S. patent office proceeding, there is no guarantee that we will be successful in defending the patent, which would result in a loss of the challenged patent right to us. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opposition or invalidation procedures are also available in
most foreign countries. Many foreign authorities, such as the authorities at the European Patent Office, have only post-grant opposition proceedings. However, certain countries, such as India, have both
<FONT STYLE="white-space:nowrap">pre-grant</FONT> and post-grant opposition proceedings. These procedures have been used frequently against pharmaceutical patents in foreign countries. For example, in some foreign countries, these procedures are
used by generic companies to hold up an innovator&#146;s patent rights as a means to allow the generic company to enter the market. This activity is particularly prevalent in India, China and South America and may become more prevalent in Africa and
other parts of Asia as certain countries reach more established economies. If any of our patents are challenged in a foreign opposition or invalidation proceeding, we could face significant costs to defend our patents and may not be successful.
Further, in many foreign jurisdictions, the losing party must pay the attorneys&#146; fees of the winning party, which can be substantial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may have to file one or more lawsuits in court to prevent a third party from selling a product or using a product in a manner
that infringes our patent, which could be expensive, time consuming and unsuccessful, and ultimately result in the loss of our proprietary market. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because competition in our industry is intense, competitors may infringe or otherwise violate our issued patents, patents of our licensors
or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement lawsuits, which can be expensive and time consuming. Any claims we assert against perceived infringers could provoke these parties
to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#146;s
claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk
of being invalidated or interpreted narrowly. We may also elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes prior to litigation, and any such license agreements may require us to pay
royalties and other fees that could be significant. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be
compromised by disclosure. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because our ProTides
are small molecules, after commercialization they will be subject to the patent litigation process of the Hatch-Waxman Act, which allows a generic company to submit an Abbreviated New Drug Application, or ANDA, to the FDA to obtain approval to sell
our drug using bioequivalence data only. Under the Hatch-Waxman Act, since our candidates will be considered new chemical entities, we will have the opportunity to list all of our patents that cover our drug product or its method of use in the
FDA&#146;s compendium of &#147;Approved Drug Products with Therapeutic Equivalence Evaluation,&#148; sometimes referred to as the FDA&#146;s Orange Book. A generic company can submit an ANDA to the FDA four years after our drug approval. The
submission of the ANDA by a generic company is considered a technical act of patent infringement. The generic company can certify that it will wait until the natural expiration date of our listed patents to sell a generic version of our product or
can certify that one or more of our listed patents are invalid, unenforceable, or not infringed. If the latter, we will have 45 days to bring a patent infringement lawsuit against the generic company. This will initiate a challenge to one or more of
our Orange Book-listed patents based on arguments from the generic company that either our patent is invalid, unenforceable or not infringed. Under the Hatch-Waxman Act, if a lawsuit is brought, the FDA is prevented from issuing a final approval on
the generic drug until the earlier of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">seven-and-a-half</FONT></FONT></FONT> years from our drug approval or a final decision of a court holding that
our asserted patent claims are invalid, unenforceable or not infringed. If we do not properly list our relevant patents in the Orange </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Book, timely file a lawsuit in response to a certification from a generic company under an ANDA or prevail in the resulting patent litigation, we can lose our proprietary market, which can
rapidly become generic. Further, even if we do correctly list our relevant patents in the Orange Book, bring a lawsuit in a timely manner and prevail in that lawsuit, it may be at a very significant cost to us of attorneys&#146; fees and employee
time and distraction over a long period. Further, it is common for more than one generic company to try to sell an innovator drug at the same time, so we may be faced with the cost and distraction of multiple lawsuits. We may also determine it is
necessary to settle the lawsuit in a manner that allows the generic company to enter our market prior to the expiration of our patent or otherwise in a manner that adversely affects the strength, validity or enforceability of our patent. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A number of pharmaceutical companies have been the subject of
intense review by the U.S. Federal Trade Commission, or FTC, or a corresponding agency in another country based on how they have conducted or settled drug patent litigation, and certain reviews have led to an allegation of an antitrust violation,
sometimes resulting in a fine or loss of rights. We cannot be sure that we would not also be subject to such a review or that the result of the review would be favorable to us, which could result in a fine or penalty. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FTC has brought a number of lawsuits in federal court in
the past few years to challenge Hatch-Waxman ANDA litigation settlements between innovator companies and generic companies as anti-competitive. The FTC has taken an aggressive position that anything of value is a payment, whether money is paid or
not. Under their approach, if an innovator as part of a patent settlement agrees not to launch or delay launch of an authorized generic during the <FONT STYLE="white-space:nowrap">180-day</FONT> period granted to the first generic company to
challenge an Orange Book-listed patent covering an innovator drug, or negotiates a delay in entry without payment, the FTC may consider it an unacceptable reverse payment. The biopharmaceutical industry argues that such agreements are rational
business decisions to dismiss risk and are immune from antitrust attack if the terms of the settlement are within the scope of the exclusionary potential of the patent. In 2013, the U.S. Supreme Court, in a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">five-to-three</FONT></FONT> decision in <I>FTC v. Actavis, Inc.</I>, rejected both the biopharmaceutical industry&#146;s and FTC&#146;s arguments with regard to <FONT STYLE="white-space:nowrap">so-called</FONT> reverse
payments, and held that whether a &#147;reverse payment&#148; settlement involving the exchange of consideration for a delay in entry is subject to an anticompetitive analysis depends on five considerations: (a)&nbsp;the potential for genuine
adverse effects on competition; (b)&nbsp;the justification of payment; (c)&nbsp;the patentee&#146;s ability to bring about anticompetitive harm; (d)&nbsp;whether the size of the payment is a workable surrogate for the patent&#146;s weakness; and
(e)&nbsp;that antitrust liability for large unjustified payments does not prevent litigating parties from settling their lawsuits, for example, by allowing the generic to enter the market before the patent expires without the patentee&#146;s paying
the generic. Furthermore, whether a reverse payment is justified depends upon its size, its scale in relation to the patentee&#146;s anticipated future litigation costs, its independence from other services for which it might represent payment, as
was the case in Actavis, and the lack of any other convincing justification. The Court held that reverse payment settlements can potentially violate antitrust laws and are subject to the standard antitrust <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">rule-of-reason</FONT></FONT> analysis, with the burden of proving that an agreement is unlawful on the FTC and leaving to lower courts the structuring of such rule of reason analysis. If we are faced with drug patent
litigation, including Hatch-Waxman litigation with a generic company, we could be faced with such an FTC challenge based on that activity, including how or whether we settle the case, and even if we strongly disagree with the FTC&#146;s position, we
could face a significant expense or penalty. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of
which would be uncertain and could hurt our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our commercial success depends upon our ability to develop, manufacture, market and sell Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and our other product candidates and use our proprietary
technologies without infringing the proprietary rights of third parties. While our product candidates are in preclinical studies and clinical trials, we believe that the use of our product candidates in these preclinical studies and clinical trials
falls within the scope of the exemptions provided by 35 U.S.C. Section&nbsp;271(e) in the United States, which exempts from patent infringement liability activities reasonably related to the development and submission of information to the FDA. As
Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and our other product candidates progress toward commercialization, the possibility of a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
patent infringement claims against us increases. There can be no assurance that our product candidates do not infringe other parties&#146; patents or other proprietary rights, however, and
competitors or other parties may assert that we infringe their proprietary rights in any event. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights covering our products and technology, including interference or derivation
proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, including against our product candidates themselves, our formulation and manufacturing
processes or our drug administration methods. In particular, because Acelarin and <FONT STYLE="white-space:nowrap">NUC-3373</FONT> are transformations of widely used approved chemotherapeutic agents, there is significant intellectual property held
by third parties with respect to the formulation and manufacturing of those existing agents, which may increase the risk that such third parties allege infringement by us in the formulation and manufacture processes of our product candidates.
Furthermore, if any of our future ProTides are transformations of an existing chemotherapeutic agent that remains on patent, we could be subject to claims of infringement by the holder of such patents. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are found to infringe a third party&#146;s intellectual
property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all.
Even if we were able to obtain a license, it could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. Alternatively, we may need to redesign infringing products,
which may be impossible or require substantial time and monetary expenditure. Under certain circumstances, we could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found
liable for monetary damages, including treble damages and attorneys&#146; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of
our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be able to effectively enforce our
intellectual property rights throughout the world. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We generally file our first patent application, or priority filing, at the United Kingdom Intellectual Property Office. International applications under the Patent Cooperation Treaty, or PCT, are usually
filed within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in additional jurisdictions where we believe our product candidates may be marketed or manufactured. Filing,
prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and therefore we only file for patent protection in selected countries. The requirements for patentability may differ
in certain countries, particularly in developing countries. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The laws of foreign countries may not protect our rights to
the same extent as the laws of the United States. For example, Europe, India, China and certain other countries do not allow patents for methods of treating the human body. Many companies have encountered significant problems in protecting and
defending intellectual property rights in certain foreign jurisdictions that do not favor patent protection on drugs. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual
property rights. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own drugs and, further, may export otherwise infringing drugs to territories where we have patent protection, if our
ability to enforce our patents to stop infringing activities is inadequate. These drugs may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceedings to enforce our patent rights in
foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects of our business. Furthermore, while we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
intend to protect our intellectual property rights in the major markets for our product candidates, we cannot ensure that we will be able to initiate or maintain similar efforts in all
jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A number of foreign countries have stated that they are
willing to issue compulsory licenses to patents held by innovator companies on approved drugs to allow the government or one or more third-party companies to sell the approved drug without the permission of the innovator patentee where the foreign
government concludes it is in the public interest. India, for example, has used such a procedure to allow domestic companies to make and sell patented drugs without innovator approval. There is no guarantee that patents covering any of our drugs
will not be subject to a compulsory license in a foreign country, or that we will have any influence over if or how such a compulsory license is granted. Further, Brazil allows its regulatory agency, ANVISA, to participate in deciding whether to
grant a drug patent in Brazil, and patent grant decisions are made based on several factors, including whether the patent meets the requirements for a patent and whether such a patent is deemed in the country&#146;s interest. In addition, several
other countries have created laws that make it more difficult to enforce drug patents than patents on other kinds of technologies. Further, under the treaty on the Trade-Related Aspects of Intellectual Property, or TRIPS, as interpreted by the Doha
Declaration, countries in which drugs are manufactured are required to allow exportation of the drug to a developing country that lacks adequate manufacturing capability. Therefore, our drug markets in the United States or foreign countries may be
affected by the influence of current public policy on patent issuance, enforcement or involuntary licensing in the healthcare area. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2015, members of the World Trade Organization, or the WTO, which administers TRIPS, voted to extend the exemption against
enforcing pharmaceutical drug patents in least developed countries until 2033. We currently have no patent applications filed in least developed countries, and our current intent is not to file in these countries in the future, at least in part due
to this WTO pharmaceutical patent exemption. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition, some countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Further, some countries limit the enforceability of patents against government agencies or government
contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant
to our business, our competitive position may be impaired. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and
our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents or applications will be due to be
paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and
rely on our outside counsel to pay these fees due to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by
payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market, which could compromise our competitive position. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intellectual property litigation could cause us to
spend substantial resources and distract our personnel from their normal responsibilities. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable, generally expensive and time consuming and is likely to divert significant
resources from our core </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or
other interim proceedings or developments and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our ADSs. Such litigation or proceedings could substantially
increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may
be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be
able to prevent third parties from infringing upon, misappropriating or successfully challenging our intellectual property rights. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could
narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our intellectual property licenses with third parties may be subject to disagreements over contract interpretation, which could narrow the
scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors. The agreements under which we currently license intellectual property or technology from third parties are
complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant
intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of our licenses or material relationships or any <FONT STYLE="white-space:nowrap">in-licenses</FONT> upon which our licenses are
based are terminated or breached, we may: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lose our rights to develop and market our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lose patent protection for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">experience significant delays in the development or commercialization of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">not be able to obtain any other licenses on acceptable terms, if at all; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">incur liability for damages. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These risks apply to any agreements that we may enter into in the future for our current or any future product candidates. If we
experience any of the foregoing, it could have a negative impact on our business, financial condition, results or operations and prospects. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or
otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into license agreements with third parties and may need to obtain additional licenses from one or more of these same third
parties or from others to advance our research or allow commercialization of our product candidates. It is possible that we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be
required to expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we
are unable to do so, we may be unable to develop or commercialize our product candidates, which would harm our business. We cannot provide any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
assurances that third-party patents or other intellectual property rights do not exist which might be enforced against our current manufacturing methods, product candidates or future methods,
resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is possible that in any future license agreements, patent
prosecution of our licensed technology may be controlled solely by the licensor, and we may be required to reimburse the licensor for their costs of patent prosecution. If our licensors fail to obtain and maintain patent or other protection for the
proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property.
Disputes may arise regarding intellectual property subject to a licensing agreement, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope of rights granted under the license agreement and other interpretation-related issues; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the sublicensing of patent and other rights under our collaborative development relationships; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inventorship or ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use of
intellectual property by our licensors and us and our partners; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the priority of invention of patented technology. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If disputes over intellectual property that we have licensed
prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize our product candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be subject to claims by third parties asserting
that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our
competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that these
employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#146;s former employer. Litigation may be necessary to defend against these claims. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, while it is our policy to require our employees
and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual
property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership
of what we regard as our intellectual property. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to management. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to protect the confidentiality of our
trade secrets, our business and competitive position would be harmed. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other
proprietary information, to maintain our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
competitive position. We seek to protect these trade secrets, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have
access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We seek to protect our confidential proprietary information but enforcing a
claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to
protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to
compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our proprietary information, or that of our suppliers and any future collaborators, may be lost or we may suffer security breaches.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the ordinary course of our business,
we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personally identifiable information of our employees and, potentially in the future, personally identifiable information of
our clinical trial subjects, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure
may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Although to our knowledge we have not experienced any such material security breach to date, any such breach could compromise our networks
and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal
information, regulatory penalties, disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay the clinical development of our
product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intellectual property
rights do not necessarily address all potential threats to our competitive advantage. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us
to maintain our competitive advantage. The following examples are illustrative: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Others may be able to make, use or sell compounds that are similar to our product candidates but that are not covered by the claims of the patents that
we own or have exclusively licensed. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We, our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application
that we own or have exclusively licensed. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We, our licensors or strategic partners, or future licensors or strategic partners, might not have been the first to file patent applications covering
certain of our inventions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Others may independently develop similar or alternative technologies, or duplicate any of our technologies without infringing our intellectual property
rights. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is possible that our pending patent applications will not lead to issued patents. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable as
a result of legal challenges by our competitors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned
from such activities to develop competitive products for sale in our major commercial markets. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not develop additional proprietary technologies that are patentable. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patents of others may have an adverse effect on our business. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently have a limited number of
employees, and our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage company, and, as of September 18, 2017, had 16 employees, including three executive officers. We are highly
dependent on the research and development, clinical and business development expertise of Hugh S. Griffith, our Chief Executive Officer, as well as the other principal members of our management team and our collaborators&#146; scientific and
clinical team. Although we have entered into employment agreements with our executive officers, each of them may at any time serve notice to terminate their employment with us. Other than for Mr.&nbsp;Griffith, we do not maintain &#147;key
person&#148; insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization
strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we or our collaborators are unable to
continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recruiting and retaining qualified scientific, clinical, manufacturing, finance, sales and marketing personnel will also be critical to
our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business
strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to
successfully develop, obtain marketing approval of and commercialize products. Competition to hire from this limited pool is intense and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the
competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in
clinical trials may make it more challenging to recruit and retain qualified scientific personnel. If we or our collaborators are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be
limited. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect to expand our
development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To manage our anticipated development and expansion, we must
continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its
attention away from its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities and devote a substantial amount of time to managing these development activities. Due to our limited resources, we may not
be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of
employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the development of our product candidates. If our
management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or increase our revenue could be reduced and we may not be able to implement our business
strategy. Our future financial performance and our ability to commercialize our product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The United Kingdom&#146;s withdrawal from the European Union may have a negative
effect on global economic conditions, financial markets and our business, which could reduce the price of our ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following the BREXIT referendum held on June&nbsp;23, 2016, the United Kingdom government served notice under Article 50 of the Treaty of
the European Union on March&nbsp;29, 2017 to formally initiate the process of withdrawing from the European Union. The United Kingdom and the European Union have a <FONT STYLE="white-space:nowrap">two-year</FONT> period under Article 50 to negotiate
the terms of withdrawal. Any extension of the negotiation period for withdrawal will require the consent of all of the remaining 27 member states. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The referendum and withdrawal have created significant uncertainty about the future relationship between the United Kingdom and the
European Union Lack of clarity about future U.K. laws and regulations as the United Kingdom determines which E.U.-derived laws and regulations to replace or replicate as part of a withdrawal, including financial laws and regulations, tax and free
trade agreements, intellectual property rights, supply chain logistics, environmental, health and safety laws and regulations, immigration laws and employment laws, could decrease foreign direct investment in the United Kingdom, increase costs,
depress economic activity and restrict our access to capital. If the United Kingdom and the European Union are unable to negotiate acceptable terms for the United Kingdom&#146;s withdrawal from the European Union, or if other E.U. member states
pursue withdrawal from the European Union, barrier-free access between the United Kingdom and other E.U. member states or across the European Economic Area overall could be diminished or eliminated. In addition, the United Kingdom could lose the
benefits of global trade agreements negotiated by the European Union on behalf of its members. These developments, or the perception that any of them could occur, have had and may continue to have a significant adverse effect on global economic
conditions and the stability of global financial markets, and could significantly reduce global market liquidity and restrict the ability of key market participants to operate in certain financial markets. Asset valuations, currency exchange rates
and credit ratings may be especially subject to increased market volatility. These developments, or the perception that any of them could occur, may also have a significant effect on our ability to attract and retain employees, including scientists
and other employees who are important for our and our collaborators&#146; research and development efforts. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If Scotland decides to secede from the United Kingdom, our business may be adversely affected. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A referendum on Scottish independence from the United
Kingdom took place on September&nbsp;18, 2014, the result of which was that Scotland remained part of the United Kingdom. There may in the future be a second referendum on Scottish independence from the United Kingdom. Any such referendum, even if
it again ultimately resulted in Scotland remaining part of the United Kingdom, could lead to uncertainty and disrupt the markets in which we operate, and might cause us to lose potential customers, suppliers, collaborators and employees, including
scientists and other key employees employed by us or our collaborators. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our results of operations could be adversely affected by general conditions in the global economy and in the
global financial markets. The 2008 global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as resulted from the 2008 global financial crisis, could result in
a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business and operations could suffer in the event
of information technology and other internal infrastructure system failures. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Despite the implementation of security measures, our information technology and other internal infrastructure systems and those of our third-party CROs and other contractors and consultants, including
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
corporate firewalls, servers, leased lines and connections to the Internet, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and
telecommunication and electrical failures. Furthermore, we have little or no control over the security measures and computer systems of our third-party CROs and other contractors and consultants. While we have not experienced any such system
failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data for our product candidates
could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other
data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product candidates could be delayed.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our employees, principal investigators,
CROs and consultants may engage in misconduct or other improper activities, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements and insider trading. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to the risk that our employees, principal
investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violate the
regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or
laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct,
kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements.
Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause
serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or
other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition
of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and
future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect
our ability to operate our business and our results of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of
success. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because we have limited
financial and managerial resources, we focus on specific product candidates. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later prove to have greater commercial potential. Our resource allocation
decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any
commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or
other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may acquire businesses or drugs, or form strategic alliances in the future and we
may not realize the benefits of such acquisitions. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may acquire additional businesses or drugs, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire
businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and strategy. We may encounter numerous
difficulties in developing, manufacturing and marketing any new drugs resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following
any such acquisition, we will achieve the expected synergies to justify the transaction. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We or the third parties upon which we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious
disaster. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natural disasters could
severely disrupt our operations and hurt our financial condition. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such
as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster
recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity
plans. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject to certain U.K., U.S.
and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, violations of which can have a negative impact on our business. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are subject to certain U.K., U.S. and foreign anti-corruption, anti-money laundering, export control,
sanctions, and other trade laws and<B><I> </I></B>regulations. Among other matters, these laws and regulations prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and
other partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of these laws
and regulations can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct
or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our international activities to increase over time. We engage third parties to
obtain necessary permits, licenses, patent registrations and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents or other partners, even if we do not explicitly authorize or have
prior knowledge of such activities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to the ADSs
and This Offering </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The price of our
ADSs may be volatile and may fluctuate due to factors beyond our control. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The trading market for publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market
price of our ADSs may fluctuate significantly due to a variety of factors, including: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">positive or negative results from, or delays in, testing and clinical trials by us, collaborators or competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">technological innovations or commercial product introductions by us or competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in government regulations; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments concerning proprietary rights, including patents and litigation matters; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public concern relating to the commercial value or safety of Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> or <FONT
STYLE="white-space:nowrap">NUC-7738;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">financing, collaborations or other corporate transactions; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">publication of research reports or comments by securities or industry analysts; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general market conditions in the pharmaceutical industry or in the economy as a whole; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the loss of any of our key scientific or senior management personnel; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of our ADSs or ordinary shares by us, our senior management and board members, holders of our ADSs or our ordinary shares in the future; or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">other events and factors, many of which are beyond our control. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These and other market and industry factors may cause the
market price and demand for our ADSs to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the liquidity of our ADSs. In
addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the
past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of the holders of our ADSs were to bring such a lawsuit against us, we could
incur substantial costs defending the lawsuit and the attention of our senior management would be diverted from the operation of our business. Any adverse determination in litigation could also subject us to significant liabilities. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will incur increased costs as a result of operating
as a public company in the United States, and our senior management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a public company, and particularly after we no longer qualify as an &#147;emerging growth company&#148;, or
EGC, we will incur significant legal, accounting and other expenses that we did not incur previously. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select
Market, or Nasdaq, and other applicable securities rules and regulations impose various requirements on <FONT STYLE="white-space:nowrap">non-U.S.</FONT> reporting public companies, including the establishment and maintenance of effective disclosure
and financial controls and corporate governance practices. Our senior management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and
financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance,
which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as
a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions
to disclosure and governance practices. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant
to Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Section&nbsp;404, we will be required to furnish a report by our senior management on our internal control over financial reporting. However, while we remain an EGC we will not be required to
include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To prepare for eventual compliance with Section&nbsp;404, once we no longer qualify as an EGC, we will be engaged
in a process to document and evaluate our internal control </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed
work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous
reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting
is effective as required by Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>There has been no public market for our ADSs prior to
this offering, and an active market may not develop in which investors can resell our ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior this offering, there has been no public market for our ADSs or our ordinary shares and, subsequent to this offering, there will
continue not to be a public market for our ordinary shares. We cannot predict the extent to which an active market for our ADSs will develop or be sustained after this offering, or how the development of such a market might affect the market price
for our ADSs. The initial public offering price of our ADSs in this offering has been agreed upon between us and the underwriters based on a number of factors, including market conditions in effect at the time of this offering, which may not be
indicative of the price at which our ADSs will trade following completion of this offering. Investors may not be able to sell their ADSs at or above the initial public offering price. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Certain of our existing shareholders, members of our board of directors and senior management will
maintain the ability to exercise significant control over us. Your interests may conflict with the interests of these existing shareholders. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of September 15, 2017, after giving effect to the closing of this offering, including the purchase by certain of our existing
shareholders of 933,332 ADSs that they have agreed to purchase in this offering, our senior management, board of directors and greater than 5% shareholders and their respective affiliates, in the aggregate, will own 64.8% of our ordinary shares
(including ordinary shares in the form of ADSs), assuming that we sell the number of ADSs set forth on the cover page of this prospectus. These shareholders either alone or voting together as a group may be in a position to determine or
significantly influence the outcome of decisions taken at any such general meeting. Any shareholder or group of shareholders controlling more than 50% of the share capital present and voting at our general meetings of shareholders may control any
shareholder resolution requiring a simple majority, including the appointment of board members, certain decisions relating to our capital structure, the approval of certain significant corporate transactions and amendments to our Articles of
Association. Among other consequences, this concentration of ownership may have the effect of delaying or preventing a change in control and might therefore negatively affect the market price of our ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future sales, or the possibility of future sales, of a
substantial number of our ADSs or ordinary shares could adversely affect the price of our ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future sales of a substantial number of our ADSs or ordinary shares, or the perception that such sales will occur, could cause a decline
in the market price of our ADSs. Based upon the number of shares outstanding as of August 31, 2017, after giving effect to the closing of this offering, we will have 30,881,641 ordinary shares (including ordinary shares in the form of ADSs)
outstanding, assuming that we sell the number of ADSs set forth on the cover page of this prospectus. ADSs issued and sold in this offering may be resold in the public market immediately without restriction, unless purchased by our affiliates. A
significant portion of our ordinary shares outstanding prior to the completion of this offering will be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described in &#147;Shares and ADSs Eligible for Future Sale&#148; and
&#147;Underwriting.&#148; If, after the end of such <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, these shareholders sell substantial amounts of our securities in the public market, or the market perceives that such sales may occur,
the market price of our ADSs and our ability to raise capital through an issue of equity </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
securities in the future could be adversely affected. We have also entered into a registration rights agreement to be effective upon the completion of this offering and pursuant to which we have
agreed under specified circumstances to file a registration statement to register the resale of the ordinary shares (which may be converted to ADSs) held by some of our existing shareholders, as well as to cooperate in specified public offerings of
such shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If you purchase ADSs in this
offering, you will suffer immediate dilution of your investment. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We expect the initial public offering price of our ADSs in this offering to be substantially higher than the pro forma as adjusted net tangible book value per ADS, and per underlying ordinary share, prior
to this offering. Therefore, if you purchase ADSs in this offering, you will pay a price per ADSs, and per underlying ordinary share, that substantially exceeds our net tangible book value per ADS, and per underlying ordinary share, after this
offering. To the extent outstanding options are exercised for ordinary shares, you may experience further dilution. Based on the initial public offering price of $15.00 per ADS, you will experience immediate dilution of $11.24 per ADS, representing
the difference between our pro forma as adjusted net tangible book value per ADS after giving effect to this offering and the offering price. See &#147;Dilution.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Because we do not anticipate paying any cash dividends
on our ADSs or ordinary shares in the foreseeable future, capital appreciation, if any, will be your sole source of potential gains and you may never receive a return on your investment. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under current English law, a company&#146;s accumulated
realized profits must exceed its accumulated realized losses on a <FONT STYLE="white-space:nowrap">non-consolidated</FONT> basis before dividends can be paid. Therefore, we must have distributable profits before issuing a dividend. We have not paid
dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs or ordinary
shares will be your sole source of potential gains for the foreseeable future, and you will suffer a loss on your investment if you are unable to sell your ADSs at or above the public offering price. Investors seeking cash dividends should not
purchase our ADSs in this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have
broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our senior management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in
ways that do not improve our results of operations or enhance the value of our ADSs. The failure by our senior management to apply these funds effectively could result in financial losses, cause the price of our ADSs to decline and delay the
development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Purchasers of our ADSs may not have the same voting
rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise their right to vote. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as described in this prospectus, holders of our ADSs will not be able to exercise voting rights attaching to the ordinary shares
evidenced by our ADSs on an individual basis. Holders of our ADSs will appoint the depositary or its nominee as their representative to exercise the voting rights attaching to the ordinary shares in the form of ADSs in accordance with the deposit
agreement. Purchasers of ADSs in this offering may not receive voting materials in time to instruct the depositary to vote, and it is possible that they, or persons who hold their ADSs through brokers, dealers or other third parties, will not have
the opportunity to exercise a right to vote. In certain cases, the shares represented by your ADSs may be voted contrary to your instructions and you may be deemed to have instructed the depositary to give a discretionary proxy to a person we
designate to vote shares represented by your ADSs in such person&#146;s discretion. Furthermore, the depositary will not be liable for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of
any such vote. As a result, purchasers of ADSs in this offering may not be able to exercise voting rights and may lack </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
recourse if their ADSs are not voted as requested. In addition, in their capacity as ADS holders, purchasers of our ADSs will not be able to call a shareholders&#146; meeting. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Purchasers of our ADSs may not receive distributions on
our ordinary shares in the form of ADSs or any value for them if it is illegal or impractical to make them available to holders of ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary for our ADSs has agreed to pay to purchasers of our ADSs the cash dividends or other distributions it or the custodian
receives on our ordinary shares or other deposited securities after deducting its fees and expenses and certain taxes. Purchasers of our ADSs will receive these distributions in proportion to the number of our ordinary shares their ADSs represent.
However, in accordance with the limitations set forth in the deposit agreement, it may be unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any other action to permit the distribution of our
ADSs, ordinary shares, rights or anything else to holders of our ADSs. This means that purchasers of our ADSs may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them
available to them. These restrictions may have a negative impact on the market value of our ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Purchasers of our ADSs may be subject to limitations on transfer of their ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to
time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any
time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason in accordance with the terms of the
deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The rights of our
shareholders may differ from the rights typically offered to shareholders of a U.S. corporation. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are incorporated under English law. The rights of holders of ordinary shares and, therefore, certain of the rights of holders of ADSs,
are governed by English law, including the provisions of the Companies Act 2006, and by our Articles of Association. These rights differ in certain respects from the rights of shareholders in typical U.S. corporations. See &#147;Description of Share
Capital&#151;Differences in Corporate Law&#148; in this prospectus for a description of the principal differences between the provisions of the Companies Act 2006 applicable to us and, for example, the Delaware General Corporation Law relating to
shareholders&#146; rights and protections. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Shareholder protections found in provisions under the U.K. City Code on Takeovers and Mergers, or the Takeover Code, will not apply
if our place of management and control is considered to change to outside the United Kingdom. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a public limited company incorporated in England and Wales and have our place of central management and control in the United
Kingdom. Accordingly, we are currently subject to the Takeover Code and, as a result, our shareholders are entitled to the benefit of certain takeover offer protections provided under the Takeover Code.&nbsp;The Takeover Code provides a framework
within which takeovers of companies are regulated and conducted. If, at the time of a takeover offer, the Panel on Takeovers and Mergers determines that we do not have our place of central management and control in the United Kingdom, then the
Takeover Code would not apply to us and our shareholders would not be entitled to the benefit of the various protections that the Takeover Code affords. In particular, we would not be subject to the rules regarding mandatory takeover bids. The
following is a brief summary of some of the most important rules of the Takeover Code: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">When a person or group acquires interests in shares carrying 30% or more of the voting rights of a company (which percentage is treated by the Takeover
Code as the level at which effective control is obtained), they must make a cash offer to all other shareholders at the highest price paid by them in the 12&nbsp;months before the offer was announced. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">When interests in shares carrying 10% or more of the voting rights of a class have been acquired by an offeror (i.e. a bidder) in the offer period and
the previous 12 months, the offer must include a cash alternative for all shareholders of that class at the highest price paid by the offeror in that period. Further, if an offeror acquires for cash any interest in shares during the offer period, a
cash alternative must be made available at a price at least equal to the price paid for such shares. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the offeror acquires an interest in shares in an offeree company (i.e. a target) at a price higher than the value of the offer, the offer must be
increased accordingly. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The offeree company must appoint a competent independent adviser whose advice on the financial terms of the offer must be made known to all the
shareholders, together with the opinion of the board of directors of the offeree company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Favorable deals for selected shareholders are banned. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">All shareholders must be given the same information. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Those issuing takeover circulars must include statements taking responsibility for the contents. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Profit forecasts, quantified financial benefits statements and asset valuations must be made to specified standards and must be reported on by
professional advisers. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Misleading, inaccurate or unsubstantiated statements made in documents or to the media must be publicly corrected immediately.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Actions during the course of an offer by the offeree company, which might frustrate the offer are generally prohibited unless shareholders approve
these plans. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stringent requirements are laid down for the disclosure of dealings in relevant securities during an offer. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employees of both the offeror and the offeree company and the trustees of the offeree company&#146;s pension scheme must be informed about an offer. In
addition, the offeree company&#146;s employee representatives and pension scheme trustees have the right to have a separate opinion on the effects of the offer on employment appended to the offeree board of directors&#146; circular or published on a
website. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Claims of U.S.
civil liabilities may not be enforceable against us. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are incorporated under English law. Substantially all of our assets are located outside the United States. The majority of our senior management and board of directors reside outside the United States.
As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce judgments obtained in U.S. courts against them or us, including judgments predicated upon the civil liability
provisions of the U.S. federal securities laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The United States and the United Kingdom do not currently have a treaty providing for the reciprocal recognition and enforcement of
judgments (other than arbitration awards) in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be
recognized or enforceable in England and Wales. In addition, uncertainty exists as to whether the English and Welsh courts would entertain original actions brought in England and Wales against us or our directors or senior management predicated upon
the securities laws of the United States or any state in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of England and Wales as a cause of action in
itself and sued upon as a debt so that no retrial of the issues would be necessary, provided that certain requirements are met consistent with English law and public policy. Whether these requirements are met in respect of a judgment based upon the
civil liability provisions of the U.S. securities laws is an issue for the English court making such decision. If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods
generally available for this purpose. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result, U.S. investors may not be able to enforce against us or our senior management,
board of directors or certain experts named herein who are residents of the United Kingdom or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal
securities laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We qualify as a foreign
private issuer and, as a result, we will not be subject to U.S. proxy rules and will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, we
will report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company with foreign private issuer status. Because we qualify as a foreign private issuer under the
Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i)&nbsp;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in
respect of a security registered under the Exchange Act; (ii)&nbsp;the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a
short period of time; and (iii)&nbsp;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> containing unaudited financial and other specified information, or
current reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> until 120 days after the end of each fiscal year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT>
within 75 days after the end of each fiscal year. Foreign private issuers also are exempt from Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, you may not
have the same protections afforded to shareholders of companies that are not foreign private issuers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters
that differ significantly from Nasdaq corporate governance listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with Nasdaq corporate governance listing standards.
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a foreign private issuer listed on
Nasdaq, we will be subject to corporate governance listing standards. However, Nasdaq rules permit a foreign private issuer like us to follow the corporate governance practices of its home country in lieu of certain Nasdaq corporate governance
listing standards. Certain corporate governance practices in the United Kingdom, which is our home country, may differ significantly from Nasdaq corporate governance listing standards. For example, neither the corporate laws of the United Kingdom
nor our Articles of Association require a majority of our directors to be independent; we can and intend to include <FONT STYLE="white-space:nowrap">non-independent</FONT> directors as members of our nominations and remuneration committees; and our
independent directors would not necessarily hold regularly scheduled meetings at which only independent directors are present. Therefore, our shareholders may be afforded less protection than they otherwise would have under Nasdaq corporate
governance listing standards applicable to U.S. domestic issuers. See &#147;Management&#151;Foreign Private Issuer Exemption.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act&#146;s domestic reporting
regime and cause us to incur significant legal, accounting and other expenses. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a foreign private issuer, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. We may no longer
be a foreign private issuer as of June&nbsp;30, 2018 (the end of our second fiscal quarter in the fiscal year after this offering), which would require us to comply with all of the periodic disclosure and current reporting requirements of the
Exchange Act applicable to U.S. domestic issuers as of January&nbsp;1, 2019. In order to maintain our current status as a foreign private issuer, either (a)&nbsp;a majority of our voting securities must be either directly or indirectly owned of
record by <FONT STYLE="white-space:nowrap">non-residents</FONT> of the United States or (b)(i) a majority of our executive officers or directors cannot be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
U.S. citizens or residents, (ii)&nbsp;more than 50% of our assets must be located outside the United States and (iii)&nbsp;our business must be administered principally outside the United States.
If we lose our status as a foreign private issuer, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign
private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with
the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and
financial compliance costs and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and
expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to
attract and retain qualified members of our board of directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are an &#147;emerging growth company,&#148; and we cannot be certain if the reduced reporting requirements applicable to &#147;emerging growth companies&#148; will make our ADSs less attractive
to investors. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an EGC as defined
in the JOBS Act. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the
auditor attestation requirements of Section&nbsp;404, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an EGC, we
are able to report only two years of financial results and selected financial data compared to three and five years, respectively, for comparable data reported by other public companies. We may take advantage of these exemptions until we are no
longer an EGC. We could be an EGC for up to five years, although circumstances could cause us to lose that status earlier, including if the aggregate market value of our ADSs and ordinary shares held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the end of our second fiscal quarter before that time, in which case we would no longer be an EGC as of the following December 31st (the last day of our fiscal
year). We cannot predict if investors will find our ADSs less attractive because we may rely on these exemptions. If some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and the price of
our ADSs may be more volatile. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail
to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public
reporting, which would harm our business and the trading price of our ADSs. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent
fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with
Section&nbsp;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or
retroactive changes to our financial statements or identify other areas for further attention or improvement. Inadequate internal controls could also cause investors to lose confidence in our reported financial information, which could have a
negative effect on the trading price of our ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management will be required to assess the effectiveness of our internal controls annually. However, for as long as we are an EGC under the
JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&nbsp;404. An independent assessment of the effectiveness of our
internal controls could detect problems that our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
management&#146;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements requiring us to incur the expense of remediation and
could also result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the
price of our ADSs and our trading volume could decline. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The trading market for our ADSs will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently,
and may never, publish research on us. If no or too few securities or industry analysts commence coverage on us, the trading price for our ADSs would likely be negatively affected. In the event securities or industry analysts initiate coverage, if
one or more of the analysts who cover us downgrade our ADSs or publish inaccurate or unfavorable research about our business, the price of our ADSs would likely decline. If one or more of these analysts cease coverage of us or fail to publish
reports on us regularly, demand for our ADSs could decrease, which might cause the price of our ADSs and trading volume to decline. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be classified as a passive foreign investment company, or a PFIC, in any taxable year and U.S. holders of our ADSs could be
subject to adverse U.S. federal income tax consequences. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Generally, if for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the
production of passive income, including cash, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. The determination of whether we are a PFIC depends on the particular facts and
circumstances (such as the valuation of our assets, including goodwill and other intangible assets, and the characterization of our income, including whether certain research and development tax credits received from the government of the United
Kingdom will constitute gross income, and if they do, whether they will constitute passive income for purposes of the PFIC income test) and may also be affected by the application of the PFIC rules, which are subject to differing interpretations.
Based on our estimated gross income, the average value of our assets, including goodwill and the nature of our active business, we do not expect to be treated as a PFIC for U.S. federal income tax purposes for the taxable year ending
December&nbsp;31, 2017. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are a PFIC, U.S.
holders of our ADSs may be subject to adverse U.S. federal income tax consequences, such as the ineligibility for any preferred tax rates on capital gains or on actual or deemed dividends for individuals who are U.S. holders, having interest apply
to distributions by us and the proceeds of sales of the ADSs, and additional reporting requirements under U.S. federal income tax laws and regulations. Investors should consult their own tax advisors regarding all aspects of the application of the
PFIC rules to our ADSs. For more information related to classification as a PFIC, see &#147;Taxation&#151;Material U.S. Federal Income Tax Consideration&#151;Passive Foreign Investment Company Considerations.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus contains estimates and
forward-looking statements, principally in the sections titled &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business.&#148; Some of the matters discussed
concerning our operations and financial performance include forward-looking statements and estimates within the meaning of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. The words &#147;believe,&#148;
&#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148; and similar words are intended to identify forward-looking statements and estimates. Forward-looking
statements include, but are not limited to, statements about: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the development of Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT STYLE="white-space:nowrap">NUC-7738,</FONT> including
statements regarding the expected initiation, timing, progress and availability of data from our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the potential attributes and benefit of our ProTides and their competitive positions; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to successfully commercialize our ProTides, if approved; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding the use of proceeds from this offering; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our estimates regarding expenses, capital requirements and our need for additional financing; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> new product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potential collaborations; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the duration of our patent portfolio. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that could cause our
actual results of operations, financial condition, liquidity, performance, prospects, opportunities, achievements or industry results, as well as those of the markets we serve or intend to serve, to differ materially from those expressed in, or
suggested by, these forward-looking statements. Factors that could cause actual results, financial condition, liquidity, performance, prospects, opportunities, achievements or industry results to differ materially include, but are not limited to,
those discussed under &#147;Risk Factors&#148; in this prospectus. Additional risks that we may currently deem immaterial or that are not presently known to us could also cause the forward-looking events discussed in this prospectus not to occur.
These forward-looking statements are based on assumptions regarding our present and future business strategies and the environment in which we expect to operate in the future. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forward-looking statements and estimates speak only at the
date they were made, and we undertake no obligation to update or to review any forward-looking statement or estimate because of new information, future events or other factors. Forward-looking statements and estimates involve risks and uncertainties
and are not guarantees of future performance. Our future results may differ materially from those expressed in these forward-looking statements and estimates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In light of the risks and uncertainties described above, the forward-looking statements and estimates discussed in this prospectus might
not occur and our future results and our performance may differ materially from those expressed in these forward-looking statements and estimates due to, inclusive of, but not limited to, the factors mentioned above. Because of these uncertainties,
you should not make any investment decision based on these forward-looking statements and estimates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_6"></A>EXCHANGE RATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fluctuations in the exchange rate between the pound sterling
and the U.S. dollar will affect the U.S. dollar amounts received by owners of the ADSs on conversion of dividends, if any, paid in pound sterling on the ordinary shares and will affect the U.S. dollar price of the ADSs on Nasdaq. The table below
shows the period end, average, high and low exchange rates of U.S. dollars per pound sterling for the periods shown. Average rates are computed by using the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar on the last
business day of each month during the relevant year indicated or each business day during the relevant month indicated. The rates set forth below are provided solely for your convenience and may differ from the actual rates used in the preparation
of our consolidated financial statements included in this prospectus and other financial data appearing in this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Noon Buying Rate</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Period<BR>End</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>High</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Low</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>($ per &pound; 1.00)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Period:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6262</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5924</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5668</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4837</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5578</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5517</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2337</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3444</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4648</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5882</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017 (through September 8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2854</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2585</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">February 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2495</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2583</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">April 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2639</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2905</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2929</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2795</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2628</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">July 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2996</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2851</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">August 2017 </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2952</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2787</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">September 2017 (through September 8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3073</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2972</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The average of the noon buying rate for pounds sterling on the last day of each full month during the relevant year or each business day during the relevant month
indicated. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September 8, 2017,
the noon buying rate of the Federal Reserve Bank of New York for the U.S. dollar was &pound;1.00 to $1.3211. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_7"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that we will receive total estimated net proceeds
from this offering of approximately $90.7&nbsp;million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their over-allotment option in full, we estimate that the net
proceeds to us from this offering will be approximately $104.7&nbsp;million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We intend to use the net proceeds we receive from this offering, together with our existing cash and cash equivalents, as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approximately $38.0 to $50.0 million to further the development of Acelarin, including (i) completing an ongoing Phase 2 trial, completing a planned
Phase 2 trial in combination with Avastin, and initiating a planned Phase 3 trial in combination with carboplatin, each in patients with ovarian cancer, (ii) completing an ongoing Phase 1b trial in combination with cisplatin and initiating a planned
Phase 3 trial in combination with cisplatin, each in patients with biliary cancer, and (iii) funding the ongoing Phase III trial in pancreatic cancer that is being facilitated by The National Cancer Research Institute in the United Kingdom;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approximately $28.0 to $35.0 million to further the development of NUC-3373, including (i) completing a Phase 1 trial in patients with advanced solid
tumors, (ii) completing a Phase 1b trial and initiating a Phase 3 trial, each in patients with colorectal cancer, and (iii) completing a Phase 2 trial in patients with breast cancer; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approximately $3.0 to $4.0 million to further the development of NUC-7738, including completing a Phase 1 trial in patients with solid tumors and a
Phase 1 trial in patients with hematological malignancies; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the remaining proceeds to fund other research and development activities, working capital and other general corporate purposes, including costs and
expenses of being a public company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This expected use of the net proceeds from this offering and our existing cash and cash equivalents represents our intentions based upon our current plans and business conditions, which could change in
the future as our plans and business conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development and commercialization efforts, the status of
and results from clinical trials, any collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs. Moreover, our estimates of the costs to fund our trials are based on the current designs of the
trials. If we were to modify the design of any of these trials, for instance, to increase the number of patients in the trials, our costs to fund the trials could increase. As a result, our management will retain broad discretion over the allocation
of the net proceeds from this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on
our planned use of the net proceeds of this offering and our current cash and cash equivalents, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements at least through the
first quarter of 2020. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pending specific utilization of the net proceeds as described
above, we intend to invest the net proceeds from this offering in short- and intermediate-term interest-bearing obligations and certificates of deposit. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_8"></A>DIVIDENDS AND DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since our incorporation, we have not declared or paid any
dividends on any class of our issued share capital. We intend to retain any earnings for use in our business and do not currently intend to pay dividends on our ordinary shares. The declaration and payment of any future dividends will be at the
discretion of our board of directors and will depend upon our results of operations, cash requirements, financial condition, contractual restrictions, any future debt agreements or applicable laws and other factors that our board of directors may
deem relevant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_9"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents our total capitalization and
cash and cash equivalents as of June&nbsp;30, 2017 on: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a pro forma basis to give effect to the automatic conversion, immediately prior to the completion of this offering, of all issued series A convertible
participating shares, series B convertible participating shares, founder ordinary 1 shares and founder ordinary 2 shares into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a pro forma as adjusted basis to give further effect to the sale by us of 6,667,000 ADSs in this offering at the initial public offering price of
$15.00 per ADS after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read this table in conjunction with our unaudited consolidated financial statements, audited consolidated financial statements
and related notes appearing elsewhere in this prospectus and &#147;Exchange Rate Information,&#148; &#147;Use of Proceeds,&#148; &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of June 30, 2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro Forma</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma&nbsp;as<BR>Adjusted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity attributable to equity holders:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Founder ordinary 1 shares, nominal value &pound;0.04 per share, 1,000,000 shares issued and outstanding, actual; no shares issued
and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Founder ordinary 2 shares, nominal value &pound;0.04 per share, 1,000,000 shares issued and outstanding, actual; no shares issued
and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A convertible participating shares, nominal value &pound;0.04 per share, 7,483,334 shares issued and outstanding, actual;
no shares issued and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B convertible participating shares, nominal value &pound;0.004 per share, 8,462,500 shares issued and outstanding, actual;
no shares issued and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ordinary shares, nominal value &pound;0.04 per share, 6,238,807 shares issued and outstanding, actual; 24,184,641 shares issued
and outstanding, pro forma; and 30,881,641 shares issued and outstanding, pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,234</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share premium</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share option reserve</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(28,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital reserve(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Own share reserve</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign currency translation reserve</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The capital reserve balance arose from the reduction of our share premium account and corresponding increase to our capital reserve account reflected as of
June&nbsp;30, 2017 in connection with our re-registration as a public limited company, as further described in footnote&nbsp;10 to the unaudited consolidated interim financial statements. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of our ordinary shares to be outstanding
immediately after this offering is based on 24,184,641 of our shares outstanding as of June 30, 2017, and gives effect to the automatic conversion, immediately prior to the completion of this offering, of all issued series A convertible
participating shares, series B convertible participating shares, founder ordinary 1 shares and founder ordinary 2 shares into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The outstanding share information excludes:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,233,937 ordinary shares issuable upon exercise of outstanding options under our equity compensation plans as of June&nbsp;30, 2017 at a weighted
average exercise price of &pound;0.71 per share; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,000 ordinary shares issued upon exercise of options under our equity incentive plans subsequent to June 30, 2017 at an exercise price of &pound;4.00
per share; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,261,783 ordinary shares issuable upon exercise of outstanding options under our equity incentive plans that were granted after June 30, 2017 at a
weighted average exercise price of &pound;1.09 per share; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">215,782 ordinary shares issuable upon exercise of options approved for grant under our equity incentive plans as of and in connection with the pricing
of this offering to be issued at an exercise price equal to the initial public offering price per ADS in this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,545,409 ordinary shares authorized for issuance pursuant to future awards under our equity incentive plans. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_10"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you invest in the ADSs, your interest will be diluted to
the extent of the difference between the initial public offering price per ADS and our pro forma net tangible book value per ADS after this offering. Our net tangible book value as of June 30, 2017 was &pound;19.6&nbsp;million, or &pound;3.14 per
ordinary share, equivalent to $4.08 per ordinary share and $4.08 per ADS. Net tangible book value represents the amount of total assets minus intangible assets and total liabilities. Net tangible book value per share represents net tangible book
value divided by the total number of ordinary shares outstanding. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">After giving effect to the automatic conversion, immediately prior to the completion of this offering, of all issued series A convertible participating shares, series B convertible participating shares,
founder ordinary&nbsp;1 shares and founder ordinary&nbsp;2 shares into ordinary shares on a one-for-one basis, our pro forma net tangible book value as of June 30, 2017 would have been &pound;0.81 per ordinary share, equivalent to $1.05 per ordinary
share and $1.05 per ADS. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After giving further
effect to the sale by us of 6,667,000 ADSs in this offering at the initial public offering price of $15.00 per ADS after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted
net tangible book value as of June&nbsp;30, 2017 would have been &pound;2.90 per ordinary share, equivalent to $3.77 per ordinary share and $3.77 per ADS. This represents an immediate increase in pro forma net tangible book value of $2.72 per
ordinary share and ADS to existing shareholders and an immediate dilution in pro forma net tangible book value of $11.23 per ordinary share and ADS to purchasers of ADSs in this offering. The following table presents this dilution to new investors
purchasing ADSs in the offering: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial public offering price per ADS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net tangible book value per ADS as of June 30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decrease per ADS attributable to the pro forma adjustments described above</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.03</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net tangible book value per ADS as of June 30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in pro forma net tangible book value per ADS attributable to this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma as adjusted net tangible book value per ordinary share and ADS after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per ADS to new investors in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters exercise
their over-allotment option in full, the pro forma as adjusted net tangible book value per ADS after the offering would be $4.08, the increase in net tangible book value per ordinary share and ADS to existing shareholders would be $3.03 and the
immediate dilution in net tangible book value per ordinary share and ADS to new investors in this offering would be $10.92. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes, on the pro forma as adjusted basis described above as of
June&nbsp;30, 2017, the differences between the existing shareholders and the new investors in this offering with respect to the number of ordinary shares purchased from us (including ordinary shares underlying ADSs), the total consideration paid to
us and the average price per ordinary share (including ordinary shares underlying ADSs), based on the initial public offering price of $15.00 per ADS before deducting underwriting discounts and commissions and estimated offering expenses payable by
us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ordinary</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Purchased(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Consideration</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average&nbsp;Price<BR>per&nbsp;Ordinary<BR>Share(1)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,184,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,441,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;(2)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,667,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,005,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,851,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">156,446,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Including ordinary shares underlying ADSs. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reflects &pound;43,432,874 translated into U.S.&nbsp;dollars at the noon buying rate of the Federal Reserve Bank of New York on June&nbsp;30, 2017 of &pound;1.00 to
$1.2995. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters
exercise their over-allotment option in full, the percentage of ordinary shares held by existing shareholders will decrease to 76.0% of the total number of ordinary shares outstanding after the offering, and the number of shares held by new
investors will be increased to 7,667,050, or 24.0% of the total number of ordinary shares outstanding after this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The share information above excludes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,233,937 ordinary shares issuable upon exercise of outstanding options under our equity incentive plans, as of June&nbsp;30, 2017 at a weighted
average exercise price of &pound;0.71 per share; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,000 ordinary shares issued upon exercise of options under our equity incentive plans subsequent to June 30, 2017 at a weighted average exercise
price of &pound;4.00 per share; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,261,783 ordinary shares issuable upon exercise of outstanding options under our equity incentive plans that were granted after June 30, 2017 at a
weighted average exercise price of &pound;1.09 per share; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">215,782 ordinary shares issuable upon exercise of options approved for grant under our equity incentive plans as of and in connection with the pricing
of this offering to be issued at an exercise price equal to the initial public offering price per ADS in this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,545,409 ordinary shares authorized for issuance pursuant to future awards under our equity incentive plans. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent these outstanding options or any newly issued
options are exercised, there will be further dilution to the new investors purchasing ADSs in this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_11"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables summarize our consolidated financial
data as of the dates and for the periods indicated. The selected consolidated financial data as of and for the years ended December&nbsp;31, 2015 and 2016 have been derived from our consolidated financial statements, which have been prepared in
accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, and audited in accordance with the standards of the Public Company Accounting Oversight Board (United States)
and included elsewhere in this prospectus. The consolidated financial data as of and for the six months ended June 30, 2016 and 2017 have been derived from our unaudited consolidated interim financial statements included elsewhere in this
prospectus. The unaudited consolidated interim financial statements have been prepared on the same basis as our audited consolidated financial statements and include all normal recurring adjustments that we consider necessary for a fair statement of
our financial position and operating results as of the dates and for the periods presented. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our historical results are not necessarily indicative of the results that may be expected in the future. The following selected consolidated financial data should be read in conjunction with
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements included elsewhere in this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except per share data)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated statement of comprehensive loss data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial public offering related expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange (losses) gains</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive (expense) income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that may be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange differences on translation of foreign operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated statement of financial position data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash, cash equivalents and short-term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,685</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,214</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share premium</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capital reserve(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total equity attributable to equity holders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,960</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,387</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,973</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The capital reserve balance arose from the reduction of our share premium account and corresponding increase to our capital reserve account reflected as of
June&nbsp;30, 2017 in connection with our re-registration as a public limited company, as further described in footnote&nbsp;10 to the unaudited consolidated interim financial statements. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_12"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>You
should read the following discussion and analysis of financial condition and operating results together with the information in &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and the related notes to those
statements included elsewhere in this prospectus. We present our consolidated financial statements in pounds sterling and in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards
Board, or IASB, which may differ in material respects from generally accepted accounting principles in other jurisdictions, including generally accepted accounting principles in the United States, or U.S. GAAP. </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The statements in this discussion regarding industry
outlook, our expectations regarding our future performance, liquidity and capital resources and other <FONT STYLE="white-space:nowrap">non-historical</FONT> statements are forward-looking statements. These forward-looking statements are subject to
numerous risks and uncertainties, including the risks and uncertainties described in the sections titled &#147;Risk Factors.&#148; Our actual results may differ materially from those contained in or implied by any forward-looking statements.
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage biopharmaceutical company focused on
significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these
conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are
developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and <FONT
STYLE="white-space:nowrap">NUC-3373,</FONT> are new chemical entities derived from the nucleoside analogs gemcitabine and <FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> respectively, two widely used chemotherapy agents. Acelarin is
currently being evaluated in three clinical trials across several solid tumor indications, including ovarian cancer, biliary cancer and pancreatic cancer. <FONT STYLE="white-space:nowrap">NUC-3373</FONT> is currently in a Phase 1 trial for the
potential treatment of a wide range of advanced solid tumor cancers. We have retained worldwide rights to these lead product candidates as well as our preclinical product candidates, all of which we refer to as ProTides. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acelarin, our most advanced product candidate, is a ProTide
transformation of gemcitabine. We have begun a Phase 2 trial of Acelarin in patients with platinum-resistant ovarian cancer for which we expect to report interim data in 2018. Acelarin is also being evaluated in another Phase 1b trial in patients
with biliary cancer to determine its optimal dose in combination with cisplatin. We expect to report data from this trial in 2018, after which we plan to commence a multi-national Phase 3 trial. In addition, the National Cancer Research Institute in
the United Kingdom is facilitating a Phase 3 trial of Acelarin for the treatment of patients with pancreatic cancer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">NUC-3373,</FONT> our second product candidate, is a ProTide transformation of the active anti-cancer
metabolite of <FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> or <FONT STYLE="white-space:nowrap">5-FU.</FONT> <FONT STYLE="white-space:nowrap">NUC-3373</FONT> is currently being evaluated in a Phase 1 clinical trial of patients with
advanced solid tumors for which we reported interim data in September 2017. We expect to report final data from this trial in 2018. Contingent on regulatory guidance and other factors, we plan to initiate a number of clinical trials in 2018: a Phase
1b trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in patients with colorectal cancer together with other agents routinely used in <FONT STYLE="white-space:nowrap">5-FU</FONT> combination regimens; a Phase 3 trial in patients with advanced
colorectal cancer; and a Phase 2 trial in patients with advanced breast cancer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">NUC-7738,</FONT> our third product candidate, is a ProTide transformation of cordycepin, a novel nucleoside analog that has shown potent anti-cancer activity in
preclinical studies. We are evaluating <FONT STYLE="white-space:nowrap">NUC-7738</FONT> in preclinical studies and we expect to initiate a Phase 1 clinical trial in 2018. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have any approved products and, as a result, have
not generated any revenue from product sales or otherwise. Our ability to generate revenue sufficient to achieve profitability will depend on our successful </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
development and eventual commercialization of our product candidates, if approved, for one or more of their targeted indications. Since our inception, we have incurred significant operating
losses. For the years ended December&nbsp;31, 2015 and 2016, we incurred net losses of &pound;5.3&nbsp;million and &pound;6.0&nbsp;million, respectively. For the six months ended June 30, 2016 and 2017, we incurred net losses of &pound;3.1 million
and &pound;4.4 million, respectively. As of June 30, 2017, we had an accumulated deficit of &pound;26.6 million. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our
ProTides, and seek regulatory approval and pursue commercialization of our product candidates, if approved. In addition, if we obtain regulatory approval for our product candidates, we expect to incur significant commercialization expenses related
to product manufacturing, marketing, sales and distribution. In addition, we may incur expenses in connection with the <FONT STYLE="white-space:nowrap">in-license</FONT> or acquisition of additional product candidates and the potential clinical
development of any such product candidates. Furthermore, after the closing of this offering, we expect to incur additional costs associated with operating as a foreign private issuer listed on the Nasdaq Global Select Market, or Nasdaq, including
significant legal, accounting, investor relations and other expenses that we did not previously incur as a private company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of these anticipated expenditures, we will need additional financing to support our continuing operations. Until such time as
we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate
additional financing may not be available to us on acceptable terms, or at all. Our inability to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need
to generate significant revenue to achieve profitability, and we may never do so. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the laws of England and Wales in 1997 and commenced business operations in 2008. On August 29, 2017, we re-registered as a public limited company and changed our name from
NuCana BioMed Limited to NuCana plc. Our principal executive offices are located in Edinburgh, United Kingdom. We have raised &pound;43.4&nbsp;million in gross proceeds from investors since our incorporation, of which &pound;33.9&nbsp;million was
raised in our most recent equity financing in 2014, primarily with a number of European and U.S.-based institutional investors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Strategic Licensing Agreements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2009, we entered into a research, collaboration and license agreement with Cardiff University and University College Cardiff
Consultants Ltd., or Cardiff Consultants, which we refer to as the Cardiff Agreement. Under the Cardiff Agreement, we collaborate with Cardiff University in the design, synthesis, characterization and evaluation of phosphoramidate prodrugs, which we
refer to as ProTides, based on certain nucleosides. We are responsible for funding certain work performed by Cardiff University and making other payments, which we expect will total approximately &pound;141,350 in aggregate in 2017. On our filing,
or that of a sublicensee, of patent applications resulting from research under the Cardiff Agreement, we will owe Cardiff Consultants certain immaterial payments. If we or our sublicensees develop and commercialize a product resulting from such
research, we will owe Cardiff Consultants clinical development milestone payments of up to &pound;1,875,000; provided, that such milestone payments are due only with respect to the first product within each nucleoside family to achieve the
milestone. We will also owe Cardiff Consultants royalties equal to a low-single digit percentage on our sales of a product resulting from such research. Should we sublicense our right to commercialize a product resulting from the research, we will
owe Cardiff Consultants a high-single digit percentage of payments received in consideration of the sublicense. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In October 2009, we entered into a license and collaboration agreement with Cardiff ProTides Ltd., or Cardiff ProTides, which agreement
was subsequently amended and restated as an assignment, license and collaboration agreement in March 2012 and was further amended in May 2012, which we refer to as the ProTides Agreement. Under the ProTides Agreement, we collaborated with Cardiff
ProTides in the discovery, drug design </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and in vitro screening of purine and pyrimidine based nucleosides as potential drug candidates. If we or a sublicensee develop one or more products covered by a valid claim of an assigned patent
or patent resulting from Cardiff ProTides&#146; research, such as Acelarin, we will owe Cardiff ProTides up to approximately $4.5 million in development and approval milestone payments in the aggregate for the first such product. Additional
development and approval milestones would be payable for the first additional product in a new nucleoside series covered by a valid claim of an assigned patent or a patent resulting from Cardiff ProTides&#146; research, although the maximum
potential value of such milestone payments is approximately half the value of the milestone payments associated with the first product. We will also owe Cardiff ProTides royalties equal to a percentage in mid- to high-single digits on sales of such
products, subject to reduction under certain circumstances. Royalties on sales by sublicensees are set by formula, which formula would be likely to result in a royalty in the mid-single digits. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Operations Overview </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenues </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have any approved products. Accordingly, we have
not generated any revenue, and we do not expect to generate any revenue from the sale of any products unless and until we obtain regulatory approvals for, and commercialize any of, our product candidates. In the future, we will seek to generate
revenue primarily from product sales and, potentially, regional or global collaborations with strategic partners. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We classify our operating expenses into two categories: research and development expenses and administrative expenses. Personnel costs,
including salaries, benefits, bonuses and share-based payment expense, comprise a significant component of each of these expense categories. We allocate expenses associated with personnel costs based on the function performed by the respective
employees. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development
Expenses</I></B>. The largest component of our total operating expenses since inception has been costs related to our research and development activities, including the preclinical and clinical development of our product candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development costs are expensed as incurred. Our
research and development expense primarily consists of: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs incurred under agreements with contract research organizations, or CROs, and investigative sites that conduct preclinical studies and clinical
trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs related to manufacturing active pharmaceutical ingredients and drug products for preclinical studies and clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">salaries and personnel-related costs, including bonuses, benefits and any share-based payment expense, for our personnel performing research and
development activities or managing those activities that have been <FONT STYLE="white-space:nowrap">out-sourced;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fees paid to consultants and other third parties who support our product candidate development; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">other costs incurred in seeking regulatory approval of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of related office space allocated to our research and development function, materials and equipment; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">payments under our license agreements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The successful development of our product candidates is highly uncertain. Product candidates in later stages of clinical development
generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
expect research and development costs to increase significantly for the foreseeable future as programs progress. However, we do not believe that it is possible at this time to accurately project
total program-specific expenses through commercialization. We are also unable to predict when, if ever, material net cash inflows will commence from our product candidates to offset these expenses. Our expenditures on current and future preclinical
and clinical development programs are subject to numerous uncertainties in timing and cost to completion. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors including:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, rate of progress, results and expenses of our ongoing and future clinical trials, preclinical studies and research and development
activities; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the potential need for additional clinical trials or preclinical studies requested by regulatory agencies; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potential uncertainties in clinical trial enrollment rates or <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">competition with other drug development companies in, and the related expense of, identifying and enrolling patients in our clinical trials and
contracting with third-party manufacturers for the production of the drug product needed for our clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the achievement of milestones requiring payments under <FONT STYLE="white-space:nowrap">in-licensing</FONT> agreements; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any significant changes in government regulation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms and timing of any regulatory approvals; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to market, commercialize and achieve market acceptance for any of our product candidates, if approved. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We track research and development expenses on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis for both clinical-stage and preclinical product candidates. Manufacturing and nonclinical research and development expenses are assigned or allocated
to individual product candidates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Administrative Expenses</I></B>. Administrative expenses consist of personnel costs, allocated expenses and other expenses for
outside professional services, including legal, audit and accounting services. Personnel costs consist of salaries, bonuses, benefits and share-based payment expense. Other administrative expenses include office space-related costs not otherwise
allocated to research and development expense, professional fees and costs of our information systems. We anticipate that our administrative expenses will continue to increase in the future as we increase our headcount to support our continued
research and development and potential commercialization of our product candidates. We also expect to incur additional expenses as a public company, including expenses related to compliance with the rules and regulations of the SEC and Nasdaq,
additional insurance expenses, and expenses related to investor relations activities and other administrative and professional services. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Initial Public Offering Related Expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial public offering, or IPO, related expenses primarily
relates to legal, accounting and other advisors&#146; fees in relation to our anticipated IPO.<B> </B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Foreign Exchange Gains (Losses) </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gains (losses) primarily includes gains
or losses on cash held in U.S. dollars and on advances paid to suppliers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Finance Income </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Finance income relates to interest earned on our cash, cash equivalents and short-term deposits. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Tax Credit </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are subject to corporate taxation in the United Kingdom. Our wholly owned U.S. subsidiary, NuCana, Inc., is
subject to corporate taxation in the United States. Due to the nature of our business, we have generated losses since inception. Our income tax credit recognized represents the sum of the research and development tax credits recoverable in the
United Kingdom and income tax payable in the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a company that carries out extensive research and development activities, we benefit from the U.K. research and development tax credit regime and are able to surrender some of our losses for a cash
rebate of up to 33.35% of expenditures related to eligible research and development projects. Qualifying expenditures largely comprise clinical trial and manufacturing costs, employment costs for relevant staff and consumables incurred as part of
research and development projects. Certain subcontracted qualifying research and development expenditures are eligible for a cash rebate of up to 21.68%. A large portion of costs relating to our research and development, clinical trials and
manufacturing activities are eligible for inclusion within these tax credit cash rebate claims. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may not be able to continue to claim research and development tax credits in the future under the current research and development tax credit scheme when we become a public company because we may no
longer qualify as a small or medium-sized company. However, we may be able to file under a large company scheme. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unsurrendered tax losses are carried forward to be offset against future taxable profits. After accounting for tax credits receivable,
there were accumulated tax losses for carry forward in the United Kingdom of &pound;8.5&nbsp;million as of June&nbsp;30, 2017. There were also temporary differences on share-based compensation arrangements of &pound;31.4&nbsp;million. No deferred
tax asset is recognized in respect of accumulated tax losses or temporary differences on share-based compensation arrangements because future profits are not sufficiently certain. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event we generate revenues in the future, we may
benefit from the new &#147;patent box&#148; initiative that allows profits attributable to revenues from patents or patented products to be taxed at a lower rate than other revenue. The rate of tax for relevant streams of revenue for companies
receiving this relief will be 10%. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Value Added
Tax, or VAT, is charged on all qualifying goods and services by <FONT STYLE="white-space:nowrap">VAT-registered</FONT> businesses. An amount of 20% of goods and services is added to all sales invoices and is payable to the U.K. tax authorities.
Similarly, VAT paid on purchase invoices is reclaimable from the U.K. tax authorities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><I></I><B><I>Comparison of Six Months Ended
June 30, 2016 and 2017 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following
table summarizes the results of our operations for the six month periods ended June 30, 2016 and 2017. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial public offering related expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange (losses) gains</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,462</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive (expense) income:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that may be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange differences on translation of foreign operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><I></I><B><I>Research and Development Expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses were &pound;3.7 million
for the six months ended June 30, 2017 as compared to &pound;3.8 million for the six month period ended June 30, 2016, a decrease of &pound;0.1&nbsp;million, which decrease resulted from differences in the phases of our ongoing research projects.
The following table summarizes the costs incurred for each of our research and development programs for the six month periods ended June&nbsp;30, 2016 and 2017: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acelarin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,361</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,248</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NUC-3373</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">537</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NUC-7738</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">267</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">358</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B><I></I><B><I>Administrative Expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses were &pound;0.6 million for the six
months ended June 30, 2017 as compared to &pound;0.9 million for the six months ended June 30, 2016. The decrease was largely attributable to higher legal fees in 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Initial Public Offering Expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>In the six months ended June 30, 2017, costs of
&pound;1.1 million were incurred, primarily related to legal, accounting and other advisors&#146; fees in connection with our anticipated IPO. There were no such costs in the six months ended June 30, 2016. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Foreign Exchange Gains (Losses) </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the six months ended June 30, 2017, we reported a net
foreign exchange loss of &pound;0.2 million as compared to a net foreign exchange gain of &pound;0.3 million for the six months ended June 30, 2016. In the six months ended June 30, 2017, the loss arose from revaluation of cash balances and advance
supplier payments made in U.S. dollars, which depreciated during the first six months of 2017 relative to the U.K. pound sterling. In the six months ended June 30, 2016, the gain arose primarily from higher average cash balances held in U.S.
dollars, which appreciated during 2016 relative to the U.K. pound sterling. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Finance Income </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Finance income represents bank interest and was &pound;0.1 million for the six months ended June 30, 2017 and &pound;0.2 million for the six months ended June 30, 2016. The decrease in bank interest for
the six month ended June 30, 2017 was primarily due to lower average cash balances as compared to the same period in 2016 as well as lower rates of interest on bank balances. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Tax Credit </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our consolidated effective tax rate for the full year 2017
is estimated to be 19.7%, which is consistently applied to the 2017 interim period. In 2016, our consolidated effective tax rate was 25.9% which is consistently applied to the 2016 interim period. The income tax credit, which is largely comprised of
research and development tax credits, amounted to &pound;1.1 million for both the six months ended June 30, 2016 and 2017. Research and development credits are obtained at a maximum rate of 33.35% of our qualifying research and development expenses.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Comparison of Years Ended December&nbsp;31,
2015 and 2016 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table
summarizes the results of our operations for the years ended December&nbsp;31, 2015 and 2016. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gains (losses) </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss before tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive expense:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that may be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange differences on translation of foreign operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses for the year ended
December&nbsp;31, 2016 were &pound;7.9 million as compared to &pound;5.7&nbsp;million for the year ended December&nbsp;31, 2015, an increase of &pound;2.2&nbsp;million. The increase was attributable to the number and size of clinical trials being
performed in 2016 as compared to 2015 as well as an increase in the number of research and development personnel. The following table summarizes the costs incurred for each of our research and development programs for the years ended December 31,
2015 and 2016: </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acelarin</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,729</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NUC-3373</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,122</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,413</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NUC-7738</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">873</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Administrative Expenses
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses were &pound;1.1
million for the year ended December 31, 2016 as compared to &pound;1.3&nbsp;million for the year ended December&nbsp;31, 2015. This decrease was largely attributable to lower recruitment expenses in 2016 as compared to 2015. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Foreign Exchange Gains (Losses) </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended December&nbsp;31, 2016, we reported a net
foreign exchange gain of &pound;0.6&nbsp;million as compared to a net foreign exchange loss of &pound;8,000 for the year ended December&nbsp;31, 2015. This was primarily from a higher average cash balance being held in U.S. dollars, which
appreciated during 2016 relative to the U.K. pound sterling. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Finance Income </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Finance income represents bank interest and was &pound;0.3 million for the year ended December 31, 2016 and &pound;0.4&nbsp;million for the year ended December 31, 2015. The decrease in bank interest for
2016 was primarily due to lower average cash balances in 2016 as compared to 2015. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Tax Credit </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The income tax credit, which is largely comprised of research and development credits, amounted to &pound;2.1&nbsp;million for the year ended December&nbsp;31, 2016 as compared to &pound;1.2&nbsp;million
for the year ended December&nbsp;31, 2015, an increase in the net credit amount of &pound;0.9&nbsp;million. Research and development credits are obtained at a maximum rate of 33.35% of our qualifying research and development expenses, and the
increase in the net credit was primarily attributable to an increase in our eligible research and development expenses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since our inception, we have incurred significant operating losses and negative cash flows. We anticipate that we will continue to incur
losses for at least the next several years. We expect that our research and development and administrative expenses will increase in connection with conducting clinical trials and seeking marketing approval for our product candidates, as well as
costs associated with operating as a public company. As a result, we will need additional capital to fund our operations, which we may obtain from additional equity financings, debt financings, research funding, collaborations, contract and grant
revenue or other sources. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2016 and June 30, 2017, we had cash and cash equivalents of
&pound;20.0&nbsp;million and &pound;15.9&nbsp;million, respectively. As of December 31, 2015, we had cash, cash equivalents and short-term deposits of &pound;29.2 million. We do not currently have any approved products and have never generated any
revenue from product sales or otherwise. To date, we have financed our operations primarily through the issuances of our equity securities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no ongoing material financing commitments, such as lines of credit or guarantees, that are expected to affect our liquidity over
the next five years, other than operating leases. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash Flows </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the results of our cash flows for the six months ended June 30, 2016 and 2017. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,670</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash (used in) provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash from financing activities </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating
activities</I></B>. The decrease in net cash used in operating activities to &pound;3.7 million for the six months ended June 30, 2017 from &pound;4.4 million for the six months ended June 30, 2016 was primarily due to the utilization of advance
payments made during 2016 to two vendors to manufacture drug substance and to manage our clinical trials, and the receipt of a research and development tax credit. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investing activities</I></B>. The decrease in cash
relating to investing activities of &pound;5.6&nbsp;million from the six months ended June&nbsp;30, 2016 to June&nbsp;30, 2017 is primarily due to proceeds from maturing deposits of &pound;5.1&nbsp;million, received in the six months ended
June&nbsp;30, 2016. The six months ended June&nbsp;30, 2017 also included higher acquisition payments in respect of intangible assets. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the results of our cash flows for the years ended December&nbsp;31, 2015 and 2016. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash (used in) provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash from financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,648</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating
activities</I></B>. The increase in net cash used in operating activities to &pound;9.3&nbsp;million for the year ended December&nbsp;31, 2016 from &pound;4.5&nbsp;million for the year ended December&nbsp;31, 2015 was primarily due to advance
payments made during 2016 to two vendors to manufacture drug substance and to manage our clinical trials and an increase in the research and development tax credit receivable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investing activities</I></B>. Net cash used in
investing activities was &pound;0.2 million for the year ended December 31, 2015. Net cash provided by investing activities was &pound;14.9 million for the year ended December 31, 2016. This change was primarily due to an increase in proceeds from
maturing deposits. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Financing activities</I></B>. The increase in net cash from financing activities to
&pound;0.2&nbsp;million for the year ended December&nbsp;31, 2016 from zero for the year ended December&nbsp;31, 2015 was due to proceeds received from the issuance of ordinary shares upon the exercise of share options. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating and Capital Expenditure Requirements
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not achieved profitability on a
quarterly or annual basis since our inception, and we expect to incur net losses in the future. We expect that our operating expenses will increase as we continue to invest to grow our ProTide pipeline, hire additional employees and increase
research and development expenses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally,
as a public company, we will incur significant audit, legal and other expenses that we did not incur as a private company. We believe that our existing capital resources, including the net proceeds from this offering, will be sufficient to fund our
operations, including currently anticipated research and development activities and planned capital spending, at least through the first quarter of 2020. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future funding requirements will depend on many factors, including but not limited to: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, rate of progress and cost of our clinical trials, preclinical programs and other related activities; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent of success in our early preclinical and clinical stage research programs, which will determine the amount of funding required to further the
development of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the progress that we make in developing new product candidates based on our proprietary ProTide technology; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any products that we may develop;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs involved in filing and prosecuting patent applications and enforcing and defending potential patent claims; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the outcome, timing and cost of regulatory approvals of our ProTide product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost and timing of establishing sales, marketing and distribution capabilities; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs of hiring additional skilled employees to support our continued growth and the related costs of leasing additional office space.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations and Commitments
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our
contractual commitments and obligations as of December 31, 2016. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Payments Due by Period</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Less&nbsp;than<BR>1&nbsp;year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1 - 3<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>3 - 5<BR>years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>More&nbsp;than<BR>5&nbsp;years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating lease obligations
relate to rental of office space. As of June&nbsp;30, 2017, we had operating lease obligations of &pound;50,140, which are due in less than one year. On August&nbsp;11, 2017 and August&nbsp;31, 2017, we entered into new lease obligations for office
space. The lease obligations are for a period of five years with a break clause after three years. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have agreed to make milestone payments and pay royalties and annual maintenance fees to third parties under various licensing and related agreements and we have agreed to make payments to CROs and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
manufacturers under various CRO and manufacturing agreements. We have not included any such contingent payment obligations in the table above as the amount, timing and likelihood of such payments
are not fixed or determinable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have variable interests in variable interest
entities or any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Quantitative and Qualitative Disclosures about Market Risk </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Market risk arises from our exposure to fluctuation in interest rates and currency exchange rates. These risks are managed by maintaining
an appropriate mix of cash deposits in the two main currencies we operate in, placed with a variety of financial institutions for varying periods according to expected liquidity requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Interest Rate Risk </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June 30, 2017, we had cash and cash equivalents of
&pound;15.9&nbsp;million. As of December 31, 2016, we had cash and cash equivalents of &pound;20.0&nbsp;million. Our exposure to interest rate sensitivity is impacted primarily by changes in the underlying U.K. bank interest rates. Our surplus cash
and cash equivalents are invested in interest-bearing savings accounts and certificates of deposit from time to time. We have not entered into investments for trading or speculative purposes. Due to the conservative nature of our investment
portfolio, which is predicated on capital preservation of investments with short-term maturities, an immediate one percentage point change in interest rates would not have a material effect on the fair market value of our portfolio, and therefore we
do not expect our operating results or cash flows to be significantly affected by changes in market interest rates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Currency Risk </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our functional currency is U.K. pounds sterling, and our transactions are commonly denominated in that currency. However, we incur a
portion of expenses in other currencies, primarily U.S. dollars, and are exposed to the effects of this exchange rate. Since <FONT STYLE="white-space:nowrap">mid-2016,</FONT> there has been significantly increased volatility in the exchange rate
between the pound sterling and the U.S. dollar and an overall weakening of the pound sterling related to Britain&#146;s exit from the European Union. Although we are based in the United Kingdom, we source our active pharmaceutical ingredient, or
API, and other raw materials and our research and development, manufacturing, consulting and other services worldwide, including from the United States, the European Union and India. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any weakening of the pound sterling against the currencies of such other jurisdictions makes the purchase of
such goods and services more expensive for us. We seek to minimize this exposure by maintaining currency cash balances at levels appropriate to meet foreseeable short to <FONT STYLE="white-space:nowrap">mid-term</FONT> expenses in these other
currencies. We do not use forward exchange contracts to manage exchange rate exposure. A 1% increase in the value of the pound sterling relative to the U.S. dollar would not have had a material effect on the carrying value of our net financial
assets and liabilities in foreign currencies at December&nbsp;31, 2016 or at June&nbsp;30, 2017. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies, Judgments and Estimates </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the application of our accounting policies, we are required to make judgments, estimates, and assumptions about the value of assets and
liabilities for which there is no definitive third-party reference. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. We
review our estimates and assumptions on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revisions and future periods
if the revision affects both current and future periods. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following are our critical judgments that we have made in the process of applying our accounting policies and that have the most significant effect on the amounts recognized in our consolidated
financial statements included elsewhere in this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recognition of Clinical Trial Expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of the process of preparing our consolidated
financial statements, we may be required to estimate accrued expenses related to our clinical trials. In order to obtain reasonable estimates, we review open contracts and purchase orders. In addition, we communicate with applicable personnel in
order to identify services that have been performed, but for which we have not yet been invoiced. In most cases, our vendors provide us with monthly invoices in arrears for services performed. We confirm our estimates with these vendors and make
adjustments as needed. The following are examples of our accrued expenses: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fees paid to CROs for services performed on preclinical studies and clinical trials; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fees paid for professional services. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-Based Payments </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We award share options to certain of our employees, directors and consultants as part of their compensation. All of these compensation
arrangements are settled in equity at a predetermined price and generally vest over a period of three to four years. All share options have a term of 10 years before expiration. We measure share-based awards at the grant date based on the fair value
of the award and we recognize it as a compensation expense over the vesting period with a corresponding increase in reserves. We determine the fair value of our share options using the Black-Scholes option-pricing model. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In future periods, we expect our share-based payment expense
to increase due in part to our existing unrecognized share-based payment expenses and the grant of additional share-based awards to continue to attract, incent and retain our employees, directors and consultants. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Valuation of Share Options</I></B>. The Black-Scholes
option pricing model requires the input of subjective assumptions, including assumptions about the expected life of share-based awards and share price volatility. In addition, as a privately held company, one of the most subjective inputs into the
Black-Scholes option pricing model is the estimated fair value of our ordinary shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a privately held company, our share price does not have sufficient historical volatility for us to adequately assess the fair value of the share option grants. As a result, our management considered
the historical volatility of other comparable publicly traded companies and, based on this analysis, concluded that a volatility range of 60.92% to 69.05% was appropriate for the valuation of our share options. We intend to continue to consistently
apply this methodology using the same comparable companies until a sufficient amount of historical information regarding the volatility of our own share price as a public company becomes available. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expected life of the option, beginning with the option
grant date, was used in valuing our share options. The expected life used in the calculation of share-based payment expense is the time from the grant date to the expected exercise date. The life of the options depends on the option expiration date,
volatility of the underlying shares and vesting features. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">IFRS 2, <I>Share-based Payment</I>, requires the use of the risk-free interest rate of the country in which the entity&#146;s shares are principally traded, with a remaining term equal to the expected
life of the option. The third-party valuation firm applied the appropriate risk-free rate using the Bank of England&#146;s estimates of gilt <FONT STYLE="white-space:nowrap">zero-coupon</FONT> yield curve as at the respective share option grant
dates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Valuation of Ordinary
Shares</I></B>. There are significant judgments and estimates inherent in the determination of the fair value of our ordinary shares. These judgments and estimates include assumptions regarding our future operating performance, the likelihood and
time to complete an IPO or other liquidity event, the related company valuations associated with such events, and the determinations of the appropriate valuation methods. If we had made different assumptions, our share-based payment expense, loss
for the year and total comprehensive loss, on both an absolute and <FONT STYLE="white-space:nowrap">per-share</FONT> basis, could have been significantly different. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In conducting our valuations, we considered all objective and subjective factors that we
believed to be relevant for each valuation conducted, including our best estimate of our business condition, prospects, and operating performance at each valuation date. Within the valuations performed, a range of factors, assumptions, and
methodologies were used. The significant factors considered included: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the lack of an active public market for our ordinary shares, as well as our series A and series B convertible participating preferred shares;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the prices of our series A and series B convertible participating preferred shares that we had sold to outside investors in arm&#146;s length
transactions, and the rights, preferences and privileges of the series A and series B convertible participating preferred shares relative to our ordinary shares; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the data generated from our research and development programs and financial condition; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the material risks related to our business and industry; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our business strategy; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the market performance of publicly traded companies in the life sciences and biotechnology sectors; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the likelihood of achieving a liquidity event for the holders of our ordinary shares, such as an IPO, given prevailing market conditions.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2016, we issued share
options on June&nbsp;30, August&nbsp;22, October&nbsp;28 and December 12. These share options were awarded based on the underlying share price of &pound;4.00 per ordinary share. We made contemporaneous estimates of the valuation of the share price,
which for share options issued in 2016 was retrospectively revalued upon contemplation of this offering. After considering the market approach, the income approach and the asset-based approach, we utilized the market approach to determine the
estimated fair value of our ordinary shares based on its determination that this approach was most appropriate for a clinical-stage biopharmaceutical company at this point in its development. Consideration was given to the American Institute of
Certified Public Accountants&#146; Practice Aid: &#147;Valuation of Privately-Held Company Equity Securities Issued as Compensation,&#148; or the Practice Aid, in addition to input from management, the likelihood of completing an IPO and recent
transactions with investors. Once a public trading market for our ordinary shares (in the form of ADSs) has been established in connection with the completion of this offering, it will no longer be necessary to estimate the fair value of our
ordinary shares in connection with our accounting for share-based payment expenses, as the fair value of our ordinary shares will be determinable by reference to the trading price of our ADSs on Nasdaq. The retrospective valuation dates for
June&nbsp;30, 2016, August&nbsp;22, 2016, October&nbsp;28, 2016 and December&nbsp;12, 2016 resulted in valuations of our ordinary shares of &pound;6.97, &pound;8.61, &pound;8.76 and &pound;9.19 per share, respectively, as of those dates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ordinary share valuations were prepared using the
guideline public company, or GPC, method under the market approach. In the application of the&nbsp;GPC method, we considered the pricing of IPOs completed by clinical-stage oncology companies between April 2015 and May 2016. We converted prospective
IPO value to present value by applying a discount rate of 25%. The discount rate was derived from studies of rates of return required by venture investors in <FONT STYLE="white-space:nowrap">IPO-stage</FONT> companies. In addition to the IPO GPCs,
we considered the enterprise values indicated by a group of eight trading GPCs. The trading prices of these clinical-stage GPCs provided contemporaneous indications of value as of each appraisal date. We applied a discount for lack of marketability
to the ordinary shares to account for the lack of access to an active public market. We estimated the discount for lack of marketability using an Asian put model. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the six months ended June 30, 2017, we issued share
options on May 16. These share options were awarded based on the underlying share price of &pound;11.08 per ordinary share. We made contemporaneous estimates of the valuation of the share price using the same methodology described above and updated
for pricing of initial public offerings completed by clinical stage oncology companies between April 2015 and May 2017. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes by grant date the number of ordinary shares subject to options granted between January&nbsp;1, 2016 and
June 30, 2017, the per share purchase or exercise prices, the fair value of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
ordinary shares on the dates of grant, the <FONT STYLE="white-space:nowrap">re-assessed</FONT> fair value of the ordinary shares on the dates of grant, if applicable, and the estimated fair value
per option utilized to calculate share-based payment expense. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>options&nbsp;granted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise&nbsp;price&nbsp;per<BR>share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;value&nbsp;of<BR>ordinary&nbsp;share&nbsp;at<BR>grant date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Re-assessed</FONT><BR>fair&nbsp;value&nbsp;of<BR>ordinary&nbsp;
share<BR>at&nbsp;grant date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated&nbsp;fair<BR>value per<BR>option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June 30, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">270,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug. 22, 2016 </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug. 22, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug. 22, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug. 22, 2016 </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug. 22, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug. 22, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct. 28, 2016 </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct. 28, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dec. 12, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 16, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">n/a</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsequent to June 30, 2017
and prior to the date of this prospectus, we granted options under our equity incentive plans for 1,261,783 ordinary shares at a weighted average exercise price of &pound;1.09 per share. We intend to assess the fair value of these options grants for
financial reporting purposes, and the associated share-based expense to be recorded, by reference to the initial public offering price per ADS in this offering. We have also approved for grant as of and in connection with this offering options under
our equity incentive plans for 215,782 ordinary shares to be issued at an exercise price equal to the initial public offering price per ADS in this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The initial public offering price set forth on the cover of this prospectus, $15.00 per ADS, was determined as a result of negotiations
between us and the underwriters. As is typical in initial public offerings, the initial public offering price was not derived using a formal determination of fair value, but was determined by negotiation between us and the underwriters. Among the
factors that were considered in setting this price were the following: (i) the history and prospects for the industry in which we compete; (ii) our financial information; (iii) the ability of our management and our business potential and earning
prospects; (iv) the prevailing securities markets at the time of this offering; and (v) the recent market prices of, and the demand for, publicly traded shares of generally comparable companies. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Deferred Tax and Current Tax Credits
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax on the profit or loss for the year
comprises current and deferred tax. Tax is recognized in the statement of operations, except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable on
the taxable income or loss for the year, using tax rates enacted or substantively enacted at the balance sheet date, and any adjustment to tax payable in respect of previous years. Tax credits are accrued for the year based on calculations that
conform to the U.K. research and development tax credit regime applicable to small and medium-sized companies. We may not be able to continue to claim research and development tax credits in the future under the current research and development tax
credit scheme, when we become a U.S. public company because we may no longer qualify as a small or medium-sized company. However, we may be able to file under a large company scheme. Deferred tax is recognized on temporary differences between the
carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The amount of deferred tax is based on the expected manner of realization or settlement of the carrying amount of assets and
liabilities, using tax rates enacted or substantively enacted at the balance sheet date. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the asset can be utilized.
No deferred tax assets are recognized on our losses carried forward because there is currently no indication that we will make sufficient profits to utilize these tax losses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The International Accounting Standards Board, or IASB, and International Financial Reporting Interpretations
Committee, or IFRIC, have issued the following standards and interpretations, which are considered relevant to us, with an effective date after December 31, 2017. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Effective Date</B></FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 9: Financial Instruments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2018</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16: Leases</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2019</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendments to IFRS 2: Classification and Measurement of Share-based Payment Transactions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2018</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Improvements to IFRSs 2014-2016 Cycle</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1,&nbsp;2018</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRIC Interpretation 22 Foreign Currency Transactions and Advance Consideration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;1, 2018</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will adopt these standards
and interpretations in accordance with their effective dates. See Note 2 &#147;Significant Accounting Policies&#151;Accounting Standards&#148; of the notes to our audited consolidated financial statements for the year ended December 31, 2016
included elsewhere in this prospectus for more information. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jumpstart Our Business Startups Act of 2012 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2012, the U.S. Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107(b) of the JOBS Act provides
that an &#147;emerging growth company,&#148; or EGC, can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those
standards would otherwise apply to private companies. Given that we currently report and expect to continue to report under IFRS as issued by the IASB, we have irrevocably elected not to avail ourselves of this extended transition period, and, as a
result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to rely on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an EGC, we
may rely on certain of these exemptions, including exemptions from (1)&nbsp;providing an auditor&#146;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and
(2)&nbsp;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and
the financial statements, known as the auditor discussion and analysis. We will remain an EGC until the earliest of (a)&nbsp;the last day of our fiscal year during which we have total annual gross revenue of at least $1.07&nbsp;billion; (b)&nbsp;the
last day of our fiscal year following the fifth anniversary of the completion of this offering; (c)&nbsp;the date on which we have, during the previous three-year period, issued more than $1.0&nbsp;billion in
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt; or (d)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; under the Securities Exchange Act of 1934, as amended, which would occur if the market value of our
equity securities that are held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the last business day of our most recently completed second fiscal quarter. Once we cease to be an EGC, we will not be entitled
to the exemptions provided in the JOBS Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_13"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for
cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care
for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key
cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine
and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in three clinical trials across several solid tumor indications, including ovarian cancer, biliary cancer and pancreatic cancer. NUC-3373 is
currently in a Phase&nbsp;1 trial for the potential treatment of a wide range of advanced solid tumor cancers. We have retained worldwide rights to these lead product candidates as well as our preclinical product candidates, all of which we refer to
as ProTides. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acelarin, our most advanced product
candidate, is a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> ProTide that has been evaluated in over 140 patients. Acelarin is a ProTide transformation of gemcitabine that we believe could
replace gemcitabine in certain cancer indications and have utility across a range of other cancers. In a Phase 1 dose-ranging trial in 49 evaluable patients with advanced metastatic solid tumors, Acelarin was well tolerated, achieved a 78% disease
control rate and was associated with intracellular levels of active anti-cancer metabolite over 200 times higher than those reported for gemcitabine. A subset of 14 evaluable patients with relapsed/refractory gynecological cancers achieved a 93%
disease control rate. In a Phase 1b dose-ranging trial in 23&nbsp;evaluable patients with recurrent ovarian cancer, Acelarin was combined with carboplatin and achieved a 96% disease control rate. Based on these disease control rates and the
tolerability profile,&nbsp;we have begun a Phase&nbsp;2 trial of Acelarin in patients with platinum-resistant ovarian cancer for which we expect to report interim data in 2018.&nbsp;Acelarin is also being evaluated in another Phase 1b trial in
patients with biliary cancer to determine its optimal dose in combination with cisplatin. We expect to report data from this trial in 2018, after which we plan to commence a multi-national Phase 3 trial.&nbsp;In addition, the National Cancer
Research Institute in the United Kingdom is facilitating a Phase 3 trial of Acelarin for the treatment of patients with pancreatic cancer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">NUC-3373,</FONT> our second product candidate, is a ProTide transformation of the active anti-cancer
metabolite of <FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> or <FONT STYLE="white-space:nowrap">5-FU,</FONT> which we believe has the potential to replace <FONT STYLE="white-space:nowrap">5-FU</FONT> as the standard of care in the
treatment of a wide range of cancers. In preclinical studies, we observed that <FONT STYLE="white-space:nowrap">NUC-3373</FONT> overcame the key resistance mechanisms associated with <FONT STYLE="white-space:nowrap">5-FU</FONT> and generated
intracellular levels of active anti-cancer metabolite over 300 times higher than that of <FONT STYLE="white-space:nowrap">5-FU.</FONT> <FONT STYLE="white-space:nowrap">NUC-3373</FONT> is currently being evaluated in a Phase 1 clinical trial of
patients with advanced solid tumors for which we reported interim data in September 2017. We expect to report final data from this trial in 2018. Contingent on regulatory guidance and other factors, we plan to initiate a number of clinical trials in
2018: a Phase 1b trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in patients with colorectal cancer together with other agents routinely used in <FONT STYLE="white-space:nowrap">5-FU</FONT> combination regimens; a Phase 3 trial in patients
with advanced colorectal cancer; and a Phase 2 trial in patients with advanced breast cancer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">NUC-7738,</FONT> our third product candidate, is a ProTide transformation of cordycepin, a novel nucleoside analog that has shown potent anti-cancer activity in
preclinical studies. We are evaluating <FONT STYLE="white-space:nowrap">NUC-7738</FONT> in preclinical studies and we expect to initiate a Phase 1 clinical trial in 2018. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite the widespread use of nucleoside analogs, their
efficacy is severely limited by cancer cell resistance mechanisms and they are often poorly tolerated. Harnessing the power of phosphoramidate chemistry, we convert nucleoside analogs into activated nucleotide analogs with the addition of a
phosphate group, which is protected by specific combinations of aryl, ester and amino acid groupings. By adding and protecting this </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
phosphate group, we design our ProTides to avoid or overcome key cancer resistance mechanisms in the uptake, activation and breakdown of nucleoside analogs. As a result, we believe our ProTides
have the potential to generate hundreds of times higher concentrations of the active anti-cancer metabolites inside tumor cells, potentially making our ProTides more effective than the current standards of care. Because our ProTides resist
breakdown, and are thus more stable, we believe they are also able to reduce or eliminate the generation of toxic byproducts that can result from the breakdown of nucleoside analogs like gemcitabine and <FONT STYLE="white-space:nowrap">5-FU.</FONT>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our proprietary ProTide technology was invented
in the Cardiff University laboratory of our late Chief Scientific Officer, Professor Christopher McGuigan, who conceived of, and filed the original composition of matter patents for our initial ProTides. The unique feature of his discovery was the
specific combination of aryl, ester and amino acid groupings that protect the activated, or phosphorylated, nucleoside analog. This phosphoramidate chemistry approach is the key to the ProTide technology. Every ProTide grouping is distinct, and
Professor McGuigan and his team synthesized and tested thousands of compounds in order to identify the optimal ProTide grouping for each underlying nucleoside analog. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We have licensed what we believe to be
the foundational patent estate for the application of phosphoramidate chemistry in oncology. We have granted patents in key markets, including the United States, Europe and Japan, protecting the composition of matter of Acelarin, NUC-3373 and other
of our product candidates. Professor McGuigan&#146;s work preceded and helped lead to the development of several FDA-approved anti-viral drugs containing nucleotide analogs, including: sofosbuvir, or Sovaldi<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, which is also a key component of Harvoni<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>; and tenofovir alafenamide fumarate, or TAF, which is a key component of Genvoya<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, Descovy<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Odefsey<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are led by Hugh S. Griffith, our founder and Chief Executive Officer, who brings over 25 years of experience in the biopharmaceutical
industry including at Abbott Laboratories (now AbbVie Inc.) and Parke-Davis Warner Lambert (now Pfizer Inc.). Before founding NuCana, he led the operations of Bioenvision, Inc. from <FONT STYLE="white-space:nowrap">start-up</FONT> through its
acquisition by Genzyme Corporation. While at Bioenvision, he was instrumental in developing and commercializing clofarabine, a nucleoside analog for the treatment of pediatric leukemia. We are backed by leading life sciences investors, including
Sofinnova Partners, Sofinnova Ventures, Morningside Group and Scottish Enterprise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our goal is to transform standards of care and improve survival for patients across a wide range of cancer indications. Our strategy includes the following key components: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rapidly develop Acelarin as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> nucleotide analog for
the treatment of patients with cancer</B>. We believe that Acelarin has the potential to replace the core chemotherapy component of treatment regimens for patients with various cancers, including: </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Platinum-resistant ovarian cancer. </I>We expect to report data from a Phase 2 trial of Acelarin in 2018. We also intend to explore the use of
Acelarin in combination with Avastin, a widely used agent in the treatment of several cancers, and expect to report data from this trial in 2018. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Platinum-sensitive ovarian cancer. </I>Contingent on regulatory guidance and other factors, we expect to commence a Phase 3 trial of Acelarin in
combination with carboplatin for this indication in 2018. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Biliary cancer. </I>We expect to report data from a Phase 1b trial of Acelarin in combination with cisplatin in 2018. Contingent on regulatory
guidance and other factors, we plan to commence a Phase&nbsp;3 trial of Acelarin in combination with cisplatin as a first-line treatment in 2018. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pancreatic cancer. </I>The National Cancer Research Institute in the United Kingdom is facilitating a Phase&nbsp;3 trial of Acelarin as a first-line
treatment compared to gemcitabine. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rapidly develop <FONT STYLE="white-space:nowrap">NUC-3373</FONT> to replace <FONT STYLE="white-space:nowrap">5-FU</FONT> as the standard of care for
the treatment of patients with various cancers</B>. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Advanced solid tumors</I>. We expect to report final data from a Phase 1 trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in patients with
advanced solid tumors in 2018. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Colorectal cancer</I>. We plan to establish the optimal dose of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in combination with other agents in
a Phase&nbsp;1b trial in 2018. Contingent on regulatory guidance and other factors, we also intend to initiate a Phase 3 trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> monotherapy in 2018. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Breast cancer</I>. We intend to conduct a Phase 2 trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> compared to capecitabine, the oral
version of <FONT STYLE="white-space:nowrap">5-FU,</FONT> in patients with recurrent breast cancer and anticipate reporting interim data from this trial in 2018. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rapidly advance <FONT STYLE="white-space:nowrap">NUC-7738</FONT> into clinical trials</B>.<B> </B><FONT STYLE="white-space:nowrap">NUC-7738,</FONT>
a ProTide based on a novel nucleoside analog, is currently undergoing preclinical studies and we expect to initiate a Phase 1 trial in 2018 for solid tumors. In addition, we plan to develop <FONT STYLE="white-space:nowrap">NUC-7738</FONT> for the
treatment of hematological malignancies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Leverage our proprietary ProTide technology platform to develop additional product candidates</B>. We are pursuing both the transformation of
well-established and widely used nucleoside analogs as well as novel nucleoside analogs, which we believe have the potential to address additional areas of unmet medical need in oncology. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Continue to strengthen our intellectual property position</B>. We own or have exclusive rights to the core technologies underlying our ProTide
technology platform. We have granted patents in key markets, including the United States, Europe and Japan, protecting the composition of matter of Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and other of our product candidates. We
intend to further expand and enhance our intellectual property position. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Build a focused commercial organization</B>. We have worldwide rights to all product candidates that we are developing. We believe that many of the
cancers we are initially targeting with our ProTides can be addressed by a focused sales and marketing team. We plan to commercialize any product candidates for which we receive regulatory marketing approval using a specialized sales force in the
United States and Europe. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Pipeline </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We take a scientifically driven approach to designing
ProTides, which we believe have the potential to result in highly efficacious cancer therapies with improved tolerability. Our pipeline of product candidates is summarized below. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g80f34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cancer and the Need for Improved
Treatment Options </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancer is the second
leading cause of death in the United States, with approximately 1.7&nbsp;million new cases and 600,000 deaths expected in 2017 according to the American Cancer Society. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The medical treatment of cancer can be divided into three
major categories: surgery, radiotherapy and therapeutics. Therapeutics include chemotherapy, immunotherapy, and targeted and hormonal agents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The backbone of treatment for patients with cancer consists of chemotherapeutics, which generated sales of $20.6&nbsp;billion worldwide in
2016. These therapies exert their effects by killing cancer cells or preventing them from replicating. Within the larger universe of chemotherapy, nucleoside analogs, such as gemcitabine and <FONT STYLE="white-space:nowrap">5-FU,</FONT> play a
significant role. Nucleoside analogs have been in clinical use for over 50 years and have become cornerstones of treatment for patients with cancer. The FDA has approved 16&nbsp;nucleoside analogs for the treatment of cancer and many of these have
become the standard of care globally for patients. <FONT STYLE="white-space:nowrap">FDA-approved</FONT> anti-cancer nucleoside analogs are: gemcitabine; <FONT STYLE="white-space:nowrap">5-FU;</FONT> capecitabine; floxuridine; clofarabine;
fludarabine; cytarabine; azacytidine; decitabine; nelarabine; cladribine; pentostatin; <FONT STYLE="white-space:nowrap">6-mercaptopurine;</FONT> tipiracil; <FONT STYLE="white-space:nowrap">6-thioguanine;</FONT> and trifluorothymidine. The World
Health Organization has classified seven of these nucleoside analogs, including gemcitabine and <FONT STYLE="white-space:nowrap">5-FU,</FONT> as Essential Medicines, which they define as medicines that satisfy the priority&nbsp;healthcare&nbsp;needs
of the population and should be available at all times. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Many <FONT STYLE="white-space:nowrap">on-patent</FONT> chemotherapies have generated significant sales, including, for example, gemcitabine, marketed as Gemzar<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, which had peak annual sales of $1.7&nbsp;billion before losing patent protection in 2010. Gemcitabine is still used
extensively and remains an important part of the standard of care for many cancers, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">
including pancreatic, ovarian, biliary, non-small cell lung, bladder and breast cancers.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex"> </SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, approximately 500,000 patients per year in North America receive
<FONT STYLE="white-space:nowrap">5-FU,</FONT> which is widely used for the treatment of many cancers, including colorectal, breast, stomach, head and neck, and pancreatic cancers. The oral version of a derivative of
<FONT STYLE="white-space:nowrap">5-FU,</FONT> known as capecitabine and marketed as Xeloda<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> for the treatment of
colorectal, breast and stomach cancer, had worldwide sales of $1.5&nbsp;billion in 2012, before the market launch of generic competitors. We believe the number of patients receiving capecitabine represents a small proportion of the overall number of
patients treated with <FONT STYLE="white-space:nowrap">5-FU</FONT> and its derivatives. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Shortcomings of Existing Nucleoside Analog Drugs </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite the widespread use of nucleoside analogs, their efficacy is severely limited by cancer cell resistance and they are often poorly
tolerated. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nucleoside analogs are based on the
principle of blocking the replication of cancer cells by providing faulty DNA and RNA building blocks during the cell replication process, thus leading to cancer cell death, known as apoptosis. Some nucleoside analogs exert their effect by blocking
enzymes necessary for the production of these DNA and RNA building blocks. However, there are critical barriers and cellular defenses that limit the efficacy of existing nucleoside analogs. The three critical shortcomings of nucleoside analogs are:
(1)&nbsp;the need for uptake into cells by way of membrane proteins known as transporters; (2)&nbsp;the need for activation by the addition of one or more phosphate groups; and (3)&nbsp;the potential for enzymatic breakdown. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>1.</I></B> <B><I>Uptake by transporters</I></B>.
Nucleoside analogs require specific active-transport proteins in the cell membrane to enter cancer cells. If these proteins are missing or down-regulated, nucleoside analogs cannot enter the cancer cell to exert their anti-cancer effect. Transport
proteins, such as the human equilibrative nucleoside transporter 1, or hENT1, are often not expressed at sufficient levels in many solid tumor cancers. For example, based on the published results of multiple studies assessing the correlation of
hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2. Conversion to the active form</I></B>. Nucleoside
analogs are all dosed as inactive precursors, or prodrugs, because their active forms are unstable and their negative charge further prevents them from entering cells. Naturally occurring enzymes in cells must add at least one chemical entity known
as a phosphate group to activate these prodrugs and enable them to be incorporated into nucleic-acid chains or to bind to their target enzymes and thereby exert their anti-cancer effect. This process of activation by adding a phosphate group is
known as phosphorylation. However, the addition of phosphate groups often occurs at such an insufficient rate in cancer cells that it limits or prevents the generation of active anti-cancer metabolites, and in some cases phosphorylation does not
occur at all. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>3.</I></B>
<B><I>Breakdown</I></B>. Multiple enzymatic processes can break down nucleoside analogs, resulting in their degradation prior to phosphorylation, as well as the release of toxic byproducts that can lead to
<FONT STYLE="white-space:nowrap">off-target</FONT> toxicity. Breakdown can take place either inside or outside the cancer cell. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our ProTide Technology and its Key Advantages </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use our ProTide technology to design new chemical
entities to overcome the three key challenges associated with existing nucleoside analogs: uptake, activation and breakdown as shown below: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g32d01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Harnessing the power of
phosphoramidate chemistry, we transform nucleoside analogs into activated nucleotide analogs with the addition of a phosphate group, which is protected by specific combinations of aryl, ester and amino acid groupings. We refer to these compounds as
ProTides. We are applying our ProTide technology both to nucleoside analogs currently approved for use as a chemotherapy and to nucleoside analogs that have not, to date, been successfully developed. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A graphical representation of the chemical structure of
nucleoside analogs, nucleotide analogs and ProTides is set forth below: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g77v72.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our researchers have invested over a decade of work in designing, synthesizing and screening
ProTides, which we believe are optimally designed to overcome cancer cell resistance mechanisms. We have gained considerable insight from our scientific founders and executives in understanding phosphoramidate chemistry and the biology of how
nucleotide analogs are able to exert their anti-cancer effects. Based on these learnings, we are able to efficiently create hundreds of target candidates from the millions of potential candidates. We then perform biological testing on these target
candidates to select our lead ProTides. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Acelarin: A
Transformation of Gemcitabine </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead
product candidate, Acelarin, was designed to overcome the key cancer resistance mechanisms associated with the nucleoside analog, gemcitabine. We are rapidly advancing Acelarin in the clinic and exploring its use as a therapy against
platinum-resistant and platinum-sensitive ovarian cancer, biliary cancer and pancreatic cancer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Gemcitabine and its Limitations </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Gemcitabine is a nucleoside analog that is used as a chemotherapeutic to treat a wide range of tumors and has been investigated in over 1,900 clinical trials. It is approved as a single agent for the
treatment of pancreatic cancer and in combination with other chemotherapeutic drugs for the treatment of advanced ovarian, metastatic breast, and <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancers. Gemcitabine is also used to treat
many other types of tumors, including biliary cancer, both as monotherapy and in combination with other therapeutics. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gemcitabine is a conventional nucleoside analog which, like all nucleoside analogs, is an inactive prodrug. There are three key cancer
resistance mechanisms that have been associated with a poor survival prognosis for gemcitabine therapy: transport, activation and breakdown. While there have been attempts to address the requirement for active transport of gemcitabine into cancer
cells, we believe we are the first to address all three limitations at once. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>1. Requires active transport.</I></B> Gemcitabine requires the membrane transporter hENT1 to enter the cancer cell. Patients with a low level of hENT1 who receive gemcitabine have lower overall
survival as compared to patients with a high level of hENT1. In a study published in 2004 in the journal <I>Clinical Cancer Research</I>, it was reported that pancreatic cancer patients with a high level of hENT1 expression had a median overall
survival of 13&nbsp;months compared to four&nbsp;months for those patients with a low level of hENT1 expression. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In a study published in 2009 in the <I>Journal of Clinical Oncology</I>, non-small cell lung cancer patients with low levels of hENT1 who
were treated with therapies that included gemcitabine survived for less than half as long as those with high levels of hENT1, specifically, 316 days in the case of low levels of hENT1, and 714 days in the case of high levels of hENT1. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Some previous product candidates that have been tested
clinically by others were designed to address the challenge of membrane transport but these efforts failed even when the transport of these candidates across the cell membrane appeared to succeed. We believe that this was due to the failure of those
candidates to address the other cancer resistance mechanisms of activation and breakdown. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>2. Requires activation within the cancer cell.</I></B> Once gemcitabine enters cells, it must be activated by the addition of phosphate groups before it can exert its cell-killing effect. The
rate-limiting addition of the first phosphate group is rapidly followed by the addition of a second and third phosphate group. The end result of this phosphorylation is the creation of the active anti-cancer metabolite, which is known as dFdCTP. A
specific enzyme, deoxycytidine kinase, or dCK, is responsible for the first rate-limiting phosphorylation step. Initially, about <FONT STYLE="white-space:nowrap">one-third</FONT> of cancer cells have reduced levels of dCK, which has negative
consequences for the efficacy of gemcitabine. A study published in the journal <I>Gastroenterology </I>in 2012 reported that decreased expression of dCK led to resistance to gemcitabine treatment in cellular assays. In another published study, low
levels of dCK in the pancreatic cancer cells of patients who were treated with gemcitabine were associated with a median </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">93 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
overall survival that was seven months shorter than that observed in patients with medium to high levels of dCK. dCK is also associated with acquired resistance and studies have shown that cancer
cells can downregulate the production of dCK in the presence of gemcitabine leading to reduced efficacy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because gemcitabine has a short half-life, ranging from 42 to 94 minutes, even with dCK present in the cancer cell, much of the
gemcitabine will have broken down before it can be converted to its active anti-cancer metabolite, dFdCTP. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>3. Subject to breakdown.</I></B> Gemcitabine, prior to being phosphorylated to its active form, is susceptible to being broken down
chemically by metabolic enzymes, such as cytidine deaminase, or CDA, which irreversibly degrades up to 90% of gemcitabine to an inactive form in less than three hours. A study published in the <I>British Journal of Cancer</I> in 2005 showed that
increased levels of CDA were associated with an approximate five-month reduction in median overall survival in gemcitabine-treated pancreatic cancer patients. CDA is also expressed by various microorganisms in the body, such as mycoplasma that have
been found to be associated with 30% to 50% of solid tumors, which further exacerbates the breakdown of gemcitabine. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Contribution of resistance mechanisms to survival </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each of these resistance mechanisms on its own negatively
impacts the survival of cancer patients receiving gemcitabine therapy by at least five months. While studies have not been done on the effect of the combination of all three of these resistance mechanisms, one study in pancreatic cancer patients who
had undergone resection found that two of these resistance mechanisms had a cumulative effect. Specifically, patients with low levels of hENT1 and any level of dCK experienced a median overall survival of 16.2 months, while patients with high levels
of hENT1 and low levels of dCK had a median overall survival of 33.6 months and patients with high levels of hENT1 and moderate to high levels of dCK had a median overall survival of 61.4 months. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Solution: Acelarin </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our lead product candidate, Acelarin, was designed to
overcome the key cancer resistance mechanisms associated with gemcitabine. Acelarin is designed to generate and maintain higher concentrations of the anti-cancer metabolite inside the tumor compared to gemcitabine. This ProTide is comprised of
gemcitabine, a phosphate group and a specific combination of aryl, ester and amino acid, also referred to as the phosphoramidate moiety. Acelarin&#146;s distinctive feature is this proprietary moiety, which protects the phosphate group. The moeity
also changes the chemical properties of the molecule, enabling Acelarin to enter the cancer cell independent of the presence of the hENT1 transporter. Once Acelarin has entered the cell, the moeity is optimally cleaved off, resulting in
&#147;deprotection&#148; and the release of an activated, phosphorylated form of gemcitabine in the cell. Accordingly, the activating enzyme, dCK, which drives the rate-limiting phosphorylation of gemcitabine, is no longer required and the cancer
cells&#146; deficiency of dCK does not result in resistance to Acelarin, as it does with gemcitabine. This activated nucleotide analog, dFdCMP, is then rapidly converted to dFdCDP and then the key anti-cancer metabolite, dFdCTP. Moreover, Acelarin,
like the phosphorylated forms of gemcitabine, is not subject to breakdown by CDA, thus bypassing another key resistance mechanism. As a result, Acelarin achieves much higher levels of dFdCTP than does gemcitabine. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">94 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The metabolism of Acelarin compared to gemcitabine as described above is illustrated in the
following graphic. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g22t34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Data
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acelarin has been evaluated in one Phase
1 dose-ranging clinical trial and one Phase 1b clinical trial for recurrent ovarian cancer and is being evaluated in three clinical trials across numerous solid tumor cancer indications: Phase 2 for platinum-resistant ovarian cancer; Phase 1b for
biliary cancer; and Phase 3 for pancreatic cancer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The vast majority of patients in the completed Phase 1 and Phase 1b trials were resistant or refractory to all existing standards of care
and yet a high proportion obtained significant tumor regression or stable disease when treated with Acelarin. Both of these investigator-sponsored trials were conducted in the United Kingdom under a clinical trial authorization, or CTA, by the
Medicines and Healthcare products Regulatory Agency, or MHRA. These trials were designed to assess the safety, pharmacokinectics and clinical activity of Acelarin as monotherapy or in combination with carboplatin. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Acelarin: Phase 1 clinical trial <FONT
STYLE="white-space:nowrap">(PRO-001)</FONT></I></B>. In the completed Phase 1 trial, 68 patients with advanced solid tumors and metastatic disease that had previously been treated with other systemic anti-cancer therapies received Acelarin as
monotherapy at doses ranging from 375 mg/m</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> to 1,000
mg/m</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">. All of these patients had rapidly progressing
recurrent disease, had received on average 2.7 prior lines of chemotherapy, and had exhausted all other standard treatment options. Initial signs of efficacy were evaluated using the standard scoring system known as Response Evaluation Criteria In
Solid Tumors, or RECIST. A subset of 49 patients received two or more cycles of Acelarin, equivalent to two or more months of therapy, and had at least one <FONT STYLE="white-space:nowrap">follow-up</FONT> radiographic assessment to measure changes
in tumor size. Of these patients, five achieved a partial response, with at least a 30% decrease in tumor size, although not all of these five patients received a final confirmatory </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">95 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
scan as technically required by the RECIST criteria for classification as a partial response. Another 33 patients had tumors that either decreased by up to 30% or increased by less than 20% and
were scored as having stable disease. This resulted in an overall disease control rate, the combination of both partial response and stable disease, of 78% in the total <FONT STYLE="white-space:nowrap">49-patient</FONT> evaluable population.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following graph illustrates the best
percentage change from baseline tumor size in the 49 evaluable patients. Asterisks in the graph below indicate patients who had disease progression as a result of a new lesion rather than an increase in size of any existing measurable tumors. These
patients are accordingly not included in the partial response or stable disease classifications. The median progression-free survival in the 49 evaluable patients was 4.0 months with a range of two to 25 months. Of the 33 patients who achieved
stable disease, 32 maintained stable disease for at least 12 weeks. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g62y23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An analysis was performed
on a subset of 18 patients from the same trial who had some form of gynecological cancer: ovarian, endometrial, cervical or uterine cancers. This patient subset had received on average 3.5 prior lines of chemotherapy. Of these patients, 14 were
evaluable. Two of these 14 heavily <FONT STYLE="white-space:nowrap">pre-treated</FONT> patients with gynecological cancer achieved a partial response and an additional 11 achieved stable disease, resulting in a disease control rate of 93% with a
median progression-free survival duration of 8.0 months. In the seven evaluable patients with platinum-refractory or platinum-resistant ovarian cancer, the median progression-free survival duration was also 8.0 months. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">96 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following graph illustrates the best percentage change from baseline tumor size in the
14 evaluable patients with gynecological cancer. The asterisk in the graph below indicates the one patient who experienced progressive disease as a result of a new lesion rather than an increase in size of any existing measurable tumor. This patient
is therefore not included in the partial response or stable disease classifications. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g29a71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While not directly
comparable to Acelarin, Doxil, or pegylated liposomal doxorubicin, a standard of care for patients with recurrent ovarian cancer, was assessed in the AURELIA clinical trial in patients who had received no more than two prior lines of chemotherapy.
Doxil was associated with an overall response rate of 8% and a median progression-free survival duration of 3.5 months. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">97 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the Phase 1 trial, Acelarin had a plasma half-life of 8.3 hours, as compared to the
plasma half-life of gemcitabine, which ranges from 42 minutes to 94 minutes. The median intracellular levels of the active anti-cancer metabolite, dFdCTP, achieved with Acelarin were over 200 times higher than those reported in the literature for
gemcitabine on an equimolar dose comparison, as shown in the graphic below. Equimolar means that all of the doses being compared contained the same number of molecules of Acelarin or gemcitabine. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g68e09.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We observed levels of dFdCTP that were still higher 24&nbsp;hours after dosing with Acelarin
than the maximum reported concentration generated with gemcitabine at its peak level two hours after dosing. Furthermore, the concentration of intracellular dFdCTP over a <FONT STYLE="white-space:nowrap">24-hour</FONT> period, as measured by the
area under the curve, or AUC, a measure of drug exposure over time, was 139&nbsp;times higher for Acelarin on an equimolar dose comparison compared to the levels reported for gemcitabine in the literature referenced above. We have combined the data
from those four studies in order to derive the curve shown in the graphic below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">


<IMG SRC="g393013g30u61.jpg" ALT="LOGO">
1 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that
the higher concentrations of dFdCTP results from Acelarin&#146;s ability to bypass the key cancer resistance mechanisms and its favorable pharmacokinetics, or the process by which Acelarin is distributed and metabolized in the body. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Acelarin was generally well-tolerated.
The most common Grade 3 and Grade 4 treatment-related adverse events, which occurred in 10% to 20% of patients, were fatigue and decreased counts of blood cells, including neutrophils, lymphocytes and platelets. A total of eight dose-limiting
toxicities were observed in four patients at doses of 725&nbsp;mg/m</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> and above. These included Grade 3 increases in liver enzymes known as transaminases, and Grade&nbsp;4 decreases in platelets and neutrophils. All of these adverse events were transient and all patients
recovered. To date, we have not observed any treatment-related adverse events that have not previously been associated with gemcitabine. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Acelarin: Phase 1b clinical trial in combination with carboplatin
<FONT STYLE="white-space:nowrap">(PRO-002)</FONT></I></B>. In the Phase&nbsp;1b trial, 25&nbsp;patients with recurrent ovarian cancer received Acelarin at doses from 500 mg/m</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> to 750&nbsp;mg/m</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> in combination with carboplatin for a maximum of six treatment cycles lasting three weeks each. Patients had received
on average three prior lines of chemotherapy and had a median age of 64. Of the 25&nbsp;patients enrolled, 23 were evaluable and these patients were characterized by their platinum status: seven were platinum-refractory, 10
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
were platinum-resistant, four were partially platinum-sensitive and two were platinum-sensitive. Efficacy was evaluated using the RECIST standard scoring system. The 23 evaluable patients had
received one or more cycles of Acelarin in combination with carboplatin and had at least one <FONT STYLE="white-space:nowrap">follow-up</FONT> radiographic assessment to measure changes in tumor size. Of these patients, one achieved a complete
response, with a complete disappearance of all target lesions, and eight achieved a partial response, with at least a 30% decrease in tumor size, although not all of these patients have received a confirmatory scan. This resulted in an overall
response rate of 39%. Another 13&nbsp;patients had tumors that either decreased by up to 30% or increased by less than 20% and were scored as having stable disease. This resulted in a disease control rate of 96%. The median progression-free survival
duration for all 25&nbsp;patients recruited was 7.3&nbsp;months and for the evaluable population was 7.4&nbsp;months. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following graph illustrates the best percentage change from baseline tumor size in the 23 evaluable patients. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g86p18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although gemcitabine has
never been approved as a single agent for patients with ovarian cancer, it is approved in combination with carboplatin in patients who have relapsed at least six months after completion of platinum-based therapy. These patients are
platinum-sensitive or partially platinum-sensitive. In this population, as a second line treatment, the combination of gemcitabine and carboplatin achieved an overall response rate of 47% and a disease control rate of 85%. Due to the toxicity burden
of gemcitabine, carboplatin is limited to a suboptimal dose. Even at the suboptimal dose of carboplatin, the incidence of Grade&nbsp;3 and Grade&nbsp;4 neutropenia, or low neutrophils, and thrombocytopaenia, or low platelets, was 71% and 35%,
respectively, with this combination. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The results
of the Phase 1b Acelarin trial suggest that Acelarin can be combined with carboplatin at a higher, more optimal carboplatin dose. In the seven patients with platinum partially sensitive and sensitive disease, the incidence of Grade&nbsp;3 and
Grade&nbsp;4 neutropenia and thrombocytopaenia was 43% and 0%, respectively. In all 25&nbsp;patients, the incidence of Grade&nbsp;3 and Grade&nbsp;4 neutropenia and thrombocytopaenia was 52% and 32%, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The data from the Phase 1b trials are interim because the Phase 1b trial is still ongoing.
Interim data are not necessarily predictive of final results and may change as the data are further examined, more patient data become available and the final clinical study report is prepared and issued. As a result, interim data should be viewed
with caution until the final data are available. Initial success with either interim or final data in early-stage clinical trials may not be indicative of results obtained in later-stage trials, and the results of our clinical trials may not meet
the level of statistical significance required by the FDA or comparable foreign regulatory authorities for marketing approval. Statistical significance means that an effect is unlikely to have occurred by chance. Clinical trial results are
considered statistically significant when the probability of the results occurring by chance, rather than from the efficacy of the product candidate, is sufficiently low. We plan to design our later stage trials to establish the statistical
significance of the efficacy of our ProTides. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Acelarin development strategy and ongoing clinical trials </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acelarin has been administered to over 140 patients with a wide range of advanced cancers. We are developing
Acelarin for multiple indications: in both platinum-resistant and platinum-sensitive ovarian cancer; as first-line treatment in biliary cancer, an indication in which no drug has ever been approved; and as first-line treatment in pancreatic cancer.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ongoing clinical trials are: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Phase 2 trial, in up to 64 patients with platinum-resistant ovarian cancer, to establish the optimal dose of Acelarin as monotherapy, with the
expectation of interim data in 2018; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Phase 1b trial, in up to 24 patients with biliary cancer, to establish the optimal dose of Acelarin in combination with cisplatin as a first-line
treatment, with the expectation of interim results in 2018; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Phase 3 trial expected to enroll 328 patients with metastatic pancreatic cancer to compare Acelarin to gemcitabine as a first-line treatment,
facilitated by the National Cancer Research Institute in the United Kingdom. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Phase 2 trial in platinum-resistant ovarian cancer is being conducted under an Investigational New Drug application, or IND, in the United States and a CTA in the United Kingdom. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Phase 1b trial in biliary cancer and the Phase 3 trial in
pancreatic cancer are investigator-sponsored trials and being conducted under a CTA in the United Kingdom. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Ovarian cancer </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview</I></B>. Ovarian cancer is the fifth-leading cause of cancer death in women in the United States. According to the U.S.
National Cancer Institute, there are approximately 22,000 new cases and 14,000 cancer-related deaths each year from ovarian cancer in the United States. Worldwide, there are approximately 225,000 new cases of ovarian cancer and 140,000 deaths
yearly. Surgery and cytotoxic chemotherapies are widely used to treat ovarian cancer; however, the outcomes have changed little over several decades. The five-year survival rate for ovarian cancer patients in the United States has improved only
marginally from 42.2% in 1995 to 46.6% in 2009. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Limitations of current treatment options in ovarian cancer</I></B>. First-line therapy for patients with advanced ovarian cancer is
typically a combination of a platinum drug, such as carboplatin, and a taxane drug such as paclitaxel. Due to toxicities, most patients undergo a maximum of six cycles, equivalent to four and a half months, of this therapy. Between 62% and 85% of
patients will relapse depending on the stage of the disease, and these patients can be divided into four groups depending on length of time between the end of treatment and the relapse. Those with disease progression while receiving platinum-based
therapy or who relapse within four weeks of the last platinum dose are defined as platinum-refractory. Those relapsing after more than one month </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">101
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
but less than six months are deemed platinum-resistant and have a worse prognosis than partial platinum-sensitive patients, who relapse between six and 12 months, and platinum-sensitive patients,
who relapse after more than 12&nbsp;months. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Relapsed platinum-sensitive patients typically receive a platinum-containing agent such as carboplatin or cisplatin in combination with
other therapies such as gemcitabine. The addition of gemcitabine to carboplatin in these patients increased the progression-free survival to 8.6 months from 5.8 months with carboplatin alone but had no significant effect on overall survival.
Gemcitabine as monotherapy, although not approved, is used in relapsed, platinum-resistant ovarian cancer patients resulting in progression-free survival of approximately four months. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recently, a new class of anti-cancer drugs, known as PARP inhibitors, has been approved for the third- or
fourth-line treatment of a subset of ovarian cancers, specifically those containing mutations in BRCA genes, or BRCAm, which constitute approximately 15% of ovarian cancer patients. PARP inhibitors have also been approved as maintenance therapy in
patients with recurrent ovarian cancer with a complete or partial response to platinum-based chemotherapy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">102
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The market can be simplified into platinum-resistant and platinum-sensitive (including
partially platinum-sensitive) ovarian cancer patients. The following illustrations show how platinum-resistance increases with line of therapy and highlights where some existing therapies are being utilized and the ovarian cancer indications we are
targeting with Acelarin. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:5%" ALIGN="center">


<IMG SRC="g393013g36d58.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g22k80.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">103
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biliary cancer </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview</I></B>. Biliary cancers, including cholangiocarcinoma, gallbladder and ampullary carcinoma, are
cancers originating in the bile duct, a vessel that transports bile from the liver to the gall bladder and small intestine. Approximately 178,000 new cases of biliary cancer are diagnosed each year worldwide, with approximately 9,000 of those
diagnoses in the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Limitations
of current treatment options in biliary cancer</I></B>. There are currently no agents approved for the treatment of biliary cancer; however, the worldwide standard of care in biliary cancer patients with advanced or metastatic disease is the
combination of gemcitabine and cisplatin. Patients receiving this regimen have a median overall survival of 11.7 months compared to 8.1 months for patients receiving gemcitabine as monotherapy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pancreatic cancer </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview</I></B>. Pancreatic cancer is the
third-leading cause of cancer deaths in the United States with approximately 53,000 new diagnoses and 41,800 deaths in 2016. Worldwide, there were approximately 338,000 new pancreatic cancer diagnoses in 2012. Approximately 85% of patients diagnosed
with pancreatic cancer have advanced disease at the time of diagnosis, are ineligible for surgery and are treated with chemotherapy. Patients with pancreatic cancer have a poor prognosis, with a five-year survival rate of only 7.7%. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Limitations of current treatment
options in pancreatic cancer</I></B>. First-line treatment in pancreatic cancer for patients with a good performance score, which is a standard measure of general well-being, is a combination of <FONT STYLE="white-space:nowrap">5-FU,</FONT>
oxaliplatin, leucovorin and irinotecan, a treatment regimen known as FOLFIRINOX. Treatment with FOLFIRINOX is, however, associated with high levels of toxicity, so it is generally not recommended for patients without good performance scores. For
patients with a less robust performance score, a common first-line treatment is a combination of gemcitabine and <FONT STYLE="white-space:nowrap">nab-paclitaxel,</FONT> or Abraxane<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. For patients who are less fit or who have <FONT STYLE="white-space:nowrap">co-morbidities,</FONT> the standard of care is single-agent gemcitabine. In separate
clinical trials, patients treated with FOLFIRINOX had a median overall survival of 11.1 months and patients treated with the combination of gemcitabine and <FONT STYLE="white-space:nowrap">nab-paclitaxel</FONT> had a median overall survival of 8.5
months. The addition of nab-paclitaxel to gemcitabine resulted in a <FONT STYLE="white-space:nowrap">seven-week</FONT> improvement in median overall survival compared to gemcitabine alone. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">104
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Acelarin preclinical data </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to progressing our product candidates into clinical
trials, we wanted to evaluate in preclinical studies whether Acelarin would: (1)&nbsp;be able to enter cells independent of transporters, including hENT1; (2) generate the active anti-cancer metabolite, dFdCTP, inside cancer cells without the need
for the phosphorylating enzyme dCK; and (3)&nbsp;not be susceptible to breakdown by enzymes like CDA. The results of these preclinical studies are summarized below: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>1. Acelarin is not dependent on transporters to enter
cancer cells</I></B>. Gemcitabine requires the hENT1 transporter to cross the cell membrane. Evidence of this can be seen in cellular assays we completed in which hENT1 was specifically blocked by an inhibitor known as NBTI in human cancer cells. A
group including our researchers published a study in the <I>Journal of Medicinal Chemistry</I> in which we observed that Acelarin did not require hENT1 in order to enter cells and that NBTI had no effect on intracellular levels of dFdCTP. These
results are illustrated below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g49h81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;margin-left:16%;border-bottom:0.5pt solid #000000; width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(&#134;)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">p-value is a conventional statistical method for measuring the statistical significance of preclinical study and clinical trial results. A p-value of 0.05 or less
represents statistical significance, meaning that there is a 1-in-20 or less likelihood that the observed results occurred by chance. A p-value of 0.0001 or less means that there is a 1-in-10,000 or less likelihood that the observed results occurred
by chance. </FONT></TD>
<TD WIDTH="11%"><FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This finding was confirmed in a separate study where hENT1 was blocked by dipyridamole, a commonly used nucleoside transporter inhibitor,
with the result that gemcitabine&#146;s ability to kill the cancer cells was significantly reduced while Acelarin retained its activity. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">105
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2. Acelarin does not require rate-limiting activation step.</I></B> Gemcitabine must
be phosphorylated, or activated, inside the cell by the addition of a phosphate group to the molecule in order to exert a cytotoxic effect. This phosphorylation requires the enzyme dCK. In our preclinical studies, inhibition of dCK by a specific
inhibitor, known as 2T2D, significantly reduced the phosphorylation step to generate dFdCTP within human cancer cells while Acelarin was unaffected by 2T2D and was still able to generate the same level of the key active anti-cancer metabolite,
dFdCTP. These results are illustrated below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g36w38.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This observation is
consistent with the fact that Acelarin already includes the first phosphate group and thus does not require the action of dCK for activation. Furthermore, we confirmed these findings in a separate study in which we blocked the action of dCK with the
inhibitor deoxycytidine, which significantly reduced the ability of gemcitabine to kill the cancer cells while Acelarin retained its activity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>3. Acelarin not susceptible to breakdown by CDA.</I></B> Nucleoside analogs such as gemcitabine are susceptible to breakdown by
enzymes such as CDA. The presence of the phosphate on Acelarin protects it from breakdown by CDA. In our preclinical studies, incubation of Acelarin with purified CDA resulted in no degradation of Acelarin over the full <FONT
STYLE="white-space:nowrap">30-minute</FONT> assay while gemcitabine under these same conditions was almost completely degraded in two minutes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the ability of Acelarin to generate the active anti-cancer metabolites within the cancer cells in higher concentrations
than gemcitabine gives Acelarin the potential to have greater efficacy and to overcome the key cancer cell resistance mechanisms, while avoiding breakdown and release of toxic byproducts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">106
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">NUC-3373:</FONT> A Transformation of
<FONT STYLE="white-space:nowrap">5-FU</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have designed our second ProTide, <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> to overcome the key cancer resistance mechanisms,
improve upon the safety profile and reduce the dosing administration burdens associated with the nucleoside analog, <FONT STYLE="white-space:nowrap">5-FU.</FONT> We are advancing <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in the clinic and
developing this new chemical entity as a therapy for colorectal cancer, breast cancer and other solid tumors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">5-FU</FONT> and its Limitations </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">First introduced in 1957, <FONT STYLE="white-space:nowrap">5-FU</FONT> is still widely used for the treatment
of many cancers, including colorectal, breast, stomach, head and neck, and pancreatic cancers. Approximately 500,000 patients per year in North America receive <FONT STYLE="white-space:nowrap">5-FU.</FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">5-FU</FONT> requires
conversion to the phosphorylated anti-cancer metabolite, fluorodeoxyuridine monophosphate, or <FONT STYLE="white-space:nowrap">FUDR-MP,</FONT> before it can exert its primary cytotoxic activity through the inhibition of an intracellular enzyme,
thymidylate synthase, or TS. TS is required to convert uridine, specifically deoxy-uridine monophosphate, or dUMP, to thymidine, specifically deoxy-thymidine monophosphate, or dTMP, one of the four nucleotides that comprise DNA. The inhibition of TS
therefore results in an imbalance in the ratio of the nucleotides dUMP and dTMP, disrupting DNA synthesis and repair, which leads to cancer cell death. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Two other drugs have been approved that aim to generate the same active anti-cancer metabolite as <FONT
STYLE="white-space:nowrap">5-FU:</FONT> fluorodeoxyuridine, or Floxuridine, marketed as FUDR<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, and capecitabine,
marketed as Xeloda<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. Like <FONT STYLE="white-space:nowrap">5-FU,</FONT> both of these drugs must be converted to
<FONT STYLE="white-space:nowrap">FUDR-MP</FONT> inside the cancer cell in order to exert their primary cytotoxic activity. Capecitabine is a derivative of <FONT STYLE="white-space:nowrap">5-FU</FONT> containing a chemical modification of the
nucleoside ring, which allows oral dosing of capecitabine. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Similar to gemcitabine, the key cancer resistance mechanisms of breakdown, activation and transport have been associated with a poor prognosis to a <FONT STYLE="white-space:nowrap">5-FU</FONT> therapeutic
regimen. We believe our ProTide, <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> overcomes these specific key resistance mechanisms as well as dosing administration challenges associated with <FONT STYLE="white-space:nowrap">5-FU.</FONT>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>1. Subject to breakdown.</I></B> More than
85% of an injected dose of <FONT STYLE="white-space:nowrap">5-FU</FONT> is degraded by dihydropyrimidine dehydrogenase, or DPD, an enzyme largely expressed in the liver. This breakdown destroys most of the drug before it has an opportunity to enter
the cancer cell, become activated and exert any therapeutic effect. Furthermore, this breakdown results in the generation of a toxic byproduct, <FONT STYLE="white-space:nowrap">F-BAL,</FONT> which has been associated with <FONT
STYLE="white-space:nowrap">off-target</FONT> toxicity, such as &#147;hand-foot syndrome,&#148; which is reported in various sources as affecting at least half of patients treated with <FONT STYLE="white-space:nowrap">5-FU.</FONT> Hand-foot syndrome
is a reddening, swelling, numbness and skin sloughing or peeling on the palms of the&nbsp;hands&nbsp;and soles of the&nbsp;feet<B>.</B> In addition, levels of DPD have also been found to be elevated in tumors that are resistant to <FONT
STYLE="white-space:nowrap">5-FU.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2.
Requires activation within the cancer cell.</I></B> Once <FONT STYLE="white-space:nowrap">5-FU</FONT> enters cells, it must be processed by a series of enzymes to generate the active anti-cancer metabolite,
<FONT STYLE="white-space:nowrap">FUDR-MP.</FONT> <FONT STYLE="white-space:nowrap">FUDR-MP</FONT> binds to and inhibits TS, leading to decreased levels of thymidine and resulting in cancer cell death. There are several key enzymes involved in the
conversion of <FONT STYLE="white-space:nowrap">5-FU</FONT> to the active anti-cancer metabolite, <FONT STYLE="white-space:nowrap">FUDR-MP.</FONT> One of these is orotate phosphoribosyl transferase, or OPRT. Lower levels of OPRT in tumor cells are
associated with resistance to <FONT STYLE="white-space:nowrap">5-FU.</FONT> Another intracellular enzyme, thymidine phosphorylase, or TP, can reversibly convert <FONT STYLE="white-space:nowrap">5-FU</FONT> to fluorodeoxyuridine, or FUDR, an
intermediate to the formation of <FONT STYLE="white-space:nowrap">FUDR-MP.</FONT> Low expression of TP in human cancer cells is associated with resistance to <FONT STYLE="white-space:nowrap">5-FU.</FONT> In addition, thymidine kinase, or TK, is the
enzyme that converts FUDR to the active anti-cancer metabolite, <FONT STYLE="white-space:nowrap">FUDR-MP.</FONT> Low expression of TK in human cancer cells is associated with resistance to <FONT STYLE="white-space:nowrap">5-FU.</FONT> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>3. Requires active transport.</I></B> Similar to
gemcitabine and all nucleoside analogs, <FONT STYLE="white-space:nowrap">5-FU</FONT> relies on specific transporters in order to cross the cellular membrane. If these transporters are not present or are expressed in low
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">107
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
levels, <FONT STYLE="white-space:nowrap">5-FU&#146;s</FONT> ability to enter into the cancer cell will be limited. For example, low expression of the nucleoside transporter, hENT1, has been
associated with cancer cell resistance to <FONT STYLE="white-space:nowrap">5-FU.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>4. Dosing administration challenges.</I></B> The pharmacokinetic and pharmacodynamic properties of <FONT STYLE="white-space:nowrap">5-FU</FONT> also lead to dosing administration challenges.
Pharmacodynamic properties refer to the biochemical and physiological effects of a drug on the human body. <FONT STYLE="white-space:nowrap">5-FU</FONT> has a half-life between eight and 14&nbsp;minutes in plasma. In an effort to counter this short
time period, healthcare providers often administer <FONT STYLE="white-space:nowrap">5-FU</FONT> as a continuous infusion over extended periods of time, often days. For example, patients being treated for colorectal or pancreatic cancer typically
receive their first dose, or loading dose, of <FONT STYLE="white-space:nowrap">5-FU</FONT> over 46 hours using a portable infusion pump. This dosing regimen creates burdens for providers, inconveniences patients and contributes additional costs to
the healthcare system. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Solution: <FONT
STYLE="white-space:nowrap">NUC-3373</FONT> </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We designed our second ProTide, <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> to overcome the key cancer resistance mechanisms,
improve upon the safety profile and reduce the dosing administration burdens associated with the nucleoside analog, <FONT STYLE="white-space:nowrap">5-FU.</FONT> <FONT STYLE="white-space:nowrap">NUC-3373</FONT> is a nucleotide analog that delivers
the same active anti-cancer metabolite, <FONT STYLE="white-space:nowrap">FUDR-MP,</FONT> that <FONT STYLE="white-space:nowrap">5-FU</FONT> aims to generate within a cancer cell, but at far higher concentrations.
<FONT STYLE="white-space:nowrap">NUC-3373</FONT> is in a Phase 1 clinical trial in patients with advanced solid tumors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unlike <FONT STYLE="white-space:nowrap">5-FU,</FONT> <FONT STYLE="white-space:nowrap">NUC-3373</FONT> consists of the active anti-cancer
metabolite, <FONT STYLE="white-space:nowrap">FUDR-MP,</FONT> and a protective phosphoramidate moiety. This moiety allows <FONT STYLE="white-space:nowrap">NUC-3373</FONT> to enter the cell without the need for any membrane transporters. Once inside
the cancer cell, the phosphoramidate moiety is optimally cleaved off, resulting in deprotection and the release of <FONT STYLE="white-space:nowrap">FUDR-MP.</FONT> This bypasses the need for any activating enzymes, resulting in significantly higher
levels of the active anti-cancer metabolite, which we believe may lead to improved efficacy as compared to <FONT STYLE="white-space:nowrap">5-FU.</FONT> In addition, because <FONT STYLE="white-space:nowrap">NUC-3373</FONT> avoids breakdown by the
enzyme DPD, certain toxic byproducts such as <FONT STYLE="white-space:nowrap">F-BAL</FONT> are not released, which we believe may lead to an improved tolerability profile as compared to <FONT STYLE="white-space:nowrap">5-FU.</FONT> Lastly, we
believe that the improved pharmacokinetic and pharmacodynamic profile, including the significantly longer half-life of <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> may result in a more favorable dosing regimen relative to <FONT
STYLE="white-space:nowrap">5-FU.</FONT> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">108
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The metabolism of NUC-3373 compared to 5-FU as described above is illustrated in the
following graphic. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g40y33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Data
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NUC-3373 is currently being evaluated in
a Phase&nbsp;1 trial in patients with advanced solid tumors. We are planning further clinical trials across a number of indications, including colorectal cancer and metastatic breast cancer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">NUC-3373:</FONT> Phase 1 clinical trial</I></B>. We have initiated a
Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in which we are planning to enroll approximately 76 patients. We have currently enrolled over 20 patients with ten different advanced solid tumor types. We have completed
four dose cohorts and we are continuing with dose-escalation cohorts to establish the optimal dose and frequency of administration. Patients are being dosed with a short infusion of <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> initially once
per week. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this trial, we are measuring various
pharmacokinetic and pharmacodynamic parameters, including plasma concentration of <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> intracellular concentrations of the active anti-cancer metabolite, <FONT STYLE="white-space:nowrap">FUDR-MP,</FONT>
the ability of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> to bind to its target enzyme, TS, and the downstream effects on the levels of dTMP. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">109
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have interim data from 21 of the patients currently enrolled in the trial. The following
graphs on the left labeled &#147;Plasma NUC-3373&#148; illustrate the maximum plasma concentrations, or Cmax, of NUC-3373 among the four cohorts as measured after one administration and the plasma concentrations of NUC-3373 over time, as measured by
AUC. The following graphs on the right labeled &#147;Intracellular FUDR-MP&#148; illustrate the corresponding data for intracellular levels of the active anti-cancer metabolite, FUDR-MP. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g63b14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The interim data from
these 21 patients also showed: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pharmacokinetics were consistent across patients and showed a linear dose response; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">NUC-3373 had a plasma half-life of 9.7 hours compared with the half-life of 8 to 14 minutes for 5-FU reported in the literature;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">intracellular FUDR-MP was detected within five minutes after infusion with a half-life of 14.9 hours while the literature reports that 5-FU does not
generate detectable levels of intracellular FUDR-MP; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">intracellular FUDR-MP was still detectable up to 48 hours after dosing; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">within one hour after infusion, FUDR-MP had bound to the target enzyme, TS, leading to depletion of intracellular dTMP two to four hours after
administration; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the toxic byproducts, FBAL and dhFU, were undetectable both intracellularly and in the patient&#146;s plasma. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These interim pharmacokinetic and pharmacodynamic data
support our belief that NUC-3373 may have greater anti-cancer activity, an improved safety profile and a lower dosing administration burden than 5-FU. We expect final data from this Phase 1 trial in 2018. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">NUC-3373</FONT>
Development Strategy and Planned Clinical Trials </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are rapidly developing <FONT STYLE="white-space:nowrap">NUC-3373</FONT> for multiple indications and initially targeting advanced colorectal cancer and metastatic breast cancer. We intend to initiate
the following clinical trials in 2018: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Phase 1b trial in approximately 36 patients with recurrent metastatic colorectal cancer in combination with standard agents that are routinely used
in combination with <FONT STYLE="white-space:nowrap">5-FU,</FONT> including leucovorin, oxaliplatin </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">110
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
and irinotecan. The FDA recently provided authorization, following review of our IND, for this study to proceed; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Phase 3 trial in 400 patients with <FONT STYLE="white-space:nowrap">end-stage</FONT> metastatic colorectal cancer; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Phase 2 trial in 50 metastatic breast cancer patients who have been previously treated with post-anthracycline and taxane therapy.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Phase 1 trial in advanced
solid tumors is investigator-sponsored and being conducted under a CTA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Colorectal Cancer Overview </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the United States, approximately 135,000 new cases of colorectal cancer and 50,000 deaths due to the disease are expected in 2017. Worldwide, there were an estimated 1.4&nbsp;million new colorectal
cancer cases and 694,000 deaths in 2012, and the global burden is expected to increase to more than 2.2&nbsp;million new cases and 1.1&nbsp;million deaths annually by 2030. Most systemic therapies for colorectal cancer include <FONT
STYLE="white-space:nowrap">5-FU,</FONT> either as monotherapy or in combination with another chemotherapeutic, typically oxaliplatin or irinotecan. Both alone and in combination, <FONT STYLE="white-space:nowrap">5-FU</FONT> is the single most
effective compound against these tumors. Nevertheless, despite being the standard of care, the effectiveness of <FONT STYLE="white-space:nowrap">5-FU</FONT> is modest. Overall response rates are in the range of 10% to 15%. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Breast Cancer Overview </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximately one in eight women will be diagnosed with
breast cancer at some point in their lifetime. In the United States alone, approximately 253,000 women are expected to be diagnosed with the disease and over 40,000 women are projected to die from it in 2017. On a worldwide basis, approximately
1.7&nbsp;million women were diagnosed with breast cancer in 2012. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An estimated 30% of all breast cancers become metastatic and require systemic treatment. There are many available agents to treat metastatic breast cancer and the choice of therapy depends on factors such
as tumor burden, the patient&#146;s overall health, prior history of cancer treatment, the importance to the patient of minimizing toxicity, dosing convenience, and the physician&#146;s preferences. Physicians often prefer to treat patients with
limited metastatic disease with these agents used as monotherapy in a sequential fashion. Initially, taxanes, such as docetaxel, paclitaxel and nabpaclitaxel, and anthracyclines, such as doxorubicin and epirubicin, are frequently prescribed.
However, these categories of therapeutics must be administered intravenously and are commonly associated with neutropenia, or low neutrophils, and gastrointestinal toxicities. The nucleoside analog, capecitabine, which is a prodrug of <FONT
STYLE="white-space:nowrap">5-FU,</FONT> has advantages over taxanes and anthracyclines and has become a standard of care for patients with metastatic breast cancer. Recently, the PARP inhibitor olaparib has shown a clinical benefit for metastatic
breast cancer patients with a BRCA mutation, who represent approximately 5% of this population. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">NUC-3373</FONT> Preclinical Data </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">NUC-3373</FONT> avoids breakdown</I></B>. In our preclinical studies, <FONT
STYLE="white-space:nowrap">NUC-3373,</FONT> unlike <FONT STYLE="white-space:nowrap">5-FU,</FONT> was not susceptible to breakdown by the enzyme DPD, which is a major factor in limiting the efficacy of <FONT STYLE="white-space:nowrap">5-FU.</FONT>
Therefore, the ability of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> to generate the active anti-cancer metabolite, <FONT STYLE="white-space:nowrap">FUDR-MP,</FONT> should be unaffected by DPD activity and result in much higher intracellular
concentrations of <FONT STYLE="white-space:nowrap">FUDR-MP.</FONT> Furthermore, in patients receiving <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> the toxic byproduct, FBAL, produced by DPD&#146;s breakdown of
<FONT STYLE="white-space:nowrap">5-FU</FONT> has not been observed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, a study published in the <I>World Journal of Gastroenterology</I> in 2001 indicated that approximately half of patients with colorectal cancer had tumors that were infected with a type of
bacteria called mycoplasma. A 2008 study published in the <I>International Journal of Cancer Research and Treatment</I> highlighted that <FONT STYLE="white-space:nowrap">5-FU&#146;s</FONT> activity was reduced by up to 100&nbsp;times in cancer cell
lines infected with mycoplasma. In our preclinical studies, the anti-cancer activity of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> was unaffected by the presence of mycoplasma infection. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">111
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">NUC-3373</FONT> has greater anti-cancer activity than
<FONT STYLE="white-space:nowrap">5-FU</FONT></I></B>. In preclinical studies, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> was not reliant on activating enzymes, including OPRT, TP and TK, all of which are essential for activating the prodrug, <FONT
STYLE="white-space:nowrap">5-FU.</FONT> For example, we measured the anti-cancer activity of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT STYLE="white-space:nowrap">5-FU</FONT> across a range of human tumor cell lines, including
colorectal, ovarian and lung cancers. <FONT STYLE="white-space:nowrap">NUC-3373</FONT> had up to 330&nbsp;times greater activity than <FONT STYLE="white-space:nowrap">5-FU.</FONT> The following figure shows the levels of <FONT
STYLE="white-space:nowrap">NUC-3373</FONT> or <FONT STYLE="white-space:nowrap">5-FU</FONT> required, in various tumor cell lines, to kill half of the cancer cells, with the shorter bars representing more potent activity. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g61t74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Studies in human
colorectal cancer cells showed that <FONT STYLE="white-space:nowrap">NUC-3373</FONT> generated levels of the active anti-cancer metabolite, <FONT STYLE="white-space:nowrap">FUDR-MP,</FONT> 366 times higher than those achieved by administering
equivalent amounts of <FONT STYLE="white-space:nowrap">5-FU.</FONT> We believe that these increased levels of <FONT STYLE="white-space:nowrap">FUDR-MP</FONT> could translate into the ability of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> to
kill various cancer cells at much lower doses than those of <FONT STYLE="white-space:nowrap">5-FU.</FONT> Moreover, in a preclinical colorectal cancer xenograft study, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> showed a greater ability to
reduce tumor weight and volume than <FONT STYLE="white-space:nowrap">5-FU.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">NUC-7738:</FONT> A Transformation of Cordycepin </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">NUC-7738</FONT> is a ProTide transformation of cordycepin, a nucleoside analog that was isolated from the
fungus cordyceps militaris in 1950. Since that time, cordycepin has not been successfully developed or approved as a chemotherapy, but has shown potent anti-cancer activity in preclinical studies conducted by other companies and research
institutions. Similar to our other ProTide products, <FONT STYLE="white-space:nowrap">NUC-7738</FONT> is designed to generate the active anti-cancer metabolite of cordycepin directly inside cells, bypassing the resistance mechanisms of
transportation, activation and breakdown. In a preclinical study, we examined the in vitro cytotoxic activity of NUC-7738 across a range of different human cancer cell lines, including leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, T-cell
leukemia, multiple myeloma, pancreas, colon, liver and breast cancers, as compared with cordycepin. NUC-7738 was found, in 16 of the 20 cell lines examined in this study, to be more potent than cordycepin when comparing the concentrations of the
respective compounds required to kill 50% of the cancer cells. In three leukemia cell lines, NUC-7738 was found to be more than 50-times more potent than cordycepin based on the method of comparison described above. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cordycepin and its limitations </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cordycepin must be converted to its active form once inside
the cancer cell. Similar to other nucleoside analogs such as gemcitabine, the rate-limiting step of activation requires the addition of a phosphate group, in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">112
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
this case by an enzyme called adenosine kinase, or AK. This phosphorylated form of cordecypin is subsequently converted into its active metabolite, 3&#146; deoxyadenosine triphosphate, or 3&#146;
dATP. This metabolite interferes with multiple pathways in cancer cells, including purine biosynthesis, RNA synthesis and growth factor signalling pathways, such as mTOR, and therefore inhibits the proliferation of cancer cells. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until cordycepin is converted to its phosphorylated form, it
is subject to breakdown by adenosine deaminase, or ADA. Because of this potential for breakdown of cordycepin by ADA, cordycepin must be administered together with inhibitors of ADA. Given the critical role of ADA in multiple human metabolic
pathways, we believe the need to inhibit ADA when administering cordycepin represents a significant obstacle to the clinical development of cordycepin. Therefore, we designed <FONT STYLE="white-space:nowrap">NUC-7738</FONT> to generate 3&#146; dATP
inside cancer cells while avoiding breakdown by ADA and the requirement for AK. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Solution: NUC-7738 </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a ProTide of cordycepin, <FONT STYLE="white-space:nowrap">NUC-7738,</FONT> once inside the cancer cell, is rapidly converted into 3&#146; dATP. There is no need for AK to act on it, a process that has
been shown to be rate-limiting. There is also no breakdown by ADA. This results in significantly higher levels of 3&#146; dATP in cells. We have observed in our preclinical studies that <FONT STYLE="white-space:nowrap">NUC-7738</FONT> enters into
cancer cells independent of any nucleoside transporters and is converted to 3&#146; dATP regardless of ADA or AK levels. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The metabolism of NUC-7738 compared to cordycepin as described above is illustrated in the following graphic. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g38x85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are targeting <FONT
STYLE="white-space:nowrap">NUC-7738</FONT> for development in both solid and hematological tumors based on the broad activity seen with cordycepin in preclinical studies. We are currently evaluating <FONT STYLE="white-space:nowrap">NUC-7738</FONT>
in preclinical toxicology studies and we expect to initiate a Phase 1 clinical trial in 2018 in patients with solid tumors, with a second Phase 1 clinical trial planned for 2019 in patients with hematological tumors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">113
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Molecular Profiling </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Healthcare professionals often use molecular-profiling tools
to help choose the optimal therapy for patients with cancer. Therapeutic responses vary among patients because cancers are heterogeneous, even for tumors arising from the same site in the body. Molecular diagnostics assays that detect specific
biomarkers can provide a framework to classify tumors according to their molecular signature. In turn, the cancer profile can guide the choice of therapy for a particular patient. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of our clinical development strategy, we are building
a molecular profiling tool with the aim of identifying patients who may receive the greatest benefit from our ProTides compared with the current nucleoside analog standards of care. We are working to identify and quantify key biomarkers relevant to
Acelarin and <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> as well as to assess their predictive nature with regard to treatment. In addition, such assays may become relevant to our eventual commercial and reimbursement strategy by helping to <FONT
STYLE="white-space:nowrap">pre-identify</FONT> those patients for whom existing nucleoside analogs are unlikely to provide a significant benefit due to the existence in these patients of one or more cancer-resistance mechanisms. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Manufacturing </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently rely, and expect to continue to rely, on
third-party contract manufacturing organizations, or CMOs, for the supply of clinical trial materials of Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> <FONT STYLE="white-space:nowrap">NUC-7738</FONT> and any future product candidates
under the current good manufacturing practices, or cGMP, specified by the FDA. cGMP is a regulatory standard for the production of pharmaceuticals to be used in humans. In the future, we intend to also rely on our CMOs to produce sufficient
commercial quantities of Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> <FONT STYLE="white-space:nowrap">NUC-7738</FONT> and any future product candidates, if approved. We source key materials from third parties, either directly from
suppliers or indirectly through our CMOs. These raw materials are generally available from multiple vendors, which provides us with a robust and cost-effective supply chain. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manufacturing of any product candidate is subject to
extensive regulations that impose various procedural and documentation requirements governing recordkeeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. We expect that all of our CMOs will
manufacture Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT STYLE="white-space:nowrap">NUC-7738</FONT> under cGMP conditions and in compliance with any similar regulatory requirements outside the United States. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The development and commercialization of new drug therapies is highly competitive. While we believe that our
scientific knowledge, proprietary ProTide technology and development experience provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, biotechnology and specialty
pharmaceutical companies, academic institutions, governmental agencies and public and private research institutions. Any ProTide candidates that we successfully develop and commercialize will compete with existing products and new products that may
become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include efficacy, safety profile, price, convenience of administration and level of promotional activity. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The most common methods of treating patients with cancer are
surgery, radiation and drug therapy, including chemotherapy, hormone therapy, immunotherapy and targeted drug therapy. There are a variety of available drug therapies marketed for cancer, including many which are administered in combination to
enhance efficacy.&nbsp;We believe that our product candidates, if approved, will principally face competition from other chemotherapies, immunotherapy and targeted drug therapies. In the field of chemotherapy, our competitors include companies that
manufacture <FONT STYLE="white-space:nowrap">off-patent</FONT> chemotherapies, including gemcitabine and <FONT STYLE="white-space:nowrap">5-FU,</FONT> as well as companies that have developed new or improved chemotherapies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">114
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our product candidates, if approved, may face competition from cancer therapies
developed by other companies using phosphoramidate chemistry, as well as other approved drugs or drugs that may be approved in the future for indications for which we may develop our product candidates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The availability of reimbursement from government and other
third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could
result in our competitors establishing a strong market position before we are able to enter the market. Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for
clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Intellectual Property </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We actively seek to protect the intellectual property and proprietary technology that we believe is important to our business, including seeking, maintaining, enforcing and defending patent rights for our
therapeutics and processes, whether developed internally or licensed from third parties. Our success will depend on our ability to obtain and maintain patent and other protection including data/market exclusivity for our product candidates and
platform technology, preserve the confidentiality of our <FONT STYLE="white-space:nowrap">know-how</FONT> and operate without infringing the valid and enforceable patents and proprietary rights of third parties. See &#147;<I>Risk
Factors</I><I></I>&#151;<I>Risks Related to Our Intellectual Property</I>.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our policy is to seek to protect our proprietary position, generally by filing an initial priority filing at the U.K. Intellectual Property Office. This is followed by the filing of a patent application
under the Patent <FONT STYLE="white-space:nowrap">Co-operation</FONT> Treaty claiming priority from the initial application(s) and then filing applications for patent grant in territories including, for example, the United States, Europe and Japan.
In each case, we determine the strategy and territories required after discussion with our patent attorneys so that we obtain relevant coverage in territories that are commercially important to us and our product candidates. We additionally rely on
data exclusivity, market exclusivity and patent term extensions when available. We also rely on trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our underlying platform technology and product candidates. Prior to making
any decision on filing any patent application, we consider with our patent attorneys whether patent protection is the most sensible strategy for protecting the invention concerned or whether the invention should be maintained as confidential.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of September 5, 2017, we owned 176 granted
patents (of which five are U.S.-issued patents) and 142&nbsp;pending patent applications (of which eight are U.S. pending patent applications). Commercially or strategically important non-U.S. jurisdictions in which we hold issued or pending patent
applications include: Australia, Canada, China, Eurasia (in the form of a regional patent), Europe (in the form of a regional patent), Hong Kong, Israel, Japan, South Korea, Malaysia, Mexico, Philippines, Singapore and South Africa. Not included in
the patent count is one U.S. patent that is currently in reissue proceedings which were initiated by us for purposes of narrowing the claims covered by such patent. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Acelarin </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We own 33 granted patents covering the composition of matter
of our Acelarin product candidate which is a mixture of two diastereoisomers, both of which are therapeutically active. The patent claims are directed to the Acelarin product candidate and to a genus around that candidate. The patent has been
granted in major territories, including Europe and Japan. These granted patents are expected to expire in 2024, excluding any patent term adjustments and any patent term extensions. As disclosed above, there is also one patent in the United States
for Acelarin that is currently under reissue. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">115
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We own 37 granted patents, as well as 46 pending patent applications, directed towards
Acelarin in single diastereoisomer form. A patent claiming the more soluble single diastereoisomer of Acelarin has been granted in Europe and corresponding patent applications are pending in other major territories, including the United States and
Japan. These granted patents and patents arising from the pending applications, if issued, are expected to expire in 2033 and 2035, excluding any patent term adjustments and any patent term extensions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We own patent applications covering formulations of Acelarin
(including those used in the clinical trials), methods of making Acelarin (including as a single diastereoisomer), and specific uses of Acelarin, including the use of Acelarin in combination with carboplatin. Patents arising from these pending
applications have been filed in all major territories, including the United States, Europe and Japan and are expected to expire in 2035, 2036 and 2038 excluding any patent term adjustments and any patent term extensions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">NUC-3373</FONT>
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We own 54 granted patents and 9 pending
applications covering the composition of matter of <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> a genus around <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and specific uses of <FONT STYLE="white-space:nowrap">NUC-3373.</FONT> Those patents
were granted in major territories, including the United States, Europe and Japan. These granted patents and patents arising from the pending applications, if issued, are expected to expire in 2032, excluding any patent term adjustments and any
patent term extensions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT
STYLE="white-space:nowrap">NUC-7738</FONT> </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We own 19 pending applications covering the composition of matter of <FONT STYLE="white-space:nowrap">NUC-7738,</FONT> a genus around <FONT
STYLE="white-space:nowrap">NUC-7738</FONT> and specific uses of <FONT STYLE="white-space:nowrap">NUC-7738.</FONT> The patent applications are pending in major territories, including the United States, Europe and Japan. Patents arising from these
pending applications, if issued, are expected to expire in 2035 excluding any patent term adjustments and any patent term extensions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Laws and Regulations Regarding Patent Terms </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of individual patents depends upon the legal term
of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United
States, a patent term may be shortened if a patent is terminally disclaimed over another patent or as a result of delays in patent prosecution by the patentee. A patent&#146;s term may be lengthened by a patent term adjustment, which compensates a
patentee for administrative delays by the USPTO in granting a patent. The patent term of a European patent is 20 years from its effective filing date, which, unlike in the United States, is not subject to patent term adjustments in the same way as
U.S. patents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of a patent that covers an
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug or biologic may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug
Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the
drug or biologic is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar
provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug, for example Supplementary Protection Certificates. In the future, if and when our products receive FDA approval, we expect to
apply for patent term extensions on patents covering those products. We anticipate that some of our issued patents may be eligible for patent term extensions but such extensions may not be available and therefore our commercial monopoly may be
restricted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">116
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Collaboration and License Agreements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cardiff University License </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In August 2009, we entered into a research, collaboration
and license agreement with Cardiff University and University College Cardiff Consultants Ltd., or Cardiff Consultants, which we refer to as the Cardiff Agreement. Under the Cardiff Agreement, we collaborate with Cardiff University in the design,
synthesis, characterization and evaluation of phosphoramidate prodrugs, which we refer to as ProTides, based on certain nucleosides. We are responsible for funding certain work performed by Cardiff University and making other payments, which we
expect will total approximately &pound;141,350 in aggregate in 2017. Cardiff University and Cardiff Consultants, which is a holder of intellectual property developed by Cardiff University, have assigned to us all rights in the results of the
research under the Cardiff Agreement, and agreed not to undertake any research for any competing third party on nucleoside families of interest to us where such research would make use of ProTide-related intellectual property owned or controlled by
Cardiff University as of the date of the Cardiff Agreement or which at any time thereafter becomes owned or controlled by Cardiff University, which we refer to as the Cardiff intellectual property, or to grant rights in the Cardiff intellectual
property to any third party for use in connection with nucleosides of interest to us. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Upon our completion of the evaluation of the ProTides, we have the right to select one or more of the evaluated ProTides as candidates for potential development of a commercial product. Cardiff University
and Cardiff Consultants have granted us an exclusive worldwide license to use for all purposes the Cardiff intellectual property in respect of the nucleoside family of our selected ProTides. The exclusive dealing obligations of Cardiff University
and Cardiff Consultants will continue for these nucleoside families. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On our filing, or that of a sublicensee, of patent applications resulting from research under the Cardiff Agreement, we will owe Cardiff Consultants certain immaterial payments. If we or our sublicensees
develop and commercialize a product resulting from such research, we will owe Cardiff Consultants clinical development milestone payments of up to &pound;1,875,000; provided that such milestone payments are due only with respect to the first product
within each nucleoside family to achieve the milestone. We will also owe Cardiff Consultants royalties equal to a low-single digit percentage on our sales of a product resulting from such research. Should we sublicense our right to commercialize a
product resulting from the research, we will owe Cardiff Consultants a high-single digit percentage of payments received in consideration of the sublicense. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Cardiff Agreement currently expires on December&nbsp;31, 2017, although prior expiration dates have been repeatedly extended through
the agreement of the parties. Upon expiration, we have the right to extend the period in which we may evaluate products for three months, and for a further three months in exchange for an additional payment. The Cardiff Agreement may also be
terminated for an uncured material breach. Licenses to use the Cardiff intellectual property in the development and commercialization of products we have selected for commercialization, and related payment obligations, will survive expiration of the
Cardiff Agreement, but not on termination for an uncured material breach. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cardiff ProTides Agreement </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In October 2009, we entered into a license and collaboration agreement with Cardiff ProTides Ltd., or Cardiff ProTides, which agreement was subsequently amended and restated as an assignment, license and
collaboration agreement in March 2012 and was further amended in May 2012, which we refer to as the ProTides Agreement. Under the ProTides Agreement, we collaborated with Cardiff ProTides in the discovery, drug design and in vitro screening of
purine and pyrimidine based nucleosides as potential drug candidates. We funded certain work at Cardiff ProTides, and Cardiff ProTides has assigned to us all rights in the results of its research under the ProTides Agreement. Cardiff ProTides also
assigned to us patents related to certain compounds of interest, including with respect to Acelarin, and granted us an exclusive, worldwide license, including the right to grant sublicenses, to rights in and technical information related to certain
unpatented compounds for all therapeutic, diagnostic, prognostic and prophylactic applications. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">117
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we or a sublicensee develop one or more products covered by a valid claim of an assigned
patent or patent resulting from Cardiff ProTides&#146; research, such as Acelarin, we will owe Cardiff ProTides up to approximately $4.5&nbsp;million in development and approval milestone payments in the aggregate for the first such product.
Additional development and approval milestones would be payable for the first additional product in a new nucleoside series covered by a valid claim of an assigned patent or a patent resulting from Cardiff ProTides&#146; research, although the
maximum potential value of such milestone payments is approximately half the value of the milestone payments associated with the first product. We will also owe Cardiff ProTides royalties equal to a percentage in mid- to high-single digits on sales
of such products, subject to reduction under certain circumstances. Royalties on sales by sublicensees are set by formula, which formula would be likely to result in a royalty in the <FONT STYLE="white-space:nowrap">mid-single</FONT> digits.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ProTides Agreement expires, on a country by
country basis, on the later of the expiration, invalidity, abandonment, lapsing or rejection of the last valid claim of an assigned patent or patent resulting from Cardiff ProTides&#146; research, or, if certain technical information licensed from
Cardiff ProTides remains confidential or the product is covered by a period of data exclusivity, ten years from the date of first commercial sale of a product in such country. The ProTides Agreement may be sooner terminated on an uncured material
breach, bankruptcy of a party or, by Cardiff ProTides, if we challenge, or assist in a challenge, of the validity or ownership of an assigned patent or patent resulting from Cardiff ProTides&#146; research, or fail to pay amounts payable under the
ProTides Agreement. It may also be sooner terminated where sums payable by us remain unpaid for 45 days after we receive a notice from Cardiff ProTides that the relevant sums are overdue. Upon a termination of the ProTides Agreement, our license
rights will terminate except where the breach results from certain breaches by Cardiff ProTides, in which case our license rights continue on a non-exclusive basis, subject to reduced payment obligations. Upon termination of the ProTides Agreement,
including as a result of our breach, we will be under an obligation to assign back to Cardiff ProTides the patents which Cardiff ProTides originally assigned to us. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulation and Product Approval </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA Approval Process </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, pharmaceutical products are subject to
extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping,
approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of
administrative or judicial sanctions, such as FDA refusal to approve pending new drug applications, or NDAs, warning letters, voluntary product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines,
civil penalties and criminal prosecution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pharmaceutical product development in the United States typically involves the performance of nonclinical laboratory and animal tests, the
submission to the FDA of an IND which must become effective before clinical testing may commence, and adequate, well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is
sought. Satisfaction of FDA <FONT STYLE="white-space:nowrap">pre-market</FONT> approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or
disease. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preclinical tests include laboratory
evaluation of product chemistry, formulation, and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical and other nonclinical tests must comply with certain
federal regulations and requirements, including good laboratory practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and
controls, and a proposed clinical trial protocol. Long term nonclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">118
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A <FONT STYLE="white-space:nowrap">30-day</FONT> waiting period after the submission of each
IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this <FONT STYLE="white-space:nowrap">30-day</FONT> period, the clinical trial proposed in the IND may begin.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials involve the administration of the
investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&nbsp;in compliance with federal regulations, (ii)&nbsp;in compliance with good clinical practice, or
GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors, and (iii)&nbsp;under protocols detailing the objectives of the clinical trial, the
parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol and subsequent protocol amendments must be submitted to the FDA as part of the IND. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time or impose other
sanctions if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The clinical trial protocol and informed consent information for
patients in clinical trials must also be submitted to an institutional review board, or IRB, at each site where a clinical trial will be performed for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily
or permanently, for failure to comply with the IRB&#146;s requirements or it may impose other conditions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In
Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early
evidence on effectiveness. Phase 2 usually involves clinical trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance, and optimum dosage, and to identify common adverse effects
and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials are undertaken to obtain the additional information about clinical efficacy and safety in a
larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases,
the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 clinical trial with other confirmatory evidence may be sufficient in rare instances where the clinical trial is a
large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity, or prevention of a disease with potentially serious outcome, and
confirmation of the result in a second clinical trial would be practically or ethically impossible. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">After completion of the required clinical testing, a new drug application, or NDA, is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in
the United States. The NDA must include the results of all nonclinical, clinical, and other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting an
NDA is substantial. Under federal law, the submission of most NDAs is additionally subject to a substantial application user fee and the manufacturer or sponsor under an approved NDA is also subject to annual product and establishment user fees.
These fees are typically increased annually. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#146;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is
accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review. The FDA has agreed to certain performance goals in the review of NDAs. Most such applications for standard review drug products are reviewed within ten
to twelve months, while most applications for priority review drugs are reviewed in six to eight months. Priority review can be applied to drugs that the FDA determines offer major advances in treatment, or provide a treatment where no adequate
therapy exists. For biologics, priority review is further limited only for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">119
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
drugs intended to treat a serious or life-threatening disease relative to the currently approved products. The review process for both standard and priority review may be extended by FDA for
three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to
an advisory committee, which is typically a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory
committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which
the drug is manufactured. The FDA will not approve the product unless compliance with current good manufacturing practice requirements, or cGMP, is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and
effective in the indication studied. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the
FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional
testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has
committed to reviewing such resubmissions in two or six months depending on the type of information included. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a
condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for health care
professionals, and elements to assure safe and effective use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and
the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#146;s
safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory requirements is not maintained or problems are identified following initial marketing or any time thereafter. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Disclosure of Clinical Trial Information
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sponsors of clinical trials of certain <FONT
STYLE="white-space:nowrap">FDA-regulated</FONT> products, including prescription drugs, are required to register and disclose certain clinical trial information on a public website maintained by the U.S. National Institutes of Health. Information
related to the product, patient population, phase of investigation, clinical trial sites and investigator, and other aspects of the clinical trial is made public as part of the registration. Sponsors are also obligated to disclose the results of
these clinical trials after completion if the product candidate is ultimately approved, and disclosure of the results of these clinical trials will be delayed until such approval. Competitors may use this publicly-available information to gain
knowledge regarding the design and progress of our development programs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The Hatch-Waxman Act </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Orange Book Listing.</I></B> In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#146;s product. Upon approval of
a drug, each of the patents listed in the application for the drug is then published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn,
be cited by potential generic competitors in support of approval of an abbreviated new drug application, or ANDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">120
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing,
ANDA applicants are not required to conduct, or submit results of, nonclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#147;generic equivalents&#148; to
the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#146;s Orange Book.
Specifically, the applicant must certify that: (i)&nbsp;the required patent information has not been filed; (ii)&nbsp;the listed patent has expired; (iii)&nbsp;the listed patent has not expired, but will expire on a particular date and approval is
sought after patent expiration; or (iv)&nbsp;the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement, certifying that its proposed ANDA label does not contain or
carve out any language regarding the patented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use,</FONT></FONT> rather than certify to a listed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">method-of-use</FONT></FONT> patent. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming
the referenced product have expired. A certification that the new product will not infringe the already approved product&#146;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has
provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate
a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the
ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ANDA application also will not be approved until any
applicable <FONT STYLE="white-space:nowrap">non-patent</FONT> exclusivity listed in the Orange Book for the referenced product has expired. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Exclusivity.</I></B> Upon NDA approval of a new chemical entity, or NCE, which is a drug that contains no active moiety that has
been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity during which time the FDA cannot receive any ANDA seeking approval of a generic version of that drug. Certain changes to a drug, such as the addition
of a new indication to the package insert, are associated with a three-year period of exclusivity during which the FDA cannot approval an ANDA for a generic drug that includes the change. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If
there is no listed patent in the Orange Book, there may not be a Paragraph IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity period. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Patent Term Extension.</I></B> After NDA approval,
owners of relevant drug patents may apply for up to a five-year patent term extension. The allowable patent term extension is calculated as half of the drug&#146;s testing phase&#151;the time between IND submission and NDA submission&#151;and all of
the review phase&#151;the time between NDA submission and approval up to a maximum of five years. The time can be shortened if FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension
may not exceed 14 years. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For patents that might
expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the
post-approval patent extension is reduced by one year. The director of the PTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a
drug for which an NDA has not been submitted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">121
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Advertising and Promotion </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Once an NDA is approved, a product will be subject to
certain post-approval requirements. For instance, FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, <FONT STYLE="white-space:nowrap">off-label</FONT> promotion, industry-sponsored scientific and educational activities and promotional
activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in
indications, labeling, or certain manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data
similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Adverse Event Reporting and cGMP Compliance </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adverse event reporting and submission of periodic reports
is required following FDA approval of an NDA. The FDA also may require post-marketing testing, sometimes called Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval
that could restrict the distribution or use of the product. In addition, quality-control, drug manufacture, packaging, and labeling procedures, among other things, must continue to conform to cGMP after approval. Drug manufacturers and certain of
their subcontractors are required to register their establishments with FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing
facilities to assess compliance with cGMP. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production, quality control and record keeping to maintain compliance with cGMP. Regulatory authorities may impose a
range of enforcement actions, including bringing a seizure and injunction in court, withdraw product approvals or request a product recall if a company fails to comply with cGMP requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pediatric Information </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Pediatric Research Equity Act, or PREA, NDAs or
supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the
drug is safe and effective. The sponsor must submit an initial Pediatric Study Plan, or PSP, within 60 days of an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or as may be agreed between the
sponsor and the FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for
not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must
reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials or other
clinical development programs. The FDA may grant full or partial waivers, or deferrals, for submission of data. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Best Pharmaceuticals for Children Act, or BPCA, provides NDA holders a <FONT STYLE="white-space:nowrap">six-month</FONT> extension of
any exclusivity&#151;patent or <FONT STYLE="white-space:nowrap">non-patent&#151;for</FONT> a drug if certain conditions are met, including satisfaction of a pediatric trial as described above. Conditions for exclusivity include the FDA&#146;s
determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric clinical trials, and the applicant agreeing to perform, and
reporting on, the requested clinical trials within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">122
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Special Protocol Assessment </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A company may reach an agreement with FDA under the Special
Protocol Assessment, or SPA, process as to the required design and size of clinical trials intended to form the primary basis of an efficacy claim. Under the FDC Act and FDA guidance implementing the statutory requirement, an SPA is generally
binding upon the FDA except in limited circumstances, such as if the FDA identifies a substantial scientific issue essential to determining safety or efficacy after the clinical trial begins, public health concerns emerge that were unrecognized at
the time of the protocol assessment, the sponsor and FDA agree to the change in writing, or if the clinical trial sponsor fails to follow the protocol that was agreed upon with the FDA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Expedited Review and Approval </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has various programs, including Fast Track, priority review, accelerated approval and breakthrough
designation which are intended to expedite or simplify the process for reviewing drugs or provide for approval on the basis of surrogate endpoints. Even if a drug qualifies for one or more of these programs, the FDA may later decide that the drug no
longer meets the conditions for qualification or that the time period for FDA review or approval will not be shortened. Generally, drugs that may be eligible for these programs are those for serious or life-threatening conditions, those with the
potential to address unmet medical needs, or those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the development, and expedite the review, of drugs to treat serious diseases and
fill an unmet medical need. The request may be made at the time of IND submission and generally no later than the <FONT STYLE="white-space:nowrap">pre-NDA</FONT> meeting. The FDA will respond within 60 calendar days of receipt of the request.
Priority review, which is requested at the time of NDA submission, is designed to give drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists an initial review within six months as compared to a standard
review time of ten months. Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated drug and expedite review of the
application for a drug designated for priority review. Accelerated approval provides an earlier approval of drugs to treat serious diseases, and that fill an unmet medical need based on a surrogate endpoint, which is a laboratory measurement or
physical sign used as an indirect or substitute measurement representing a clinically meaningful outcome. Discussions with the FDA about the feasibility of an accelerated approval typically begin early in the development of the drug in order to
identify, among other things, an appropriate endpoint. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform post-marketing clinical trials to confirm the appropriateness of the surrogate
marker clinical trial. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Another expedited program
is that for Breakthrough Therapy. A Breakthrough Therapy designation is designed to expedite the development and review of drugs that are intended to treat a serious condition where preliminary clinical evidence indicates that the drug may
demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). A sponsor may request Breakthrough Therapy designation at the time that the IND is submitted, or no later than at the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting. The FDA will respond to a Breakthrough Therapy designation request within 60&nbsp;days of receipt of the request. A drug that receives
Breakthrough Therapy designation is eligible for all fast track designation features, intensive guidance on an efficient drug development program, beginning as early as Phase 1 and commitment from the FDA involving senior managers. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Regulation of Companion Diagnostic Devices
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we decide that a diagnostic test
would provide useful information for patient selection or if the FDA requires us to develop such a test, we may work with a collaborator to develop an <I>in vitro </I>diagnostic, or companion test. The FDA regulates <I>in vitro</I> diagnostic tests
as medical devices, and the type of regulation to which such a test will be subjected will depend in part on a risk assessment by the FDA as well as a determination of whether the test is intended to yield results that would be helpful to know
versus one that the FDA or we believe is necessary to know for the safe and effective use of our drugs under development. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">123
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA issued Guidance on <FONT STYLE="white-space:nowrap">In-Vitro</FONT> Companion
Diagnostic Devices in August 2014, which is intended to assist companies developing <I>in vitro</I> companion diagnostic devices and companies developing therapeutic products that depend on the use of a specific <I>in vitro</I> companion diagnostic
for the safe and effective use of the product. The FDA defined an <I>in vitro</I> companion diagnostic device, or IVD companion diagnostic device, as a device that provides information that is essential for the safe and effective use of a
corresponding therapeutic product. The use of an IVD companion diagnostic device with a therapeutic product will be stipulated in the instructions for use in the labeling of both the diagnostic device and the corresponding therapeutic product,
including the labeling of any generic equivalents of the therapeutic product. The FDA expects that the therapeutic sponsor will address the need for an approved or cleared IVD companion diagnostic device in its therapeutic product development plan
and that, in most cases, the therapeutic product and its corresponding companion diagnostic will be developed contemporaneously. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Europe/Rest of World Government Regulation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to regulations in the United States, we are and
will be subject, either directly or through our distribution partners, to a variety of regulations in other jurisdictions governing, among other things, clinical trials and commercial sales and distribution of our products, if approved. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whether or not we obtain FDA approval for a product, we must
obtain the requisite approvals from regulatory authorities in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the
United States have a process that requires the submission of a clinical trial application much like an IND prior to the commencement of human clinical trials. In Europe, for example, a clinical trial authorization, or CTA, must be submitted to the
competent national health authority and to independent ethics committees in each country in which a company plans to conduct clinical trials. Once the CTA is approved in accordance with a country&#146;s requirements, clinical trials may proceed in
that country. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The requirements and process
governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country, even though there is already some degree of legal harmonization in the E.U. member states resulting from the national implementation
of underlying E.U. legislation. In all cases, the clinical trials are conducted in accordance with GCP and other applicable regulatory requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To obtain regulatory approval of a new drug, or medicinal product, in the European Union a sponsor must obtain approval of a marketing
authorization application, or MAA. The way in which a medicinal product can be approved in the European Union depends on the nature of the medicinal product. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The centralized procedure results in a single MAA granted by the European Commission that is valid across the European Union, as well as
in Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for human drugs that are: (i)&nbsp;derived from biotechnology processes, such as genetic engineering, (ii)&nbsp;contain a new active substance indicated for the treatment
of certain diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative diseases, autoimmune and other immune dysfunctions and viral diseases, (iii)&nbsp;officially designated &#147;orphan drugs&#148; (drugs used for rare human diseases) and
(iv)&nbsp;advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines. The centralized procedure may at the request of the applicant also be used for human drugs which do not fall within the above mentioned
categories if the human drug (a)&nbsp;contains a new active substance which, on the date of entry into force of this Regulation, was not authorized in the Community; or (b)&nbsp;the applicant shows that the medicinal product constitutes a
significant therapeutic, scientific or technical innovation or that the granting of authorization in the centralized procedure is in the interests of patients or animal health at European Community level. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the centralized procedure in the European Union, the
maximum timeframe for the evaluation of a MAA by the EMA is 210 days (excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for
Human </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">124
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Use, or CHMP), with adoption of the actual marketing authorization by the European Commission thereafter. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a
medicinal product is expected to be of a major public health interest from the point of view of therapeutic innovation, defined by three cumulative criteria: the seriousness of the disease to be treated; the absence of an appropriate alternative
therapeutic approach, and anticipation of exceptional high therapeutic benefit. In this circumstance, EMA ensures that the evaluation for the opinion of the CHMP is completed within 150 days and the opinion issued thereafter. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The mutual recognition procedure, or MRP, for the approval of
human drugs is an alternative approach to facilitate individual national marketing authorizations within the European Union. Basically, the MRP may be applied for all human drugs for which the centralized procedure is not obligatory. The MRP is
applicable to the majority of conventional medicinal products, and is based on the principle of recognition of an already existing national marketing authorization by one or more member states. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The characteristic of the MRP is that the procedure builds on
an already existing marketing authorization in a member state of the European Union that is used as reference in order to obtain marketing authorizations in other E.U. member states. In the MRP, a marketing authorization for a drug already exists in
one or more E.U. member states and subsequently marketing authorization applications are made in other E.U. member states by referring to the initial marketing authorization. The member state in which the marketing authorization was first granted
will then act as the reference member state. The member states where the marketing authorization is subsequently applied for act as concerned member states. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The MRP is based on the principle of the mutual recognition by E.U. member states of their respective national marketing authorizations.
Based on a marketing authorization in the reference member state, the applicant may apply for marketing authorizations in other member states. In such case, the reference member state shall update its existing assessment report about the drug in 90
days. After the assessment is completed, copies of the report are sent to all member states, together with the approved summary of product characteristics, labeling and package leaflet. The concerned member states then have 90 days to recognize the
decision of the reference member state and the summary of product characteristics, labeling and package leaflet. National marketing authorizations shall be granted within 30 days after acknowledgement of the agreement. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Should any Member State refuse to recognize the marketing
authorization by the reference member state, on the grounds of potential serious risk to public health, the issue will be referred to a coordination group. Within a timeframe of 60 days, member states shall, within the coordination group, make all
efforts to reach a consensus. If this fails, the procedure is submitted to an EMA scientific committee for arbitration. The opinion of this EMA Committee is then forwarded to the Commission, for the start of the decision making process. As in the
centralized procedure, this process entails consulting various European Commission Directorates General and the Standing Committee on Human Medicinal Products or Veterinary Medicinal Products, as appropriate. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For other countries outside of the European Union, such as
countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in
accordance with GCP and the other applicable regulatory requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals,
product recalls, seizure of products, operating restrictions and criminal prosecution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Healthcare Reform </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There have been and continue to be legislative and regulatory changes to the healthcare system in the United States that could affect our future results of operations. The Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively referred to as the ACA, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">125
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
includes measures that have significantly changed health care financing by both governmental and private insurers. The provisions of the ACA of importance to the pharmaceutical and biotechnology
industry are, among others, the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs agents and biologic agents, which is
apportioned among these entities according to their market share in certain government healthcare programs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for
branded and generic drugs, respectively; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts to negotiated prices of
applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations, unless the drug is subject to discounts under the 340B drug discount program; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted or injected; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals
and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">new requirements under the federal Physician Payments Sunshine Act for drug manufacturers to report information related to payments and other transfers
of value made to physicians and teaching hospitals as well as ownership or investment interests held by physicians and their immediate family members; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along
with funding for such research; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">creation of the Independent Payment Advisory Board, which, if and when impaneled, will have authority to recommend certain changes to the Medicare
program that could result in reduced payments for prescription drugs; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and
Medicaid spending, potentially including prescription drug spending. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There have been judicial and Congressional challenges to certain aspects of the ACA, and we expect the current administration and Congress will likely continue to seek legislative and regulatory changes,
including repeal and replacement of certain provisions of the ACA. In January 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or
delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. The U.S. House of
Representatives passed legislation known as the American Health Care Act of 2017 in May 2017. More recently, the Senate Republicans introduced and then updated a bill to replace the ACA known as the Better Care Reconciliation Act of 2017. The Senate
Republicans also introduced legislation to repeal the ACA without companion legislation to replace it, and a &#147;skinny&#148; version of the Better Care Reconciliation Act of 2017. Each of these measures was rejected by the full Senate. Congress
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">126
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
will likely consider other legislation to replace elements of the ACA. It is uncertain whether the American Health Care Act or similar legislation will become law or how any future healthcare
reform legislation will impact our business. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition, other federal health reform measures have been proposed and adopted in the United States since the ACA was enacted. For example, as a result of the Budget Control Act of 2011, providers are subject to Medicare payment reductions of
2%&nbsp;per fiscal year through 2025 unless additional Congressional action is taken. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government
to recover overpayments from providers from three to five years. Further, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent
Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to product pricing, contain the cost of drugs, review the relationship between pricing and manufacturer patient programs, and
reform government program reimbursement methodologies for products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment
models. The U.S. Department of Health and Human Services, or HHS, set a goal of moving 30% of Medicare payments to alternative payment models tied to the quality or value of services by 2016 and 50% of Medicare payments into these alternative
payment models by the end of 2018. In March 2017, HHS announced that it has achieved its goal for 2016. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed
products. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in
reduced demand for our product candidates or additional pricing pressures. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing,
including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could compromise our ability to profitably commercialize any of our product candidates, if approved. In addition, regional healthcare
authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate
demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the European Union, similar political, economic and
regulatory developments may affect our ability to profitably commercialize any of our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or
member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing
and reimbursement of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and
the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service
providers. Coupled with increasing European Union and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval
activities and affect our ability to commercialize any products for which we obtain marketing approval. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price
ceilings on specific products and therapies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">127
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Healthcare Laws </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Physicians, other healthcare providers, and third-party
payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Although we currently do not have any products on the market, our current and future business operations are and
will be subject to various U.S. federal and state and other foreign fraud and abuse laws and other healthcare laws and regulations. These laws and regulations may impact, among other things, our arrangements with third-party payors, healthcare
professionals who participate in our clinical research programs, healthcare professionals and others who purchase, recommend or prescribe our approved products, and our proposed sales, marketing, distribution, and education programs. The U.S.
federal and state healthcare laws and regulations that may affect our ability to operate include: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal Anti-Kickback Statute, which prohibits persons from, among other things, knowingly and willfully soliciting, receiving, offering or paying
anything of value, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federally funded
healthcare programs, such as Medicare and Medicaid; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal civil and criminal false claims laws, including, without limitation, the federal civil monetary penalties law and the civil False Claims
Act (which can be enforced by private citizens through <I>qui tam</I> actions), prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment of federal funds, and
knowingly making, or causing to be made, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal liability for executing or attempting to
execute a scheme to defraud any healthcare benefit program and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the
delivery of or payment for healthcare benefits, items or services; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, which
imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without the appropriate authorization by entities subject to the
law, such as healthcare providers, health plans, and healthcare clearinghouses and their respective business associates that perform certain functions or activities that involve the use or disclosure of protected health information on their behalf;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the federal transparency requirements under the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs,
devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or CHIP to report to HHS information related to payments and other transfers of value provided to physicians and teaching hospitals and physician ownership and investment
interests; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">analogous state laws and regulations, such as state anti-kickback and false claims laws, that impose similar restrictions and may apply to items or
services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#146;s voluntary compliance guidelines
and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other health care providers; and state health information privacy and data
breach notification laws, which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus
complicating compliance efforts. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">128
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will be required to spend substantial time and money to ensure that our business
arrangements with third parties comply with applicable healthcare laws and regulations. In the United States, healthcare reform legislation has strengthened these federal and state healthcare laws. For example, the ACA amends the intent requirement
of the federal Anti-Kickback Statute and criminal healthcare fraud statutes to clarify that liability under these statutes does not require a person or entity to have actual knowledge of the statutes or a specific intent to violate them. Moreover,
the ACA provides that the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. Because
of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Violations of these laws can subject us to criminal, civil
and administrative sanctions including monetary penalties, damages, fines, disgorgement, individual imprisonment, and exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, additional reporting
requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we may be required to curtail or restructure our operations.
Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our future operations and business. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Coverage and Reimbursement </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Significant uncertainty exists as to the coverage and
reimbursement status of any products for which we may obtain regulatory approval. Sales of any of our product candidates, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors,
including government healthcare programs such as Medicare and Medicaid, and private payors, such as commercial health insurers and managed care organizations. Third-party payors determine which drugs they will cover and the amount of reimbursement
they will provide for a covered drug. In the United States, there is no uniform system among payors for making coverage and reimbursement decisions. In addition, the process for determining whether a payor will provide coverage for a product may be
separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not
include all of the FDA-approved products for a particular indication. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In order to secure coverage and reimbursement for our products, if approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and
cost-effectiveness of the product, in addition to the costly studies required to obtain FDA or other comparable regulatory approvals. Even if we conduct pharmacoeconomic studies, our product candidates may not be considered medically necessary or
cost-effective by payors. Further, a payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The containment of healthcare costs has become a priority of
federal, state and foreign governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost-containment programs to limit the
growth of government-paid healthcare costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs. For example, in the United States, the ACA contains provisions
that may reduce the profitability of products, including, for example, increased rebates for products sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D
beneficiaries and annual fees based on pharmaceutical companies&#146; share of sales to federal health care programs. CMS may develop new payment and delivery models, such as bundled payment models. For example, HHS set a goal of moving 30% of
Medicare payments to alternative payment models tied to the quality or value of services by 2016 and 50% of Medicare payments into these alternative payment models by the end of 2018. Adoption of government controls and measures, and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">129
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for our products. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The marketability of any products for which we receive regulatory approval for commercial sale may suffer if
the government and third-party payors fail to provide adequate coverage and reimbursement. The focus on cost containment measures in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing.
Coverage policies and third-party reimbursement rates may change at any time. Even if we attain favorable coverage and reimbursement status for one or more products for which we receive regulatory approval, less favorable coverage policies and
reimbursement rates may be implemented in the future. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employees </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of September 18, 2017, we had 16 full-time employees. We have never had a work stoppage and none of our employees are covered by
collective bargaining agreements or represented by a labor union. We believe our employee relations are good. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Facilities </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our corporate headquarters and most of our operations, are located at 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom, which has a total leasable area of 5,632 square feet. We believe that our office
facilities in the United Kingdom are sufficient to meet our current needs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Proceedings </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">From time to time, we may be party to litigation that arises in the ordinary course of our business. We do not have any pending litigation that, separately or in the aggregate, would, in the opinion of
management, have a material adverse effect on our results of operations, financial condition or cash flows. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">130
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_14"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the names, ages and positions
of our executive officers and directors: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:27pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Executive Officers</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hugh Griffith</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher Wood</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairman and Chief Medical Officer</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Donald Munoz</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Isaac Cheng</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">James Healy</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin Mellish</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rafa&egrave;le Tordjman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Officers </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Hugh Griffith</I></B><I> </I>is our <FONT
STYLE="white-space:nowrap">co-founder</FONT> and has served as our Chief Executive Officer and as a member of our board of directors since our operations began in March 2008. In addition, he currently serves as a
<FONT STYLE="white-space:nowrap">non-executive</FONT> director of EdixoMed Limited and MedAnnex Limited, biotech companies which he <FONT STYLE="white-space:nowrap">co-founded</FONT> in 2009. He also serves as director of Alida Capital
International, a biotech business angel syndicate that he formed in 2009. Prior to founding NuCana, Mr.&nbsp;Griffith was Chief Operating Officer of Bioenvision, Inc., a biopharmaceutical company, from July 2004 until December 2007, when it was
acquired by Genzyme Corporation (now Sanofi). He previously served as Commercial Director of Bioenvision, Inc. from September 2002 to June 2004. Before that, Mr.&nbsp;Griffith held several senior commercial positions at Quantanova Limited, a
biopharmaceutical company, from January 2002 to July 2002, Abbott Laboratories (now AbbVie Inc.) from October 1995 to December 2001 and Warner-Lambert Company (now Pfizer Inc.) from April 1992 to October 1995. He currently serves on the advisory
board of the Scottish Lifesciences Association. Mr.&nbsp;Griffith received an M.B.A. from Cardiff Business School and a B.Sc. Honours in Biology from the University of Stirling. We believe that Mr.&nbsp;Griffith possesses specific attributes that
qualify him to serve as a member of our board of directors, including the perspective and experience he brings as our Chief Executive Officer, which provides historic knowledge of our company, operational expertise and continuity to our board of
directors, and his significant experience in the biopharmaceutical industry in positions including chief executive officer, chief operating officer and executive director. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Christopher Wood</I></B><I> </I>is our <FONT
STYLE="white-space:nowrap">co-founder</FONT> and has served as a member of our board of directors since our founding, as our Chairman since 2008 and as our Chief Medical Officer since July 2017. Dr.&nbsp;Wood also currently serves as chairman of
several biopharmaceutical or biotechnology companies including: Edixomed Limited, MedAnnex Limited and OncoBioPharm Limited. In addition, he is a director of MiNA Therapeutics Limited, a biotechnology company. Prior to joining our board of
directors, Dr.&nbsp;Wood was a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Bioenvision, Inc., a biopharmaceutical company, and served as its Chairman and Chief Executive Officer from 2000 until 2007, when it was acquired by Genzyme
Corporation (now Sanofi). From 1995 through 1999, Dr.&nbsp;Wood was chairman of the board and Chief Executive of Eurobiotech, Inc. From 1989 through 1990, Dr. Wood was co-founder and director of Genethics Ltd until it was acquired by Proteus
International plc. Dr.&nbsp;Wood <FONT STYLE="white-space:nowrap">co-founded</FONT> and served as chairman from 1986 to 1992 of Medirace Ltd., a biotechnology company, which later became Medeva PLC and was acquired by Celltech Group PLC (now UCB).
From 1979 to 1991, Dr.&nbsp;Wood was a surgical oncologist at The Royal Postgraduate Medical School and a consultant surgeon at Hammersmith Hospital, both in London, England. Dr.&nbsp;Wood is an honorary Professor at Imperial College London, a
Fellow of the Royal College of Surgeons of Edinburgh and a Fellow of the Learned Society of Wales. Dr.&nbsp;Wood received an M.D. from the University of Wales School of Medicine. We believe that Dr.&nbsp;Wood possesses specific attributes that
qualify him to serve as a member of our board of directors, including his extensive experience in the biotechnology sector and his having founded and managed four companies, including our company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">131
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Donald Munoz</I></B><I> </I>has served as our Chief Financial Officer since October
2015. Prior to joining NuCana, Mr.&nbsp;Munoz served as Group Chief Financial Officer of NOXXON Pharma AG (now NOXXON Pharma N.V.), a biopharmaceutical company, from September 2014 to September 2015. Before that, he was Head of Investment Banking at
Summer Street Research Partners, an investment banking and institutional securities firm focused exclusively on healthcare, from August 2012 to September 2014. Mr.&nbsp;Munoz previously served as a Managing Director leading the medical technology
investment banking franchises at Cowen&nbsp;and Company, LLC from 2009 to 2011 and Leerink Partners LLC from 2005 to 2009. Prior to that, he spent approximately ten years in the healthcare investment banking group at Alex. Brown&nbsp;&amp; Sons and
its successor, Deutsche Bank Securities. Mr.&nbsp;Munoz received an M.B.A. in Finance and Accounting from Columbia Business School and a B.A. from Dartmouth College. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Rafa&egrave;le Tordjman</I></B> has
served as a member of our board of directors since November 2011. From February 2017 to August 2017, Dr.&nbsp;Tordjman was a Special Advisor at Sofinnova Partners, an independent venture capital firm based in Paris, where she specialized in life
sciences investments. She joined Sofinnova Partners in 2001 and served as a Managing Partner from January 2011 to February 2017. Dr.&nbsp;Tordjman currently serves as a director of ObsEva SA, a Nasdaq-listed biopharmaceutical company, and Lysogene,
a Euronext-listed biotechnology company, and has previously served as a director of several biopharmaceutical or biotechnology companies, including: Ascendis Pharma A/S, DBV Technologies S.A., Medtronic CoreValve LLC and Flexion Therapeutics, Inc.
Previously, Dr.&nbsp;Tordjman was a research scientist at the Institut National de la Sant&eacute; et de la Recherche M&eacute;dicale (INSERM) in Cochin Hospital, Paris, France. Before joining INSERM, Dr.&nbsp;Tordjman was a medical doctor
specializing in clinical hematology and internal medicine. Dr.&nbsp;Tordjman received a Ph.D. with high honors in hematopoiesis and angiogenesis, and a post-doctoral fellowship in immunology, from the University Paris VII. Dr.&nbsp;Tordjman received
an M.D. and fellowship in hematology and internal medicine from the Paris University Hospitals. We believe that Dr.&nbsp;Tordjman possesses specific attributes that qualify her to serve as a member of our board of directors, including her medical
background, clinical and research experience, and industry knowledge. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>James Healy</I></B> has served as a member of our board of directors since March 2014. Dr.&nbsp;Healy has also been a General Partner of Sofinnova Ventures since 2000, and currently serves as a
director of Ascendis Pharma A/S, Coherus BioSciences, Inc., Edge Therapeutics, Inc., Natera, Inc., ObsEva SA and several private companies. Dr.&nbsp;Healy has previously served as a board member of Amarin Corporation, Auris Medical Holding AG,
Hyperion Therapeutics, Inc., InterMune, Inc., Anthera Pharmaceuticals, Inc., Durata Therapeutics, Inc., CoTherix, Inc., Movetis NV and several private companies. Prior to 2000, Dr.&nbsp;Healy held various positions at Sanderling Ventures, Bayer
Healthcare Pharmaceuticals (as successor to Miles Laboratories) and ISTA Pharmaceuticals, Inc. Dr.&nbsp;Healy also currently serves on the board of directors of the U.S. National Venture Capital Association and the Biotechnology Industry
Organization. Dr.&nbsp;Healy holds an M.D. and a Ph.D. in Immunology from Stanford University School of Medicine and a B.A. in Molecular Biology and Scandinavian Studies from the University of California, Berkeley. We believe that Dr.&nbsp;Healy
possesses specific attributes that qualify him to serve as a member of our board of directors, including extensive experience in biomedical research, development and finance. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Isaac Cheng</I></B><I> </I>has served as a member of
our board of directors since May 2017. Dr.&nbsp;Cheng is currently an investment advisor at Morningside Technology Advisory LLC, a venture capital firm, which he joined in 2006, and is also a director of Cognoa, Inc., a digital health company, and
several biopharmaceutical or biotechnology companies, including: Liquidia Technologies, Inc., Artugen Therapeutics Limited, Amylyx Pharmaceuticals, Inc. and <FONT STYLE="white-space:nowrap">K-Gen,</FONT> Inc. Previously, he was a board member of
Advanced Cell Diagnostics, Inc., a biotechnology company, and a board observer of both Chimerix, Inc., a biotechnology company, and Argos Therapeutics, Inc , a biotechnology company. From 2004 to 2005, Dr.&nbsp;Cheng was Director of Research and
Development at Serica Technologies, Inc., a Morningside portfolio company. Prior to that, Dr.&nbsp;Cheng was an Associate Director at </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">132
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Novartis Pharmaceuticals Corporation in Clinical Development and Medical Affairs. Dr.&nbsp;Cheng received his M.D. from Tufts University School of Medicine. We believe that Dr.&nbsp;Cheng
possesses specific attributes that qualify him to serve as a member of our board of directors, including his medical background, clinical and research experience and industry knowledge. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Martin Mellish</I></B><B> </B>has served as a member of our board of directors since December 2009. Since
1994, Mr.&nbsp;Mellish has served as the Executive Director of Aspen Advisory Services Ltd., a London-based private investment office overseeing private and publicly traded investments in North America, Europe and Asia. Mr.&nbsp;Mellish also
currently serves as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director of Kensington Green (Management) Limited, a real estate management company, Levitronix Technologies LLC, a technology company, Alturki Holding, an industrial
investment and development holding company, Livercyte Limited, a biotechnology company, and Omnicyte Limited, a biotechnology company. From 1992 to 1994, Mr. Mellish pursued studies at the Massachusetts Institute of Technology. From 1984 to 1992, he
was controller and subsequently Chief Financial Officer of Alturki Holding. Prior to that, Mr.&nbsp;Mellish trained at Price Waterhouse Coopers. He was awarded an SM (Management) from the Massachusetts Institute of Technology and an M.Sc.
(Accounting) from Northeastern University. We believe that Mr.&nbsp;Mellish possesses specific attributes that qualify him to serve as a member of our board of directors, including his significant experience in accounting and finance. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign Private Issuer Exemption </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a &#147;foreign private issuer,&#148; as defined by the
SEC, although we are permitted to follow certain corporate governance practices of England and Wales, instead of those otherwise required under The Nasdaq Stock Market, or Nasdaq, for domestic issuers, we intend to follow the Nasdaq corporate
governance rules applicable to foreign private issuers. While we voluntarily follow most Nasdaq corporate governance rules, we intend to take advantage of the following limited exemptions: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exemption from filing quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> or provide current reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> disclosing significant events within four days of their occurrence. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exemption from Section&nbsp;16 rules regarding sales of ordinary shares by insiders, which will provide less data in this regard than shareholders of
U.S. companies that are subject to the Exchange Act. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exemption from the Nasdaq rules applicable to domestic issuers requiring disclosure within four business days of any determination to grant a waiver of
the code of business conduct and ethics to directors and officers. Although we will require board approval of any such waiver, we may choose not to disclose the waiver in the manner set forth in the Nasdaq rules, as permitted by the foreign private
issuer exemption. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exemption from the requirements that director nominees are selected, or recommended for selection by our board of directors, either by
(1)&nbsp;independent directors constituting a majority of our board of directors&#146; independent directors in a vote in which only independent directors participate, or (2)&nbsp;a committee comprised solely of independent directors, and that a
formal written charter or board resolution, as applicable, addressing the nominations process is adopted. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, Nasdaq Rule&nbsp;5615(a)(3) provides that a foreign private issuer, such as us, may rely on home country corporate governance
practices in lieu of certain of the rules in the Nasdaq Rule&nbsp;5600 Series and Rule&nbsp;5250(d), provided that we nevertheless comply with Nasdaq&#146;s Notification of Noncompliance requirement (Rule&nbsp;5625), the Voting Rights requirement
(Rule&nbsp;5640) and that we have an audit committee that satisfies Rule&nbsp;5605(c)(3), consisting of committee members that meet the independence requirements of Rule&nbsp;5605(c)(2)(A)(ii). Although we are permitted to follow certain corporate
governance rules that conform to U.K. requirements in lieu of many of the Nasdaq corporate governance rules, we intend to comply with the Nasdaq corporate governance rules applicable to foreign private issuers as set forth in the prior sentence.
Accordingly, our shareholders will not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. We may utilize these exemptions for as long as we continue to qualify
as a foreign private issuer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">133
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Composition and Director Independence </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business affairs are managed under the direction of our board of directors, which is currently composed of
six members. Under the rules and regulations of Nasdaq a director will qualify as &#147;independent&#148; if our board of directors affirmatively determines that he or she has no material relationship with us (either directly or as a partner,
stockholder or officer of an organization that has a relationship with us). Our board of directors will establish guidelines to assist it in determining whether a director has such a material relationship. Ownership of a significant amount of our
shares, by itself, does not constitute a material relationship. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to Nasdaq rules, a director employed by us cannot be deemed to be an &#147;independent director,&#148; and consequently Mr.&nbsp;Griffith and Dr.&nbsp;Wood do not qualify as independent
directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has reviewed
the materiality of any relationship that each of our directors has with us, either directly or indirectly. Based on this review, our board of directors has determined that the following directors are &#147;independent directors&#148; as defined by
the applicable rules and regulations of Nasdaq: Rafa&#232;le Tordjman, James Healy, Isaac Cheng and Martin Mellish. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Committees of the Board of Directors and Corporate Governance </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to certain exceptions, the rules of the Nasdaq permit a foreign private issuer to follow its home country practice in lieu of the
listing requirements of Nasdaq. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The committees of
our board of directors will consist of an audit committee, a remuneration committee and a nominations committee. As permitted by home country practice, our remuneration and nominations committees may include non-independent directors. Each of these
committees has the responsibilities described below. Our board of directors may also establish other committees from time to time to assist in the discharge of its responsibilities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Audit Committee </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Immediately upon completion of the offering, the members of
our audit committee will be three of our <FONT STYLE="white-space:nowrap">non-executive</FONT> directors,&nbsp;Martin Mellish,&nbsp;James Healy and&nbsp;Isaac Cheng, and each of these members is an &#147;independent director&#148; as such term is
defined in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. Martin Mellish will serve as chair of the audit committee. Our board of directors has determined that Martin Mellish is a financial expert as contemplated by the
rules of the SEC implementing Section&nbsp;407 of the Sarbanes Oxley Act of 2002. Our audit committee will meet at least four times per year and oversee the monitoring of our internal controls, accounting policies and financial reporting and provide
a forum through which our external auditors and independent registered public accounting firm reports. Our audit committee will meet at least once a year with the external auditors and our independent registered public accounting firm without
executive board members present. The audit committee will also be responsible for overseeing the activities of the external auditors and our independent registered public accounting firm, including their appointment, reappointment, or removal as
well as monitoring their objectivity and independence. The audit committee will also review and approve the fees paid to our external auditors and independent registered public accounting firm and determine whether the fee levels for <FONT
STYLE="white-space:nowrap">non-audit</FONT> services, individually and in aggregate, relative to the audit fee are appropriate so as not to undermine their independence. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration Committee </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Immediately upon the completion of this offering, the
members of the remuneration committee will be Hugh Griffith and two of our <FONT STYLE="white-space:nowrap">non-executive</FONT> directors, Rafa&#232;le Tordjman and James Healy. Each of these non-executive director members is a non-employee
director as defined in Rule 166-3 under the Exchange Act and an outside director as defined in Section 162(m) of the Internal Revenue Code of 1986, as amended. Rafa&#232;le Tordjman will serve as chair of the remuneration committee. Our remuneration
committee will review, among other things, the performance of the executive officers and sets the scale and structure of their remuneration and the basis of their </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">134
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
service agreements with due regard to the interests of the shareholders. It will be a policy of the remuneration committee that no individual participates in discussions or decisions concerning
his or her own remuneration. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nominations
Committee </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Immediately upon completion of
this offering, the members of the nominations committee will be Hugh Griffith and Christopher Wood and one of our non-executive directors, Rafa&#232;le Tordjman. Hugh Griffith will serve as chair of the nominations committee and oversee the
evaluation of the board of directors&#146; performance. The nominations committee will meet at least twice a year and review the structure, size and composition of the board of directors, supervise the selection and appointment process of directors,
making recommendations to the board of directors with regard to any changes and using an external search consultancy if considered appropriate. For new appointments, the nominations committee will make a final recommendation to the board of
directors, and the board of directors will have the opportunity to meet the candidate prior to approving the appointment. Once appointed, the nominations committee will oversee the induction of new directors and provide the appropriate training to
the board of directors during the course of the year in order to ensure that they have the knowledge and skills necessary to operate effectively. The nominations committee will also be responsible for annually evaluating the performance of the board
of directors, both on an individual basis and for the board of directors as a whole, taking into account such factors as attendance record, contribution during board of directors meetings and the amount of time that has been dedicated to board
matters during the course of the year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Business
Conduct and Ethics </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the completion of
this offering, we will adopt a Code of Business Conduct and Ethics that will cover a broad range of matters including the handling of conflicts of interest, compliance issues and other corporate policies such as equal opportunity and <FONT
STYLE="white-space:nowrap">non-discrimination</FONT> standards. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following discussion provides the amount of compensation paid, and benefits in kind granted, by us and our subsidiaries to our
directors and members of management for services in all capacities to us and our subsidiaries for the year ended December&nbsp;31, 2016, as well as the amount contributed by us or our subsidiaries into money purchase plans for the year ended
December&nbsp;31, 2016 to provide pension, retirement or similar benefits to, our directors and members of the executive management board. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Directors&#146; and Executive Officers&#146; Compensation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended December&nbsp;31, 2016, we paid an aggregate of &pound;1.3&nbsp;million in cash and benefits
to our executive officers and directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Bonus Plans </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The summary set forth below describes the bonus plan pursuant to which compensation was paid to our executive officers and directors for
the year ended December&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
executive officers and directors are eligible for an annual bonus at the discretion of the Remuneration Committee. Bonus awards are reviewed at the end of each calendar year and any such awards are determined by the performance of the individual and
our company as a whole based upon the achievement of strategic objectives set at the beginning of the year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Outstanding Equity Awards, Grants and Option Exercises </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended December&nbsp;31, 2016, options to
purchase 366,440 ordinary shares were awarded to our executive officers and directors. As of December&nbsp;31, 2016, our executive officers and directors held options </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">135
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to purchase 2,655,687 ordinary shares. Our executive officers and directors exercised options to purchase 45,750 ordinary shares during the year ended December&nbsp;31, 2016. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We periodically grant share options to employees, directors
and consultants to enable them to share in our successes and to reinforce a corporate culture that aligns their interests with that of our shareholders. From December 31, 2014 through August 31, 2017, we have granted options to purchase 389,690
ordinary shares to our executive officers and directors. Subsequent to August 31, 2017, we have granted options to purchase 1,074,283 ordinary shares to our executive officers and directors and we have approved for grant, as of and in connection
with this offering, options to purchase 178,282 ordinary shares to our executive officers and directors.&nbsp;From December&nbsp;31, 2014 through August 31, 2017, we have granted options to purchase 191,250 ordinary shares to 12&nbsp;employees and
consultants who are not directors or executive officers. Of these, options to purchase 50,000&nbsp;shares were cancelled in 2016. Subsequent to August 31, 2017, we have granted options to purchase 187,500 ordinary shares to five employees who are
not executive officers or directors and we have approved for grant, as of and in connection with this offering, options to purchase 37,500 ordinary shares to one employee who is not an executive officer or director. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pension, Retirement and Similar Benefits
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the year ended December&nbsp;31,
2016, we and our subsidiaries contributed a total of &pound;33,722 into money purchase plans to provide pension, retirement or similar benefits to our executive officers and directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Insurance and Indemnification </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent permitted by the Companies Act 2006, we are permitted to indemnify our directors against any
liability they incur by reason of their directorship. We maintain directors&#146; and officers&#146; insurance to insure such persons against certain liabilities. In connection with this offering, we expect to enter into a deed of indemnity with
each of our directors and executive officers prior to completion of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification of liabilities arising under the Securities Act may be permitted to our directors, executive officers or persons controlling us pursuant to the foregoing provisions, we have
been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity Compensation Plans&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted options to purchase our shares under three share option schemes, which are summarized in this section. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2009 Share Option Scheme </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;1, 2009, we adopted a share option scheme, or
the 2009 Share Option Scheme, for the purpose of enabling the grant of share options to incentivize our employees, consultants and directors and those employees, consultants and directors of our subsidiary companies. The 2009 Share Option Scheme was
subsequently amended and approved by our board of directors and by our shareholders on November&nbsp;15, 2011 and November&nbsp;17, 2011, respectively. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2009 Share Option Scheme permits grants of (i)&nbsp;enterprise management incentive options which are potentially <FONT
STYLE="white-space:nowrap">tax-advantaged</FONT> in the United Kingdom under the terms of Schedule 5 to the United Kingdom Income Tax (Earnings and Pensions) Act 2003 (subject to the relevant conditions being met by the company and the grantee) and
(ii) &#147;unapproved&#148; options (which do not attract tax advantages as they have not been &#147;approved&#148; by the U.K. tax authority, HMRC). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">136
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2017, we had granted options to purchase 1,032,500 ordinary shares to
directors, employees and consultants under the 2009 Share Option Scheme. 7,500 of these options lapsed in 2017. The remainder of these options have vested and are exercisable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Class&nbsp;of Share.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;An
option granted under the 2009 Share Option Scheme entitles the option holder, subject to the satisfaction, waiver or acceleration of specific exercise conditions, to subscribe for ordinary shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Exercise
Conditions.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>Options granted under our 2009 Share Option Scheme may be granted subject to vesting schedules, performance targets or other conditions which must be satisfied or waived before exercise. Exercise conditions
may be removed or varied by our board of directors, provided that any variation shall be (in the reasonable opinion of our board of directors) no more difficult to satisfy than the original exercise condition. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each option grant is documented through an option agreement.
Most of the option agreements entered into under the 2009 Share Option Scheme provide that all unexercised options are exercisable upon one or more of the following events: (i)&nbsp;the admission of part of or the entirety of issued share capital
(or of any holding company) to listing on the Official List of the U.K. Listing Authority and to trading on the market for listed securities of London Stock Exchange plc, or to trading on AIM, a market of the London Stock Exchange, or to trading on
any recognized investment exchange (as that term was defined in Section 841 of Income and Corporate Taxes Act 1988, or ICTA, and as now contained in Section 1137 of the Corporation Tax Act 2010, or CTA); (ii) a change of control; or (iii)&nbsp;a
sale of our company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Takeovers and
Corporate Events.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>If (a)&nbsp;any person or group of persons acting in concert obtains control (as defined in section 840 of ICTA and as now contained in section 995 Income Tax Act, or ITA) of the company, as a result
of making either (i)&nbsp;an offer to acquire shares amounting to more than 50% of the issued share capital of the company on a condition such that if it is satisfied the person or group of persons will have control of the company, or (ii)&nbsp;a
general offer to acquire all of the issued share capital of the company (or all of the ordinary shares of the company in issue); or (b)&nbsp;any person becomes entitled or bound to acquire shares in the company under sections 428 to 430F of the
Companies Act 1985 (since repealed and replaced by sections 974 to 991 of the Companies Act 2006); or (c)&nbsp;under section 425 of the Companies Act 1985 (since repealed and replaced by sections 895 to 901 of the Companies Act 2006) the courts of
England and Wales sanction a compromise or arrangement proposed for the purpose of or in connection with a scheme for the reconstruction of the company or its amalgamation with any other company or companies, and, in each case an option
holder&#146;s option agreement expressly so provides, an option holder may at any time exercise his or her options or any part thereof which has not lapsed within a specified period. To the extent they are not exercised, such options will lapse at
the end of the specified period for exercise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Lapse of Options.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;If not otherwise lapsed in accordance with the provisions of the 2009 Share Option
Scheme, an option granted under the 2009 Share Option Scheme shall lapse at 5p.m. on the day before the 10th anniversary of the grant of the option. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If an option holder dies, his or her personal representatives may exercise his or her options within a period ending on the earlier of
(i)&nbsp;the expiry of 12 months after the date of death, and (ii) 5 p.m. on the day before the 10th anniversary of the grant of the option, only to the extent that any exercise conditions have been met at the time of death. Failing such exercise
the deceased option holder&#146;s options shall lapse. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Adjustment of Awards.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In the event that there is any variation in our share capital that affects the value of the options, our board of directors will make such
adjustments to the number and exercise price of shares subject to each option or the option price as our board of directors considers appropriate in accordance with the rules of the 2009 Share Option Scheme. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transferability.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;No
options under the 2009 Share Option Scheme may be transferred, assigned or have any created over them and will lapse immediately upon an attempt to do so. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">137
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendment.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>Our board of directors may, with the
approval of the shareholders of the company at a general meeting, amend the 2009 Share Option Scheme, provided that any amendment shall not, without the consent of an option holder, materially increase his or her liabilities or materially decrease
the value of his or her subsisting rights under an outstanding option. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">With effect from closing of this offering, the rules of the 2009 Share Option Scheme shall be amended such that any amendment to the scheme shall take effect without the requirement for the prior approval
of our shareholders, except as otherwise required by applicable laws or the rules of any securities exchange on which our securities are listed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2012 Share Option Scheme </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;3, 2012, we adopted a share option scheme, or the 2012 Share Option Scheme, for the purpose of enabling the grant of share
options to incentivize our employees and directors and those employees and directors of our subsidiary companies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2012 Share Option Scheme permits grants of (i)&nbsp;enterprise management incentive options, which are potentially tax advantaged in
the United Kingdom, and (ii) &#147;unapproved&#148; options, which do not attract tax advantages as they have not been &#147;approved&#148; by HMRC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2017, we had granted options to purchase 1,908,935 ordinary shares to directors and employees under the 2012 Share Option
Scheme. Of these, options to purchase 105,188&nbsp;shares have been cancelled and options to purchase 37,500 shares were exercised in 2016. The remaining options to purchase 1,766,247&nbsp;shares have vested and are exercisable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Class&nbsp;of Share.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;An
option granted under the 2012 Share Option Scheme entitles the option holder, subject to the satisfaction, waiver or acceleration of specific exercise conditions, to subscribe for ordinary shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Exercise
Conditions.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>Options granted under our 2012 Share Option Scheme may be granted subject to vesting schedules, performance targets or other conditions which must be satisfied or waived before exercise. Exercise conditions
may be removed or varied by our board of directors, provided that any variation shall be (in the reasonable opinion of our board of directors) no more difficult to satisfy than the original exercise condition. Each option grant is documented through
an option agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Leaver
Provisions.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Absent summary dismissal with just cause, options will be retained by an option holder once they have ceased to be an employee or director of us or a subsidiary. Where an option holder has been summarily
dismissed for cause, such option holder&#146;s unexercised options shall immediately cease to be exercisable and shall lapse after 90 days unless our board of directors determines within such 90 day period that the option holder may exercise all or
part of his options within a specified period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Lapse of Options.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;If not otherwise lapsed in accordance with the provisions of the 2012 Share Option
Scheme, an option granted under the 2012 Share Option Scheme shall lapse at 5 p.m. on the day before the 10th anniversary of the grant of the option. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If an option holder dies, his personal representatives may exercise his options within a period ending on the earlier of (i)&nbsp;the
expiry of 12 months after the date of death, and (ii) 5 p.m. on the day before the 10th anniversary of the grant of the option, only to the extent that any exercise conditions have been met at the time of death. Failing such exercise the deceased
option holder&#146;s options shall lapse. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Takeovers and Corporate Events.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;If (a)&nbsp;any person or group of persons acting in concert obtains
control (as defined in section 840 of ICTA and as now contained in section 995 of ITA) of the company, as a result of making either (i)&nbsp;an offer to acquire shares amounting to more than 50% of the issued share capital of the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">138
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
company on a condition such that if it is satisfied the person or group of persons will have control of the company, or (ii)&nbsp;a general offer to acquire all of the issued share capital of the
company (or all of the ordinary shares of the company in issue); or (b)&nbsp;any person becomes entitled or bound to acquire shares in the company under sections 428 to 430F of the Companies Act 1985 (since repealed and replaced by sections 974 to
991 of the Companies Act 2006); or (c)&nbsp;under section 425 of the Companies Act 1985 (since repealed and replaced by sections 895 to 901 of the Companies Act 2006) the courts of England and Wales sanction a compromise or arrangement proposed for
the purpose of or in connection with a scheme for the reconstruction of the company or its amalgamation with any other company or companies, and, in each case an option holder&#146;s option agreement expressly so provides, an option holder may at
any time exercise his or her options or any part thereof which has not lapsed within a specified period. To the extent they are not exercised, such options will lapse at the end of the specified period for exercise. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Adjustment of Awards.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In
the event that there is any variation in our share capital that affects the value of the options, our board of directors will make such adjustments to the number and exercise price of shares subject to each option or the option price as our board of
directors considers appropriate in accordance with the rules of the 2012 Share Option Scheme. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transferability.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;No options under the 2012 Share Option Scheme may be transferred, assigned or have any charge created over them and will lapse immediately upon an
attempt to do so. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendment.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>Our board of directors may, with the approval of the shareholders of the company at a
general meeting, amend the 2012 Share Option Scheme, provided that any amendment shall not, without the consent of an option holder, materially increase his or her liabilities or materially decrease the value of his or her subsisting rights under an
outstanding option. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With effect from closing of
this offering, the rules of the 2012 Share Option Scheme shall be amended such that any amendment to the scheme shall take effect without the requirement for the prior approval of our shareholders, except as otherwise required by applicable laws or
the rules of any securities exchange on which our securities are listed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>2016 Share Option Scheme </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;14, 2016 we adopted a share option scheme, or the 2016 Share Option Scheme, for the purpose of enabling the grant of share options to incentivize our employees and directors and those
employees and directors of our subsidiary companies. The 2016 Share Option Scheme incorporates a <FONT STYLE="white-space:nowrap">sub-plan</FONT> for option holders subject to taxation in the United States, or the 2016 U.S. <FONT
STYLE="white-space:nowrap">Sub-Plan.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
2016 Share Option Scheme permits grants of (i)&nbsp;enterprise management incentive options, (ii)&nbsp;&#147;unapproved&#148; options, and (iii)&nbsp;incentive stock options and <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock options
under the 2016 U.S. <FONT STYLE="white-space:nowrap">Sub-Plan.</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2017, we had granted options to purchase 518,440 ordinary shares to directors and employees under the 2016 Share Option Scheme. Of these, options to purchase 45,750&nbsp;shares were
exercised in 2016 and options to purchase 30,000 shares were exercised in 2017. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Class&nbsp;of Share.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;An option granted under the 2016 Share Option Scheme entitles the option holder, subject to the satisfaction, waiver or acceleration of specific
exercise conditions, to subscribe for ordinary shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Exercise Conditions.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Options granted under our 2016 Share Option Scheme may be granted subject to vesting schedules, performance targets or other conditions which must
be satisfied or waived before exercise. Exercise conditions may be removed or varied by our board of directors, provided that any variation shall be (in the reasonable opinion of our board of directors) no more difficult to satisfy than the original
exercise condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">139
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each option grant is documented through an option agreement. Most of option agreements
entered into under the 2016 Share Option Scheme provide that all unvested options shall immediately vest if, following one of the Takeover and Corporate Events listed below, the option holder (i)&nbsp;remains an eligible employee for the purpose of
the plan; and (ii)&nbsp;has experienced a material reduction in base compensation that was payable as at the date of grant or has otherwise experienced a material change or reduction in authority, duties, reporting or responsibilities. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Leaver Provisions.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;If an
option holder ceases to be an employee or director of the company or a subsidiary for a variety of specified reasons (including ill health, retirement, sale of a subsidiary company or part of the business to a third party, or if his
employment/directorship ceases for any reason part from summary dismissal from fraud or gross misconduct) then the option holder may exercise his options during the 12 months after the date of such cessation of employment/directorship only to the
extent that any exercise conditions have been met at the time of such cessation of employment/directorship. Any part of an option in respect of which the relevant exercise conditions have not been met at the point at which the option holder ceases
his employment/directorship shall lapse. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Lapse of Options.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;If not otherwise lapsed in accordance with the provisions of the 2016 Share Option
Scheme, an option granted under the 2016 Share Option Scheme shall lapse at 5 p.m. on the day before the 10th anniversary of the grant of the option. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If an option holder dies, his personal representatives may exercise his options within a period ending on the earlier of (i)&nbsp;the
expiry of 12 months after the date of death, and (ii) 5 p.m. on the day before the 10th anniversary of the grant of the option, only to the extent that any exercise conditions have been met at the time of death. Failing such exercise the deceased
option holder&#146;s options shall lapse. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Takeovers and Corporate Events.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;If (a)&nbsp;any person or group of persons acting in concert obtains
control (as defined in section 840 of ICTA and as now contained in section 995 of ITA) of the company, as a result of making either (i)&nbsp;an offer to acquire shares amounting to more than 50% of the issued share capital of the company on a
condition such that if it is satisfied the person or group of persons will have control of the company, or (ii)&nbsp;a general offer to acquire all of the issued share capital of the company (or all of the ordinary shares of the company in issue);
or (b)&nbsp;any person becomes entitled or bound to acquire shares in the company under sections 974 to 991 of the Companies Act 2006; or (c)&nbsp;under sections 895 to 901 of the Companies Act 2006 the courts of England and Wales sanction a
compromise or arrangement proposed for the purpose of or in connection with a scheme for the reconstruction of the company or its amalgamation with any other company or companies, and, in each case an option holder&#146;s option agreement expressly
so provides, an option holder may at any time exercise his or her options or any part thereof which has not lapsed within a specified period. To the extent they are not exercised, such options will lapse at the end of the specified period for
exercise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Adjustment of
Awards.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In the event that there is any variation in our share capital that affects the value of the options, our board of directors will make such adjustments to the number and exercise price of shares subject to each
option or the option price as our board of directors considers appropriate in accordance with the rules of the 2016 Share Option Scheme. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transferability.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;No options under the 2016 Share Option Scheme may be transferred, assigned or have
any charge created over them and will lapse immediately upon an attempt to do so. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendment.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may, with the approval of the shareholders of the company at a general meeting, amend the 2016 Share Option Scheme, provided that any
amendment shall not, without the consent of an option holder, materially increase his or her liabilities or materially decrease the value of his or her subsisting rights under an outstanding option. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With effect from closing of this offering, the rules of the
2016 Share Option Scheme shall be amended such that any amendment to the scheme shall take effect without the requirement for the prior approval of our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">140
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shareholders, except as otherwise required by applicable laws or the rules of any securities exchange on which our securities are listed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2016 U.S. <FONT STYLE="white-space:nowrap">Sub-Plan</FONT> </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2016 U.S.
<FONT STYLE="white-space:nowrap">Sub-Plan</FONT> applies to grantees that are subject to U.S. federal income tax. The 2016 U.S. <FONT STYLE="white-space:nowrap">Sub-Plan</FONT> provides that options granted to the U.S. grantees will either be
incentive stock options pursuant to Section&nbsp;422 of the Internal Revenue Code or nonqualified stock options. Options, other than certain incentive stock options described below, must have an exercise price not less than 100% of the fair market
value of an underlying share on the date of grant. Incentive stock options that are not exercised within 10 years from the grant date expire, provided that incentive stock options granted to a person holding more than 10% of our voting power will
expire within five years from the date of the grant date and must have an exercise price at least equal to 110% of the fair market value of an underlying share on the date of grant. The number of shares available under the 2016 Share Option Scheme
for grants of incentive stock options shall not exceed 5,008,284 ordinary shares, subject to any applicable adjustment pursuant to the 2016 Share Option Scheme due to a variation of capital. With respect to grantees that are subject to U.S. federal
income tax, the 2016 Share Option Scheme, the 2016 U.S. <FONT STYLE="white-space:nowrap">Sub-Plan</FONT> and all options issued thereunder are intended to comply with, or be exempt from, Section 409A of the Internal Revenue Code, and they are to be
interpreted accordingly. In the event that any option is subject to Section 409A of the Internal Revenue Code, our board of directors or our general counsel may, in their sole discretion, amend the 2016 Share Option Scheme, the 2016 U.S. <FONT
STYLE="white-space:nowrap">Sub-Plan</FONT> and any option issued thereunder, adopt policies and procedures or take such other actions as our board of directors or our general counsel deem appropriate, to exempt the 2016 Share Option Scheme, the 2016
U.S. <FONT STYLE="white-space:nowrap">Sub-Plan</FONT> or any option from Section 409A of the Internal Revenue Code, preserve the intended tax treatment of such option or comply with the requirements of Section&nbsp;409A of the Internal Revenue Code.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Employee Benefit Trust </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;19, 2011, we established a discretionary
employee benefit trust under the terms of a trust deed, or the Employee Benefit Trust, to operate in conjunction with our share option schemes. The beneficiaries of the Employee Benefit Trust are our employees and former employees (including
executive directors) and their spouses, civil partners, surviving spouses and civil partners, children and step-children under the age of 18. The trustee of the Employee Benefit Trust is NuCana BioMed Trustee Company Limited, or the Trustee, our
wholly owned subsidiary. As of August&nbsp;31, 2017, the Trustee holds 500,000 of our ordinary shares in trust under the terms of the trust deed, which, pursuant to the terms of our three option schemes, and at the election of the Trustee, may be
used to satisfy awards under our share option schemes. Under the terms of the trust deed, unless we direct otherwise, the Trustee must abstain from voting at a general meeting any of our shares held in the trust fund for which the Trustee holds the
whole of the beneficial interest. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">141
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_15"></A>RELATED PARTY TRANSACTIONS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a description of related party transactions
we have entered into since January&nbsp;1, 2014 with any members of our board of directors or executive officers or the holders of more than 5% of our share capital. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Participation in th</B><B>is </B><B>Offering</B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain of our existing shareholders have agreed to purchase
an aggregate of 933,332 ADSs in this offering at the initial public offering price. The underwriters will receive the same underwriting discount on any securities purchased by these investors as they will on any other securities sold to the public
in this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Series B Share Placement </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2014, we issued an aggregate of 8,462,500 series B
convertible participating shares, or Series B Shares, to new and existing institutional and other investors at a price of &pound;4.00 per share for an aggregate subscription price of &pound;33.85&nbsp;million, or the Series B Placement. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the aggregate number of our
Series B Shares issued to our 5% or greater shareholders and their affiliates and one of our former executive officers in the Series B Placement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:51pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Participants(1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Series B<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sofinnova Capital VI FCPR (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sofinnova Venture Partners VIII, L.P. (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Morningside Venture Investments Limited (4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,800,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scottish Enterprise</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher McGuigan (5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For further information, see &#147;Principal Shareholders.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rafa&egrave;le Tordjman, a member of our board of directors, was a Managing Partner at Sofinnova Partners SAS, the management company of Sofinnova Capital VI FCPR, at
the time of the Series&nbsp;B Placement. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">James Healy, a member of our board of directors, is a managing member of Sofinnova Management VIII, L.L.C., the general partner of Sofinnova Venture Partners VIII, L.P.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Isaac Cheng is a member of our board of directors who has been designated by Morningside Venture Investments Limited. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher McGuigan was our Chief Scientific Officer at the time of the Series B Placement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shareholders&#146; Agreement and Registration Rights </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Series B Placement, we entered into a shareholders&#146; agreement with all of our
then-existing shareholders, including certain of our directors and executive officers, on March&nbsp;31, 2014, or the 2014 Shareholders&#146; Agreement. Among other things, the 2014 Shareholders&#146; Agreement provided piggyback registration rights
to certain of our then-existing shareholders. The 2014 Shareholders&#146; Agreement will terminate upon the completion of this offering. We have entered into a registration rights agreement to be effective upon the completion of this offering and
pursuant to which we have agreed under specified circumstances to file a registration statement to register the resale of the ordinary shares (which may be converted into ADSs) held by some of our existing shareholders, as well as to cooperate in
specified public offerings of such shares. See &#147;Description of Share Capital &#150; Registration Rights&#148;. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Management Rights Letter </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the Series B Placement, we entered into a management rights letter with Sofinnova Venture Partners VIII, L.P., or Sofinnova Ventures, on March&nbsp;31, 2014, which holds more than 5% of
our Series B Shares, pursuant to which Sofinnova Ventures is entitled to consult and advise our management on significant business. The management rights letter will terminate upon the completion of this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">142
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Agreements with Our Executive Officers&nbsp;and Directors </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into service agreements with our three
executive officers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Related Person Transaction Policy
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the completion of this offering, we
intend to adopt a related person transaction policy requiring that all related person transactions required to be disclosed by a foreign private issuer pursuant to the Exchange Act be approved by the audit committee or another independent body of
our board of directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification Agreements</B>
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, we expect to
enter into deeds of indemnity with each of our directors and executive officers. See &#147;Management&nbsp;&#151; Compensation&nbsp;&#151; Insurance and Indemnification.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">143
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_16"></A>PRINCIPAL SHAREHOLDERS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table and related footnotes set forth
information with respect to the beneficial ownership of our ordinary shares as of September&nbsp;15, 2017 and as of the consummation of this offering, in each case, giving effect to the automatic conversion, immediately prior to the completion of
this offering, of all of our outstanding series A convertible participating shares, series B convertible participating shares, founder ordinary 1 shares and founder ordinary 2 shares into ordinary shares, by: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each of our executive officers and directors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each person beneficially owning more than 5% of our share capital as of September&nbsp;15, 2017; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all executive officers and directors as a group. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficial ownership is determined in accordance with the
rules and regulations of the SEC. In computing the number of ordinary shares owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60&nbsp;days from September&nbsp;15,
2017, including through the exercise of any option, warrant or other right or the conversion of any other security. These ordinary shares, however, are not included in the computation of the percentage ownership of any other person except with
respect to the percentage ownership of all board members and executive officers, as a group. Ownership of our ordinary shares by the &#147;principal shareholders&#148; identified below has been determined by reference to our share register, which
provides us with information regarding the registered holders of our ordinary shares but generally provides limited, or no, information regarding the ultimate beneficial owners of such ordinary shares. As a result, we may not be aware of each person
or group of affiliated persons who beneficially owns more than 5% of our ordinary shares. Based on our share register and other information made available to us by certain of our shareholders, as of September&nbsp;15, 2017, 4,790,480 ordinary
shares, representing 19.8% of our issued and outstanding ordinary shares, were held by four U.S. record holders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This table assumes no exercise of the underwriters&#146; over-allotment option to purchase additional ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, the address for each of the
shareholders in the table below is c/o NuCana plc, 3 Lochside Way, Edinburgh, EH12 9DT, United Kingdom. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain of our existing shareholders have agreed to purchase an aggregate of 933,332 ADSs in this offering at the initial public offering
price. The following table does not reflect any potential purchases by these investors or their affiliated entities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">144
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ordinary&nbsp;
Shares</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Beneficially</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Owned(1)</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percentage&nbsp;of&nbsp;Ordinary<BR>Shares Beneficially<BR>Owned</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:89pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Before&nbsp;the<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>After&nbsp;the<BR>Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Greater than 5% Shareholders</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sofinnova Capital VI FCPR(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,833,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sofinnova Venture Partners VIII, L.P.(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Morningside Venture Investments Limited(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,911,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scottish Enterprise(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,246,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Named Executive Officers and Directors</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hugh Griffith(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,403,531</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher Wood(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,949,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Donald Munoz(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rafa&egrave;le Tordjman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">James Healy(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,045,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Isaac Cheng(10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Martin Mellish(11)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our current executive officers and directors, as a group (7&nbsp;persons)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,562,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34.53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates beneficial ownership of less than one percent of our ordinary shares. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Number of shares owned as shown both in this table and the accompanying footnotes and percentage ownership before the offering is based on 24,214,641 ordinary shares
outstanding on September&nbsp;15, 2017, which gives effect to the automatic conversion of all of the 1,000,000 founder ordinary 1 shares, 1,000,000 founder ordinary 2 shares, 7,483,334 series A convertible participating shares preferred shares and
8,462,500 series&nbsp;B convertible participating shares outstanding into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All shares are held by Sofinnova Capital VI FCPR (&#147;Sofinnova Capital&#148;). Sofinnova Partners SAS, a French corporation, is the management company of Sofinnova
Capital, and may be deemed to have sole voting and investment power with respect to the shares held by Sofinnova Capital. Denis Lucquin, Antoine Papiernik, Monique Saulnier and Graziano Seghezzi are the managing partners of Sofinnova Partners SAS,
and, as such, may be deemed to have joint voting and investment power with respect to the shares held by Sofinnova Capital. The address of Sofinnova Capital is Sofinnova Partners, Immeuble le Centorial, <FONT STYLE="white-space:nowrap">16-18</FONT>
Rue du Quatre-Septembre, 75002 Paris, France. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All shares are held by Sofinnova Venture Partners VIII, L.P. (&#147;Sofinnova Ventures&#148;). Dr.&nbsp;James Healy, a member of our board of directors, together with
Dr.&nbsp;Michael&nbsp;F. Powell and Dr.&nbsp;Anand Mehra, are the managing members of Sofinnova Management VIII, L.L.C., the general partner of Sofinnova Ventures, and as such, may be deemed to have joint voting and dispositive power with respect to
the shares held by Sofinnova Ventures. Each of Dr.&nbsp;Powell, Dr.&nbsp;Mehra and Dr.&nbsp;Healy disclaims beneficial ownership of the shares held by Sofinnova Ventures, except to the extent of his pecuniary interest therein, if any. The mailing
address of Sofinnova Ventures is c/o Sofinnova Ventures, Inc., 3000 Sand Hill Road, Bldg. 4, Suite 250, Menlo Park, CA 94025. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">All shares are held by Morningside Venture Investments Limited (&#147;MVIL&#148;). Raymond Tang, Louise Garbarino, Peter Stuart Allenby Edwards and
Jill Franklin are directors of MVIL, and may be deemed to have joint voting and dispositive power with respect to the shares held by MVIL. Each of Mr.&nbsp;Tang, Ms.&nbsp;Garbarino, Mr.&nbsp;Edwards and Ms.&nbsp;Franklin disclaim beneficial
ownership of the shares held by MVIL, except to the extent of his or her pecuniary interest therein, if any. The mailing address of MVIL is 2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor, Le Prince de Galles, <FONT STYLE="white-space:nowrap">3-5</FONT> Avenue des Citronniers, MC 98000, Monaco.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 2,246,915 ordinary shares owned of record by Scottish Enterprise. Scottish Enterprise is a non-departmental body of the Scottish government and has sole
voting and investment power with respect to the shares. The address of Scottish Enterprise is Atrium Court, 50&nbsp;Waterloo Street, Glasgow G2 6HQ, Scotland. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (a) 1,000,000 ordinary shares and (b)&nbsp;options to purchase 2,403,531 ordinary shares that are or will be immediately exercisable within 60 days of
September&nbsp;15, 2017. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">145
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (a) 1,011,875 ordinary shares and (b)&nbsp;options to purchase 937,499 ordinary shares that are or will be immediately exercisable within 60 days of
September&nbsp;15, 2017. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (a) 30,000 ordinary shares and (b) options to purchase 105,345 ordinary shares that are or will be immediately exercisable within 60 days of
September&nbsp;15, 2017. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (a) 45,750 ordinary shares held in the Healy Family Trust, for which Dr. James Healy&#146;s spouse is the trustee, and (b) 4,000,000 ordinary shares owned
of record by Sofinnova Ventures. Dr.&nbsp;James Healy, a member of our board of directors, together with Dr.&nbsp;Michael&nbsp;F. Powell and Dr.&nbsp;Anand Mehra, are the managing members of Sofinnova Management VIII, L.L.C., the general partner of
Sofinnova Ventures, and as such, may be deemed to share voting and investment power with respect to such shares. Dr.&nbsp;Healy disclaims beneficial ownership with regard to the 4,000,000 shares owned by Sofinnova Ventures, except to the extent of
his proportionate pecuniary interest therein. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Isaac Cheng is a member of our board of directors who has been designated by MVIL. Dr. Cheng has no voting or investment power with respect to the shares held by MVIL.
</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of options to purchase 28,312 ordinary shares that are or will be immediately exercisable within 60 days of September&nbsp;15, 2017. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">146
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_17"></A>DESCRIPTION OF SHARE CAPITAL </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The following describes our issued share capital,
summarizes the material provisions of our articles of association and highlights certain differences in corporate law in the United Kingdom and the United States. Please note that this summary is not intended to be exhaustive. For further
information please refer to the full version of our articles of association, which is included as an exhibit to the registration statement of which this prospectus is part. </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated in England and Wales with the Registrar of Companies of England and Wales, United Kingdom
on January&nbsp;28, 1997 under the name Biomed (UK) Limited as a private company limited by shares with company number 03308778. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;28, 2008, our name was changed to NuCana BioMed Limited. On August&nbsp;29, 2017, we
<FONT STYLE="white-space:nowrap">re-registered</FONT> as a public limited company and changed our name to NuCana plc. Such <FONT STYLE="white-space:nowrap">re-registration</FONT> required the passing of special resolutions by our shareholders to
approve the <FONT STYLE="white-space:nowrap">re-registration</FONT> as a public limited company, the name change to NuCana plc and to effect certain amendments to our articles of association. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our registered office is located at 77/78 Cannon Street, London, EC4N 6AF, United Kingdom. The principal
legislation under which we operate and our shares are issued is the Companies Act 2006. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prior to completion of this offering, certain resolutions will be passed by our shareholders. These include resolutions for: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The adoption of new articles of association that will become effective upon the completion of this offering. See &#147;&#151;Articles of
Association&#148; below. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The general authorization of our directors for purposes of section 551 Companies Act 2006 to issue shares in the company and grant rights to subscribe
for or convert any securities into shares in the company up to a maximum aggregate nominal amount of &pound;791,497.28 for a period expiring at the conclusion of our next annual general meeting. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The empowering of our directors pursuant to section 570 Companies Act 2006 to issue equity securities for cash pursuant to the section 551 authority
referred to above as if the statutory <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights under section 561(1) Companies Act 2006 did not apply to such allotments. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Issued Share Capital </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our issued share capital as of August 31, 2017 is &pound;663,935, divided into: 7,483,334 series A convertible participating shares of
&pound;0.04 each; 8,462,500 series B convertible participating shares of &pound;0.004 each; 6,268,807 ordinary shares of &pound;0.04 each; 1,000,000 founder ordinary 1 shares of &pound;0.04 each; and 1,000,000 founder ordinary 2 shares of
&pound;0.04 each. A summary of increases in, and changes to, our issued share capital since our incorporation is set out below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We issued one quarter of one ordinary share of &pound;4.00 each to each of London Law Services Limited and London Law Secretarial Limited,
respectively, upon incorporation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
March&nbsp;20, 2008, we subdivided the outstanding issued fractions of ordinary shares of &pound;4.00 each into 50 ordinary shares of &pound;0.04 each and we subdivided the remaining authorized yet unissued fractions of the ordinary shares of
&pound;4.00 each into 2,450 ordinary shares of &pound;0.04 each. Further, our authorized share capital was increased from &pound;100 to &pound;500,000 by the creation of 12,497,500 new ordinary shares of &pound;0.04 each. On March&nbsp;20, 2008, we
issued 4,499,950 ordinary shares of &pound;0.04 each. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">147
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;27, 2008, we issued a further 200,000 ordinary shares of &pound;0.04 each. On
August&nbsp;20, 2009, we issued 350,000 ordinary shares of &pound;0.04 each. On December&nbsp;18, 2009, we issued 1,816,976 ordinary shares of &pound;0.04 each (500,000 of which were available for such issue, having previously been issued to, but
subsequently surrendered by, a shareholder). On December&nbsp;14, 2010, we issued 1,566,359 ordinary shares of &pound;0.04 each. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;24, 2011, we issued 7,483,334 series A convertible participating shares of &pound;0.04 each. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;28, 2012, we issued 222,222 ordinary shares of
&pound;0.04 each. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;31, 2014, we
issued 8,462,500 series B convertible participating shares of &pound;0.004 each. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;30, 2016, we issued 37,500 ordinary shares of &pound;0.04 each, pursuant to the exercise of share options granted under the 2012 Share Option Scheme. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;31, 2016, we issued 45,750 ordinary shares
of &pound;0.04 each, pursuant to the exercise of share options granted under the 2016 Share Option Scheme. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August 17, 2017, we issued 30,000 ordinary shares of &pound;0.04 each, pursuant to the exercise of share options granted under the 2016
Share Option Scheme. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September 14, 2017, we
completed a one-for-four reverse share split and an associated, prior, bonus allotment of three ordinary shares and five series A convertible participating shares to eliminate fractional entitlements.&nbsp;References to the one-for-four reverse
share split in this prospectus include the associated bonus allotment. The share numbers and nominal values set out above have, for presentational purposes, been adjusted to reflect the aforementioned reverse share split (which has necessitated
reference to notional fractions of shares and resulted in certain numbers of shares having been rounded up). These share numbers and nominal values are therefore not representative of, for example, the entries made at the relevant time in our
statutory registers nor filings we have made at the UK Registrar of Companies. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Ordinary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2017, we had issued and outstanding 6,268,807 ordinary shares of &pound;0.04 each, held by 20&nbsp;shareholders of record. Each issued ordinary share is fully paid. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of ordinary shares are entitled to one vote for each
share held of record on all matters submitted to a vote of shareholders and do not have cumulative voting rights. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, in the event of any distribution of capital, whether as a result of
<FONT STYLE="white-space:nowrap">winding-up,</FONT> dissolution or liquidation of the company or otherwise, or payment of any dividend, the holders of ordinary shares will rank pari passu with the holders of founder ordinary 1 shares, founder
ordinary 2 shares, series A convertible participating shares and series B convertible participating shares in proportion to the number of fully paid shares held. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following this offering, any distribution made as result of <FONT
STYLE="white-space:nowrap">winding-up,</FONT> dissolution or liquidation of our company and any dividend declared will be distributed in proportion to the number of fully paid ordinary shares held. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Founder Ordinary 1 Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2017, we had issued and outstanding
1,000,000 founder ordinary 1 shares of &pound;0.04 each, held by one shareholder of record, Hugh S. Griffith. Each issued founder ordinary 1 share is fully paid. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">148
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of founder ordinary 1 shares are entitled to vote on all matters submitted to a vote
of shareholders either on a show of hands or on a poll. As an exception to the general rule that, on a poll, each of our shareholders has one vote for each share held: the holders of the founder ordinary 1 shares are, collectively entitled, on a
poll, to exercise such number of votes that equals at least 5% of all votes exercisable by our shareholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accordingly, (i) where the holders of the founder ordinary 1 shares, as a class, hold a number of shares that would (on a one vote per
share basis) entitle them to exercise a number of votes less than 5% of the total number of votes exercisable by all shareholders on a poll vote, the holders of the founder ordinary 1 shares shall, as a class, be entitled to exercise such number of
votes as equals 5% of the total number of votes exercisable by all shareholders on such poll; and (ii) where the holders of the founder ordinary 1 shares, as a class, hold a number of shares that would (on a one vote per share basis) entitle them to
exercise 5% or more of the total number of votes exercisable by all shareholders on a poll vote, the holders of the founder ordinary 1 shares shall, as a class, be entitled to exercise the number of votes equal to the number of founder ordinary 1
shares so held. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The founder ordinary 1 shares
will automatically convert into ordinary shares on a one-for-one basis immediately prior to the completion of this offering. Upon completion of this offering, there will be no founder ordinary 1 shares outstanding, and we have no present intention
to issue any founder ordinary 1 shares at any time after completion of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Founder Ordinary 2 Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2017, we had issued and outstanding 1,000,000 founder ordinary 2 shares of &pound;0.04 each, held by one shareholder of record, Christopher Wood. Each issued founder ordinary 2 share is
fully paid. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of founder ordinary 2 shares
are entitled to vote on all matters submitted to a vote of shareholders either on a show of hands or on a poll. As an exception to the general rule that, on a poll, each of our shareholders has one vote for each share held: the holders of the
founder ordinary 2 shares are, collectively entitled, on a poll, to exercise such number of votes that equals at least 5% of all votes exercisable by our shareholders. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accordingly, (i) where the holders of the founder ordinary 2
shares, as a class, hold a number of shares that would (on a one vote per share basis) entitle them to exercise a number of votes less than 5% of the total number of votes exercisable by all shareholders on a poll vote, the holders of the founder
ordinary 2 shares shall, as a class, be entitled to exercise such number of votes as equals 5% of the total number of votes exercisable by all shareholders on such poll; and (ii) where the holders of the founder ordinary 2 shares, as a class, hold a
number of shares that would (on a one vote per share basis) entitle them to exercise 5% or more of the total number of votes exercisable by all shareholders on a poll vote, the holders of the founder ordinary 2 shares shall, as a class, be entitled
to exercise the number of votes equal to the number of founder ordinary 2 shares so held. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The founder ordinary 2 shares will automatically convert into ordinary shares on a one-for-one basis immediately prior to the completion of this offering. Upon completion of this offering, there will be
no founder ordinary 2 shares outstanding, and we have no present intention to issue any founder ordinary 2 shares at any time after completion of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Series A Convertible Participating Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2017, we had issued and outstanding 7,483,334 series A convertible participating shares of &pound;0.04 each. Each issued
series A convertible participating share is fully paid. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The holders of series A convertible participating shares are entitled to one vote for each share held of record on all matters submitted to a vote of shareholders and do not have cumulative voting rights.
The series&nbsp;A </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">149
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
convertible participating shares will automatically convert into ordinary shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis immediately
prior to the completion of this offering. Upon completion of this offering, there will be no series&nbsp;A convertible participating shares outstanding, and we have no present intention to issue any series A convertible participating shares at any
time after completion of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Series B Convertible
Participating Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of August 31, 2017,
we had issued and outstanding 8,462,500 series B convertible participating shares of &pound;0.004 each, or Series B Shares. Each issued Series B Share is fully paid. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The holders of Series B Shares are entitled to one vote for
each share held of record on all matters submitted to a vote of shareholders and do not have cumulative voting rights. Following the allotment and consolidation described below, the Series B Shares will automatically convert into ordinary shares on
a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis immediately prior to the completion of this offering. Upon completion of this offering, there will be no Series&nbsp;B Shares outstanding, and we
have no present intention to issue any Series B Shares at any time after completion of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Conversion of Series B Shares into Ordinary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purpose of facilitating a conversion of each Series B Share (nominal value &pound;0.004 per share), into an ordinary share
(nominal value &pound;0.04 per share), immediately prior to the completion of this offering, we will allot to holders of Series B Shares an additional nine Series B Shares for each Series B Share held. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to and conditional upon this allotment, every 10
Series B Shares of &pound;0.004 will be consolidated into a single Series B Share of &pound;0.04. Immediately prior to the completion of this offering, each Series&nbsp;B Share of &pound;0.04 will then be automatically converted into one ordinary
share of &pound;0.04. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will fund the allotment
of these additional shares with reserves that are standing to the credit of our share premium account and obtain all shareholder resolutions and permissions as are necessary for the purpose of authorizing our directors to (i)&nbsp;capitalize the
specified sum; (ii)&nbsp;allot the additional Series B Shares; and (iii)&nbsp;consolidate the Series B Shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Registration Rights </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the Series B Placement, we entered into a shareholders&#146; agreement with all of our then-existing shareholders, including certain of our directors and executive officers, on
March&nbsp;31, 2014, or the 2014 Shareholders&#146; Agreement. Among other things, the 2014 Shareholders Agreement provided certain piggyback registration rights to certain of our then-existing shareholders. The 2014 Shareholders&#146; Agreement
will terminate effective upon completion of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into a registration rights agreement to be effective upon the completion of this offering and pursuant to which we have agreed under specified circumstances to file a registration
statement to register the resale of the ordinary shares held by some of our existing shareholders, as well as to cooperate in specified public offerings of such shares. These rights are described below. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Demand Registration Rights</I></B>. If at any time when
we are eligible to use a <FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> registration statement, the holders of at least 25% of the registrable securities then outstanding have the right to demand that we file a
<FONT STYLE="white-space:nowrap">Form&nbsp;F-3</FONT> registration statement with respect to such registrable securities. These registration rights are subject to specified conditions and limitations, including the right of the underwriters, if any,
to limit the number of shares included in any such registration under specified circumstances. Upon such a request, we are required to use commercially reasonable efforts to effect such registration. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">150
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Company Registration</I></B>. If we propose to register any of our equity securities
under the Securities Act, other than in connection with certain specified registrations, including a registration relating solely to our employee equity incentive plans or a registration relating solely to certain business combinations or mergers
involving us, the holders of these registrable securities are entitled to notice of such registration and are entitled to include their ordinary shares in the registration. Under certain circumstances, the underwriters, if any, may limit the number
of ordinary shares included in any such registration. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Termination of Registration Rights</I></B>. The registration rights granted under the registration rights agreement shall terminate upon the earlier to occur of (i) the fifth anniversary of the
closing of this offering and (ii) the date on which there are no registrable securities remaining pursuant to the registration rights agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Articles of Association </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>As described above, prior to this offering, our shareholders will pass a special resolution to adopt new articles of association which
will become effective upon the completion of this offering. The following is a summary of certain provisions of the new articles of association. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Please note that this is only a summary and is not intended to be exhaustive. For further information please refer to the full version
of our articles of association that will become effective upon the completion of this offering, which is included as an exhibit to the registration statement of which this prospectus is a part. </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Shares and Rights Attaching to Them </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General.</I></B> All ordinary shares have the same
rights and rank pari passu in all respects. Subject to the provisions of the Companies Act 2006 and any other relevant legislation, our board of directors may, from time to time, allot and issue shares following an ordinary resolution of the
shareholders granting authority to the directors to allot shares (and if applicable, and not already disapplied, a special resolution to disapply <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our shares may be issued with or have attached to them any
preferred, deferred, qualified or other special rights or restrictions, whether in relation to dividends, returns of capital, voting or otherwise, as set out in our articles of association or as the shareholders may determine by ordinary resolution
(or, if the shareholders have not so determined, as our board of directors may determine). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Voting rights.</I></B> Subject to any other provisions of our articles of association and without prejudice to any special rights, privileges or restrictions as to voting attached to any shares
forming part of our share capital, the voting rights of shareholders are as follows. Unless a poll vote is demanded, shareholders shall vote on all resolutions on a show of hands. Our articles of association provide that a poll vote may be demanded
before, or on the declaration of, the result of a vote on a show of hands: (a)&nbsp;by the chairman of a general meeting, (b)&nbsp;by at least five shareholders present at a meeting and entitled to vote, or (c)&nbsp;by any shareholder or
shareholders present representing not less than ten per cent of the total voting rights or more than ten per cent of the total sum paid up on all voting shares. For these purposes, a shareholder will be present at a meeting if attending in person,
by proxy, or, in the case of a shareholder that is a corporation (as broadly defined under the Companies Act 2006), by duly authorized representative. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On a show of hands, each shareholder present in person, and each duly authorized representative present in person of a shareholder that is
a corporation, has one vote. On a show of hands, each proxy present in person who has been duly appointed by one or more shareholders has one vote, but a proxy has one vote for and one vote against a resolution if the proxy is instructed to vote on
a resolution by more than one shareholder and is instructed to vote in different ways on such resolution. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">151
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On a poll, each shareholder present in person or by proxy or, with respect to a corporation,
by a duly authorized representative has one vote for each share held by the shareholder. We are prohibited from exercising any rights to attend or vote at meetings in respect of any shares held by us as treasury shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Restrictions on voting where sums overdue on
shares.</I></B> None of our shareholders is entitled to vote at any general meeting or at any separate class meeting in respect of any share held by him or her unless all calls or other sums payable by him or her in respect of that share have been
paid. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Calls on shares.</I></B> The
directors may from time to time make calls on shareholders in respect of any amounts unpaid on their shares, whether in respect of nominal value of the shares or by way of premium. Shareholders are required to pay the called amount on shares subject
to receiving at least 14 clear days&#146; notice specifying the time and place for payment. Under our articles of association, a period of &#147;clear days&#148; excludes the day on which a notice is given or deemed to have been given and the day
for which it is given or on which it is to take effect. If a shareholder fails to pay any part of a call, the board of directors may serve further notice naming another day not being less than 14 clear days from the date of the further notice
requiring payment and stating that in the event of <FONT STYLE="white-space:nowrap">non-payment</FONT> the shares in respect of which the call was made will be liable to be forfeited. Subsequent forfeiture requires a resolution by the board of
directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Dividends.</I></B> Subject to
the Companies Act 2006 and the provisions of all other relevant legislation, we may by ordinary resolution declare dividends out of profits available for distribution in accordance with the respective rights of shareholders, but no such dividend
shall exceed the amount recommended by the board of directors. If, in the opinion of the board of directors, our profits available for distribution justify such payments, the board of directors may pay fixed dividends payable on any of our shares
with preferential rights, half-yearly or otherwise, on fixed dates and from time to time pay interim dividends to the holders of any class of shares. Subject to any special rights attaching to, or terms of issue of, any shares, all dividends shall
be declared and paid according to the amounts paid up on the shares on which the dividend is paid. No dividend shall be payable to us in respect of any shares held by us as treasury shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may, upon the recommendation of the board of directors, by ordinary resolution, direct payment of a dividend
wholly or partly by the distribution of specific assets. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All dividends unclaimed for one year after having been declared may be invested or otherwise used at the directors&#146; discretion for our benefit until claimed (subject as provided in the articles of
association), and all dividends unclaimed after a period of 12 years from the date when such dividend became due for payment shall be forfeited and shall revert to us. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The board of directors may, if so authorized by ordinary
resolution passed at any general meeting, offer any holders of the ordinary shares the right to elect to receive in lieu of that dividend an allotment of ordinary shares credited as fully paid. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may cease to send any cheque or warrant by mail or may
stop the transfer of any sum by any bank or other funds transfer system for any dividend payable on any of our shares, which is normally paid in that manner on those shares if in respect of at least two consecutive dividends the cheque or warrants
have been returned undelivered or remain uncashed or the transfer has failed, or in respect of one dividend the cheque or warrant has been returned undelivered or remains uncashed or the transfer has failed and reasonable inquiries made by us have
failed to establish any new address of the holder. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We or the directors may specify a &#147;record date&#148; on which persons registered as the holders of shares shall be entitled to
receipt of any dividend. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">152
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Distribution of assets on <FONT STYLE="white-space:nowrap">winding-up.</FONT></I></B>
Subject to any special rights attaching to, or the terms of issue of any shares, on any <FONT STYLE="white-space:nowrap">winding-up</FONT> of the company our surplus assets remaining after satisfaction of our liabilities will be distributed among
our shareholders in proportion to their respective holdings of shares and the amounts paid up on those shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On any <FONT STYLE="white-space:nowrap">winding-up</FONT> of the company (whether the liquidation is voluntary, under supervision or by
the Court), the liquidator may with the authority of a special resolution of the company and any other sanction required by any relevant legislation, divide among our shareholders (excluding the company itself to the extent that it is a shareholder
by virtue of its holding any shares or treasury shares) in specie or in kind the whole or any part of our assets (subject to any special rights attached to any shares issued by us in the future) and may for that purpose set such value as he deems
fair upon any one or more class or classes of property and may determine how that division shall be carried out as between the shareholders or different classes of shareholders. The liquidator may, with that sanction, vest the whole or any part of
the assets in trustees upon such trusts for the benefit of the shareholders as he with the relevant authority determines, and the liquidation of the company may be closed and the company dissolved, but so that no shareholders shall be compelled to
accept any shares or other property in respect of which there is a liability. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Variation of rights.</I></B> The rights or privileges attached to any class of shares may (unless otherwise provided by the terms of the issue of the shares of that class) be varied or abrogated
with the consent in writing of the holders of three-fourths in requisite nominal value of the issued shares of that class (excluding any shares of that class held as treasury shares) or with the approval of a special resolution passed at a separate
general meeting of the shareholders of that class, but not otherwise. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transfer of shares.</I></B> All of our shares are in registered form and may be transferred by a transfer in any usual or common form or any form acceptable to the board of directors and permitted
by the Companies Act 2006 and any other relevant legislation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The board of directors may decline to register a transfer of a share that is: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">not fully paid or on which we have a lien; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(except where uncertificated shares are transferred without a written instrument) not lodged duly stamped (if it is required to be stamped) at our
registered office or at such other place as the board of directors may appoint; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(except where a certificate has not been issued) not accompanied by the certificate of the share to which it relates or such other evidence reasonably
required by the directors to show the right of the transferor to make the transfer; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in respect of more than one class of share; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of a transfer to joint holders of a share, the number of joint holders to whom the share is to be transferred exceeds four.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Capital
variations.</I></B> We may, by ordinary resolution, consolidate and divide all or any of our share capital into shares of a larger nominal amount than our existing shares or <FONT STYLE="white-space:nowrap">sub-divide</FONT> our shares, or any of
them, into shares of a smaller nominal amount than our existing shares. Subject to the provisions of the Companies Act 2006 and any other applicable legislation, we may by special resolution reduce our share capital, any capital redemption reserve
fund or any share premium account and may redeem or purchase any of our own shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Pre-emption</FONT> rights.</I></B> There are no rights of <FONT STYLE="white-space:nowrap">pre-emption</FONT> under our articles of association in respect of
transfers of issued ordinary shares. In certain circumstances, our shareholders may have statutory <FONT STYLE="white-space:nowrap">pre-emption</FONT> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">153
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
rights under the Companies Act 2006 in respect of the allotment of new shares in the company. These statutory <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights, when applicable, would
require us to offer new shares for allotment to existing shareholders on a pro rata basis before allotting them to other persons. In such circumstances, the procedure for the exercise of such statutory
<FONT STYLE="white-space:nowrap">pre-emption</FONT> rights would be set out in the documentation by which such ordinary shares would be offered to our shareholders. These statutory <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights may be
disapplied by a special resolution passed by shareholders in a general meeting in accordance with the provisions of the Companies Act 2006. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Directors </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Number.</I></B> Unless and until we in a general meeting of our shareholders otherwise determine, the number of directors comprising
our board of directors shall not be subject to any maximum but shall not be less than two. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Classified board of directors.</I></B> Our board of directors will be divided into three classes, &#147;Class&nbsp;I,&#148; whose initial term shall expire at the annual general meeting of the
shareholders to be held in 2020, &#147;Class&nbsp;II,&#148; whose initial term shall expire at the annual general meeting of the shareholders to be held in 2019, and &#147;Class&nbsp;III&#148;, whose initial term shall expire at the annual general
meeting of the shareholders to be held in 2018, with the classes as nearly equal in number as possible. At the closing of the offering made hereby, the Class&nbsp;I directors will be Hugh Griffith and Christopher Wood, the Class&nbsp;II directors
will be Rafa&egrave;le Tordjman and James Healy, and the Class&nbsp;III directors will be Isaac Cheng and Martin Mellish. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Borrowing powers.</I></B> Our board of directors may exercise all the powers of the company to borrow money, mortgage or charge all
or any part or parts of its undertaking, property and uncalled capital, and issue debentures and other securities whether outright or as collateral security for any debt, liability or obligation of the company or of any third party. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Directors&#146; interests and restrictions
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The board of directors may, in
accordance with our articles of association and the requirements of the Companies Act 2006, authorize a matter proposed to us which would, if not authorized, involve a breach by a director of his or her duty under section 175 of the Companies Act
2006 to avoid a situation in which he or she has, or can have, a direct or indirect interest that conflicts, or possibly may conflict, with our interests. A director is not required, by reason of being a director, to account to the company for any
remuneration or other benefit that he or she derives from a relationship involving a conflict of interest or possible conflict of interest that has been authorized by the board of directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Subject to the provisions of any relevant legislation and provided that he or she has disclosed to the
directors the nature and extent of any material interest of his or hers, a director may be a party to, or otherwise interested in, any transaction, contract or arrangement and that director shall not, by reason of his or her office, be accountable
to the company for any benefit that he or she derives from any such transaction or arrangement; and no such transaction or arrangement shall be liable to be voided on the ground of any such interest or benefit. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Except as provided in our articles of association, a
director shall not vote at a meeting of the directors in respect of any transaction or arrangement or any other proposal whatsoever in which he or she has an interest that is to his or her knowledge material (together with any person connected with
him or her within the meaning of section 252 of the Companies Act 2006), other than (i)&nbsp;an interest in shares or debentures or other securities of the company, (ii)&nbsp;where permitted by the terms of any authorization of a conflict of
interest or by an ordinary resolution, or (iii)&nbsp;in the circumstances set out in paragraph (d)&nbsp;below, and shall not be counted in the quorum at a meeting in relation to any resolution on which he or she is not entitled to vote. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">154
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) A director shall (in the absence of some material interest other than those indicated
below) be entitled to vote (and be counted in the quorum) in respect of any resolution concerning any of the following matters: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) the giving of any guarantee, security or indemnity to him or her in respect of money lent to or an obligation incurred
by him or her at the request of or for the benefit of us or any of our subsidiaries; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) the giving to a third party of any guarantee, security or indemnity in respect of a debt or obligation of ours or any
of our subsidiaries for which he himself or she herself has assumed responsibility in whole or in part under a guarantee or indemnity or by the giving of security; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) any proposal or contract concerning an
offer of shares or debentures or other securities of or by the company or any of its subsidiaries, if he or she takes part because he or she is or may be entitled to participate as a holder of shares, debentures or other securities, or if he or she
takes part in the underwriting, <FONT STYLE="white-space:nowrap">sub-underwriting</FONT> or guarantee of the offer; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) any proposal concerning any other company in which he or she is interested, directly or indirectly and whether as an
officer or shareholder or otherwise, provided that he or she (together with persons connected with him or her) does not to his or her knowledge hold an interest in shares representing one percent or more of the issued shares of any class of such
company or of the voting rights available to shareholders of the relevant company; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(v) any proposal concerning arrangements pursuant to which benefits are made available to our employees and which does not award him or her any privilege or benefit not generally awarded to the employees
to whom such arrangement relates; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) any proposal under which he or she may benefit concerning the giving of indemnities to our directors or other
officers that the directors are empowered to give under our articles of association; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) any proposal under which he or she may benefit concerning the purchase or maintenance of insurance for any of our
directors or other officers; and </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(viii) any proposal under which he or she may benefit concerning the provision to directors of funds to meet expenditures
in defending proceedings. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Where proposals are
under consideration to appoint two or more directors to offices or employments with us or with any company in which we are interested or to fix or vary the terms of such appointments, such proposals may be divided and considered in relation to each
director separately and in such case each of the directors concerned (if not debarred from voting under paragraph (d)(iv) above) shall be entitled to vote (and be counted in the quorum) in respect of each resolution, except that concerning his or
her own appointment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) If any question shall
arise at any meeting as to the materiality of a director&#146;s interest or as to the entitlement of any director to vote and such question is not resolved by his or her agreeing voluntarily to abstain from voting, such question shall be referred to
the chairman of the meeting (or where the interest concerns the chairman himself to the deputy chairman of the meeting) and his or her ruling in relation to any director shall be final and conclusive, except in a case where the nature or extent of
the interests of the director concerned have not been fairly disclosed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Remuneration </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Each of the directors (other than alternate directors) may (in addition to any amounts payable under paragraph (b)&nbsp;and (c) below or under any other provision of our articles of association) be
paid out of the funds of the company such sum by way of directors&#146; fees as the board of directors may from time to time determine. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">155
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Any director who is appointed to hold any employment or executive office with us or who,
by our request, goes or resides abroad for any purposes of the company or who otherwise performs services that in the opinion of the board of directors are outside the scope of his or her ordinary duties may be paid such additional remuneration
(whether by way of salary, commission, participation in profits or otherwise) as the board of directors (or any duly authorized committee of the board of directors) may determine and either in addition to or in lieu of any remuneration provided for
by or pursuant to any other article. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Each
director may be paid his or her reasonable traveling expenses (including hotel and incidental expenses) of attending and returning from meetings of the directors or committees of the board of directors or general meetings or any separate meeting of
the holders of any class of our shares or any other meeting that as a director he or she is entitled to attend and shall be paid all expenses properly and reasonably incurred by him or her in the conduct of the company&#146;s business or in the
discharge of his or her duties as a director. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pensions and other benefits.</I></B> The board of directors may exercise all the powers of the company to provide benefits, either
by the payment of gratuities or pensions or by insurance or in any other manner whether similar to the foregoing or not, for any director or former director, or any person who is or was at any time employed by, or held an executive or other office
or place of profit in, the company or any body corporate that is or has been a subsidiary of the company or a predecessor of the business of the company or of any such subsidiary and for the families and persons who are or was a dependent of any
such persons and for the purpose of providing any such benefits contribute to any scheme trust or fund or pay any premiums. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Appointment and retirement of directors </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The board of directors shall have power to appoint any
person who is willing to act to be a director, either to fill a casual vacancy or as an additional director but so that the total number of directors shall not exceed the maximum number fixed (if any) by or in accordance with our articles of
association. Any director so appointed shall retire from office at our annual general meeting following such appointment, and then shall be eligible for re-election for the remaining portion of the term of office of the Class to which he or she is
eligible for election. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Subject as provided in
our articles of association, the shareholders may by ordinary resolution elect any person who is willing to act as a director either to fill a casual vacancy or as an addition to the existing directors or to replace a director removed from office
under our articles of association but so that the total number of directors shall not at any one time exceed any maximum number fixed by or in accordance with our articles of association. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Subject to paragraph (a) above and the initial terms described in &#147;Description of Share
Capital&#151;Articles of Association&#151;Directors&#151;Classified board of directors&#148;, each director within each class shall retire at the third annual general meeting following the annual general meeting at which he or she was elected or
last re-elected. Except where there is an increase in the number of directors (in which case the newly created directorships shall be apportioned by our board amongst our existing classes) or in accordance with paragraph (a) above, directors elected
or re-elected at an annual general meeting shall be appointed to the class whose term expires at such meeting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) A director retiring at an annual general meeting shall be eligible for re-election. If a retiring director is not re-elected, he or
she shall hold office until the meeting elects someone in his or her place or, if it does not do so, until the end of the meeting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Company name.</I></B> The board of directors may resolve to change our company name. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Indemnity of officers.</I></B> Subject to the
provisions of any relevant legislation, each of our directors and other officers may be indemnified by us against all costs, charges, losses, expenses and liabilities incurred by him in the execution and discharge of his duties or in relation to
those duties. The Companies Act 2006 renders void an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">156
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
indemnity for a director against any liability attaching to him or her in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he or she
is a director as described in &#147;&#151;Differences in Corporate Law&#151;Liability of Directors and Officers.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Shareholders&#146; Meetings </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Annual general meetings.</I></B> We shall in each year hold an annual general meeting of our shareholders in addition to any other
meetings in that year, and shall specify the meeting as such in the notice convening it. The annual general meeting shall be held at such time and place as the board of directors may appoint. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Calling of general meetings.</I></B> The board of directors may call a general meeting of shareholders.
The board of directors must call a general meeting if the shareholders and the Companies Act 2006 require them to do so. The arrangements for the calling of general meetings are described in &#147;&#151;Differences in Corporate Law&#151;Notice of
General Meetings&#148; below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Quorum of
meetings.</I></B> No business shall be transacted at any general meeting unless a quorum is present when the meeting proceeds to business but the absence of a quorum shall not preclude the appointment of a chairman, which shall not be treated as
part of the business of a meeting. One or more qualifying persons present at a meeting and between them holding (or being the proxy or corporate representative of the holders of) at least <FONT STYLE="white-space:nowrap">one-third</FONT> in number
of the issued shares (excluding any shares held as treasury shares) entitled to vote on the business to be transacted are a quorum. A qualifying person for these purposes is an individual who is a shareholder, a person authorized to act as the
representative of a shareholder (being a corporation) in relation to the meeting or a person appointed as proxy of a shareholder in relation to the meeting. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other United Kingdom law considerations </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Mandatory purchases and acquisitions.</I></B> Pursuant
to Sections 979 to 991 of the Companies Act 2006, where a takeover offer has been made for us and the offeror has acquired or unconditionally contracted to acquire not less than 90% in value of the shares to which the offer relates and not less than
90% of the voting rights carried by those shares, the offeror may give notice to the holder of any shares to which the offer relates which the offeror has not acquired or unconditionally contracted to acquire that he wishes to acquire, and is
entitled to so acquire, those shares on the same terms as the general offer. The <FONT STYLE="white-space:nowrap">&#147;squeeze-out&#148;</FONT> of the minority shareholders can be completed at the end of six weeks from the date the notice has been
given, subject to the minority shareholders failing to successfully lodge an application to the court to prevent such <FONT STYLE="white-space:nowrap">squeeze-out</FONT> any time prior to the end of those six weeks, following which the offeror can
execute a transfer of the outstanding shares in its favor and pay the consideration to us, to be held on trust for the outstanding minority shareholders. The consideration offered to the outstanding minority shareholders whose shares are
compulsorily acquired under the Companies Act 2006 must, in general, be the same as the consideration that was available under the takeover offer. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Sell-out.</FONT></I></B> The Companies Act 2006 also gives our minority shareholders a right to be
bought out in certain circumstances by an offeror who has made a takeover offer for all of our shares. The holder of shares to which the offer relates, and who has not otherwise accepted the offer, may require the offeror to acquire his shares if,
prior to the expiry of the acceptance period for such offer, (i)&nbsp;the offeror has acquired or agreed to acquire not less than 90% in value of our voting shares, and (ii)&nbsp;not less than 90% of the voting rights carried by those shares. The
offeror may impose a time limit on the rights of minority shareholders to be bought out that is not less than three months after the end of the acceptance period. If a shareholder exercises his rights to be bought out, the offeror is required to
acquire those shares on the terms of this offer or on such other terms as may be agreed. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Disclosure of interest in shares.</I></B> Pursuant to Part 22 of the Companies Act 2006 and our articles of association, we are empowered to require, by notice in writing, any person whom we know to
be, or have </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">157
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
reasonable cause to believe to be, interested in our shares, or at any time during the three years immediately preceding the date on which the notice is issued has been so interested, within a
reasonable time to disclose to us particulars of that person&#146;s own interest and (so far as is within that person&#146;s knowledge) particulars of any other interest, agreement or arrangement relating to the exercise of any rights conferred by
the holding of the shares that subsists or subsisted in those shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under our articles of association, if a person defaults in supplying us with the required particulars in relation to the shares in question (referred to herein as &#147;default shares&#148;), the board of
directors may by notice direct that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in respect of the default shares, the relevant shareholder shall not be entitled to vote or exercise any other right conferred by his holding shares in
relation to general meetings; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where the default shares represent at least 0.25% of their class, (a)&nbsp;any dividend or other money payable in respect of the default shares shall
be retained by us without liability to pay interest and, if applicable, any election to receive ordinary shares instead of money in respect of the default shares shall be ineffective; (b)&nbsp;no transfers of shares by the relevant shareholder other
than certain approved transfers may be registered (unless the shareholder himself is not in default and the transfer does not relate to default shares) or (c)&nbsp;any shares held by the relevant shareholder in uncertificated form shall be converted
into certificated form. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Purchase of own shares.</I></B> Under English law, a limited company may only purchase its own shares out of its distributable
profits or the proceeds of a fresh issue of shares made for the purpose of financing the purchase, provided it is are not restricted from doing so by its articles. A limited company may not purchase its own shares if, as a result of the purchase,
there would no longer be any issued shares of the company other than redeemable shares or shares held as treasury shares. Shares must be fully paid in order to be repurchased. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may purchase our own fully paid shares otherwise than on a
recognized investment exchange pursuant to a purchase contract authorized by resolution of shareholders before the purchase takes place. Any authority will not be effective if any shareholder from whom we propose to purchase shares votes on the
resolution and the resolution would not have been passed if he had not done so. The resolution authorizing the purchase must specify a date, not being later than five years after the passing of the resolution, on which the authority to purchase is
to expire. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>City code on takeovers and
mergers, or the Takeover Code.</I></B> As a public company incorporated in England and Wales with its place of central management and control in the United Kingdom, we are subject to the United Kingdom City Code on Takeovers and Mergers (referred to
herein as the Takeover Code). The Takeover Code contains rules concerning the conduct of takeover offers for the company. For example, under Rule 9 of the Takeover Code, if a person: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) acquires an interest in our shares that, when taken together with shares in which he or persons acting in
concert with him are interested, carries 30% or more of the voting rights of our shares; or </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) who, together with persons acting in concert with him, is interested in shares that in the aggregate carry not less than 30% and not more than 50% of the voting rights in the company, acquires
additional interests in shares that increase the percentage of shares carrying voting rights in which that person is interested; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">the acquirer and, depending on the circumstances, its concert parties, would be required (except with the consent of the Takeover Panel) to make a cash
offer for our outstanding shares at a price not less than the highest price paid for any interests in the shares by the acquirer or its concert parties during the previous 12 months. Some provisions in the Takeover Code might have anti-takeover
effects that could discourage an acquisition of us by others even if an acquisition would be beneficial to our shareholders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">158
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Distributions and dividends.</I></B> Under the Companies Act 2006, before a company
can lawfully make a distribution or dividend, it must ensure that it has sufficient distributable reserves (on a <FONT STYLE="white-space:nowrap">non-consolidated</FONT> basis). The basic rule is that a company&#146;s profits available for the
purpose of making a distribution are its accumulated, realized profits, so far as not previously utilized by distribution or capitalization, less its accumulated, realized losses, so far as not previously written off in a reduction or reorganization
of capital duly made. The requirement to have sufficient distributable reserves before a distribution or dividend can be paid applies to us and to each of our subsidiaries that has been incorporated under English law. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is not sufficient that we, as a public company, have made
a distributable profit for the purpose of making a distribution. An additional capital maintenance requirement is imposed on us to ensure that the net worth of the company is at least equal to the amount of its capital. A public company can only
make a distribution: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) if, at the time that the
distribution is made, the amount of its net assets (that is, the total excess of assets over liabilities) is not less than the total of its called up share capital and undistributable reserves; and </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) if, and to the extent that, the distribution itself, at
the time that it is made, does not reduce the amount of the net assets to less than that total. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Exchange controls.</I></B> There are no governmental laws, decrees, regulations or other legislation in the United Kingdom that may affect the import or export of capital, including the availability
of cash, cash equivalents and short-term deposits for use by us, or that may affect the remittance of dividends, interest, or other payments by us to <FONT STYLE="white-space:nowrap">non-resident</FONT> holders of our ordinary shares or ADSs, other
than withholding tax requirements. There is no limitation imposed by English law or in the articles of association on the right of <FONT STYLE="white-space:nowrap">non-residents</FONT> to hold or vote shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">159
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Differences in Corporate Law </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The applicable provisions of the Companies Act 2006 differ from laws
applicable to U.S. corporations and their shareholders. Set forth below is a summary of certain differences between the provisions of the Companies Act 2006 applicable to us and the Delaware General Corporation Law relating to shareholders&#146;
rights and protections. This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and English law. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>England and Wales</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Delaware</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Number of Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Companies Act 2006, a public limited company must have at least two directors and the number of directors may be fixed by or in the manner provided in a company&#146;s
articles of association.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Removal of Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Companies Act 2006, shareholders may remove a director without cause by an ordinary resolution (which is passed by a simple majority of those voting in person or by proxy
at a general meeting) irrespective of any provisions of any service contract the director has with the company, provided 28 clear days&#146; notice of the resolution has been given to the company and its shareholders. On receipt of notice of an
intended resolution to remove a director, the company must forthwith send a copy of the notice to the director concerned. Certain other procedural requirements under the Companies Act 2006 must also be followed such as allowing the director to make
representations against his or her removal either at the meeting or in writing.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an
election of directors, except (a)&nbsp;unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, shareholders may effect such removal only for cause, or (b)&nbsp;in the case of a
corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an
election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vacancies on the Board of Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under English law, the procedure by which directors (other than a company&#146;s initial directors) are appointed is generally set out in a company&#146;s articles of association,
provided that where two or more persons are appointed as directors of a public limited company by resolution of the shareholders at a general meeting, resolutions appointing each director must be voted on individually unless the shareholders present
vote to</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining
director unless (a)&nbsp;otherwise provided in the certificate of incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> of the corporation or (b)&nbsp;the certificate of incorporation directs that a particular class of stock is to elect
such director, in</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">160
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">disapply this requirement without any vote in opposition.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual General Meeting</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Companies Act 2006, a public limited company must hold an annual general meeting in each <FONT STYLE="white-space:nowrap">six-month</FONT> period following the
company&#146;s annual accounting reference date.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or
as provided in the certificate of incorporation or by the bylaws.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Meeting</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Companies Act 2006, a general meeting of the shareholders of a public limited company may be called by the
directors.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shareholders holding at least 5% of the <FONT
STYLE="white-space:nowrap">paid-up</FONT> capital of the company carrying voting rights at general meetings can require the directors to call a general meeting and, if the directors fail to do so within a prescribed period, may themselves call a
general meeting.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of
incorporation or by the bylaws.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notice of General Meetings</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Companies Act 2006, 21 clear days&#146; notice must be given for an annual general meeting and any resolutions to be proposed at the meeting. Subject to a company&#146;s
articles of association providing for a longer period, at least 14 clear days&#146; notice is required for any other general meeting. In addition, certain matters, such as resolutions to remove directors or auditors, require special notice, which is
28 clear days&#146; notice. The shareholders of a company may in all cases consent to a shorter notice period, the proportion of shareholders&#146; consent required being 100% of those entitled to attend and vote in the case of an annual general
meeting and, in the case of any other general meeting, a majority in number of the shareholders having a right to attend and vote at the meeting, being a majority who together hold not less than 95% in nominal value of the shares giving a right to
attend and vote at the meeting.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, unless otherwise provided in the certificate of incorporation or bylaws, written notice of any meeting of the stockholders must be given to each stockholder
entitled to vote at the meeting not less than 10 nor more than 60 days before the date of the meeting and shall specify the place, date, hour, and purpose or purposes of the
meeting.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">161
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proxy</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Companies Act 2006, at any meeting of shareholders, a shareholder may designate another person to attend, speak and vote at the meeting on their behalf by
proxy.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon
after three years from its date, unless the proxy provides for a longer period. A director of a Delaware corporation may not issue a proxy representing the director&#146;s voting rights as a director.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Pre-emptive</FONT> Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Companies Act 2006, &#147;equity securities&#148;, being (i)&nbsp;shares in the company other than shares that, with respect to dividends and capital, carry a right to
participate only up to a specified amount in a distribution (&#147;ordinary shares&#148;) or (ii)&nbsp;rights to subscribe for, or to convert securities into, ordinary shares, proposed to be allotted for cash must be offered first to the existing
equity shareholders in the company in proportion to the respective nominal value of their holdings, unless an exception applies or a special resolution to the contrary has been passed by shareholders in a general meeting or the articles of
association provide otherwise (in each case in accordance with the provisions of the Companies Act 2006).</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, shareholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent
that, such rights are expressly provided for in the certificate of incorporation.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authority to Allot</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Companies Act 2006, the directors of a company must not allot shares or grant rights to subscribe for or to convert any security into shares unless an exception applies or
an ordinary resolution to the contrary has been passed by shareholders in a general meeting or the articles of association provide otherwise (in each case in accordance with the provisions of the Companies Act 2006).</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, if the corporation&#146;s charter or certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock. It may
authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof. It may determine the amount of such consideration by approving a formula. In
the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liability of Directors and Officers</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Companies Act 2006, any provision (whether contained in a company&#146;s articles of association or</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, a corporation&#146;s certificate of incorporation may include a</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">162
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">any contract or otherwise) that purports to exempt a director of a company, to any extent, from any liability that would otherwise
attach to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any provision by which a company directly or indirectly provides an indemnity, to any extent, for a director of the company or of an associated company
against any liability attaching to him in connection with any negligence, default, breach of duty or breach of trust in relation to the company of which he is a director is also void except as permitted by the Companies Act 2006, which provides
exceptions for the company to (a)&nbsp;purchase and maintain insurance against such liability; (b)&nbsp;provide a &#147;qualifying third party indemnity&#148;(being an indemnity against liability incurred by the director to a person other than the
company or an associated company as long as he is successful in defending the claim or criminal proceedings or in obtaining relief from the court); and (c)&nbsp;provide a &#147;qualifying pension scheme indemnity&#148;(being an indemnity against
liability incurred in connection with the company&#146;s activities as trustee of an occupational pension plan).</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from
a breach of fiduciary duty as a director. However, no provision can limit the liability of a director for:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;anybreach of the director&#146;s duty of loyalty to the corporation or its
stockholders;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;actsor omissions not in good faith or that involve intentional misconduct or a knowing
violation of law;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;intentionalor negligent payment of unlawful dividends or stock purchases or redemptions;
or</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;anytransaction from which the director derives an improper personal
benefit.</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Voting Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under English law, unless a poll is demanded by the shareholders of a company or is required by the chairman of the meeting or by the company&#146;s articles of association,
shareholders shall vote on all resolutions on a show of hands. Under the Companies Act 2006, a poll may be demanded by (a)&nbsp;not fewer than five shareholders having the right to vote on the resolution; (b)&nbsp;any shareholder(s) representing not
less than 10% of the total voting rights of all the shareholders having the right to vote on the resolution; or (c)&nbsp;any shareholder(s) holding shares in the company conferring a right to vote on the</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such
stockholder.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">163
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">resolution being shares on which an aggregate sum has been paid up equal to not less than 10% of the total sum paid up on all the shares
conferring that right. A company&#146;s articles of association may provide more extensive rights for shareholders to call a poll.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under English law, an ordinary resolution is passed on a show of hands if it is approved by a simple majority (more than 50%) of the votes cast by
shareholders present (in person or by proxy) and entitled to vote. If a poll is demanded, an ordinary resolution is passed if it is approved by holders representing a simple majority of the total voting rights of shareholders present, in person or
by proxy, who, being entitled to vote, vote on the resolution. Special resolutions require the affirmative vote of not less than 75% of the votes cast by shareholders present, in person or by proxy, at the meeting.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shareholder Vote on Certain Transactions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Companies Act 2006 provides for schemes of arrangement, which are arrangements or compromises between a company and any class of
shareholders or creditors that are used in certain types of reconstructions, amalgamations, capital reorganizations or takeovers. These arrangements require:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;theapproval at a shareholders&#146; or creditors&#146; meeting convened by order of the court,
of a majority in number of shareholders or creditors representing 75% in value of the capital held by, or debt owed to, the class of shareholders, or class thereof present and voting, either in person or by proxy; and</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;theapproval of
the court.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock,
completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#146;s assets or dissolution requires:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;theapproval of the board of directors; and</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;approvalby the
vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of a corporation entitled to vote on the
matter.</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">164
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Standard of Conduct for Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under English law, a director owes various statutory and fiduciary duties to the company, including:</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;toact in the way
he considers, in good faith, would be most likely to promote the success of the company for the benefit of its shareholders as a whole, subject in certain specified circumstances to consider or act in the interests of the creditors of the
company;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;toavoid a situation in which he has, or can have, a direct or indirect interest that conflicts,
or possibly conflicts, with the interests of the company;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;toact in accordance with the company&#146;s constitution and only exercise his powers for the purposes for which they are conferred;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;toexercise
independent judgement;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;toexercise reasonable care, skill and diligence;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;notto accept
benefits from a third party conferred by reason of his being a director or doing, or not doing, anything as a director; and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;aduty to declare any interest that he has, whether directly or indirectly, in a proposed or
existing transaction or arrangement with the company.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delaware law does not contain specific provisions setting forth the standard of conduct of a director. The scope of the fiduciary duties
of directors is generally determined by the courts of the State of Delaware. In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the
stockholders.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors of a Delaware corporation owe fiduciary
duties of care and loyalty to the corporation and to its shareholders. The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this
duty, a director must inform himself of all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the
corporation. He must not use his corporate position for personal gain or advantage. In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that
the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Delaware courts have also imposed a heightened standard of conduct upon directors of a
Delaware corporation who take any action designed to defeat a threatened change in control of the corporation.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or <FONT STYLE="white-space:nowrap">break-up</FONT> of a
corporation,</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">165
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shareholder Litigation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under English law, generally, the company, rather than its shareholders, is the proper claimant in an action in respect of a wrong done to the company or where there is an
irregularity in the company&#146;s internal management. Notwithstanding this general position, the Companies Act 2006 provides that (i)&nbsp;a court may allow a shareholder to bring a derivative claim (that is, an action in respect of and on behalf
of the company) in respect of a cause of action arising from an act or omission involving a director&#146;s negligence, default, breach of duty or breach of trust and (ii)&nbsp;a shareholder may bring a claim for a court order where the
company&#146;s affairs have been or are being conducted in a manner that is unfairly prejudicial to some or all of its shareholders.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to
enforce the right itself. The complaint must:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;statethat the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation
of law; and</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;allegewith particularity the efforts made by the plaintiff to obtain the action the plaintiff
desires from the directors and the reasons for the plaintiff&#146;s failure to obtain the action; or</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.80em; text-indent:-0.80em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;Statethe reasons for not making the effort.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, the plaintiff must remain a stockholder through the duration of
the derivative suit. The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">166
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_18"></A>DESCRIPTION OF AMERICAN DEPOSITARY SHARES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>American Depositary Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citibank, N.A., or&nbsp;Citibank, has agreed to act as the
depositary for the ADSs. Citibank&#146;s depositary offices are located at 388 Greenwich Street, New York, New York 10013. ADSs represent ownership interests in securities that are on deposit with the depositary. ADSs may be represented by
certificates that are commonly known as American Depositary Receipts, or ADRs. The depositary typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A., London Branch. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have appointed Citibank as depositary pursuant to a
deposit agreement. A copy of the deposit agreement is on file with the SEC under cover of a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-6.</FONT> You may obtain a copy of the deposit agreement from the SEC&#146;s Public
Reference Room at 100&nbsp;F Street, N.E., Washington, D.C. 20549 and from the SEC&#146;s website (www.sec.gov). Please refer to registration <FONT STYLE="white-space:nowrap">number&nbsp;333-220392</FONT> when retrieving such copy. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are providing you with a summary description of the
material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by
reference to the terms of the deposit agreement and not by this summary. We urge you to review the deposit agreement in its entirety. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, one ordinary share that is on deposit
with the depositary or custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary or the custodian on behalf of the owner of the ADS but that has not been
distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary may agree to change the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-share</FONT></FONT> ratio by amending
the deposit agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary and their respective nominees will hold all deposited property for the benefit of the holders and beneficial
owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary, the custodian or their nominees. Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the
beneficial owners of the ADSs. The depositary, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A
beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the
registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary, and the depositary (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees,
in each case upon the terms of the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of any ADR that represents your ADSs. The deposit agreement and
the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary. As an ADS holder you appoint the depositary to act on your behalf in certain circumstances. The deposit agreement and the
ADRs are governed by New York law. However, our obligations to the holders of ordinary shares will continue to be governed by the laws of England and Wales, which may be different from the laws in the United States. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, applicable laws and regulations may require you
to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary, the custodian, us or any of
their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">167
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
reporting requirements or obtain such regulatory approvals under applicable laws and regulations. You agree to comply with information requests from us pursuant to applicable laws, stock exchange
rules and our Articles of Association. We may restrict transfers of ADSs and take other actions necessary to comply with any applicable ownership restrictions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary will
hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary only to
the extent contemplated in the deposit agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an owner of ADSs, you may hold your ADSs either by means
of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary (commonly
referred to as the direct registration system or DRS). The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary. Under the direct registration system, ownership of ADSs is evidenced
by periodic statements issued by the depositary to the holders of the ADSs. The direct registration system includes automated transfers between the depositary and The Depository Trust Company, or DTC, the central book-entry clearing and settlement
system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically
hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank
if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC, which nominee will be the only &#147;holder&#148; of such ADSs for purposes of the deposit agreement
and any applicable ADR. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#147;holder.&#148; When we refer to &#147;you,&#148; we assume the
reader owns ADSs and will own ADSs at the relevant time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The registration of the ordinary shares in the name of the depositary or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary or the custodian the record
ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary or the custodian
shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dividends and Other Distributions </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a holder of ADSs, you generally have the right to receive
the distributions we make on the securities deposited with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms
of the deposit agreement in proportion to the number of ADSs held as of the specified record date, after deduction the applicable fees, taxes and expenses. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Distributions of Cash </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon
receipt of confirmation of the deposit of the requisite funds, the depositary will arrange for the funds to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to the laws and regulations of England
and Wales. The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary will apply the same </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">168
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The distribution of cash will be made net of the fees,
expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary will hold any cash amounts it is unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for
the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the
United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Distributions of Shares
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whenever we make a free distribution of
ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary will either distribute to holders new ADSs
representing the ordinary shares deposited or modify the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> shares ratio, in which case each ADS you hold will represent rights and interests in the
additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The distribution of new ADSs or the modification of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> shares ratio upon a distribution of ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms
of the deposit agreement. In order to pay such taxes or governmental charges, the depositary may sell all or a portion of the new ordinary shares so distributed. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No such distribution of new ADSs will be made if it would
violate a law (<I>e.g.</I>, the U.S. securities laws) or if it is not operationally practicable. If the depositary does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit
agreement and will distribute the proceeds of the sale as in the case of a distribution of cash. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Distributions of Rights </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Whenever we intend to distribute rights to purchase additional ordinary shares, we will give prior notice to the depositary and we will assist the depositary in determining whether it is lawful and
reasonably practicable to distribute rights to purchase additional ADSs to holders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary will establish procedures to distribute rights to purchase additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make
the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). You may have to pay fees, expenses, taxes and other
governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to purchase new ordinary shares other than
in the form of ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will
<I>not</I> distribute the rights to you if: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we do not timely request that the rights be distributed to you or we request that the rights not be distributed to you; or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we fail to deliver satisfactory documents to the depositary; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">it is not reasonably practicable to distribute the rights. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will sell the rights that are not exercised or
not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary is unable to sell the rights, it will allow the rights to lapse.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">169
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Elective Distributions </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whenever we intend to distribute a dividend payable at the
election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary
in determining whether such distribution is lawful and reasonably practicable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the
depositary will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in England
and Wales would receive upon failing to make an election, as more fully described in the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Distributions </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whenever we intend to distribute property other than cash, ordinary shares or rights to purchase additional ordinary shares, we will
notify the depositary in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary in determining whether such distribution to holders is lawful and reasonably practicable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If it is reasonably practicable to distribute such property
to you and if we provide all of the documentation contemplated in the deposit agreement, the depositary will distribute the property to the holders in a manner it deems practicable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under
the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary may sell all or a portion of the property received. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will <I>not</I> distribute the property to you and will sell the property if: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we do not request that the property be distributed to you or if we ask that the property not be distributed to you; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we do not deliver satisfactory documents to the depositary; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the depositary determines that all or a portion of the distribution to you is not reasonably practicable. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The proceeds of such a sale will be distributed to holders as
in the case of a cash distribution. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Redemption </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Whenever we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary in advance. If it is
practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary will provide notice of the redemption to the holders. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The custodian will be instructed to surrender the shares
being redeemed against payment of the applicable redemption price. The depositary will convert the redemption funds received into U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable holders to receive the net
proceeds from the redemption upon surrender of their ADSs to the depositary. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired
will be selected by lot or on a <I>pro rata</I> basis, as the depositary may determine. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">170
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Changes Affecting Ordinary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a
change in nominal or par value, <FONT STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of our
company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any such change were to occur, your
ADSs would, to the extent permitted by law, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary may in such circumstances deliver new ADSs to you, amend the deposit
agreement, the ADRs and the applicable registration statement(s) on <FONT STYLE="white-space:nowrap">Form&nbsp;F-6,</FONT> call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the
ADSs the change affecting the ordinary shares. If the depositary may not lawfully distribute such property to you, the depositary may sell such property and distribute the net proceeds to you as in the case of a cash distribution. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Issuance of ADSs upon Deposit of Ordinary Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon closing of this offering, the ordinary shares being
offered pursuant to this prospectus will be deposited by us with the custodian. Upon receipt of confirmation of such deposit, the depositary will issue ADSs to the underwriters named in this prospectus. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the closing of this offering, the depositary may create
ADSs on your behalf if you or your broker deposit ordinary shares with the custodian. The depositary will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the
transfer of the ordinary shares to the custodian and provide such documentation as may be required pursuant to the deposit agreement. Your ability to deposit ordinary shares and receive ADSs may be limited by U.S. and England and Wales legal
considerations applicable at the time of deposit. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The issuance of ADSs may be delayed until the depositary or the custodian receives confirmation that all required approvals have been
given and that the ordinary shares have been duly transferred to the custodian. The depositary will only issue ADSs in whole numbers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">When you make a deposit of ordinary shares, you will be responsible for transferring good and valid title to the depositary. As such, you
will be deemed to represent and warrant that: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ordinary shares are duly authorized, validly allotted and issued, fully paid, not subject to any call for the payment of further capital and
legally obtained; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived, disapplied or exercised;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">you are duly authorized to deposit the ordinary shares; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are
not, and the ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement); and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ordinary shares presented for deposit have not been stripped of any rights or entitlements. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of the representations or warranties are incorrect in
any way, we and the depositary may, at your cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer, Combination and Split Up of ADRs </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs,
you will have to surrender the ADRs to be transferred to the depositary and also must: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">171
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">provide such proof of identity and genuineness of signatures, and of such other matters contemplated in the deposit agreement, as the depositary deems
appropriate; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">comply with applicable laws and regulations, including regulations imposed by us and the depositary consistent with the deposit agreement, the ADR and
applicable law; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">provide any transfer stamps required by the State of New York or the United States; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement,
upon the transfer of ADRs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To
have your ADRs either combined or split up, you must surrender the ADRs in question to the depositary with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to
the terms of the deposit agreement, upon a combination or split up of ADRs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Withdrawal of Ordinary Shares Upon Cancellation of ADSs </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a holder, you will be entitled to present your ADSs to the depositary for cancellation and then receive the corresponding number of
underlying ordinary shares at the custodian&#146;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and England and Wales considerations applicable at the time of withdrawal. In order to
withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of
all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you hold ADSs registered in your name, the depositary may ask you to provide proof of identity and genuineness of any signature and
such other documents as the depositary may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary receives satisfactory evidence of compliance with all
applicable laws and regulations. Please keep in mind that the depositary will only accept ADSs for cancellation that represent a whole number of securities on deposit. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will have the right to withdraw the securities
represented by your ADSs at any time except as a result of: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed, or (ii)&nbsp;ordinary shares are
immobilized on account of a shareholders&#146; meeting or a payment of dividends; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">obligations to pay fees, taxes and similar charges; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement may not be modified to impair your
right to withdraw the securities represented by your ADSs except to comply with mandatory provisions of law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Voting Rights </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As a holder, you generally have the right under the deposit agreement to instruct the depositary to exercise the voting rights for the ordinary shares represented by your ADSs. The voting rights of
holders of ordinary shares are described in &#147;Description of Share Capital&#151;Articles of Association&#148; in this prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At our request, the depositary will distribute to you any notice of shareholders&#146; meeting received from us together with information
explaining how to instruct the depositary to exercise the voting rights of the securities represented by ADSs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">172
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the depositary timely receives voting instructions from a holder of ADSs, it will
endeavor to vote the securities (in person or by proxy) represented by the holder&#146;s ADSs as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In the event of voting by show of hands</I>, the depositary will vote (or cause the custodian to vote) all ordinary held on deposit at that time in
accordance with the voting instructions received from a majority of holders of ADSs who provide timely voting instructions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In the event of voting by poll</I>, the depositary will vote (or cause the custodian to vote) the ordinary shares held on deposit in accordance with
the voting instructions received from the holders of ADSs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary will not join in demanding a vote by poll. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securities for which no voting instructions have been received will not be voted (except as otherwise contemplated herein). If voting is
by poll and the depositary does not receive timely voting instructions from a holder of ADSs, such holder shall be deemed to have instructed the depositary to give a discretionary proxy to a person designated by us to vote the deposited securities
represented by such ADSs in any manner such person wishes, which may not be in your best interests; provided, however, that no such discretionary proxy shall be given with respect to any matter to be voted upon as to which we inform the depositary
that (a) we do not wish such proxy to be given, (b) substantial opposition exists, or (c) the rights of holders of deposited securities may be adversely affected. Please note that the ability of the depositary to carry out voting instructions may be
limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary in a timely manner. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fees and Charges </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an ADS holder, you will be required to pay the following
fees under the terms of the deposit agreement: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Service</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fee</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issuance of ADSs (e.g.,&nbsp;an issuance of ADS upon a deposit of ordinary shares or upon a change in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT></FONT> shares ratio), excluding ADS issuances as a result of distributions of ordinary shares</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to $0.05&nbsp;per ADS issued</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancellation of ADSs (e.g.,&nbsp;a cancellation of ADSs for delivery of deposited property or upon a change in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-ordinary</FONT></FONT> shares ratio)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to $0.05&nbsp;per ADS cancelled</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution of cash dividends or other cash distributions (e.g.,&nbsp;upon a sale of rights and other entitlements)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to $0.05&nbsp;per ADS held</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution of ADSs pursuant to (i)&nbsp;share dividends or other distributions, or (ii)&nbsp;exercise of rights to purchase additional ADSs</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to $0.05&nbsp;per ADS held</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g.,&nbsp;upon a <FONT STYLE="white-space:nowrap">spin-off)</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to $0.05&nbsp;per ADS held</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADS services</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Up to $0.05&nbsp;per ADS held on the applicable record date(s) established by the depositary </FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an ADS holder you will
also be responsible to pay certain charges such as: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">taxes (including applicable interest and penalties) and other governmental charges; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the registration fees as may from time to time be in effect for the registration of ordinary shares on the share register and applicable to transfers
of ordinary shares to or from the name of the custodian, the depositary or any nominees upon the making of deposits and withdrawals, respectively; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">173
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain cable, telex and facsimile transmission and delivery expenses; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the expenses and charges incurred by the depositary in the conversion of foreign currency; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the fees and expenses incurred by the depositary in connection with compliance with exchange control regulations and other regulatory requirements
applicable to ordinary shares, ADSs and ADRs; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the fees and expenses incurred by the depositary, the custodian, or any nominee in connection with the servicing or delivery of deposited property.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADS fees and charges payable
upon (i)&nbsp;the issuance of ADSs, and (ii)&nbsp;the cancellation of ADSs are charged to the person to whom the ADSs are issued (in the case of ADS issuances) and to the person whose ADSs are cancelled (in the case of ADS cancellations). In the
case of ADSs issued by the depositary into DTC, the ADS issuance and cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC
participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and
practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of
the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i)&nbsp;distributions other than cash and (ii)&nbsp;the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS
fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from
distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for
whom they hold ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of refusal to
pay the depositary fees or charges, the depositary may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary fees and charges from any distribution to be made to
the ADS holder. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Certain of the depositary fees
and charges (such as the ADS services fee) may become payable shortly after the closing of the ADS offering. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary. You will
receive prior notice of such changes. The depositary may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such
terms and conditions as we and the depositary agree from time to time.</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Amendments and Termination </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may agree with the depositary to modify the deposit agreement at any time without your consent. We undertake to give ADS holders 30&nbsp;days&#146; prior notice of any modifications that would
materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be
registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any
modifications or supplements that are required to accommodate compliance with applicable provisions of law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the modifications to the deposit
agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">174
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have the right to direct the depositary to terminate the deposit agreement. Similarly,
the depositary may in certain circumstances on its own initiative terminate the deposit agreement. In either case, the depositary must give notice to the holders at least 30&nbsp;days before termination. Until termination, your rights under the
deposit agreement will be unaffected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Termination
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After termination, the depositary will
continue to collect distributions received (but will not distribute any such property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary will hold the proceeds from such sale
and any other funds then held for the holders of ADSs in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account. At that point, the depositary will have no further obligations to ADS holders other than to account for the funds then
held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the termination of the deposit agreement, the depositary may, but shall not be obligated to, independently and without
the need for any action by us, make available to holders a means to withdraw the ordinary shares and other deposited securities represented by their ADSs and to direct the deposit of such ordinary shares and other deposited securities into an
unsponsored American depositary shares program established by the depositary, upon such terms and conditions as the depositary may deem reasonably appropriate, subject however, in each case, to satisfaction of the applicable registration
requirements by the unsponsored American depositary shares program under the Securities Act, and to receipt by the depositary of payment of the applicable fees and charges of, and reimbursement of the applicable expenses incurred by, the depositary.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Books of Depositary </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will maintain ADS holder records at its
depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will maintain in New York
facilities to record and process the issuance, cancellation, combination, <FONT STYLE="white-space:nowrap">split-up</FONT> and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transmission of Notices, Reports and Proxy Soliciting Material
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will make available for your
inspection at its office all communications that it receives from us as a holder of deposited securities that we make generally available to holders of deposited securities. Subject to the terms of the deposit agreement, the depositary will send you
copies of those communications or otherwise make those communications available to you if we ask it to. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Limitations on Obligations and Liabilities </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement limits our obligations and the depositary&#146;s obligations to you. Please note the following: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary are obligated only to take the actions specifically stated in the deposit agreement without negligence or bad faith.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of
any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">175
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary disclaims any liability for any failure to accurately determine the lawfulness or practicality of any action, for the content of any
document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for any tax consequences that
result from the ownership of ADSs or other deposited property, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to
give notice or for any act or omission of or information provided by DTC or any DTC participant. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary shall not be liable for acts or omissions of any successor depositary in connection with any matter arising wholly after the resignation
or removal of the depositary. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary disclaim any liability if we or the depositary are prevented or forbidden from or subject to any civil or criminal penalty or
restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, including regulations of any stock exchange or by
reason of present or future provisions of our Articles of Association, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our or the depositary&#146;s control.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit agreement
or in our Articles of Association or in any provisions of or governing the securities on deposit. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel,
accountants, any person presenting ordinary shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary also disclaim liability for the inability by any ADS holder or beneficiary owner to benefit from any distribution, offering,
right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed
or presented by the proper parties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary also disclaim liability for any consequential or punitive damages for any breach of the terms of the deposit agreement.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the depositary disclaim liability arising out of losses, liabilities, taxes, charges or expenses resulting from the manner in which a holder or
beneficial owner of ADSs holds ADSs, including resulting from holding ADSs through a brokerage account. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Pre-Release</FONT> Transactions
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the terms and conditions of the
deposit agreement, the depositary may issue to broker/dealers ADSs before receiving a deposit of ordinary shares or release ordinary shares to broker/dealers before receiving ADSs for cancellation. These transactions are commonly referred to as <FONT
STYLE="white-space:nowrap">&#147;pre-release</FONT> transactions,&#148; and are entered into between the depositary and the applicable broker/dealer. The deposit agreement limits the aggregate size of
<FONT STYLE="white-space:nowrap">pre-release</FONT> transactions (not to exceed 30% of the ordinary shares on deposit in the aggregate, such limit being subject to change or disregard in the depositary&#146;s discretion) and imposes a number of
conditions on such transactions (e.g.,&nbsp;the need to receive collateral, the type of collateral required, the representations required from brokers, etc.). The depositary may retain the compensation received from the <FONT
STYLE="white-space:nowrap">pre-release</FONT> transactions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">176
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Taxes </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We,
the depositary and the custodian may deduct from any distribution the taxes and governmental charges payable by ADS holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by ADS holders. You will be
liable for any deficiency if the sale proceeds do not cover the taxes that are due. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The depositary may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable ADS holder. The depositary
and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary and to the custodian proof of taxpayer
status and residence and such other information as the depositary and the custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary and the custodian for any claims with respect to taxes based on any tax
benefit obtained for you. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign Currency Conversion
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The depositary will arrange for the
conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in
converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a
reasonable cost or within a reasonable period, the depositary may take any of the following actions in its discretion: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the ADS holders for whom the conversion and
distribution is lawful and practical. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distribute the foreign currency to ADS holders for whom the distribution is lawful and practical. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hold the foreign currency (without liability for interest) for the applicable ADS holders. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Governing Law/Waiver of Jury Trial </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The deposit agreement and the ADRs will be interpreted in
accordance with the laws of the State of New York. The rights of holders of ordinary shares (including ordinary shares represented by ADSs) are governed by the laws of England and Wales. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">AS A PARTY TO THE DEPOSIT AGREEMENT, YOU WAIVE YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT
OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US OR THE DEPOSITARY. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">177
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_19"></A>SHARES AND ADSs ELIGIBLE FOR FUTURE SALE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before this offering, there has been no public market for our
ordinary shares or ADSs. Upon completion of this offering, we will have outstanding 30,881,641 ordinary shares (including 6,667,000 ordinary shares in the form of&nbsp;ADSs), after giving effect to the sale of 6,667,000&nbsp;ADSs in this offering,
assuming no exercise by the underwriters of their over-allotment option to purchase additional ADSs from us. All of the ADSs to be sold in this offering will be freely tradable without restriction under the Securities Act unless purchased by our
&#147;affiliates,&#148; as that term is defined in Rule 144. ADSs or ordinary shares purchased by our affiliates may not be resold except pursuant to an effective registration statement or an exemption from registration, including the safe harbor
under Rule 144 described below. In addition, following this offering, ordinary shares issuable pursuant to awards granted under our equity plans that are covered by a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> will be
freely tradable in the public market, subject to contractual and legal restrictions described below. The remaining ordinary shares outstanding after this offering will be &#147;restricted securities,&#148; as that term is defined in Rule 144, and we
expect that substantially all of these restricted securities will be subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. These restricted securities may be sold in the public market only if the sale is
registered or pursuant to an exemption from registration, such as Rule 144. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our directors and officers and the other existing holders of substantially all of our equity securities have agreed, subject to
limited exceptions, not to offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, including the filing (or participation in the filing) of a registration statement with the Securities and Exchange Commission in
respect of, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position, with respect to, any ADSs, ordinary shares or securities convertible into, or exercisable or exchangeable for ADSs or ordinary shares
of the Company, or publicly announce an intention to effect any such transaction, for a period of 180 days after the date of this prospectus, without the prior written consent of the representatives of the underwriters; provided that the
restrictions in such lock-up agreements do not apply to ADSs purchased in this offering, among other exceptions. See the section titled &#147;Underwriting.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rule 144 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, a person who has beneficially owned our ordinary shares or ADSs that are restricted securities for
at least six months would be entitled to sell such securities, provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (ii)&nbsp;we are subject to
the Exchange Act periodic reporting requirements for at least 90 days before the sale. Persons who have beneficially owned our ordinary shares or ADSs that are restricted securities for at least six months but who are our affiliates at the time of,
or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the
following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1% of the number of our ordinary shares then outstanding, which will equal approximately 308,816 ordinary shares or ADSs immediately after this
offering, assuming no exercise of the underwriters&#146; over-allotment option; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the average weekly trading volume of our ordinary shares in the form of ADSs on Nasdaq during the four calendar weeks preceding the filing of a notice
on Form 144 with respect to the sale; provided, in each case, that we are subject to the Exchange Act periodic reporting requirements for at least 90 days before the sale. Such sales both by affiliates and by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> must also comply with the manner of sale, current public information and notice provisions of Rule 144 to the extent applicable. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Regulation S </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulation S under the Securities Act provides that securities owned by any person may be sold without
registration in the United States, provided that the sale is effected in an offshore transaction and no directed </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">178
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
selling efforts are made in the United States (as these terms are defined in Regulation S), subject to certain other conditions. In general, this means that our ordinary shares may be sold in
some manner outside the United States without requiring registration in the United States. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Rule 701 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In general, under Rule 701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in connection with a compensatory share
plan or other written agreement executed prior to the completion of this offering is eligible to resell such ordinary shares in reliance on Rule 144, but without compliance with some of the restrictions, including the holding period, contained in
Rule 144. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity Incentive Plans </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to file with the SEC a registration statement on
Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act covering the ordinary shares or ADSs reserved for issuance under our equity incentive plans. The registration statement is expected to be filed and become effective as soon as
practicable after the closing of this offering. Accordingly, ordinary shares or ADSs registered under the registration statement will be available for sale in the open market following its effective date, subject to Rule 144 volume limitations and
the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above, if applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">179
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_20"></A>TAXATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Material U.S. Federal Income Tax Considerations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following discussion describes the material U.S. federal
income tax consequences to U.S. Holders (as defined below) under present law of the purchase, ownership and disposition of the ADSs. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended or the Code for purposes of this
discussion, in effect as of the date of this prospectus and on U.S. Treasury regulations in effect or, in some cases, proposed, as of the date of this prospectus, as well as judicial and administrative interpretations thereof available on or before
such date. All of the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax consequences described below. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This discussion applies only to U.S. Holders that acquire the ADSs in the initial offering and hold the ADSs as capital assets for U.S.
federal income tax purposes. It does not purport to be a comprehensive description of all tax considerations that may be relevant to a decision to purchase the ADSs by any particular investor. In particular, this discussion does not address tax
considerations applicable to a U.S. Holder that may be subject to special tax rules, including, without limitation, a dealer in securities or currencies, a trader in securities that elects to use a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for securities holdings, banks, thrifts, or other financial institutions, an insurance company, a <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organization, a person
that holds the ADSs as part of a hedge, straddle or conversion transaction for tax purposes, a person whose functional currency for tax purposes is not the U.S. dollar, certain former citizens or residents of the United States or a person that owns
directly, indirectly or constructively 10% or more of the company&#146;s voting shares. Moreover, this description does not address the U.S. federal estate, gift, or alternative minimum tax consequences, or any state, local or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences, of the acquisition, ownership and disposition of the ADSs. In addition, the discussion does not address tax consequences to an entity or arrangement treated as a partnership for U.S.
federal income tax purposes that holds the ADSs, or a partner in such partnership. The U.S. federal income tax treatment of each partner of such partnership generally will depend upon the status of the partner and the activities of the partnership.
Prospective purchasers that are partners in a partnership holding the ADSs are urged to consult their own tax advisers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The discussion below of the U.S. federal income tax consequences to &#147;U.S. Holders&#148; will apply to an investor that is a
beneficial owner of ADSs and that is, for U.S. federal income tax purposes, </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an individual who is a citizen or resident of the United States; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state
therein or the District of Columbia; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an estate whose income is subject to U.S. federal income taxation regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust that (i)&nbsp;is subject to the primary supervision of a court within the United States and subject to the control of one or more U.S. persons
for all substantial decisions or (ii)&nbsp;has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For U.S. federal income tax purposes, a beneficial owner of
ADSs generally will be treated as the owner of the underlying ordinary shares represented by such ADSs. Accordingly, deposits or withdrawals of the underlying ordinary shares for ADSs generally will not be subject to U.S. federal income tax.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prospective purchases are urged to consult
their tax advisors about the application of the U.S. federal income tax rules to their particular circumstances as well as the state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> and other tax consequences to them of the purchase,
ownership and disposition of the ADSs. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Passive Foreign Investment Company Considerations </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, a corporation organized outside the United
States will be classified as a passive foreign investment company, or PFIC, in a particular taxable year if either (i)&nbsp;75% or more of the corporation&#146;s gross </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">180
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
income for the taxable year is passive income or (ii)&nbsp;on average at least 50% of the value of the corporation&#146;s assets produce passive income or are held for the production of passive
income. Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of property that gives rise to passive
income. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In making this determination, we will be
treated as earning our proportionate share of any income and owning our proportionate share of any assets of any corporation in which we hold a 25% or greater interest (by value). Because PFIC status must be determined annually based on tests which
are factual in nature, our PFIC status will depend on our income, assets and activities each year, including whether certain research and development tax credits received from the government of the United Kingdom will constitute gross income, and,
if they do, whether they will constitute passive income for purposes of the PFIC income test. If we are classified as a PFIC for any taxable year, a U.S. Holder may be able to mitigate some of the resulting adverse U.S. federal income tax
consequences described below with respect to owning the ADSs, provided that such U.S. Holder is eligible to make, and validly makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT>
election, described below. In certain circumstances a U.S. Holder can make a &#147;qualified electing fund&#148; election to mitigate some of the adverse tax consequences described with respect to an ownership interest in a PFIC by including in
income its share of the PFIC&#146;s income on a current basis. However, we do not currently intend to prepare or provide the information that would enable a U.S. Holder to make a qualified electing fund election. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event that we are classified as a PFIC in any year in
which a U.S. Holder holds the ADSs, and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election described below is not made by a taxable U.S. Holder, a special tax regime will apply
with respect to such U.S. Holder to both (a)&nbsp;any gain realized on the sale or other disposition of the ADSs and (b)&nbsp;any &#147;excess distribution&#148; by us to such U.S. Holder (generally, such U.S. Holder&#146;s ratable portion of
distributions received by such U.S. Holder in any year which are greater than 125% of the average annual distribution received by such U.S. Holder in the shorter of the three preceding years or such U.S. Holder&#146;s holding period for the ADSs).
Any gain recognized by such U.S. Holder on a sale or other disposition (including a pledge) of the ADSs and any excess distribution would be allocated ratably over such U.S. Holder&#146;s holding period for the ADSs. The amounts allocated to the
taxable year of the sale or other disposition and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals or
corporations, as appropriate, for that taxable year, and the interest charge generally applicable to underpayments of tax would be imposed on taxes deemed to have been payable in for the relevant taxable PFIC years. Classification as a PFIC may also
have other adverse tax consequences, including, in the case of U.S. Holders that are individuals, the denial of a <FONT STYLE="white-space:nowrap">step-up</FONT> in the basis of such U.S. Holder&#146;s ADSs at death. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on current estimates of our gross income and gross
assets, the nature of our business and our current business plan (all of which are subject to change), we believe that we will not be classified as a PFIC for the year ending December&nbsp;31, 2017. The PFIC tests must be applied each year, and it
is possible that we may become a PFIC in a future year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Mark-to-Market</FONT></FONT> Election </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are a PFIC for any taxable year during which a U.S.
Holder holds the ADSs, then in lieu of being subject to the special tax regime and interest charge rules discussed above, a U.S. Holder may make an election to include gain on the ADSs as ordinary income under a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method, provided that the ADSs are treated as &#147;regularly traded&#148; on a &#147;qualified exchange.&#148; In general, the ADSs will be treated as &#147;regularly traded&#148; for a given
calendar year if more than a <I>de minimis</I> quantity of the ADSs are traded on a qualified exchange on at least 15&nbsp;days during each calendar quarter of such calendar year. Although the U.S. Internal Revenue Service, or the IRS, has not
published any authority identifying specific exchanges that may constitute &#147;qualified exchanges,&#148; Treasury Regulations provide that a qualified exchange is (a)&nbsp;a U.S. securities exchange that is registered with the Securities and
Exchange Commission, or the SEC, (b)&nbsp;the U.S. market system established pursuant to section&nbsp;11A of the Securities and Exchange Act of 1934, or (c)&nbsp;a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> securities exchange that is
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">181
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
regulated or supervised by a governmental authority of the country in which the market is located, provided that (i)&nbsp;such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> exchange has
trading volume, listing, financial disclosure, surveillance and other requirements designed to prevent fraudulent and manipulative acts and practices, to remove impediments to and perfect the mechanism of a free and open, fair and orderly, market,
and to protect investors; and the laws of the country in which such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> exchange is located and the rules of such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> exchange ensure that such requirements
are actually enforced and (ii)&nbsp;the rules of such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> exchange effectively promote active trading of listed shares. We have received approval to list our ADSs on the Nasdaq Global Select Market, which
is a U.S. securities exchange that is registered with the SEC. However, no assurance can be given that the ADSs will meet the requirements to be treated as &#147;regularly traded&#148; for purposes of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. In addition, because a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election cannot be made for any lower-tier PFICs that we may own,
a U.S. Holder may continue to be subject to the special tax regime with respect to such holder&#146;s indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes, including
shares in any future subsidiary of ours that is treated as a PFIC. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If a U.S. Holder makes this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, such U.S. Holder will be required in any year in which we are a PFIC to
include as ordinary income the excess of the fair market value of such U.S. Holder&#146;s ADSs at <FONT STYLE="white-space:nowrap">year-end</FONT> over its basis in those ADSs. In addition, the excess, if any, of such U.S. Holder&#146;s basis in the
ADSs over the fair market value of such U.S. Holder&#146;s ADSs at <FONT STYLE="white-space:nowrap">year-end</FONT> is deductible as an ordinary loss in an amount equal to the lesser of (i)&nbsp;the amount of the excess or (ii)&nbsp;the amount of
the net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gains that have been included in income in prior years by such U.S. Holder. Any gain recognized by such U.S. Holder upon the sale of such U.S.
Holder&#146;s ADSs will be taxed as ordinary income in the year of sale. Amounts treated as ordinary income will not be eligible for the preferential tax rate applicable to qualified dividend income or long-term capital gains. A U.S. Holder&#146;s
adjusted tax basis in the ADSs will be increased by the amount of any income inclusion and decreased by the amount of any deductions under the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> rules. If a
U.S. Holder makes a <FONT STYLE="white-space:nowrap">mark-to</FONT> market election, it will be effective for the taxable year for which the election is made and all subsequent taxable years unless the ADSs are no longer regularly traded on a
qualified exchange or the IRS consents to the revocation of the election. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Information Reporting Requirements </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If we are a PFIC for any taxable year during which a U.S Holder holds the ADSs, each such U.S. Holder generally will be required to file an annual information return on IRS Form&nbsp;8621 containing such
information as the U.S. Treasury Department may require. The failure to file IRS Form&nbsp;8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The U.S. federal income tax rules relating to PFICs are
complex. U.S. Holders are urged to consult their tax advisors with respect to the purchase, ownership and disposition of the ADSs, the availability of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
election and whether making the election would be advisable in their particular circumstances, and the IRS information reporting obligations with respect to the purchase, ownership and disposition of the ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Taxation of Dividends and Other Distributions on the
ADSs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the discussion above
under the heading &#147;&#151;Passive Foreign Investment Company Considerations,&#148; generally, the gross amount of distributions made by us, if any, to a U.S. Holder with respect to the ADSs, before reduction for any <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> taxes withheld therefrom, will be includable in gross income as a dividend to the extent that such distribution is paid out of our current or accumulated earnings and profits (as determined under U.S.
federal income tax principles). To the extent, if any, that the amount of any cash distribution exceeds our current and accumulated earnings and profits, it will be treated first as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of such
U.S. Holder&#146;s tax basis in its ADSs, and to the extent the amount of the distribution exceeds such U.S. Holder&#146;s tax basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal
income tax principles. Therefore, a U.S. Holder should expect that a distribution will generally </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">182
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
be treated as a dividend even if that distribution would otherwise be treated as a <FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital or as capital gain under the rules
described above. A dividend in respect of the ADSs will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations. <FONT STYLE="white-space:nowrap">Non-corporate</FONT>
U.S. Holders may qualify for the lower rates of taxation with respect to dividends on ADSs applicable to long term capital gains (i.e.,&nbsp;gains from the sale of capital assets held for more than one year), provided that certain conditions are
met, including certain holding period requirements and the absence of certain risk reduction transactions. However, such reduced rate shall not apply if we are a PFIC for the taxable year in which we pay a dividend, or were a PFIC in the preceding
taxable year. As indicated in the section titled &#147;Dividends and Dividend Policy&#148; herein, we intend to retain any earnings for use in our business and do not currently intend to pay dividends on our ordinary shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the paragraph below, dividends generally will
constitute income from sources outside the United States, which may be relevant in calculating a U.S. Holder&#146;s foreign tax credit limitation. Subject to certain conditions and limitations, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax
withheld on dividends may be deducted from such U.S. Holder&#146;s taxable income or credited against such U.S. Holder&#146;s U.S. federal income tax liability. The limitation on foreign taxes eligible for credit is calculated separately with
respect to specific classes of income. For this purpose, dividends that we distribute generally should constitute &#147;passive category income,&#148; or, in the case of certain U.S. Holders, &#147;general category income.&#148; A foreign tax credit
for foreign taxes imposed on distributions may be denied if a U.S. Holder does not satisfy certain minimum holding period requirements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the paragraph above, if 50% or more of the ADSs are treated as held by U.S. persons, we will be treated as a
&#147;U.S.-owned foreign corporation.&#148; In that case, dividends may be treated for U.S. foreign tax credit purposes as income from sources outside the United States to the extent paid out of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
source earnings and profits, and as income from sources within the United States to the extent paid out of our U.S. source earnings and profits. There can be no assurance that we will not be treated as a U.S.-owned foreign corporation. If the
dividends are taxed at the lower tax rates generally applicable to long-term capital gains (as discussed above), the amount of the dividend taken into account for purposes of calculating the U.S. foreign tax credit limitation will generally be
limited to the gross amount of the dividend, multiplied by the preferential rate divided by the highest rate of tax normally applicable to dividends. The rules relating to the determination of the foreign tax credit are complex, and U.S. Holders are
urged to consult their tax advisors to determine whether and to what extent such U.S. Holder will be entitled to a foreign tax credit. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Taxation of Dispositions of ADSs </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the discussion above under &#147;&#151;Passive Foreign Investment Company Considerations,&#148; a U.S. Holder will recognize
taxable gain or loss on any sale, exchange or other taxable disposition of an ADS equal to the difference between the amount realized (the amount of cash (in U.S. dollars) plus the fair market value of any property received) for the ADS and such
U.S. Holder&#146;s tax basis (in U.S. dollars) in the ADS. The gain or loss will generally be capital gain or loss. Such capital gain or loss generally will be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or
long-term capital loss if, on the date of sale, exchange or other disposition, the ADSs were held by the U.S. Holder for more than one year. The deductibility of capital losses is subject to limitations. Any such gain or loss generally will be
treated as U.S. source income or loss for U.S. foreign tax credit purposes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Disposition of Foreign Currency </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">U.S. Holders are urged to consult their tax advisors regarding the tax consequences of receiving, converting or disposing of any <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency received as
dividends on our ADSs or on the sale or retirement of an ADS. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tax on Net Investment Income </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Additional 3.8% Medicare tax on some or all of such U.S. Holder&#146;s &#147;net investment income.&#148; Net investment income generally includes income from the ADSs unless such income is derived in the
ordinary </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">183
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
course of the conduct of a trade or business (other than a trade or business that consists of certain passive or trading activities). You should consult your tax advisors regarding the effect
this Medicare tax may have, if any, on your acquisition, ownership or disposition of the ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Information Reporting and Backup Withholding </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distributions with respect to ADSs and proceeds from the sale, exchange or disposition of ADSs may be subject to information reporting to
the IRS, and possible U.S. backup withholding. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes any other required certification or who is otherwise exempt from backup
withholding. U.S. Holders who are required to establish their exempt status generally must provide such certification on U.S. Internal Revenue Service <FONT STYLE="white-space:nowrap">Form&nbsp;W-9.</FONT> U.S. Holders are urged to consult their tax
advisors regarding the application of the U.S. information reporting and backup withholding rules. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against a U.S. Holder&#146;s U.S. federal income tax liability, and a U.S. Holder may obtain a refund of
any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the IRS and furnishing any required information. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign Financial Asset Information Reporting </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Holders who are either individuals or certain domestic
entities may be required to submit certain information to the IRS with respect to such holder&#146;s beneficial ownership of the ADSs, if such ADSs are not held on such holder&#146;s behalf by a financial institution, as our ordinary shares are
considered &#147;specified foreign financial assets.&#148; This law also imposes penalties and potential other adverse tax consequences if a U.S. Holder is required to submit such information to the IRS and fails to do so. U.S. Holders are urged to
consult their tax advisors regarding the potential information reporting obligations that may be imposed with respect to the ownership and disposition of the ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The above description is not intended to constitute a
complete analysis of all tax consequences relating to acquisition, ownership and disposition of the ADSs. Prospective purchases are urged to consult their tax advisors concerning the tax consequences related their particular circumstances.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>United Kingdom Tax Considerations </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a general summary of certain United Kingdom
tax considerations relating to the ownership and disposal of the ADSs and does not address all possible tax consequences relating to an investment in the ADSs. It is based on current U.K. tax law and published HM Revenue&nbsp;&amp; Customs, or HMRC,
practice as of the date of this prospectus, both of which are subject to change, possibly with retrospective effect. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This United Kingdom taxation section is written on the basis that the company is and remains resident for tax purposes in the United
Kingdom only and will therefore be subject to the U.K. tax regime and not the U.S. tax regime (save as discussed in the section titled &#147;Material U.S. Federal Income Tax Considerations&#148; above). On this basis, dividends paid by the company
will be regarded as U.K. dividends, not U.S. dividends. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Except as provided otherwise, this summary applies only to persons who are resident (and, in the case of individuals, domiciled) in the United Kingdom for tax purposes and who are not resident for tax
purposes in any other jurisdiction, and do not have a permanent establishment or fixed base in any other jurisdiction with which the holding of the ADSs is connected. Such persons are referred to herein as U.K. Holders. Persons (a)&nbsp;who are not
resident (or, if resident, are not domiciled) in the United Kingdom for tax purposes, including those individuals and companies who trade in the United Kingdom through a branch, agency or permanent establishment in the United Kingdom to which the
ADSs are attributable, or (b)&nbsp;who are resident or otherwise subject to tax in a jurisdiction outside the United Kingdom, are recommended to seek the advice of professional advisers in relation to their taxation obligations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">184
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This summary is for general information only and is not intended to be, nor should it be
considered to be, legal or tax advice to any particular investor. It does not address all of the tax considerations that may be relevant to specific investors in light of their particular circumstances or to investors subject to special treatment
under U.K. tax law. In particular: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">this summary only applies to the absolute beneficial owners of the ADSs (and where the ADSs are not held through an Individual Savings Account or a
Self-Invested Personal Pension) and any dividends paid in respect of the related ordinary shares or ADSs where the dividends are regarded for U.K. tax purposes as that person&#146;s own income (and not the income of some other person); and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">this summary: (a)&nbsp;only addresses the principal U.K. tax consequences for investors who hold the ADSs as capital assets, (b)&nbsp;does not address
the tax consequences that may be relevant to certain special classes of investor such as dealers, brokers or traders in shares or securities and other persons who hold the ADSs otherwise than as an investment, (c)&nbsp;does not address the tax
consequences for holders that are financial institutions, insurance companies, collective investment schemes, pension schemes, charities or <FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations, (d)&nbsp;assumes that the holder is not an
officer or employee of the company (or of any related company) and has not (and is not deemed to have) acquired the ADSs or related ordinary shares by virtue of an office or employment, and (e)&nbsp;assumes that the holder does not control or hold
(and is not deemed to control or hold), either alone or together with one or more associated or connected persons, directly or indirectly (including through the holding of the related ordinary shares or ADSs), an interest of 10% or more in the
issued share capital (or in any class thereof or ADSs), voting power, rights to profits or capital of the company, and is not otherwise connected with the company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This summary further assumes that a holder of ADSs is the beneficial owner of the underlying ordinary shares
for U.K. tax purposes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Potential investors in
ADSs should satisfy themselves prior to investing as to the overall tax consequences, including, specifically, the consequences under U.K. tax law and HMRC practice of the acquisition, ownership and disposal of ADSs in their own particular
circumstances by consulting their own tax advisers. In particular, <FONT STYLE="white-space:nowrap">non-U.K.</FONT> resident or domiciled persons are advised to consider the potential impact of any relevant double taxation agreements.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Taxation of dividends
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Withholding Tax.</I></B> Dividend
payments in respect of ADSs or ordinary shares may be made without withholding or deduction for or on account of U.K. tax. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>United Kingdom Income Tax.</I></B> An individual U.K. Holder (being an individual who is resident for tax purposes in the United
Kingdom) who receives a dividend from the company will generally be subject to income tax on the dividend. An individual U.K. Holder will generally pay tax at a rate of zero per cent on the first &pound;5,000 of dividends received by such U.K.
Holder. Finance Bill 2017, or the Bill, as published on September 8, 2017, contained a provision reducing the current &pound;5,000 limit in respect of the tax-free allowance to &pound;2,000 from April 2018. The Bill is expected to become law later
this year although it is possible that this provision will either be amended or will not be retained in the resulting Finance Act. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An individual U.K. Holder who is subject to income tax at the basic rate will be liable to tax on the dividend at the rate of 7.5%. An
individual U.K. Holder who is subject to income tax at the higher rate (but not the additional rate) will be liable to income tax on the dividend at the rate of 32.5% to the extent that such sum, when treated as the top slice of that holder&#146;s
income, exceeds the threshold for higher rate income tax. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An individual U.K. Holder liable to income tax at the additional rate will be subject to income tax on the dividend at the rate of 38.1%. to the extent that the holder&#146;s income (including the
dividend) exceeds the threshold for the additional rate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">185
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An individual who is not a U.K. Holder (other than one carrying on a trade, profession or
vocation in the United Kingdom) who is resident for tax purposes outside the United Kingdom will not have any U.K. tax to pay on dividends received from the company. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>United Kingdom Corporation Tax.</I></B> A U.K. Holder
within the charge to U.K. corporation tax may be entitled to exemption from U.K. corporation tax in respect of dividend payments. If the conditions for the exemption are not satisfied, or such United Kingdom Holder elects for an otherwise exempt
dividend to be taxable, United Kingdom corporation tax will be chargeable on the amount of any dividends. The main rate of United Kingdom corporation tax for the 2017/2018 tax year is 19%. If potential investors are in any doubt as to their
position, they should consult their own professional advisers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A corporate holder of ADSs that is not a U.K. Holder will not be subject to U.K. corporation tax on dividends received from the company, unless it carries on a trade in the United Kingdom through a
permanent establishment to which the ordinary shares or the ADSs are attributable. In these circumstances, such holder may, depending on its individual circumstances and if the exemption from U.K. corporation tax discussed above does not apply, be
chargeable to U.K. corporation tax on dividends received from the company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Taxation of Disposals </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.K. Holders.</I></B> A disposal or deemed disposal of ADSs by an individual U.K. Holder may, depending on his or her individual circumstances, give rise to a chargeable gain or to an allowable loss
for the purpose of U.K. capital gains tax. The principal factors that will determine the capital gains tax position on a disposal of ADSs are the extent to which the holder realizes any other capital gains in the tax year in which the disposal is
made, the extent to which the holder has incurred capital losses in that or any earlier tax year and the level of the annual allowance of <FONT STYLE="white-space:nowrap">tax-free</FONT> gains in that tax year (the &#147;annual exemption&#148;). The
annual exemption for the 2017/2018 tax year is &pound;11,300. If, after all allowable deductions, an individual U.K. Holder who is subject to U.K. income tax at either the higher or the additional rate becomes liable to U.K. capital gains tax on the
disposal of ordinary shares or ADSs, the current applicable rate would be 20%. For an individual U.K. Holder who is subject to U.K. income tax at the basic rate and, after all allowable deductions, liable to U.K. capital gains tax on such disposal,
the current applicable rate would be 10%, save to the extent that any capital gains exceed the unused basic rate tax band. In that case, the current rate applicable to the excess would be 20%. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An individual U.K. Holder who ceases to be resident in the United Kingdom (or who fails to be regarded as
resident in a territory outside the United Kingdom for the purposes of double taxation relief) for a period of less than five years and who disposes of his or her ADSs during that period of temporary
<FONT STYLE="white-space:nowrap">non-residence</FONT> may be liable to U.K. capital gains tax on a chargeable gain accruing on such disposal on his or her return to the United Kingdom (or upon ceasing to be regarded as resident outside the United
Kingdom for the purposes of double taxation relief) (subject to available exemptions or reliefs). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A disposal of ADSs by a corporate U.K. Holder may give rise to a chargeable gain or an allowable loss for the purpose of U.K. corporation tax. Such a holder should be entitled to an indexation allowance,
which applies to reduce capital gains to the extent that such gains arise due to inflation. The allowance may reduce a chargeable gain but will not create or increase an allowable loss. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-United</FONT> Kingdom Holders.</I></B> An individual holder who is
not a U.K. Holder will not be liable to U.K. capital gains tax on capital gains realized on the disposal of his or her ADSs unless such holder carries on (whether solely or in partnership) a trade, profession or vocation in the United Kingdom
through a branch or agency in the United Kingdom to which the ADSs are attributable. In these circumstances, such holder may, depending on his or her individual circumstances, be chargeable to U.K. capital gains tax on chargeable gains arising from
a disposal of his or her ADSs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">186
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A corporate holder of ADSs that is not a U.K. Holder will not be liable for U.K. corporation
tax on chargeable gains realized on the disposal of its ADSs unless it carries on a trade in the United Kingdom through a permanent establishment to which the ADSs are attributable. In these circumstances, a disposal of ADSs by such holder may give
rise to a chargeable gain or an allowable loss for the purposes of U.K. corporation tax. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Inheritance Tax </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If, for the purposes of the Taxes on Estates of Deceased Persons and on Gifts Treaty 1978 between the United States and the United Kingdom (enacted in the United Kingdom as Statutory Instrument No 1454 of
1979), an individual holder is domiciled in the United States and is not a national of the United Kingdom, any ADSs beneficially owned by that holder will not generally be subject to U.K. inheritance tax on that holder&#146;s death or on a gift made
by that holder during his or her lifetime, provided that any applicable U.S. federal gift or estate tax liability is paid, except where (i)&nbsp;the ADSs are part of the business property of a U.K. permanent establishment or pertain to a U.K. fixed
base used for the performance of independent personal services; or (ii)&nbsp;the ADSs are comprised in a settlement unless, at the time the settlement was made, the settlor was domiciled in the United States and not a national of the United Kingdom.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stamp Duty and Stamp Duty Reserve Tax
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The statements below in relation to U.K.
stamp duty and stamp duty reserve tax, or SDRT, apply irrespective of whether the relevant holder of ADSs is resident or domiciled in the United Kingdom. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Issue and Transfer of Ordinary Shares </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Issue (including to a depositary or clearance
service).</I></B> No U.K. stamp duty is payable on the issue of the ordinary shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Based on current published HMRC practice and recent case law, there should be no SDRT payable on the issue of ordinary shares to a depositary receipt system or a clearance service. We understand that HMRC
recognizes DTC as a clearance service for United Kingdom stamp duty and SDRT purposes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transfer to a depositary or clearance service.</I></B> Transfers of ordinary shares to, or to a nominee or agent for, a person whose business is or includes issuing depositary receipts or the
provision of clearance services, will generally be regarded by HMRC as subject to stamp duty or SDRT at a rate of 1.5% of the amount or value of the consideration or, in certain circumstances, the value of the ordinary shares transferred unless such
transfer can be regarded as an integral part of an issue of share capital. We anticipate that this liability for stamp duty or SDRT would be borne by the person depositing the relevant shares in the depositary receipt system or clearance service.
Transfers of ordinary shares between depositary receipt systems and clearance services will generally be exempt from stamp duty and SDRT unless, in the case of a clearance service, it has made an election under section 97A(1) Finance Act 1986. Our
understanding is that DTC has not made such an election. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transfer on sale.</I></B> The transfer on sale of ordinary shares by a written instrument of transfer will generally be liable to U.K. stamp duty at the rate of 0.5% of the amount or value of the
consideration for the transfer. The purchaser normally pays the stamp duty. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The transfer of ordinary shares within a depositary receipt system or clearance service should not be subject to stamp duty or SDRT, except where a clearance service has made an election under section
97A(1) Finance Act 1986. Our understanding is that DTC has not made such an election. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">An agreement to transfer ordinary shares outside a depositary receipt system or a clearance service will generally give rise to a liability on the purchaser to SDRT at the rate of 0.5% of the amount or
value of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">187
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
consideration. Such SDRT is payable on the seventh day of the month following the month in which the charge arises, but where an instrument of transfer is executed and duly stamped before the
expiry of a period of six years beginning with the date of that agreement, (i)&nbsp;any SDRT that has not been paid ceases to be payable, and (ii)&nbsp;any SDRT that has been paid may be recovered from HMRC, generally with interest. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transfer of ADSs </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No U.K. stamp duty will be payable on a written instrument
transferring an ADS or on a written agreement to transfer an ADS provided that the instrument of transfer or the agreement to transfer is executed and remains at all times outside the United Kingdom. Where these conditions are not met, the written
instrument for the transfer of, or written agreement to transfer, an ADS could, depending on the circumstances, attract a charge to U.K. stamp duty at the rate of 0.5% of the value of the consideration given in connection with the transfer.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No SDRT will be payable in respect of an
agreement to transfer an ADS. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">188
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_21"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citigroup Global Markets Inc., Jefferies LLC and Cowen and
Company, LLC are acting as joint book-running managers for the offering and as representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement, dated the date of this prospectus, each
underwriter named below has severally agreed to purchase, and we have agreed to sell to that underwriter, the number of ADSs set forth opposite the underwriter&#146;s name. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:43pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underwriter</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number<BR>of&nbsp;ADSs</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citigroup Global Markets Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,333,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jefferies LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,000,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cowen and Company, LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,500,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">William Blair &amp; Company, L.L.C.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">833,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,667,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriting agreement
provides that the obligations of the underwriters to purchase the ADSs included in this offering are subject to approval of legal matters by counsel and to other conditions. The underwriters are obligated to purchase all the ADSs (other than those
covered by the over-allotment option described below) if they purchase any of the ADSs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ADSs sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. Any ADSs sold by the underwriters to securities
dealers may be sold at a discount from the initial public offering price not to exceed $0.63 per ADS. If all the ADSs are not sold at the initial offering price, the underwriters may change the offering price and the other selling terms. The
representatives have advised us that the underwriters do not intend to make sales to discretionary accounts. Delivery of the ADSs will be made against payment in New York, New York on or about October&nbsp;2, 2017. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters sell more ADSs than the total number set
forth in the table above, we have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to 1,000,050 additional ADSs at the initial public offering price less the underwriting discount. The
underwriters may exercise the option solely for the purpose of covering over-allotments, if any, in connection with the offering. To the extent the option is exercised, each underwriter must purchase a number of additional ADSs approximately
proportionate to that underwriter&#146;s initial purchase commitment set forth in the table above. Any ADSs issued or sold under the option will be issued and sold on the same terms and conditions as the other ADSs that are the subject of this
offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We, our officers and directors and
substantially all of our other securityholders have agreed that, subject to specified limited exceptions, for a period of 180 days from the date of this prospectus, we and they will not, without the prior written consent of Citigroup Global Markets
Inc., Jefferies LLC and Cowen and Company, LLC, offer, sell, contract, sell, pledge or otherwise dispose of, including the filing of a registration statement in respect of, or hedge any of our ordinary shares, ADSs, or any securities convertible
into, or exercisable or exchangeable for our ordinary shares; provided, that these restrictions do not apply to ADSs purchased in this offering, among other exceptions. Citigroup Global Markets Inc., Jefferies LLC and Cowen and Company, LLC in their
sole discretion may release any of the securities subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time, which, in the case of officers and directors, shall be with notice. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, there has been no public market for
our ADSs. Consequently, the initial public offering price for our ADSs was determined by negotiations between us and the representatives. Among the factors considered in determining the initial public offering price were our results of operations,
our current financial condition, our future prospects, our markets, the economic conditions in and future prospects for the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">189
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
industry in which we compete, our management, and currently prevailing general conditions in the equity securities markets, including current market valuations of publicly traded companies
considered comparable to our company. We cannot assure you, however, that the price at which our ADSs will sell in the public market after this offering will not be lower than the initial public offering price or that an active trading market in our
ADSs will develop and continue after this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have received approval to list our ADSs on the Nasdaq Global Select Market under the symbol &#147;NCNA.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the offering price, underwriting
discounts and commissions that we are to pay to the underwriters and proceeds to us, before expenses, in connection with this offering. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; over-allotment
option. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;ADS</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No&nbsp;exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Full&nbsp;exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,005,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115,005,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions paid by us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,000,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,050,403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds to us, before expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,004,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">106,955,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that expenses
payable by us in connection with this offering, exclusive of underwriting discounts and commissions, will be approximately $2.3 million. We have also agreed to reimburse the underwriters for expenses in an amount up to $30,000 relating to the
clearance of this offering with the Financial Industry Regulatory Authority, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with this offering, the underwriters may purchase and sell ADSs in the open market. Purchases and sales of ADSs in the open market may include short sales, purchases to cover short
positions, which may include purchases pursuant to the underwriters&#146; over-allotment option, and other transactions that would stabilize, maintain or otherwise affect the price of our ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short sales involve secondary market sales by the underwriters of a greater number of ADSs than they are required to purchase in the offering.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Covered&#148; short sales are sales of ADSs in an amount up to the number of ADSs represented by the underwriters&#146; over-allotment option.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Naked&#148; short sales are sales of ADSs in an amount in excess of the number of ADSs represented by the underwriters&#146; over-allotment
option. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Covering transactions involve purchases of ADSs either pursuant to the underwriters&#146; over-allotment option or in the open market in order to cover
short positions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To close a naked short position, the underwriters must purchase ADSs in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there may be downward pressure on the price of the ADSs in the open market after pricing that could adversely affect investors who purchase in this offering. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To close a covered short position, the underwriters must purchase ADSs in the open market or exercise their over-allotment option. In determining the
source of ADSs to close the covered short position, the underwriters will consider, among other things, the price of ADSs available for purchase in the open market as compared to the price at which they may purchase ADSs through the over-allotment
option. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of our common stock on the Nasdaq Global
Select Market, as long as such bids do not exceed a specified maximum, to stabilize the price of the shares of our common stock. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">190
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain of our existing shareholders have agreed to purchase an aggregate of 933,332 ADSs in
this offering at the initial public offering price. The underwriters will receive the same underwriting discount on any securities purchased by these investors as they will on any other securities sold to the public in this offering. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases to cover short positions and stabilizing purchases,
as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of our ADSs. They may also cause the price of the ADSs to be higher than the price that would
otherwise exist in the open market in the absence of these transactions. The underwriters may conduct these transactions on the NASDAQ Global Select Market, in the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. The underwriters are not required to engage in any of these transactions and, may discontinue them at any time. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed to indemnify the underwriters against certain
liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make because of any of those liabilities. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A prospectus in electronic format may be made available on
websites maintained by one or more of the underwriters or their respective affiliates. The representatives may agree with us to allocate a number of ADSs to underwriters for sale to their online brokerage account holders. Any such allocation for
online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; or their respective affiliates&#146; websites and any information
contained in any other website maintained by any of the underwriters or their respective affiliates is not part of this prospectus, has not been approved or endorsed by us or the underwriters and should not be relied upon by investors in this
offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conflicts of Interest </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters are full-service financial institutions
engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The underwriters and their
respective affiliates may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business for which they may receive customary fees and reimbursement of expenses. In the ordinary course of their
various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (which may include
bank loans and/or credit default swaps) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investments and securities activities may involve
securities or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or financial instruments and may hold,
or recommend to clients that they acquire, long or short positions in such securities and instruments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the European Economic Area </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In relation to each member state of the European Economic Area that has implemented the Prospectus Directive (each, a relevant member
state), with effect from and including the date on which the Prospectus Directive is implemented in that relevant member state (the relevant implementation date), an offer of ADSs described in this prospectus may not be made to the public in that
relevant member state other than: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to fewer than 100 or, if the relevant member state has implemented the relevant provision of the 2010 PD Amending Directive, 150 natural or legal
persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by us for any such offer; or
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in any other circumstances falling within Article 3(2) of the Prospectus Directive; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">191
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">provided that no such offer of securities shall require us or any underwriter to publish a prospectus
pursuant to Article 3 of the Prospectus Directive. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of this provision, the expression an &#147;offer of securities to the public&#148; in any relevant member state means the
communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe for the securities, as the expression may be varied in
that member state by any measure implementing the Prospectus Directive in that member state, and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the
extent implemented in the relevant member state) and includes any relevant implementing measure in the relevant member state. The expression 2010 PD Amending Directive means Directive 2010/73/EU. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The sellers of the ADSs have not authorized and do not
authorize the making of any offer of ADSs through any financial intermediary on their behalf, other than offers made by the underwriters with a view to the final placement of the ADSs as contemplated in this prospectus. Accordingly, no purchaser of
the ADSs, other than the underwriters, is authorized to make any further offer of the ADSs on behalf of the sellers or the underwriters. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the United Kingdom </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within
the meaning of Article 2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order) or (ii)&nbsp;high net
worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order (each such person being referred to as a &#147;relevant person&#148;). This prospectus and its contents are
confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant person should not act or rely on
this document or any of its contents. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective
Investors in Australia </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No prospectus or
other disclosure document, as defined in the Corporations Act 2001 (Cth) of Australia, or Corporations Act, in relation to our ADSs has been or will be lodged with the Australian Securities&nbsp;&amp; Investments Commission, or ASIC. This document
has not been lodged with ASIC and is only directed to certain categories of exempt persons. Accordingly, if you receive this document in Australia: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">you confirm and warrant that you are either: </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) a &#147;sophisticated investor&#148; under section
708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant&#146;s certificate to us which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the
offer has been made; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) a person associated
with the company under section 708(12) of the Corporations Act; or </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iv) a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act, and to the extent that you are unable to confirm or warrant that you are an exempt
sophisticated investor, associated person or professional investor under the Corporations Act, any offer made to you under this document is void and incapable of acceptance; and </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">you warrant and agree that you will not offer any of our ADSs for resale in Australia within 12 months of that ADSs being issued unless any such resale offer is exempt
from the requirement to issue a disclosure document under section 708 of the Corporations Act. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">192
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Canada </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ADSs may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are
accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions </I>or subsection 73.3(1) of the <I>Securities Act </I>(Ontario), and are permitted clients, as defined in National
Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> <I>Registration</I> <I>Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the ADSs must be made in accordance with an exemption from, or in a transaction not
subject to, the prospectus requirements of applicable securities laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a
misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any
applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to section&nbsp;3A.3 (or, in the case of securities
issued or guaranteed by the government of a <FONT STYLE="white-space:nowrap">non-Canadian</FONT> jurisdiction, section&nbsp;3A.4) of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105</FONT> <I>Underwriting Conflicts </I><FONT
STYLE="white-space:nowrap">(&#147;NI&nbsp;33-105&#148;),</FONT> the underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105</FONT> regarding underwriter conflicts of interest in
connection with this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors
in Chile </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ADSs are not registered in the
Securities Registry (Registro de Valores) or subject to the control of the Chilean Securities and Exchange Commission (Superintendencia de Valores y Seguros de Chile). This prospectus and other offering materials relating to the offer of the ADSs do
not constitute a public offer of, or an invitation to subscribe for or purchase, the ADSs in the Republic of Chile, other than to individually identified purchasers pursuant to a private offering within the meaning of Article 4 of the Chilean
Securities Market Act (Ley de Mercado de Valores) (an offer that is not &#147;addressed to the public at large or to a certain sector or specific group of the public&#148;). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in France </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither this prospectus nor any other offering material
relating to the ADSs described in this prospectus has been submitted to the clearance procedures of the <I>Autorit&eacute; des March&eacute;s Financiers</I> or of the competent authority of another member state of the European Economic Area and
notified to the <I>Autorit&eacute; des March&eacute;s Financiers</I>. The ADSs have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material
relating to the ADSs has been or will be: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">released, issued, distributed or caused to be released, issued or distributed to the public in France; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">used in connection with any offer for subscription or sale of the ADSs to the public in France. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such offers, sales and distributions will be made in France
only: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to qualified investors (<I>investisseurs qualifi&eacute;s</I>) and/or to a restricted circle of investors (<I>cercle restreint
d&#146;investisseurs</I>), in each case investing for their own account, all as defined in, and in accordance with articles <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.411-1,</FONT> <FONT
STYLE="white-space:nowrap">D.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.734-1,</FONT> <FONT STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the
French <I>Code mon&eacute;taire et financier</I>; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to investment services providers authorized to engage in portfolio management on behalf of third parties; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">193
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in a transaction that, in accordance with article
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.411-2-II-1&deg;</FONT></FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-or-2&deg;</FONT></FONT> <FONT
STYLE="white-space:nowrap">-or</FONT> 3&deg; of the French <I>Code mon&eacute;taire et financier</I> and article <FONT STYLE="white-space:nowrap">211-2</FONT> of the General Regulations (<I>R&egrave;glement G&eacute;n&eacute;ral</I>) of the
<I>Autorit&eacute; des March&eacute;s Financiers</I>, does not constitute a public offer (<I>appel public &agrave; l&#146;&eacute;pargne</I>). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ADSs may be resold directly or indirectly, only in compliance with articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT
STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> and <FONT STYLE="white-space:nowrap">L.621-8</FONT> through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the
French <I>Code mon&eacute;taire et financier</I>. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Hong Kong </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ADSs may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an
offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules
made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating
to the ADSs may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong
Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to the ADSs which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning of the
Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Japan </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The ADSs offered in this prospectus have not been and will not be registered under the Financial Instruments and Exchange Law of Japan. The ADSs have not been offered or sold and will not be offered or
sold, directly or indirectly, in Japan or to or for the account of any resident of Japan (including any corporation or other entity organized under the laws of Japan), except (i)&nbsp;pursuant to an exemption from the registration requirements of
the Financial Instruments and Exchange Law and (ii)&nbsp;in compliance with any other applicable requirements of Japanese law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Singapore </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any
other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the ADSs may not be circulated or distributed, nor may the ADSs be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a
relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of,
any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where the ADSs are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant party which is: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the
entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual
who is an accredited investor, </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">securities of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six
months after that corporation or that trust has acquired the securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">194
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to an institutional investor (for corporations, under Section&nbsp;274 of the SFA) or to a relevant person defined in Section&nbsp;275(2) of the SFA,
or to any person pursuant to an offer that is made on terms that such securities of that corporation or such rights and interest in that trust are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for
each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions specified in Section&nbsp;275 of the SFA; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where no consideration is or will be given for the transfer; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where the transfer is by operation of law. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">195
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_22"></A>EXPENSES OF THE OFFERING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the expenses payable by us in connection
with this offering, other than the underwriting discounts and commissions, will be as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,901</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer agent and registrar fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nasdaq listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Printing and engraving expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">450,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Road show expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Miscellaneous costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,844</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,290,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All amounts in the table are
estimates except the SEC registration fee, the Nasdaq listing fee and the FINRA filing fee. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">196
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_23"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are being represented by Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C. with respect to certain legal matters of U.S. federal securities and New York State law. The validity of our ordinary shares underlying the ADSs and certain matters governed by English law will be passed on for us by Bristows
LLP. Legal counsel for the underwriters is Cooley LLP. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_24"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements as of December&nbsp;31, 2015 and December&nbsp;31, 2016, and for each of the two years in the period ended December&nbsp;31, 2016, appearing in this prospectus and
the registration statement, have been audited by Ernst&nbsp;&amp; Young LLP, an independent registered public accounting firm, as set forth in their report thereon appearing elsewhere, and are included in reliance upon such report given on the
authority of such firm as experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The registered business address of Ernst&nbsp;&amp; Young LLP is 10 George Street, Edinburgh, EH2 2DZ, United&nbsp;Kingdom. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_25"></A>SERVICE OF PROCESS AND
ENFORCEMENT OF JUDGMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a public
limited company incorporated under the laws of England and Wales. Certain of our directors and executive officers and experts named in this prospectus reside outside of the United States, and all or a substantial portion of our assets and the assets
of such persons are located outside the United States. As a result, it may be difficult for an investor to serve process on us or our directors and executive officers or to compel any of them to appear in Court in the United States or to enforce
judgments obtained in U.S. courts against them or us, including judgments based on civil liability provisions of the securities laws of the United States. In addition, awards of punitive damages in actions brought in the United States or elsewhere
may be unenforceable in the United Kingdom. An award for monetary damages under the U.S. securities laws would be considered punitive in the United Kingdom if it does not seek to compensate the claimant for loss or damage suffered and is intended to
punish the defendant. The enforceability of any judgment in the United Kingdom will depend on the particular facts of the case as well as the laws and treaties in effect at the time. The United States and the United Kingdom do not currently have a
treaty providing for the mutual recognition and enforcement of judgments (other than arbitration awards) in civil and commercial matters. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have appointed Corporation Service Company as our authorized agent upon whom process may be served in any action instituted in any U.S.
federal or state court having subject matter jurisdiction in the Borough of Manhattan in New York, New York, arising out of or based upon the ADSs, the deposit agreement or the underwriting agreement related to the ADSs. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_26"></A>WHERE YOU CAN FIND MORE
INFORMATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed with the SEC a
registration statement on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> including amendments and relevant exhibits and schedules, under the Securities Act. This prospectus, which constitutes a part of the registration statement, summarizes
material provisions of contracts and other documents that we refer to in the prospectus. Since this prospectus does not contain all of the information contained in the registration statement, you should read the registration statement and its
exhibits and schedules for further information with respect to us and the ADSs. You may review and copy the registration statement, reports and other information we file at the SEC&#146;s public reference room at 100 F Street, N.E., Washington, D.C.
20549. You may also request copies of these documents upon payment of a duplicating fee by writing to the SEC. For further information on the public reference facility, please call the SEC at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330.</FONT></FONT></FONT> Our SEC filings, including the registration statement, are also available to you on the SEC&#146;s website at http://www.sec.gov. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">197
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc393013_27"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_9">Unaudited Consolidated Interim Statements of Operations for the six months ended June 30, 2017 and
2016</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_10">Unaudited Consolidated Interim Statements of Comprehensive Loss for the six months ended June 30, 2017 and 2016
</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_11">Consolidated Statements of Financial Position</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_12">Unaudited Consolidated Interim Statements of Changes in Equity for the six months ended June 30, 2017 and 2016
</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_13">Unaudited Consolidated Interim Statements of Cash Flows for the six months ended June 30, 2017 and
2016</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_14">Notes to the Unaudited Consolidated Interim Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_1">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-14</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_2">Consolidated Statements of Operations for the years ended December&nbsp;31, 2016 and
2015</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-15</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_3">Consolidated Statements of Comprehensive Loss for the years ended December&nbsp;31, 2016 and
2015</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">F-16</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_4">Consolidated Statements of Financial Position as of December&nbsp;31, 2016 and 2015</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_5">Consolidated Statements of Changes in Equity for the years ended December&nbsp;31, 2016 and
2015</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_6">Consolidated Statements of Cash Flows for the years ended December&nbsp;31, 2016 and
2015</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#fin393013_7">Notes to the Consolidated Financial Statements </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_9"></A>UNAUDITED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE SIX MONTHS ENDED JUNE&nbsp;30, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Notes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands&nbsp;except<BR>per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&pound;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&pound;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,784</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial public offering related expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange (losses) gains</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating loss</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss before tax</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,462</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,207</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss for the period</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,385</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,117</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes form an
integral part of these unaudited consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_10"></A>UNAUDITED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE SIX MONTHS ENDED JUNE&nbsp;30, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&pound;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&pound;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive expense:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that may be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange differences on translation of foreign operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive (expense) income for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total comprehensive loss for the period</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,386</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,113</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Attributable to:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity holders of the Company</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,386</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,113</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes form an
integral part of these unaudited consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_11"></A>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AS AT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Notes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,808</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,395</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepayments, accrued income and other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,882</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current income tax receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,035</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21,835</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25,819</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>23,643</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27,214</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity and liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Capital and reserves</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share capital and share premium</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">967</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,061</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(26,641</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total equity attributable to equity holders</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21,387</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25,241</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">728</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payroll taxes and social security</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenditure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,256</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,973</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,256</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,973</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total equity and liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>23,643</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27,214</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes form an
integral part of these unaudited consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_12"></A>UNAUDITED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE SIX MONTHS ENDED JUNE&nbsp;30, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Own<BR>Share<BR>reserve</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share<BR>option<BR>reserve</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Foreign<BR>currency<BR>translation<BR>reserve</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Capital<BR>reserve</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>deficit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;equity<BR>attributable<BR>to equity<BR>holders</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="30" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at December&nbsp;31, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>659</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>42,574</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(339</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,291</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(16,224</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29,960</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive income for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive income (loss) for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at June&nbsp;30, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>659</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>42,574</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(339</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,430</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(19,341</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26,986</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>663</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>42,770</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(339</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4,406</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(22,256</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25,241</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduction in share premium</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at June&nbsp;30, 2017</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>663</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>304</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(339</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4,938</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>42,466</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(26,641</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21,387</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes form an
integral part of these unaudited consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_13"></A>UNAUDITED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE SIX MONTHS ENDED JUNE&nbsp;30, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments for:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,077</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,090</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization and depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(167</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Movements in working capital:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decrease (increase) in other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Decrease) increase in trade payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase (decrease) in payroll taxes, social security and accrued expenditure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(164</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Movements in working capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash used in operations</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,905</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,380</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporation tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used in operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,670</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,380</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments for office and computer equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments for intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(492</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from short-term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash (used in) provided by investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(399</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5,210</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net (decrease) increase in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">830</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents at beginning of period</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19,990</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14,112</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign currency translation differences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents at end of period</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15,918</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14,951</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes form an
integral part of these unaudited consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_14"></A>NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. General information </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NuCana BioMed Limited (&#147;NuCana&#148; or the
&#147;Company&#148;) is a clinical-stage biopharmaceutical company developing a portfolio of new medicines to treat cancer. We are harnessing the power of phosphoramidate chemistry to generate new medicines called ProTides. These compounds have the
potential to improve cancer treatment by enhancing the efficacy and safety of several current standards of care. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is registered in England and Wales and domiciled in the United Kingdom. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has two wholly owned subsidiaries, NuCana, Inc.
and NuCana BioMed Trustee Company Limited. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant
accounting policies </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Basis of
preparation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The interim condensed
consolidated financial statements for the six months ended June&nbsp;30, 2017 have been prepared in accordance with International Accounting Standard 34 &#147;Interim Financial Reporting&#148; (&#147;IAS&nbsp;34&#148;). The accounting policies and
methods of computation applied in the preparation of the interim financial statements are consistent with those applied in the Company&#146;s annual financial statements for the year ended December&nbsp;31, 2016. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s financial statements comprise the
financial statements of the Company and its subsidiaries at June&nbsp;30, 2017. The financial statements are presented in pounds sterling, which is also the Company&#146;s functional currency. All values are rounded to the nearest thousand, except
where otherwise indicated. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The interim
consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Company&#146;s annual financial statements as at December&nbsp;31, 2016.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Going concern </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In common with many companies in the biopharmaceutical
sector, the Company incurs significant expenditure in its early years as it researches and develops its potential products for market. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The board of directors, having reviewed the operating budgets and development plans, consider that the Company has adequate resources to
continue in operation for the foreseeable future. The board of directors is therefore satisfied that it is appropriate to adopt the going concern basis of accounting in preparing the financial statements. The Company believes that its cash and cash
equivalents of &pound;15.9&nbsp;million at June&nbsp;30, 2017, will be sufficient to fund its current operating plan for at least the next 12 months. As the Company continues to incur losses, the transition to profitability is dependent upon the
successful development, approval and commercialization of its product candidates and achieving a level of revenues adequate to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will continue to
need to raise additional capital. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
intends to fund future operations through additional equity offerings and may seek additional capital through arrangements from other sources. There can be no assurances, however, that additional funding will be available on acceptable terms.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies&nbsp;(continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Initial public offering (&#147;IPO&#148;) related expenses </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incremental costs incurred and directly attributable to the
expected offering of securities are deferred and deducted from the related proceeds of the offering. The net amount will be recorded as contributed shareholders&#146; equity in the period when such shares are issued. Other costs incurred in the
offering will be expensed as incurred and included in IPO related costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Segment reporting </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company operates in one operating segment. The Company&#146;s chief operating decision maker (the &#147;CODM&#148;), its Chief Executive Officer, manages the Company&#146;s operations on an integrated
basis for the purposes of allocating resources. The Company&#146;s principal operations and decision-making functions are located in the United Kingdom. The CODM makes decisions on a global basis from there. Accordingly, the Company has determined
that it operates in a single reporting segment. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. IPO related
expenses </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;Six&nbsp;Months</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>ended&nbsp;
June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IPO related expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IPO related expenses
primarily relates to legal, accounting and other advisors&#146; fees in relation to the Company&#146;s anticipated listing on the Nasdaq Global Market.<B> </B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. Income tax credit </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s consolidated effective tax rate for the full financial year 2017 is estimated at 19.7% (December 31, 2016: 25.9%).
Therefore, the consolidated effective tax rate used for the six months ended June&nbsp;30, 2017 was 19.7% (June 30, 2016: 25.9%). The income tax credit for the six months ended June&nbsp;30, 2017 is &pound;1.1&nbsp;million (June&nbsp;30, 2016:
&pound;1.1 million). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is no deferred tax
charge for the six months ended June&nbsp;30, 2017 (June 30, 2016: &pound;nil). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>5. Basic and diluted loss per share </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For Six Months<BR>ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss for the period</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,385</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3,117</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted weighted average number of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Basic and diluted loss per share</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(0.18</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(0.13</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic loss per share is
calculated by dividing the loss for the period attributable to the equity holders of the Company by the weighted average number of shares outstanding during the period. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. Basic and diluted loss per share&nbsp;(continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The dilutive effect of potential shares through equity settled transactions were
considered to be anti-dilutive as they would have decreased the loss per share and were therefore excluded from the calculation of diluted loss per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Intangible assets </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets comprise patents with a carrying value of &pound;1.7&nbsp;million as of June 30, 2017 (as of December&nbsp;31, 2016:
&pound;1.4 million) and computer software with a carrying value of &pound;0.1&nbsp;million as of June 30, 2017 (as of December&nbsp;31, 2016: &pound;7,000). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the six months ended June&nbsp;30, 2017, the Company acquired intangible assets with a cost of &pound;0.5&nbsp;million. The
additions comprised &pound;0.4&nbsp;million in relation to patents and &pound;0.1&nbsp;million in relation to computer software (year ended December&nbsp;31, 2016: &pound;0.5&nbsp;million on patents, &pound;10,602 on computer software). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There were no disposals of assets in the six months ended
June&nbsp;30, 2017 (year ended December&nbsp;31, 2016: &pound;nil). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. Cash and cash equivalents </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,918</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents
comprise cash at bank with maturity of three months or less, which are subject to insignificant risk of changes in value. Cash at bank earns interest at fixed or variable rates based on the terms agreed for each account. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents are measured at fair value and
classified as Level&nbsp;1 under the fair value level hierarchy. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. Share-based payments </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has three share-based payment plans for employees, directors and consultants. The share options granted will be settled in
equity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May&nbsp;16, 2017, 23,250 share
options were granted to a director under the U.K. share-based payment agreement, which will vest equally over a period of four years if the option holder remains a director of the Company. Upon vesting, each option allows the holder to purchase one
ordinary share at a specified option price determined at grant date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. Share-based payments&nbsp;(continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following principal assumptions were used in the valuation for share options:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Options&nbsp;granted&nbsp;on<BR>May&nbsp;16, 2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vesting dates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct&nbsp;28, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct&nbsp;28, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66.56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free investment rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of option at grant date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of share at grant date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise price at date of grant</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lapse date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;16,&nbsp;2027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected option life (years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Number of options granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair values of options
granted were determined using the Black-Scholes model that takes into account factors specific to the share incentive plan such as the assumption that the options will be exercised at a single point in time, in December 2019. This has been
incorporated into the measurement by means of actuarial modelling. As NuCana BioMed Limited was unlisted on the grant date of the options, it was not possible to derive historical volatility from the Company&#146;s own share price. The underlying
expected volatility was therefore determined by using the historical volatility of similar listed entities as a proxy. The volatility percentage applied to each tranche is the average of the historical volatility of comparable companies to NuCana
BioMed Limited. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted average remaining
contractual life of the share options outstanding as at June&nbsp;30, 2017 is 5.71&nbsp;years (June 30, 2016: 6.49). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the six months ended June&nbsp;30, 2017, the Company has recognized &pound;0.5&nbsp;million of share-based payment expense in the
statement of operations (June 30, 2016: &pound;0.1 million). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. Related party disclosures </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation of key management personnel of the Company </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>For&nbsp;Six&nbsp;Months&nbsp;ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term employee benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">446</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">612</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Severance payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pension and other benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">123</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>830</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>911</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts disclosed in the
table above are the amounts recognized as an expense during the reporting period related to key management personnel. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Share capital and share premium </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share premium</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>967</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>43,433</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:106pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Issued share capital comprises:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ordinary shares of &pound;0.01 each</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,239 </FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Founder Ordinary 1 shares of &pound;0.01 each</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Founder Ordinary 2 shares of &pound;0.01 each</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A shares of &pound;0.01 each</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B shares of &pound;0.001 each</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24,185</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24,185</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table above does not
total due to rounding. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to facilitate the
Company being re-registered as a public company, the directors of the Company signed a solvency statement on June 29, 2017 with the agreement of the shareholders and undertook a capital reduction reducing its share premium by
&pound;42.5&nbsp;million, from &pound;42.8&nbsp;million to &pound;0.3&nbsp;million with the amount by which the share premium was reduced credited to the Company&#146;s capital reserve. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No. of<BR>shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fully paid shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduction in share premium account</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at June&nbsp;30, 2017</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24,185</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>663</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>304</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. Other reserves </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>June&nbsp;30,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Own share reserve</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign currency translation reserve</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share option reserve</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of share options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4,</B><B>938</B><B></B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>4,406</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B>&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Capital reserve</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduction in share premium account</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>42,466</B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total o</B><B>ther reserves</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>47,061</B><B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>4,064</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B>&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign currency
translation reserve </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foreign currency
translation reserve is used to record exchange differences arising from the translation of the financial statements of foreign operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Own share reserve </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The own share reserve represents the cost of 500,000&nbsp;shares of NuCana BioMed Limited purchased by NuCana Employee Benefit Trust and
that may, at the discretion of the trustee, be used to satisfy future exercise of options under the Company&#146;s share options plan. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share option reserve </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The share option reserve is used to recognize the value of equity-settled share-based payments provided to employees, directors and
consultants as part of their remuneration. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Capital reserve </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to facilitate the Company being re-registered as a public limited company, the directors of the Company signed a solvency
statement on June&nbsp;29, 2017, with the agreement of the shareholders and undertook a capital reduction reducing its share premium by &pound;42.5&nbsp;million, from &pound;42.8&nbsp;million to &pound;0.3&nbsp;million with the amount by which the
share premium was reduced credited to the Company&#146;s capital reserve. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>12. Events after the reporting period </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On August 11, 2017 and August 31, 2017, the Company entered into new lease obligations for office space. The lease obligations are for a period of five years with a break clause after three years.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August 29, 2017, the Company <FONT
STYLE="white-space:nowrap">re-registered</FONT> as a public limited company and changed its name to NuCana plc. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-12
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Events after the reporting period&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September 14, 2017, the Company completed a one-for-four reverse share split and an
associated bonus allotment of shares to take into account fractional entitlements. This had the effect of consolidating every four ordinary shares of &pound;0.01 to one ordinary share of &pound;0.04, every four founder ordinary 1 shares of
&pound;0.01 to one founder ordinary 1 share of &pound;0.04, every four founder ordinary 2 shares of &pound;0.01 to one founder ordinary 2 share of &pound;0.04, every four series A shares of &pound;0.01 to one series A share of &pound;0.04 and every
four series B shares of &pound;0.001 to one series B share of &pound;0.004. After the reverse share split, the Company has 24,214,641 shares outstanding. This includes an issue of 30,000 shares in August 2017, upon the exercise of options.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of the reverse share split, the
exercise prices and the numbers of shares issuable upon the exercise of any outstanding options to purchase ordinary shares were proportionally adjusted pursuant to the respective anti-dilution terms of the share based payment plans. All references
in these financial statements and accompanying notes to units of ordinary shares or per share amounts are reflective of the reverse share split for all periods presented. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Directors of NuCana plc: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have audited the accompanying consolidated statements of
financial position of NuCana plc (formerly known as NuCana Biomed Limited) (the &#147;Company&#148;) and subsidiaries as of December&nbsp;31, 2016 and 2015, and the related consolidated statements of operations, comprehensive loss, changes in equity
and cash flows for each of the two years in the period ended December&nbsp;31, 2016. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based
on our audits. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We conducted our audits in
accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. We were not engaged to perform an audit of the Company&#146;s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe
that our audits provide a reasonable basis for our opinion. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of NuCana plc and subsidiaries at December&nbsp;31, 2016 and 2015,
and the consolidated results of their operations and their cash flows for each of the two years in the period ended December&nbsp;31, 2016, in conformity with International Financial Reporting Standards as issued by the International Accounting
Standards Board. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/
Ernst&nbsp;&amp; Young LLP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Edinburgh, United Kingdom </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;26, 2017, except for the restatement to give effect to the reverse share split described in Note 16 to the
financial statements, as to which the date is September 18, 2017 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-14
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_2"></A>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>YEAR ENDED DECEMBER&nbsp;31, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Notes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands,&nbsp;except<BR>per-share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&pound;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&pound;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,904</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net foreign exchange gains (losses)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating loss</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(8,448</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(6,914</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss before tax</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(8,165</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(6,508</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax&nbsp;credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss for the year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(6,049</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,332</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes form an
integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-15
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_3"></A>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>YEAR ENDED DECEMBER&nbsp;31, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Notes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive expense:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Items that may be reclassified subsequently to profit or loss:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange differences on translation of foreign operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive expense for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total comprehensive loss for the year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(6,051</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,333</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Attributable to:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Equity holders of the Company</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(6,051</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,333</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes form an
integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-16
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_4"></A>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AT DECEMBER 31, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Notes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,<BR>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">927</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,395</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>941</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepayments, accrued income and other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current income tax receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,195</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25,819</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>30,744</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27,214</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>31,685</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EQUITY AND LIABILITIES</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Capital and reserves</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share capital and share premium</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,233</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,951</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22,256</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total equity attributable to equity holders </B><B><I></I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25,241</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29,960</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trade payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">728</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">507</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payroll taxes and social security</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenditure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,160</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current income tax payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,973</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,725</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,973</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,725</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total equity and liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27,214</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>31,685</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes form an
integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-17
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_5"></A>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Own<BR>share<BR>reserve</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share<BR>option<BR>reserve</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Foreign<BR>currency<BR>translation<BR>reserve</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accumulated<BR>deficit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;equity<BR>attributable<BR>to equity<BR>holders</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at January&nbsp;1, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>659</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>42,574</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(339</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,506</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(10,892</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>34,508</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive expense for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at December&nbsp;31, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>659</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>42,574</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(339</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,291</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(16,224</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29,960</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other comprehensive expense for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total comprehensive loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of share options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of share capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>663</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>42,770</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(339</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4,406</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(22,256</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25,241</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes form an
integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-18
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_6"></A>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE YEAR ENDED DECEMBER 31, </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,049</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments for:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income tax credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,116</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amortization and depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finance income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,085</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Movements in working capital:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Increase) decrease in other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,404<B><I></I></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)<B><I></I></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B>36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I></I></B>&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in trade payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">220<I></I></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>133</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in payroll taxes, social security and accrued expenditure</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">418</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Movements in working capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash used in operations</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(10,366</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,498</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporation tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash used in operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(9,264</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)</B>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(4,467</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)</B>&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest received</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">410</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments for office and computer equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments for intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from (investment in) short-term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(75</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by (used in) investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14,931</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(181</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issue of share capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash from financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>200</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net increase (decrease) in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4,648</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents at beginning of year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14,112</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18,761</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign currency translation differences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash and cash equivalents at end of year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19,990</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14,112</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes form
an integral part of these consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-19
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="fin393013_7"></A>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. General information </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NuCana BioMed Limited (&#147;NuCana&#148; or the &#147;Company&#148;) is a clinical-stage biopharmaceutical company developing a portfolio
of new medicines to treat cancer. We are harnessing the power of phosphoramidate chemistry to generate new medicines called ProTides. These compounds have the potential to improve cancer treatment by enhancing the efficacy and safety of several
current standards of care. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is
incorporated in England and Wales and domiciled in the United Kingdom. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company has two wholly owned subsidiaries, NuCana, Inc. and NuCana BioMed Trustee Company Limited. The financial statements for the Company were authorized for issue by the board of directors on
June&nbsp;26, 2017. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Re-registration
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to completion of the initial
public offering (&#147;IPO&#148;), the Company intends to re-register as a public limited company and change its name to NuCana plc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Basis of preparation </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial statements have been prepared in accordance with International Financial Reporting Standards (&#147;IFRS&#148;) as issued by
the International Accounting Standards Board (&#147;IASB&#148;). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s financial statements comprise the financial statements of the Company and its subsidiaries at December&nbsp;31, 2016. The financial statements are presented in pounds sterling, which is
also the Company&#146;s functional currency. All values are rounded to the nearest thousand, except where otherwise indicated. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Going concern </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In common with many companies in the biopharmaceutical sector, the Company incurs significant expenditure in its early years as it
researches and develops its potential products for market. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The board of directors, having reviewed the operating budgets and development plans, consider that the Company has adequate resources to continue in operation for the foreseeable future. The board of
directors is therefore satisfied that it is appropriate to adopt the going concern basis of accounting in preparing the financial statements. The Company believes that its cash and cash equivalents of &pound;20.0 million at December&nbsp;31, 2016,
will be sufficient to fund its current operating plan for at least the next 12 months. As the Company continues to incur losses, the transition to profitability is dependent upon the successful development, approval and commercialization of its
product candidates and achieving a level of revenues adequate to support its cost structure. The Company may never achieve profitability, and unless and until it does, it will continue to need to raise additional capital. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company intends to fund future operations through
additional equity offerings and may seek additional capital through arrangements from other sources. There can be no assurances, however, that additional funding will be available on acceptable terms. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Judgements and estimates </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The preparation of the financial statements requires
management to make estimates and assumptions that affect the amounts reported for assets and liabilities at the balance sheet dates and the amounts reported for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-20
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
revenue and expenses during the year. The nature of estimations means that actual outcomes could differ from those estimates. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following judgements have had the most significant effect
on the amounts recognized in the financial statements: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and development expenses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company recognizes research and development expenses in the statement of operations in the period in which it is incurred. When development activities reach the advanced stage, as set out in the
specific criteria of International Accounting Standard (&#147;IAS&#148;) 38, <I>Intangible Assets</I>, there will be a requirement to capitalize such costs as intangible assets. Management will continue to exercise judgement in the appropriate
treatment of development costs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Taxation
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management judgement is required to
determine the amount of deferred tax assets that should be recognized, based upon the likely timing and level of future taxable profits. Further details are contained in Note&nbsp;6. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following estimate has had the most significant effect on the amounts recognized in the financial
statements: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-based payments
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimating fair value for share-based
payment transactions requires determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model, including
the expected life of the share option or appreciation right, volatility, dividend yield and making assumptions about them and, in the case of the Company, the value of an ordinary share. For the measurement of the fair value of equity-settled
transactions with employees at the grant date, the Company uses the Black-Scholes model. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 12. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Basis of consolidation </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated financial statements comprise the financial
statements of the Company as of December&nbsp;31, 2016 and 2015. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries are consolidated from the date of acquisition, being the date on which the Company obtains control, and continue to be consolidated until the date when such control ceases. The financial
statements of the subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies. All intra-group balances, transactions, unrealized gains and losses resulting from intra-group transactions and
dividends are eliminated in full. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets,
liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Company gains control until the date the Company ceases to control the subsidiary.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-21
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Segment reporting </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company operates in one operating segment. The
Company&#146;s chief operating decision maker (the &#147;CODM&#148;), its Chief Executive Officer, manages the Company&#146;s operations on an integrated basis for the purposes of allocating resources. The Company&#146;s principal operations and
decision-making functions are located in the United Kingdom. The CODM makes decisions on a global basis from there. Accordingly, the Company has determined that it operates in a single reporting segment. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Property, plant and equipment </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office and computer equipment is stated at cost, net of
accumulated depreciation and accumulated impairment losses, if any. There are no restrictions on title or equipment pledged as security for liabilities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Depreciation is provided on office and computer equipment over their expected useful economic life as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="61%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Asset class</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Depreciation method and rate</B></FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office and computer equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Straight-line over 3 years</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intangible assets
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets are stated at cost,
net of accumulated amortization and accumulated impairment losses, if any. Cost in relation to patents includes registration, documentation and other legal fees associated with obtaining the patent. Software costs represent the initial purchase
price of the asset. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amortization method and
period for the principal categories of intangible assets is calculated as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="70%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Asset class</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amortization method and rate</B></FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reverse sum of digits over 20 years</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer software</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Straight-line between 3 and 5 years</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amortization period and
the amortization method for an intangible asset with a finite useful life are reviewed at least at each financial <FONT STYLE="white-space:nowrap">year-end.</FONT> We also consider the profile of patents on a case-by-case basis and in appropriate
circumstances we will use the straight-line method. Changes in the expected useful economic life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by changing the amortization period or
method, as appropriate. These changes are made on a prospective basis and treated as changes in accounting estimates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets are tested for impairment when a trigger event occurs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cash, cash equivalents and short-term deposits </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents in the statement of financial
position include cash at banks with a maturity of less than three months, which are subject to an insignificant risk of changes in value. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term deposits represent certificates of deposits with banks with maturities of greater than three months but less than one year.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-22
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and development </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses are currently recognized
in the statement of operations in the year in which it is incurred. Development expenditures on an individual project will be recognized as an intangible asset when the Company can demonstrate: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the technical feasibility of completing the intangible asset so that the asset will be available for use or sale; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">its intention to complete and its ability and intention to use or sell the asset; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">how the asset will generate future economic benefits; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of resources to complete the asset; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ability to measure reliably the expenditure during development. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income Taxes </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current income tax </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current income tax assets and liabilities are measured at
the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Company operates
and generates taxable income. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Deferred
income tax </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred income tax is
provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the Company&#146;s financial statements. However, the deferred income tax is not accounted
for, if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using
tax rates and laws that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred tax liability is settled. Deferred tax assets are
recognized to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilized. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income tax credit </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company benefits from the U.K. research and development tax credit regime whereby a portion of the Company&#146;s losses can be
surrendered for a cash rebate of up to 33.35% of eligible expenditures. Such credits are accounted for within the tax provision, in the year in which the expenditures were incurred. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating leases </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leases where the lessor retains substantially all the risks
and benefits of ownership of the asset are classified as operating leases and rentals payable are charged in the consolidated statement of operations on a straight-line basis over the lease term. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Impairment of
<FONT STYLE="white-space:nowrap">non-financial</FONT> assets </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, the Company estimates the asset&#146;s recoverable amount. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-23
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An impairment loss is recognized whenever the carrying amount of an asset or its
cash-generating unit exceeds its recoverable amount. Impairment losses are recognized in the consolidated statements of operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A cash-generating unit is the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash
inflows from other assets or groups of assets. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Calculation of recoverable amount </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The recoverable amount of assets and cash-generating units is the higher of their fair value less costs to sell and value in use. In
assessing value in use, the estimated future cash flows are discounted to their present value using a <FONT STYLE="white-space:nowrap">pre-tax</FONT> discount rate that reflects current market assessments of the time value of money and the risks
specific to the asset. For an asset that does not generate largely independent cash inflows, the recoverable amount is determined for the cash-generating unit to which the asset belongs. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Reversal of impairment </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An assessment is made at each reporting date as to whether
there is an indication that a previously recognized impairment loss may no longer exist or may have decreased. If such an indication exists, the recoverable amount is estimated. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A previously recognized impairment loss is reversed only if
there has been a change in the estimates used to determine the recoverable amount since the last impairment loss was recognized. If that is the case, the carrying value is increased to its recoverable amount. An impairment loss is reversed only to
the extent that the asset&#146;s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share-based payments </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employees, directors and consultants of the Company receive
remuneration in the form of share-based payments, whereby individuals render services as consideration for equity instruments (share options). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under IFRS 2 <I>Share-based Payment</I>, equity share-based payments are measured at the fair value of the equity instruments at the grant
date. Details regarding the determination of fair value of equity settled share-based transactions are set out in Note&nbsp;12. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value determined at the grant date of equity settled share-based payments is expensed on a straight line basis over the vesting
period, with a corresponding increase in equity to the share option reserve. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Fair value measurement </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement
date. In order to increase consistency and comparability in fair value measurements, IFRS 7 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are
described as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level&nbsp;1: Quoted
(unadjusted) prices in active markets for identical assets or liabilities.</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-24
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Level&nbsp;2: Other techniques for which all inputs that have a significant effect on
the recorded fair value are observable, either directly or indirectly.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Level&nbsp;3: Techniques that use inputs that have a significant effect on the recorded fair value that are not based on observable market data. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accounting Standards </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In preparing these financial statements, the Company has
applied all relevant IAS, IFRS and International Financial Reporting Interpretations Committee (&#147;IFRIC&#148;) Interpretations as of the date of approval of these financial statements and which are mandatory for the financial year ended
December&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following accounting
standards and interpretations have been adopted as of January 1, 2016 in these financial statements and have not had a material impact on the Company&#146;s accounts in the period of initial application: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendments to IAS 1 Disclosure Initiative
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amendments to IAS 1 clarify, rather
than significantly change, existing IAS 1 requirements. The amendments clarify: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The materiality requirements in IAS 1 </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">That specific line items in the statement(s) of operations and other comprehensive income (&#147;OCI&#148;) and the statement of financial position may
be disaggregated </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">That entities have flexibility as to the order in which they present the notes to financial statements </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">That the share of OCI of associates and joint ventures accounted for using the equity method must be presented in aggregate as a single line item, and
classified between those items that will or will not be subsequently reclassified to profit or loss. Furthermore, the amendments clarify the requirements that apply when additional subtotals are presented in the statement of financial position and
the statement(s) of operations and OCI. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendments to IAS 27: Equity Method in Separate Financial Statements </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amendments allow entities to use the equity method to account for investments in subsidiaries, joint ventures and associates in their
separate financial statements. Entities already applying IFRS and electing to change to the equity method in their separate financial statements have to apply that change retrospectively. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Annual Improvements 2012-2014 Cycle </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These improvements include: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>IFRS 5 Non-current Assets Held for Sale </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assets (or disposal groups) are generally disposed of either
through sale or distribution to the owners. The amendment clarifies that changing from one of these disposal methods to the other would not be considered a new plan of disposal, rather it is a continuation of the original plan. There is, therefore,
no interruption of the application of the requirements in IFRS 5. This amendment is applied prospectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-25
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>IFRS 7 Financial Instruments: Disclosures </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(i)</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Servicing contracts </I></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amendment clarifies that a servicing contract that includes a fee can constitute continuing involvement in a financial asset. An
entity must assess the nature of the fee and the arrangement against the guidance for continuing involvement in IFRS 7 in order to assess whether the disclosures are required. The assessment of which servicing contracts constitute continuing
involvement must be done retrospectively. However, the required disclosures need not be provided for any period beginning before the annual period in which the entity first applies the amendments. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>(ii)</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Applicability of the amendments to IFRS 7 to condensed interim financial statements </I></FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amendment clarifies that the offsetting disclosure requirements do not apply to condensed interim financial
statements, unless such disclosures provide a significant update to the information reported in the most recent annual report. This amendment is applied retrospectively. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>IAS 19 Employee Benefits </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amendment clarifies that market depth of high quality
corporate bonds is assessed based on the currency in which the obligation is denominated, rather than the country where the obligation is located. When there is no deep market for high quality corporate bonds in that currency, government bond rates
must be used. This amendment is applied prospectively. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>IAS 34 Interim Financial Reporting </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The amendment clarifies that the required interim disclosures must either be in the interim financial statements or incorporated by cross-reference between the interim financial statements and wherever
they are included within the interim financial report (e.g., in the management commentary or risk report). The other information within the interim financial report must be available to users on the same terms as the interim financial statements and
at the same time. This amendment is applied retrospectively. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendments to IAS 16 and IAS 38: Clarification of Acceptable Methods of Depreciation and Amortization </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amendments clarify the principle in IAS 16 <I>Property,
Plant and Equipment </I>and IAS 38 <I>Intangible Assets </I>that revenue reflects a pattern of economic benefits that are generated from operating a business (of which the asset is a part) rather than the economic benefits that are consumed through
use of the asset. As a result, a revenue-based method cannot be used to depreciate property, plant and equipment and may only be used in very limited circumstances to amortise intangible assets. The amendments are applied prospectively and do not
have any impact on the Company, given that it has not used a revenue-based method to depreciate its non-current assets. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The IASB and IFRIC have issued the following standards and interpretations, which are considered relevant to the Company, with an
effective date after the date of these financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendments to IAS 12: Recognition of Deferred Tax Assets for Unrealized Losses </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amendments clarify that an entity needs to consider whether tax law restricts the sources of taxable profits against which it may make
deductions on the reversal of that deductible temporary difference. Furthermore, the amendments provide guidance on how an entity should determine future taxable profits and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-26
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
explain the circumstances in which taxable profit may include the recovery of some assets for more than their carrying amount. Entities are required to apply the amendments retrospectively.
However, on initial application of the amendments, the change in the opening equity of the earliest comparative period may be recognized in opening retained earnings (or in another component of equity, as appropriate), without allocating the change
between opening retained earnings and other components of equity. Entities applying this relief must disclose that fact. These amendments are effective for annual periods beginning on or after January&nbsp;1, 2017, with early application permitted.
These amendments are not expected to have a material impact on the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendments to IAS 7: Disclosure Initiative </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amendments to IAS 7 <I>Statement of Cash Flows</I> aim to help users of financial statements better understand changes in an
entity&#146;s debt. The amendments require entities to provide disclosures about changes in their liabilities arising from financing activities, including both changes arising from cash flows and <FONT STYLE="white-space:nowrap">non-cash</FONT>
changes (such as foreign exchange gains or losses). This amendment is effective for annual periods on or after January&nbsp;1, 2017. This amendment is not expected to have a material impact on the Company&#146;s disclosure. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>IFRS 9: Financial Instruments </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2014, the IASB issued the final version of IFRS 9
<I>Financial Instruments</I> that replaces IAS&nbsp;39 <I>Financial Instruments: Recognition and Measurement</I> and all previous versions of IFRS 9. IFRS&nbsp;9 brings together all three aspects of the accounting for financial instruments project:
classification and measurement, impairment and hedge accounting. IFRS 9 is effective for annual periods beginning on or after January&nbsp;1, 2018, with early application permitted. Except for hedge accounting, retrospective application is required
but providing comparative information is not compulsory. For hedge accounting, the requirements are generally applied prospectively, with some limited exceptions. The Company expects no material impact on its balance sheet and equity. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>IFRS 16: Leases </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IFRS 16 was issued in January 2016 and it replaces IAS 17
<I>Leases</I>, IFRIC 4 <I>Determining Whether an Arrangement Contains a Lease</I>, <FONT STYLE="white-space:nowrap">SIC-15</FONT> <I>Operating Leases-Incentives</I> and <FONT STYLE="white-space:nowrap">SIC-27</FONT> <I>Evaluating the Substance of
Transactions Involving the Legal Form of a Lease</I>. IFRS 16 sets out the principles for the recognition, measurement, presentation and disclosure of leases and requires lessees to account for all leases under a single <FONT
STYLE="white-space:nowrap">on-balance</FONT> sheet model similar to the accounting for finance leases under IAS 17. The standard includes two recognition exemptions for lessees&#151;leases of
<FONT STYLE="white-space:nowrap">&#146;low-value&#146;</FONT> assets (e.g., personal computers) and short-term leases (i.e., leases with a lease term of 12 months or less). At the commencement date of a lease, a lessee will recognize a liability to
make lease payments (i.e., the lease liability) and an asset representing the right to use the underlying asset during the lease term (i.e., the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset).
Lessees will be required to separately recognize the interest expense on the lease liability and the depreciation expense on the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset. Lessees will also be
required to remeasure the lease liability upon the occurrence of certain events (e.g., a change in the lease term, a change in future lease payments resulting from a change in an index or rate used to determine those payments). The lessee will
generally recognize the amount of the remeasurement of the lease liability as an adjustment to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lessor accounting under IFRS 16 is substantially unchanged
from today&#146;s accounting under IAS 17. Lessors will continue to classify all leases using the same classification principle as in IAS 17 and distinguish between two types of leases: operating and finance leases. IFRS 16 also requires lessees and
lessors to make more </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-27
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. Significant accounting policies&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
extensive disclosures than under IAS 17. IFRS 16 is effective for annual periods beginning on or after January&nbsp;1, 2019. Early application is permitted, but not before an entity applies IFRS
15 <I>Revenue from Contracts with</I> <I>Customers</I>. A lessee can choose to apply the standard using either a full retrospective or a modified retrospective approach. The standard&#146;s transition provisions permit certain reliefs. The Company
is currently assessing the potential impact of IFRS 16 on its consolidated financial statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Amendments to IFRS 2: Classification and Measurement of Share-based Payment Transactions </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The IASB issued amendments to IFRS 2 <I>Share-based Payment</I> that address three main areas: the effects of vesting conditions on the
measurement of a cash-settled share-based payment transaction; the classification of a share-based payment transaction with net settlement features for withholding tax obligations; and accounting where a modification to the terms and conditions of a
share-based payment transaction changes its classification from cash settled to equity settled. On adoption, entities are required to apply the amendments without restating prior periods, but retrospective application is permitted if elected for all
three amendments and other criteria are met. The amendments are effective for annual periods beginning on or after January&nbsp;1, 2018, with early application permitted. This amendment is not expected to have a material impact on the Company.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Annual Improvements to IFRSs 2014-2016
Cycle </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>IFRS 1 First-time Adoption of
IFRS </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This amendment deleted the short-term
exemptions in paragraphs E3&#150;E7 of IFRS 1, because they have now served their intended purpose. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>IFRS 12 Disclosure of Interests in Other Entities </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This amendment clarified the scope of the standard by specifying that the disclosure requirements in the standard, except for those in
paragraphs B10&#150;B16, apply to an entity&#146;s interests listed in paragraph 5 that are classified as held for sale, as held for distribution or as discontinued operations in accordance with IFRS 5 <I>Non-current Assets Held for Sale and
Discontinued Operations</I>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These amendments are
not expected to have a material impact on the Company. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>IFRIC Interpretation 22 Foreign Currency Transactions and Advance Consideration</I></B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The interpretation clarifies that in determining the spot exchange rate to use on initial recognition of a related asset, expense or
income (or part of it) on the derecognition of a <FONT STYLE="white-space:nowrap">non-monetary</FONT> asset or <FONT STYLE="white-space:nowrap">non-monetary</FONT> liability relating to advance consideration, the date of the transaction is the date
on which an entity initially recognises the <FONT STYLE="white-space:nowrap">non-monetary</FONT> asset or <FONT STYLE="white-space:nowrap">non-monetary</FONT> liability arising from the advance consideration. If there are multiple payments or
receipts in advance, then the entity must determine a date of the transactions for each payment or receipt of advance consideration. This interpretation is not expected to have a material impact on the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-28
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. Staff costs </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Included in research and development expenses:
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wages and salaries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Social security costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pension costs and other benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,027</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,575</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,318</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Included in administrative expenses: </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wages and salaries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Social security costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pension costs and other benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">209</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total employee benefit expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,784</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,569</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The average number of staff employed under contracts of service were: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Directors&#146;
remuneration &amp; other benefits </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors&#146; remuneration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pension and other benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>583</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>603</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of directors who exercised share options in 2016 is 1 (2015: nil). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-29
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. Staff costs&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above amounts for remuneration include the following in respect of the highest paid
director: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors&#146; remuneration</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pension and other benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>407</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>379</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. Basic and diluted loss per share
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss for the year</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(6,049</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(5,332</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted weighted average number of shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,107</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Basic and diluted loss per share</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(0.25</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(0.22</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic loss per share is
calculated by dividing the loss for the year attributable to the equity holders of the Company by the weighted average number of shares outstanding during the year. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The dilutive effect of potential shares through equity
settled transactions were considered to be anti-dilutive as they would have decreased the loss per share and were therefore excluded from the calculation of diluted loss per share. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. Operating lease arrangements </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating leases relate to rental of office space. The
leases are renewed for 12 or 24 months. All operating lease contracts contain clauses for market rental reviews on renewal. The Company does not have an option to purchase the leased office at the expiry of the lease periods. Operating lease expense
for the years ended December&nbsp;31, 2016 and 2015 was &pound;0.2&nbsp;million and &pound;0.1&nbsp;million, respectively. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Future minimum rentals payable under <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating leases are as follows: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not later than 1 year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Later than 1 year and not later than 5 years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Later than 5 years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>254</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>166</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-30
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Income tax credit </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The major components of income tax for the years ended
December&nbsp;31, 2016 and 2015 are as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Current tax:</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In respect of current year U.K.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;1,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;1,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In respect of current year U.S.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In respect of prior years U.K.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">In respect of prior years U.S.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total current tax</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,116</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,176</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Current income tax receivable:</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.K. tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current income tax receivable</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,195</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,182</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Current income tax payable:</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The credit for the year can
be reconciled to the loss per the statement of operations as follows: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Loss before tax</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(8,165</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(6,508</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax on loss at standard U.K. tax rate of 20.00% (2015: 20.25%)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effects of:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments in respect of prior years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenses not deductible</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deduction for R&amp;D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Losses surrendered for R&amp;D tax credit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,629</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,650</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overseas tax payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D tax credit&#151;current year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">R&amp;D tax credit&#151;prior years</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(235</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax asset not recognized</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">430</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Income tax credit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(2,116</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1,176</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>)&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has not
recognized a deferred tax asset in respect of tax losses carried forward as at December&nbsp;31, 2016 on the basis that the timing during which tax losses could be regarded as recoverable against future taxable profits cannot be determined with
reasonable certainty. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary differences and
cumulative carry forward tax losses for which deferred tax has not been recognized amount to &pound;32.5&nbsp;million (2015: &pound;10.1&nbsp;million). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.K. tax legislation, which was substantively enacted on October&nbsp;26, 2015, includes legislation that will reduce the main rate of
U.K. corporation tax from 20% to 18%. This decrease is to be phased in with a reduction </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-31
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Income tax credit&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to 19%, effective from April&nbsp;1, 2017, and a reduction to 18%, effective from April&nbsp;1, 2020. Further, as announced on March&nbsp;16, 2016, that the full rate of U.K. corporation tax will
reduce by a further 1% to 17% from April&nbsp;1, 2020. This further reduction was included within the U.K. tax legislation, which was substantively enacted on September&nbsp;6, 2016. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. Intangible assets </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Patents</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Computer<BR>Software</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">390</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,004</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,004</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated amortization:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charge for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>77</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#151;&nbsp;&nbsp;</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>77</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,533</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,543</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated amortization:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charge for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">89</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>163</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>166</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net book value:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,370</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1,377</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">927</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">927</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-32
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. Property, plant and equipment </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Office and<BR>computer<BR>equipment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of foreign currency exchange differences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>37</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charge for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of foreign currency exchange differences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>23</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disposals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of foreign currency exchange differences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>52</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charge for the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disposals</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of foreign currency exchange differences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>34</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net book value:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>At December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. Prepayments, accrued income and other
receivables </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepayments&#151;manufacturing and clinical</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepayments&#151;other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">VAT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,634</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>375</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-33
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Share capital and share premium </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share premium</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>43,433</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>43,233</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued share capital comprises:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ordinary shares of &pound;0.01 each</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,239</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Founder ordinary 1 shares of &pound;0.01 each</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Founder ordinary 2 shares of &pound;0.01 each</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A shares of &pound;0.01 each</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B shares of &pound;0.001 each</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24,185</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24,102</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table above does not
total due to rounding. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of&nbsp;shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share<BR>capital</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Share<BR>premium</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands) </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fully paid shares:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at January&nbsp;1, 2015 and December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">659</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issue of shares on exercise of options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">83</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">196</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance at December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24,185</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>663</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>42,770</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Ordinary shares
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The ordinary shares rank equally with
all other shares in issue in that on a poll every member shall have one vote for each ordinary share held (save for the enhanced voting rights referred to in the founder ordinary shares). The ordinary shares rank equally with all other shares in
issue in respect of any rights to any dividend distribution. The ordinary shares rank equally with all other shares in issue in respect of any rights to any capital distribution. The ordinary shares are not redeemable.<B> </B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Founder ordinary shares </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon shareholder vote, the founder ordinary 1 shares and the
founder ordinary 2 shares shall as separate classes of shares each confer upon the holders of such classes of shares such number of votes, which equals at least 5% of all votes exercisable by all holders of shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Series A shares </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The series A shares rank equally with all other shares in
issue in that on a vote every member shall have one vote for each series A share held (save for the enhanced voting rights conferred upon the founder ordinary shares). The series A shares rank equally with all others shares in respect of any rights
to any dividend </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-34
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Share capital and share premium&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
distribution. The series A shares rank equally with all other shares in issue in respect of any rights to any capital distribution. The series A shares are not redeemable. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Series B shares </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The series B shares rank equally with all other shares in
issue (save for the enhanced voting rights conferred upon the founder ordinary shares). The series B shares rank equally with all other shares in issue in respect of any rights to any dividend distribution. The series B shares rank equally with all
other shares in respect of any rights to any capital distribution. The series B shares are not redeemable. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Capital management </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purpose of the Company&#146;s capital management, capital includes issued capital, share premium and all other equity reserves
attributable to the equity holders of the Company. The purpose of the Company&#146;s capital management is to maximize shareholder value and ensure adequate capital is available to meet the medium-term operating plan. Review of operations and
commitments is key to identifying future capital management and a full review is undertaken on a quarterly basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No changes were made in the objectives, policies or processes for managing capital during the year ended December&nbsp;31, 2015 or the
year ended December&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. Other reserves
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Own share reserve</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foreign currency translation reserve</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share option reserve</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at beginning of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,132</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of share options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Balance at end of year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,291</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total other reserves</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4,064</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,951</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Foreign currency
translation reserve </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foreign currency
translation reserve is used to record exchange differences arising from the translation of the financial statements of foreign operations. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Own share reserve </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The own share reserve represents the cost of 500,000&nbsp;shares of NuCana BioMed Limited purchased by NuCana Employee Benefit Trust and
that may, at the discretion of the trustee, be used to satisfy future exercise of options under the Company&#146;s share options plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-35
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. Other reserves&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Share option reserve </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The share option reserve is used to recognize the value of
equity-settled share-based payments provided to employees, directors and consultants as part of their remuneration. Refer to Note 12 for further details of these plans. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Share-based payments </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has three share-based payment plans for
employees, directors and consultants. The share options granted will be settled in equity. In 2016, share options were granted under the following share-based payment plans: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>U.K. share-based payment plans </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options granted under these plans will vest if the option
holder remains under their respective employment/consultancy contract for the agreed vesting period. The majority of the share options granted under these plans will vest equally over a period of four years, with the exception of the following:
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">options granted to a director, under which a third of the options granted vested immediately with the remaining <FONT STYLE="white-space:nowrap">two-thirds</FONT>
vesting each subsequent year; and </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">options granted to three employees, under which two thirds of the options vested immediately with the remaining third vesting in 2017. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon vesting, each option allows the holder to purchase one
ordinary share at a specified option price determined at grant date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock option plan (U.S. <FONT STYLE="white-space:nowrap">Sub-Plan)</FONT> </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;30, 2016, share options were granted under this sub-plan, which will vest equally over a period of four years if the option
holder remains under the respective employment contract. Upon vesting, each option allows the holder to purchase one ordinary share at a specified option price determined at grant date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;12, 2016, 45,750 share options were granted to a director with an exercise price of
&pound;4.00 each, which could be exercised within six&nbsp;months after the grant date. The options were exercised on December&nbsp;29, 2016. Under the employment requirements within the stock option agreement, the director does not have
unconditional ownership of these shares until he has provided four&nbsp;years of service from the grant date. Consequently, these options vest over a period of four&nbsp;years, with the share-based payment expense recognized on a straight line
basis. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cancelled share option arrangement
</I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the year ended December 31, 2016,
the share-based payment arrangements for three employees were cancelled. The cancellation of the original plan resulted in an acceleration of the remaining vesting period, with the remaining charge recognized in 2016 deemed immaterial. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-36
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Share-based payments&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share options and weighted average exercise prices are as follows for the reporting
periods presented: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighted<BR>average<BR>exercise&nbsp;price<BR>per share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding at January&nbsp;1, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>2,873,747<B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Outstanding at December&nbsp;31, 2015</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,873,747</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0.26</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">507,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancelled</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.95</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(83,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Outstanding at December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3,248,187</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0.72</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Vested and exercisable at December&nbsp;31, 2016</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2,841,419</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0.36</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vested and exercisable at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,262,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The weighted average
remaining contractual life of the share options outstanding as at December&nbsp;31, 2016 is 6.66 years (2015: 6.18). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-37
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Share-based payments&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following principal assumptions were used in the valuation for share options.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Options granted on</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Jun&nbsp;30,&nbsp;2016</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Aug&nbsp;22,&nbsp;2016</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Aug&nbsp;22,&nbsp;2016</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Aug&nbsp;22,&nbsp;2016</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Aug&nbsp;22,&nbsp;2016</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vesting dates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 12, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug 22, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug 22, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dec 07, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mar 01, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 12, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug 22, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug 22, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dec 07, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mar 01, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 12, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dec 07, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mar 01, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 12, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dec 07, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mar 01, 2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free investment rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of option at grant date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of share at grant date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise price at date of grant</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lapse date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;30, 2026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug 22, 2026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug 22, 2026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug 22, 2026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug 22, 2026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected option life (years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Number of options granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">270,690</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Options granted on</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Aug&nbsp;22,&nbsp;2016</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Aug 22, 2016</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Oct 28, 2016</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Oct 28, 2016</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dec 12, 2016</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vesting dates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 01, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;16, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dec 12, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 01, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;16, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dec 12, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 01, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;16, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dec 12, 2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">May 01, 2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;16, 2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dec 12, 2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Volatility</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk-free investment rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of option at grant date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of share at grant date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise price at date of grant</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&pound;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lapse date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug 22, 2026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aug 22, 2026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oct 28, 2026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dec 12, 2026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expected option life (years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Number of options granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair values of options
granted were determined using the Black-Scholes model that takes into account factors specific to the share incentive plan such as the assumption that the options will be exercised at a single point in time, in December 2018. This has been
incorporated into the measurement by means of actuarial modelling. As NuCana BioMed Limited was unlisted at the grant date of the options, it is not possible to derive historical volatility from the Company&#146;s own share price. The underlying
expected volatility was therefore determined by using the historical volatility of similar listed entities as a proxy. The volatility percentage applied to each tranche is the average of the historical volatility of comparable companies to NuCana
BioMed Limited. In prior years, management made contemporaneous valuation of the share price, based on recent capital transactions, as an input to the Black-Scholes model. For the 2016 awards, the Company&#146;s ordinary share valuations were
prepared using the guideline public company, or GPC, method under the market approach. In the application of the GPC method, we considered the pricing of IPOs completed by clinical-stage oncology companies between April 2015 and May 2016. We
converted prospective IPO value to present value by applying a discount rate of 25%. The discount rate was derived from studies of rates of return required by venture investors in IPO-stage companies. In addition to the IPO GPCs, we considered the
enterprise values indicated by a group of eight trading GPCs. The trading prices of these clinical-stage GPCs provided contemporaneous </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-38
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Share-based payments&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
indications of value as of each appraisal date. We applied a discount for lack of marketability to the ordinary shares to account for the lack of access to an active public market. We estimated
the discount for lack of marketability using an Asian put model. In the year ended December&nbsp;31, 2016, an employee remuneration expense, all of which related to equity-settled share-based payments, of &pound;1.1&nbsp;million (2015: &pound;0.8
million) has been included in the statement of operations and credited to equity. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>13. Related party disclosures </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation of key management personnel of the Company </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term employee benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,053</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Severance payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pension and other benefits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Share-based payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">726</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;1,981</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;1,450</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts disclosed in the
table above are the amounts recognized as an expense during the reporting year related to key management personnel. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>14. Cash, cash equivalents and short-term deposits </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents are
comprised of cash at bank with maturity of three months or less, which are subject to insignificant risk of changes in value. Cash at bank earns interest at fixed or variable rates based on the terms agreed for each account. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&pound;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,075</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short-term deposits represent
certificates of deposits with maturities greater than three months but less than one year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Liquidity risk is minimal and is managed using deposits with immediate and varied fixed term dates. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash, cash equivalents and short term deposits are measured at fair value and classified as Level 1 under the fair value level hierarchy.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. Financial instruments </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The fair value of the financial assets and liabilities are
included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced liquidation or sale. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-39
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NUCANA BIOMED LIMITED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. Financial instruments&nbsp;(continued) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following methods and assumptions were used to estimate the fair values: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash, cash equivalents, short-term deposits, other
receivables, trade payables and other payables approximate their carrying amounts largely due to the short-term maturities of these instruments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. Events after the reporting period </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On September 14, 2017, the Company completed a one-for-four reverse share split and an associated bonus allotment of shares to take into
account fractional entitlements. This had the effect of consolidating every four ordinary shares of &pound;0.01 to one ordinary share of &pound;0.04, every four founder ordinary 1 shares of &pound;0.01 to one founder ordinary 1 share of &pound;0.04,
every four founder ordinary 2 shares of &pound;0.01 to one founder ordinary 2 share of &pound;0.04, every four series A shares of &pound;0.01 to one series A share of &pound;0.04 and every four series B shares of &pound;0.001 to one series B share
of &pound;0.004. After the reverse share split, the Company has 24,214,641 shares outstanding. This includes an issue of 30,000 shares in August 2017, upon the exercise of options. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of the reverse share split, the exercise prices
and the numbers of shares issuable upon the exercise of any outstanding options to purchase ordinary shares were proportionally adjusted pursuant to the respective anti-dilution terms of the share based payment plans. All references in these
financial statements and accompanying notes to units of ordinary shares or per share amounts are reflective of the reverse share split for all periods presented. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-40
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2px;margin-top:0px;margin-bottom:0px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>6,667,000 American Depositary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g393013g18b14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Representing 6,667,000
Ordinary Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>September&nbsp;27, 2017 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Citigroup </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Jefferies </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Cowen </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>William Blair </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Through and including October&nbsp;22, 2017 (25 days after the date of this prospectus), all dealers that buy, sell, or trade the ADSs,
whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or
subscriptions. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:4px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g393013g18b14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g18b14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[12D4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'2"T.         *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #P     $  0/      0 !.$))300F       .
M #^    X0DE- _(       H  /_______P  .$))300-       $    >#A"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          CA"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #-0    8              *X   ,[          $
M             0             #.P   *X                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   *X     4F=H=&QO;F<   ,[
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   "N     %)G:'1L;VYG   #.P    -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !3A"24T$#      *      $
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ME\JI(*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G_]DX0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!
M&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %
M )P!.P "    "0   +"':0 $     0   +P   #H #(38   )Q  ,A-@   G
M$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#8Z,C$@,3DZ
M-#0Z,#4 <G(R,#8P,S0       .@ 0 #     ?__  "@ @ $     0   SN@
M P $     0   *X         !@$#  ,    !  8   $:  4    !   !-@$;
M  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
M          !(     0   $@    !.$))30/]       (          #_X0%(
M34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4    !
M=@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[  (    )
M    L(=I  0    !    O    .@   /      0   \     !061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP-CHR,2 Q.3HT-#HP-0!R<C(P
M-C S-        Z !  ,    !__\  * "  0    !   #.Z #  0    !
MK@         & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^
M 2@  P    $  @   @$ !     $   %& @( !     $              \
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M/:]B0ZE9OMBL(#'1%PJ*KAY<DUVN][$Z;K.G6MS;J+'4#:6Q,T2DQ3MW$?\
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MTL\7:7$2TD8,>O[</E),9ML(L8,8 B1.Q&C#-1XY3PHS*\ZGJU[%J&HW5[#
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M !S_ )YY\YU!6CKSC^3\3H%UW<I>M)P=OM'N^-DH?60S.6R2Z%6\9P%9-L2
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MC8*^X+(2N6,J8[IMYN,,N&Y\B2"?##8\0-O]]3/ZI+RD]68&:FZU)TV8E8D
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+<E"K@;=!U-*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g393013g22k80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g22k80.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1O$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "T< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 13W9A<FEA;B!3<&5C
M=')U;3( .$))300E       0PR7T0%88\"T)RV&?9QWP\#A"24T$.@     !
M?P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M $-L<E,     4D="0P    !.;2 @5$585    !$ 00!D &\ 8@!E "  4@!'
M $( (  H #$ .0 Y #@ *0       $EN=&5E;G5M     $EN=&4     0VQR
M;0    !-<$)L8F]O; $    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4    )P!( %  ( !, &$ <P!E '( 2@!E '0 (  U #
M,  P "  4P!E '( :0!E ', (  H #  ,  P #$ 10 V #8 1  P #( .0!%
M "D       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3
M &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB
M=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO
M;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O
M<&QO;F<      #A"24T#[0      $ /      0 ! \     !  $X0DE-!"8
M      X             /X   #A"24T$#0      !    %HX0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      S4
M   &              4N   'L0         !
M  $             ![$   4N                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   4N     %)G:'1L;VYG   'L0    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   %+@    !29VAT;&]N9P  ![$    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     0X0DE-! P     $)4    !    H    &P
M  '@  #*@   $'D &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( &P H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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MS?\ ^]*;_P =?ZU?]QL/_MF__P!Z5U_[<ZK_ *?_ *#/_(I?MSJO^G_Z#/\
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ME&+^I$_7_P!!5;H_^.O]:O\ N-A_]LW_ /O2H6_XUOK4:GM.-AZM(_F;^_\
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M:]KFE_N:YJ!XJ.RG_]'H,S^FY/\ QUG_ %;E7=56X[G"258S/Z;D_P#'6?\
M5N044,/0J_=1V],+\<9#=KMP>X5"3816=KBUC6^[Z*&K55N"VEHLI+K@UX+X
MTW$CTW?SC=VQ)36S^C/KP,O?M:_[-80T[IEU5[@V0W;N;Z-C7KSYWU:ZA6!N
M=46Q.]I<YH;^E:U[G-9[-UF-93[O\/\ H?YQ>D9>1T@8N4YV*[TO1L+F#4D
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M5ZCMESHE^O\ />QK&?I7>_Z*KJV$*5SHW_+73?\ PYC?^?JU35SHW_+73?\
MPYC?^?JTCL5/_]/H,S^FY/\ QUG_ %;D%&S/Z;D_\=9_U;D%)"DDDD5),?\
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MDDO^=7UB_P"YA_[;J_\ 22I_Y+_[M_\ @*7^2_\ NW_X"DIN?\ZOK%_W,/\
MVW5_Z26;=;9?<^^UV^VUQ>]T 2X_2=M;[47_ "7_ -V__ 4_^2_^[?\ X"BI
MK)*S_DO_ +M_^ I?Y+_[M_\ @*2FLDK/^2_^[?\ X"E_DO\ [M_^ I*:K@'"
M#PH^DSP5O_)?_=O_ ,!3_P"2_P#NW_X"DIJ>FSB$O29X*W_DO_NW_P" I?Y+
M_P"[?_@*2FH*V2!YKDLD 95__&O_ .J<NX;^R]P_I?/_  *Y3)_87VFZ?MT^
MH^8]#G<5/RV\O(*<Z$H5W_(/_=[_ , 2_P @_P#=[_P!6?HII*YT;_EKIO\
MX<QO_/U:?_(/_=[_ , 5OI'[#_;'3]GVW?\ :\?;N]&)]6O;NV^[Z21V.G13
M_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @
M $, 4P V     0 X0DE-!"(      7Y-30 J    "  , 0   P    $).@
M 0$  P    $%M@   0(  P    0   "> 08  P    $ !0   1(  P    $
M 0   14  P    $ !    1H !0    $   "F 1L !0    $   "N 2@  P
M  $  @   3$  @   !X   "V 3(  @   !0   #4AVD !     $   #H   !
M(  (  @ "  ( #Q%L   )Q  /$6P   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,3<Z,#@Z,S$@,30Z,3@Z-#,   20   '    !# R,C&@
M 0 #     ?__  "@ @ $     0  ![&@ P $     0  !2X         !@$#
M  ,    !  8   $:  4    !   !;@$;  4    !   !=@$H  ,    !  (
M  (!  0    !   !?@("  0    !              !(     0   $@    !
M.$))30/]       (          #_X0& 34T *@    @ # $   ,    !"3H
M  $!  ,    !!;8   $"  ,    $    G@$&  ,    !  4   $2  ,    !
M      $5  ,    !  0   $:  4    !    I@$;  4    !    K@$H  ,
M   !  (   $Q  (    >    M@$R  (    4    U(=I  0    !    Z
M 2  "  (  @ "    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$W.C X.C,Q(#$T.C$X.C0S   $D   !P    0P,C(Q
MH $  P    '__P  H ( !     $   >QH , !     $   4N          8!
M P #     0 &   !&@ %     0   6X!&P %     0   78!*  #     0 "
M   " 0 $     0   7X" @ $     0             #P     $   /
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M 0$! 0$! 0'_P  1" %" =\# 1$  A$! Q$!_\0 'P !  (" P$! 0$
M      @*!PD$!08# @$+_\0 9Q    4# 0(%"!(-"@0""@,  0(#! 4 !@<(
M"1$2&2%8UA,4%3$X49>8"A@:.4%35V%WD926H;.TMM'7%A<B,G%T=79X@9*W
MU2,V0E)55I/3XO W8K'2<L$D)31#14999J*U@K+A_\0 ' $!  (" P$
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M/G*!9AJ]CE'I6!E'C1\"S7K1[F4%:ZY/CJ,*;OITKXV%G2JRT4 H!0"@% *
M4 H!0"@% 1<UH2<G#:;,AR4/(/HJ1;N;%!N_C7;AB]0!?(UHME@1=-5$ETP6
M;K*H*@0X=41542/O(<Q1E'QE?G]3,2U;K^BZN>WU&9J@=.V$\AYAN'J2C6R[
M><O8^/44ZD,U<#D2,+;@4SAO,529G'+"/ZH4#=0374<G $T3F#"5VE\<_4&T
ME=FCO9FZ\=5&HC5,C8.7,FDN:S'5DWE.# )6;8D(@C(1_8]2/.B_@K9CI@$V
MG5U")IJ22I5"" .>KF#A5.48I7U=+[2$9-O2^3F+&%5E@H!0"@% * 4 H!0"
M@% * 4!5%VU.*; QUJ LNX+-MY*%E\GVO-WE?3Q-]*.QG[E/<2[0\HHC(/G;
M9BH9NF4@MXQ%DT'=P^M^&(F&R#UK9JZRF:L_3IZV: -I1JRU3X7O;339N'=2
MN?L46B;2%C&8-:V-<Q9#L:W#2SZ],H)/9,82V+BBXT9!XFT:INGHMNN5R-D"
MJJ'*DF!>^^YODC)..X/3KXW)F3\76_U+%0XW$X/#UZF9&&'S89]6G*6;&[LK
MV5W;6459RBX*,I136FS_ .YGLR67M'CZOH_22&U U2!)R&ETFILM[?;FSH+!
M.-/IU6U"_8D:%^VCUP9\$>B-L]E@D00Z\,$EUEU .M*^EQ_!K_1999\%<E9D
M<J?Z9Q'>>!SL[_4%D_CN,[UM:[XW,S;V^;G7^<9M//S.-GXF=??^!,]'9X;6
M5*]F%O3&U0U,1=IW):&E&Z[*OY/+&>WT9<A]3&3(+%\I;ZK(N6&YXN=Q1*S\
M=+3S,SQX,S!R<"];C&=F4R-_BOA'P1>'E5AP3R7*M2K95HU\.\-@(RI_Z;AI
MXJ%12[S>=3Q<*<H0EFQS*D*D7GYCO8J=1_\ FSM9._IUKH[#6=KZOW79HAR9
M;N-&VTLUVY)?R\#(3,D[NY?61IS4CS,9^1@$PA8K,-P1KR]8-ZM%NU6=W6L+
MZVW)D56S=\NJDINY/P=P^0,O86KBGP8R#A8PJ0A!4?\ 1\I*2E3C4^?/!TY*
MA.*DDZ-7-J*Z;BD4U7.G:U2;OM3CZ]9!'C#=?G/AU?>,IF7IG7(/!O@]YBR/
M]6X/W)3QM3RY;QQANOSGPZOO&4S+TSIX-\'O,61_JW!^Y'&U/+EO'&&Z_.?#
MJ^\93,O3.G@WP>\Q9'^K<'[D<;4\N6\<8;K\Y\.K[QE,R],Z>#?![S%D?ZMP
M?N1QM3RY;QQANOSGPZOO&4S+TSIX-\'O,61_JW!^Y'&U/+EO'&&Z_.?#J^\9
M3,O3.G@WP>\Q9'^K<'[D<;4\N6\<8;K\Y\.K[QE,R],Z>#?![S%D?ZMP?N1Q
MM3RY;QQANOSGPZOO&4S+TSIX-\'O,61_JW!^Y'&U/+EO'&&Z_.?#J^\93,O3
M.G@WP>\Q9'^K<'[D<;4\N6\<89K\]'7#J^'UAU*9E$/:^S.G@WP>\Q9'^K<'
M[DRJM2Z^?+6N4_T*+!T@6=K+V<VCAED7(=Q6.UL7':%WK3[ T6X(NH^C'"4B
M[G5IPID^H-TDU'BKPSE Q-[A1=42F$Q?)6(M#$UU&*LJLXI+19*322V+5H-Z
M*SH1TVLM97JS/;F.I;+<)BG3<C(7S"00M,<6]=98[K:>S#=#VZ9IW]E!XQ%5
M9-,SYW/M;6M\B1B]<VY 0;M9)NNY601BN?\ XZ2.C4M/MTF ,W2VN/)&U0U#
MZ.<;:Z]1F%X'&5NWY)1#>W<Q9:;VA%,,%:?D[X?PD-:MO7Q ,(Y&=^Q9VS;'
M9@@W:.I#KU1LN!5$S]^Y)P^0L!P,R/E7%Y!R;CZM582C5E4PF$=:<\7CEAE4
MG6J4*DIN#J*3SM+C&R:T%;SW4E%3DE%<CV)\G1_R=3L_\,;3#7[C.&R#:>U(
MU+8^<W!GB_,#1L'<.:\[RB 35E:?I#/!)U],L\F-"M8N508EM@R1(YPM'++#
M+F,[22%B>_A%C>"_![%SPU7@IDS$JGD_#Y0E4IX/ P>97R@L Z<82PLKR@WQ
MJ;FE)?,^:_G""J35^-DOG2C:^SE))XUT);3NX\>N+XR5M4M;F.).&QYCB\[M
MQ_:[/6'G?(%MS=_Y-S;BUS9REFXCOV>NV1<VK-X3DUYJ:86\I'(MI=%5R#)O
M'KNE_F8G+_!:GB%0PO!/(>)C/$XFA1Q%:>1\GX>K3P^&P6*595L9AZ=&*JT\
M;',IRJ*3<&EG.22DJ=2UW5J+FLVUN]9H4O37=KSM6\;LM=GKRUC2[2V[FGH!
MK+.\]9XMMU)MH>4=1R$BYMV:N]&8@'#U)N5RM"RR24G%**F8OTR.D%2AV#0X
M/\'ZU"C6ED#(T)5:5.HX+ 8"JH.<%)Q56%%PJ*+=E.#S9I9T=#1K2J5(R:XR
M6CG/,\8;K\Y\.K[QE,R],ZM\&^#WF+(_U;@_<D>-J>7+>.,-U^<^'5]XRF9>
MF=/!O@]YBR/]6X/W(XVIY<MXXPW7YSX=7WC*9EZ9T\&^#WF+(_U;@_<CC:GE
MRWCC#=?G/AU?>,IF7IG3P;X/>8LC_5N#]R.-J>7+>.,-U^<^'5]XRF9>F=/!
MO@]YBR/]6X/W(XVIY<MXXPW7YSX=7WC*9EZ9T\&^#WF+(_U;@_<CC:GERWCC
M#=?G/AU?>,IF7IG3P;X/>8LC_5N#]R.-J>7+>.,-U^<^'5]XRF9>F=/!O@]Y
MBR/]6X/W(XVIY<MYZ.SM>FN6XKNM:W[@UFZK9V!G;C@X:;A)C4/ER3B)B(DY
M-JRDHJ4C7MWK,Y".D&2ZS1\Q=HJMG;995!=)1)0Y!^?E?@_D&EDG*=2GD7)-
M.I3R?C9TZD,G82,X3AAJLHSA*-%.,HR2<9)III-.YF-6HY13G)IM)Z>1L_T7
M,_:1<"YJTSV7FS*UOW+/7!A[2NSDH1I"7>\MEN\8VW81[M+&.!2:2""9GCQ-
M1$[X62ZJ*2H#U)4$BICY4SFI/9=^O6?0<4XI\JBNI&@#2Y9,+JKUKXR81;.T
M\3VFVF+#DQMQW<38JJMNXMA[<8C!PCETC&N[IO:ZFEM@X=J,X]-PYDY"6GUV
MJ35NX LWHB^7M?L_X*TKM+XT+U^TU33.5M>^<=1NTQ2M'7[J@QS :4(C4[GE
MK;S3.&8SQ<K;6-\R-;5:6# ,HR_8QE;:0M[F:%CG";=PPC6<:#1*-,0Z?4O2
M,,'P?P&3>"_'<'LEXFIE>62\ ZCP.#4H5,3@G6EB*DI8>;JN])YRNI2E*[EK
MO4W-RJVJ26:Y-)/1H:T=9GG2EIMVJ.KW3Q:>;,9[3/4^%RWUBO5%D:TL6.LU
MYR/)3<IIJO?&-CEL=M<09/19EE\C2.3&00+Q6.(UC73$K-Z1<KX'37Y^5\I\
M$\C92JX#%<%\E\50Q62\/6Q<<%@<V$,IT,37X]TN]6\S#1PTN,6?>2><FK-$
MHPJ2BI*K.[3:5]=G:U]&LSNAH>VB,=C";RC>>UWUN14="FQVW7AK"MC6SG"=
M;O;_ -/UCY] )R)Q)>]SR]JQ$#'7F-M2ERW!&,H%*4C"G<OF:LFS85\]Y>X-
MRQ5/"T.!V0YRJ+$24\16R+@:;C0RA7R?>$\7AZ4*LJDJ/&QITY2J9LFE&2A*
M1G,FE=UJFYODOIM=K<5Z.,-U^<^'5]XRF9>F==C^#?![S%D?ZMP?N35E4J)M
M9\MXXPW7YSX=7WC*9EZ9T\&^#WF+(_U;@_<F.-J>7+>.,-U^<^'5]XRF9>F=
M/!O@]YBR/]6X/W(XVIY<MXXPW7YSX=7WC*9EZ9T\&^#WF+(_U;@_<CC:GERW
MCC#=?G/AU?>,IF7IG3P;X/>8LC_5N#]R.-J>7+>.,-U^<^'5]XRF9>F=/!O@
M]YBR/]6X/W(XVIY<MXXPW7YSX=7WC*9EZ9T\&^#WF+(_U;@_<CC:GERWCC#=
M?G/AU?>,IF7IG3P;X/>8LC_5N#]R.-J>7+>.,-U^<^'5]XRF9>F=/!O@]YBR
M/]6X/W(XVIY<MY(;29K5UD9)U+X/L?(FK+4M?MEW#DBV6D_:%YYURA=%KSC1
M-^F[3:S$!-W2^BI)NFZ;MW)$7K19,CA!%8I042(8O&>&.0\BX7@SE>OALD9,
MP]>GAX2IUJ&!PM*K3;KTDW"I"E&<6TVFTU=-K4R=.I.4XQE*33DKJ^LN&[9G
M/$QDG(MDZ0\<F6E?L41/D'(C-@8#=5N(8-[)0T:\,4Q>I(6M9@R=TRG5=[8J
M$VR=*B16*$4_-<%R[O;R_'(;LWR;-?Q\:R#&RT=NF&H:]WS%RNS>LM.N;';-
MXU64;NFCIO;:2S=RV<)&(J@X06(15%9(Y5$E"E.0Q3% 0VL/&,L1AHR2E&6(
MH1<6KIIU8IIIZ+--IWT-.W*8AKZ.PK]8FS;M#<JZ9M6NI-MM$-6,-'Z4BX(-
M)VHOGW-CQY>?V\LA/K 9@QE4\A-T(;['EV1I)SUPR?\ 9!)0&R76IRBL/IG&
M8'@Y@\JY'R8^#>29RROW_FUE@,%%4.\</'$.\.]VZG&)YJM*&9:_SM1JPE4E
M"4G4DLUKEUWT=1L/L32KM6<H:2Y#5!C[:9ZH+C?1^G+&NI0V*TLS9V1G7MJ7
MM?V7[3N&'BY@,GK(OYJRX##=PWF9%.+*:X6JI8A@BV?I$.ZXWB,K<$L)E=9+
MQ'!;)=.+RCBLF]]]YX%P56AA\)5I3E3[T3C"O4QE.A=SM2?SY-QT*V,:DHYR
MJ3=XJ25].F^C9R<]^8R5J#T;;0?3EAO+66[OVO6M><#&\AGB(CHBQK?UJ7]#
M3,E@\3HK!=]_V)?%SVEAZ+NIX=D@PG\E.H:%8HJOWQWKQI"2JC;6R=EK@[E+
M&X/!T>!N1*??2P$I3KU<BT)TXX[5Q6'KT*57&2I+.<J>&4YR:C%14IP3RX32
M;=6IRVLF[VVM:NDK_P#&&Z_.?#J^\93,O3.NQ/!O@]YBR/\ 5N#]R:KJU$VL
M^6O:.,-U^<^'5]XRF9>F=/!O@]YBR/\ 5N#]R8XVIY<MXXPW7YSX=7WC*9EZ
M9T\&^#WF+(_U;@_<CC:GERWCC#=?G/AU?>,IF7IG3P;X/>8LC_5N#]R.-J>7
M+>.,-U^<^'5]XRF9>F=/!O@]YBR/]6X/W(XVIY<MXXPW7YSX=7WC*9EZ9T\&
M^#WF+(_U;@_<CC:GERWCC#=?G/AU?>,IF7IG3P;X/>8LC_5N#]R.-J>7+>.,
M-U^<^'5]XRF9>F=/!O@]YBR/]6X/W(XVIY<MXXPW7YSX=7WC*9EZ9T\&^#WF
M+(_U;@_<CC:GERWFSG8W:U-8^2=I#IRLO(FK+4M?MG3/VWNS%IWGG7*%T6U*
M]CL#Y0E8_LE!3=TOHM]UC*,64DSZY:J];/V;5XCP'#=)0G%^&F0\BX7@UE*O
MALD9,P]:'>>96HX'"TJL,['X6$LV<*491SH2E&5FKQDT]#9=0J3E42E*35GH
M;YBQ-MWO^,^#?8PF/G6ZKS;3Y>CVFS/7T>UE<3:2:1-5N;;TTTWIAK3/GW+%
MGETAXQAC75C;$&0+WMP)=A>F3U7T6,U;5OR4:$@S2=M5'3/KGKA CE RJ905
M()N^NYOEC). X/3H8W*>3\)6>4L5/BL3C,/1J9DH8?-GF5*D99LK.SM9V=M3
M->K"4G!QC*22TV7_ ',EA)9WUHN[NLC+<?L-<[1&?[7PPM@F:S,C:>JMU+7?
M8)].URZ>T8Y[:;JRCV5%];1LU%7,5Q&0B;]1];C6/4?BW?OG!Y1R?D-4*^#E
MP[P,\GU<8L=#!.IDM0HXC_4:64'.-55N.E>4)TK2GFYM1RS;QBB>=/7Q,KVM
M>SU6MM,D6?K\VO-KO;\;.]EKJ/N"S+KO[2/D>W[0?8BSVFG8MP:7(;#\(_)"
MR@8X566C<L-\+6HZGF!VJ"$#(&>/HT'3APZ.ZUJW![@=55!QX5Y.IUJ6'RMA
MJM:.*P+=>GE.>+G'/CWRDI81XRJH2NW4CFQE9*-LJI55_P G.VBVC59)==O6
M:QM<6'-;VL+(,'D*#V7&M#$4@RCYAK.MY2*U@9W&==2LVYFR+,'N78J8<6?&
M,%WKXC6V[7"/@4Q=**ILDS[JY3D'&9"R+AZF'GPJR-C(RE3=-Q>2,!Q:A!0M
M)8.4%6E)*-ZE7.J?-MG,JJ*I/_RII\]WNNW;U$)N+FV@G,;U>>+AF#H?7W?"
M7@[Y]R1]8X3WI3Q53R);AQ<VT$YC>KSQ<,P=#Z>$O!WS[DCZQPGO1Q53R);A
MQ<VT$YC>KSQ<,P=#Z>$O!WS[DCZQPGO1Q53R);AQ<VT$YC>KSQ<,P=#Z>$O!
MWS[DCZQPGO1Q53R);AQ<VT$YC>KSQ<,P=#Z>$O!WS[DCZQPGO1Q53R);AQ<V
MT$YC>KSQ<,P=#Z>$O!WS[DCZQPGO1Q53R);AQ<VT$YC>KSQ<,P=#Z>$O!WS[
MDCZQPGO1Q53R);AQ<VT$YC>KSQ<,P=#Z>$O!WS[DCZQPGO1Q53R);AQ<VT$Y
MC>KSQ<,P=#Z>$O!WS[DCZQPGO1Q53R);AQ<VT$YC>KSQ<,O]#Z>$O!WS[DCZ
MQPGO3*I5+KYDM:Y"ZGJ;RO?N-MD]HFQQ;SUS;[3*=HH05^"F"S26<0ML,$WB
MMLJ'WD5:LI&1=(]FT."19T@P[&+B+%W(-G/DRNXRQ5>2::=6<HM:4TY.S3]#
MT;S=O:G%;5IZ""^B?5'A?2A<CC(UT8&E,N9/;G71M>>=7RP@H2SF2Z)4EEX6
M"5L^;.-Q.BF<(+3SF0.=NQ5%G&M&(J/G#ZN2;T7L832TM7V:?P(GYKA-:F&]
ML-J"UHXZV?&H+4-C^]'5\-6$)'8NS I9%XVGF+"Z5ERY6%^V99S_ *[:MF%Q
M/DTY"%. K.&QBI+M5-YTN^LFU\AY1X$Y+R1B>$&3\FXB%/#5)2EBL)Q]"KA<
M9WQ!2H5JT;-RA&ZFM3U,K>>JDI*G*2DEJU:>?I/E9&;-<N&[&O'&&G_8I:@,
M,X[N>^,D7]'6Q"V9JDN0MM3>3-+$OICFE&,S=UDS$\Y,DA,+7Z@HXD@ DNF2
M)03;,=S@DZ^ R#C<11Q>4.&^ QN(I8?#8>52I5R93=6&&RK'*D,Z-*O""NXK
M#M*/B7FVY:#*E-*RHR2TO>K<MS.+G7UM2;XM1[;><MDAJKR6\G\18&QE>%SV
MM':O,'W-<TM@NX,GW(VOQ6X\46K W+&2MYRF37KJYHF-G48A=9B("DLT?J,T
M-%<'N"E"M&K@>%^2L-&GC,?BJ%*J\D8ZG2CCZ>%I.@J>+JU*4XT88:,:4Y4\
M]*6M-)F>,J6LZ4]2N]6G;H::N5_+RT Z][FO"Z[DC- FK^ CKAN2=G(^"4P1
MG.XE(1E+2CI^UB#W!-VJXFIT\:@X39FF)=PO*29D1>R"RKM=4YNPZ'"'@_2H
MT:4N$&2*DJ=*G3E46.P5//E""BY\7"JH4\YK.S()1C?-BK)&M*G4E)OBY:>8
M\WQ<VT$YC>KSQ<,P=#ZM\)>#OGW)'UCA/>D>*J>1+<.+FV@G,;U>>+AF#H?3
MPEX.^?<D?6.$]Z.*J>1+<.+FV@G,;U>>+AF#H?3PEX.^?<D?6.$]Z.*J>1+<
M.+FV@G,;U>>+AF#H?3PEX.^?<D?6.$]Z.*J>1+<.+FV@G,;U>>+AF#H?3PEX
M.^?<D?6.$]Z.*J>1+<.+FV@G,;U>>+AF#H?3PEX.^?<D?6.$]Z.*J>1+<.+F
MV@G,;U>>+AF#H?3PEX.^?<D?6.$]Z.*J>1+<.+FV@G,;U>>+AF#H?3PEX.^?
M<D?6.$]Z.*J>1+<>BL_0!KLMN[;7N*X=&&JN"@(&XH2:G)N8T^Y7C8B&AXN3
M;/I.5E)%Y:B+1A'1[)!=V^>NEDFS5LBJNNH1),Q@^=E?A%D"KDG*=.GEK)52
MI4R?C84X0Q^%E.<YX:K&,(Q55N4I2:44E=MI(E&E44HMPDDI)MVY$R[1M!-5
M^I_3U"Z8[8Q9>I+7QE?NE^R323!U9-B7,RG+B:M5F%R-EW%VVQ.KG2"!?6TB
M[C2+$9&0<D,=L)G*QE/*ZBFY/ESGRO0;K;25M6:N0U"Q%\W!D[4[C6\K(A&]
MM7K,WIAEO&,;:8QD2BK?T2WLZ!>SL;&6[&PT5&*7+=L:[N46$;&M6[->64;E
M!3J9EE)VLFO3KY^DALVZ.3E5M-O3I(H618FM;2WK2U]7FZV7^HK4]BS4>[U%
MX<G[4D<69\MBV+FQ]?V:6EW#,QEVV/:*LFX:R3.V6B;%U$/FQ'+*3Z]:R!>"
MD*GHC$8C(>5LB<'Z*X4Y/R7BLF1R=C:=6.*P-6K2Q&'P3HJ$J5>LHJ4)5&Y*
M:E:4;..LKM.,ZGY.4E)R6K19V]&PRC%:@=I'CG%"F(M/>R0U*8&M^$M_.D+B
M]S;&.]2,_(8O<9GRWA#,#:6A7]SV&_E91Y8]Q83CR10R\FN>1).NE7:R(,4$
M5=.>3>#.)QBQF4>&&3L?4G/ SQ2JU\G4UBE@L)CL&X35+$1C!5Z>.EGYD5F\
M7'-6ELEG5$K1I25KVT/1=WVF<\C:Y=HSFN(R'#9AV,^JB?:Y$OBV<AORV OK
M2PD+*X[?PQ:V&E4P=8IMRVI:6M^2CK<6F%;9FY20ADW4D1%5J[4C&;VM'#9!
MX-8*>'G@^&F2Z;P^'J8:/?$,C8[.IU,;6QJ>;BZE6$:D955!5*<(SM%V:4Y1
M,\94>NE/7=VNN1+D=^ME=KBYMH)S&]7GBX9@Z'UV1X2\'?/N2/K'">]-65.H
MVWF2W#BYMH)S&]7GBX9@Z'T\)>#OGW)'UCA/>F.*J>1+<.+FV@G,;U>>+AF#
MH?3PEX.^?<D?6.$]Z.*J>1+<.+FV@G,;U>>+AF#H?3PEX.^?<D?6.$]Z.*J>
M1+<.+FV@G,;U>>+AF#H?3PEX.^?<D?6.$]Z.*J>1+<.+FV@G,;U>>+AF#H?3
MPEX.^?<D?6.$]Z.*J>1+<.+FV@G,;U>>+AF#H?3PEX.^?<D?6.$]Z.*J>1+<
M.+FV@G,;U>>+AF#H?3PEX.^?<D?6.$]Z.*J>1+<.+FV@G,;U>>+AF#H?3PEX
M.^?<D?6.$]Z.*J>1+<2$TGZ(-9V,]2N$+ZR-I*U*V#9-N9'MEY<%WWG@[)EL
M6Q!M%'Z;1-U+STU;+*+C6ZCIPW;$6>.D4S.%T42F%10A1XUPQR[D3%<&<KX?
M#97R;B*]7#PC3HT<;AJM6I+CZ3M"G"HY2=DW9)Z$WR$Z=.<9QE*,DE)7=M1:
M UXZ+-6<YJ6U$9JM?$]QN,=K2\U="5Y,IZV6J!K696TAV7? B:X4)4&I(]L^
M3<-A9@NLW*J@#=0J@$/YLC)62OIZ=N@VW%W;MHNR"&D*R[]OG/=F1N/(B7FI
M2..\GI=G"K F["UHMN)YY0Z?5T%'K?K50$E8Y#KAS("J1HW:.EE2(FV<-*,,
M3AY3:C&->BY2;244JD6VV]"2UM\B5S$=:]*->.BRP]:.ES'>I#$63]D'J/U/
MXOU+M\2HW?9UV8RU*X[;LU</W+/7;;CAO*V':+><5,><F&KQ0B4BQ(!HE%)4
M'3=RX0'T9EROD/*V)R9C,+PPR=DO%9,>+=&M1Q.3L0WWY3ITJEXUZS@K4X2C
MIC+Q[K-:3**:G",HNE*6<U?1LZ]?QI)@V_JIVJN.<>V+8>&MECJ2QB7&8X)9
MV3(,L2Z@YHD;;F#,RYFRFRM)\TD;"(ZF("[H7,TOC6Y4'TJ9R[M=B=55TX=2
MKHJ7Q:F2.">)Q.(Q&-X5Y-Q7?2Q[KQEB<!#.JX[!X/"NM%QQ%H5*-3!PQ5)J
M%E5=K)118IU$DE2DK6MHY$[VZ;M>@[S47J@V@6IW%.1<:9'V.&K1)>\);.\]
M;L[:;G6=8[&UI?.1@<.UIRS+(MJV[7RBPME\VC7,?"9#9S4.\3:.6:K)NTEY
M1)S#)N2>#N2\7AL5AN&>26J,,!3J0K1R-7E5A@/%S*U>I5JX655.2E4P[A.+
M:DI-P@T<ZC33I3Y=5UKYD[/I-#?%S;03F-ZO/%PS!T/KL#PEX.^?<D?6.$]Z
M:KI5/T<MPXN;:"<QO5YXN&8.A]/"7@[Y]R1]8X3WHXJIY$MPXN;:"<QO5YXN
M&8.A]/"7@[Y]R1]8X3WHXJIY$MPXN;:"<QO5YXN&8.A]/"7@[Y]R1]8X3WHX
MJIY$MPXN;:"<QO5YXN&8.A]/"7@[Y]R1]8X3WHXJIY$MPXN;:"<QO5YXN&8.
MA]/"7@[Y]R1]8X3WHXJIY$MPXN;:"<QO5YXN&8.A]/"7@[Y]R1]8X3WHXJIY
M$MPXN;:"<QO5YXN&8.A]/"7@[Y]R1]8X3WHXJIY$MPXN;:"<QO5YXN&8.A]/
M"7@[Y]R1]8X3WHXJIY$MQLWV..B'6;C/:/Z<[WR-I+U*6#9D+]M[LQ=EYX.R
M9;-MQ79+!&4(F/[)3DU;+*,8]?2K]C&L^N7*77+]XU9H\-PX23/Q;AIEW(F*
MX-92H8;*^3<16GWGF4:.-P]6K/-Q^%G+-A"I*4LV$92E9.T8MO0F74*<XU$Y
M1DE9Z6N8N0;0G3+IQU%Y(LUWEO4([Q-<=FVB>,;03*%0DQ>1LI*.)!&06473
M'J8F5*LD0A#& 2IB)MPUYNA=)V5^FQM3S;Z96=N4D5@++&F# >';!P]%9RA[
M@CK"A A6DS(M7C1[()]=NG@KN&[9B=!(_#=&+P$S&*!2EY1'?6'&3;=M?.@I
MP2MG(S!Y;;3AZK-M?LR?\/IF2V=:[3/&0\I#RVVG#U6;:_9D_P"'TS);.M=H
MXR'E(>6VTX>JS;7[,G_#Z9DMG6NT<9#RD/+;:</59MK]F3_A],R6SK7:.,AY
M2'EMM.'JLVU^S)_P^F9+9UKM'&0\I#RVVG#U6;:_9D_X?3,ELZUVCC(>4AY;
M;3AZK-M?LR?\/IF2V=:[1QD/*0\MMIP]5FVOV9/^'TS);.M=HXR'E(>6VTX>
MJS;7[,G_  ^F9+9UKM'&0\I#RVVG#U6;:_9D_P"'TS);.M=HXR'E(>6VTX>J
MS;7[,G_#Z9DMG6NT<9#RD/+;:</59MK]F3_A],R6SK7:.,AY2/$9%U^:.\46
MC)WSD//5G6M:<29DE(S;]*<4:M%))ZWC6)5"LXAROO<OG;=L02(F #JEX0E+
MO,&U@LGXW*.)AA,#AZF)Q-53=.C3LYR5.#G.UVE\V$7)Z=28XR'E(T,2VK'9
M*:E=*NFW&>8]=]M8UGL3Q\PZ<,(%M*+/0?S*RB*[21Z_L^2;\%)!!NJD+4X#
MO5,!S&Y +R'P*X5YS:R'C-.U4O>D%*#2O*UK];,&_8WL,/\ ZGJON OU>4\"
M^%OF/%[J7O1>GY?QN-U]N[:'9/VS;\%;C;6UC%PVM^&BX1NX69WD99="*8H,
M4EEA1M,J0JJ)H%.IU,I2<,QN"4H;@"#X$<+'I_T/&?TO>$U4@M&<CN..\V4W
M/5Q;[BO;HI3P(X5^8\9_2]X.,AY2''>;*;GJXM]Q7MT4IX$<*_,>,_I>\'&0
M\I#CO-E-SU<6^XKVZ*4\".%?F/&?TO>#C(>4AQWFRFYZN+?<5[=%*>!'"OS'
MC/Z7O!QD/*0X[S93<]7%ON*]NBE/ CA7YCQG]+W@XR'E(<=YLIN>KBWW%>W1
M2G@1PK\QXS^E[P<9#RD..\V4W/5Q;[BO;HI3P(X5^8\9_2]X.,AY2''>;*;G
MJXM]Q7MT4IX$<*_,>,_I>\'&0\I#CO-E-SU<6^XKVZ*4\".%?F/&?TO>#C(>
M4AQWFRFYZN+?<5[=%*>!'"OS'C/Z7O!QD/*0X[S93<]7%ON*]NBE/ CA7YCQ
MG]+W@XR'E(Q=G#;0[+NYL*Y?MN"UD8QDIRX,79 A(:.19WD59_*RUIRS".9)
M&5M=-(JCIVX103%50B8&4 3G*7>8,K@1PKNO_HF,UK]%[PPZD+/YRU,P5?\
MK\V+NI/3AC'$^;]6V.$'UL659Y&,K$J73'W995R,;8CHV14B)$UHOVA5!,BH
MSD&+QK(Q+XJ29G#1=5LS70SX$\+$VUD3&:7LI:5_^0QG4VDG):EZ3#NE_-.P
M?TQWTWR9':X[6R+>T4*PVS(WR:9486NJLF=$TA$Q$/8<:W/,=0451))2)WQF
MH'%6.18N-ZPGP+X6/1_H>,7_ .+WIA.FM.<FS90.V\V4P"(>75Q;R<G(SO80
M_4(6H(#^$!W#Z%1\".%?F/&?TO>$^,AY2''>;*;GJXM]Q7MT4IX$<*_,>,_I
M>\'&0\I#CO-E-SU<6^XKVZ*4\".%?F/&?TO>#C(>4AQWFRFYZN+?<5[=%*>!
M'"OS'C/Z7O!QD/*0X[S93<]7%ON*]NBE/ CA7YCQG]+W@XR'E(<=YLIN>KBW
MW%>W12G@1PK\QXS^E[P<9#RD..\V4W/5Q;[BO;HI3P(X5^8\9_2]X.,AY2''
M>;*;GJXM]Q7MT4IX$<*_,>,_I>\'&0\I#CO-E-SU<6^XKVZ*4\".%?F/&?TO
M>#C(>4AQWFRFYZN+?<5[=%*>!'"OS'C/Z7O!QD/*0X[S93<]7%ON*]NBE/ C
MA7YCQG]+W@XR'E(<=YLIN>KBWW%>W12G@1PK\QXS^E[P<9#RD1SU9;8S9E7]
M@&^;3M#5_C2<N&4<6:9A&-FMWIK.2QU^6O*/1(=S;*"!0;Q[)TY/PU2[R(F
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MY5JOIM;\2,>E_2MFK6!E%AB;"-KA.39VCB:N.>E':4+9./;0C^">;OK(=UO
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MB+4G9&18W5Q(W<YB#W#BO*>';]L''-@LW;Z\<N73BO),;$72A8<:1F#"/DI
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MM:]*.I.;AG,<?1$0#UB@([@]KM^OOKBV)JRK5ISE?QK16R*T16[EY6V^4O\
MCX?*?FJ .T("'; =X#Z(#ZU9C)QDI1=I1:::Y&M3![NUKB:0#I)ZZM6VKI*!
MBG%G<J<RLS. ;MZ9DXB:AU1((@._<L!^4?N@Y #DMGBJ$)*M6HY\$VZ3@I)M
M:;9].:T.]M'(0S[-IJZZ;^M?&HW :.=5>SB81T\[UIZ4\>BTM06LS9]H8,QC
M<LI=^6)F-;N'3>V[UO\ R)EZ1@K&LAY($9)286U;*]T3!QX!K@A(-K(Q5T<0
MRSDCA.YTXY$ROBFZRE"M7Q^+I0HX2,VHNI0P^&PD*E>M&.<XNI4XJ"TJG.HX
MSI70J4VKR45S+6][LNCJY>WO#;+Y!SSJ\THY?R[8ECV)AK3?G[&=\6K8V.+?
M5?N<<XILV\[<D#V18;.2D6T#'BSMF"21<.[?A[6EKLD4B-IJ4^QQI;UOV[&C
MP)P^3\CY7P>#Q%?$8[*63\50JU\3545B<57H5(\=7E&+J2SJL[I5)U84HN\(
M<8ZM2IAU\Z4;I)1E?4M"7(G?F6R^XV$:E]N;HUR)ES6?:C; &3LHZ7M<>.\/
MQV2YV-GH["F=+<O7&5O'M$H1CGJ-[0T_;Z</#VR[BV<DZ9((/AETGR$K%R;V
M+5X]DS@'EO#X/(M9Y0PN%RKD+%8N6%ISA+&X"I0Q-15OG)<5.%7C)U5)Q3;C
MF.+A.$9EDJU.\N522O;0U;1;KNNDU38RU3[-;"&H73UE+'.BS.DW;&#+V>Y#
MF5<H:CH&Y+MRM/L6A7%@QTY"Q.+8*P[8@[(NQO'W.F6&CG;RX!:*1$VJZ8NB
MBTY9BLD\*,=D[*.$Q.7,GPJX^A'#06%R;4I4<)3DVL1*G4EBIXBK4KTG*D\^
M2C3NIPM)-2K52E%QM&3MIO=-\U]2T:]NTE3JOVR..]1L=E88=WM(K,D,O2RR
M<[:BFN1HYPM%67<LVV2OBSXG%$/BJ#CC03BQEYNV[?A'$EV.1<.6+B=&9;)/
MVTA\G)/ K%9-EA,]<&JT<'&].JLA26-G6I0;H59XN>*G+/5=0J5*BCG-*2@H
MMQ<<RQ$6FK3T\ZM;_CDZ-1XS71M(M!>M> LIK(Z3-1E@26%\)ML+:?K=MW41
M9:>)\:1<2T61@Y)>R Q $K/'2<=C59Y(+LC'UQ,82,BC2\8FW0=-[L@\&>$.
M0YUW3RODRO'&XYXW*%2KD^N\7BIS=ZD57[[<*=UG<6^)E&G*<YYDVVG&=6E-
M6S):(VBD[);-"9'J_-I/$V9I]:Z3=%6$X; N$IZWTR9OF[[5A,JY=U#WJJGU
M%Q<&2[A=0,7;2]MQ+8SAO:6/D;97MBWUWKJ90;GF$89U#?1P_!>=?*+ROEW'
M3RACJ=2^!IX?C,)@\G44[JGAJ:J2JJI)V=7$<:JM114&\QS4W'I1S:<<U6Y;
M.^BVGL)O6SMV;6MK4[H"U&M]/ESG<:1M)\CI?R/!ER!%)JY68*V2A!QDW#O@
MM@26XW8W05:X3QL@WES'1%)J1RFL0S@WPZO *M5R7P@R=+*-*V5\K0RIAI][
MSMA)*M*<X3CQGY1RI-4\Z+CIN[6LB2Q$4XO-E\V.:]7-J(W6#M7HO&Y-?]X0
M=EY7E\\:T9>4L2T<UWEE,+LNO ^F6>NQQ*S>.+;>S$6YDY*['=N/UH5O<!9*
M-BHY_!6A*L(EOV'5;.OIXC@C/$^#U&=;!PR?D2G"O6P-'"\51Q^5*=%1IXFJ
MH245256*G*FXRG*-2M%S;FFL<?'Y^B5Y:$V[VCLU[.?VGM;BVUDU&ZX](&H;
M#&*9#&&G31CCVW\.8RTX)7>E("XQ@Z@?L?R>UE;B)#-V#FY[W8+%2+-*PBP-
MSVY:$@\1>2<8N[<44N \)9"RSD[&XN&*RGEO$U,;BLI<2XVQ4:G&85QIN;DJ
M=&5[P4U=5:T8VC)(=\+/BTFHQ5LWU\OQ9&$]J5M.8O7PZQ+9>)<-DTXZ>\0I
MWQ<,+B1G.M9IO(93RC=\Q=V0K^?+1L3!QX*2KJ2*$<P+'G&+</+C<H.@3GU6
MK?>X)\%I\'UC*^,QO^I91QCH4IXMPE#-PF%HPHX?#Q4YU))04?G/.M)1I)J]
M.[A5JJ:2BG%*^CTWOJ?QI-1]<Q*!0"@% * 4 H"=VAK9QZG-HA-9#@--,+:<
MU(XPBX"8NLEU7='6DD@RN5W)LHL[-60*8KU0Z\2\!9-+<9$I4S&W@H%? R]P
MER7P<AAJF4YUH1Q<JD*+HT95KRI*#GG9K6;HG&VW3L+:=*52[5M%NLV+^9F-
MJE_<7$'AEMK_ "ZXW\I_!3]-C?Y*I]XL[UGM7QTCS,QM4O[BX@\,MM?Y=/E/
MX*?IL;_)5/O#O6>U?'2/,S&U2_N+B#PRVU_ET^4_@I^FQO\ )5/O#O6>U?'2
M/,S&U2_N+B#PRVU_ET^4_@I^FQO\E4^\.]9[5\=(\S,;5+^XN(/#+;7^73Y3
M^"GZ;&_R53[P[UGM7QTCS,QM4O[BX@\,MM?Y=/E/X*?IL;_)5/O#O6>U?'2/
M,S&U2_N+B#PRVU_ET^4_@I^FQO\ )5/O#O6>U?'2/,S&U2_N+B#PRVU_ET^4
M_@I^FQO\E4^\.]9[5\=(\S,;5+^XN(/#+;7^73Y3^"GZ;&_R53[P[UGM7QTC
MS,QM4O[BX@\,MM?Y=/E/X*?IL;_)5/O#O6>U?'2/,S&U2_N+B#PRVU_ET^4_
M@I^FQO\ )5/O#O6>U?'2/,S&U2_N+B#PRVU_ET^4_@I^FQO\E4^\.]9[5\=(
M\S,;5+^XN(/#+;7^73Y3^"GZ;&_R53[P[UGM7QTCS,QM4O[BX@\,MM?Y=/E/
MX*?IL;_)5/O#O6>U?'2;=]B/L7=<VAC7%'9WS_;&/HG'S;%F0;45=VWD2&N:
M2"8N).(+&)A&,2 N*!Q9K]57W\!'<7A??!7#N'/#7(67LAO 9/J8F6([\P]:
MU7#3I1S*:J*7SFVK_.5ERE]&E*FW>UFG[.PVC;0_N@P_,6VOE$O74$-73[$1
MK>-\;$05J92* 4!_0Y! ?7H" %V0;BW;AE(EP0Q>MW2HMSF 0!9HJ85&BY!'
MD,55 Q##N^]/PB&W&(8 H:L_C4;!YVL ^J"*KE9)N@F=9==0B**291.HHJH8
M"$(0A=XF.<P@4I0#>(B !0$_[9BC0=O0T0H("LPCFR#@0$!*+D$P,Y$HAOWE
M%P93@CO'>7<.\:O6A)<Q3)WD^;0=Y62)X')L(XGK-E6K0@J.VY4I!ND4-YEC
M,S@HJD0H<IE#MQ6!(@;Q.KP"@ B-1DKI_&XE#0_CE:W_  ^0@[VN0:I+A0&2
M,4PCB8O.*43(;K:)5"5=K;ON4@:?RC8!$>3A+.^HIE( \(2BH8 X)#"$HJ[7
M-I(R>AZM7*>0VI'<396_*.._WBVM7/>YU]+<F_J8W^RQ!2_%G^J_6BI=7IDU
MS@NB[C%-Z!@X/ZPWC\(#R?@]OXN5*3SZ=5+YKCF-[&FVMZ;W,NB[I<V@XM?)
M)"@.<U*(%,8>T80 /U;]X_@WCN_" U]S)=)QISJ-6XQQ4>=1OIZ6[7YB$WHM
MM.57U"H4,K6O2=2<HD,8HANW#R=[=VPW?J$/U[PKBN(I.C6G!\DFUSQ>E/<7
MGYJD#_\ P/;Y*RDY-1BKMM)):VWJ0.U3*)"%*/; H /X?1^&N548<72IPY8Q
M2?IY>LIGXSZ/4C]U:1% * 4 H!0"@% * 4 H!0"@% * 4 H!0%PKR(I_Q6UL
M^Q[AGYR7[73?=@_\+D/_ -1CO_CPYNX35/TKU,D[M5?)!FJ_0CKBRWIAQAB/
M3U=5EV!'8Y>14Y?L-DAW=#M2\<;6I><@60<6]DFW8DY&TC/.FS+K>);&*R2;
ME7,NN"BZGR>"?<\R7E_(>%RIB<;E"C6KSQ,94Z#PZI15'$5:,<WC*$YZ8P3E
M>3^<W:RLEFK7E3FXJ*:26N_*C7=YK+UW>H#I)][F8OKDKD?R1Y$\Y95_BPG^
M*5]]3\F/7VCS67KN]0'23[W,Q?7)3Y(\B><LJ_Q83_%'?4_)CU]H\UEZ[O4!
MTD^]S,7UR4^2/(GG+*O\6$_Q1WU/R8]?:/-9>N[U =)/O<S%]<E/DCR)YRRK
M_%A/\4=]3\F/7VCS67KN]0'23[W,Q?7)3Y(\B><LJ_Q83_%'?4_)CU]H\UEZ
M[O4!TD^]S,7UR4^2/(GG+*O\6$_Q1WU/R8]?:/-9>N[U =)/O<S%]<E/DCR)
MYRRK_%A/\4=]3\F/7VCS67KN]0'23[W,Q?7)3Y(\B><LJ_Q83_%'?4_)CU]H
M\UEZ[O4!TD^]S,7UR4^2/(GG+*O\6$_Q1WU/R8]?:/-9>N[U =)/O<S%]<E/
MDCR)YRRK_%A/\4=]3\F/7VCS67KN]0'23[W,Q?7)3Y(\B><LJ_Q83_%'?4_)
MCU]H\UEZ[O4!TD^]S,7UR4^2/(GG+*O\6$_Q1WU/R8]?:/-9>N[U =)/O<S%
M]<E/DCR)YRRK_%A/\4=]3\F/7VFTC8_;>75%M#=8S#3KEG%6 [0M%UC>^;R4
MF,=P^0V5QA(VNG%F9-B+W+D2YHP&2XOE.NBC&"N8"DZDNEN-PN*\,> .3.#F
M1WE'"XS'5ZO?5"AF8AX=T\VJJCE+\G0IRSEF*WSK:=*9=1K.H[-):]5^0G)M
M#^Z##\Q;:^42]=6PU=/L1&MXWQL1!6IE(H!0&,\B9#;V8W3:M$TW<\[3%1NW
M5W];M4-XE*[=@42G,4QRG(B@0Q#*B0YC'(0GW<92MZ=GQ_SZ"R$+Z6M[2]&A
MZ_41)G9Z:N5YU]-/3/' %ZFF)BD3312X1C@DBDD0B:28&,80*0H!O$3#O,8P
MC3K+<WT;UVG2< ?6^'Z*"SYMZ[3EL7;V-=H/F#@[5VV."B#A(PE42.')PBCN
M[PB ^@("(#R"--6E"WHWKM)/XURFM/.$X&XQ2"44#<PD4RE23?G*&\6[E(H
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MOD%6K-,KUH*SA5\?@&<!P2*$2<*(L_0M&M='+V:@J6EWE91V:R!^OC1A]M?
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M!0"@-*VL7N@+P_$K7^;$37I?N<?1')O[7*'^X8DTZOYR71]E$8*YR5B@% *
M4 H!0"@% * 4 H!0%AWR,+YZ+#>P1E[XFWZZX[J?T6?[QP?V:QM8;QM_J1:E
MVA_=!A^8MM?*)>O.<-73[$65O&^-B(*U,I% * 4 H!0"@% 9>P5-V=;N3("7
MOB>NVUH9H+DQ+DLIUUK-0C\R)BM7@\%A)*N8\^]1I(M$&BJJS5T?>FND51LM
MAWMHM?G5^@G!I26<VEM6WXN3;RIG;$TA;5@1#[)!<PW="Y2M6XD[\/82EKO+
M8M2+F6CQXW==0C68OEBLD5D%"QK<RDD9;KA=FDLU;E4@HN[=K?-:2OR\_P <
MGIO;*<+*\LYJ2=\W3;7JT?&A[#L<Z9TQWD&)OE.W=3LLRA)>W'*#'&B>*GBK
M&2>-HH"DC#7*_@F\@U)-R2!3*NU'"96 NC<$X(HA11::O'IO^/L)2G%IVFM6
MJVOFY'I/0,M8N-(R\\>0SB9[-XV-CVWF-R+J0<P8;4ONVW1G\7*H,W4:1V[!
M-1)%NY4C$'.]0L>\15,,=U-0XO3;7G/I3'&13BKW6:KO79KF^.0QQ:F8L6&R
M-FJY8O.%X8KF;FO(TI;5Q(6^K<=CSUO\!J*196RWT NZ/+-U"R:9'#Y6,420
M?("T4 Z3E!PL[)9M]>BZ36OEO;9M(J<;S>>XZ;IVNFO1;T[.2Q&O7GJKTY6O
M8FH"_GD\G!VZ^PM!V0]N]"TYU).[[WDL@076SD(>(B7<BCU9-5NT[(R+)N ]
M2!-94&K=LJ?D/!7"8C%Y;P-##T^,K2G5E&&=&/S849U)N\Y1BK1@Y:].I7;L
M352&=)WT."TI/2\Z^JVCIMN*7VBK/N)\2:====B9 NGL#=.9,61MN8YC.PMP
M2?V0S+>ULJQJK/KR(BW["*X+RY(5'J\RYCVP]>=4*L*2#DZ/HO+F3L9C,I\'
M\1AZ/&4<%C)5<3//IQXJ#K822EFSG&4OFTINT%)_-M:[2>O2E%1JIOQKYNMW
MUKD6VW-I/ABW/6*;<V;&I' ,S='6>6+]RM;%RVG:W8:>7"5A8^8Q"Z>/.S3:
M+6@&744+7G#];R$HU<GZRX*:)SN&I5\8S)V,J\*<EY1A1SL'A\)4IUJV?369
M.5/&14<QR51W=6GIC%KYVO0[(RBJ+BW:3LTN99O1R,EO:FOS"D;HTC921GW0
M:R;-P'=FG*UVQ(:X3.#VU/3\+'Q5P)W&6)/ D<PMNQ$3/%4<32+PTC'RC;J"
MRD@D53Y%7@[CI9<E"%)?Z+6RA1RE5EQE.W&PIU)3INFY<8U.I.=*T8.*C*#N
MDF6*K%4]+^>HM:M.R_4GZ5;T]]IFUA85M+13AK#I=7DOIKRA:,Y>,C<SR'PQ
M,9,<+Q<I>E\2;.#4+(6G*6\5%ZUFXB8%['.U72!VQ&2@IF.Z2+3E3(N.K9=Q
MV->1XY3PE>%%4HRQ<<.E*&'P\'4O"O3JIQE3G#-DLUIYW)%B-2"@HN>8]+>B
M_*]J>TT^ZE)F%N+.>1K@M_*#S-,9.3*$N7*$A:HV0\N]])14>\EWZ]JBT8!#
MF;2ZSZ-! C-NDJ1D5TBF"*Y-_-LEPJ4\GX:G5PBP,X0<.]8U>/5&,9R4(JJY
M3<[P49Z9-K.S6[HU:UG-M2SK\NKD7)9&#:^@5"@% * 4 H!0"@% 67O(JGGC
M]_\ Z)^2?WD8<KK#NL?1O"_O?#_VN--K"^/+]7VHW#;<KNLK!_1_M7]X.3Z\
M]PU=/L1LSU]'M9ICJ9 4 H!0"@% * 4 H!0"@% * 4!I6UB]T!>'XE:_S8B:
M]+]SCZ(Y-_:Y0_W#$FG5_.2Z/LHC!7.2L4 H!0"@% * 4 H!0"@% * L.^1A
M?/18;V",O?$V_77'=3^BS_>.#^S6-K#>-O\ 4BU+M#^Z##\Q;:^42]><X:NG
MV(LK>-\;$05J92* 4 H!0"@% * 4 H!0"@% :^-J1W$V5ORCCO\ >+:U<W[G
M7TMR;^IC?[+$!^+/]5^M%2ZO3)KB@% * 4 H!0"@% * 4 H!0"@++WD53SQ^
M_P#]$_)/[R,.5UAW6/HWA?WOA_[7&FUA?'E^K[4;AMN5W65@_H_VK^\')]>>
MX:NGV(V9Z^CVLTQU,@* 4 H!0"@% * 4 H!0"@% * TK:Q>Z O#\2M?YL1->
ME^YQ]$<F_M<H?[AB33J_G)='V41@KG)6* 4 H!0"@% * 4 H!0"@% 6'?(PO
MGHL-[!&7OB;?KKCNI_19_O'!_9K&UAO&W^I%J7:']T&'YBVU\HEZ\YPU=/L1
M96\;XV(@K4RD4 H!0"@% * 4 H!0"@% * U\;4CN)LK?E''?[Q;6KF_<Z^EN
M3?U,;_98@/Q9_JOUHJ75Z9-<4 H!0"@% * 4 H!0"@% * 4!9>\BJ>>/W_\
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MZM:?*MP9_0Y6_E</_F#O5[5O?W1YEIVF?]L:9?"I='U:T^5;@S^ARM_*X?\
MS!WJ]JWO[H\RT[3/^V-,OA4NCZM:?*MP9_0Y6_E</_F#O5[5O?W1YEIVF?\
M;&F7PJ71]6M/E6X,_H<K?RN'_P P=ZO:M[^Z;C]A[L5]8NSSU>W3G'/C_#CJ
MRYG!EWXZ:)V#>TS<4T$_.W?CZ<9'68R%H0*!(\&5L2(+. >F4(L+=,J!P5,=
M/AG#GAOD?A'DBC@<GT\=&M3Q]+$R>)HTJ=/BX4,33:4H8BJ\[.JQLLVUKN^C
M3;2HNG)NZ:<6M?+=6Y%SG:[<KNLK!_1_M7]X.3ZZKAJZ?8B<]?1[6:8ZF0%
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M[-8VL-XV_P!2+4NT/[H,/S%MKY1+UYSAJZ?8BRMXWQL1!6IE(H!0"@% * 4
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MO_C'<GXI ?\ Z*/KO/@/]','^UQG]W6*GKZ%ZD8"KEI@Y#8X@IP/0. \G_,
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M&X0Y!H4-6]'XM>P^5#!]FS=5VX1;(%$ZRZA$DRAZ)CCN#?W@#MF'M%* F'D
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MSD>G[+/!;>S^<NF7\AY4^7V%4:?+T>TV*G)T^PKYU85B@% * 4 H!0"@% *
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M 7,;T>^+/A;H33PAR_Y\RQ]9XWWXS(>3'^%=@XO+0%S&]'OBSX6Z$T\(<O\
MGS+'UGC??C,AY,?X5V#B\M 7,;T>^+/A;H33PAR_Y\RQ]9XWWXS(>3'^%=@X
MO+0%S&]'OBSX6Z$T\(<O^?,L?6>-]^,R'DQ_A78.+RT!<QO1[XL^%NA-/"'+
M_GS+'UGC??C,AY,?X5V#B\M 7,;T>^+/A;H33PAR_P"?,L?6>-]^,R'DQ_A7
M8.+RT!<QO1[XL^%NA-/"'+_GS+'UGC??C,AY,?X5V#B\M 7,;T>^+/A;H33P
MAR_Y\RQ]9XWWXS(>3'^%=@XO+0%S&]'OBSX6Z$T\(<O^?,L?6>-]^,R'DQ_A
M78.+RT!<QO1[XL^%NA-/"'+_ )\RQ]9XWWXS(>3'^%=@XO+0%S&]'OBSX6Z$
MT\(<O^?,L?6>-]^,R'DQ_A78.+RT!<QO1[XL^%NA-/"'+_GS+'UGC??C,AY,
M?X5V&6L*Z2-*>&KW2O3$&F33WBF\4XN0C$[LQMA?'%C7*2-?@D#Z/).VQ;<7
M*%8O022!VT*Z!!R":8+)GX!=VIC,KY5QM'B<9E/*&+HY\9<5B<;B:]+.BGFR
6XNK4G'.C=V=KJ[L948K2HI/F21__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g393013g22t34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g22t34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1^<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $H< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' (   (  !P"!0 63E5#+3$P,S$@34]!($YE=R!&:6YA;#A"24T$)0
M$,5\9R5_05''9J82V:?4IW X0DE-!#H      4T    0     0      "W!R
M:6YT3W5T<'5T    !@    !#;')396YU;0    !#;')3     $=R>7,
M26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L 0    ]P<FEN
M=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    G $@ 4  @
M $P 80!S &4 <@!* &4 =  @ #4 ,  P #  ( !3 &4 <@!I &4 <P @ "@
M,  P #  ,0!% #8 -@!$ #  ,@ Y $4 *0      #W!R:6YT4')O;V93971U
M<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T
M=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--
M64L .$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO
M;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
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M;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M   08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N
M9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H
M=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0
M \     !  $#P     $  3A"24T$)@      #@             _@   .$))
M300-       $    6CA"24T$&0      !    !XX0DE- _,       D
M      $ .$))300*       !   X0DE-)Q        H  0         ".$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       %Z@  "3H          0                         !
M      DZ   %Z@                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   %Z@    !29VAT;&]N9P  "3H    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !>H
M4F=H=&QO;F<   DZ     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    $.$))300,     !1V     0   *    !G   !X   P2
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M^]_+_N/5<7(-]>[<'?RFR ?DXHECG;>3SXE5\$[JR\O%FZ#O:(:=/S K#@#
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M=K;61H=VNV%TW7FDXUKVMK<^NLN:;#&T_O5N_?\ Y*X>KK74;754N>UPW-:
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M=C1H0RMKIUG_  OJ?U4/]CF1/6K8',55B1)+O\&B(R&P/V(XX?O#[4=5%-+
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MR11UTVW642B"NQQ$ Z]R-/BFM:QKMK23'TOC_)3?=A[@Q;S(XC6O /Z_[JC
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MMOJH=K.HNL+JKLJMCG26;,=P _=8YWN_S]Z^:DDU(JSWZOTD:NK$:964#/\
MHL97L0N=;D/<TLW/;[7%LZ,8-=CGKY?202_522^54DE/U4DOE5))3__9.$))
M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      7Y-30 J    "  , 0   P    $).@   0$  P
M  $%Z@   0(  P    0   "> 08  P    $ !0   1(  P    $  0   14
M P    $ !    1H !0    $   "F 1L !0    $   "N 2@  P    $  @
M 3$  @   !X   "V 3(  @   !0   #4AVD !     $   #H   !(  (  @
M"  ( #DH;   )Q  .2AL   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3<Z,#DZ,34@,#<Z-#,Z-3<   20   '    !# R,C&@ 0 #
M ?__  "@ @ $     0  "3J@ P $     0  !>H         !@$#  ,    !
M  8   $:  4    !   !;@$;  4    !   !=@$H  ,    !  (   (!  0
M   !   !?@("  0    !              !(     0   $@    !.$))30/]
M       (      $   #_X0& 34T *@    @ # $   ,    !"3H   $!  ,
M   !!>H   $"  ,    $    G@$&  ,    !  4   $2  ,    !      $5
M  ,    !  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (
M  $Q  (    >    M@$R  (    4    U(=I  0    !    Z    2  "  (
M  @ "    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$W.C Y.C$U(# W.C0S.C4W   $D   !P    0P,C(QH $  P
M  '__P  H ( !     $   DZH , !     $   7J          8! P #
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M)BDY261GDK;$QO_$ !X! 0 " @,! 0$            ! P(%! 8(!PD*_\0
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M/]3&!/+XGYPQJY_ ?*#V6V/[+NOPI_J8P)Y?$_.&-7/X#Y0>RVQ_9=U^%/\
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MII^:0E5QOBB4*AF&188I%5>RL;5%)R;(JJ @<S=VS<<H.6+M,"BHV7 @F+N
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M%3H4!'8/*5;FZ7-3KSM+D7:?++6HH:=F-_9-_P $;M):OK@WKH03A2H@"_\
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MO1.BF*3K9M@^EN"AL4RA@#9-;L-S[%6,8H@*?4JM1 D*=83A6D$J0D>BL#B
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M3I5N[!R8J9?%0-6Q1(F;HG!7*D:FZ+SD$Y ,=BF*9A$AS$Z0@GW(L!?<D$Y
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M6/8H$1KV9T,TCG1Z1W0JZV<@8BB;Z(8DA'R*R1@.DND[B.I+$62.!3$4YA,
ME+_S0VV\MM1M!*@I159MQ"@4J:FG/+&EI4+*0IN:#R"E0)!3:Q!/,Q\5VG^X
M\^YFVK6A^;Z'-CJ+/LO-34M5MB9)SH_K$I.R[@>EYV7J>Q+U G&YQAY*76WR
MZI8<0A2BK"+;ZTXG'U,2+&2-AL<U%%*1)LH[69'?-$RG$P HJT:QYGQ2D$J/
M.N?K(I$ ZBR[@3JGZ].!$RHN-L,2[BE%2PSO$MK)ULA2UI;SS"4!*!HE*4V
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MD2F]F)6IRDW,3E20^RVHORK:-].8D7IUIQ),=)'DEIM"Q3*SL:]8[S)L(C4
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M&+TB $IO8W(  '&_#+D!PCZ+T;2E:I\P$F<F&)1*BM]*WEHE0E/I.+=0I6Y
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M@I625%*@<P4DV&6?"XAX7]O7E[.$1/9,7"C@@ F8-A#T_;[.S[6P^O(;;4%
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MP8],NLJZFZ'/!657:BBRD6]0%=B0YS"800,F'.4HB([%]P4O< ;=_;93:FR
MB<9*R  7&R,2K"PQ)/$\2#>$:SHW@K'</*(2,]>HX 9JE<-BQS)913K")@4;
MG'I-B\A52$.<H"4P@ @!@WW#DN[428 W4JXM0TQ$) [=>>D(Y&Z^Z4ZBZ>:B
M3M<N$/(,)-J^7V%5-4S=Z@*QP1?QSKE!-ZP<E+TC9TB)DU2^4#@8I=\AU$ZT
MV_+.!QM>8L<T\2E0U2M.BDG3VZPC=_#'4Y%DUF;5:($)*I0S0QWI)1EUB-4=
MJIG*Q;'%<@I%675 O(!#E7Z)-50G8F80Y%R$(:+F%QSU0%#%8:JM?0#*^@)Y
MQ!^N'UG&O[]JD@PDW1*^P8Q*(*' G4T")F(',(!R']\7;N[#!MW!V;Y:I80+
M7N;6OE<Z=F1X6]IM$QK%+4=>66Z.8*G))G'8W60$RH .P;E5W!0! .[WQ?A#
MLS!+N(VSM;W>[/C?MB!?B+<NJ-L-JQ4SU-[;639P\78'1,I%#RD(":O, J&=
M!TA@*50"$$.KCOSAVAV;VV&N'VBU@;^//6V748F-//\ 5BV+JIQ<9T,!%)KE
M 6$451$SGHS@)#/W9C&<NN4Q0-T0'2:"<I5 :E4*4P<4NKW@%@$@V&6G#_"W
M;I#+W?"\=@.&;2!EQ;Z2%KFI)WZ2=.<=<KU@2#I'D<M*DZ%ZQ2%4W(HVD2,F
MRZZ0CV*1S<X;#OS:NL5'S4IEUM"5J?.%QI1*<2$ G'<9@I) S%O3.69M''Z^
MOKCE;=->\%EIE%R9'<G;IB1:)J ?JB;5NB*A0'?D.H'NB@/9N)!W[\TZ]K%8
M"&I1(5;52L@>=@#?MUO[YCH7ISI;2M*X-*!IL,WC&A"@"JI2E,Y=&[-U'"_*
M!E#&VW'?LW^$>T>MSD_,SSF.87BMZJ1DE/4/$]EH1L/.'"#$(Z;<)G[E _XS
M3'Z)AE2]>SQ,6HT[? 0Z]2/KZV_DQ#_27>9(T[? 1BO7L\3&OLSC"#$(,0@Q
M"#$(,0@Q",=V@@Y:N6SH %LN@JBX 3<@="HF8BFY]PY/<"/NMPY>_<-L?#,=
M\7RSSTO,,/RY(?9>;<9(&([U"PI%DV.+T@/1L;Z6SB%>I3*4GVZE.B))1V@X
M$%8^6,S32=M$TU.4CQL5<5DQ7#8Z"2XHD36 53 GT0F1'DLD)(6I(RU02<)N
M#D;6(OKJ+<,\X]0[*-J0R:O,ERAS:4):?\D>9F5[U6!:FL#[+C!2I(QK9?3,
MI9NA*T.*LJ.;'&!PS:AVG3N6C&%\L@'*Q7,M"KJ,&D=8RE3$WBV1=L&+)^W1
M>" H&,DZZD)%#=<8.4A$H=QV5KM-I-39F9VDRLVUC3]]N\I^5-P-\PVXZN7<
M4V#B&\;+A(&[>;58G1=.'1YMYTX]'=4V2Z-NF/:'H^K3TF\@R2)39U%!VM.
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MQ51,ZQ%$%#+"H0>E $A,=8@@(?31Z//7=#EYB2HE,DWVPIUBGRS3P*K8%I9
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MT\LJG2M,<G%[MJ0EYR8FU.$ %#VX#31N?2<<W*PAK-2BX@)!QB\J0[  ![P
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MD?7UM_)B'^DN\R1IV^ C%>O9XF-?9G&$&(08A!B$&(08A!B$8$J\&.C7SX"
MH9HU67*01V YTR")"F'R%$VP&'R%W''UE]<(YE.E1/3\G)E10)F9994L"Y2E
M:PE2@.)"22!Q-HB)JQ6%K(S(P\8/#V6PH=-UYH=--6+;)*$Y7:1#)J(IFZ0H
MHLTQ2,4>C6,?FZ+E4Y,NH-J"L*5)1;T%9I5KDJQ22#E?";Y9$</2.R5I=F91
M*.O4:FR!W#<S*[LS:GW!B4EE<RV\TMP(]-U4PV^VG>("F%I78<P>,/A6O]OT
MZDHR/U&MC9=./6$\8JO%M8JPB"7:TEW#*'2?H$<"7D!1FNFW0.?I3L5^0@!W
M+9;:"0I%49FIJE2C[6\'WU)?\HE H@;V5#C[C>-L>DDK073HAYLF\:WIHZ.-
ML.G+HWJ>QFQ?2WM'LG5W),X9-V3V:&S^U[K"2M-(VL53*'2JKYNJJTIEIQN6
MJ":-@>6J?V?JDLDRD?,7)MP9S#Z,>%<PKJ,D%XU^]EE73Q9D\8GZNL1>0)&J
MF:F063,W$594@I&3$JI4B%'D]/,/,NM)?:N67&D.HF/34%MK2E25AP((""D@
MYN7YC(B/Y]JULMM10)Q^A5>61,5ZF3TY3JAL=)-TFFEBHR$[,RLW(IH1JS*Y
MJ:3,M.XFY?9Q3<PI85+N3)=277(T0:MTTS25V>&B%E#@5PSEP38JJ<RA#(+S
M +G>MRF6Z00.+A$3JD*@5X/*5OF90G!B+Y*+YJ"@ <U)MCS4!BR%E@WRQ6 $
M=/F)JJO5)R7IG1C()VC1+C=T^=V>>FY]EL-2[_E;.SBY=NGS<PF4#:MVY39F
M7;E77)LT_>+5.C.:L(90H=5O[Y>/3*)P;DFXYX(!OS$ [A5-PLJD4O<5;G,I
M[XZAO=<TH!(&!TJ2D&UE)6;:YJS)%M2?2OJKA&KJLQ7Y9^855^C"4D*M,NA"
MW7Z#7*2VETE27=Q3F7Y.6EGUN&V"62U+,6W3,HW9(0X:70G.H5QA:C5+BU=3
M$L]!FV;'2C'BR)BE4677<MTSIH"@S035<N!+' Y%)$X$5*?EVX-5J4O3)":G
MYIX!B5:*W$HP*<6;AMMI(OA*G7%)0D*3:ZKW S'T;HBZ-MN.E#;G9#8"@]'4
M^U6MJZLU+257G'J[2Z'39-E*I^HUJ8G$,*G6I>CTN4G*DXY*U0JW<J=S*3;R
MD2[OU#\.'#]<JO2(IE,W"9NCIO'MTE'$L4K9L"I42E$S-*.,W> B4P =%*1D
M90X  %557)S%-Y4K53EZC.O3,O3I6FH<6I6YE=X4F]LU!;BFPM1S.X;91<Y-
MI%H_I&V2IE0Z,]EZ;LA7^DS;#I)GJ:RS+':+:MO9YRI%#608:FF*,FJ3$NE(
M#2'J[5:[5B@7<JJUA)1T#T[;^((PTHP.9H[C%B,YB,4,!DU4DRE, %Y@^IKH
M>[;K)E R:A3$'?HC@;0NBYL1<'-*OJ^AX<K"US'S[;2634YI4A.#?M3B%3-.
MG@DI<;6LD8E$'-QMT87FEDI6@XO1QH4F3P#N #\( /X<I&8!YQYW(L2.1(]T
M5Q$08A!B$->P?56_WL_YP8A#?Q"#$(,0@Q"#$(,0@Q"#$(8\K]<'/W1/T9,@
M:=I[S"//R808A!B$&(08A!B$&(0FM]25^]G_ #1Q"&'B$&(08A!B$&(08A!B
M$&(08A!B$&(08A!B$&(08A!B$&(08A#3L?U5K][4_.+B$-O$(,0@Q"#$(,0@
MQ"#$(,0@Q"#$(,0@Q"#$(,0@Q"#$(,0CIMPF?N4#_C-,?HF&5+U[/$Q:C3M\
M!#KU(^OK;^3$/])=YDC3M\!&*]>SQ,:^S.,(,0@Q"#$(,0@Q"#$(0=-D7C9P
MT<%YT'**B"Q-Q#F35()#@ AL(")3#L(" @/:';@^[D?:,Q%TN^[+/LS#*L#S
M#B'FE6!PN-J"DFQR-B!D<CH8C38$%J#;F+F7<B^BY!D#>,?JI]'R"S65.HP7
M'F,3ITTW!%0.7D*X*<ZA$R=&J5.YLXTD  *2<QS!MF+'V9<N9X^C-E*BSM9L
M_-R\FR)6H2<UO9V40O'B1,-MI1-,BR5[E2V5ME*L19(0E2U8VRK2&O5[AW\.
MN@V BSA=,444$B]*LJLKL1))%,@"=110XE(0A"B8YC 4H"(YR&4'$-!X 6O?
MJM;PRS^J]'M G)6;0\^2VRT2ZZZZK=M--H]-;CBU$)0AM*2I2E$)2D$J($0V
M>>"YTSNJ2<[=*(S<6&93))S1ND>ME@DWP=9>$5.R=(B90BRIR*& 0YCE,;RY
M]*DND6J2,C+2#4U]XE66Y=M*D,JLAM(2D K259 9&_*VD?EMTI=%&SVU'2[T
M@[>4EMYD;1[95^M2[[4Q,(0^W.5*8>;F"P' S_I(4'U)4U8EPA8)CS$_!#Z$
MH$,#6@IM%><%4W2$E-]:;KE 0(X;JJR"O1+$ 1+S  @<ACI*E.D<Y#6CI)J@
M*3OT^B;@8&@"1EG8"^1.>HO<$'.- _T83,TAUJ:FWIAE]@RKS3J65-NRJEH<
M5++&[%Y=3C;3A9!#9<::<PXVT*2FT\$1HNBH"KVI%F#$2413(_2:-VQ"*B G
M'J4,RBF2JH[=BZ[=9<@"8"*%YC;VGI.J># DRZ$Z_P 4AS/V;]3N&_$(P@\1
M:-2OH7"WU3'G.M-.K4VI3DO6*C*NJW63:5S$O,M3+J&\BAMYYQ"5)2L)"T(4
MG$2\&CIWH,X4U:T_J3QK-5<IG2K=N^D%VZ<.L8$)A5&/5<&;B9HP56<B<4SJ
MD;(+ D/,8 -JZWMS/5V0739A3 :<6VLI:89:"E-&Z00T$I%SP  )MED(]+?<
MH[*2NPW3#1ZA5:G.3*:E2ZWL^Q4*S-NU*8EYNJR:DR2#4)XS$\$S4VVU)#%,
MX=Y-@N$(Q&.B^D.H4"C74 ,H@.[<O[XO9[@/5MZ,^>.(5B.5^>1.EOH9<H]H
M;:;-5%RI.62X+.DY \3[+6ZN?LUVQ08=6VR,K/E6,VKAWK9N")4S<TLK'BJ=
M0J:@B!2M4SK] LJ4IS*'*J@44SIF,6AQ5K)_"L2;?@Z6/'.XR'#C>]H^5[?5
MU% 8D:,AM+U83*NNK=4L6I[<WNTH*T %1F%H9WK:%*0$)4T\H.(6E*I$96,@
M!RCX)!B$&(08A#7L'U5O][/^<&(0W\0@Q"#$(,0@Q"#$(,0@Q"&/*_7!S]T3
M]&3(&G:>\PCS\F$&(08A!B$&(08A!B$)K?4E?O9_S1Q"&'B$&(08A!B$&(08
MA!B$&(08A!B$&(08A!B$&(08A!B$&(08A#3L?U5K][4_.+B$-O$(,0@Q"#$(
M,0@Q"#$(,0@Q"#$(,0@Q"#$(,0@Q"#$(,0CIMPF?N4#_ (S3'Z)AE2]>SQ,6
MHT[? 0Z]2/KZV_DQ#_27>9(T[? 1BO7L\3&OLSC"#$(,0@Q"#$(,0B)2G'+P
MQHB[*K>[ 15C8I>I.&XZ2:RBZ]DE=BY.;LD0@T#3X7+QW6H>&D96R S27)7H
M] CN9.Q0<M#KS8\N%]1\^/#GPB;'Z^OAK'OSG&-POUI&TN9O6VC,6M)TXI^K
MMK>&D55V<'IO?W;1E3;8]>-FZS8(ZPKR$:9@1-51X9M*Q+U5LDRE8]PYBQRL
M";DI&6I&HSY0L;VTX>_3NC'M'$GPN2LV73&SZCU1],/[,XJ"L,LE*N$F%D9S
M[.I$;2<NV8'CJTHXMLBUJ<)+R<E%M):V*'KD$_>3K=PR2D7'I"XRO?V'/CD<
MA<BQL!G:-C2JM4Z'.M5"E3C\C.-7"'F%6)2<E-N(-T.M+T6RZA;3@%EH4,HT
M=4=>> "+;-=2(&]1:ZJ9XAQ"GF8[4R0L2K6=J[^\PMCJ]*L,0M8Y&">TV,E;
M8SN\'7W<,6MQDI,EG$XU@]<(YJ<>-T%1L/6 2$WT%E%( R.HYV%KVCN%9Z4=
MNZ]37*34*XH4Y]."9EY*3IU-\K0<BW-.4^5EGYAE=O3EW'%,+(NIHD"V[G'&
MGPRH2CN(3U2923EHV.X3=059N=BA984J%&ZIK,:S8X&M25?MTRAIM+L+TO U
M:3F)M&JJJS:L>1@U=K(883EE]7MGQUROSXQ\^L>7U]&/.C^.3ADE6+N487V:
M6B8ZGM=0I:9'2G5Y"%A*(_CIF8C;A/S#B@I1D!6I2(KTU+1,S,NV+"5C(]>0
MCUW+/HUCBDCAG>UKB][VMKK<PL?KV:^[WP[&W%=H(ZI5EOZ=Z.E7J=;JM0K*
MB\J%XC[3%7.\J59*E5E:A/JRVO:LQ;S7>I&J[)M6UU9]*P1J\4#M!P"@+&X%
MLR"1R(%[F^EA8WSX0L>1^O\ ./++QB\.#H61&.H?CE)]4VUW<.8&F7RQ1L#4
MGDY;JP69NLG!U60C:&U1L% O,-(IW9U .(N0J-D;2:#12&?@A'PX:C6P.7/(
M@Y7&<2 H&XR(S!!S!''(W&8]_MB/\;J]P"V2R-B5R7D9&T3*DB]]A53I6N:D
MX1O&L*/-/)F1TW@:N,M7ZZ>-U+H,DWFW]?BJ[*M;;#.&3QZF] V6[Q["+JND
M#502<OZR@2<@0=3[;B/I372_TBM2+=.^T*WVFF]RV]-R-,G)Y#8]$ U":DWI
MQQ0'HI<>?<<0+!"T@"V["<9'"E#1L C%:IUYVSEG-DAJS$T^#LMF>R+VE71S
MIU8XN(@*G 2LHZ=Q%Q8OH51FU8'76,Q?/VB;B,9NGR55C<W!OZQ)OQ%[DGV?
M5X^=S,Q-3LP[-S;[LU,S#BG'IA]U3SSKBS=2W'%J4M:B3FI1.L+.>-GA?;1\
ME-$U4:R5=A*&SU.GK9 U>\62FUZAR-6=W5C8[%<J_69.K0#5W5F+J8;MYB79
M/E6Z94R-!<+((J38WM;.]K<;\K:Q18_7U]#/2/1?<8/#JRGXNLDU 6F)F;L#
M*J1#>JTK4&YMI&RR.GM?U89P;23J54FXM:25TSM$)>C-B/!41K#I:67!-K'2
M1V<6/+VYY97(OG[1;KRUA8_5OKZ/(Q)?$1!B$->P?56_WL_YP8A&H=2M3J7I
M'60MU[D9"/AE)JOUQH6'K5HN,Y*6"U3#. KT)"56EPUAM,]*2TN_:LVK&&AG
M[D>D,NHF1LBNLDU_Q-OB<A#6-%->.7A<>/(1FWU+<F)/MX!9I+GT]U00J\>O
M:/'I:_#6>X+TI.J4RSRJM:G6K6HV^9@[29_&KQYH<KXR3=2<)Y=ETW/.POF!
M?47'*%OKZZH]AOQA\/BM:I5P?6ZQ5JN:D7JD:;Z?25YTIU>T]+=[?J.D+BF,
M:HVO5#KKV?C9EJ4[P;-&-G-7C6)%'TO,L&B9UBK'.V=@2;$&P&M[7MV\<M8F
MQ'T(QYGC1X:8)S-L76I"C^1KDZZK$W%UJD:BW"6C[$WU53T/;PJL54JC-R)Y
M&<U:,M0ZBU1;**W:>CII&H%G$8&:6CUCRM?G896Q7SMEA](\@<X6/=\?'V0J
MAQE\-3I:L(-]345C6LT4BS43JMX,V@7<[<I73J$CM0W@5GJFE4M,:A04W0HN
M(U/6J$H_NL-*U1JT5GH]W'HSA5RTORX"YMGG8'$;7RSXBZW^'U]9Y:WAGRGA
M"^#2%K4K;I'72!1@(2MZ;6V5=)P%V=N6,!J[0[5JAIX\5BF=87EQ6G]/*3:+
MB>.(P/*0L%%'>V!E%$<LNLL*OYIU(]Q"3[B0.O(9PL?H_7^6>F<27I&I%'U(
M)9%:-8F=E;U&QA4YYW'IN^HMI\:[7K6#-J^7;HLY=+Q#:X%[XQAUW\9SO3L>
MN>,&,@T:8_7Q(\(@BT/?$(8\K]<'/W1/T9,@:=I[S"&],2\77XB4GIR0:1,+
M"1SZ7F)1^L1LQC8N-;*O9"0>N%1*FW:,VB*SAPLH8I$D4SJ'$"E$<F$1[1XO
M^'1U 4"SL]1B/X34R(/8JF\CZI>9 XUI*=;5A>T6=DSK*[^@U=K8WC:">66_
M-:S!LY=4L>ZD$70&2"<)S]G,@?$FQ[(FQO;C'@)\<?#,:4"'=W:SPKX;2XI0
M!9]'-;*DT&TL96,A).'+)6?3J(C#.(64FH=K/J%=BV@!EHQ::78-W[555A/7
MU$7[X6/U;Z^K0Y)#BYX>8ZV.J(;4$9&YLT+ZX/6*[4;W:IMREI@Y%C>AC(^L
MUB7<3!X&12D(HZ421ZK(2\#:HB)(_DJC:&L0"21<#++V:Z:_7.(M]?&&S&\<
MW#%,-8YQ'7RP.7$U!U2SU^##2/6=*VV>NWEK;I"I3=3I2^GJ5NMD9/1-#N4Z
MQ>5R$E$35RN2EC4,G!-_&(R4*%\M,CF+ Y#,WL,R!F=3:)M]7$/&J<5_#M>I
MZ/K%-U5KMGG96>IM;C8^#3E9([V6U!TGD]<J81!=K'*-3L)_2B%EKDTF@7\2
MD8QSMFZD$)5(S#(L1J+:_ V/N.77"QM?A$A<B(A-;ZDK][/^:.(0P\0C4UIU
MUTBI-Y9Z;VV^0D!='M'L6I1(>2.Y0*VHE3Z09^T2DH+88>&BV)4'BA5)>08J
M/48R86CTW2,-*G9S8VO;*]NWE]>,(UJ?C*X?RMX%=.?O;P;-8S5*#91FANNT
MO+/[":LI75G&EA(O35Y,('FJ<H>UUIPZ8H-+36V4K.5QQ*QD/*NF<X5<M/:.
MKGSB;?5Q]?5M8H'&GPQC2Y/4(NJ;)2I1%DD:B\DDJY<U5S3\5I\.JKYHPATZ
MX:;EFZ>G8>RQ&3B8Y[%.XL2F9O5US B+">6HOJ-+V[,\LX6-[<?HP[[%Q):/
MTS3*2U@O$]/T'3^)DVL._E-0-.M2:'*IR#UXS8-4T:A;ZC"W)X@NX?(]&]9U
M]PQ%NF]>=9ZG&R*[6,))L!<^P@]T1;ZN(P9WBHT%KL]::J_OG6K32K46E66L
MP%7N=KL4?9SZ;OM7 C$X.K5V8E)'_P 'D9(V$SV+:O8\H,'<49V$XW5C"L)L
M#;(\>W#WY1-B8LIO%7H->Z[;K;!7A9I6J)2Z]J-;)FWU"\Z>,H>B6QI/2%:M
MBA]0*S6#.8.;CJS-2,>_8E<I.(YLB_(/5)&-6>24D6RU-A8@W(MEE?G$1>'%
M1H.6.JDD]O)X4MVU.A=&JY'62JW6KV)WJ98DF3B$JKNJV*N1=FAG,FUDXI\U
M?3<3'1)X^6B9#Q@#&48.'$83UV&(V(.7/*$>3]&-PUG0!9MJE&R)E)*YPK9E
M#PEJFI:0G:!?873&S0$5"Q,"]EY:?1O-BAH.&@HQB[EK6+TLC4V<W$HN'Z+"
M1J.7Q%Q\/=QA"2_&/P]((2CP+=9'D= 4[V?6B7BM*-7IF#IE5!K87JC^]SL3
M0WL/173="J6(7<+;WT).LU8ETV=1J+GHT3R$DZ<[6N+DY"P%[G7A$V/U\](]
M!UQ:Z 1NGERU3FKN]K=,T]LD#4;JYME%U#J4[6[%:$JNYKD;)TNRU.*NR)YM
MG=:M(QC@*\9F[BYEM*I.#1Q5W23"2; 7)SRL>Z(C!A^,7AZLMG?4VJ7"?N=D
MBK-9*C+1U&TMU:NX1,S49IC7;$:6?5.C3,=&0L=-R+:.&T/W;>KNEP==2F'*
M;!^=LPGC897S(&O6?AJ.,38^_G8?6D)1'&9PZS,A"Q:-SGHQ_8]1R:0P"%IT
MMU;I7CC4GKLC&.JC'*W"BP2#N2B92+<Q-A,BH9I6I56-C+ YC'\S#MWS KEH
M,6HTYZ_788B%4^,;AT56G6X7UXFY@7AX\6KBA:D-'5E>DN3O3SJVG+5U4$5]
M553W=BZK* :9)VWK$JEU= 5.D2,=A5K;7D0>%\['++6]K<80Y8GB:T,FZM=;
MK&7]DXK.G%!+J=>Y,T38FWL5IO7+]'.'LRS=0Z+]K*QLEI=?XR:JIFHVR"DJ
MT]CYF#8/%62#H4J!L1G>W6; Y<\B/9G"&@;C-T!+*2,(67U(6F(NYCITYC&O
M#]Q!O'RU[+6%+N:HQC9KI<LM-SY:2D>Z&C88C]R6G\EI,0(%5*0.PFP.6>>H
MTO:YSRSRSXQ-C]6ZX?M'XA-)=1;<^HE3L<D[MD8P6D'T1*4R\U@[?J;6N/):
M,,[M-;AF!K)7$;?62VVI)NCVBH.)IBSM$/$.U!0+!! OP[/KMB(W3D0AIV/Z
MJU^]J?G%Q"&WB$&(08A!B$:$G>)K1NM7>8T[G)RS1]I@'%);3"*FE^JBL(Q5
MU)GBU6@"K;F]*5J!D+C9NEKU==)3IVLK-M)&+:K*/8R00:SA-K\,^(OD+G*]
M\AGI"WSAL6'C2X8:K(VF)G]6(R.D:6P>2=C:F@K<NHS9L-4E]%79FPM*^N26
M72U0;.*D#.&/(/%':"SU)NI$I'D"SA5R[N5^XQ-B?KZY1ZSGBSX?VJDZD:^J
M+J0"J")R1]/O<H>P*.+U$Z8E+0"QM8=CJ;T.H<]"4MZ;3GV4EC['*Q\4_%L[
M=(IG85<M>KE?/EEGG;+/2(CUWG$OHA&Z?P^J,I>V\32IZYCIU&R,M"6:+D37
MI.QR%2=U-[6)"%;6F)G8NP1$NQFX^6A62\$2)E'TR5C'QSQV@PJO:V=K\+6Y
MWTMRY\(1X\MQ:</\%8)^L3%[7C9BMO)6+>$>4V^H,)*;A)>N0$I6ZE-GJX0E
M[M+.=M]8AE*M29&PV$TK.1T>G&'=KE1QA-@;:]7MX:C0Z\H?7CW1CDXO>'Q1
M]!QJ5VDEGL\YBF""".GNI:PQ,K.7B8TSAH*X'2IQTJ#8I74. F:3'5R\'KLZ
M\M$>O"MX]1^!4#,"N7Q&>5\L\\L\KY0CRD.-;AN69*2*EUL,>R0-8#.EYK2;
M6* *P85&7/7[C/203=!CSQE4I<^0T'=;A(%;5:GS'+&668BWIR(&8%<N7$<<
MP-=2,P-3RA#E=<5>@#&9EH%]J&U92$+8CU1X=W VMM%+3S:>&KRC*)GEH(D%
M/IURQ >&M[^!DI*.IC]-5"UNX8R2O(PFU[<+ZC37NSA8F-@:::L4+5^$<V'3
M^9<R\8S>(,78OX"QUA^W7>1$9/L#+0UKB(293:2D#-1$W$2!F ,)>'DF,G&.
M7;%RBN>""-81L7(A!B$&(08A'3;A,_<H'_&:8_1,,J7KV>)BU&G;X"-B7BOS
M$K+(.(]D=RB1@DD8Y5$2 "A5W!Q+LHJ0W84Y1W -NWOWWR4* &9XQ"TDG(<(
M9GL,LWV*5_GFO[?,L:>?P/RC' KE\1\X/899OL4K_/-?V^,:>?P/RA@5R^(^
M<'L,LWV*5_GFO[?&-//X'Y0P*Y?$?.#V&6;[%*_SS7]OC&GG\#\H8%<OB/G!
M[#+-]BE?YYK^WQC3S^!^4,"N7Q'S@]AEF^Q2O\\U_;XQIY_ PP*Y?$?..=&I
MW@JZIJ[5?8O=)RXO")O>*ZSM)!#Q$@NTU%XH[^RO!KV"',=J[=Z8-V[VHU:$
MD4WD',U>5?Q=I9RC1=9LK.\'"V6#*QM9(((_O9$\B+BVD964-!;W?/ZXW.<-
M4/!!5!U936><MM]GU;+.M9G52N/PK@T34%K$:PZ(:L5FK-Z84!AJ93ZTRT!H
M&E\; U](J2NF<8U@9!9XLT3>FD.V%@0 !86"KCT5))O[<:CRN;VUNLKD;\RH
M'E\A'@Q?@<FD#5Z+5X36;5V/&@Q^HZ<1;2M=/QU(-+ZE6G4:W6!\YU(1B6US
MD(6>DK\U2NM,G)B9J]I;4FK&0CX%Z$P\E1=!OF-0;6-L@!IIP-CJ+D<K+*_F
M^\CX]FO,Y\[[F<^#%J=?0HRVB;^TZ%6.HTFXZ:R%PJ:%3L=CM%*OM>H-:G$Y
M%]?&5E,C9HF/TSJ'L%L"8*MZ<5F^CVD*[A91Y%GC>#11"A<&Q!MD21I;F;\^
M.D+*O>V?6/JWLY1KRH^!\TST[:3P4!>R5N8FM,-?]*&\\HC!S4A7H'6:/AZ[
M5I6N'EUG)X>T:.TF#9T:K3S%5%Y8*TL^86\99-9L5G.]N;E5\TDY'.U\C:U[
MDW.AY6A8VMAY?A<C[;]GC&=>/!0Q5VM.ITHO9'S*MZH4.#TRD((*I67DQ7Z'
M"Z21^CPUBM6Q>2!S'QC^ ;RKUTD>,7.60LDV9!1)-PF"4!Q(L>().AM>Y-[<
M_A8#*'I<4WO[1?WZVZ[GVP^"^#:1KNGR^G^E\_(Z=M"\4#3BAC)!"M5:?<H6
M",?(3<'5IKQDX(O:H:LSK.)6K#Z==N96#@:W4ZFT<>(ZU&()1C!-U&_HX+9C
M+V:V]HT)N=<X65_-[+CCJ<NWJOEEE&FE? [QA5[X#?4.UN4-1M.[#0K%+6"L
MTV8O!%[BWU*D+C:H>TME8EG#3-EONKM_U!>-F%=2B&<S/KLHAA'1B+5!#+>@
MD'*X5<"QPVRL+<<@!<G36\!B%\M?:+^.O?<C6-F2G@L:,UUBI>K&GD7&T-*I
MP[:,7JZM5B+<E,O2V""EY"S.+%/39I[V3R$54Z?5@E)!S+ R@:E ,6K<K6/0
M;%C> IPE1.G/4 @9: 9DV%LR<\X *XB]^9&G+ZRR&64:GHW@;66E%HI]WTLU
M:U%JUKI[;2E5G(R4-2+4R/9-.=(]2])9NWI0DPD,4WF]14]1AO=I(=LZCE=0
MJW$6$[%T*KYNXDN@@A5B#BX$9$@V[+6'LR]L+*_FGV^D+'KTUXYY\8NB? R5
M*!+;H>,MMB6J-Q8T.%D6<[7JO-V\*Y2Z+0=.Y""]FRSQ!0S*[U^E2"UK*2$0
M*XE[Q;7S%-DB\09H"Z"03J,\@0-2<@!E:]AGH!>\+&Q&'77,7OU^$;_T.\&W
M7M!IFA2%6DK=(QFG-\UNOM;A)IQ$.46KW5J$KM'KT65V4Y')8O2;2NNM],Z8
MGN9=2MJ%"06.JW2 8+@.I&82#Z)%[9W/M)SZ]-3>"%<N7$96X#V==^TYQ.;V
M&6;[%*_SS7]OD8T\_@?E$8%<OB/G![#+-]BE?YYK^WQC3S^!^4,"N7Q'SCP)
MF@V]RHB*$*LH!2& P@X9!L(F 0]\Y#_-C&GG\#\H8%<OB/G$7.)7@JE.)FI5
M*H6?QM"1U2U"A]1$DFL;1;)'S<C!PMBB6$588&YQM@@Y6&26L/CHK99ATA)F
M'B'150(V426D.!-['4$?A Y\B+<+CJ,,*AP^(B(B7@5=,VE?"-9+:@!9$(>1
MJ\=J#(FTXE;=%5&0X;TN'0E;C%7=:&(C&D.@FIJ=6W,7%,'M9U!>2!8)>/J$
MB^JSC+?9ZY99 *%[*Q9\\\L[Z9W.<965P&7*XY6O<6^NLQ[8^!\JCJ,A(R1E
MM06R%-;\] ;452C:4P]6L"TO4I5_;7==TWBJW!7>>?!0J;&J'OS&RL48V$Z%
MNQ25?/5E0= T/7>Y.EM>TGM]D191-R+]OMOEG&2S\$;&5MX66T]M^J%!FI.[
M0FI]ZD(L^G<JEJ/J=5M5;7J]5M0+=%V&ORD8ZLL#9;G+LFSINU02<032MQCU
M%PG5X0S1OM+D&PPC)0L,(%LN&5[<[\23#"K/+7VC+J[NJ'-5_!60]3=&086C
M5]Y4YVV4G4;4VF2DQIV[C=7-3:)>I?4]A=[K*DJ3>QM5YW468/<[96J;+U6G
M3$PP8H(5^.A'$]#SD%T&_J@V(!LKT01AR!-C9.0)!58G,FQ )4.''F/KASC5
M5+\"-I-1R5\C!34^2+"T33V@/"3<[5)%&QQU"UF<:MEDIU \45)S,S,0Z<:+
MJ/$BH%@]%W+REUM**2>.'1\B_?7#J5>J;W(M\/6]JLR;PPJY>S7*W+6_QB:/
M#5P5I\+.F8:5Z>QEE?UXEIMMH2=6:8C9.7(-FFG,@SB#/4SMNEC*M#C%U&OE
M53.Z1KT#%(O'#MVFLZ6P4X%&Y.?4?K/4^V(PJY?$?.-_^UQ=?L"O^,L/G61C
M3S^!^4,"N7Q'SAJ2&E&H2SQ=1.M.#D.8HE,#N-#?8A0'L%Z ]X"':&0%)Y\3
MP/,PPJY=T:9UNX0[1KQIW+:66R/M<73[,[B"6]K5Y]A!R-EKD?*-).2J#B9:
MO"RD;"6@C,L/8585U'2[B#<R#!G),A>'7+D%@&X.8TRT//34<+Y>R&%7+N^<
M:#T\\&78]*)R#FM/KQK77?%[:4A9MN:PT*Q.;?4'.MU_UUBJI-V"WP%BLZ36
M(L6I=LKJLU%3+"SSM1?E9S<T\F&K*<:R7018V]Q%O1">%AH!K?/K-Q2H\+=1
M_P 8P[3X+0EOC)UA+.-0A<S->XFXIM*HR-,!]"3W%#JG7M6+/=XSI6"K<;-3
M9BJ5Z(HIWJ+N.CH*/!M(L91PNLY-.^'L_!X'/ G"+]8O?VGA# KE\1\X9$;X
M':$@Y%M88&8UJBK<RBYVO-+&2_1SGHJ[,Z,7O1]./5KCHRE3=R3)SJ/;M4SV
MQU!JVV4U2GYZ?E9MVPG9*(6G?WUM;++#;0@WTN#D$\@D6 $,*N7Q^&L/5]X+
MF22O3+4NEV;573>\PU8K="KM@JCG2YTK7]/JYIW[7C>IQL?;JI9X@B71+/;0
MSE5(\\K%V5XN9DY)!N'\&^C>IT-B-;'%J3>^5B.6NE_99A5:UNZ/,T@\$?3=
M$M2=/=3J3!7A&8TW):V\,P>V&#<QDBSF*;&Z<U%"?*8 =RJ^E^G[25J=(DEG
M02:4=:;*I,.Y1S)"JF+UP1?6U\CP)-NHDW(]@Y1.%6EA\/GQ]L3V]J/47XLN
M?QR,^>YAC3S^!^41@5R^(^<6*:1:C&34 *PY$1(8 #KD9VB)1 /^6XQIY_ _
M*&!7+XCYPT/:1U3^*+O\=B?^T,8T\_@?E# KE\1\X@SJ9X)@-6[I==0+F;5U
MU9;\G:H6>59WR.:Q"=%LFD=LTA9T:*JYW#BJQ\;6&%OD[9"R_B1>QGN"KQY*
M2TA%2\M$/,P\$VM;*Q&1U!!N?;D!U90PJY?$1M<G ;JZ^6H4G;KAJ?=[#IU:
MK9<J_.39]+H\S6<LVFD]I6T%M$5:OUZ#:,ZW7K//.XA%&.ZRM,RKYY*/'Z:P
M-B1O$B]K"X MZ1T(/&^I&??#"KEW?/NB-ZO@6X<("6@&:.HS9K(:2Z7Z1LTU
MY*C23"(C=.V]#BY>QMH>08KQCNSZF5O3.EU2]OI%N[1<5V,=1L.VB4I>5ZWE
MOL[WXD\>-\A[!>X]NM[0PJY?$?.'Y=_!0+:CZ;5'2FVM[VC3J;$:FMXZ(HDE
M4]+8YS9=2XV3KZUSD([3PM>9.92NU:P6FN1429'V,2+&USRMHA9YTZ15;8AV
MQ)!S-L[< ;VT]@OEP$3A43>WQOWDQYG]R,5"XS.HA5]327NP5?6BN3%D+-4X
M'$@XU=:R$4PL;EKU;JBL_I=7INQU[3YT=(R+.+L4NE+(2IW '*WHM;*UP;6/
M#4<['*^>=@=<XC"KEW?7URCV;)X)N.M3:])247JFT<W"-KD-&N8'44T"QJ45
M4=/:EI_6F36HQ\LG0KDE!EJ:=GB$]3ZG>6\399B:=QC=FW>&; #H%M,N8.=R
M3KKQMD1< 7OK#"KEW?1@N_@L[EJE*0-BU1NNN%XLU1&+<TV7<6NGUEM6I1CJ
M1!ZG/'S>N4AC6:O+I2$O4*-&!&V.'F64?$TV(69IDL"\M.R,[T"X39-]; \K
M:FYYGK)X6$,*N7=\X8-<\#*C3)R$N%0D=5X"[UM+3I_"69*4TZD1:W:D1-C@
M)V^*P4S"R-<=3NIT+8>I7M)6*\7N58B%DX9M$2K$CT6^%B,K&_ C6UA?6P(R
MSYWUAA5R[N'^<>M:/!#3-UL&H%AMTS?[3(:F5N,JMKF+#$:*R%N<PS33:*TR
MDVK&X)U)I+PK>RQ+&3DIQA"#&Q2LI:+&5DP91;Y.-0;U-A:PL;BV*PSOQSO[
M;Z91("QH/CWYYV^LH]6V>"+8671:V:"1\+;*=I_;-3[MJDNUJBE#CGK*5N5>
ML,0C%HNSLEA>1E1DYQK/5!24(^DH?V+U.O$?*5B":1)0> (/$ #CP-^%NWG<
M\X85<K]9!\8;>EW@;6^DE]K=YK3>U2)ZL:)"*BK;%:3VDK).$O=MO+!2+FY6
M#5L$+)]):&T*\G8J2:S+^.JU:<NGJDLR5D%Q>!%K]=@>0'&_+2Y%R;6RLLKE
M[-0.?(@<>7C#C=^"05DYZN6>6=:N/INEV]*]4U5*Z145&P=E><12G$S;I%Q!
MQ#AE#V52\7U"OLIXMI9S*3>!I]73A$XJ6CUI9TWP]F?L.@3A O[!VPPJY=W'
MM^NTW9M$\#,_T\?Q-EK=FU2CKW7']6E:];V#315BLWEZTGJ"V6G)^%2IQH.[
M3UB8:H7%A-S-N92SY)%ZU<0*D(_9@\4G?BQ%A8@BWI<;:9Y 6%O=<@P*5'AW
M?/M/,PZHSP2UEA8+4VGQMHU3"EZQM&+?4F$?GTM?O;6XZX\F+/(O[ :!1DT'
M%XL<Y;[)96L89A#FE;E/%BXR-CE6S!O&]%P>(_K<K#P]N6L1@5R^(^<>]J#X
M*^:U"Z$TD%HYBZU7W71VA+1>EUNBY&W7BL*4E%%["VN(EHM9C4J@H,!6#&;"
M^:-2D5<.W*Y"*%@.@<?P0!KP-_\ ,:& 2H</C_C#[TK\'5:M*=6+=J]&!=)6
M<MT$XK;J)<!IG P(1:LTRF(_QFUID%6E[7)55M'M*K2)NVN9N7JM(2/6&#TS
M5R[57%T%(3E8>P^W2][:YVM<YG@ *5<OB(E![2.J?Q1=_CT3_P!H9CC3S^!^
M4,"N7Q'SANS>@FKCI1 6],>* 0AP,(/X8-A$P"'OI(OP>3&-//X'Y0P*Y?$?
M./#^AZUD^([W\HPG_:>,:>?P/RA@5R^(^<'T/6LGQ'>_E&$_[3QC3S^!^4,"
MN7Q'S@^AZUD^([W\HPG_ &GC&GG\#\H8%<OB/G!]#UK)\1WOY1A/^T\8T\_@
M?E# KE\1\XCC>/!SZAW:3O<\HRN\)8+I;M&KFA+QC^BN3UR2T*DH^=HS*.8S
M2$I&OH<EA:/)J083+1^*CV8?K,5X]P5DX:9!T"WL"AH=%"Q^$,"N7Q'SB-SW
MP(3>3ME:N,JUU5E):MRC^8$7E@H((3TA.V&J6RTKV!LS8-&KX+)9(>VS;QNB
MW:L6$EJ19G4*TC3LJWXERWXS&6?6=+VUOI?46R%CD3$X5<OB.(MW0[TO [O7
M3:E1-L8:BWVLZ<-8:NTBJVN1TV5A(.@0MGC[DG1U4XB*B'<VSDK%7J4\FIR?
M=RECD$Z+6DQE$E0F7$P+P-^%];7S-K7_ ,/;U6C"KE\1\X6L7@?I&SZ;Z?:6
M2#35)E5=*:';*=0$*Y;Z]5%(B9MA3-E]0Y4M:<1;>V7)E&&4CBJVA"5AI4)*
MQ/[!$2\E9)9TO&^ OIF1?+4#@,C;L]G(1.%7*_78^,.5UX)]P=!:5CJ5/0VJ
M!M5)G5]MK&S-I\[OK6S3&I3_ %,/'=+--96%<5=)^\;0(P*\29!Q!0\(953Q
MY$QTRU%X'E;"$VL;9 "_.^5]>)B,*N7=&=IMX*GVOKG(:B/].YG4:\OGD=,E
MM6H3FCRTJRL[6TW:\OK4P*P2BHYA-RERU"LT]TC"/:-(119@QK+2%CHMDU2@
MN@\;#/(7TL!;VY #/MUB<*K6MEUCV^WVQX#SP35M=PK:O$<ZJ1\1):=2FE6I
M32/E]-BCJK2IVYSU\L$;8W3Z(?OX1:PS=LMS>=D*4[K3V0AK/),S+INVT)(Q
M$[X:^C>]P;*R-K9=61 -\P.%P8P*Y?$?./*5\$/;EKI*WDTKJRWEY6R.+2J6
M*=Z/PC49L*GJA4H2<D&455FD=9+/6FNJ#AQ%6FV,9V:6&GTMK+N9-HPETIMO
MAPM_^7,*MKD"1\3V,*N7=\XD!H-P$ZB: 4U]2ZU7K%*QTA9I:TBF_7HT3&1+
MF839IK1-5K-63@:Q4ZTAU(CAM 0,2S8$D7<I)F(=[)NU5(4XE1O?O)/M)MF?
M:88%<OC_ (QNOZ'K63XCO?RC"?\ :>8XT\_@?E# KE\1\X/H>M9/B.]_*,)_
MVGC&GG\#\H8%<OB/G!]#UK)\1WOY1A/^T\8T\_@?E# KE\1\X/H>M9/B.]_*
M,)_VGC&GG\#\H8%<OB/G$\>'2IV&F:>##6:,4BI/Q])N^JJJMEC=7739@DKS
MM5ETMCBF< #I.8.7W10W#>M9!.7*+$ @9\XW:N_9-3@FX=(HG$H& JBA2F$H
MB( 8 $=Q#<!#?NW 0S-#+KH);;6L V)2"0#ROSS$5N3##)"77FVU$7 4H VT
MO8\(Q_',4'?(-/YXG^O,_))G^@<_-,5^6R?XRS^D3\XIX[B/LBS_ )\G^O'D
MDS_0.GJ0H]PAY;)_C+/Z1/SBGCR'^R;+\83_ ->/))K\7>_1J^4/+I/\99_2
M)^<5\=Q'V29_SY/]>/))K\7>_1J^41Y?)?C3'Z1/S@\=Q'V29_SZ?^O'DDU^
M+O?HU?*'E\E^-,?I$_.*>/(;[)LOQA/];'DDU^+O?HU_*'E\E^-,?I$_.*>/
M8;[*,?QA/];'DDT=)=[]&OY0\ODAK-,?I4_. 9V&#ODV7XPG^MD^13?XL_\
MHE_*(\X2/XW+_I4?.*#/PH=\HQ_&$_ULGR*;/_LSWZ-0[Q#SA(_C<O\ I4?.
M*>R"$'_QJQ_&4P]9L>13GXL]^C5\H@U&0&LY+_I4_. ;!!AWRT>'G=(A_P#:
MR?(9PZ2K_P"C5\HCSE3_ ,<EOTJ!WF+?9' _9>/_ !I(?4;'D$[^*O\ Z-7R
MB?.5/_');],CYP>R.!^R\?\ C27ZV/()W\5?_1J^41YSIWX[*_IV_P!Z#V1P
M/V7C_P :2_6QY!._BK_Z-7RAYSIWX]*_IV_WHH-EKX#L,S' /P"[1W_.QY!.
M_BK_ .C5\HCSI3OQV6_3(/<8I[)J]]FHW\;1_6QY!._BK_Z-7RAYTIWX[+?I
M4?.#V35[[-1OXVC^MCR"=_%7_P!&KY1'G6F_CTK^F1\XI[)Z[]FXS\<1_6QY
M!._BK_Z-7RB?.M-_'I;]*CYQ3V45W[-QOXVE^MD^;Y[\4F/T2_E$>=J9^/2O
MZ9'SBOLHKH?^.XS\<1_7QYOGOQ28_1+^4/.U,_'Y7],CYQ;[*JV'?.1GXXC^
MMD^;I_\ $YG]"OY1'G>E_C\I^G;^<4]E=:^SL7^.(_K8\VS_ .)S/Z%?RAYW
MI?Y0E/T[?[T'LLK(=\]%A_\ /$/U\>;:A^)S/Z%?RB#6*4-:A*?IT?.*>RVL
M?9Z*_'4/U\GS;4#I)37Z%S]V'GFE?E&3_3MCO,'LMK'V>BOQU#]?'FNH_B4U
M^A6.\0\\4K\HR?Z=O]Z*>RVL!WS\3^.H?KY/FNH_B4S^B7\H>>*5^49/]8;_
M 'HI[,*L'9[((G?_  U'];'FNH_B4S^B7\HCSU2?RC)_IT?/ZUBGLPJOQ@B?
MQU'];'FNH_B4S^B7\H>>J1^4I/\ 6&^[%>*>S*J?&&(_'D/U\>:ZC^)3/Z)?
MRB//=(_*4G^G1\X/9E5/C#$?CR'Z^3YJJ7XC-?H5_*'GND?E*3_3H^<4]F=3
M^,</^/M_U\>::G^(S7Z%?RB//E'&1J<E^L-_O0>S.I_&*'_'D/U\>::G^(S7
MZ%?RAY\H_P"4Y+]8;_>BGLTJ7QBB/QU'];'FFI_B,U^A7\H>?*-^4Y+]8;_>
M@]FM2^,<1^.H_K8\TU/\1FOT*_E$>?:-^5)']8;_ 'HI[-JC\8X?\>0_7QYI
MJ?XA-?H5_*'GZB_E21_66OWH/9M4?C)#_CR'Z^3YHJGY/F_T#G[L//U%_*DC
M^LM?O13V;T_XRPWX^A^OCS15/Q";_0.?*(\_T3\JR'ZRU^]%/9S3OC-"_E!O
M^OCS15/R?-_H'/W8>?Z)^59#]9:_>BGLZIOQGA/R@W_7R11ZJ=*?-_H%_*(.
MT%#&9JLA^LM?O0>SJF_&>$_*+;]?)\RU;\G3?Z%?RB/M%0ORM(?K+?[T4]G=
M,'NM$&/_ -(MOVF/,M6_)TW^A7\H?:*A?E:0_66_WHK[.J;\9X3\H-_U\CS-
M51_[NG/T#A[A#[14+\K2'ZRW^]%!OE,#OL\)^4&_Z^3YFJWY.F_T"QWB)^T-
M#_*U/_6FOWHI[/*7\:(,//(M@]9\>9:M^3IP]3#A[A$':*A#6KT_]::_>BGL
M]I0?^5,'^46P^I3!HU6&M.G!_P#3N?NQ'VBH)_\ >]/_ %IH=ZHH.H%(#OM4
M$'GDFP?_ &\D42KJS%-G2/\ EW/W8':.@#6L4[];9_>@]L"D#W6N"_*3;]ID
M^8ZQ^3)W]7<^41]I=GQK6:=^ML_O0>S^D?&J"_*+;]?'F.L?DR=_5W/W8C[3
M;/?EJF_K;/[T4]L&C]WLK@=_Y2;?M,>8ZQ^3)W]7<_=A]IMGORU3?UMG]Z*#
MJ%1@[[; !YY-J'_WF/,=8_)D[^KN?NP^TVSWY:IOZVS^]%/;#HOQNK_Y4:_M
M,>8ZQ^3)W]7<_=A]IMGORU3?UMG]Z#VPZ+\;J_\ E1K^TQYCK'Y,G?U=S]V'
MVFV>_+5-_6V?WHI[8E$^-T!^4VW[3)\Q5DZ4R>/_ -.Y^[#[3;/?EJF_K;/[
MT4]L:A_&ZO\ Y3:_M,CS%6?R9._J[G[L/M-L]^6J;^ML_O0>V-0_C?7_ ,IM
M?VF3YBK)TI<]^KN?NQ'VGV=&M:IGZXS^_![8]"#OM]?#_P"E&O[3'F&M?DN>
M_5G?W8?:?9W\MTS]<9_?BT=2*"'?<*Z'GE&O[3'F&M?DN>_5G?W8C[4;.?ER
ME_KK'[\'MDT#XXUW\JM/VF/,-:.E*GC_ /3._NP^U.S8UKE+_76/WXI[96GX
M=]RKGY5:?M,GS!6_R5/_ *L[^[$?:K9K\NTK]=E_WXH.I>GP=]SKGY5:?M,D
M;/UPZ4F?_5G?W8?:K9K\NTK]=E_WX/;,T]^.=;_*S/\ :X^SU<_)-0_57?W8
M?:K9K\NTK]=8_?@]LS3WXYUO\K,_VN/L_7/R34/U5[]V'VJV:_+M*_79?]^#
MVS-/0_\ +.M_E9H/J4Q]GJY^2:A^JNCO3#[5;-?EVE?KK'[\6CJ=IX':-TK@
M?_2K7]ID_9VN_DF?_5G/W8@[5[-#6O4K]=8_?BWVT=.OCK6_RJU_:8^SM=_)
M,_\ JSG[L1]K=F/R]2OUUC]^#VT=.OCK6_RJU_:8^SM=_),_^K.?NP^UNS'Y
M>I7ZZQ^_![:.G7QUK?Y5:_M,?9VN_DF?_5G/W8C[7;+_ )?I/Z\Q^_%/;2TX
M^.U:_*S3]ID_9RO?DBH?JKO[L/M=LO\ E^D_KS'[\'MI:<?':M?E9I^TR/L[
M7?R3/_JSG[L/M=LO^7Z3^O,?OP>VEIQ\=JU^5FG[3'V=KOY)G_U9S]V(^U^R
MW^\%(_7I?]^*>VGIO\=ZS^5VG[3)^SE>_)%0_57?W8?:_9;_ '@I'Z]+_OP>
MVGIO\=ZS^5VG[3'V<KWY(J'ZJ[^[#[7[+?[P4C]>E_WX/;3TW^.]9_*[3]IC
M[.5[\D5#]5=_=B/MALJ-=H:./_KY?]^*#JKIL'?>:P'GEV8?_>X^S=?.E'J!
M_P#I7?W8?;'90:[14?\ ]0EO_P")#JAYR'L+/QA!R;*68BH=$';!PFY;]*GM
MTB?2I&,7G)S!S%WW#<-^_-=-2<U(N[B<EWI9["%[IY"FUX57PJPJ -C8V/&T
M;B1J$C4V/*J?-R\[+E:FP_+.H>:*T6QI"T$IQ)N+B^5X95R^N3?_  ,GZ9;-
MA3OXA?\ :G]A$:>K_P"M)_L4?M+B.>O&N.EG#=IG8M7=:+C%T6B5=J9P_EI1
M405=N#)G,SAH2/3YGT[8)51,6T1!Q2#J3DG(@DU;J"!N7=R4K,3KZ9:5:4\\
MXH!*$9VYJ4KU4(2,UK40E(S)C5AEQY24(222"<P0 ,O2-]![8XU:&>%UU0LW
M&%?-..)+1:%X8>&Y#A=M/$UIU(WY*81UK+2H"7C"1EAU#;(3[Z%B2V.ML+C.
MHTAA5RV)@<L$Q2E)8_,I*=D>H(1(-/R<SY=,&H(D'4L6+!>6DDH:5A!5@46T
M%TJP$XC8<.<]3D)9265K=?WB6U)R"+G(X<L0L2DFZLA<D :2WJ7%SQB:XU2N
M:L</7!76EM&;<>,DZC-:^\0S?274&Y4>5<( SO,?0:YICJ:UK<"^C%O'T86R
MVI&=D83H'S6OG,^8H.. [)RTJXXQ,SOW]K$EU,M+EYIMU-\39=4ZR5J0H8%8
M$%(5EC-B1Q52LJA>!V95O4^LEIK&D*X))QI*CPR%KY&(K47PRD]K=JS:]-=!
MM'=$+.V8:H2>E]!D;[Q.V"BSNJCF((U1<VVJ5N'X=[PF2E/'QWQ8>;D9EMUJ
M.8+R3UO&D2=(-><]07)5A#TTN81=A+[N[E$N)8"KV;<4J:;LZ!8J2$FQ4$@G
M*]QI2$("G'70<.)02R%!'_"3C OIIJ2+7N(Z"\%_%M)<8D!JKJ%%:<I572&K
M:GSNG.D]_+:59PFM3*GJFC;3?X6+/6H7Q/3AL":T5671W\JZFBLY!5XWAUV9
MF9]=/R*I!;3+B\3ZV4//-8<)ERZ I#2SB-W,!2I8L G$!=6L:^;EDRQ0@.%;
MJF\:T6MN\7JI]8W.M\@!E;6(X:H>%6HE7XCM'-$M,]-YG5FB7W7JL\.5\XA(
M^=;PVE5&U4MH+GC:56),8F6)JA:8E)HY5N3."=1\/4E#QT;(3QYIZI&,^6U1
M9A<L_,.K2RMF45.HEE)*GW)9! +RD7&Z;)(W96,3@N4(*1>+6Z8M3"W75X'$
MMJ=0R02M2$C,J%Q@!)LDFYOJ!#R+Q[VB.OR]<F])J=+TZNN;B.I-YTSU9F+J
MEI7$4INX7E)*\,Y/2:I1,:[4.W!DR@@LAI60DS>+HU)V[.V2<]=$Z0Y93:%)
M2%AQ;3I7NPBY)6-VD G0)O<G(9Y&/-J2UB2ZXE:]WN6WF4M[Y2S9(;(>6H@7
MN58<(3Z1-@;:TFO"A6& BZ1+R7#?+ QD(&O7C54[6]%<FTAH5XMK>OT&3F0"
MFIED[#:85=&U(5L#QO01\G!I%DG!GSM6-P54L(2HLFQ2E;EE$[IMQ02V3Z.:
ME)./#Z-P4B^9(M31PLN)$R+A:FF;MV#[K2,;J4_?,DH4"@JSS"O1R&*8^E?$
M+*ZJ:UZK::0U.BG%&THCX1*4U5B;8M)Q<K<IY))\WJ,5%J5MDFY5C8DSAS.R
M",RL6+?)H1QVBG6TG.<QM\NO.MA'H-807 JX*U"^ #"+V&:B";9"V8,:]Z5W
M###JED+?*BEE3>%0;3EC)QFV)7J@I](7-\C$GC]WI^0<Y2/6';W&. YP[?"$
MQ\GF^4<M&IZ_ 17"!_?#Z/4&3%*_6/9W"+<1C" ]X^<?7DW/,^^$)*>^#[DO
MJP=3UGOA">1%"M3UF*#W#YA]62-1UCOB(0R^$6G]Z/H]89DCUAV]QC%?JGL[
MQ".713%A^[T_(.8GUD]O="$LRA!EC?'L\8K<X=OA"1^_T?*.0O7L\3$HT[?
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MG*9(KJ<Y.2(>39\S4NVB6D'T(>ES,SDLXX=QC4)+4:+U$MR0V*6N]H5DG/\
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M*932.NZAI-HWBB+"50I2-GIH^337>MP.90Y$C-U$Q$"*")3&YM%./+6<"5)
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MC!<J)LV;"#5.:+0,LW32?.'+YBI+IG<%0 S(A5&Q[%("[*5C%[9-J*0#Q](
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ME76"I2"47"DDI(6!Z)!X<";Y6RTM'6"$"0G$1*H[Z-NF( 4"" <VP 'O2]@
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MU-EMM-(6&W\"DJ=>+K3GWENSL)*YP(MWD"#L80ZPF2YS+*@H90PB7<1YA$!
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M&H:D@J9)95LUK$N-F,U3!=[6(\3]&$NS<]3T#SU)*;8("A5)$+F) A0!O,(
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MVIP!*3+@J+@39K+[ZX4,M8W7$(4WW-OXAG)@*S\-UI^45#"FF*?$QQ=&*=0
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M,'>N-I4H9(*DZ.#A,E8E(8T53)[;(CWAVAL00  'X2]VX;=NP=^3MFP]O)@
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MI4"4(8F+DVPXB!?$8F-_<X?#7_\ 6S-O\K[C!#UZ>9YY\HH'^XS_ /Z71O\
MNX]E_;+9K\MRGNF/_P"'&2Q\&IX;F3>M8YCX6!%T]>K)MVK9/B_XO^=9=4W(
MFF3FT^*7F.8>4.8P!V]HY6].;.,,NS#VQ#R&64*<<6JET:R$)%U$_P"EDY#D
M(NE]JZ!-S#,K+UB5=F)AQ+3+20_B<<60E*4W0!<D@9D"/F9T=X==>>(K4=73
MG0_3BX:J7LCQ8SQM4XYT^)'@F[.BK-SLTJ"$;78DKDACK3UA?1D<@/NW#M(=
M]N]3=1D*?+)F)V89E6%) 0'5 %=T@AMML76ZNQL&VTK4> ,;FQS5>P2+J42
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M+23BBI-#VPZ1IM@[024QLWLNVXEZ8E9DENJ5()4%B7#'KR[2_P -QU*!A5=
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M0;0Q]19NRP[ RL"4"G!,P@IT)%C<P=H#LH0Y=@^#EW^$?AYRUJ3< X>1RO\
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M)%*X6+4FXTNQSTL6R2<<HWJ_CQ\X=)C),'!E3,6PR1UTDG3AH<XQYBE*<!(
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M2"9+/+I'40BH5_(+;#(&>R(-W7.!7A.C>!2EYQP.MH&[+2@A:W2D.#>#$FR
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M:H^B7I+LY*(F3*HGES+.+=!P?6YH1P\4V J$?&UN"BH)@S;$!JSB639@@@(
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M"2BQ4&9 1;E**AQ79K-V?7R]%RH@OTJC0[@0*U(502HFN#N))(F#>X )0$Y
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M1.,C$$BU@F]K"QL(5:Z:U9H=Y&TNKP]?9O!VD7,;'(M'$F?G P"X5(7G%'I
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M7DRV^VI2KX">&0N"%:^RXO8<18F]]=M3M0W/T]<LRG<M' H@KNM>%25)"K6
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M:J_81':ZO_K2?[%'[2X92_<7SCZLV;?'L\8T[G#M\(L)[T/3ZQSDHT[? 17
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M*2"N-4(^$'XA-/WU+6U8JFFELCI2L:%,;3"Z;4BZ5JT-=<N(71O7#4FC:+P
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M+\,N46&X9J^;WUEF!V__ )9D'J+F0Z09P:4Z5_2O1!Z)Z8?_ 'K/?HI?V?\
M#[(M'ADKX_\ E+,]@;?[V9?JY/\ "%._D^5X_P"T=XYQB>B6F'_WM/</]E+\
M,N489^%2HJ"Y$\W(&%Z4I'O-'QANN$(42$(ZYDAZP0A!$A2J\Y2D$2@  (AC
M^$&;]*],DSBR5=;IN,]>>L9?P42 PVK-0&#-%FV?1)SNG^:>JT5-PK5,Y%4S
M3LD9-=($%TQ81HD71*04RI+$%+E43!,13!,X"0"") #E'; Z0IP CS9)V5D1
MC=S%K 'F - 8C^">GW!\\5"X-P=VQ<&][@\#?._.,5'A)I#=-1%O)N4$EBF(
MLDC$Q"::I#;<Q%"$0*4Y3<I>8I@$!V#<!V# Z09H7 I<B <B IP7'(\]!$GH
MID2036JB2,P2ADD=1.D+!PHU HIF)-ORBBDJ@D(1T8 I(K" K(IB"0"FDJ)2
MBJF78B@@ F 1 ,G^$*<R_P#+)(6! LMW('4#V'B-#QC'^">GG_WQ4,R"?O;.
M9&A/,CA?2*?0HU/E,4L[(%*=!-J< CHT .U2*H5)L8 3 #-TRK*@FB.Z9 4.
M!2ASFWG^$2=%_P#RV3S2$GTW<TC1/4.6D0>B6G'6L5#4J'WMC(G4C+4\3J<L
M\A:P_";4E.43SL@<2(J-B&/&QIC$;K%*59N0QB")4%2D*55(NR:A2E Q1  V
MG^$6=)!-,DC8%(!6[;"<K6Y>R('1)3@"!6*A8D$_>V/6!N%:>L.!UA+Z$BF\
MJQ/';[D<$,DX+XKBN5=,QSJ&36+T6RI#***',0X&*)U#F$-SF$8_A$G,QYKD
M1?6RWLQR.>>>?62>)B#T1T[+_P ZJ0*3=)"& 0;6N#;+*PRX "+QX3*D8.V?
MDA]T@IVQ\:/TQKL+53WG:=N)2B@;WR0E+R"7E#:?X19W\FR6H/K.ZBUCV6%N
M7",?X(:;^6:EGB'\7+Z+]8>K^%QYPD/"-3Q!$!GI 0;&YFX#&1>R!NE37YD0
MZ/9(W3I)+;DY1Z5)-3WY"B#^$6=_)DEEIZ;N6=[#/+.Q-N(!UA_!#3<__.JE
MGD?08S%B+'+/(D9\"1QB\_"7555"+*6.4.LF11--8\?&F5336  5(10Q!.0B
MH%*"A2B!3@4O, [!C^$6>N#YNDR1H=X]<7UL;W%^-HQ'0_3 % 5FI *-R-W+
MV)&F6&QMPO>T4^A*J@$03"QR@)MN3JQ 81P$;]&04T^A+R\J71IB*9!( "0@
MB4NP=F9?PC3N7_EDI9/JC>.V&5LA;+LC'^!VF74?/52NKUCNI>ZL[YFV>?.$
MC<(E/.5R4\_(F*]V%X4T;%F*[V("8=9 4Q!?9, ('2\^Q  H>Y  R?X2)W/_
M ,LD\];N.F_#/GEEGPB?X'J:,)%;J0*/4(;8]'^K_-[(H/"%3A$!&>D!Y5TG
M1=XR*]RY12(BBY+]*[%TD4TTDU@^F)IID3(8"%* /X2)W\ER6H5Z[F1%@",L
MK  #D,M(?P/4[/\ \[J>8*3][8S23<I.6A))(T)-S&0;A.K1]N:U3?9W;-&(
M=_?Y/M9D.DN?3I39//\ ^*]%2NA>D+M>L5'*_P#LI;C_ '?&+1X2ZSY+5.?B
MK$?DS+^$RH?DV3_2O?.,/X%*/^6*C^BEOW8WQIW16>G==+7&+YS((%>NGH.'
M2:2:O.ZZ/F)RI>XY2]&&P]X[COG2ZY6':[/F?>9;866FVMVVI2DV;O8W5G<W
MSCZ/LQLZQLO2TTJ6F'9EI+[SX=>2A*[O824V1Z-AARXYP^LT\=B@Q"#$(,0@
MQ"#$(,0@Q"#$(,0@Q"#$(,0@Q"#$(,0@Q"-)ZF\1^A>C4U&US5#4^K4N>F(M
M2;C(>8>')(NXA)V9B>22:H(KK R!Z0[4'!RE3,N0Z93"8A@"0DG00C77T=/"
M-_#S1OQE_P#,,G KE\1\X0?1T\(W\/-&_&7_ ,PQ@5R^(^<(/HZ>$;^'FC?C
M+_YAC KE\1\X0?1T\(W\/-&_&7_S#&!7+XCYP@^CIX1OX>:-^,O_ )AC KE\
M1\X0?1T\(W\/-&_&7_S#&!7+XCYP@^CIX1OX>:-^,O\ YAC KE\1\X0?1T\(
MW\/-&_&7_P PQ@5R^(^<(/HZ>$;^'FC?C+_YAC KE\1\X0?1T\(W\/-&_&7_
M ,PQ@5R^(^<(/HZ>$;^'FC?C+_YAC KE\1\X0?1T\(W\/-&_&7_S#&!7+XCY
MP@^CIX1OX>:-^,O_ )AC KE\1\X0?1T\(W\/-&_&7_S#&!7+XCYP@^CIX1OX
M>:-^,O\ YAC KE\1\X0?1T\(W\/-&_&7_P PQ@5R^(^<(/HZ>$;^'FC?C+_Y
MAC KE\1\X0?1T\(W\/-&_&7_ ,PQ@5R^(^<(/HZ>$;^'FC?C+_YAC KE\1\X
M0?1T\(W\/-&_&7_S#&!7+XCYP@^CIX1OX>:-^,O_ )AC KE\1\X0?1T\(W\/
M-&_&7_S#&!7+XCYP@^CIX1OX>:-^,O\ YAC KE\1\X0?1T\(W\/-&_&7_P P
MQ@5R^(^<(/HZ>$;^'FC?C+_YAC KE\1\X0?1T\(W\/-&_&7_ ,PQ@5R^(^<(
M/HZ>$;^'FC?C+_YAC KE\1\X0?1T\(W\/-&_&7_S#&!7+XCYP@^CIX1OX>:-
M^,O_ )AC KE\1\X0?1T\(W\/-&_&7_S#&!7+XCYP@^CIX1OX>:-^,O\ YAC
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MEO33N_FYJ:FGES$U-S3V% <???<6M6!MMI *6F6FF6VVT]R??<F'2ZY;$0
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M0@Q"#$(,0@Q"#$(,0@Q"#$(,0@Q"#$(,0@Q"#$(,0@Q"(N-/^&K8/_5<I_\
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MJ2MO>-N(4%H6C$E:%I(*5I4+%*DD I4#<$ B,5I;<0IMP(6VM*D+0L)4A:%
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M/853?BE6?R#%?-,0AP-FS=F@DU:((M6R!"I(-VZ1$4$4R !2)I))E*FFF0H
M!2$*4I0#8  ,0A;$(,0@Q"#$(,0@Q"#$(,0@Q"#$(,0@Q"#$(,0@Q"#$(,0C
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g393013g29a71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g29a71.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1N>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     % < 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 T0D]2("AB97-T($]V
M97)A;&P@4F5S<&]N<V4M1WEN864@4W5B<V5T*2!#35E+($-O;&]U<CA"24T$
M)0      $*KNM*%:SW )"(5Y:(/H .8X0DE-!#H      4T    0     0
M    "W!R:6YT3W5T<'5T    !@    !#;')396YU;0    !#;')3     $=R
M>7,     26YT965N=6T     26YT90    !#;')M     $UP0FQB;V]L 0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    G
M $@ 4  @ $P 80!S &4 <@!* &4 =  @ #4 ,  P #  ( !3 &4 <@!I &4
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M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!VZI-P        "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 \     !  (#P     $  CA"24T$)@      #@             _
M@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8             !H@
M  D(          $                          0             )"
M!H@                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!H@     4F=H=&QO;F<   D(    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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MLRH&QJ>'\>%+W_20(RW "'Y-C@X?G AFUZ3X/6JSH8QW@G602^MP;^[[]O\
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MYVZ][&_2L8I890>")%<)WM#Q?^+SZ'U@_P#3<[_T:L'ZJ_\ BBZ/_P"&Z/\
MJFKL?JE]6.O]%Q^N7]4Q?LU5V ]E;O4K?+@+'$?H++/S5QWU5_\ %%T?_P -
MT?\ 5-4P()R$&]!_T5=G_]7U!K<7#H.T,QZ&23$,8WQ/YK6H#,S&RK,=^/8+
M&N+B".XVG57$![6MNH:T!K=SC T&K7)*3I)))*4DDDDI22222E))))*4DDDD
MI22222E))))*4DDDDII=;_Y%S_\ PM=_Y[>O#OJK_P"*+H__ (;H_P"J:O>K
MZ*LBBS'N&ZJYKJ[&R1+7#:\;FP[Z*P<3_%_]4<+)IR\;!++\9[;*7>O>[:YA
MW,=M?>YCO[2FQ9(QC(&_5V4__];U#*W_ &>S9NW;3'IQN_L;E2Z=ZVS'^T^O
MZD/CUMG/N^GL_2;]G_6E\SI)*?JEVW:=WT8U^"Q,?['ZU?V3[?\ 9Y9Z>S?]
MGVZ1LW_X';_X']!?.*22GZ-.V3N_:? G;Q$-^CZ/M^C_ *);;/HCG@<\_-?*
MZ22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G
MZJ27RJDDI__9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '  ( !# %, -@    $ .$))300B      %^34T *@    @ # $   ,
M   !"3H   $!  ,    !!J\   $"  ,    $    G@$&  ,    !  4   $2
M  ,    !  $   $5  ,    !  0   $:  4    !    I@$;  4    !
MK@$H  ,    !  (   $Q  (    >    M@$R  (    4    U(=I  0    !
M    Z    2  "  (  @ "  W\K(  "<0 #?RL@  )Q!!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$W.C Y.C$W(# R.C V.C T   $D   !P
M  0P,C(QH $  P    '__P  H ( !     $   D(H , !     $   :(
M      8! P #     0 &   !&@ %     0   6X!&P %     0   78!*  #
M     0 "   " 0 $     0   7X" @ $     0              2     $
M  !(     3A"24T#_0      "           _^$!@$U- "H    (  P!   #
M     0DZ   ! 0 #     0:O   ! @ #    !    )X!!@ #     0 %   !
M$@ #     0     !%0 #     0 $   !&@ %     0   *8!&P %     0
M *X!*  #     0 "   !,0 "    '@   +8!,@ "    %    -2':0 $
M 0   .@   $@  @ "  (  @   /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP.3HQ-R P,CHP-CHP-   !)    <
M   $,#(R,: !  ,    !__\  * "  0    !   )"* #  0    !   &B
M       & 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@
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M([<K,,MET?9(O*&^P;HKA_9XV]KY$P =:;N:?U L<6=W<V6/.*IO?#H,)\3
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M3VWOPZ[7,B/R2[\\WI'V8C?>K7N>=<USZEPSNHGJE07:7Z;NU]J&?3G/YG#
M& , 8 P!@$6..OR1ROVH^X_WU^@< E/@# & , 8 P!@# & , 8 P!@# & ,
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M:WFJ&YR[.OU6C/,0N2=(X(QFIS2QB3+4J941O>RSR"C0B!H"7^ , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M2(3NB^M%LK=%4X5X;WO>_D[!\Q&O&3F# .]&X[G.NU<-MB4U',HU$FVS+TC
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MN:6+SL^%+HP!@# & , 8!%CCK\D<K]J/N/\ ?7Z!P"4^ , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M>;:O5A!JY6H6&$(.M^B6]"28I.&<,I$@1V*2D1)"Q#V!.D2DE)TQ.@$D%@*
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8!CX=L3J*13NA\3,/77)G+T]C2;F.ZWQH[77-,?B
MT\5Q!KON(0]YJ62H;=@[X[-S,@E3VALB N[:B 2Z%15[CDC:0R)_&XBI$NFI
M5Y.#5KR5.'(M[X]B,)@W--11NN[0CUUQ--&SG!';426,*V*V$XR!X<Y#(Y3&
M119P=HXEC[K)'1W/9FIE='%N9&[:=G3+51:'1PQ224P!@# & 18XZ_)'*_:C
M[C_?7Z!P"4^ , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MQ2C":,*50K0$\;.)*)2<1H!AZ0IP7E)C1")+6J@@T>,0<9<;N=K;IE6,R$P
M"U5>_>2V4IPV;(1IF6<%]CWR8V1QA5[J<!DEBRMS$J1KYFO1Q9U;D))#BG@K
MH>I,;$H$G1NUQZ1FF%P*MAN&H4B7DI3+9DQ:,RQ3#_1<8J8N#3)IQ4,2IO\
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MI.>D+L,M3Z#7%BEHZ73G'0U8C_UZ^>"0$/3:I_!$]=.A7X;@!<[7*6B=3&V
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MT 4,@6D7RX,;]J V5(!*M5OI+Z94MTCW502MS8:W\',K[UW3&6E_# V6:;^
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P"A_IFWSZE[[N0I1V&3QFWR:BJ"5I@MG.1MXI[A5M3M;*54
M_P DD#HVOK1$9%"23TL>0,+<F953S'7%O<W!3(=(T1,:#@[_ ,Y>WO<9<%04
MB#+:;KR2ALS[,@7F.IUFK0^29,%^6VAFG!^._D@G3(R6#X?T?@_B\M*2$OX+
MTO0UZ?GV!R]@# & , BQQU^2.5^U'W'^^OT#@$I\ 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M)65ZRJ!'W2<1UJ)3-D>G3O&0,SK-F!O2(D3)*ECNUID*(E*!*2()&8 P!@#
M(L<=?DCE?M1]Q_OK] X!*? & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M_(Q;" 0M $9L(1"T 'H^F/>M;WH ?3$ 'I"_N#Z0PA\^]>D(.O/O0&/YT)34
MTN:X[O=ZJI2\]2&;R:)IK3>TL!XML5;5+G8O--",L]@P7-=W96LJC5E1&+0G
MGZP8(\JF!\25Q8C [3"/$VS")Q&#$3B^?"5<6?)K3*_:KEKY=5T,@7!2, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M8QAX?H9(IE7#RG@+FTR"1!35Z =KO3Y^>(JRMGP]AODX;<%\\_ F2C@I& ,
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M!1)6BE"Y@<I$C4Q^,-C6>D>5T3&.+*'%*:F&0I'&ABC^C"]@9M[;0IL$'-&
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MC<89+&U^>XF[-*\L"%X.E;'%QER1]BS.UJ%;Y(V-A-(=WEE;5S8WJ$ZI44<
M$^?E<BN#PMB@1>Y[ZKH;3S2C<8['?4W<CG:L;)@:V.#BMO61"H\590)Y>-NE
M($5F0AFBUN4XC1$,ZI^A$H<G0WX5N;6M<\"56Z(O'PY9W[S;]DN]P0, 8! [
MQ%6(V74"U0<$$K";@G-N5A%MG71&99,:OA:]>^[/C4QED;A,CA\@<2RI<DC\
M<9#2)2PHVB3R1D?'1Q+;6Q4 P$RSXN+7R9HJ>'@.!/")D"=[J6U"DS53;<!'
M.X@J4ZH^ 3J 1IN>9#4, D,DA$O;9]:EL.I5L5K)')V@]A,Y#TB*CZQG0(5C
M<E=QN21()77Q=C+PI9$U]_E+;,$# & 5)>*^WJGJ)U2WD593LY&REW'9+?(K
MGKFR+1:61XK2NS)";#X5%ZTG=;.FK)GL-^6JN/+E\L3I#&R%R%B3-[BYOJ$L
ML2BV7ERX.'E13G_PWW) X\KQ\+4;5B]H:; N-@9Y#1T?D,=IZ7LS':DM;&F8
M5TFE$ZLEW6Q^2MR=,Z"=!S%W1+74]R$UGB;0)!C!=?\ Z]B)YK\>9.[! P!@
M%%7BB-*)XNV'+W:%\M-+7"*NB"UUN3I2M+5G)+;$+!MU9 I6<U/$&MZG6*(P
M>I9$HK-_M=P>7AW-3LUF,LA4)VUMC)HW(2B\&N_)[46_8+3>17L^2\K<X2%2
MRH(ZI>J.JUT4,32S.D=9V@];"V90:@9F)\=7UZ:F9,8,1;2A=WET<R&X*8"Y
M>J4Z-.&()$8 P!@&/?T(DIVK^I[=CZNE^'Y]$6&-0B6D*[3Y!F$M54!"*UK2
MF8D]08-A06L7&*$,$.C;K&;3*B*0]P>*TKZ0J95(#6F$#82&Y9%X$*DOQKKX
M%U]G7K[V?'<R#];T+6A!WH01:UL(M;UO6];UY];UO7WMZWK[^MZ^]O6"DZX
MP!@&-(WB P]V-<N6UCR37JN:=>*D;-'3:>NC?0<WD"/I*2UI.G-EF2J]&:&O
MEA,D'U5?1TB=BJJ.8$51V8KDB%$Z,T)2N,L%7!;RY>Y53BUZ]=LS);P4C &
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M$UT5/'H/>B-<J+#%&JW1$2SE5.)"IK&M^BEN^OM4FF/F6=& &6/L_K 0!A$
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M)^-Q_EANMW[-G\WXC*:\"&\^N_$8YUM^T.A>R[T)DT'NHV LNH"P\\QIMVQ
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MUO!"_KDQL1MLKZ-FU?*VZ7#Z>H$B-.LN3L]MD(8/'T+XXO8X6)6\#4*UD+1
M$\'#KX%3L<:+V"W^EI&FF-.5-+D8V\Q)*:S@DC2F-#*BC;4-.]Q9J<R1-D=;
M9+-&Y@;Q%J0[1LJ"8RQ&U)_@T*62OI! '14(.3, 8 P"F/Q%H-,?LAMDC8I#
M-*]KUDKI-8TI4TVS<R%25_:HY:4>0=%R.4GW'$I/*G-T@-.25JGT#"PH1QX\
MV.SA!*#CGARB#<X!\YWXNQX,[:RQ;DG4QUR]SYJP25A,VU3U?:D^G$;()Q.=
M]1AN];6.((T<HCJ9P7C_  U:A8E*MG;E2@U"VJU2-.2H,!20V , 8!3?XDT@
M2P:[^?9RP@;9!/TT"GL%+ACMQP?UH@/CMG6K1$2:'DT2CH;GYKKM:ILQ3"(@
MTC)>71SEBF2FEG(_BN/*52(3Q^]$X^-%^>4L+Y1F(I_SM5$O,1HVT]ZC7PJI
MM0UN53Q+8L3.*Y"L;3:K*GMGCKU<WJDIR-SB*R=R%S8W(A6@=CTKH2K;D8CY
MX/9D2%P!@# *J.EK&\1-@[.IJ+43"(P]\T'EHRK!FRN%29P;8H98VBXPQ?+-
M$DDZ1SL4V+R.+2!]7JJ]60Y+6\=EL:=I^0\-@MK# X.R6KX P"CGRC;YHKI+
M_$%$^_BN<^ZYF_3AAG[NO]0J2S4;R_[/I--9;G3QK1@# -L7X2WS9G"_LS55
M_P ,HLY)V7=,^/=U*S^JXVL>]Q]HWT4*>O*R?S#:%]KB,^YRY\^RYDGU_B'<
M>7UVA+53O?VD]IK^<Z$->, 8)36G*GG-R[5OY,JZ_P "1'_A]OSBZJ_S-1^_
ME_J.-N8:7E>GXR\%?H/I#]OI#/:.8]O>R#M\,]&O,6J^BWO^=IAGY[28(P"3
MG$_YYG)'M.4)[U(IFJQWZDQGN5B'JDQ<BWQG;(;?S./#:&O5\JY^<8JGV.ZY
M]\%]9T/S)>ERM[LU'J5 8-5]-O:^U3&1SU$Q1@%L?@8_.Q<7_K#D7NUF^?([
M/.E'&_X>+UJ R*;?$^?]+C::YRJ; U=WC\?.Z]C?I^J_<-5F=2\SWI/P;M*S
M_<:LUU1OJ\C?,4\9]F6!@&23Y+%\Y=)/9<M+_C.J\\TYJW2Q%W5I?Z%695+]
M-W:^U#8GYSD9QJ)?$(_/X[?]K[I7WSS3.O\ 8YTO8%W&POU& UDV^.Y5])2(
M.;DM# ,Q3R1+\I/</^!Z-_\ /K*SQKFP?Y; OW]?_3I3-I-3^5/,IFUR/\7G
MW]#.G["?GA\>^1]NWTD,LTP._P"_?^W?^_.U34+K7E7SG3! P#/K\DN_,OZ0
M]I]1[J:[SG[FN?7>&]RF^MU1L:?>^_\ \6EYOB9?-U]S^R7T![KI-GP>QKIB
MP+NOAWK<1=?]!W:N\RFI'SKTU2ZUY5\XP0, V6'DUWS3M._K"NWWEOV<R\TO
MINK?X>A]5C-E!O;3V'E(GS2E\_XRH[WP0[*>9KTWX?\ N:_U*<5&\O\ L^DT
MUG^=.&M& , VUWA?_-O\&^R'SS[JXOG(NRGIEQ_NQB/K<IM8][C[1OHH4:>5
MI_F=<T^TN+W6SG/N^9%]<XGW,3UJ M5.]_:3VF YGOYKQ@#!*:TY4\YN?HW^
M+K!^A6O]A(SBJ3?).W=Z2FW*6NSAQ\KI.RD=0-_7\INW44YQL62@Y^HB"7!
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M(FJY:RB5&HKW-15LBK9,[(J\"EFI15CLB*JZ2:L^,P.O[-?1G_0#=?U5SK^
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MV0X705=N<AGLCZJB,/;9I-9"OL-SI>MUT;9^>92X%P=F()EQSO:YR)Q<8_\
M' XW'(]*C$CT2TT$WRX,^QFG@5//Y+%F?&DW!8O,%.R_2V<.*ARC!B9T5V1)
MFB:S,Q]97=S8I"!XF; TL3', IWQL<$[9*FEF;&Z1,Y3>\)$2<A8 O0A23F
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M;^9QX;0UZOE7/SC%4^QW7/O@OK.A^9+TN5O=FH]2H#!JOIM[7VJ8R.>HF*,
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M;<V_'DKD[J[R)V"V-S>V%N#FH+;D")$$A,4(.4L 8 P!@# & , 8 P!@# &
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M4\RF;7(_Q>??T,Z?L)^>'Q[Y'V[?20RS3 [_ +]_[=_[\[5-0NM>5?.=,$#
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M9D5['XP3*GU(G='X#@M)+."%_GY\G$21P"+''7Y(Y7[4?<?[Z_0. 2GP!@#
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M4*=.6()0X P!@# (L<=?DCE?M1]Q_OK] X!*? & , 8 P!@# & , 8 P!@#
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M# & 18XZ_)'*_:C[C_?7Z!P"4^ , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M+W6SG/N^9%]<XGW,3UJ M5.]_:3VF YGOYKQ@#!*:TY4\YN?HW^+K!^A6O\
M82,XJDWR3MW>DIMS%>L?L'F+K.?QRZ!N?",<M%;1-5);"!:GB[]3<=S&'KG9
M3+7LRHE45K>MT+$Y+J^<35Y,K3+0H)4PR9P5M\G8&PSXL/7T%2(MM2_=1>_>
M_"9&G)JEJ6<X4^J8UL'<6@^'I!H%M;75*^C((I3[4*=!,C%XSA*BEMEM>]ZW
MHJ3/R4A>I'HPDPO02 ><4K\\'D)#X P!@# (L<=?DCE?M1]Q_OK] X!*? &
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MP&U,VRN00M,M7[21%1 $[TC"L6)V.7EP17K2J%:G#"2V3(434!"='1OHF@P
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MV!+C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@'II'^+S[^AG3]A/RN/?(^W;Z2
MTP._[]_[=_[\[5-0NM>5?.=,$# ,^OR2[\R_I#VGU'NIKO.?N:Y]=X;W*;ZW
M5&QI][[_ /Q:7F^)E\W7W/[)?0'NNDV?![&NF+ NZ^'>MQ%U_P!!W:N\RFI'
MSKTU2ZUY5\XP0, V6'DUWS3M._K"NWWEOV<R\TOINK?X>A]5C-E!O;3V'E(G
MS2E\_P",J.]\$.RGF:]-^'_N:_U*<5&\O^SZ336?YTX:T8 P#;7>%_\ -O\
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MOB4GXB-ROXT^>^/N9;Q4?^9%/?7)'/\ Y..>?L4_;5OB4GXAN5_&GSWS*W\
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MXS.97,)%+I(^RB-/Z9T87I>YR=^,,7-QVB'16D"G-$*5UKRKJU=ZUDMQ$E<
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M@HG1Z/\ !< ["*$2M*8QC47%8#B%J-EQC@4K9ZH+!)@2,(@LA#SM!6J(U,7
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M<5TOTR5#ZT"0@5:/%9@0;J_:+<Q-)UZD8V#1BKS2?>QE08M7YE.@.\X0>6+
M/@4UR6"TB=2(H4WF(6:IS1QDR/"")Z4L^G.M' M2=.]:V"3!D('Q.A +>X61
M$QZ"/0'DFPZ3&*SE +7G!)!LU02@M 6TUD)*G8$B<)*FN"C#J^-6BB+H;K:M
M:Y'JSI^4>(0&V;($OHIP@45^481&2(/"@NA2LM*:O9".S*R=%3>XM5;D)'9
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MQV%UU>[P<>O,E;@$6..OR1ROVH^X_P!]?H' )3X P!@# & , 8 P!@# & ,
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MUK7WM:U_=EDDZX P!@# & , BQQU^2.5^U'W'^^OT#@$I\ 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P"+''7Y(Y7[4?<?[Z_0. 2GP!@# & >+M:BTMTW;5I=. DHEH4&U!7KHD0#
M0$#5Z2^G\/M* \P!(E&@?!!-& O8]#%K6P/*P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M63+ANMLN!<O-?5D7:ZWY]:W_ /'6M_\ ]X(.N , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P#\&EA-+,*'Z7H&@&6/T!C+'Z(P["+T3"Q ,+%Y
MM[]$98@C#OS""+0M:WH"!DYY!G+!'6Z+\N6M'Z\8E[?8;!/&GHJ*V%UQ\<-5
ME)(FWN;M&)58-SL]D15Y9$<5"0W1K<X=:I> NJPZ15\N<B$#FF$\J>"R>SV'
M%]$>'?*:*?J7@S7>#<_\K<]6*[7-6%:NE<J=6\.R'VMY= ER>:7!J=FL$@A*
M=XL&:V.B;V^K6*3#E+HV(E\H5LC*-*ZA?7QKKXO!;L)P\!+Q9Q_R4XJU3@X<
MN<ZKEZY2>L6K5E)5HI5K%:DT1RE4J4G1D9RA2H.&,T\\T8S331B,,$(8M[V(
M.:8K$HI!(^VQ.$1F/0V+,Q9I+1&HJRML>C[44>I.6'E-K,T)D;<A+.5J%"HT
M"5,4$Q2><>/6S31B$!]#@# & , 8!Q,?1%,JH_#HJIK"$J8Y7D_2VI!&91'V
M\Y#$+)1/SI*$DYCI)I(M-,G(D#V\NI;PB^!6:5.KCOX7T%B@!@7]QZ!BY<YP
MB[G/GF.4753&Z6DTR!@L)<UP>/(E$M89:K4.,L9'@:="#X=GE3HL5O$F:PZ
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4 , 8 P!@# & , 8 P!@# & ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g393013g30u61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g30u61.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1924&AO=&]S:&]P(#,N,  X0DE-! 0
M     "4< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 )055#(&=R87!H #A"
M24T$)0      $"0ZL!3BR@\LI!(D,T>S2-\X0DE-!#H      7\    0
M 0      "W!R:6YT3W5T<'5T    !P    !#;')396YU;0    !#;')3
M %)'0D,     3FT@(%1%6%0    1 $$ 9 !O &( 90 @ %( 1P!" "  *  Q
M #D .0 X "D       !);G1E96YU;0    !);G1E     $-L<FT     37!"
M;&)O;VP!    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    "< 2 !0 "  3 !A ', 90!R $H 90!T "  -0 P #  ,  @ %,
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0'<J!"         *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      ! #P     $  @/      0 ".$))300F       .
M         #^    X0DE- _(       H  /_______P  .$))300-       $
M    6CA"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8             !<    DA          $
M                     0             )(0  !<
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !<      4F=H=&QO;F<
M  DA    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   7      %)G:'1L;VYG   )(0    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
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M# P,# P,# P,# P,# P,_\  $0@ 90"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M)))*0Y.'B9;/3RJ*\BO]RUH>/\UX<JG[ Z<R?LPMQ)X&-=;4P'_PO58W'_\
M 5HI(V5.=^S^IUP:.IV.C\W)JJL;_P" ,P[?_!DO^R&L_P#:/*'_ %W&_P#D
MBM%)*U6YWV_JS#%W3'/\\:ZIX_\ 9HX+DOVR6&+\#,I\_2%O_MF_)6BDE8[*
M<X]=P!])N2P>+\3):/O?CM1NF]0IZCCG)I_F][F-.NH:=H=#VL<W?])6T.JF
MNEKFUB YSGG4GW..]Y]W\HI:*T?_U/54*_(KQV!]DAI<U@@$ZN.QO'Q14DE.
M%US) Z!F-8Q[R]SF$;'C1]WIO_,_<>M!W47&S93CVN$2;'LL8V9^CK4Y[O\
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M &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
M( !# %, -@    $ .$))300B      %^34T *@    @ # $   ,    !"3D
M  $!  ,    !!<\   $"  ,    $    G@$&  ,    !  4   $2  ,    !
M  $   $5  ,    !  0   $:  4    !    I@$;  4    !    K@$H  ,
M   !  (   $Q  (    >    M@$R  (    4    U(=I  0    !    Z
M 2  "  (  @ "  XC90  "<0 #B-E   )Q!!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$W.C X.C R(#$T.C(U.C S   $D   !P    0P,C(Q
MH $  P    '__P  H ( !     $   DAH , !     $   7           8!
M P #     0 &   !&@ %     0   6X!&P %     0   78!*  #     0 "
M   " 0 $     0   7X" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!@$U- "H    (  P!   #     0DY
M   ! 0 #     07/   ! @ #    !    )X!!@ #     0 %   !$@ #
M 0     !%0 #     0 $   !&@ %     0   *8!&P %     0   *X!*  #
M     0 "   !,0 "    '@   +8!,@ "    %    -2':0 $     0   .@
M  $@  @ "  (  @   /      0   \     !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q-SHP.#HP,B Q-#HR-3HP,P  !)    <    $,#(R
M,: !  ,    !__\  * "  0    !   )(: #  0    !   %P          &
M 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@  P    $
M @   @$ !     $   %^ @( !     $              \     !   #P
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MIQ[UB Y]F
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M/"<QGC$YCCY3P]W?GV(C\>;P
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M*J*:MXX];3.)C.8XXXXCPF>3U.#\L;@
M
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M=@]-=+'.K9.CU>.S&AUL79G_  Q5[^Q:_O6_WICVPNJ'%-@
M
M                  "*W/'YU>XOUIXW^YMR2"SRCR^<I4@@  *8/3>W+6=Y
M^L^YE^-OB=.4FT[&?ISLQTDE2;E^?KG."C-S-<8\^,><^,8\YP.TZ2<-@="J
M?_Y>MK_U-=5/OB(X]OBUT?>N?O1[HPX[UM2MV*%>GY;>F,ZETSZH?(LQ=#=?
M=CVL"QWDT>="M]]<9P64H-=4)>^^WT]WLU^ON]NV70G%R]TATD__ )O17;%F
MG^\IHM7:)B.^.KF?K)<_8GNN4S/O78#B6P
M
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M?7(X^Y1-JY<MU?>MUU45>=%4TS[X;'.#
M
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M\$RAXS(
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ML
M                               !%;GC\ZO<7ZT\;_<VY)!9Y1Y?.4J0
M0  %+OHNDXRQ>I0X?CEQ]6[M7?.?TY^ [0LOSG/X_ISX\_U9_K':=-)_6=&J
M?P]$-A^^B]/9]>QKM_M_WE7R71#BVQ2GZ0&V\"G_ *H_-YYNO_!)ZA]J3=A1
MY]VIB"#WRSL<XBJ?!>V,>Q-MLC=CR=L8S@PPU1MKOMI[<CM>F'](T_1;:41_
MQG1S26+E7#%5_9]=S3W9\\31$]T1#71PFNGNJF?55QCYKK!Q38
M
M                    "*W/'YU>XOUIXW^YMR2"SRCR^<I4@@  *8/12,U4
M5UWRNT_R''U5NVENF?Q\Z&R6+:ZY\_I^A>,>?'U\?I_1V?36-W4[ I_#T3V%
M3ZXLW/KZXZ[?*K]^K/M7/CC&Q291VYU1^NKVY7YN,I6WJ_D'GSI%MTVQX(6N
MM+.QU#N.4NV/!?S."5QBA63G.5&VOM4YU^#G&P[;71&KZ";#U$<:MD[9VCLR
MKOIHUU$;0ISVXS3,4]G'&<\&N.%RJ.^F*O9P79CB6P
M
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MUVZZJ*HXTU3$Q+:Y\:P
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M:6*JZ=VJNG3WZ[5-=5/*)JBF*IB.''AP;(G,1/?$3[6<A\*@
M
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M^-0
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MUFFBS,3,;\4Q315BJF8943$Q,T\L^SA"W$<DS
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M'K_^4KJ1Q38 (8=UL$DG%!6)6L2YPE70,EL:LK4A\;-CZFBDC=7\FD,+7,#
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M9IKHKHF::J*J9Q--5-43$Q,1,3&);G+#
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MB>[PGY?6/0./S]M
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M[]NQ;U,U7K6FO:FW<JLV[NGKIO5S3&*::MS>KW:935'&(YQSX3B.7.8CNEV
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MZO[WV:8C^@WZIWK%<4Q11,[L;M,Q;M84U3$[E7/LG\4?*>^%V@XEL
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MN;<D@L\H\OG*5(( *]_4SD%2Q7E:RGJU+9D]5FX@%JH:_P 1JTY?6>\UG?\
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MER]*:ISNU<*H\OM1^*//W>V(MN'),P
M                     '7Y7*H[!HT]S"6NR5BC4;;53N]NZW;;5*WMR,O)
MJA0;\/4PW?VZX\:$DEFGGF9T)(*,.WTTV$SB,SV.:3J"%9!*I,<6H3*2BSTY
MY.^IA)Y)NN-RCBC-,YT,+,TVUW+WUSG7?3;&V,YQD!]@
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M1RAE3,S&9F/5&/G/UW)K#Q60
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M?V9S-5RF;DMS&9IQ%-6(SB(Q.,\8QSYQ[^YZ:!^9-H
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M-PJPIVQ5YM#)A+%<O<8SI%XVX.:5GC+HN52)]T3#E&/&)[^__;ZQFUX$
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M<XVUVQC;7;7.,XVUSCSC.,X^F<9QGSC./IG X=L:@
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M0HB"_P#,)2)2B"]/^KH7KK_L''5U37755/&:JJJIGQF9F?BV.2&(
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M$W+VCU=JW3C>N7-/>HHIS,1&]551%,9F8B,S&9F(CG"9B>4Q[651\J@
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M444U3:9S/W9B)Y3]F8Y1W3/<N*''LP
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M'9!K
M     !'7K"QK:J2A)K8U'UZ?:]CQ59"5S972%A>I,[RQA.L"+(9VUQYD85[6
MM62G:!*I,=%=E#D@9$DC):UTE5D1U,ZF:AUJE>KB;IE?W3UYTZNJDW[$5/6S
M_==*KX!%-<I#$96S1]OFN[BDW>S\K/>E0E?$U4E)5AA1VVA'G8)7@
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MT='J-'=XXIOVYHBO'.;=?&W=I_MVZJZ.ZIG$Q/*8GREG<?"H
M                                              (@]W0Z=V#R]842
MKA!(WZ1+':L'5VAT,F>E?3.PJVC%MP647%6D3F.[W&](_(K+J1FF\!97$V0L
M*<MQD2<M0]-1!ABX@1,1/&8CGS^/J]:MGA_EITI3L[)['SA9D$;HDU]5H9'<
M<VFVLLKJ857:%K1&P.:(_ ]'&RY@[IK,@\05+Z[F^$,<8B$K=$G@F3.L@RJ@
MZW<N8GE,=G"/+$\N'9\/%?(" "I*Z[CZ@@G72V02YRZ%K3C:+6/SG6S6^P*%
M<J/U62]VLIPBK4L<+ 66$4Z]':1^1V//62IWEVJQO1)(:G08?2516V[X\,Q>
M$1[>_,1CPC'#$SQS\D9MNTNNHE3]-7HMM6-RW3M_GZ36'7$$>JWBC<P\QSN1
MSNBF6LOLMQCQ;9(9Y"XI&;K4ZV$18+P[N;Q)HLVK&UXCS6\+&9.)CGX3CXY]
M<]GSEFEPN+JQCN%%P\;T4I<9M)^@8O&V[J4VJZL(GC%5;SRM:5_N3%B"IXZ7
M42VP=)?4:^-MCTIA6S:1 I02N61QP?V?#JO'UCCCG[O:D!S_ -WU*AJQ$U=1
M]%TE$[EB=@WW5DD.D4KB5=J9KI1'0MK4(DLA-$E[P5]D)YYK6&\B4H4&-FEN
M=UCFU-NWRJ O74D_E\&1>/; @UH2SM";UO+XW/(:\]4,^&F4Q)Y02!@<\M_(
MG*38OPA=FP]2B5?)N*-6A4_!.W^"K3'IS/::5OKJ6>SR^<IL @ I9]3?!#KV
MGZ,T4-]V^ZSL&=R[0C'X;?<2IUSE\?/]J4Y<1OC/Z,;[9QG [7HQFC8G32['
M[.QM/9F?[_644X]<4S[FNO[UO]Z?@NF'%-@                     _.^F
MAFNVAFNN^F^N==]-]<;:[:[8SC;7;7;&<;:[8SG&<9QG&<9SC/T 53WWZ.''
M-N2TRVZQ:)AR#T&5DX]MO7DN3*J;EA2T[?XQISPQL&ND+D.BX_&N7@Y?'=7E
MT(]Y!CT5C?WZ]7H.F6V='9]$U5=G;&SIX5;/VO:IUMF8XQBBY<_7VIB)^QNW
M=RF>.XPFW3/&,TSWTSC_ &\V#\'^M1Q9K[5"6I_52IAKTTQJ>DV;><>L&YL(
MSG7;8U+G1QK.:F(D?LVUU(W<I;(U9.WQ-R#U&=]_MQT)VU/"=9T4UE?95O[3
MV355/=,31JK&:N&9BFU:B>VF(A/UE/=7'LJQ\)Q[9^&8:7]:/BRQ9275UOO4
MVXRO(O8A.X4[V#$EM)OQ*T[^A@M#)7[;,%<2%)^,%M6?O*D<G0LU*82U%[J-
M2<?)K>A>V]/:G5:.BQMK0<Z=;L:]3KK<QS^U:M_TBB8C[^;4TT3$Q-7#*Q<I
MF<3FF>ZJ,3^7'LXK7D*]"Z(TKBVK$K@WKB"U2)<A4%*T:M,=KC<E0E4D;F$G
MD&Z9QN6:5ON69KG&VNV<9QD<G5353,TU1--5,XFFJ)B8F.<3$\8F.Z6;=B
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MFP9W.B73>YWT='[,</\ J[1NYX^49]W>UU?UEO\ QY_R_79\UTXXML
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M<Q,33,Q5$Q,3B8F,3$QSB8GC$LVX$
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M^Q_)_K)Q_7]*=-;SX6]FUW.'E/#UM?#K8[]R9Y^,1R]OFNE'%-@
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MZ_I5J+OG%K9D6O=-7CV^#7_]R?W(_P#E*Z<<4V
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MLFY13$^$QF)[&<3$\IB?*<LV#XE
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M]F;0TN,Y](T>HLQPY\;ENF.'?$X9Q5$\IB?*8E(0>?E0
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M_B]5F,YSC&<XSKG.,9SC/CSC/]6?&<X\X_#Z9SC^K.1^5MK4
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M&FFU;HJJQ$1+3;QFOC^W./M3Q]_'A'/CF'JX'Y0W
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MAQ:+7*F.VFJ<_P"6J.?K^N./82/QYO
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M1W,5Z:=#555%$8IQ3J:-Z<U9B)BF-5F/LQ/?G/?SGMR])@_-FT
M
M                        $5N>/SJ]Q?K3QO\ <VY)!9Y1Y?.4J01C&[7[
M,5IBW)1C.-<QNL9\_8VVSG&N,L\5=G#&<YQXSC&/E_.<XSC.,?4?3HK?6ZS2
M6O\ JZK3V_\ 4NT41\4GA$SW1*NWT-6/[O>E!Q>A^GE373^_9SCS]<RBQYK)
MLYSY_'.<NWUS^G/G./IX'1].KG6=+=MU=VJHM_Z6GLVO^S@QM_<I\OC,RM@'
M)LP
M                                     16YX_.KW%^M/&_W-N206>4>
M7SE*D$11[P?-8QP_V/(]_P#)8N6.@7;/U]O_ *OJB6*O/N^OCQ\+\?QQ^CZC
MUM@V^MVYL:W$9ZS:NSJ,?O:NS'S8U?=J_=GX,5^E&P[1OTT^%FW?3!>QO+]/
M/6VF/IXS)H<V23/NQ^C?.7;R9C/UQOG;&?KY'U=++G6])MO5QR_2NMH_TK]=
MK_L*/N4_NQ\%@0Y]D
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M1S;'!&;J>D7MZ].6J1+$IVF<Z')U28TL\DW3.=3"]]=M<YQG #?@
M
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ML\DLS&=<8\N?!LB8GC$YAW %
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MF3ZK+PH7K3<9+2I"O>>HWQ[2B]]OH!F>Z?=^;DORH?*OZ2>B,?V9Y&Z@\_\
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MZ-I>5+8K=421/+Y4^(TQ2]4RM)ZG)"<LPPQN2;9W\DZ>!B,Y[>6<RRJ"@
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M.C#A8":8HI"HQ(66&N2=/(V*-%*8ZJ2LRV3$-KE)4_\ OXB9T\?4LKH]!*$
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MWP%C]L\O.--3G4[R)G/N]T82H!
M
M                                                           !
M#^:>H'P_7$N=X!/>KZ%A\W871<R/,4D5EQAJ?VQX;/=]HMBMK5N!2LI:A]NV
M52?8KXA&-<Y,UUQC.07$]T^Q(*$6I6UEX4YKZ=1:9_),\2D*S$;>D+ME*QSQ
METDD+=E&J,XW)*"4L!FCPQ*3,:E.3=MA6EV,)S[@1WX
M
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M#&FN"O9\/&NN-?&"SPF8\6= 0
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LUUT+TUUTTUQKC& 'W                                      '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g393013g32d01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g32d01.jpg
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M 0$! 0$! 0$!_\  $0@ TP)< P$1  (1 0,1 ?_$ !\  0 " @,! 0$!
M       '" 4&! D* P(!"__$ $H0  $$ @(  04.! 0$ PD! 04#! 8' @@
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M===?_3KKKKK_  ZYYN%81A+K1Q=A>'./GV*-EUE;$PW%+QK1)I:-: UHT#0
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MK0YIVBPM$C.-G:@=O2O)!S]?743A$X1.$3A$X1.$3A$X1.$3A$X1.$7'0_\
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M$A;I8E)0/ DBCDJ0!,G,1QZ]WSW<ZGO1N\+VOW7.NMC[R#U%%X[<=(TM<D'
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MN+8I4>ZY+Z5';%6XL6-IBW>^KR0?LN%.JQGK8#"XU"Z0'. B")8T903H"<S
MSZ\INL?P=(I8 7:P6A?TQB[G9G86G+Z;/!4$AJ[: 84:M%L*[KKT6\]^VE\-
MB0J-=AXH-?YBA@=J_P"\W8DRHT2]_P!*V\LJMN_"7'#Z-487AU[AY:ZXK W!
MOQ6\YN=IN=&O6?5VZSF[;GEHA[))5=2V@[UCZS@[339B!S@;M-45\'"&FF=E
MA9WL'8MA1RX=Z(1NE9XF31:&K9S]M \6V8NE9<]0;)>E86]<CQ2K]9)LR9-$
M1R;*-1N.MG3_  =!Y95V&U?0P^VMZEG@-?!+5].K6_\ +FX)V[VBTD[-=K7.
M#02YSBXNJU*I#=G7) R"29>'GGC<>;[ 6/*^#'#$ZZA< AU_3,0/JK<^2;@U
M$"ET$A4]K.$*24G+";RI%JW<X!&LCAOE)D8]\2(G$SG:N>.399FVZ\SZTSRT
MK&YK7%;#Z+W7>"TL&O*E*XK4+JOR3*+!>"Y&V:=:*#/5:PLUG:/K*<EE <1#
M]L3F!OV8RD9[U?B4ZYV*==ZU. FSEF09G1L\SE\[!1 '#0<=O4%D+78I5O*@
M0D4.&@8.,R420"C!;=UFT%I^X\5)2E-A+Q_S]+$K:F,3#\+M:[K^WY&A4K/K
M5*E@_:#C<T:CWN<^NZ)>]Q$O/JAM(NHNV6D[/K$;)SB(<.!"MESR5I.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$59-<?\[V<_F;EO\ 3^L>%3H.CYE8:0:?0HW?
M4MV1:6+<45M&:UO'*@.D8G*PHH=G6L3.2*3 (NR'J19YT/Q'GY;)"B1UHLE*
M/.2Z_79SR*+1)L2<HU$DQSG+IW#>M5DOAWZLR&C%:";0Z112-_&<C>;*<1*?
MS49=0Z^FY'(JE>J5TN3;^QR%N]O,U,7,W/2 N5(#5% 1+-X S[%\)M&9YHYH
MTB."K[/--YP&V=T:+U@[NU_":<%;/O;5O\K9T*EUDK2ZWXK6\9CQ.6KVP2-E
M)[D[8PMR'>LDH(9 1<"WC#*+C1:8(0@"D9ST]\>"LY'340.B?'B#KUS1+O#?
MUTD:%3.HZ\MRI)I3>=@=1JTZ9MJ7UW:!MC;LFRF]O"IW+Q#SMW-Q]H3I12<2
MW&0I/'64P55D(5T&)+*KYU3:.>F>Z)'-KPW=FBS<GT"HR4I7BR<OK"'!]A=>
M(KJO9 0;)VO;)W24-930<$BXQV3#$C8]_BQLBPD7TI]++2DDI,";UZ86(- C
ML20.(CF,CIRS[AKPZ9T:?>&#KG8B=K,RIZZ P:^X##X!?,=B-FOXM'[B2@ !
MA%8C+9B,$L$$6\Z%QD2*C[J11/N,YR$.+'CY.V--F:">! XB(U;I]]O:MY0T
M HP?=YB]01JYXT8E[N)F[)@0*Y9VSJ2V9I!1 L'%+!L^OU"C@7+YH/& 0#<D
M5?Y](2_T(.4G#&3*8+9+DDP!PF.O/X_$\5_8YH13T7'5**&R2SLF-*;$6'M-
M!47<B!KY-[CM5Q8[J=&R:W4637*##2UP6CEZ!<J>BV/4U?XCV[7$7&N@9).?
M. .H1'9 [,YS4S4'KM7FMT2-02M5)7C$2TOF4Q:@)/*S$H&QIQ.I2;FAT)%F
MQ9=9,-'<I')#A!NP2Q47Z\_[0=/'3=HP2:$)G,J+JUT;I>IDX4,AKJ;-HC49
MF<22@X"2-CC$/U_D=A#)(%/&:N8D@;A^DLR"S&6 X@PF9.9!8''I&9C,*%@(
MX_7$Y$))Z\CNGI[!V3JN#6&A]-5'GK#U$#5CX--0XO.872HXG(QA!J,C-BM&
M ^5"SZBD>P?R?IV.%"V35X6>K$!R8]%=B[0>K/'3DDDS._[RX>"DN7:SPN87
M,M?#J13@5/5*5E% )J!R85,,UKJ8FALE.-6XHC'B271A:1!0QA VJHL^;+"T
M&26?0E9\.=DG*-TS]_?3H%#POP[]>F(.CHD0QF4HA.OFO=A:L0.%2@R*)QQU
M1-I@(I%9Q!98WQC[9Y*&QF,P*#@\R1%]D809Q=FH@_P>D9 [,DDF><R>G/QW
M+61?AF4,/I224&^G6Q4N@9]I%0+'NP;OE5@'H3!83) \MC-<5\7F'IG.(0YB
M=CL=</4Q:.!Z0M8['A4F/&1((0Q9DDZ_(;^K-;]86B=16CELW\,I'91!/;RL
M8A4%XH-SP$>C((+"!TA$ QHGIE%D<XRX]%3"7L7Q %FR=O4Y(]654\[9 W(D
MDG+^[F.F97)+:,TX>D5DFS16P28J\!]>LK_@[N1L5(3>2U81P3$8J]GHKT)T
M]:8J1D$) RL%!"D+B,^"-,@T[CDC$O2+%X2=.;0[QO\ OI7'D^AU)3*/;01>
M2D+$("-MYK&+)M'!"7=!WC"?P<9!0\*EL%(@1HM_$RL5'U?720OIJY78J*P\
M8])LR#YR8<DR2<N;(=&9^9[>A:BZ\-VB'AN2R=>5WBYD<RN&B+]E)DG:Q@^L
M;MW7)E%&E93-VRDC8P(P=L%8/$G9 :V'-PCS$$Q"IC&T6QS YDVC '"1U'7[
MU[ N1/O#CU_LEO9^4C+6NWD%FWS'-G<9S&)^YAL\KF]HI!0U8!+#JN511@')
M0XFA7$>#PERP34? R0)JND2%NW94R[(DDY<PC0:23\3/^@5LZKK$#44-80P
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M=H.2#MJX+MW(E%^F#'$)!G7^(GJ/S68J#1[;?7N1@'%.7G2P^)SRD=?JMO\
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M_M-7+!E_U^$7$B%U4W81YU%H#;59SB3L8Z$F#V.1">1:2GF<2DS1H_C<H="
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MFN3/,NHU#*+OG4?:%LBB#\>B0$0)UVG$[\B /B.F%\-R]1#%NL]K;9HG7"0
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M==]=]=^[UWUW_CUWUWU_AWUWU_Y=\+*_O"*LFHW^D)C^8';O_NRNSA4Z]0^
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MC=60Y69JO=?[6C5)V6#6@<H92(=9$RPA:\5!A@3T<W)2AM(VEB0E\!.1YN2
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MMB:3AUCG) -&!)9DPZ$-7G;Q XL(4'/\6Y-D]Q.HT&O<MS6W!I1.4SF H$I
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M+)B=6=UE7-'4^QC\ZK^0S@J7^,)@#0#S*-RA.40V,@5VS[MKB;B?48>OBPH
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MV$?').F)+"1(N&!/BM4AMX-;6:4/.*?1B,YI6YXH_F"EA*SG$&:%"7T3$RN
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M\<<\?=]S+'K+KOKHBP,VA<5LB&2ZO)T#8R:$SR,'H9,(V3PR4&R"+2@4["2
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M078!M"@BP*%#A92%;#'64'NZ4V>7],NR;2&%_3,6CE*CH-*H]89^78O+$S$
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M/-;;D!JM >R_ACU&'L JSA#UOK_3NS7<9'VS/F!!A%V8AYBJB87]%2V:H2/
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M&D0&N--U2LVG5 ]1YD+B-5HV\G>I =$93IO_ --^]=I0(V+DH0-(P;O%^%D
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M-VR&"CEX\7[ZQ09,6B2SQ\[519M$5G*R26?)2I/K5&4J;=JI4<&-&0DDQF3
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M/H^:8>[$;JZ;?6=[;VODX<8PBVO;NS)=B5U2HNJ5<0VBRD^K2NZ]S<FWK>N
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M(3CJI[%L8-C@"+_!*3R*,CU&+)\4:*DO(D%R*;+RRS$:163Z;9E0),*?N%%
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M,A39(GQ@*PXL+E@D>;2&O20Y(LS8%D&Y%-@0?,\'::V+9XY1ZP6S(<LEK?\
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M%_"J/Y&,4F4L=AC(\IJ#&HB.,#:G+G,3SJ.2PT?"K3AT0<;"7BT:@?!0VWB
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M<$CPRDPTG8Q1"/%QE-1HZ)"X1YPLS#B3-HMP3+(0YFY999ZXZF/4M8L"P9$
M_*<^)W]:N]PHG")PB<(G")PB<(G")PB<(G")PBK)J-_I"8_F!V[_ .[*[.%3
MKU#X!=-&T\%NBX]\O$"BFM%J*Q6S'NB.JP8?$&CZ+C0]X)Q6S]B"UH4.]FI
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>H"(BF:GDWA5^MY=5OFYR\OY/-;)))'!,J !HO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g393013g36d58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g36d58.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Y>4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #(< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 63W9A<FEA;B!3<&5C
M=')U;2!"=6EL9#A"24T$)0      $)*6B'R?"VZ;^7GB<V 8<!PX0DE-!#H
M     7\    0     0      "W!R:6YT3W5T<'5T    !P    !#;')396YU
M;0    !#;')3     %)'0D,     3FT@(%1%6%0    1 $$ 9 !O &( 90 @
M %( 1P!" "  *  Q #D .0 X "D       !);G1E96YU;0    !);G1E
M $-L<FT     37!";&)O;VP!    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585    "< 2 !0 "  3 !A ', 90!R $H 90!T "
M-0 P #  ,  @ %, 90!R &D 90!S "  *  P #  ,  Q $4 -@ V $0 ,  R
M #D 10 I       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'BP           *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             %2   "$(          0
M       !              A"   %2                      !
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M;&]N9P  !4@     4F=H=&QO;F<   A"     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    $.$))300,     !,K     0   *
M  !F   !X   OT   !,/ !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !F * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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M:UCW !Y@0."?[2N.OO..!'Z4DM<Z/S8YV_1]RK,KMK<'LT<W@Q*;]]YC]_\
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      7Y-30 J    "  , 0   P    $).@   0$  P    $%
MM@   0(  P    0   "> 08  P    $ !0   1(  P    $  0   14  P
M  $ !    1H !0    $   "F 1L !0    $   "N 2@  P    $  @   3$
M @   !X   "V 3(  @   !0   #4AVD !     $   #H   !(  (  @ "  (
M #Q%L   )Q  /$6P   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3<Z,#@Z,S$@,30Z,38Z-#@   20   '    !# R,C&@ 0 #     ?__
M  "@ @ $     0  "$*@ P $     0  !4@         !@$#  ,    !  8
M  $:  4    !   !;@$;  4    !   !=@$H  ,    !  (   (!  0    !
M   !?@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0& 34T *@    @ # $   ,    !"3H   $!  ,    !
M!;8   $"  ,    $    G@$&  ,    !  4   $2  ,    !      $5  ,
M   !  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (   $Q
M  (    >    M@$R  (    4    U(=I  0    !    Z    2  "  (  @
M"    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$W.C X.C,Q(#$T.C$V.C0X   $D   !P    0P,C(QH $  P    '_
M_P  H ( !     $   A"H , !     $   5(          8! P #     0 &
M   !&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $
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MUD1C9(.&AZ.UP?_$ !X! 0 " @,! 0$            ! P($!08(!PD*_\0
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MNTW=-=-TWZ,UPKO6M@:%6W%61^GZ<U]JG!Q)@P),5SRC@<3\:[ BQC/'$7_
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M[77]>'>?N5=!_P"JWC[G>#OD9GY77_6D[8F^/^BWZ*?/^_:Z_KP[S]RKH/\
MU6\?<[P=\C,_*Z_ZTG;$WQ_T6_13Y_W[77]>'>?N5=!_ZK>/N=X.^1F?E=?]
M:3MB;X_Z+?HI\_[]KK^O#O/W*N@_]5O'W.\'?(S/RNO^M)VQ-\?]%OT4^?\
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MT;]N&Q4;F]PJC[NW47>PV-G7-;B;6J^LUTVTL*-!+L!:"MKZ4EM-N=6DJED
M!_5:-I@I*6&4T[9(:>&*1M.7B!KXXVL<(>-<Z7B@01'QCG/T,M-Q=F5J/&;G
M$!V1.K,'/IWRYE /0N_8;7X.7\CFSIL^,W\8>]8Y'F/44]"[]AM?@Y?R.--G
MQF_C#WID>8]13T+OV&U^#E_(XTV?&;^,/>F1YCU%/0N_8;7X.7\CC39\9OXP
M]Z9'F/44]"[]AM?@Y?R.--GQF_C#WID>8]13T+OV&U^#E_(XTV?&;^,/>F1Y
MCU%/0N_8;7X.7\CC39\9OXP]Z9'F/44]"[]AM?@Y?R.--GQF_C#WID>8]15<
MU=)S&RZ[G*C6,8O*G.<Y 7&,8P^OWYSGP<U*]S>T:WOF_P#5*CE'_8O630=(
M:CR\GD7]&/M*]NGK#V3^SYV,])T?3.F^QZGU.[)VADN6=\IMGLR&85T[7:JR
MJTITFV:XKA?W98*2:&<+1\>MC*)11G#'/' ;F7'/8>1<B7$ #+46CG6C6\ZF
M)J]8]1ZG=#J ?3>[JH]/+JNI=8A:+UM3U%JJFFQ??!Q>SNM@M/<S^TKNE44=
MM&I,*M3 4<0%]-'/+5D=>WJ_<L.75JV;]:P?>[2_2_LM^UK]I[LO7C0^I6Z=
M-.K^W=O/L^[13]+&:2NW%=#K!U,OJ:PL:>RV;OIURI5PG_3LG"[@;1%2Y2:%
M$@\^D66RJNN#\+14-12T]51PV"XQOJP]T.E1TK)&M>R+OSF\MS +<VY]\#DJ
M=(,DET@2'%PU [#EY/(KH]&/:V= .R5T5W;H[V4NE_:4U>"(^TL]T/V[>[;1
M+G:=1V3K7H?0RLUBWV>PH_=2#^=9WKIA?6SHZZGB,M#8TR< NLC?QG4KL'W"
M\5T%9=JRURY]S6U\4#9V1314517/E;$U^D6\;3U,;!I/U2->[,#16396L:6M
M#M>L9C8<@.;(Y$<W0LKK[_E 70[?*O;U6NG/:W[/;VYZ]T'7;L.S&QT,0:I[
M#IAJ.W4>SZQ4XZHZYNE%#0;2PVJ):8(]93N1(U%?&1JSPG4/Q,?!Y6P/A/;5
MGN#89*\AMS%>YKVU4T3XI7]J2T\@J&MB[\\:6%SW:G9@B>/',X9Y;!LRYLVG
M5T+R<VBN36=B6N3MO=Y7FR(^\0XG8>CFP22OKIK!&M)SR,P]3)<8P2-X\BA
M>8QQ]=8X!C ]T>D&M#M$][I #/1TB3HYYY9DG+;K6FX$DD ]1YET?0N_8;7X
M.7\CF6FSXS?QA[U&1YCU%/0N_8;7X.7\CC39\9OXP]Z9'F/44]"[]AM?@Y?R
M.--GQF_C#WID>8]13T+OV&U^#E_(XTV?&;^,/>F1YCU%/0N_8;7X.7\CC39\
M9OXP]Z9'F/44]"[]AM?@Y?R.--GQF_C#WID>8]13T+OV&U^#E_(XTV?&;^,/
M>F1YCU%/0N_8;7X.7\CC39\9OXP]Z9'F/45=CH0FW#K1TKG-5F,8[]JTI2D
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MR<V,M(!&6HD+M[,7X4?''*,36 ,EC9+&7W>@C+HY&A[':+YVN;I-(.3F@CE
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M;6NC<]H+BP6XUVP+:T-19&QC!7J]5DF,?2Q,HHREW?2^OGGMJV5+JRW4-6\
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M((YPOZ*()HJF&&H@>V6">*.:&5AS9)%*P/C>T\K7L<'-/*""O,'[6_ZK6?\
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M8:YEG%+:GRW&Y5UE^#<QHI*=F9AHZYSI:1Y8ZO:\Z#V/:(W.<YWM;%'9 TO
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MYSB<R7.))))S)))UKT.QC(F,CC8V..-K61QL:&,8Q@#6L8UH#6M:T!K6M
M   "Y.0LEY>_:W_5:S_S9Z9_M[SGO_L:O\V[_P#>.Z_\O;E^,79Z?Y](/]Q,
M._\ N%^6L/GH%>+,B=@S3A$X4Y'F/4G)R.K5M\A4+%'=M@8V"[9GXYY14*19
M /QYA 0IYA(V,8QCZ-G,?.G+/?+NS ?BS 4.[Y!?KC)<:^9VD33P/?#3L'@A
MC3HEX'QIBW3<3KRT6YY-&7H'#5GBM%KIXVQ_QFHC945DNCW[IGMTA&7$9Z$#
M7<6QHR;F'/RTY'DP_P ,L?3C+_1GG"KL&B>8]17>K+!RI>7?2),+"Y(SA./?
M\>._Z,<\?WPR1[X$AGXIPE*.?BSGFQ2U,U'/'4T[RR2)P<TZ\CSL<-6DUPU.
M:=3FDA:]71P5U--2547&4\["R1I&L ['L)!T9&')T;P-)C@'-R(68-6^.TKD
MK$6.X;JP6,1S].&20Q*0\_X1R\4,_P"&.>?:*6H;54M/4LU-GACER^*7M!+3
MSEIU'RA><KA1OM]=5T3SFZEJ)8=(;'ACR&O&>O)[<G#/7D1FN_S86FJ#L]OF
MBHK"RAB,C!#B"T98[\29-.(0=\>_'BC"<\$G''QY'"?=\?=SC[K6]SZ"IJ@
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MU_X$M_1<?"/$/R[>?G2M_7J?@3@OQ0PM^;UH^IJ:].]82M=TUX JI&406(+
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M?^#/^8&%O_3&?VWJN<XI=Y3A$X1.$3A$X1.$3A$X1.$3A%LA]FC_ /%+?_O
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M;)1EV^H>J]?KQ6!Z?7FPZF3&G5E/>6.JWKG4)5K6Q2NIW+%TLEI7KKY!YQ2
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MTZBTFV[1T^O]NHDH/@LJ E>G.#(W43K"+Y+)S5[DT&2 >"NY":Q#K#G @3P
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MSG.<1CC$<8SGXHXQC'Q8QS%_@GH]863/"'3ZBO:/RE7)PB<(G")PBT4^T/\
MJ@\?>+K7\(M^6LV=/L"U9O"WY@L%>9JE.$3A$X1.$3A$X1.$5Q.D/_Q8Z8?Y
MPM,_C'6\@[#YCZEDSPV_ZS?6%L:Z^=3]0H:3K#I^R;R#9;.\J$:W6>GD=;B
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M;EV:]7KYN57=H"4\-N6ZICDO*QZC#U_IK@4/H9QN=8M=M^$II?%GO@5/7U0
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M'O 4@%E09F-==<(I15-.[QKB?I8K.U>SU+AL8+$456@/0(T/,F)$ADXYJ>.
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M*&'-FO1)+CX67/MU^58)=8D6Z_J-LH'5-408F=1B26D'PQJZD6JY-@8*DF!
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ME=:ZZ^C$7OFA9.QDB;.3+PF8<P.D4"VEC7YLGA4UHUG)LRS934<RU2+LK3.
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M8B7U# 30EE:;-BY%7S5( 98(N&O1&G2EV-FM#;"%; J<IM3=&FN0J9'8%?\
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MQ<-.JZZ)=!M10=PY3(U[1:W:&FG@&8P"PQ6ALX/-"KPP7SB$9@#R; .7?)2
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MMUHFQ7"H'RJ!4,WWW^PJ]9;1N5#2.U6Q,^IMLV"(:]BV@G>^]M=(L^9V!96
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MT8*N2E%ZC,9X.!-B4A (T/+Z%.GY.3/;OR_N4"^?T:/^MQVO/_\ <.H^M_\
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MT32H**[I9],.G"6EVL[B2&86+RJ]8&;=?Z)EC.%921)F.&<"-W3AWPQGO[I
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M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6P;V5WU>_9_\
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M.-?;9&C"I79SKVP! 5D:\,LM-RHK."F6SO5[>2990L!Y.Y7V;9AL1P@Q,%5
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M-KD6!;&OC((W=+YF0W0?$P/Q*2+"ECS;Y?;U<R>?5]JM&Y)$S>(5PIK)X\H
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M,22_-)X^OF X]Y)XQ]?,8Y[OK\(2!M5.7VB@9)@0K(.)RSW1P:!E\2S^=B;
MA0SG/TL8Q+X\_%CX^% <#L]1]:K^,]_QX^/&?CQG'U^%*<(G")PBHK>Q4B),
MB9L Q)'/=* \$8E#./IQGA>!<PECZ\9=V<?7QPH+@.5<Z-S5V6<Q2=">>,=^
M1XSF!N[]%Y)<0+X<?7EX.['U\\)F-F>^^WF53X4IPB<(G")PB<(M@WLKOJ]^
MS_\ L[J!_)1O?,7^">CUA9,\(=/J*]I7*5<G")PB<(G"+13[0_ZH/'WBZU_"
M+?EK-G3[ M6;PM^8+!7F:I3A$X1.$3A$X1.$3A$X1.$3A$X1.$65?8D^J>Z8
M_P"5VO\ B/LO,7^">CUA61?RC>G^R4]NTK7^=V8K.W5MFZU./5Q28JJ8T\S8
M=GTV(*!K9E&Q41_,DSS$.:3)F\CG 4!P$8XL6<O0MA_)TK0WML--*EK;$&KJ
M,R4095[2Z*)Y6-4L\_7A2NPD?3]V7E0=)BJ(\E&P1M*Y:NL8)*F(89K->_HW
MW%>^_-[?)RPLD;G;K0YE$FW"SD//DKQ(QA8,!!47C,DN[&9^0N 'FEE C1!Q
M[\R)+&.$5R*ZI#2"**HO:P+BM@W5;'KV]UC6JFM%+%=4@*2X@4K=3$8BU5@P
M$C-ZDP@SY+B1U78 **.CT[[\Z>;S<W7R9=/)YE#-CVB+<,U5:/.4%Q027L'X
M -?PJ\8"6.NL6JIYKV575-P(&N=B #+*< PEZ=' *U:4V[Y_OR7Y1P2I&6X7
M47*>]KFES+S,%L#J!5B@/#R QFJ=9S$HR)$_CR<4HK9 "<2&*$B[)]BJ"3AL
MRP25^U2&\H_7J+"%3.G=2,KF^7S"485\B#8-FPIAKR4([B)4Y 1:(BB14G6]
M7LKIE5GW99'HQ.!][.IJE-Z>N$44[1@>!QE,OH4Y389R&)/3#\)3^7#.)9(I
MG+W[5,W>N[;6"EKGNZS*',4A9K:TGHF345QJUG ?@&)QV"F%BJ,R7O@,2"WE
MF;.30#??D\R;^W<J!6-O;7YS!A.Q*I-MNT%409:<54.:,C.L+JX_,A=^,$F0
MD QS ..XD\QAF7 ]/.BG&O4]-(#]7-;WQ836&Q95L!@S8NTQ0!LT[W1VY@&R
M*XJ5C9/94+.20M:[S9X\R RXKXS]>6^K]Z*!WB%=7'@LA=BO>[QSRXJ!@*>%
M9^"2,(X;B)B+>19F1Y;(O*3)."T3G*,_@E%)M<UF$<"LK8RB8FTYRI67AY8J
M5[695H(%O\3%E>-:7SO+C+)&!B;*N:P38JU;4,8SW^W?S(I WM-_5:_;5FP5
MM?"W#<HU9@/T]?@=M7P4LCL L%1@&!PU(S[M8IKQ;$;&O!:F6!83KWP"A.^_
M-T)R;\GKV]2MMC#5V5E@Q @7KDI,%R,41*HI18@(0%5%XXC'SWG!!&,<,8(X
MYEELL,3:;B14;A$X1.$5O-WO3*X'5*$D*9Q><T6&>Z> RE*(PQECXX^9F,I%
M[NZ7@\$>_P ,Y8R6#G$:A]O+OU<BM5PJL\]JY!%* D#!),11RQ(9!RS"<)8^
MEF,HYQG&?\7"D$CW*^FM7&;FL@<O=AD,\KLXCCNQ(D(QE@L<?6P6$HRSC&,1
MQ/QQC\4>%<#GOU>[S@J0<*4X16+V2]-</$Q&<L(KDE!4.,_0RQ'.8^HGC'Q2
M(7NS+&<]_EPEB&/[[,BJ<[/9]NL:Q[U&^%@JQ27+-*Y X92R"4HX:7[\^ XN
M_NSWQ[^[S88SG(B?3A+XL]\)3C(LFN^S[3S:_+DK^C) HQE'GQ#)")(2Q]*4
M)QQ*.<?X\9QGA7+[X14F[LXU%:R[G&)SA&, PS]*9R2Q >,]WQ^&.<^.?=G&
M?!"7=G&>%!.6^^^I6$::.X<C+19&.67BF2>>_.?SL8^M&,<?%"$<8C"/=&.,
M8QC'"I))WWWV+@X4*XVCWAL'Q3,DR0)(3DEF><RD*8X^.0(YS](4AQG.$>_N
MA*'='XI]V(V9^???V;+&NV#HZ>3+V^7+G*NER58G"*W^[WADH"K%"2$5D>2L
MEA+PSBOG,AP'"6/CCDLHS\<L=TL0AC&,]T\]Q8N.6^W?W>56GX5*^QD($D"B
MG(91RQ.!(2S&<)1^/$HRCG&8YQ];.,]^.%()'NW]:OEJ]S*YK<%-G'JUYY S
MW8Q'$Y8CB4#8CCXL8+#.._NQC'F1)B.,1QC'"M:<]]]]?*I'PLDX1.$3A$X1
M;!O97?5[]G_]G=0/Y*-[YB_P3T>L+)GA#I]17M*Y2KDX1.$3A$X1:*?:'_5!
MX^\76OX1;\M9LZ?8%JS>%OS!8*\S5*<(G")PB<(G")PB<(G")PB<(G")PBRK
M[$GU3W3'_*[7_$?9>8O\$]'K"LB_E&]/]DK\]NG>L45OV720"%U%Q#K0I;5+
M?CRC;(28Z5RFJU&$HSCF,HQ,HT&4&D&QA=3*%D(R1Q9R]'M6P_DZ?8O/)X&+
M]J4H87KJVO7Q'QDR?-?2UN#SE")"0@PQ/S&6)YQB(SN/O,SS 96#YQFS9OFJ
MU.SZC7GTQ0M9LU,Q*-Y8G&<YC52MCYB%8.58U.R&L.MN:G*Q6E V$X*6J%J8
MM4Z4ZCJW"?;O]NPJ);'?,OAK*\CD7I5]2C6ONQQ@F'S5CEL2NGADD,'/&LK;
M(50 ^?#B:ZD!CR14:TN-]]_9D]FK??8JWJVL6)%O?5=7TVT,@PLUBCB_7V+!
MTC3+7V%>[KT#PN\,&PXL19U(4")2%DRC0WO3$$3???8JGM3M,H)5:RK77GDP
M1Q3K6Y#(W]"&&/!G5MQ#-8![5"N\P3.OV()JG-7P@I+TRQ?05#IV[ZM\D4!U
MZL5MK#TK;,EA^3*</!C\T,3S!#B.&?++C'=@F2SED<HQ$*<IY&/$RC(INR1!
MLR5S2W"^M7FICK1,@PQ( )K)^3 5QKT29@25B,\^ZZHX8PPU8D/:I#D%M]2K
M'R;44%O+@EM86!A>:M6GL[!Y"JP665*X3C13P N#$O)#@4"8'^90CC.(_%\7
M"*7HEJM1N4ZZTK7N\Z-4R?8JFTLT+Y*-U7JV W:+"K0ZPRZP7!2$LZDU*R\J
M><.I8:'%,B_=LVRYPQ.G8L%[9^LD6O<OF*Q MQZ^HN'0@<KMA*O*]' R"Z&9
M=[_=F4RXS#QXC/C??D14S5M<#8%PQ8!(Z/*9'A4B;& 7-I5=]DB]94DI0*NR
M]1-*>LS4'\#%@$!9P')09RQ>3T[^U%\7U/9U:(Y9M%'M>8Q M$^/,(2N5R3C
M"6 AQ"3@S(^E&*U3;G$=:=594A)2]V^>WWZ?;TETJU"SV=ROC86)Q5X9*5.;
M>R(<Z=4F*.<A!B<Y2P%94.)2@+$PJJCSDK!5%,%8&13NJ9IZSX6T#^H"J;-:
MBL@$PP_9G]Y*J^G=FI<^>R14+WF*JVU%<4@:U65JHDO.O>1L<QA&6_-O[2G1
MZ]]7[U9WDHG")PBLOO B#O23EW^$RRY!Y^MX8PR*6,?XICEG./\ #W_7X53Q
MKSY"H?PL$X176Z>BG%*P-G&<#(T.$,_6S(0N^?=_XL,=_P"?\7UN%:P$9^7+
M?TJX7"S7&6.9B)".>Z4QSC'/YV91SC&?^S.>%!V'S+&V490E*$\9C*$LQE'/
MTXRCGNSC/^'&<9QGA4G;O]OK7SPH3A%D14"(&JK0EQG!!(J0)C/TXSB"&)1S
MW_H<X\/_ &<*\;!YE4.%*A>]B(2CC.&,YB!T!2]WUH9@8.,Y_P#YA1X_[>%B
M\$C(#/6K-\*E.$4AU04RW]=@>/[@LRRS^A@,1)3SG\[OQ]#C\_,L8^OPLFC,
M]7KW/0K[\*Y.$5FMZ$2%YYDL9\!E 2'GZW=',QRCC_#B4,YSC_YL9^OPJG[?
M3Z&A0SA8)PBNGT\$3"UF;.,^40ZXX9^MF8ADD3&/\43"[_\ 'CA6,Y>CVJXO
M"L3A$X1.$3A%L&]E=]7OV?\ ]G=0/Y*-[YB_P3T>L+)GA#I]17M*Y2KDX1.$
M3A$X1:*?:'_5!X^\76OX1;\M9LZ?8%JS>%OS!8*\S5*<(G")PB<(G")PB<(G
M")PB<(G")PBRK[$GU3W3'_*[7_$?9>8O\$]'K"LB_E&]/]DJG^WBKGK.R[+H
M*]4SAPU?7!T@01\9<*I_,O8:-B&/HI1  9#$\&)9B.$Y]WAC+.,8^7H]JV).
M3I6AA79ZNG07Q6*!--A825U6-1G)*V4SF$V%[/$5P2-&1(9*N8#GJ46H)O(%
M4:!XX6*M4&WL*OR356MQLHU#;RUH4=IY$G,-B6.%5/O6E(1AUD7GEQNQ@N6R
M\[+)5%,>4J$BEE!HVRB3LG15Y@W&58?![ND IBOA9 6PKE/*(22FTBKL%:1K
M6< M) "[-)?+XU<QC?U<FU,M>6_F^SVY+KVU[99I1XV=,A-EP1RM&S9!(&VL
M:)M(GCE<R)$;34JBV&BS2NN9(<L\N*2,59$80SZDW\_GWSU\N6J+UM';7$36
M4U;(U< ;V3VF56V%,L5U85Z%>1V,9#$=@8!+"Q(F9"P84_+E"/AR13]U/6+B
M@ S ^:^G4R0%7<Y5RU8Z\V7++Y-/VL*(8%LUF\X;/JVRB!XC3[U&_*%%Q:AC
M??V]>I3[]\_W<_1:Z"HGK+TM=F8P&-.*\WR#C. (XE+S6ICC@<,Q%&121'B?
MA[LPADN<8S.5"N<E6VU*G(&H6#Z.W5^6W+597S%[*ZJ1%+&)ZB>("8(K7P7)
M[WUWPEF<?=;2G8+",O21MS&_V[@A3YMN_L5,VS=;-IE98<*P$E$$,9P*IJI&
MIK.:PRV:]*]E6;M6KBQF=N%>HP)6IL3-QJQ*1QCC?DY]?7OD5'V<_-Y5&ZM.
MK2S6V%\T^L-R66D1HU:-K+*ZS9%<O,K6;2J3*^7%6010GF?J\JL09DL'(9,2
MBG^P6M;5R5P[64KSU>SAJIO=39;U)TE?9I)W%!;H* P>L4\)YM%>5A2 *@YX
M5/,7/XYYCR>;J16Y77M-LN&C8%ZEQCU5F]!!9$!IA#C+%@9"M%)$#+(P8*UZ
M)/$"FP,I,1Q&)219@>[/7Z2BD+2]MKXB5]=A>\I[)=RRI;H*\B!81!#!&VH"
M)XI)-H07SFQ0/B!T6AQRSA@4$BRE%&W-CM7ZU*K:,,H40^D$QD L6!$(3@56
MM9?Q'#+->B6.2(J&)(:^91C''EK)P6C+??U;$5"Y*)PB^"$@*$REG$8QQS.<
MYYQ&,(QQWRE*6>[&,8QCOSG/"*S^V;!77&1A56G.2TY>6_.7EYE"7Q3'$.89
ME(4\XC+&22'.,HXSB&,9EB15N(U^CT[>;(]/60H5PJTX17:U38ZN0%JC <H&
MA'P"Q*>""9)+.93S@OAAF)BSS*?@G'$<YSB YRSX8<;]>_O5S2-@]O,-N?HY
M.3SS[A9*FVELE3K^H<)X<9SF(A0QB1C3QCO\ H=^._N^+Q2EF,(=^/'+'?CO
M*"<E8RX>7LK [JZGHXGEXYC\S!/$3^_+GNA#$)%^*4XX\6/'XI>//BX53B"=
M6^^W9M5,X6*[:# 57%V3K8;$ L227R3RXDS#/?'$I> GQ8EC$LQS',9]WAE]
M#G/"D'+?T=.SE5]:>[1N@9*K+,20Q'SUB=V#!SGZ7?C&<XE#.<9\)(9S&7=W
M9\,L9C@K@0?7OZE6.%*AVR;)5I"/7%%[P,4<AG6A/$!CC/'Q><;NEY9/CQ*$
M1QD2.<8EGR_H,Y+$D;,]FWR>;RY_;DK,9[N_/=CNQ];&<]^<8^MC.>['?_C[
ML=_YV/I<*HY9ZMB<*%*M6O$J5@LVE9SRQB(\MCEB4P"[\9S' ,QQXHRGC$B9
MB3Q]T(XC"6<=V6^_IU+-I RRVG:/-GT>[(\I5Z '"T$;"Y(E"6.)C)#/?&4<
M_7Q]?'=GOQG&<8S'.,XSC&<9QPK5R3G 4)D).(QCCF<YSSB,81CCOE*4L]V,
M1QC&<YSG/=C'"*T6V[#6V^(+*KS))8F<C?E+R\=V>[!(#%F.9S$3NCGOGD4L
M2A'.(=WTRK<X:]G)JY_/S>0'7MSVJ#<*M.$5U]3V.L\A:GR#*)H_0CE*>"":
M-/.<REDGAAF!RRSWXA./ASG,1CGG/@AQT;Z]^E6M=G[^?H\P]')J5P>%FG")
MPB<(G"+8-[*[ZO?L_P#[.Z@?R4;WS%_@GH]863/"'3ZBO:5RE7)PB<(G")PB
MT4^T/^J#Q]XNM?PBWY:S9T^P+5F\+?F"P5YFJ4X1.$3A$X1.$3A$X1.$3A$X
M1.$3A%E7V)/JGNF/^5VO^(^R\Q?X)Z/6%9%_*-Z?[)4B]MOZN5AV:?!4V;2"
MX.K3S5Y0IE8O-294-TV(E?ID6[C>E6QZC-BH:8TG5H^&1U'@H/*XQ\O1[5LO
MY.DY\V66OHWYUYS]GMJY]@T$:VM$U-C,K2VKO.PE;-KR,'#U0BPHG.E1L(RP
MZPA$,<2;)*0AI*06KE;%4JCK'NFK6'L!9*N.HD8F2O<+,0YCDLZ*( 9##)PN
M$SY,U'QF5829*NY7&RR@6.&^^Y1?;!JRBKKOW-;QL*C;:Q==>J,3$K.O.M;)
M/]UVO", B;JI*$"E8!Q&%D-R)U(#":R46CS^C/7LWR\^T*?-OY/M"CVO51KZ
MX"IF!V9F'8'B*$I>?8,(5K=B.M 3.)RRY935BBMB,2%R9@?EB+/PCE.Q0IEK
M6PH@ Y9JHYUJYUG-;<*V&O/6RWO1*-W6(N4ED%FR9Q.4@O293<%,1LY7*J[A
MH; RJ1Z<_5N44-L[>UV9Y6#;$'6/'A-5DRM:BVS@Q\X#.S<"(,FSYD3&)-6+
M+,PQSF/J,!CR44OKM8JRTXB1<B!PK8!!V+S&%,:YL48YA\&]H6R8HDJVP**1
MJ39U_ /!8$]7+P"L%Z>#OO[AF>A-_?\ OU>Z&V\+&MLH1:L(DM%1PP;*;/CS
M6'A,F/1197SA?!@1\)"81*0(2%D&1,,#/"$HJ]3:LU%.PM&:\%BW7 $XOKC!
MF!%>1S%F3UD2*1@-&!507\;%<LVK8RA(SV<>@J;/N)GE]NSR\H/)OK5=M[[6
M7-2H<EUB H2=NE@IH6CBQJ9Q2-4RR2N=?C;F8U^X]XC-*IL<-L5]JM9&KK)<
M+Q Y)OOY]NO/R*!X&Q>LE;.=.N36&HM-EC+6$*\ Q86KTQQ"-YX\_)7\ A!$
MXZ: 6'#^9 +C4"*YTZ:AK:J&,MWE+D4*C9ZS9:=I3:*IS"['N5A^MS@6KV-2
M6%HZGBP3-,]G7G6'&:N)#'#C???RIOOOY%"K_9G[<[5;7EEA2P9#.Q!5Q950
MV.W 0@H7<:;.,119LH96(RBN. "NA@Q%<4HK@69;[[\Z(N$^K P>P3$RIL=-
M(E99*SBT'."KE$8 S#,&(VD6S0%9K2GAI)E6,<AQDBS."*%<(G"*W&\61)9'
M4ASG$/#$[?=W_1YSGO"'/=]:.,>;+&?BSF0L_P![PH)(V>T^H>W[;<>1G]#_
M *W"QS=Y.IWN3R,_H?\ 6X3-WDZG>Y/(S^A_UN$S=Y.IWN7[@,L9QG&,XSC/
M?C.,RQG&<?2SC/ULXX3-WDZG>Y7NUNSE950BGE_; ,Y79EG/]U(>,9B7/?W?
M](.492SGNQX_'W?%CA9#??5ZE:J^?+;V!F)>+((RR-6&>_\ ,P1S]#W8[OBD
M3_I)_7\4LX[^[&.XH).>KTAQ]0RZE1?(S^A_UN%&;O)U.]R>1G]#_K<)F[R=
M3O<GD9_0_P"MPF;O)U.]RJ52V>I> X'O[H2Q@T,=_P"; EG&"BSWX[OHH_''
M.?[F>(3^G''"9N\G4[VCFU*\5U:80J2NASB1"PC!3/=WXD4\>\<^[.,XS&$>
M\V<9^*6(=WU^%FK&S',DY$)WSG.69SG+,LRE*6>^4I9^GF4LYSG.<_'G.>_/
M"PS=S#J=[E\^1G]#_K<)F[R=3O<GD9_0_P"MPF;O)U.]R>1G]#_K<)F[R=3O
M<I]H]B4#)*LN<Y Q&1E^_O[AGACOG"/?W=T2CQ*4O_G'CN^.<N\I!.>L=.L>
M@^OS<R[F\61.X52"6<1)'!V^[.?HH^+. ASW8^EXHY++'U^X6?I?3(2>3+TG
MU;Z_,K:^1G]#_K<*,W>3J=[D\C/Z'_6X3-WDZG>Y/(S^A_UN$S=Y.IWN3 ,X
MSC.,?'C.,X_NOBSCX\9_[,\)F[R=3O<KV:Q9$LJL>3RS)E:65SRS_=$\.,9&
M7/\ AF/,<2S_ 'Q(SS\7TN%D,^7?T!2+A2G")PB<(M@WLKOJ]^S_ /L[J!_)
M1O?,7^">CUA9,\(=/J*]I7*5<G")PB<(G"+%;K!MO8PIMPREUVV?L]U.]8JT
M2Y4ZF7>BH;+BF))CW<3T^PM"L,5\YQ:]+/P>1*6#>7G.<2Y(TN3/HS6+@P^$
M!GY5:SYH?LROMZ['/[:.E/R[D]__ $O2L="/F;U_:GS0_9E?;UV.?VT=*?EW
M'?\ ]+TIH1\S>O[4^:'[,K[>NQS^VCI3\NX[_P#I>E-"/F;U_:GS0_9E?;UV
M.?VT=*?EW'?_ -+TIH1\S>O[4^:'[,K[>NQS^VCI3\NX[_\ I>E-"/F;U_:G
MS0_9E?;UV.?VT=*?EW'?_P!+TIH1\S>O[4^:'[,K[>NQS^VCI3\NX[_^EZ4T
M(^9O7]J?-#]F5]O78Y_;1TI^7<=__2]*:$?,WK^U/FA^S*^WKL<_MHZ4_+N.
M_P#Z7I30CYF]?VI\T/V97V]=CG]M'2GY=QW_ /2]*:$?,WK^U/FA^S*^WKL<
M_MHZ4_+N._\ Z7I30CYF]?VI\T/V97V]=CG]M'2GY=QW_P#2]*:$?,WK^U/F
MA^S*^WKL<_MHZ4_+N.__ *7I30CYF]?VJL4'63V=&J6Z=_K/5+LET%W7Y-E&
MVJ-UZ85]@IEA<JA\KMJV0S"\Y4YUR>">/&$I!R[XSEC+OOZ7I4@,&S1'5ORK
M31[:SK/TEZM.=G"?2GJ?H?47%"KU:'>ST;;:39\5'O6?3G"$+.5*\YA+%C!%
M_"L6?+]3%1K O'@)<1R8,L\]6S;TJ'D'+(Y[?8M-M72FU>2-ML];?U,&69@4
M?&FZC84+(XH/T^R5F336!:9\Z#4<HSS 9EEF, ;7;*LTIGS[^7R*M<NW@H1E
M(VSB$+]@.9$6HL QK5MZH<3);56L0QC**K89RF[K_I $7L89A#%<&9JRNE.7
MW*+T5)FVRP:9(Q72\J1AXEW'/B?F3R,?T,\CCD0"^,^!'D//@P-9@DXBD176
M!86E0^.PKGW&NF9CF6=K<FS$&L^1]'*O, <Y K]JK"8BUK]ZKF#-T] 5BHV1
MD]DL&-O)S;??LWUHK3OW=WLC A.L1:9:8'W^6JDG-UPDLC&P\10"V7G)9+*/
MK'I'8_-29R;\TGXI13;6@5"UB_0)DE'9)X9159NZRBN=>N'E9REBI]VV55-Z
MD(\<.54+<-@8^6)+8860@<A%(]&^K]QY4WUC]_7ZE3-@VE.9K*5)5I5+-R&$
MK)NH=LIINHVJHWG:MVLL6GU\L+/%A')UI+!7:1P190)8C*)D>4Y^CU;$70H]
M4Q9)&=?<C6+%)[O2>)(,TT[@D%V4 [%CS,,U%9;K3.*OMB!RK)H<ISEZ59PH
M)1<MP_N-:PH6QBW4/5%CD2YO&19N%DA*1\E#XS2GWK2;S+STX16Q!@ L2R&*
M8QD72"*TW.W9,7RH>2JY9-0KT5@!3KT\3;=]V4Z>%13E#QD/Z-,8\2G,S;4P
M@BXZ(F_FY=_<IC7AT5G4KN$6KU<'KJ<KF"KH.6M4Z"%BO7VZT1FKUK2A>P\T
MA;5\B*6%4V6K;68LA><*9%!FWI,*(:[4$?<37;L#!S,.0LO-6V:N)QP17.UB
M"_\ S/79 MYS!)LC(UG,)&@NN13"GT^: 8EL;,FM7C:#CE/*WK;=(8C5)0V@
M["DO:T3R\V!P1(LW(^$,H1.:.)D/$<9D7+L6Q242(FTM3-6MIC#-N!0]3>:T
MRWB.,([=5SJ;"8Z;99QB1:VKLCRF[#.#O)1B;T46_(BM1PB<(K7VJ9&K%P^?
M[\\L1^G_ ' ^X8_WD(\+ N&>OUN'J"I_NN?_ !G/\W"C2&[G^Y/=<_\ C.?Y
MN$TANY_N3W7/_C.?YN$TANY_N3W7/_C.?YN$TANY_N5>J1%42MQ8S_TZL<1^
MG\4LRD#.<?%\6>XWT_\ Y<9^MPFD->S9KUN/*!ELSY=2H/NN?_&<_P W":0W
M<_W)[KG_ ,9S_-PFD-W/]R>ZY_\ &<_S<)I#=S_<GNN?_&<_S<)I#=S_ ')[
MKG_QG/\ -PFD-W/]RK]B(K%54+=^<X# OB^G_P#=9\@7_=AB6,?X,\+(D9#7
MZ2.?FS/7MVJ@>ZY_\9S_ #<+'2&[G^Y/=<_^,Y_FX32&[G^Y/=<_^,Y_FX32
M&[G^Y/=<_P#C.?YN$TANY_N7<KD2+/J'Q\7EL"EGX\_W/CQB>/I?7CG.,_X^
M$TAN7'T$+FMU"-V39\Y[\9+F$?CS_<BQ@4>[XOSH=_"%PY?6X>H*F^ZY_P#&
M<_S<)I#=S_<GNN?_ !G/\W":0W<_W)[KG_QG/\W":0W<_P!R>ZY_\9S_ #<)
MI#=S_<I9JH)JF;'G^Y*.$^[ZWB%+,<9^/\_!<_Z.%DT@ZO:3Z2%-.%DG")PB
M<(M@WLKOJ]^S_P#L[J!_)1O?,7^">CUA9,\(=/J*]I7*5<NNRTJD&;+C(%%Q
MX[R'9,, 88_/F4LHPC_VRQS-D<DK@R)CY'NV,8TO<?,UH)/0%7+-%!&Z6>6.
M&)NMTDKVQQM_UGO(:.DKK5]O4VT)$JK2OLQPSW3G7NK.0AG\Z<ER$Q'/^#.<
M9YG-35%,0VHIYX'$9@3121$CG >UN?0JJ:MHZUI?1U=-5L;J<ZFGBG:/.Z)[
MP-AVGD51Y2ME.$7D;]M/]6A+_-+H?\+V3EK-G3[ J7^$>CU!:D^9K%.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$4EJ MKU5I?*UJ[WNQRK5.RXFO9*5\+&%AD<S
MU[8CIEPT13T\#N * ,\X'&,6F%YQCIWW^W:BF36X%JZI5N@(YK35\H-A^IJ6
M"CIB6%8^TGE^-<8A 1J;=$['FUTX' .U2-D A(R !>>7??\ ?UM^GG]*@-<N
M&S?,U:'*N@,@W+AE)=<C(%67EU3,*(^8H LAG<%G"T" 'B.?#',(XQC!-_,K
MA6^L@6P)VILT:#,$E2V.163$:BWIL_VL':]9.P3UU@NR2$@VFO9P:[J[F1%X
M+=TSI5#H3U\WMWZ,U;)%-VQ-Z!"!3S++!/)C+$(2R+$XP(3QSB*.88+*,)3E
M\62Y'#/B)W2(K@0 +54*FT%2TVT5;L0"O#N0,1E6R,/)I4N#*LQ+1RPOCU5+
M:H%S*X%XK #AA#/55T>3IZ\TY-SYUQ[OL0);+<S2KD(V(W&P2V*&&Q6CGBS,
M4W'E1N>YX7LQSF&Q>2KUQF<P9X( NSRUD/+OOR>1#OOZU2-<HT2O(XN'Z1:3
M<,35JKEBV2$W!F$HJR;LJU8@ZB+&91,D=PXPXQY#3T159HG-**9V;U/KC6'H
MK7]1;RJLTUGJUL)'8*.SC3,SH&J"X:";7VE88#5*M9F))UE4^5FU#A<&LY$/
M7OODG[CO[.=6X6!:[.\L(KF?#"*M8NY;.'Q6UH<0+"KKB6#4C"KU99'E5+#)
M1*BSGQ%*(,3&@3?V='J5;)?/42D:?*351?TK>(1+'SDV:]M9D99'^A-"4&HD
M#CNC('CB692^JD(D58$5-M;K-X2(:ZF7KF;,BL[,%9&<H6MK#,Q#(HE"&((
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MR62C&;*3#T (S33.F5,,YM%+B!8&6\'\+%9=*;'%P90T@F@DJR*B70?(8]3
M? <.+T69O#G!P<0 -A#OU$X!K!@F\<&M)48FOS[9<J*RTQM-#VS34C*QQ-2X
M=]4Q2=LF2H$<#H87Q/B8YTCG9/:^*?=H7?\ K5U)Z$6O2"[]0#7E=5VB@TNC
M-4CITXV(==L]<JJZ=HR&++8Z.#GNH<GG62*"EF3Q2L1R;G2V6N@;V]-2:,E9
M5TTS7OXT.+G5#"[2T0=",3/R>2UK6G_1 ;J7;)\:XHG9A>UW]\U-A^Q7:AFI
M*;M$PMCBM<S(1$)3'VQ5=SJ;3IHV22RRM&J8R39.6@/8>RWM=4C4:)>[AIC^
MT;1TGK=.HZS=.I]$O<Z%O]3L=-M1M0U*G+9KXLJ;8T\UJBL4:]]M!C:53%(!
M*>3O]?DM<S RGDFA=++2-AC;/51A]/4-E9-Q$3=,!S)6Z(&BUQ:96DG+POJ]
M)CB@G?476EH+C%0T-^FN%5/;;)5NIKK:9Z.HH!<*^H;3O,-312<<]YEFACE;
M0R-#72 -BE&ZZIM'4S=$NMEQ9='=3O%'NE]YHO32QZRZ3;BZEUG3)FS7V::N
MP)M>Z(H$=7:7$643""51U1_R2*R*2R:*6IG;6O=1PO#J:2&F=6P/%2VE+A+H
MR!V@&Y@C/6 0YIRR6G;KA0V6VRX9IH,17"FDCO=-=+S#ARY4[K-->FPNH@^D
MECX\R"-['N:-%SFOBECTFOT1/NH2?4[KQ3:K=V..SITTZ=.=1MDVYJXSNVM;
M)2OMZUK#9:E+<;:CN(5^YW@55]KLK+W9D(:VJ3P\_F,$&_*V:@5->R)[^YM+
M3&HEF+^.CE8XQ1'0;.^-^C,\ 3.=H:FL;F[P7!<1:)+)A:HKJ:$XQO=XCL]'
M0,INYU;1U,4=;6QB>:VP5-,9;=2N>ZA@AX[2=-.\Q19F5FE"M9Z';1L=MH6L
M=1NINJZK0:+TQV7I->['JW4+0K"WM**ZVEM;6:["%BQ8%24O4]AK=<7P5,38
MS807%D3#(A3HBH9)'P15-3%#'3TLM+))%40.>Z.24MB8&N)+1(V5D0[W,=Z-
M3BN4KL3T-'3W6NL]DKZ^KNE[HK[2T=?:+K#3PU5/0QNK9C+%'$V1]-)235C\
MI#&6\<YP+&$B,=.ND^TZ+M6I[U2=0^BC;]!M7CL=/^:5JC.X5?2W=:BIT2EC
M:;'BZC3V=:;6SZL#5T_#'S[:]KC(DD5^(>54U++!+%.RHHBZ.7OH14Q&5M+.
MUD#-.33T'-,1BXH<KY&ENMP"WKQ?J&Z4-?:ZFT8E9%54 XFX]Q:]ENGOEMJ)
M[I4\11FG-3!,VL97.K9->C!2RLE $)<J!J?1"R#J^BJI;_TWZ@V5OT_ZR=/4
M]5+UHTYQ;0]]V<=P&O9T(:U\*KL_?E1;TV+RI'[R;3,\[9SQ@Y:L:U<=$[B8
M&MGIIW/IZVG$1K87""HETPUU.!(&/XQCV:;.^<TN+CK+=':KL30OKKF^2TWF
MTPT]VP[=I*\8;N,;[K:J)U.Z5ET+Z0SP]JU%/4=K3GB8Y&110@EHJ"_EH^S[
MU*W@[Z.@6FD;/[SJ>C8P6-%UMU&UU"ML>F6J:A6[ ;;M#JQ;$+=E:]\@UEL'
M\F-9ZY=J 7@VP@&EEOJ9W/;3.AEXQM'DYE;"Z%KJ6*%LG'0-XP3AKCHC/+0T
MM+)P> HJL766UQQ2W6&Z4/$5&(2^*JPU<8*^:&]U]PGI&T%SG-(;;)+$USGE
MI<9N*<PNB= YS<P=NP7'5?JM@THS-B_U[!9PCF$)$QHFK8G*$,YEF,,R[\QC
MF6<QCW8[\]W?SW1P+Y_!1^>WMZ;/+5KSYE^4W#^0<6T.CF&]QZ;1!.9#3+/D
M"<AF<MIR&9UY+H<^O+X2G")PB<(HONO_ %1V/_Z.]_L)\XJ^_P"1;KJS_P 7
MU>KGRA>NP83_ )SX?UY?XXMVOF_C46M;S.EO61OJCV;^@/9CCK-/0E]VZ%55
MFWA;\ 6+)P*H:S-I6Y4AZ1=ENQQF^L0O-')/&+$2)2"DBS^=4EM%OKZR^&>2
M4<7(^2G+=88UF<FA('=\6M9^"86 9=X79'2'ZTG&4N*</V7@S%LI*%_=6&EI
M;PR7)LE3-6NCI354O$CBHY9:@&OJ&3RR./\ &60N<SB)(CU_Z.6G0C8V-2VI
M^IOXEUH>P9-40.<#%8UE]8JQDV@C-%CS*]L>5IPG$P9!)&6<&\$-ZW7.&Z4<
ME3'')&QKI(W,D#226L#CED2' M<.G,<BZGC#!=QP1?Z:RU=925-1-3TM;3U-
M(^1K V>:2%FF)6L?#(R:!^>>8T-"0.[[(>?X+W3W6)VEGCI#U0V'5]:KCU_3
MW6B]4+F_TW7=BZC:9K^W;%3ZG7RT+TU;;K:;LVQ7"3(K+9LC)K)'K12FP_4V
MF.M T\6D[M.KDAB;E3PFI?)!')4PQRR,A;Q&37B&61XR=)KB+GAFDQR^R.BN
M]:(8?A!8Z.OK)62W>M;8Z>EN5926>XU=!1U%PF%TTYJ=]PHJ.F>QT%'FVN;#
M3R5!BG@5,QCI^NKL^B:[H_5S<M/+;U>O:EKS'6JX:IM[J%MM;:48J=64Z>61
M%83MM71F85,K983S8B7>L*^#HCM89TX$M/'#630&1L<,9K7.9.P3%P+(A3.T
M<WQ-ST X-TN^<W/,W979\E%=*RZ8?MUQ;33UE?5LPW3QU-LJ'T$<;V5%=)=X
M0_*"ME:QU3)$7B%SXHI3$6LNOU=U'HMTRV<]6MT=VI-*X6Z4[U?ZQJNV@2KZ
MQ^LU_J_L$&)T'P<M8FCK"VB6OOXBEE/WBG;V+2JOJ$1K66W6PT=+(6"CF:Q[
M:2>2.*4-:QS8ZN3,QF-X_!"!_&9/.DV1Q S: [@</5^)+W1,G?B.@EEIY+]:
MZ2NKK>Z2:>&:LL%(6BJ%93EO;K[G!VIQD+>)D@AC>_0E+XNOMFZ])>IV[);#
MNW0BQMV;2D)H-:*RVX M6I*U?>M5H?6ZFFGK<2PM@-;PW:.-&@ME<X_2@R>#
MLF4HFGI*J<23T#GF1G:[0Z4"&-HGBCTH@V,$/#IRYQ.PC1&>EF,Z"V8@LELD
MI+;BJ*G;3U(NTSHK>YU?4S/M=?5<77RR5A!@<RV1P1QM+]-CA([0,89);/4[
M#I=LG33=F%^DUI:!-TO:][K6W6#ULE-;Z3RZ:6M)'7[VOZ9D@#8TP[X&OB+*
MV(U\J)BGL<QRRQ &M"ZEDI9R*5SAVJ=,/K-+**D[5<S0>VF($C14!N6B SBR
MQV69RYFNBOE'>K8Q]^@A<+W&:=\&'N+$E9?Q>8*GMNEEO(<^CD=:WS:6F3+V
MRRHAU1LTY=U"CJ ;O=:VRT#=K7??ACTVL7B:YUA:QM ]YZ?2USIKK=N<X>F2
M]E1I7N.I+5KIUV)1FPW0](S8BKZ$X_30MJ.)$D[74\[ZCCZ9SN+K#QO'TW%T
MT;S_ !8.8UXJG/AD:"Z8QEP8PY@:%I-P?3VR:&[6N"U]SKS#"*S#[.TC;+QV
MW>:V!K77I\-3+2FS,@N%,Y[(;:RI9$Z:J:=-V:/977TP73K;FM4I[FO>NG:W
M9]JL+_;B[W;7MWM_3_6-NDX]LQ%U/6-J"O8UC@XK!SAU-APD?->GGG.V<0]K
MS.B8]KGN9)*Z28SND?-3Q3:1EU9D<9H.U#OFEQUN*^9X_=<772@CKJBGFBIX
M:FBH(:2WMM<%+36^ZUM (HZ)KG\7&]U+QT1TW#BY&QM.C&,\<M(_ZH:W_P#1
MD/\ 80Y^A=@!%CM .HBW4O\ PPORYQAD<47\@Y@W6N/74R*4\Y9=;65W8?Z;
MZ9U<[4G2OIWU"IL;!I^QGVV%S42=L:[#D:S0MJNDL>MJFT; 'D65<FSWKM"R
M3R?*+XPS(.?SGA:OMUPUP>XAO=DJC17.A;;#2U(B@G,1J+S;J6;\%4Q30OTX
M)Y8^_C=EI:3<G!KA]T[&K"&'<>\-F"L)XLMS;MA^[NQ +A;W5%72"H%%A6^7
M*ESJ*&>EJH^*K:.FF_!3LTN+T'Z4;GM=DUVO]@Z@=C[JW:]&.FM5JNN=.$$+
M_9NC%K8Z9KVS;?IU-U;UP6O]0\Z9O>T5]QM%$>T<3NM?L3HVL&S(JA$<LA^3
MB/RW@ZPSA?A7L5+C/$CZ^XXC?41T6)(X[A+14-96V:72MSJNWT7:\#F]HOHY
MVM:QC-.1^B,]->A^'/'W"#V.>,*W@OP)!9;%@:&@FNF YI[+372[6NV8HIN+
MOK;;>[KVY6QO[L1W2F>]TLDW%Q0\8YP$>6+<NV7V@96EK<_"Y#+MKLU3MT\&
MUC7'4D[NKT073)@B%:_6-5P$=AT(,-9VFJDJ2LOT,>-Y6;<8,P[X[@0X/W04
M\':-<QM-1ST;'QW&ICF?'-727)CY9&.:Y\U+6R.EI)B=*')K!FP:*^-L[+7A
MH;5UM8Z\VF5U?<J2Z2PSV*@GIHIZ:TPV.6&G@E8]D-)<+7 VEN-, 8ZD.?+D
MR5Y>JI5=N/M(:ZO2HZGN-3I55K]I1V%51Z3I6G:C0+)ZXF-*HUF%)0TB-9C4
M50Q8E\',+8KB'L+$Y1S*V2?*_N%<'+A4&HME;72U--+3OJ*ZZ5M34"2>0R2U
MS)7RZ3:YSBT<?WP#6-:&Y YW'LON'"/M)E#?K5:*:@KZ:L@HK3A^U4%%Q%)"
MV""T24\-.&.L[&!SNTAHYODD>9,RW1H^J]:.MW47;-<T?76*HUOMMI6ZC25B
M.MU05QSN-6ZE],$TUP"6Q!9-?6NM.\I8\/A@M!Y=V4HEJU2B5O!AP?8?H:J^
M5D5<R"T0RW2HJ)KE,YV5'56^[O>]SOY1[I[/29 C-_?Q@$RG/*T=D#PT8VO%
MLPC;:FSOJL2U--AVBHZ:Q4D<0-SH+UAN**-C/Y&&*BQ-<07 AL/X*=S@*<$>
MPC7J9?7-?H]>3S*2E#3UE,K*>,8E)>K2 B#,L1^AQ+(@1SG&/BQGO[OBY^=%
M;525U95ULN0EK*F>JD V"2HE?*_+/DTGG)?N':Z"&U6VW6NGS[7MM#24$&>0
M/$T=/'3Q9@ #/0C;GD .89+71VK/9B]+>UEU6EU8W#?=UUZWEK=-K.*VA#3S
M0BI33>($V).K%/DQ9/E\WOGX<8C#$<8^/F_0U]LIH.+J[*ROETW.X]U?5TQT
M2  SBX"&=[D3I>$<]>P+A[O:+]6U8FMN*9[-3\4QAI([1:ZYID:7%TW'5D;Y
M07@M:69Z#=#,#-Q6-?SBSH']UKJ?^#Z[\CYN]UK%XL1?.]Q^DN+^#F+O'^J_
M-NP_J4^<6= _NM=3_P 'UWY'QW6L7BQ%\[W'Z2?!S%WC_5?FW8?U*?.+.@?W
M6NI_X/KOR/CNM8O%B+YWN/TD^#F+O'^J_-NP_J4^<6= _NM=3_P?7?D?'=:Q
M>+$7SO<?I)\',7>/]5^;=A_4I\XLZ!_=:ZG_ (/KOR/CNM8O%B+YWN/TD^#F
M+O'^J_-NP_J4^<6= _NM=3_P?7?D?'=:Q>+$7SO<?I)\',7>/]5^;=A_4I\X
MLZ!_=:ZG_@^N_(^.ZUB\6(OG>X_23X.8N\?ZK\V[#^I3YQ9T#^ZUU/\ P?7?
MD?'=:Q>+$7SO<?I)\',7>/\ 5?FW8?U*?.+.@?W6NI_X/KOR/CNM8O%B+YWN
M/TD^#F+O'^J_-NP_J4^<6= _NM=3_P 'UWY'QW6L7BQ%\[W'Z2?!S%WC_5?F
MW8?U*?.+.@?W6NI_X/KOR/CNM8O%B+YWN/TD^#N+_'ZH_-NQ_JT^<6= _NM=
M3_P?7?D?'=:Q>+$7SO<?I)\'<7^/U1^;=C_5I\XLZ!_=:ZG_ (/KOR/CNM8O
M%B+YWN/TD^#N+_'ZH_-NQ_JUR!]AET' 81Q=6^IV"!) H\Y5UR6,3'+$X9SC
M*?=G&)8QWXS\6?I<V[?B.TVVOHKC388I^V*"KIJV#3NMQ<SCJ69D\6FW3&DW
M3C;I-S&8S&87&WG ^)+[9[K8Z_'U8:&\VVNM5:(</6..4TEQI9:2H$4G%.XN
M3B9GZ#]%VB[)V1RR4X6]CETF5K[!"'5OJ!*-CZ;!3DJ=6F8,%R^=X5YY2[Q9
M+/$,%E'/T4(>'.,Y\,H_:7]D]BF2>"8X>L(XCC"UC9;F&/,C-#.0"KR=HC,M
M&7A'/4!D?+-/V G![34-?0LQIC!S:_M<22R0V!\L3*>0RZ,#C:\X^-=H"0@Z
MVMRRST2P;V._3=BM3IC]<>J1JJO,PPC7D4UV:BIFO#EB8 R5S >22QF><1QB
M,2%.2$8S8/(DM[)W$+*B6J9A/#3:F=C(YIVFXB65D>IC7O%5FX-&0UZRUK&G
M,1L#<9>P&P3-04UKFX1L?RVZCFFGI*)[[*ZGIY:C(ROBB-MT6:1TG9 9-=),
M]H#YYG/K&N^R$Z-:X59T'4;?'+51T;0W7%:.82+8_,VJMFN@O!1BOL%9'4=C
M./J)A.3 6 _%S4KNR7Q;7-DB=9;'%32Q&-T47;H>V3,.CJ(YW5+I8YX9&LDA
M+3H![!I,>-2Y2R=@AP9V.2GJX<28MJ;C353*B.KJ9+6Z-\'@3T$]$V@;334=
M9 Z6GJ0YO'NBF>(YHCEE3H>QVZ0JFMRUW57J&C"T"PH,44Z _N]%HL9G66*9
M;)2>,,?1><U,Q,J$-&69G)@\+SV3F*WMI1/8+!,:9[)7.)KV<?-&TADD@94A
MK=%YXX-C#!QK6D9,&@=)G8#<'--+<Y*'&&,J-MQAGI6QM-GE%'25$C7S00/E
MM[I'Z43>U>,J'2O[7?(#G*X2MI$?8P](XRQ+'6'J/B4<XE'/NS6,]TL9QG&>
M[*6<9^E]+/Q?G_%\6=H]E+BDC(X:P]D=1[^Y[#_\VN+'^#TX.6D$8YQMF"".
M\L.T',:C;"#YE. >R?Z=@$T*'5_J##$;@E_KY0U^O@9U&X*Y%HS&O'$O&2R[
M4,97=KBX,@W' 6" PZLNR/B']D9B![HW.PY83G2MHJYKG5[V7.E;$8V1UK'5
M)#WQGOX9V:$T6;XP\Q2/C=VV+L)L&Q,J&,QOC%F5TDO-EDB%GAGPU<I:H5$T
MUEECH&N@@J& P55%)QM)4-$4\D/;4$,[(W=>QZZ8W[TW[#K'U P27?$2Z=%J
M%?7IAR0A?3(5R5<!-%;S2E-D*P1PF<QF"8F<Q23WZ3LF\24<+88<,V$@:W22
MSW::>5V0;ISSRUKY9I-%K6:<CW$,8QC<F,:T<'=>P)P+>:Q];6X[Q@'NS;'!
M2TF&Z.BI8B]\O$45%2VF*EI(.,DDEXJ")C72R2S/#I99'ND==[)CI35]X5.H
M^W8K64Q5]M53I==RI>(Q\S) VLH &P<V9R"=9Z)1O5KB:KU:PJW$QC<?/V1V
M**GOI;-:3.R5T]+4B:X<91S'1R?3@U#F,: ',DA+70U$4LD-1')$6M;SU'V$
M?!]0 PT^(K^VAGI8J&Y6\TED[7NU&PO+XKB]M RHFE+S'-3U@F;64%5305=!
M/35(EEEC1O8Z=)R5@J@?5[J,%(5BU9^#%?K<YD89"NO#S)23Q',5EU\0#X81
MEXC,3G*6)PB/D&=D]BAM0ZI=AS#[Y701T^9=<0&L8Z20Z(%5F#(^3-^LC)C
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M7S^]/O=,-_+EW_$I?H)\ZEW?]=GL7[ENA_)^/AO-\F4W]=/[T^]TPW\N7?\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g393013g36w38.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g36w38.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1HV4&AO=&]S:&]P(#,N,  X0DE-! 0
M     " < 5H  QLE1QP"   "   < @4 #&1#2R V("8@,3)H<CA"24T$)0
M    $-<1V;#8Z$@),"=J"3F[_&LX0DE-!#H      7\    0     0
M"W!R:6YT3W5T<'5T    !P    !#;')396YU;0    !#;')3     %)'0D,
M    3FT@(%1%6%0    1 $$ 9 !O &( 90 @ %( 1P!" "  *  Q #D .0 X
M "D       !);G1E96YU;0    !);G1E     $-L<FT     37!";&)O;VP!
M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585
M "< 2 !0 "  3 !A ', 90!R $H 90!T "  -0 P #  ,  @ %, 90!R &D
M90!S "  *  P #  ,  Q $4 -@ V $0 ,  R #D 10 I       /<')I;G10
M<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *
M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'649F         *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M          !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #P     $  0/      0 !.$))300F       .
M #^    X0DE- _(       H  /_______P  .$))300-       $    6CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          CA"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #-0    8              ]L   :D          $
M             0             &I    ]L                      0
M                       0     0       &YU;&P    "    !F)O=6YD
M<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE
M9G1L;VYG          !"=&]M;&]N9P   ]L     4F=H=&QO;F<   :D
M!G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI
M8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   /;     %)G:'1L;VYG   &I     -U<FQ415A4     0
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M24T$$0       0$ .$))3004       $    !#A"24T$#      /      $
M  "@    70   >   *Y@   .Y  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D
M;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,
M# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0
M% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,_\  $0@ 70"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$!
M 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%
M!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&A
ML4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*S
MA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7
MY_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2
MT? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-U
MX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P#
M 0 "$0,1 #\ ]522224YXZ377DWY8NN>^[<=KG:-)V^VIS/2M97^C_F_6V*Q
MT]SWX..]Y+GNK:7./),=]7_]6C6?S;M8T.IB./Y0<J_3(_9V-''I,B(C@?NA
MK?\ -:DIM))))*4DDDDI'9;L(&USIT!$<_>I@R 8B>Q0[O\ !_UPBI*4DDDD
MI22222E))))*4DDDDI22222G_]#TOJ;G,Z?D/8-SFL)&NV(_.<=U?L9])_O0
M^C$GIM+B27.!+I[&2-NV7;-O[BKXW4'YG2LJR\-<6UO,T.;JQS"]NWWV^E9^
M9^E_XS_@Z[726U-Z=0VK2L [1Q&I]FWT\?9L^CZ?H5>E_-^FDID[.PWOLQQ<
MT6M#@YNH(( Y^A^_[/=[_P#!I^FF>GXQYFIAG7P_E%SO\YR1PL1EC\EM0]9P
M)<_4D_=N=_4_<_P:;IVX=.QX&HJ9H9'8?O#?_G-24VDE"MSG-W. $\09_@U3
M24LYS6M+G$-:T22=  %"O)Q[B6U6LL(U(:X$_P#10>H]4Z=TN@9'4<BO%I<X
M,;98=H+B"X,_S6.6?TOZS_5[+O&'B]1HOR+K+#54Q\N.KK-!_4]R(B:NBIY'
MKW6>L4];SJJ<VZNJNV&,:Z !M9HU=5]3,K*R^B^KE7/OM]:QN^PR8!]H7$_6
M+_E_J'_'?]]8NR^H?_((_P"/M_ZI6,H'M#0=%QV>B22259:I))))2DDDDE*2
M2224I))))3__T>WJ^VGIV>^ZR:F5!M-FXO8ZJOU';BQV[=?;06^O:W8RS>RK
MTJ_0>M+H[7LZ;0U\AX;[I.XR29W/_/=_+616S#IQ.L#$]0&MQ]9@%>@#GN<X
M>M9Z%C-N_?[J_P!7K]+T_M/J;]?I'J?LW']0;7[=00!&I[-#4E-FTQ4\\PT\
M\<>99_U2YCK^3D8_0^F.QKGT%Q:":G%DCTG';^C<[V_VWK:9UC'NRK\.MKC9
M3N!>TM<):=AVBIUUOL=_.?H?T7^$6#]9O^0^ESSN;S_Q3_)O_4I*0?5?.SKN
MLLKOR;K:S782Q]CG-D;8.UQ7:KA/JE_RY7_Q5G_?%W:14\3_ (VO_$U1_P"'
M:_\ J+UPGU#_ /%CTK_C+/\ SQ>N[_QM?^)O'_\ #M?_ %%ZX3ZA_P#BQZ5_
MQEG_ )XO5O%_,R\I(.[N_6/_ )?ZA_QW_?6+L?J'_P @C_C[?^J7'?6/_E_J
M'_'?]]8NQ^H?_(/_ %^W\J;E_FH_X*\[/1I))*LM4DDDDI22222E))))*4DD
MDDI__]+ML-X]/J]GI[2R3Z3GEQW,%KI=<P^K[G>W_@]BU.E;?L-9:TM)G<#,
MAP):[FW)_=_T]O\ 7612YAIZW9O :XO+752'@M-K&N<?9O?O9[+-_P!#]!_-
MT,6IT4!O2Z&AXL ! < 6@@.=PUT;?[/Z/_1_HTE-NV#6\'0;3S$<?R@YJY3Z
MRQ^PNEQQN;$1'\T_]T-;_FM766?0=\#Q,_\ 0]W^:N4^L\_L3IDS.YLS,SZ3
M^=_O_P _WI*:/U2_Y<K_ .*L_P"^+NUPGU2_Y<K_ .*L_P"^+K;_ -L>L_T'
M8PI)_1![7ET>G9]/:]K?Z7Z/_H-ZW^%]-$J>7_QM?^)JC_P[7_U%ZX3ZA_\
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M_ERO_BK/^^+>OZIFLR+&-<W:RQS6^WL"6K!^J7_+E?\ Q5G_ 'Q:F5_2K_\
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M &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '  ( !# %, -@    $ .$))300B      %^34T *@    @ # $   ,
M   !!LL   $!  ,    !! @   $"  ,    $    G@$&  ,    !  4   $2
M  ,    !  $   $5  ,    !  0   $:  4    !    I@$;  4    !
MK@$H  ,    !  (   $Q  (    >    M@$R  (    4    U(=I  0    !
M    Z    2  "  (  @ "  TKTX  "<0 #2O3@  )Q!!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$W.C V.C(R(#$W.C$S.C,U   $D   !P
M  0P,C(QH $  P    '__P  H ( !     $   :DH , !     $   /;
M      8! P #     0 &   !&@ %     0   6X!&P %     0   78!*  #
M     0 "   " 0 $     0   7X" @ $     0              2     $
M  !(     3A"24T#_0      "           _^$!@$U- "H    (  P!   #
M     0;+   ! 0 #     00(   ! @ #    !    )X!!@ #     0 %   !
M$@ #     0     !%0 #     0 $   !&@ %     0   *8!&P %     0
M *X!*  #     0 "   !,0 "    '@   +8!,@ "    %    -2':0 $
M 0   .@   $@  @ "  (  @   /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP-CHR,B Q-SHQ,SHS-0  !)    <
M   $,#(R,: !  ,    !__\  * "  0    !   &I* #  0    !   #VP
M       & 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@
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MU=@:(R556'25EIC7)C+4UC,T>).4L]/_Q  < 0$  @(# 0
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M& P& P& P& P& P& P& P& P& P&!C\HB<7FP5Q')E'0DJC[MR,>.@<A%LC
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MS9R#(+,Q6*9K5G)HFS/),3$Q.>)B7'C3R6?]RS]&Q\Q'$P& P& P& P& P&
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M^9M+-3>=/V? G3X0^'(V!EV%WKM;H67<U ZXP& P& P& P& P& P& P& P&
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MMB;822?#Q#T@,0>\KI,'SP2,=.VNB3AP/9+*;MDB9QV1NA.#"# 8# 8# 8#
M8# 8&D:P^D?LA]Z$3_H74F9N4_9N#OPU[^=RH;NS"# H]>+%]8+V*^TX#_2>
M!YZ-\B/=;@GH95^>REW.3>PN]4_%+G9GU:\P+'?R>_\ :W:[[.I;^9M+-3>=
M/V? G3X0^'(V!EV%WKM;H67<U ZXP& P& P& P& P& P& P& P& P& P& P&
M P& P& P& P& P*J,G:"H)*%)[ST-[=&^Y,0\5*2W+)>Q\)Z8VO)S\BZ\-^W
M,A8DF,>NH/%UG$I@I'J*HVB >%CRJT9? ]6(EB/Y5306X.=)G39I2D1-J(T1
M.$S_ !9\*3.*R+1-W#+[ASN9B:\NFLVS,\\ ; +VJ>7TY,5UF3,<]V)M(M-6
M XLY KZDM&[,RDALQ=/&A%JBILJQ7UU.$Q2:;IB8ZXK##>T-^2BB(_6R-?U9
MM<5FW):X>GJYA;N:,ZWC*LC(1.:3U\5F<_>@Y1Q%(V)B5?29WL[9Q>2%21C4
M1'Q09T^+H\I$Q'8_31LX[3RPH>;]@^O-5TL(:,&JT=)5[V0*WB[-D5'&VCMB
M1%D:$I_0$V;-N-'"+],B9V=*[<M^63?C7S]A--%9UQ$:M,I)808# 8&K[5C5
MI2<*P9U1: FJC:!31R0-F*[:V0@0%\-7*6XM,0[DL8T9+;NU&KK@CJ\7VUT;
M;MO3<\..54QK\=DHV^'4U+,>K8YD>*HGCK2].X#4T<;C= S<R6;]O[U2(E4
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M=LV/"*T"#B\[!3<\-?%-1K1M!*:M*["2+[9HZ<ZKNX[5$'G9L6QX0;K)[&2
MQH*T7W09;OM7;QJ@N/&--Z.'AT$V!KJT-,BV[]H,+7GV_)CFI0(6C1-LP?\
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M+-3>=/V? G3X0^'(V!EV%WKM;H67<U ZXP& P& P& P& P& P& P& P& P&
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MMD&CE%+E;?1-/393G7G?;5/37G;GC37CBVQAM[H56\=GU<K_ -(]A_Z>3/\
M\T'/_KLYN#N'X+4ED<@-=AM3Q\V;U:BZRV;:ERKXEPVY6=SGA7E#AXNMPCRK
MPFGPIRG[O._">GO>WW=?97>:-O<LN].SO=ZLK6( 7O<5ZRWL[$^GG7"3P>L#
MJ--.^P-S7)-H8ZL=S$8&^F#BOX%$Z_@Z<BBXA]-)M)14I?.3\J*.@48CT2=\
M\1P^0-,^&!.BNR/'-FZWRX?V(L?KY#[Q.=N++K.W8#7#VN^:LMVE8[HSGEHN
M+'(<1$;5AJCHW)9L]UMK](RP.+11Q%W#4#8F\UCS88%!DA9U/@<E-OCQ1^M_
MXD]&1B#V-+K+A-\5,>JF0TR"FE33NK7G%M-FW8*::5]4$F!Q:)DY4UF$8FLN
M2+@AK^'F#KK4M&I&'<,$30I4=L*=M>S'QJ85OXK=(#W4I92>FNU<,<UC.X;
MKTXE%,<,VM!N;'WBOZ/9#9Q1G)R CF,3%I,0I08]@C^<$&(E1P0D L,W1][8
M4YX^O?UPVSIW^J%S;RM6"X/>9T"TN%+KZ2O8%5Q$I0PJ[%'"8S>O7TT;/=RW
MK&,E62AIB2-8PZ@H.9;;QLU*F!)N[10%/Y<WC;S(P0SQ/F.UF];(84C\VG56
MVOU3[ ]C9A?P:E)-'1 ]&H)I&0R*B49'RN9J@PXH2O)6\Q::NI07T.E:N:C?
M=4F'I=!3-,\DQ&_:^];7B;CVM$]FS<)J6Z:ANFM>F%U=LZ?#]CZNXC(*Q(O6
MD<24UD0YN(EA)=P/#28_"FTGBAYY$9BT:R-CYPIIPJLLU$1ASS3'QHS\C(G7
MB55N4J2WBI 5<'7^;0;K!*.R\>+7#11+T\NJ^,CVB)JV*\A',N#.YP"C)@O'
MN3,%-R* S=LG)(VW,#P6AQJ\X%)S;(G/IY/UPULMG'B;4-7LQL>*&(=>Y8-2
M5APFLKRM:/54[?5/4AVP04 /Q<E+Y1N6154!O&-CQY4DK%A\G?Q=+99[*!X<
M4J+(DQ2:173%==,WUZN5E4S\0JDX384JA[V+7*7AM=SP!5MIWY':Z<E:%JZQ
M9&J%;M(G,IOJ11(:.!CJ2QQG+3(".GHO!G9IJVFAX L@1T8BGCE\4;R[#+]B
M^8@!$]9&]=-IY(YN !G)I:+,B=BE90)9-^\E,[^9(>0Q K8)IFDQ:A8_$6<L
MCB;@N=:E21/40(?M71&MS0%]T^U9%P3ZYB3M%2J^'?>E3IY$>R(NN96A2SX
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M#3:<%@R)D[U"N/I4\1'M1 !TBPTJ>[Y)*)<4016?.5M)LU(I@BV[A02S:IO
M)!18B<<TUU3%J.N,W>U9XE4<&6#5M-5+P +')Y:_8R&QFH7+*XK+H@1%+'CT
M(LBS$)M*K#J-VSGC<1%8C I<4&1\$ND[E<R2BT?0>"%WZ)T43'+R9^7FTZT<
MO#!E)521QMK*W%EDB]W],.O_ &?CA"4=J[_OH*R&S=DS83V-/(+=\NENU?E0
MUA;.U(C(@A0EQ,82]3'OW+8Q%#&KX37EC-,Q2(Y--:1U:.=VDP@P,8F<UA]=
M1@Q-9]* $+A\?:\/3DGE!9B# B6NRJ:&BY H27;LVNBCA9%NERLMKRJX6102
MXW55TTV#6X?LQUUD-OFNOH&]:C,WI'&R[L]3XNPHJ^LD.@T;-7CS8A#&Q10^
MUV8LWS%X_258:K,6;YDZ=IHH.VZB@IIT,GLV63J(!V+^ U27MLFY):M'8,-*
MH=$G YCRU<K;%57TT+"![A'1PD@TY:M5U7G.[K1;A+E!);?0(S^'8\($.KS%
M^6$+1\H^O;N$\) 7#MD0<!"#GN!>RSP0N_&K.!SU8:XW49JNV#A=DYW1V6:K
M*H;I[[$SCLC="(?C5?0C4?WJ+_E(WEEWIV=ZJ\T;>Y6[RQ68$D>G7[UO7/[Y
MZ[_- W(G"=4[DQC&N-ZZ?E"]!N7=T-(K*Y+&.:XV?<QT^7!\O>)=PVX>?"B#
MACZKTWS9<>G\_P CS?)\];RO>]SS5/=]_FZ+F9B)XT9XB>M7-NDS%,.?]&&%
M.[^A)!NC^C/='R"0LA[WSQX4][X:0;/_ "O=^:VGL\[T_E>9[>?+]_W_ '%/
M=]SGE%Q/\4:='+%#TG-V_H^E^O<G_JMW_P#.NO\ ]J9'H)_BCJD])S=OZ),4
M?<?%S@S)K6.\QS@26U%^FY+<%_4>\S0=^?YW T9Y7L\[R_*\I3_Y??\ ,_O>
M[Q7;L<28BM9I7MGZ.5F>-GI1Q=^4W_592S[Z:=_&"&; \V'O7<_@LM^79<+[
MU-L/-VSTJQ# S:M/I'@'\;17\=891E7V;*/N+WY=I,8QKC>]F+/%S/4>O%B^
ML%[%?:<!_I/ \]&^1'NMP3T,J_/92[G)O87>J?BESLSZM>8%COY/?^UNUWV=
M2W\S:6:F\Z?L^!.GPA\.1L#+L+O7:W0LNYJ!UQ@<J^ZOTN#?X'#_ (O(,RKC
MU)Z4[H56\=G?*(>7."??1/\ :-E?]RBW_P#>>S'O_P"Q_M=RR[T[.]T5S'6.
M55IQ>(6QXJ=;U_>0 #,8+!NET@M+K]!YJU9EHF6N)];VT3MV9,(Z8U5"F9O!
M(!Q78L6^59/B,6!3XZ['[L=#+Q;8G")IIFDZM$:ISUCFCF0;LWM&8ZA%>W8N
MG^H!KK-V$GB/2,T7 QZ85-9E9ZI=A+ZDG60)<<<KP/)(-6HBTDF04JD0;2V4
MQ #-S0.KTIT7:B-'A%4FE:5F:9]E(B:1.?-XH^^1[;][X)#[F@+XW8("5BK.
MZ A:NL?M9!NI&ESB&W:'LTC2MCBIU4O5>PB4)*P1F%:I%:VE[B/5P8-/"$QC
MWK"3V&I2+9LV?R*1CHI.:*Z(KC/Z]S_6S;M[QTXCW?([=PS4V%]$[@ZW(QMK
M(*0H5@5N^+W: IR6RV&W21CD!#L$!0)G.BH:$E:<"U+)V?/ED)0;EBB:3?1W
M_P NXS<F,<LYL\QFZM-=B3U5VUV&M.3R7L,:[>PFFZQB?>2>]8..M4P@-9Z0
M G#(%=A&@1@ G/"+5C<"/8BW2K(=,ZY<,)\RA_#B91&.?HQD+5UZY\1AFIR9
M]<5T:(TUCEG-HY^U_=UI:R7IOVID=Z1>I8[&/"^[^6C)0"511KFI1;FOK@IA
MJ[*$HI#!XV0[B2+HG#3145#%AQ]7YA<"(RY:+S20;/"8PI3&U&O3FY.QC-S=
MD^T!:H^[%%7'*NPDNA-A^$+W'O1JZ[*TUUMIB0-II"!$,B>SRJHM1CE";!JP
M,,+)*Z;!+Y$+31F_&#DA\E,[LY%PD(I6,/6B-//CHG#1FQ2+OJ]NS/66L;1A
MDCOZ*=HQ\\\+OL?VE <R&HZI0 U3-:4:U2*&,PP.- D!DPH*QF]KKM@(BV-9
M[*-G<*W1=SJ3M2A-%B(B)IFIGB,W)-?IJYF07/V5[BA W?\ OR*]@FT8A?2'
ML75\*@](-*FK0C&K)B1.HNL$]G,?M"6F@)"<\-""EM'$(B]KP[ SD;?;N'9@
MM+!O(D&%(S9HY8QG7,=F:M8PY\["[&[T=VWMH]EI_7,?N)M NM_:-Q1(6!HQ
M3IH)ZO26+PX_#@<D<W3;-MW!%.Q4?GL_0/NS$)*PI&*1:/(&X&AI$;)U=/7!
M5I[]'U[$TC3,9]?9FIKQPQAUL[K@^LC^H!TF[;JH.*?K2P(C8*L5(</BP6P)
MH*7=#(#!RE?CVI%S;C@U*S(S>*5<D(-N95.VD5T'AB)1JQ;[$171X^CD@UZ]
M[B376YO;%/@J8Z[=RO$]VM!7J$^%@>(5 (S'.E5F<5'$+)B0]!2%,)7:-Q5/
M'[HG$$&Z+QIC9!,%&W'!F2LS!$T37'FLXZ:\:,]=M,,,:8,]I.SRW7CMN9Z]
MT]S&8;UMG'BK3>I6$6%"!",:&C"?ADL>P\XA4'030U:11NW[,,7AAPPCNK+1
MN=(2$'P@EH[>->2*9J\U?\_%CLILY)1M[E.K&[S/JUKG>0#7TTKWQ3^[%<=?
M3 UH-8IQ>7]?NE%YSFC%G2S331)Z_B5MA!#P@_>;;/%MV2C=VK[4O[IRC-$S
M_ABN.$WEF)[-FGG?;E-TB^[O;/PY>V 5/9&&5OV%Z^4S&1>_F\[1VW+HZCWK
MV%[(!%N%>$]M7L<$K]=802162Y>"I)%):(<[-W2+UKH12D3$\G7GB(G?V.H'
MBIW1V3HWIY>4VZZ0%@:?AJ4MTZ?L[:U&5?GJ94!1?U8.81J/O87*>)Z304W(
MOTA.C^/<(+!VZ.[M7XEQNU(BDS%>6/&*8](RJW9A!TC%V52$IR:<D73?B(@+
M,;VPQW$)(--F)C:5-8G#$M7#]15UJJ+^#\[,N&VF_+QQPXXX3(<\Z<J9"L/%
MGNY^K/+'L0Y8O2>'S@T;L:2:&E1?K>R%FM!$0B @<P#1J'P>)B&K00  1\(R
MY6U1<&Y$[/RLL;/DB:X1R-:5#W:N*PZ%\):2GIA'7\H[BR^TX]=?#4(!;;20
M-#NK/9NP'>@5BV0UTC^PBP:]@_))P%3;[H<I["7.VJ)-9%4FD?O<T9O]ZS&?
M9+FKT%=NX-T;JGP\1;O8>MWMJ[I'/:H:\;[:*_HD[*5*AIWH0#JH[IK<.HP
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M&B]<1.L-)F5LB^):FA*5IB5!CH*7C\A)1*(KB.?#/KG-F[=&&GE:I'V%<^D
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MQB37E=E^1,. \1^^>YL$Z^ Y%3+ZIW!33ME/K/J*8NWXZ &[$Y%S*!O01(U
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M#Y@2B$99#GL)A,35X'"==7G+MV]).G@K&?\ =C5GS:L]>UOCKEUDB/7%A/'
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MS4#KC 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M37EA%NSQ[-*TV5[X5O\ _DF7=S_M"=6/_%[:_P#:K-E?UPS_ -'X_P#$Y_\
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D P& P& P& P& P& P& P& P& P& P& P& P& P& P& P/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g393013g38x85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g38x85.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1_<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     # < 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 43E5#+3<W,S@@34]!
M($9I;F%L(#DX0DE-!"4      ! @&(0G C 3<AWMC%'DD-Q_.$))300Z
M  %_    $     $       MP<FEN=$]U='!U=     <     0VQR4V5N=6T
M    0VQR4P    !21T)#     $YM("!415A4    $0!! &0 ;P!B &4 ( !2
M $< 0@ @ "@ ,0 Y #D .  I        26YT965N=6T     26YT90    !#
M;')M     $UP0FQB;V]L 0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    G $@ 4  @ $P 80!S &4 <@!* &4 =  @ #4
M,  P #  ( !3 &4 <@!I &4 <P @ "@ ,  P #  ,0!% #8 -@!$ #  ,@ Y
M $4 *0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @
M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!W:7"@        "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$
M)@      #@             _@   .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8             !?    DZ          $
M     0             ).@  !?                       0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   7P     %)G:'1L;VYG   ).@    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $     CA"24T$#      4JP    $   "@
M9P   >   ,$@   4CP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 9P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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ML?8:G7'#;C&^DAI;2;'O=5D,M_2.I];<ZF]GIU?SEEBV+&,#+'M8T/>/>X
MNC]]P]SDDQW'F\?U#IHZC<+[KVD!H#!]H; ;_9:U&Z3BCICW;;@^JPMWUBYK
MC,Z;:]OZ5_\ P>Y9GUCR[,?/#<2X$/8'/:*P(/E[3N_S5:^JF0Z^VY^1;-HV
M^G66#@_G-L].O8IS&?MW?I[-@<SR)YN6*.$CF:-Y*C7R?O\ N\?R?ZMZ&SJ1
M8YQ%#[6"PU"JO7)+@-^X8=GI_H_ZS_\ A%1:.I9>8W+O;?B58]_JXE#ZWOL#
M2TU6[Z\=CL=CGU>M4S]/D?SWJ?HEM%K=Y?M&^-N^!NC]W=]))0-5H=2Z@<>A
M]M=#WAH]PL:ZMH;W<ZRUFS8W\Y<W@]4SF/PBX"\EK_19ZP>??MMWY5%#7VL=
M1OL94Q__ %SWTKK<FFJ]AKM:'L(U!U'W*A1T'IM5A>*&'5P VMC8X-_1NAHW
M>YGJ;W_I/422ROZM11>,>VK(-II??+:7[8KG>TES6;-T?HWN;Z7\M0Q>JBYK
MQ;5#V5MN_5W'(9LL:ZQC7V55M]*UOI^_>M#5OM:2 (_!0KJJI:6TULK:3N(8
MT-!)Y=[8]R(,>$@CU?HF]OHM(E8(.G4=W,=]8*C4R^JA_I&G[38,@_9W^GN]
M/9CLL:[[1;_4=Z7_  GZ16<CJ^-1>*74Y)<ZJRYNVBR VOZ37;@',_DV?S7_
M  BM65UVN:ZUC;',.YCGM#BUW[["[Z#OZJF'$<&.Z1X?20""!4M3ZO\ !4!*
MS9T/RZ?*T<+JOKA]=E,6;:[)QR<ENRT.=6USZ:_T5OL_2;O^MH69U&C'L:7U
MWD6V"MNVFPF2"[Z&T.=]#\Q:%=5-32VJME;2=Q:QH:"3^<=H^D@V$BQT($0X
MI& X1(W5\7_25&Z D;/?9X[ZQYF.SZP5,=C@W,8VL7/+HVO#G^VJ?2]_J>C[
MVK R\_*=<7%QF5T_UJZ=US-S*?L5?J8[6@-<T-+F.G])OG])_*:N?>RJ1=>W
MTZ7N(8+ 66G;H?8[=_GJ:.HH'LN;V-U$'I%OVP.L966^E#BQX=8YM3O1M;[J
MW/KW;EV'3KVY&#1:QSG@L W6&7F/;[W#;N=HN&IQ\O.:[%QZV69=!;:S';.T
M5D;76%SSZ=MOOK_._F_H+MNDTY='3J*<S;Z[&PX-B ).UOM]J&39#__1]%!@
MRJV+@LQG BQU@K8:J6N#1LK)#]DM_G/HM][U;=]E82'Y#&ELDAQ (@-+IEWY
MOJ5_]N,439@P/UNOW-!'N&K7#<U[?=^<SWL>C1[(L=VIFXM]\UL#37:S;9ZI
M)8W:=[/U=NUWZ1W_ &H99ZE2L6AQJ(/N=$'M)[H;.E8(;[,K(<T:3Z]KM6^T
MZ^I_)1:L/&I#@R^P[XGU'/LB/W/5<[9_82H]BKB ZAXWKW0.L=5RV6X[6Y%5
M; R7 5D&/H?I![U9^KG1^I]+]:G*:*FW%KFL:T.W1&[]*SVL_MK;O^K^#;<^
MW[0YF\[BQK&Q/Y\[V/W;_P Y2Q>AX&/:VXWFQ["2PN8!#C'O_1M9[OZRD,YF
M'!6GDM'MCF9<R/GD*KB]/R\"4\E,IWX3+7-+,ZV@-Y;6UH!UF7[V6?U4,].'
M_EID?YK/_229PGL?L3Q1[C[6+^4R/=B4V"&Y;JC(,L9K _-]^_VH!Z;7K_E3
M('AHW3_P/_JDN&78_8KCC^\/M8NY3(]N'18!MS7509)8S4C]T[MW_10OV;5Q
M^U+X_JMGB(GTTN&78_8KCA^\/M8I)W=.K,_Y4O;/@UHCX?HTCTZJ2?VK>),Q
MM; '[G\W_P"9I<$OW3]B/<A^\/M65:W^<=\5<KPJ&/#W=1ML $%CFC:>VZ&M
M;[DGX>(YQ=]KB?\ @S_>CP2_=/V*]R'[T?M:*I]2Z1@=4V'-K-CJM&/#BUP'
M[FX?F+5MZ;C61MZB^J.?39S\=X>H?LK'TGJMW^8/&?W/[*0C,;1/V*]R'[\?
MM#6IJJHJ932T,KK:&L:.P' 4U8KZ=BL=N=U*RP1&U[)'Q]H:Y$&'A$@#,U)@
M?HSW^:7!/]T_8KW<?[\?\8/_TNVO^K70[\BS*LQIR+CNLL%E@)<'MO;8=MFW
M>RVNO9_Q5+/YNFI6G]/P7 @TMATSJ>#RWGZ/YNW]SV*R4+[14;?2!.Z=LP=N
MX:EF_P"CO4VIWLTP&5=:<;K5E_3>GV?LYA8W%8#7M= KDR7.:?Y_?^?N7+8G
MUJ^L-^154[(<]MC@PM#0R9Y]^SV_UM[%TOUL8'8&2XU.L+:Q#FG;L_E/XWM7
M"8+0<N@%AL][?:/:XZ_FN]-G_5J7$ 8SL!CYR4HYN3$20)"/$(_I>OKZ9<7\
MOU?^=]2QB\UD/&TM)&PG<1_)W_G(A0<1NVHM##6 ?H'4M_DN=^<]&*CCL&7F
M !EG7=B4Q3E,4YA*Q0'9F&UQ8[(I:]L[FFQ@(CZ4M+MWM1U6NQL'\^JMCK':
MO#&AQ<>_J;=V_P#E(K5VY.+8X,KOJ>\\-:]KG'3=HUKMWT5,H=6+14&$5U^I
M6-HL#&-=X<L:-O\ 91"G!:5BF3E(M< '$0'<'X)&400"0#+2(/Z7DBB;H;;L
M$Q4Q58Z(:=>\&/BE<UC'!K"7$?3/:?Y*;[T/=&(:S(,CPZ\$?Z_[JN"7"9[1
M!K7J?ZJ)"NR*:9-K@QHB7.T&J#GYUN(T/9CFY@G>=[*P!'M=ON<RMWN]GI[E
MS75NI,ZB^EES&V8KF5W68MC'Z..GZ;(8WZ-?J?X)N_?_ ,$I#*EV+!*9!.D>
M[UI(\>>$[?YQG]9OY0N1Q.MYX--=^06AA><FWTFZ5M(;7N>P[,?U/YEGM_PE
M?Z5=%TO*ORFLNLH=CM+F^RV19N#O>TUN:W]$W_!6_P"&1$@5N7EY0UL$/__3
M[OKV1EXW2K[\.1<S;+VMWEC"YK;[VUP[=Z-6Y_\ X(LSH-]M]^2VC(?U+"Q]
MCZ<FX[?TS]_K5>HVMWK;6GU/^!_MKHI,R%$DGY*<&/!PF()NQ+]W^7_=M<CU
M WMT>;^LWJ.P[_M%197L <^FUSMH_>L8W';O_JN<N-QF80R:O1?ZKMPVUAQK
M<3V:',I?M_S%VOUM+1@9,NL:?3$;!(/_ !__  ?_ *E7!X#OURCWN@/;K627
M1/Y@WO4F(>F2WG) 9>4!B)<0CK+_ "?K_1_]#?0L:_K[:XKZ;C$2?IY[PX>3
MIZ<B?:?K'_Y68G_L>[_Y'*WB$&HD%Q$G5_TC_P 9_+1BHX[!EY@UEF*O7<[N
M8<GZQ?\ E9B?^Q[O_D<F.3]8?_*S%_\ 8]W_ ,CEI%,4YA,O .79D?68L(JZ
M=A,?V=9FV/;\V5X-3O\ IJOC#ZSL>;<S%Q<J_ANW,=54P'\VC'^P6N_Z[?=?
M?_PG^#6VHHTCC_JAQWYGUI&4]@Z9C#'&,][;6Y)M<+QO]*O:ZG']??M9^K_9
M_P#T-_P2HXG4>J.W#I=SNKVG'=;DTY9-3*KA_-,8]M?L>]_Z/['^B]3_ +K^
MGZJZ4I.<YWTB3\4[TT08B6MB^A&Q6F6H( 'EU><R<S/LMPZ>M6_L9EE!LL;C
M6DAUP):YAR6;/YMOIO\ L[;+?3]7^>N3X74?K-=6TUXM>5B"BXTY]ED6O>PV
M-QOU;;^FW;&,V>G^L?SS\JO^;6]8QEC-EC&V,F=KVAPD=]K]S4B3_KY)QX2(
MW$<4=CV_>X?[WZ2WBHG05+I_+]W]%Y"JRBK%QNH8&79;UFY[06EQ<;'.(_16
MM+O>VS\]G^#6SE9/UD:ZIN/TS%<UUH;;^NN.VN'R]KCBXWI^[9^D_6O_  M^
MD6B,?&;>[(;36V]T[K@QHL,_2FT-W^Y23ID2-]>_7PC_ '8?HK8RX?T0?#IX
MR_POTGCNK''?E.PSU*_(V/+GMN'K,8?YR+'MJKLQ*?3_ $?J4^JS]]5,7$PK
M\]U7K$5AKO6<;*G-K?M=Z>10_96WJ#?2J:STZ*-_\Y_QBZ/K'3LK-<RIAK%1
M<TOL=N=:0W_ U-_FMOYSWW?H_P#@OSUS]W1[J1;]IK_2,<VBBNMH%=@?O_HN
M_P!;)?MEOJO?_-?SOJ^BHB&[CG&40 :--5EN-6PW46N%C+'-N8":*WM:T-;]
ME&VWZ;'_ ,UE,_1_X+8NTZ9>+F-+;'7-W-(L<S:(<0YK6/#6,NV?1]3_ +<7
M(XV#D5LR7UXUSAC!M9K<PDEP<'-]K19^T,>GW6/]O_%>DNKZ1CY5+&UY%GK%
MCV^E=I[ZY;LW[-OO;]'W?I/](C#=9S7"8#76W__4])*9Q Y(';56O1K\/Q*'
M=A8F0ST[ZFVLF=CQN$COM<G\88^ ^#@]>PLG,HMQ\=YK?>T-!$%A\?7G^;:Q
M<S1]2^L8]M>0;:2*G!Q-3R7Z:GTVOK:W?_:7>CHG2!QATZ$$>QO;CLF/0NC$
M!IPJ8$D#8._*='+P@@=49,7N2Q2D-<-<-&4?E/$UL8%M9+G$[B3N?HX^;F_F
MHJ)^P>BS/V*F?Z@17UU"PULI+]K0XPZ  2X-Y=_(2$P!6J<D)3D9:>HVU"F*
MM^D/^XSO\\?^33>BW_N,[_/'_DT?=CXL?LR\&HHJX*JR2!CDD<C>-/\ II_L
M[/\ N,[_ #Q_Y-$9H]+1[$_!HE1D$2"(YF5;LP\6\&JS$]1K2"6N<")&K?S_
M *34,]&Z822>FLU()^CJ1,'Z7\IR0SP.VJ/N\^X:Y(B9$?%1)$\C74:JR[HG
M2W?2Z8PZ1^;QX?23'H7273/2ZSN@.^CKM&UGYWYK4??CV*/NTNX:TB8D3X2F
M*NU='Z2V]GZBVJQH+JWZ:01NVEKO;])6G=-PG M=7((@@N=J#_:1]^/8H/*S
M[Q<8D>(GXJIF].PLY]%N0QKWXCR^AQ/T7:?^16Y_S;Z$><&KP^BG=]7>AN=N
M=A5.=Q)$Z#M_T4OO$>Q4.6R V) %R1# &DB1IV!4F?39_6'Y0M/_ )N]#U/V
M.J3R8UU.XHM/1NF4#;30*V@[H:7 3XP'?R4?O$.Q6GE,F]Q?_]7U5)?*J22G
MZJ27RJDDI^JE2S:[K6Y--+G5674;*[F036X^JUMFW<QWLW;E\Q)(QNQ7=!V-
MOT;T3$RL;">QMQBQY<P4.]>M@BMCFLNRRZU_OKMM_P",N5K,HSKNFY&+7?<W
M(M:0S(<&-VS^;^@V.:W^6W]*OFA)//%[G3BXOIQ?R^9:.'@TOAI^C^D8N71@
M>FVYT/>Y]?H$7,8QQ9LJJNR9LMV;'^]_^F_D5H_4:,O(Z7=C-ML9:^#ZSX8-
MH<VQ]3G8[F/KJLK;Z+[&?I&,>OFE)+U>YTXN+Z<2AP\'7AK\'Z2Z7CY='3:Z
M1<\F7.:ZK;:QK'O]6NJNW(FRUE-7Z&NRS_R"N6;3CFO);:]FI>]Q:R1_*-;J
M_:OF%)-E?$=KL[=TBN$?NUU[/TUZ>2VMK:+;F-:W:W<VNR1,M<7/.]WM]OTT
MBS/[7W#_ *W4OF5)!(JA3]0T^IZM8LW%S*W!SW[07$FO78P^2LKY5202_522
M^54DE/U4DOE5))3_ /_9 #A"24T$(0      50    $!    #P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '  ( !# %, -@    $ .$))300B      %^34T *@    @
M# $   ,    !"3H   $!  ,    !!?    $"  ,    $    G@$&  ,    !
M  4   $2  ,    !  $   $5  ,    !  0   $:  4    !    I@$;  4
M   !    K@$H  ,    !  (   $Q  (    >    M@$R  (    4    U(=I
M  0    !    Z    2  "  (  @ "  Y*&P  "<0 #DH;   )Q!!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C Y.C Q(# V.C,U.C0X   $
MD   !P    0P,C(QH $  P    '__P  H ( !     $   DZH , !     $
M  7P          8! P #     0 &   !&@ %     0   6X!&P %     0
M 78!*  #     0 "   " 0 $     0   7X" @ $     0
M2     $   !(     3A"24T#_0      "      !    _^$!@$U- "H    (
M  P!   #     0DZ   ! 0 #     07P   ! @ #    !    )X!!@ #
M 0 %   !$@ #     0     !%0 #     0 $   !&@ %     0   *8!&P %
M     0   *X!*  #     0 "   !,0 "    '@   +8!,@ "    %    -2'
M:0 $     0   .@   $@  @ "  (  @   /      0   \     !061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP.3HP,2 P-CHS-3HT.
M!)    <    $,#(R,: !  ,    !__\  * "  0    !   ).J #  0    !
M   %\          & 0,  P    $ !@   1H !0    $   %N 1L !0    $
M  %V 2@  P    $  @   @$ !     $   %^ @( !     $
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MF8[?MNHUC<X^K)9(@IJL0<25+I)[F-= MT@AC%<]8C^SF!.%CJA#CVGZP/\
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M#O<HI\.R6N$]6QK6AR2TC54@<D+5Z#/KR2AVD#J3J9-AA5'-8\B.KPV[_O\
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M+2U$:0\4.O@%\WCA&Q[D:G2-&J8G3W.,57$(OTG*NMC2U,D9-L(2TE2OM+4
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MCHQ'.1;BYHW/=T(!#,5Y1[',RAY*'&4K<"TA0T*+7&F8J L;'87(L>( -+\
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MC]V\(VC581$SBYWM=M!@T<4 _F]QDBS!!.URM)&@0F!\[(-R*BL*8DD 1O\
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MNDJ<?A+%M:>7.F"QN^E-2YFCFD6(ER>?LA2UO#28<6@;A+1 2WFYL9E%1N%
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MA;J05*H<65S'UI)5<74<ZN.HUZ+VW!M:?D^IF'A1VD++3;:)5(9"0G+8-@(
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M+C"(([@MRO<G-[G+\F<Z1;7,IA"] WMCQ8P!LBP:^&)_6X,*OA!!#B"ZW*T
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MTZGN&P[2,Z*@R14(<#2,FMK^X_W;=<+'J^\=G3'M"XL-E'[;Y?NM*N[^IQ+
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MPQU))4WSH%,P_E>X]_QP[(KE5H;:CK'#P^"+1[L?R6+"T.6BNC3IF7V^WL;
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M)<>+&#6M73H;WMU?P[^V&571IV_Q[NR)9?88W-Y+_P U9'U7)_C]1Z45$_\
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MK-?N0F3RJV!B8\I9U<,8V.(0A!M8QC&-5SWO<Y$1K6M17.<JHC4155435?\
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M_NT=(K45ZD$G6]7-CK] SEUC3;C:&K+ 5F.@O;4<;V-K=6IVZ8[QR?2=2?Q
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MMG:'B/SR=/R(V12Z7%SUBFII<FSJ8CYIR%D0 "#&O)OG,,80D+.25(D.DO\
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MTB/153FOT6IWJJIS[N2?@Y^I>[5R5A1"=K]/D?$CSBZ8EFV&%+*;91UW4>
MXF]@.(\7"<:-&:C'R!(K&_217MZNY._FG/Q_[>?=R[M98>:2,H5??LUU.NO3
MV=$=7,G.O++@959>P(M8#8 =7&]CXPBVPC.ZOI\D;XKW<O\ [\_1RY\_1J8*
M!U!%ON]QB%4L\V<JDW5>Q !N#IO?A;KW[0(\.3,/.,T<?J:-%[N7/FOC])53
M[Z)X<^Y/OZMSZZ;=>G;\=NATC*0PAM!+@!/&^PXV'4.)[#T1[D<;A":U[E<_
MTKZ$_ G_ !_#XZDCBWR@E60:6(OTZ;_'")/<.O\ GA_J_P#[;UK_ !U_JO\
MW[_HXVMR4^S7/^&>-1B6*^*^M??K5\;O.Y[3XPFOUT]7].I$^S^D/$12*O\
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M"4D#.%H42E22;&]P%)4"1Q(((UT,<?BG"TAAZ40^E?.AY1::04)#JG  H)2
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M=_:[YJX9DP:"S\Z%8J$TET-+>N+'*C(KCM3J&SM"".H3=(GJSF16N&S6=4G
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MO#N]?/79FTJ U.^MKWM[OCIT$: GYMMY2@VD$"_K; @7V_'K.\2SX=?\\/\
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M4_3V&VQ.R1/HY4$NM%68LJ4;(*5'UBVH^KZQ)2HI]905ZO<,'8PJ$_.KH&(
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M?;X[%L'45, #94:U7)[V%8V\M7J1A8\4,]9)^U% @*%RA[.(MMK!W<O>]G5
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MJ*$%I;ZE\\TN8F4-.)6DLL2P<SNK;+?.+;;OG=;NRA'O(]SGN5SE5>]?^/\
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M*2;*)*K@#UDC06V)OQMJ=(\E\M]-J:4OEB?0NDTR98,S3&I<2^0S"4"4J"G
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M$(YSEE92EL!*0$I L!MQOWD[DG4QTZ;F'YIQ3\PXIUUQ5U+4>HZ ;)2-DH2
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MQ4<'QWJTI&L!O'Y/4K^S K4,]&]3W= 5<U#.Y<AJYO6J=2:O$K1= :57[_\
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MJ_\ NT_-T_\ LF)(>ET_\MIGZZ1_?@^9'^%:?NH8_P#RYX#OZOI_[M/S=/\
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M."\#JC6/4:,X!/"Q)4=0$VUS$FP3:]RJP'&/IH\H]%XLP<'G#FO&G9[(6^^
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M,ZW!(!:06.YL:^*"2ID>B<D7S:7'=V)5:CE&J\NE"N:O*TYQ1>18G*XE69/
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MN:&-#CB1\B?8RB!@5\(9I<N0$ 2$9W^A8?D\*RJZO6'6I1F407++('-D: J
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M+P\M0EKEI-BLSKM51),,,2\FH<S3&42[:6FSZ&@Y9EQ*4V+TX7E*.J4-Z ;
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MIM:VH-@3KKV[[F_([=@QL;R5DR1"-E,BU4=D*Q+(L6P%B3N4B*L(4<\97L>
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M#KI]W4.S[NB//\\XRXXM3*;)-_LVZ3W?WCHB4O#K_GA_J_\ [;UT+'7^J_\
M?O\ HXV?R4^S7/\ AGC48EBOBOK7WZU?&[SN>T^,)K]=/5_3J1/L_I#Q$4BK
M_JK[/>FI1N.T>,0#?N/@8\BTJZR[A'JKFN@6]7-&X,VMLXD>? EA7DY12H<H
M98\@:N:U584;V\T1>7-$UE-.N,N)>9<6TZ@W0ZTM3;B#TI6DA23U@@Q8XTT^
MTXT\VV\TL!*VW4)<;6+[*0L%*AU$$0W>.;&[*839MO<,V>VMQ&[:JJVXQC;[
M$Z&U;U<U=RL*JHB2TZE[UY&[U\=<E-5VMSS7,3M9JLXQMS,U4)N8:TV^K=>6
MCW1QDI0:'(/>D2-&I4D^?]/*4Z3EWN/^D990OB?M<3TPY)/1[?AKBHY6,9_C
M[/BNI&^/=YQ$O?N\S%J^/L3W)J\;=Y\3%D:%N&6N^0O,YT!UD:>=H:^*(SHQ
MFRV-4C93)0VO)&2*U%<XC&/Z^I([F.&=Z:QIM;:6CG&:YLD7L<PUO?J]^W&.
M\<GTI57L0HF:;/"G(D6%.S\TMH3"#*+4$*EE2RE)1,&840E+:U)"<I?2H+92
M8AM'S4^UTF90Y"-\1SU,:!(+^M38CW]37A.Y&M(074T<AO<X947FU&N8Y>L.
MMW45 :9M]5:$Z<-_NOO'NB7I+&-9.4J--=0^IMMIJ<900')>80@(6%M E2$.
M$<XRJY2M"@ 2I*@./GE)N)3#8."7..&NG1[K-(D^AIX]:PTRV<Z;%**9.BQ8
M@SR&MKXQ"'62H5"(_8#=S>5C%[U@*AS51K<I,H;4F5D'VYF8?*2$)YE0<:;S
M'U2MQ:4A*;E64*40 E5M??*CY1*#R(_)VY0:547Z;.8PY1,)5G!>&,*34Y+-
M3-08Q-*NT*KU::8=>:6Q1*539R=>>G'"AEZ>1*4U#GI,VTD?.([,)U2Q5AYP
MV0)S5<!V94UQ5E-R3J1!6#H88)&N;S5%2N(KDY?=A)]-OI(]) 2 =;]PTM;0
M&W3O'YV6<,RE2=+4SA5Y+RDZ-X4J-,J:6UWM];(IF7YP6/M)$ZVIO?FG/\V<
MJ;N#3N\TGW3=O[>0,,0T,XG>>2"@(5%DA%*05C'JIL-W4Y\<TLD=Q'#(.2YI
M'*,,MCZUA?\ E"W1?[^S2,>6P-6PX_(4R7QI(9EOMS4LN7<ETMO!HEAQ<KFE
M'Y^6F4#U7FY9#H;2XA;*2WZV=:7F$V!6RYN,BM+@B1WK2GMZR>BC6,UXY *V
M-9SH3G]CV2C588#O:_M'=#NKG4 [7T'5N#;CM;[^.XM''2-+Q-)(+,K6G)"G
MH+J14VJ?.RB@X'E)4RY.O24M-)'.!P*'I#C2"G*,PM;H#Y.W?';/ MQ9V,,A
M$Q.=D\B)+#%LHAH:2IT1A!. AE>:%UN"J+'[,S$*J.$B=L\(WZMY3:)-3LK*
MU)A!=3)I=;F4H3F4AM9"T/6&N1!2H.&UDA25&R<Y'UU_P9'*M+T)7*'R+X]Q
M#3&W<:S-'KW)_69BIRB).H5J09?IM3PL5OEAQ%5J<O,TZ<HTNM(5.KD:E+-J
M7-+E67OJ.QW?&MFX]&K8+TERI0Q@CQHZ=L<Y7HC6C$)BN>][E7N1J*J_PZT&
M6E7M8CC8#6_0.K7JZ(^D-4P',2M0>G)K++L2ZENO//D--M-I-UN.N+(2A(%[
MDVWXP_VU$!:-S8US7O#=60I!P37'4PV,(YTP]<,/2C(SQIS>\HE)YRHG(][4
M8)K^Q4PMHLUE^M(-EDWOJ5%(Z+=/VK:[1Y)Y<7IRM)=J=-J(>H,C,2[3U/2P
M&5A24HDY>HN/!15,I6JS:6W4MF5+R<B5\XZI#YO\/;\%USK/M]QCS(O;O\C"
M6LKB>P>)B*,8_BWU+[]5A"/H7UI[ETA"1/1[?AI$;G#O\H3TB.#2$(+XKZU]
M^D(1?X^SXKJ9'LCO\3$2]^[S,6:NBR$%\5]:^_2(?M_I><4U=]H?H^ BV,?4
MT8\&D(Q]9$(M?]5?9[TTA".D(HO@OJ7W:1CPAI"+'^'M^"ZO1OW>8BQ>W?Y&
M$M7K]D]WB(BBQ_A[?@NK$;]WF(M7[)[O$0EJ6(N [3X"$G^/L^*ZD;X]WG$3
MG#O\HLU)$<>'9X]C]J<4JTHZ>RDA3I%(GUD*8<36KU-:,T@!",1'*JHC7(B*
MO-._4K;[[0*6GG6TJW2VXM /:$D ]\1K99<(4XTVX1H"M"5$<="H$C772,]S
M4:C6M1&HB=*(B(B(B<D1$1.Y$1.Y$3N3T:BB2+-(L7MW^1@U7@>T>!B*$G^/
ML^*ZD1MW^0A&A;B[:X!NOC,K#]R<0H<UQJ8YKS5.05X)\=AVM>T<N(XC>V@3
MP(]WF]A!+'FQE<K@2!N7GKD)"HS]*F43=.FWY.91HEZ7<+:K7!*56T6A1 S(
M6%(5:RDD1@5&0DJC+F5GY5B<EUZJ:?;#B+C92;ZH6G[*T%*T_94(YZVGDD.#
M^98$F0ZW<6DBE(KVT]9GLXE:%O=S$)]O$M;7LU__ #+,CTY_1>G=RV&QRM8Q
M0US:IB1>*1;G7)) <5>^J@TIMJ_8V!U1KU_DJP<XLNB3F6A<GFFYI9;UX7=2
MXX;;B[A-^,2XV2X8-B^'>&>-M+M]4XU+FA0%E?E=*N,HM!(]"=C/R2Y/.N2Q
M.U:A6U[)8JX)$1P(8N2<NJ5K$M<Q M*ZM4'II*#=MGU6I9H[71+M)0R%6-BY
MD+BA[2S':J1AZC4!OFZ33V)0K2.<> 4Y,+%[Y53#JENE%]0WG#:3[*1#ZG\&
M^M?=K@HY@;'L\Q&-I [#L\S!J9'LCO\ $Q2(>\2_!!L5Q/J.VS2GFT&<QH[8
MD/<+#S1ZO)O-AMY AVO;Q9=;D$$"M8T(;B#*D1 H0-;,@-,57=MPYC.N89)1
M(OI=E%*SKD)H*=EBH[J; 4EQA:M;J96D*593B%D".J8BP=1,2B\_+E$T$943
MLN0W, )T2E9*5MO(3<V#J%E N&U(N;\W)GD8+8<MS*SB:4=6YZJ-LW:LA9P0
MJYW2Q[H^XD>-)(C4Y.(T<1CW?2[%J?1393?+.LH'.X>0IT#4IJ5D$BUR,T@M
M21KH,RCU\8UFYR+2X<4&JXI#1/L&GDZ&VA(GDA1Z\HOT");</?DQMAMD[>NR
M_))%IO!F]85DFOLLPBPXV,U,\*HX4^IP^,LF*DL+N1(Y[RPOR0SL')@NBR1#
M*WJ>(.4FOUQMR4:+=*DG$E*VI-2E/NH5H6W9I02HH(!"DLH8"DDI6%))![?A
M_DWH%"6B94A51FT',AV92D,MK%B%M2PS)S V4DNK>*5>LC*0DCH_K7:Q8:=/
MD8[XYP[_ "A!?%?6OOU8K[/]$18=^X> BFKT;=_D(B<X=_E!J^(X\2Y?5^;N
M98M:4?)>H?3U.5.2\_1W>U=6J (UZS?HM\>8VC,E%3"%A3&A&NOL_C]T1DW#
MJL6L(A8-?B-#9LD.=VZ9!';-A*G/ZSJ]1=F5S>;E9UO=R5%Y,Y*JZXN8D6W]
MTE5M1L".!(4-4\+D'73C&R\/5VH2:@I<VMFUKAFY"@-0%Y[I5U H-M=8A$79
M67B>=V^X4:WEV@9%4*#28?\ -S%:[',2, _;-EX^:II8-N)[$1X1K(FED=!%
M8:488HX@\0]2THS^L2E5R$%2E*!/^TI1!UUM8\.BYVE(XO,ZVRTIL(6E2.<F
M,]N<0-#=L:)*[BY"K7O9(O8<K<TRC.+/>21@=G9?)L24/(H=-5"BPZFO/<3&
M&D1P%;7@@N*^S<IF/>0O;2R&[,A7*7OP,B6QMJ+ DDG;3B3L-;;"T;!04+;2
MXDY@I((4"3H1I;KMT[;WTB+LG;^)2Y1';ENU)\SM[:SD?+QI=QDF-U&-0P'\
MV&REJ<5GT\J1:2QB?9G/)D3:Q"2PP85-$;#,^30H*C<+4 1H4Y;]I*@J]^H#
M\+P;CVK6MO;WZ=W=?C$BYFV.<Q=BA^:4%;,MV74QNWT#)8T*7F1,>B@FV$R!
M6-(T;[AM>!02IK Q)"Q.1S1$BQ%,S5 M 7EOJ$^M_("CH 3;U5'6VUQP)M:E
MP5;G;6QTWT.AT';]T1>Q?!)6Z0'1-YKRCVL@@L3B@9!>R$@OG3>0D+$CT($?
M..%O2/JFQX<>!')VHWG>?K$VY1TL4J5L1EMXJ4!W7)-] =";B;#07(X#PO;L
MT\M8<C=?;B)MMA>) B18]Q,Q>::ZI;>'=?*4*>"<@7P;!$JIGFI8<I(8S1V]
M3NA_;Q#E?(CR0 JE25BZ;Z:92"DI(OH;B_5Q%M1<'4E1)/#JXVO?W>^^FQB*
MN.;A9S;968UF:38$L; TB:DIO;,E'D&<4[RB<WLU4A'N>Y.CEU.7DB=R)1).
M@MIMV6\.&AZ[<!%;<-A$G,\VRR[<&>&+@%A:QHM?0PK;)<>I:ZP!6!G@C)(-
M7,=!&L2UN21ALLF5**^Q3SA@P1WD<+K*(OJK+K;[[?=QUZ-=HH#T[ZZZ;7Z.
M'\-8D)M/O/B8\2N,(RS;NYF6>%X9=Q8.=6\=0Y#6BJG2;V37_)-H4=8"&.U"
M1&Q[$RJQ[CK)4*G)'%8MM94%H78%22I%M%:!)N=[E.G9;B(M4#<$'<]W0#Q^
M_ICWMN.&2YF8/*XE,WRW)\ VZS&):0;LNXF85&86,J*>/82I;H*XM7Q'F-D-
M5!L&0:.56.LQ-BRBM/)0X#1XN>LX64I4ZZ$YTH2@H2E*2$YC<D!*24@J!RC,
M ;$13."2D640;6&ECIWCB;]&UQ'1OA5+LSGU%*SS;B7<E@.''Q&J6_I7T$EE
M;1#'VDX0C&.DL5A+)(49ADZ6KYP%Z-(%47*DF7UO!Q=K-J4H93>ZUW%A=((R
MIX6/ QU3%,_Z)*>CJ!S/BY.X"4F^4\;DBW9KI<1-JL6RK%8D*61[&NZD8UZ]
M/>O=S3FK5[N:=W/7=Y-12G4E!%^%KV/6=>&XM[A'GNNM2\TI14VVOAFL+]@.
M_P!QT.V\.S3WTZ0QK98FJO<G5T]+E\$Y_1Y(J_?YI\=<FVXI6A(-[F_AQ U^
M#T:YGZ<PC/S69!]:P))'$['6W 6/C$R>'-R.;E[D[D5,>7O_ /C>NCXZ_P!5
M_P"_?])'?N2M.7Y]'1\V?_U$Q+-?%?6OOUJ^-VG<]I\837ZZ>K^G4B?9_2'B
M(I%7_57V>]-2C<=H\8@&_<? QCK]9OM]VIXJ/95W>,4?X>WX+I%L8Q/1[?AI
M",9_C[/BNI&^/=YQ$O?N\S%J^/L3W)J\;=Y\3%D-]N!76)X4&TJP^=2J4QI+
MXG-C7R(A1(V1V/6K6J879C*UBO;UC:5K.HJC8[$G&E.M@IW02JW2..G&U@=Q
M'?\ D]K,A3:G-2-266)6KL-2Z9K*M29>::=)8+H0%*#+O..-K4E)R++2E6;"
MU)AAF.(.WSEI-N((7U5.DN/60RA1R_=D&.9(.CT5'O.X#6M&Y.D06-3I[1Q5
M=U]4PXT2EM91ZPN0;',@W!T%Q8ZBUC]PCV;0I2B8,9E5NR[$]4GV%<Z_,?7,
MML3B4J7*MLK/,J;4T$!Y3B%J<5G2%!L@1PW\HGPJQ\0QF[W%V[IXXLMH@/.6
MO8H@QK>N:YK98NDY1QHIX86^?#<-P&RFQ70R]Y0&B[.P!BZ=9GI>CSSI?DIM
M8:9*R"Y+ON'U"%V"EMN+(;4E958E*TE-E)7Y;^6)\DWDSY5N3C%?+50),83Q
MU@>D.XEQ&[3#-?-.*,+41A3]79GJ4SSS,K5*33!,S]/J5/EFU+;9F9.?8F@_
M+S$CPK)DN[$"(LC(<"AVT56/4@<>+'D3!C1J\VG@'ES>W>Y.?-D(ID=]5&]_
M--[DVX6%KV"KF_6+CW&_E\2)?#?)O4)E,M1<=KI4V% )>Q#+3<G3W5WL#+5&
M5EPIH<0J?EI1*>+EPE*DV9G7LL8@[3:K)DMFUL@L,,.@KY!F0S'#'DJ2&RP>
M",-Q.@:27F>JL4C/N#"D8]<G@K4[$#0\+F]AP!-^K6T9"\$S"I2;7(<J&$33
M$3C+4U,3%<J;+3DPVRZ^REAQ=*1.3*DH2I991*A(4$*NZI"%)L)>;;I+&DBL
MN'RTC*\= VO;D+:0"<T,WY!C?+ :)[W=Q1.C12NY-&UO9HC$NN1UFPOH2>%C
MI<:7T.E]=[1B,4''#\K=B;I3<FJ8+8K<Q/MX?15G_5RY:S/*I*ZNEM.4I(?F
M$,Y\[F12RLS"X'-C=M>(C<"S, -X7'L7DP?/XPIECCD:5:R5,X$)(-7(K'B'
M&#'>65U0PJ3M0A:=['2AZZ%CS$\Q0I%EF2*43L[SF5TI"C+L(L%K2E5TEQ:E
M!*,P4$A*CES9"/H7\AGY)S_*W7\28TY969.=Y/N3YFGLHP^TMF<<Q=B&J<^_
M)2D]6,LU,?,5/E)1Z;J#=/J3$S-/OTMD.B57,I7]5>VVQ;<!HZVRQ03*QU8!
MGFX1C1T?LT:BO$0;^?6TO+[J[J:5RN<]"(_Z>O.SLZ^^ZIUYU3KCBB5J62N]
MS<WXF_5IL0$[#ZYSU3PVF31A.6I$E3Z(RA$O+25/:1)(EDM(2TTID,A)SMH2
ME(4X',V4!8<3<&6N!S[/+I,"X/#\R@U*&&1[G)^J+#L217@CIW$<(+GO(XSD
M:U4:QB=3GO[/F:<TI:T3&R$@VU!NH@I*;=5]2=-+#0F/)O*PY3\+R=3PTU,^
MEU&I+EU90A0$O(!]J;1,/*(R!UY+;:$,I)4,RUJLE*,[RO\ #V_!=<^S[?<8
M\U+V[_(PEK*XGL'B8BC&/XM]2^_580CZ%]:>Y=(0D3T>WX:1&YP[_*$](C@T
MA""^*^M??I"$7^/L^*ZF1[([_$Q$O?N\S%FKHLA!?%?6OOTB'[?Z7G%-7?:'
MZ/@(MC'U-&/!I",?61"+7_57V>]-(0CI"*+X+ZE]VD8\(:0BQ_A[?@NKT;]W
MF(L7MW^1A+5Z_9/=XB(HL?X>WX+JQ&_=YB+5^R>[Q$):EB+@.T^ A)_C[/BN
MI&^/=YQ$YP[_ "BS4D1PF3T>WX:0C')Z/;\-(0GI%B]N_P C!JO ]H\#$4)/
M\?9\5U(C;O\ (0A%_A[?@NKXC<X=_E&,3T>WX:D;X]WG$*_9/=XB$]21&K[/
M]$0@?P;ZU]VD4&Q[/,1C:0.P[/,P:F1[([_$Q2+'^'M^"ZNBG$=A\1&.3P3U
M)[WZD1^]_P L1+]H]W@(3]">M?<FK^)[!XF*<!VGP$4U:O;O\C$3G#O\H07Q
M7UK[]6*^S_1$6'?N'@(IJ]&W?Y"(G.'?Y0:OB./"LZE)J+S7Q^^O\"KW:=/$
M=GQ\=L9;+X; X'CT:#37KZ^/8(C?O#>S,%QJ=.PO;VZWAS,1X8*_ L6L*JNE
MRGRY@8Y9,^ZMGMK:B#!$1\J5(,TYT&SI9&)U*\>%,*<0@EELNN7 2@'*-?Y1
MN-!K<7T(UM';Z)+MS<PV:C/MTB0RJ6Y./I6HG*DE*&&D^LXM1L$@E*;7()-D
MF-&^O%-M%L:T6,;CVK7[EW-.V37[88R*-9%JYTF$LJ-7W=RI!,<0A.0GF#S5
M[/NX82"*)SN+F9P-D("0Z_8<Y98##1M<IN+E:TG@!;I4-HV'AO#$]5;3<LOT
M2CI?6&IV:2L3T^TVO+SK,K8)8:4 <JG%7O[*5"\< !;TY'Q2[Q&Q^YQ*MH+*
MQEG@8S94$*3'E4DYRE;522E0A3S5AR7"(\KD\X1S$*%S7M:U>(4Z5J4I0 .I
M-A:_=H!WQNB5E6Y&72RVM90VG53JLZC8:DDVMU 6 Z(?+)-]MR>%.&+!]X;6
MGW'RP?26!D$K%J&[/5P"Q##A E7,R&"1<2HYW1Y!FRT,0?8.B%EJ4A6AQBR@
MV_SC>MBD$H%S8ZI!L+B_WW.T2-J;?2'&S=LWL0=#8D:6TM<$&QB-5U6[Q<0>
M/9)NSD.X9<GFXT^O^8$ZA0E9=5%J6Q 6'0P\;I@QA54)P$D25FQ@!!!/%9)%
M8O,Q8TNX(2FS:$WS7-K'5-_6S*(-SL-\][:6!B3U4: 6ON3;8;DD_P!_9>)(
M89PD[F;Z8SCU]O+(F6%K7D["'8Y7-EBNIE-%BRSJA9SNJ5)("<4#VR+;M"R!
M*4/G@AL&K)TL$-+*4>JV+D#U1<] OT7)MI?8$F./?JDG+3#4L5W<=58!%B$W
M( S&XMKII>VYL (ND;*[HJ^3A5Q%@T)L>CJF'WTRM /'9U#'=+,?'\AE3$)4
M.BA[5953-L&"&]Q9C9-@M@ZO<^#G4:J"K@D!0&JDG:^2U^@$ $Z7L1>V>%#<
M7-]QQU'"UN@??I;:-<E[!YYA&-S-QG8IMC:1JR;&CQVX-8"R1)<XK#R1LG##
ME&1I'&@XAB. $4)Y>ER=30-=RJEY"E\W=>:Q-EH4C0&VF9*2=^'N@% Z>L;@
M\+:=PO?^)X&S"C@;I[T6-Y:%Q"=B9<4@V-L!F,ULZNJG.$X\U0RX4:+-(-TZ
M2J1WR80G2#2#B3L3D>C77WRV!-K&R2I0)4=>/'I]_"+M!L;CMV[.RWCO$]-B
ML2C<06"Y'M[Q !-CP5F"K13L79 H+B?/IG^:OK+2S'$(7(H+5C#4K+8DQ"R1
M1I#2(1?IT2PI:[H-O5)(7F6V";6L,P OK[.EN%HXVHSOH#274-\^K, 47-\F
MI*@1>Q&G#6_>/&WF+NGL_4T>Q.R+X55@HY]3:SH&4[D8G0VN4RZZ78-BI7CR
M6UHVEGA!/LXL8]?7-2,^:X)#JJLZ['6^:<NZD+=0DI24(40A#@05#U0H@*R)
M)!4=@1PB63F&IQE,VC7G 4Z V&4D$%0]H)-P=^C>\1ML-J>+.DW(AYOMO89O
M95<F5'D1)5::T;,@,*]#,J;NN0BGJYL;J<&75SA(U'-<C&FCO81\B7>:4E07
MS"K7LHY"1O=-[!23_*%Q8#K$2.HDYME;3R&)ALW2MM80XD\+$$6OQN-1N(^B
M+8F[RB]Q>ACY_5_)>8I716W'FX_-F/F(SD]TF)R40CD;TO,P;1(,CGM1C.72
MWNE->7-2[:W!>^8!138J )"5=>;0C8;D:&/,F.:;+TBI30IKRE,)4%\TI>?F
MRM(4II*S=7J*-K*S* LDZ@F)*"">N\0\V\NY>7-O>GBGCW>GQY_?7NURZ62F
MUCMT#I[.O77A;;AK%R;3, YLAM<'I!&X(WTOM$O.&J2IA9>YP^CE\WDY>"<O
M^7/#N_\ MX:Z/CK_ %7_ +]_TD=^Y,TI2NO93O\ -A(O>W_\AX]IO$OU\5]:
M^_6KXW.=SVGQA-?KIZOZ=2)]G](>(BD5?]5?9[TU*-QVCQB ;]Q\#&.OUF^W
MW:GBH]E7=XQ1_A[?@ND6QC$]'M^&D(QG^/L^*ZD;X]WG$2]^[S,6KX^Q/<FK
MQMWGQ,60VFXY%)'IJTQ7!KK&<5LYR*K6E0 FD!&(Y.Y1D>KBN&OUUCIZ&N36
M#/J4EI(3<!2CF(Z +V/CW1L[DPEVE5"JSW-H=G:?(M+D@H!2FE/NJ;=F&TG[
M;:0EH+'L!\VLI0,1,)FX=KK6VQ^Q>P<93R3U$M51 S:XQ%(!S"=S5+'81@90
MT[Q&8[NZ'#<[KKC=U7MH3OOQX&V_#APZ8]G2-)^FM,I]3E/6F$,LM5"6!^NE
MIQI ;="D E0;=6DN,+.BVUIU"DJ">.'E*N)7#H6 W^./NZ^/>Y? FTM7&=*0
M9D'/ 6-,L"**5%/%BPXSRO=-0P$$= C&5#N&W7>L!42:GZW*3*6UB5D'VYM]
M_*0VGF%<ZVUF/JE;B@D!%RK*5.6LE1'1?E/\H5!Y$_D\8^I-2?:F\8<H^%*U
M@?"F%65-/U6I?2>2>HE4JHD"A]P4RD4V<G)IZ9>EERCLZB3II*GYUI!^='SV
M9%AK/I,JL)#5YHA,F';LQLRL[NF+>S;171D<O/LY!"S@&1%[-C47M&>D[[;:
M:;[; [:<?>-(_.6B5E'IHRE7H4NTJQ 10ET_YZ96=C,4EBG_ .49#HY+H3)O
M-D^LXHCFUY\O(;Z,Q VUMAAJ.3!A294JT;.2+YM-.SLEK"BEF^4$?&824Q#S
MN@RL&X$AC4*@J C<$G4D_<?BX%[7XD",67HM+?6I<C3<3M55J:F)>4EI 2JG
MU3<LBSJ)YMQAHRI2ZH,+YF5+C164O,JN@K5':8Y+?)KJ>DQ2RAM43YMI)1M!
M%DR&L8X:1BE9/E3RA1!M>=Q!C8[[D(I7,(UBW$G7HTX]9TL1>QUL--2(B7)U
MIA#$U4JI7Y.8 =3*2#2S5GI9E2UASG66U2S,DAU86H,I;4M8^M<;0EQ"E]#/
M)[[N8_MMN+/QFXK\?QAF1DARZ=:L,WS2;+B-*V0*7;/K(->:44#QOAM1ZD)V
M9QH0CWA:NKN4RBS,[*2M1ED+>$F'6YE"$E2VVUE*D/622<B%)4'#]D*2?9S$
M?6O_  8/+)A>E*Y1.1?%>)'I>HXVFJ-B#!M1Q)4)*2EY^M4YF9IM0PK*R[]0
M>7+U">EYB2FZ4R>:$\N3GI5 ]+,FQ,?3[C^^-7+QR/7PBLE29(V!CQP?=3&(
M]$:T8QM57O>YR]R-3FJIS[M:#+1S;*XBP'W6-N.FFA%NHB/I95,!3,M4GIN9
M^H884IQYYX\VVVVDW6MQ:[!*0-R; #W/_M_7/H#XZ!IF_*-J"4^[ )Z.&KS"
MDS^AW2KF/=!)TA89.?-&D0;N@RH[G*:5-NMMCV5)4%CAHDJ&W0=CT:<8\L\K
M\S+5ZFU^>6T S39B3%'F'$Y7<J'I60)3<!:4SC(6ZIDVU+:EIS,BSYO\/;\%
MUV-GV^XQY47MW^1A+65Q/8/$Q%&,?Q;ZE]^JPA'T+ZT]RZ0A(GH]OPTB-SAW
M^4)Z1'!I"$%\5]:^_2$(O\?9\5U,CV1W^)B)>_=YF+-719""^*^M??I$/V_T
MO.*:N^T/T? 1;&/J:,>#2$8^LB$6O^JOL]Z:0A'2$47P7U+[M(QX0TA%C_#V
M_!=7HW[O,18O;O\ (PEJ]?LGN\1$46/\/;\%U8C?N\Q%J_9/=XB$M2Q%P':?
M 0D_Q]GQ74C?'N\XB<X=_E%FI(CA,GH]OPTA&.3T>WX:0A/2+%[=_D8-5X'M
M'@8BA)_C[/BNI$;=_D(0B_P]OP75\1N<._RC&)Z/;\-2-\>[SB%?LGN\1">I
M(C5]G^B(0/X-]:^[2*#8]GF(QM('8=GF8-3(]D=_B8I%C_#V_!=713B.P^(C
M')X)ZD][]2(_>_Y8B7[1[O 0GZ$]:^Y-7\3V#Q,4X#M/@(IJU>W?Y&(G.'?Y
M0@OBOK7WZL5]G^B(L._</ 135Z-N_P A$3G#O\H-7Q'",@;2B>)_5TD16.Z7
M*QW)R*B\G-5%3N]*+I#,4$+&Z2"+V.M^L$0W>3P9E11GBXG"9'DR$?U&"Q%/
MUN7O>]Z\R.>[GS1[G*J)W-Y:L<25)"=DG<B]R+;;[:V('98QS%-FFW)I#\\Y
MSA;L$(604)UTRIM8= TTO<7.L<RLX\G7AN[FX8-W<X^6S95%EQ9I" M7@AFD
M05;V!93%&\O-K!,8](\B.CQM1')WN5>)=IK14I>520+G0FQ)&NEB1<ZZ6X],
M;>D^49V2EFI!@,K"1D:S-W4A)O8).8)(!O;.E5KZD[#WZ?A@V>VYR4UWA&'0
M69@?MD+<H\A@5I#(K"$K ._6)*HYR=N1YNQY]04&5&O; S2@5<XXM90#F0VK
M*+V.A60+J X 6UMFO'*S6.IN8ETLD--I4D!UU (6H;*2FY(%]B0"=PG>\:EN
M3P98GNK7$=GM ME#$YY(<\!DA6T5SD5Q$CS7ADC=&=WD>"1&,G6J*)P'$*KX
MYB1SE2DJ*% $:ISH5T9D@C4'8I(WL<UA;,IN-6Y4(9]5T+(^KO92;V'JJU W
MU%B#U;QQURK=F_X=\KG;8[2;/R,.KJ>P-)R:WSE\7-IMX. 1T>(D"(_'ZRJ@
MUS^W<4:"!8R9CG1RCLHP&$ ?ABTZ%V=)N!8!&=K+>U[D+)5>PL+@=7&-H-+:
MFVD.H6AU"TA22BU@#WD@VW!U&H(CK;ML;(M_>' ]NK9^WEY>T=G3BL\=BK!D
M0S%;';\JUD([NF&X@R/&HP%"-$ZG171U<U6<G)-J5*S22Y]M 0M1&:ULQ"CN
M=R,QU*;WN1<Z\K\U+T_$=+RMAX!"GGF2K0V4I*?6MH00%@6L59;@@QS.R_&)
MA=I;78S&.(>]SS<"/F:SFTV4Y!"&O8BB2HA:ZK&EK9%"9#N8YPR3!"(_FQ8H
MB-1[L$L!*E*!;SD$>K[1N=;JL-=-M;=-M!WUJ84M:5JEE-,EHJSGAJDBZ?Y-
MKD$7.UM(9W#![D<-&WV166?3ISB9&: "HIP6AVE=(I+FMO%L"2(9%2.,)8 8
MWW*0R63SIR,1H>T>EKC*D%(=38BZ];*%BE2"-;[WN=+>Z\S,Q+S5U,.)=""
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MZ5JKV(43%,G4T],FRIV?FG&A,->AJ4$*87+E2$S'/K*4H:*T64GGPMM3*5B
M]KM,/=*8:5=C?8QJ4\Z/6#EO0[1+VC&2#(J#$QZE?&$YCG#YM:QCFHURN377
ME32VU%+2E-I.ARD FU][:[%6UKCOCW)*3%(H4M(+FI&3F9YUEI]:W&"&V^>#
M+Z6DLK=<0%(4VTM1.<AY'J$!(,<5?*-<*0,5QFYW$V^K(<?**1$FV$(L-9T:
MZJ0N=Y^%D-UA $"PC 5\J,=IQL+V)8T@9%*$L?9N ,73C,]+4>=<+TE-+#+"
ME <Y+OKT:*5V"BAQ>5M25DA-TK04V4E7D[Y87R4>33E1Y.L6\MN'Y![#./\
M!%&>Q%7G:7/3$I2<2X;I* _6%5.2$O4692>HU.3-U66GJ9)LN3*)5^3GDO\
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M!=7HW[O,18O;O\C"6KU^R>[Q$118_P /;\%U8C?N\Q%J_9/=XB$M2Q%P':?
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MP[::"6.VEE>UB1ZQR/IUAC7FU'NGR9ZC<16,%(:-"FMTT T.P.O'377B=M^
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MZ0N84TBJ5&6F9.;H\IFO-JDJA*H<7-KE&'OIZH=\ZJ1C08,4K))Y F#$"/\
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M9&P[Z.Z4.J0&#=-W4K#B@K*DJ6CU$%=BGV2/M9DIA%(SN.,>EL<XPEPS(RN
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M>/\ ^)(_JVM._.DO_(>_JH_[D>BC09HDGG9?7_:<_P"U%GS(M.I%\YK^2?\
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M^5I:A;E]EC5ODCFW@CCN5-:V&'XS(/(=/<<?R1&%'($*F&2IKM..AEY@VO\
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MHD?YB;_J,_\ ?BGT-J?\_(?K9C^RPF_9_(UY<I])W??//3_9RZ?2B1_F)O\
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M(:^OK[/'I^)SX%?!R$=G%@0I6-6EC2%B0Q C_)\PP$&B.U8WCO#30 13JGE
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M:LE"!9*0Q)V _;[D\23<DW)))C">Y$\6S"UN.U2@K<6K,I:IJHDJ)_X6+6T
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M.IJES*P(8]:QU=#5M?'CRZ^?'!!:H>40()U35S0B @V"EUM?(8UIH<=XT(]
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M$1_>/I"#[4[!_P!TOB@_G7\1']X^D(/M3L'_ '2^*#^=?Q$?WCZ0@^U.P?\
M=+XH/YU_$1_>/I"#[4[!_P!TOB@_G7\1']X^D(/M3L'_ '2^*#^=?Q$?WCZ0
M@^U.P?\ =+XH/YU_$1_>/I"#[4[!_P!TOB@_G7\1']X^D(/M3L'_ '2^*#^=
M?Q$?WCZ0@^U.P?\ =+XH/YU_$1_>/I"'RV_P7&MK\#PG;3"X):S#MO,2QS!\
M4K3SIUH>OQK$Z>'0T4(UE9R)=E8%B5D"* DZPERITMXU/+D&D$(1R$;=I"#2
J$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g393013g40y33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g40y33.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2!04&AO=&]S:&]P(#,N,  X0DE-! 0
M     "X< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 23E5#+3,S-S,@34]!
M($9I;F%L.$))300E       0GE.VKT"2ZV=Q>*0]0..,CSA"24T$.@     !
M?P   !     !       +<')I;G1/=71P=70    '     $-L<E-E;G5M
M $-L<E,     4D="0P    !.;2 @5$585    !$ 00!D &\ 8@!E "  4@!'
M $( (  H #$ .0 Y #@ *0       $EN=&5E;G5M     $EN=&4     0VQR
M;0    !-<$)L8F]O; $    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4    )P!( %  ( !, &$ <P!E '( 2@!E '0 (  U #
M,  P "  4P!E '( :0!E ', (  H #  ,  P #$ 10 V #8 1  P #( .0!%
M "D       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3
M &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB
M=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !
M       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O
M;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
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M9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L
M      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO
M;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O
M<&QO;F<      #A"24T#[0      $ /      0 ! \     !  $X0DE-!"8
M      X             /X   #A"24T$#0      !    %HX0DE-!!D
M  0    >.$))30/S       )           ! #A"24TG$       "@ !
M      (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:
M  8       $ ,@    $ 6@    8       $ -0    $ +0    8       $X
M0DE- _@      '   /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      S4
M   &              64   (P0         !
M  $             ",$   64                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   64     %)G:'1L;VYG   (P0    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   %E     !29VAT;&]N9P  ",$    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     0X0DE-! P     %2(    !    H    &8
M  '@  "_0   %08 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( &8 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M #^CMJQ][?TEDR/S&^/_ !B7MS[%'NP_>#__TO27M:[1S6N@0) .D@Q_T4Q
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M9S9,?2!W/]O\E2R'ZF)\OY4MQ2)Y_/#3AC&70<7IX:XI_/)W3TKK/_E]D?\
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      7Y-30 J    "  , 0   P    $)+0   0$  P
M  $%Y    0(  P    0   "> 08  P    $ !0   1(  P    $  0   14
M P    $ !    1H !0    $   "F 1L !0    $   "N 2@  P    $  @
M 3$  @   !X   "V 3(  @   !0   #4AVD !     $   #H   !(  (  @
M"  ( #8ZV@  )Q  -CK:   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,3<Z,#8Z,C,@,#@Z,#(Z,C,   20   '    !# R,C&@ 0 #
M ?__  "@ @ $     0  ",&@ P $     0  !90         !@$#  ,    !
M  8   $:  4    !   !;@$;  4    !   !=@$H  ,    !  (   (!  0
M   !   !?@("  0    !              !(     0   $@    !.$))30/]
M       (      $   #_X0& 34T *@    @ # $   ,    !"2T   $!  ,
M   !!>0   $"  ,    $    G@$&  ,    !  4   $2  ,    !      $5
M  ,    !  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (
M  $Q  (    >    M@$R  (    4    U(=I  0    !    Z    2  "  (
M  @ "    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$W.C V.C(S(# X.C R.C(S   $D   !P    0P,C(QH $  P
M  '__P  H ( !     $   C!H , !     $   64          8! P #
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M.$-35D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"'A5/\_\
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M&BMPE%,-:E%RS+-P],O2[DTRRZVI  ;;4$XFT.":,L0@*M4XJU-EP4?ND^D
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MMR_../:1+XNL$35)8Y0>S;V5BP/)= H1<K)H2/?+-TT>=--1832I'YR)&(+
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MS]=_U]<8DCB3AHP+@M!)/%6*ZA4G::!FQIQM&$?6AP@H4I%4G=KE3/[&Z35
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M)LI3RRMU2Q<*6LJN;Y<L?"04VOO,5WDB:S5BX:0LA(L9 XE+U%ZP04=MG(*
M=,R/*=$"**D524!$Z@%.41WU]KL#.S,GM31U,*4"_/,2CJ1<A;,TX)=Y*@"
MI(0HK -PE:4K%BD$<#ILV<HNWWV7^FFG[94]-2D*)T?[0[:4YMP->D,;1;&4
MR9VCH#DBX^VZ&IJ8J,@U3B$MJ]*E)Z9I[C;S$XZR[\Q+VN+E:(C.Y9D6R8E#
MHCI/V$8@J&P<H])TI%U^SM$YG!C#\+F 0WUZ]4FZ3=Y8&N*[:;$F_M8 ;:"]
MQRN0;Q_.+1]KI,5)"*'T*[-U.<3^+5+NR&T58F5+ (/^1&>>DD.'7=_=ZFQF
M U81=I0$.H@<S/*$^) 50ZPJ2T,5TQ,8VR1><"\Z1E=CD3V7$JINQ0B_1@0,
MX 0+.KMU+%CR-QFK, C6^8.(7!XIVGJ\M,N(G.B393TE0>(:?V0J;3S09%YH
M"55,>C(; 4GTC#)-KE4^M*N2*UETYQS6[*F7:.O,J1KMV%=LXEV]#F$NQ@?*
MM2D5#_1(9 AA 1 5A';4RA=O\\JQM;V+\]2C#GR*<N<:.7VMV4*TO3G1ML\N
M;"U%Q,O4MII:F+3A( %/:K!?96+XE+3/+;)"<,N@!6+I-X,^E,CW2RR]B<L)
M>:27CXQK(J5]O$2+=@H0[IRDJN0A2/"NW!&YCG;@5(1:)\P&,4!#H?IEFYM'
MW3(%:C+%M^:-AA"WL8;&.WJJ4RD'#DDI#RKZWC]MO\%Y2]BYK8'IGZ0]GMGU
M47:158H&R+K'X0.UYFGT5$@]6"*4B:2J>I4O6)YU!G69F9FE3*Z)*%#B1+*0
M?I_BZG635#G$K<#=6\8$'ZP/C[?* A]SM'L'H&ZL0Y7S &>1TUTS/NSCUW-U
M>J_?-@7<)=-CGP4;9<N7$#36,E1'+Z:)#F.BMU2 !V@,@J0Q2/.BZRQ:I(J&
M*'63E0,0RRI!.4HIB"INE4* UN6!('Y5C;ED"?CPZ\HZOZ25R%*55I)IUE4U
M5ERCOH;:DJ5*A?HT[,..H2?Q +J2EIM6%2@X%(24)-GJX^J%_P!F5_GFU3'2
M$6RBB:*:BRRB:**29U5553E33333*)SJ*',(%(0A0$QC&$"E !$1  WTA$=J
M#5,W\4M)>YM+DN;X:^&%073RDN:!CXF0\_Y9J;1V9K[?$D9*#M+*AU6=!,7M
M6CHRC66UOH<"SSY:.CW3=,\%+MD,XF$7S/7\O&,K$\,57N)T(G!G'[Q=0=[F
M6YRP;[+M$A;=3'K]Q7/;2A'*1%VPA0F)YEQ5E$[>RKT;:(R=6JHA96;%:$V?
M:QC(U Z_#F;?7.,E X'LRUXZ^>?E&IN&_&$5A#*N;L7WG&]9IW$@:01R-=KK
M /96:B\QTJ]2LJ>&OM*E;*LZL<55?9R+EXB2HJ[I9"H3[(R"CA\=\@]6DDW'
MUE[O//NB*A8_6>L30U*(P:0@TA!I"#2$&D(-(1 [B-P_:\Z9PPSB_ASE97'_
M !$QS]]F26R;%R1HFGT3'+8\339NSY/@46RR.2'=G!BRI=0K:R02$CU&1:.Y
M:/JC*:;/,$@9F,@$Y#Z\XD8MPMU!C/3-?S!Q\\6K2^P+-M*V&6@*S6<*XKC&
ML@#\[%W'K/<*2]-&(7")F.I&>WN?ZRG!3@F>+C#2YFM>-7(?'YQ/"G/7ZO\
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M  $-Y.FV6F'%AE]J:2DJ"7&@\$JL; V?::<SL"+HO;4@Y1^[M8EJ>Q(+K35
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MM+R;!UQJ"LE:H2.<V2QQ%U@X5,\TVC7<?/1K*4&,=-#14"1ES\C$DFQ[O?\
MO\=-8DW-9M\'CQ#QTG9)WB-PG.P4XQIC2;@+'DVG5HI4,?R%UDX5&8K%J7BK
M)"/D']ZEUG97S:/D6SEG$K-/8]XQ,LM7ZPX'*_/J$6'">(X<>6>7OB-G$OQ,
MT3B@Q3*<'7##9)3.*=Q816/\R<0*!2R6/L>T1LI'>VY^]O9(]A7+WE*S0R"K
M.#@::1X@21E33TJXB&3(B2^4I-P2,HPI0L0#]'Z^CIN==,B+!=),-DTF2R9
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M^N/JA?\ 9E?YYM51TG%N8Y4RF.<Q2$(43G.<0*0A2AN8QC&$"E*4 $3"80
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M.IHU[O,0AIZMA!I"#2$6C]^SBV3J1D'";5DS14<.7"QN5-%%,HF.<P_< -@
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M^6W-=FH=:H]OMEH9R#PSAA"Q3U\=)J58_+).UDTQ;,H]0@E.5^\609^_* K
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M&<$C70D P-5.6 OG_=\N.?=?00B2E4S'CYMC16.518F=*-@Y%Q$O2)[$$!*
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M%529*S588\LJVKBCQ5C U6&7.J@TF[6];)*NCB\725]CH)CT+Q\BW77</8M
MS)9YW#T:]$\SMNT_6*G.FB[-2CQ8<G0T'9J>F4)"W)6GM*4E%VT*27IIV[3*
MEI0EM]8<0WU3T@])S.R$Q+42E4\UW:>>9](:D-]N)20E"HH1.5*8"5J0A:TJ
M#$LTDO/X%G$RG I<+6G'EQP5-9*RW?%.*;14A4(O(0%?8VFKS!60>^52BYYY
M.V%LBX F_(J^AY @F -T@W[.R-I.@386NT"LT39;;+:+9?:2>I4_(TG:.9;I
MU99IE2F95UF3J3E+0S3C,>B/K1,)81.RX66PDK O'P$MTI])M,F&JC6-F=FZ
MM2T/-NS%-D%U&G3:I=!"G6F)V8?G6BX0" 7)8@W(RR,=K,69WP?Q'85J&3<0
MJ/DE7JJ\;8X271(UGZO88X03F:[8&J:JY$I!D=1%4BA%UVS]FY9R;!==B\;K
M'_+.G]#6V?0ITW438[!M&Y49.4G9SI K;TW4I_9?:6A3U-GC2:RU4IS\54)B
M=JB)1<H7;5>7FV9Z7F&VDR]10GU!0]M:'MYLG]_TU;7H[[FXEI-QIMBHTR?E
MW$)FZ?-RZ+EAV725!P EAQM;+S2G&W65J<&O44<2#2$&D(PTZNBWCQ476203
M%PV2!190B1!5<+D;H)\QQ*7I%UU4D$2;\RBRA$R 8YRE&:->[S$(;&K81SWX
MI>. ^(K:3#^(JDUR/E\6K9[,I2+IPVJE':OTBN(_V=.R 'TI+/FZB3I&"9.&
M!TF"R3UU(M^E;-W7=?1QT0N;6R)VBK]0<HFS0=6S++9:0[4*LZTK"\F22Z=T
MQ+M*"FUSCJ74EY*FFV7"EQ3?3^WG2G^#=23LUL[3$5[:93*'YAIUY3%-I++P
MNRNH.MA3KCSJ2'&Y-G LM$.K=;2I 7&R*XY.+['\@QL.5L3X]N-(!TDXF(JH
M-;!5;$C&\Y17")DY*:GX]59%(3'31?1X@Z$H(&=M>EZPE]+MY]GC97;+9"O[
M.;";>;0;%[45*FO25-VBFA*U1J3?=(2MS<RC=-FY9UYG>,-3TK-)?ISCR9UA
MIYV70TOXZ0Z6ND2A3;%1VDV6H5:I#;P=F9.DJG9">2R,[,+G'IV7F"W[6Z=;
M;#]MVIQL*QCKGD7+W#3G'AI@\DT&415K%MK3M51"1*2.EV$HS3<MGT%*,"*'
M.VG(>:;F8/&H'<)]804507=1ZJ3I;\GQT9[7]$W2N_L-397:.2K]'E%IJ+<S
M-3TW2J[MVTB5JW1_4=G'IE6YK4_,UK[KJC4VTE3S= 75#7!*RGIS2?5$AM/L
M;MEL+/[2UJ8DW.CRH4:HM[63<TA,LW3]C)N6F:9M;*U@^U(N-R"IZ10T%A]5
M4$LU3-].*E<7%E%51 Z2S=55!5(Q%$5DCF262.782*)J)F R:A1V$IB& Q1#
M<![-]?L@H8TE#J4+"@4N-D8VE BRDX5CUD',64,QJ.$?SJ-.KEGVYB3>?EWF
M'$NRTPVLL33*T*Q-.H=95B:>38*"VEW0O-"L@8G%@/B,D'$BQH^07@NP>G(T
M@;,Y,'62NCCR-XR94'ZH!P82I-)$X]8!<2(O#+@MUA#J';385E##U8H;.ZW(
M4[/4]L?B]V,US$H@>P&_:=8'J8+J:" @H5^@_P!F[[4-1G*E3^CWI,GS.JGE
MMR6S>UDTH":,VLX)>DUYY5A,F:44LR-47_E!F"VQ/%\S FF9V:Z=C]#8;5C_
M #-K]^K_ #2:L;X]WG"&IJR$&D(3161<))KMU4UT%B%42614(JDJF8-RG34(
M)B'(8.TIBF$HAV@(Z @Z0AH7^ZQF/JI*VF5, (,$=D4A'E%P[5]XV0 ?$!S^
M^4$-Q*B10X (EV&^6EUS3[;#>JSFJU\* +J5;C89#@5$ G.+&T%Q82,KZGD!
MJ8X49YXXY)&1E5F;PC<RR@](#8"H]-T8'!$J@IB!E"HD,8J?2"<Q"")0$-Q$
M>P)6F-,,I0 ;)!M?F3F<^)-]+#@.4;9#02D)&@RSX9\.>>>=N%N40OH'$[/9
M.RS5ZO,R"KYA(2"[L[=5<XI<\$R=6% P%W,!@*M$I@<AB\ITS'2$0 W984A"
MK)PBX*<@#8*21<&V6N6?6> B=@#?+7QZLK9=M[7YW>N8;NNHX=?31[3'\8]W
M;L&_G[?%KFLH %K9#AP^N67@(S8WS]U[\1>PY<N(OV1S^N]M7,=794=A$WUP
M]_\ ?N[/N]O?J]1L.O3EGY<_.)1'J4LBICG$5!#M'QCYPVW\W;YNW7"<7AO]
M=?8+=0Y9Q!1(L!QZL_E&$;V<X*A]--VC\8]_J^/NWUQ]\+\+W^N&O(Q@E7+Y
M:>_O)(C;51M:Z:R0 J;L,7N-MO\ \0'[GJ[]<A"KVZ_CPL>?5J;^Z)@W'7]?
MW]_&.A>$[VY [8IEC;@8@EW-\6V_8(_O?-OJT@*','+K^O,9\('AV_#ZM>.W
M_#%D)9-S'<RHF(84RG*8?>B4>P0'M'<!#<!#N$.S6CG6M>OD0<B>P7SOASR&
MHBE8T( L<QK;3JZ[<-+]<:RC>-=Y&7&YX\GW2,Q&PMIGZG*Q$VDA)QSTD',N
MHPZ3YB]!9LZ1.9ISF3624(/8(E#8-6?=Z'$(=38*4@+!22"DJ2#<*URZB#PO
M#=BR3IQTR!(UO;LL+:GCPF#P\5' :LU*WG$];CZ/8II@9*6JT$9)G4UBB8JK
MA] 0I0Z"$=J=$F"\;&"VB5D@,9G'MG72 \TU6,X9<,N+4ZAM87B7<NX0-"?R
MQQ!-U#B3<1QY@.*04WOG>VIL,QGJ>=\^W.)7:^9C70:0AX53_/\ ]R_TG5;G
M#O\ *$3ERC2:+D"GSE?R,S8N:J*2S]\Y?.2QY8<6!%5BSC>5%1$T0YC$^E7+
M)%62!!+IBK&,U473/7WY\(1QQEH#A>BYY2(C.)O(+FLI.#(.%6&.92P)-TRG
M$IB)6EDQ:LY!,H=B;^,K\DU4*'2$,L!MQ7-A;^[K^K&VMHSW_7UV]\=0\#5W
M#E+Q@O)82=M+/!.TG4E(6)-\63F['+,6IS&3GG8(H.$)%L4>KEB%&<>$4"QD
MTXUH=94%'UIE&(YI\+E6:Y1L#VTV]X21GK3*NIN9D'(E$SF1E')W;I7WPCR)
M]*L8$TBB!$D@(BF4J92E#)TZM>)^M/[X1);BAP?3ZY *]3.R6'J@'YD>C$HB
M=/?8.SO#?8?B$![]8!OGGKWW'7XP(M^[../>1/"DY QK%$X>;%AC%N7*G3F+
M".925W&PN))PU(@*T7THLGZ235[#,7*48P?L>KO4VK9%3IP<'54./4;<;\?H
M:7A$=X3PD45 RB4LUX1</O'""H+-VTY:LL6*+14*;F*/L/.6Z0BUP*8 $A73
M1P4FP<@!MII"),)>'FS@@4J0X*Q.1(A"D122D+<@4A" !0*4HR)R\A2@ %*4
MI0*   =@:0AP5CPYV;;+8(^$5Q;@FLI22X-B2]HG;VPA&BJ@;(^R,FS/)"Q0
M45Y4S/7#,C%MS=*^<M6Q%7*:,Y?7R^NR.KDMEKP@LTY;S.(\-\,=XQY+0]?D
MZ[:_==D5DIDK^"C74HX9KQAUV#F.2FU9)K&.VJRJ;N/;MG/.8RIATC$96Y7W
MPC[.?50H^!.'>8K@1M>41?S>39QA('E7%=BG%E;':H@)"M8^S*S$?'*@/,ZC
M6K1TI],6-I"(P<5,EG63R;BU?-E.J-8I[.+*E3W-5G7<TB_LLC7*8_R(WF$W
M(<C \39"N8RMJ=AY2#9"][5 <;9'?>V5N?C#Z^O'OB>V,7>,0QPL5Z#<7PLB
M@W$!2  -R!S<_9N/_#XQ'OU@WR^-_*&7RCG9-/<@M.(:KR/#S 5^TY(8+3SF
M%@K%**PM<?LQ@Y-O+DFY5K]-9LBQ:[HZ9B[BJ^*R0* G5)K/"W'^^X^NN$/C
M-%WXT'>.WB.9<5XDID,^D)%M89*BW66GY6/: :")"!'H+B!54IE5S/1LZ*H"
M1LP(V  W>&$.93TI5--WX!9%]+@&W5K8CKMIP[_^S1*M372M2O2,V6)&I3 0
MJVZ<F6I8KE L*R*VGPF:8 ]</R[:T^P3&.Q].X=;5K'*=VKN,SIQ]!R/<+D\
M:Q<;(VM\[CG+RIXZKPM',_'I/+(O-M4+2_AE73!U,PKU-9P+*+*+@NV=#Y4[
MNRYFXTA%\FTA5G'57""<(2=V%64$J20FZLH]B;1R&VKU4VF50:EM0E4SM#LS
M1J(R[-34M2)=J9;9K&TM2#S5.F5L4MN0=<I,O.I9F&I*>EU(:#\T0VK8,I5N
M&163O#DT[C-LZLE DX#'C%%^X39N)-ACM_/)Y$ZM!'EZ]1+%,VYQ68%A5K9.
M1O448ZU(B5Y+.F?+2%S@#?JND)=2ITE(N 70DL@K"5N)2@+45H2;XFS?"#?Y
MR4J_2FF5H+0I^U#K5,VBE*CM(^N7;6\W*S&TDO3U[-!VH"3J-?ILE1D52H3%
M6I$C,^D+F*0L;B4:?,"U8X;&Y89U!)XXGYF'EJ_CN<J\O>(B"9V%]0*]/2EH
MR!%V"2D&L(5G>'Z]::1:C^08UV=D8R1B32[9*2,)07-DJ"MXE*DK=2M+2E*2
M'5("&B@!2@IH!959)6D$$I)$815.E!TSK4^K::GR4Y)U+:60JTG09N??ITOM
M#4J?*4K9R<ILK+NSQ?H,NW5'II$O+OU*0EIJ7G!).JE@#B[&[X9J&TE%)AC2
M[A*6&8EFZ;"B0,?,L4(UC0ZPQ:\\BADQ\G0'@W*8FWL@YK2MSBI-W OO:TH2
M']CU%\H]+<(PE2$I"<W24FY=62 "R-X-VE(&/=J2%#'ZVG+IK/2EM"]*)DIB
MN465ITE)N&8V@J$Q(S#DU,;0568=M+N;+,':)@463D69=JIIHDW*,U"7^\TJ
MG/2$MYA&$X<X-Y:'-K:8I"LU&3E)/%9:?98BXVN[TR*JEI8D?79F6X T?RT[
M9'U!EF5:FE*O.G?I6)HU8Q<&P>$;XQ31P!!>QK"0]O$%MMMPNH44M_B[A*4)
M=25IWB G!ZRE*%^$N>Z3)]BDMTA[:[[TK4K*2NUJJU2IRBTF@UN;J]*F%2]"
M>-%WLO*2%,8VADWZI()JM/3+KIKSLQ-3S[)<;\_)X41DK?&5FO8>7;O7&&:O
M5K#)(1G*^D+L0\G9K\$66<5;5:)@Z]'^QD]".'"K:K6%^0TRZ3DSG1":?2+(
M4M3UP)A:T)!R#=@ANY1=96M6)"@+K0GU!ASC94^5VY7*T::JE2VS;<8;VWJU
M7ILJY-WEY:A%,K2MGO2S3TO5:<GZE,^E4^>:;2Y5J;+*$DRN5 <+_F$>&R-L
M]B5E(7'=;JZ3EO6ZFLP<8LR0KTU@N$4@QM3B+J&07+Y[$P=6A)X\PM/N6;UB
M6<9NR1[IZ*+4]8]+4ANRG%KL5KNEYFX0VHE%UM!(4I:DVPBQPD$@9Q\[)+Z3
MYNE4U$I/[252K*9<JE81,-;6[,HP4ZC3:WZ2B;K.SC;$O.5"JS].$DW3VGV'
MU2#S"IEI@+>3J_%-FR,USG>([!M I"V.5[A(I3;.4MBRK"JQS=&1;-7M*?1Z
MJT;-+SKE@F=0J"BS0D21([%8[5%,5:*@D[B5*SB<PG&2"E1%DD8DFQ&$FV8U
MN2 8^ ^T=(SR-@.CB;J,X]/5I4NI-8FGY4R,[-,+EY=^7-0E74HFFC(S$R9?
M"^E"_27EJ?;2^JR7E4KOX0)[;8IM?<'X$A:HN_,6P24%D::D)5DTY51,JQ:+
M!T3A4%@3)R'[!(8Q@[0#6JCQEESS[!;WWB&-YLW%C*<:_ LOFO&>*ZF_:R^;
M4::VJ5OD9IA)(/:-&)71Q*+NO?,WT5$ S<PB)/>/W9S(J=A0TAE;*_UXZ=7#
M*)DTR[^$!>6NOM+SA# D-3W$JT2LDK"9%FG\O'Q!U !XZCF2P=$Y=I);F214
M]Z<P  ]FD,N9]W[XCQG[(''T.'[RGD;%.*J+CA:-;-\C7'&E]G9F]5S'SF48
M-[O*UV/'M5=M:NK*G563 RS)GUE\B'2MR:P=-;=OGI]=<!;K.6FGSO[OA>.K
M5,QMFYM'T.GX1<35-PFF-A11>P5AQRSQF%"]L#1[A1_A]2GN7EN;0)L?@Y]M
M;B0;M92>DY".=RAIF07D)1*JX-^P6/7Q]YOV<.$6V//._7:UB!Y7X\S&91Q+
MQ:.T6\/<<A7B>92L[-H6&0AYVKPY)"%C>(*IP#-R[AE"JLH6-LW#_*76=;0$
M JY2Y6I23Z9;<R@VBS+Y?JGJX&V<#?Z[1KGIS%M,@8YE8GD,UT_+>5<?\,%)
MQU;^#BN<2DW7JY:K#<'[23K5>ZS7#Y4BL=,FIC,9BLU:W.KJ6K]#O&J/TG,:
MS.9DW2 MHO87UBHVX?7UGSRMUQL: O'A!'%NA6ECP=@./I:]CCF\]+1V1IIU
M,LJNI)HI2DBQ8G^DN)-M%&7<MFA_I:KHA$3>],.LQC+Z'[XC+=.*3CV?6_,>
M$JYA7$#:\TG%<A>74A W&=?RL9!S+9^U@I& (<XMI.VD.5-Y'P@I;+NRH)&$
MQ%.07U]?W0Y>>D=/,(U;(L)@[$"7!D=%W@RT</&+W$9/1S^GINULGNY.X7+)
M%]FS2JI)62N=B+ Q=#MPOC'60LM\9NSI)DK$ZI&597];4=N@TTMSOPTZXNSM
M<7N=>';D;YY6ZNZ-SP5)XRX&.I\G(W>6L326A6,CDFF]:K:EHBW"$U3E+#'5
M*U2#DD8TL\[$KSQ(YF1):IQ32 E(V)E8*8ML;:8&.7'7*VG7KSX7XPL>''4&
M_CJ->KLCD!Q=R.2\>9;XZJSPEU^"/@9%C6)7-,I!R*L>\Q7DB<J+AQFA7$,9
M&"#)Y:#U,(:R6Z.;[&@K4X,X*@C*.G" VI.0OR/N'UYQ6JUS:^HZQ<Z_7;W=
ML+!CMZE@'!]1X+9".JV/(]F5[7']+EV41"N:,;%-V>5%X$@FFLK)H3=U<TU^
M\<$2=.9>0=&?S9E6BLJOJKCG?SU'E>+>SZU\XSV#*_Q!-K4K*9;?3+VNVJ"R
M,K(P4Q(P$BC"2C:^Q25':N8^,%5A&GD*,[DQ2:UI9S$K)-W06+HI5.,*H-N'
M5U<#?WY&, 'CF,_C;+Z'C:.,,5+9\I6<.)*E<'>.<5W#AAKV?Y1A6G5EM;RO
MLZI.NJ]4Y'+=6Q\RC1ZDK4Z_D5]:TV#1J1.-C98TG%,@!)L9)&U-[9_O[XK-
MK_(?O[[W[HJH,'QKXJGLG5^MX2X>"8UL>2<G76,EXRRO("9<M9PKHT&\EHIH
M=1!U-20,(D9M^L)7!A<+%Z,A6J)0E&,CV]@MP[.OZSA6KW/CP<S**-MPQ@V,
M@C,Y@Z[R*R!,/7Q'R,._6A44VZ@%(9%W.)QS-XH([H,G#A<OOTBZKLBYS^.7
M<?WF&77[K>9BNIW+CM=S[-"Y89P?%5TZ4B+Y_#Y EWL@BLG&/%8PB+94H)G(
MXEB,6SDP]J359=8OODPT 1S]^7D(9<+^[]YB.?$=;^-Y_@+,C/(^'\+0-'<8
MWMQ+),5Z^2LG-Q[#V%=CTT<P7 $72_3@BGT9]PZ,YS?6ZRD(OD<\]?[OKXP[
M";_7&\00X#L_\=2THTJF,8.2S+CB-61:2C3(#APC5:HT(7F,DSR._.56N*(-
MA%5K"%=3"8H)F&/JSM0-M3M?*U[\/KPC!Z\LNS+ZXPXL?VBKY)XXLWVNPRT!
M-B_NS-JV?0TRG8H((V+AXJ,9M86=!LT3E(MDBS!HV?I-&9'8("N+5N=0R1?<
MLE(3]'Z*]D9),I,2#R*4MZ9EGFEL/(FYF9?F'R\TL)6EQ:W NRTXL)3R%O(L
MA/4ZK]*6VLZJ;EYY)JDNQ+3#3K<PRJ3EI*7880RXA2DEM*D.))02G>)7QCMU
MG:"P6EA=JI%*,C2@QI^M%$J(%*<"#R\@AN)NS81$=MAW !'O'I[9Z8VA-=6'
MPO<;P;L@G,$_#EJ0>HQWA5V:2*5ZI1B+9QWM89<].S+OCCUP3SG$?7[?Q&->
M'&BT*ZU-6S4U69+>+*]KS&,L'L=/$5&%%ES [=/6!6/LN!_S!-K%;#]-'6P^
MT-NE2NP*W;"?5)5I+Q_TIDTOR!E O*^[#RYW=?[Q=[!\1T(@IJO2&VS<4Y-0
MHBV@D#=>GKE9X3V&QMO"PBGEWJW<= ?;WX13[1/#Y_*7-_U=>9K(YGZ[H]!9
M<S[A\X/;WX13[1/#Y_*7-_U=+(YGZ[H9<S[A\X/;WX13[1/#Y_*7-_U=+(YG
MZ[H9<S[A\XB_QG6[C6D.&C*#3*&)<.5JB*LZ^,].5>]2LK.L$T[= *LCQ[!P
M )+J*29&2"H&_,T%552^^3#4DA/ W/UV0RZ_#S,18X'<_<;3U5"+@81;*^)X
MH1),3>3I):&@ZK'M  SP663WY57"!F+8 ,:).E:C,V9>9I!))$,H2U"%N+2V
MVE2W%J2A"$)*EK6HA*4I2D%2E*40$I ))( %X@I24)4M:DH0A)4M:B$I2E(N
MI2E&P2E(!))(  N<HO>%68I]\XGLUVN?E8V;]GLRW=XWE6SPDG'O(4;,_)!*
M13\R:8/(<(8C(L0Y*D0BL<1L8B9"& FO==9E)ZE;![)4]F6=DERFS%(;=E5M
MJ9<9G#(M*G4/((2M$QZ67?2$KLL/%S$+@V\A[&3=/JNVFVM17,M3AFMK*N69
MI"T.MOR2)MQ%.4RX"4+E_0DLAA224EH(*24D&.T7%5!8/1Q,@>!.S.\-$B+L
M#%0+RK]&(;$$NXF*/O1W'8=]]P\>NG=D'Z^JL*])"PWOO4S4;IQ<;Z'7LRCN
MW:)BD_=AP8"=R<5[9&Q%O*WCPY&<*\"24X?^)P_(7VM5W,:4K4UQW!-*;-7H
M MC;M3=@ BJ@>$,JDG[PZYN8X"<1'7#^T"\W3>D/H;K[ "*]+3-!H\TI(&]>
MHVU>T*]EYB5>-L2V5,U-Z>W2CA])I=/F",4HR4]*R-$E]I.@7[1E G4I70VI
M+:':BEERV[E-H-B:!+;6RTU+$Y-O&:IGW:MQ !5+5>I2@5AFW@<<'<&_?MXM
M=A'4]IC\H4Z#L'A'NXAVE$2F#M*8!$#%,'<8!#M 0'M 0[0T'7F.(YCB._KC
M-R+%)*5#-*@2"E0S2H$6((.8(((.8,3"I^8.,VUPY'= QGAZV5V-.G")3MAN
M<O$3KYW'LF@.EI5@03I(O%3J@L8Z)A27(J1<I4ND%%/S)M?244:OSTHR,,LM
M29J52-$,3(WJ6QU,J*V1QLW?KC]L^@#;M[I$Z*MF*]/NK=J[$NY1:TZOUEOU
M.CK]#=FW#?-RH,HEZ@NV05-E(M:POYFZ\>QR(=;PK@M( ,IR"ED.7/S#L7FW
MW+V;!MM\>OFTXL["^E_JXCN7+AX6\S& ]N/'1]IO"/X?R_\ 5U.Z^0^N^$'M
MQXZ/M-X1_#^7_JZ77R'UWPCCQP_9?XIJKD61KF%2SMH<N)R2<RN.BMG5BIP*
M+22W75W+995)O7F?6E!!Q/MW\&;8"&=R()[E&L$C3YPCI9QJ6+(X<,]6E[O7
MHRIVEU8D$[#"U^</8(U@N:(E#-B^R74F1>=42*&.V2,^;-E/I*<I( 4JY_I]
MF;*GG L>MZ.</9O&PKR/'+WQS).V\4.)0?=<7ZQV_"/EER_9)!P]=\RJNPJ'
M^N-V;CW]H]_C_>U]\O)!L.&4;/0#3Z' #PY0Q.'2U>Q&?<<NWBW1H+S+N(*8
MQA O6+!#R<"T+N([;G>2*! W[Q, :U!40^B^A7;WW3GP^/OSBNPR-R;WN3;0
M9<;]7/PB>&6EENG="/-\,_QAXA]/_P#/:.MLWIW_ %]?W18#D.SN\!G]#C$&
M;@*AC*#N.^P^OT>?[O=J:P2.LB]^OCWYD9>,#J!P-[^[W1HV3!0PG#RA]W[G
MW0_X:UKZ22;=>OUV^=X@<E#EJ;GGR[-1;.,(BDJ*@=@_"W_N(#VCX_+OKAX#
M]?7UPC-P..++M/7EP%M<_.^T:R50%40'F[-ON>(![O%__(ZYK2<A<::Y6/(:
M>_J$81>]_CWZ7X]O9GPB<^'#+%<-QW-MN3U!XO[[ZY@'JGOMRR[O=SM;+.\S
MI[^KASX1VFX;7*Q5F B?E*4Q!,8QN4I0#81$QA'E*4 W$1'L* =NM5. &^A]
M4GM-M<M=+'KBI1ND'CF.VW7V^9C@X_S0O:<OY(N#%X<[*U9$N5E9'*8Y0.TF
M[))2;4X%$=R[MW)!#?M .P>T-;*639I"<@$H2FU@/93:WPRY]M[V Y <0/?;
M(\3H<OGK'8+@XS1*-):*$KQ0!*HB("!S]P&#<-@$?N]GEW#7#GY=*D*/?SUY
M]61OJ=.Z*TW!(M<:?76.\6L,C'?E@[*_9-7Q=N5XW1= !0Y2E!PF58" 'Q$
MX$ ?'R[^/77#Z-V\Z@:)<4$]E[CW V[HTS@"5J T!R[#F(N]51"'A5/\_P#W
M+_2=5N<._P H15Q_VN6>.\:X@8NEF<-;G,O8K4"1S)>R;6#=1K:&BU3%,'2,
MNNO'3]VV. D4<,HQ3?Z2(#6-?#CRU'[C\3"+J@\)L)+4)67!NW$J#4IU!]X
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M6/,B(GZO'3K2$&D(TW>S&6=-HP5SMV\B]7(Z.F<R9E$D2%'JXF+L()JB?F4
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M6$TE-BFY3/1WLDRH%5-4Z003OIN=5U6PI>0D\S<<LLS'RU4_PDOVIJC)I?\
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ML(;G Y^??<!+KE7().1N/=<7&@OQ[.'7Y3VO>77:;4:E4&TB<DW6WF7PD)4
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M0(.)E6;][,*%6D%%5^L'7$IE.F3,9/HS"(%[$BD!(I=@ I2 4H    <A9(L
M,LM,A;(WMKD>6?"\>E:W.3<AZ#*T]!1*MLLAM+0*4%*T!:E@ F^]45.$DJ)*
MRHDW!CEEX2BBU"7Q/>&SXAP2:1+N4;JL%2MWZ+R+(9^T,R6#E,FNHJW*AMN
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M E>>2C?%N':W'-'\!72T62<M%JU54[',2[@["*5>NG+UG)3UHL5AE%HU=U,
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MZK1+[%Z=GF/\=LP0S&*9IBYD)!9D@R0;-4B\ZJ[A<YP223*4!$QO>@ =P=H
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M8IXD88UTX. B95%1,0%L<Y_A!MR=HB)1W'7U--VC5+H2U-I4M*19+J;8K<E
MZVY^Z.>U.6 2X";98AYCZTCGU$>"$S$>7(E(!6D&/3;&=GD>D(! -\,$RH@I
MW (@&Y=QV#?M[=PO:2G8;^NHZX0VH&^O+NSU^,<@S3&N+X9Q&CCJPID7 DU
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M!I"#2$&D(;5C_,VOWZO\TFK&^/=YPAJ:LA!I"#2$&D(-(0:0AC7W&= RC$!
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M]K5U.N3%126@A+#!(*D!16M8!R"EV2 GCA2D<+DV %#TRIT80,*3J+W)T.O
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M.$-35D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"'A5/\_\
MW+_2=5N<._RA'2-3\T4^_-_.'5<(HTA!I"#2$&D(-(0:0CF5X07BXR7PZS6*
MZIB9[34;-<JWDRSN&5IBXN=<S#FINJ+%U*L0T&\OE&F)=W9Y6U20'C:46V7A
MVUA'):[4Y1=-;HHGAG;SZN'C[HDD<QR'9S/=$<;]QV<4M3<99L+DF-*C0U)&
M098>D;Y Q4*RD(=WQ/PF%:];V%A4R?T,U%1-,97.UWY*YQ>/2P"KFE.4%W,/
M.(O%\YYY]]K6^N_GF#&; D"QZ]>O(Y9'LRM>'TPX_P#(T&YQRZF"1-[H<12K
M[+YDRG4Z'+.<>R=O#%&3LQ5.J5+(59F[/CN,D*I6J;2F\]'>V6=D+8MDV-5B
M"1YX"7;A@*T%^%S?PX#^XW@4ZY6/ 7Z[7SYGLAL37')Q#UZ%@*YDRS8QP7FL
MZ5H"<H<]CV0OCI9]1,1T>T0T%7(V$OD4]NMCSE:\BP;B CZDZ7"L-64U2(PM
MKG*U+3[S/C[].H=M\OW0 !.AL>76==-!8ZZ\AP=EMXV\_P 8I=I)!&AQ$W18
M;)CK(.!U:!;9:ZXCK./,63-K;Y<N%X2LJ,8ZA[C>HJ-KU0KJ%7;(6*NVV-=0
M\X^EH2?!OBYT_?;+4]_OL86RTXBQ.5[VRM?3C<1:?1K<63N4FA:8Q@FR-6RJ
MG'RM:>5R8+-251E\:)<2A*#'O?97H!R11L#5BPP-J?)(+1+_ "??Z*A')I,F
M;YFY9B^>G.W('@.WA>%@2,M1POK<B_AQ$=+^'^[S^3,+8UR194FS>3R#58^\
M)M6C->/39PML \_66*C1RJLND\95N0B6L@*IP.J_1<K"FCTG0IY'UX_NRO$3
MD?KAE#K?_5CG]E-K,8B,O$1P^UOB!-A^-M=3Q_:JY2<L1EUM+6\P$?/+K5F)
MKMC7]A:\C(0TJ@*L]<TJ0A8V+E:-CY2HMIQL\6>&!M%O<$#W9_7[HR#:_9'(
M1E@:HT&;R]5D\]8;K=BG:JHAGE^\QQ.+DAHQ?(3F^9YQS Q%#QSBA]Q"UBR6
M&4Q+0NEL&2Y"_P!+IEBN5?8!&%F(N*6QE<D\!UCK.?NB5S8=HMGW#*YMH>J^
MMXS$54V063#@V'.U';69"E8,HUBK=A@\[5FO6ZH89I*C?$,I+/IC'-:<4^;?
M<5E6MSN$]EEH9:4J<E*.X"2D+0C&Q)'9?W$:99GN^N(WS-K6OR.N9/7ZN7Q[
M,94<$X%OL)0:WD/+]/JF)8FOYRLT! QE ;'G[+!(4O#;U_(M;!E'AEH\78)"
MCXPHDP]'--&IE9RJPC)R&29VB3FF<Q:9MKQTOPYZBW[M;==\W(N2,\N=AK[L
M^%^>F4+R^,,=V$]QK]HRKAVHN(&5/6LS7JI5^[6#)^?XQYQ-8PFK)9;K'WC"
MTI WRX5^WUVMXNA\:H-<SU. DLAS-<D))A .&%5>Y!&E]+7X>_S^,8SN,M=!
MEUZ6M8<;Y7M>_&,LVX?,*K8T]B6DG@-WDJH<-=XHD3*SN/9JHV='(_$QG"2C
M:CD-I62X1936/8Y*7KEE2QU#5&DKDQQ)7*R,J]$)5AZUL=CQPSTSUZSEPR\K
M]49SOQS(X\AVYY:Z7M[E,.\%E-SS"5BR4ASCF.I^.9B$8*5B&KD6M'3LQ(9.
M;.<SK^W&R\(.&9J LQ<=TNA154O.,JS 7%A:X63JUALZ,8U(_4:^ZW'GF,[:
MY"_.!41VGPX:$\;WYQWD'M[?CU**X:KCZH7_ &97^>;2$(Z0@TA!I"#2$8R;
MF8JN0TO89U\WBX2!C'\U,R;L_1M8Z*BVBKZ1?.5!^ W:-$%G"Q_K4TS#XM(1
MROC^-K*LM$39K8E%\/R4OF!./BK=E3$E^3)CC%,YCJ8MU%9SM0D9.K/+5>KC
M.UQS5HN3;2D;6Y&8?/&%?3G7[&)83&+]W;W\/J]CVQ*V>E[<CD<QJ<^?NL3:
M'W8\P<3S;(I8>(NV/U8@Y^%* +#^X[8X]5Q<LUS$DAD=DW?SEV0FXUG2:-77
MV2&[>:KR<JW3GF-:EVR*T2[D7:^?5V<_EF3U<(6&'3//.^67U81J9+CRS1)P
MF,9V-I:B;5V&*%,H'3QM<IIG!Q</*L:WGZP/7L6H="F1$E>WUDHN/)6S'0B6
MBV',B2[AU,HOH AESQZN?+7J[[6XF,V%R.VWD!S-K>_F(<D]Q+\2E%%W(R%G
MH%MBGUWSE%L7'N4S<%'5/'^&+_#87G,D6E>-O<V\>P<+?+U"6N9:M CE5*33
M)SJT@F:6._AF=_H99=^OR/",$#E;3KN3F.7?\!&(E^,[/T2P5&OMJADJ#;EN
M,'&91B*#8J]$V]U?'=7I/#;D&.JRUDFEF]0D<RC><?S:B$R[86>*A65TA)!G
M#O"&UB_(?#X\!;OSUTS*PY]U\^-^_+C;E'7, $  !-SB   FVY>80[S<NX\N
M_?MN.V^V^I1&/=(0:0@TA%N[^I'?^JN/^2?2$1WRG$WJ?Q]:('&LY&5>ZSD<
M,-#6F6([6;U;V4618R%F;-&1#+2$O7XM=[+P,6=5DTDYMG'L'TE&,G#A^VI3
M8$WY<>T0B 5>X)K[!5['E'L$;@?*U0ICK+D8RC+<C>8> IT?D?);*\L+W2*F
MFG:'H7B$B%)>L1;=:]Q<Q6TSMG<'DL >2Z#J8PV&G$9G, _5O")8L[YC3X=?
M[NZ,!FOA*H=4C,G9*MH89QC V"V9MLLI<HZ!582<=,Y,QZUP/A%JLXA*>$@N
MU0=6R>MEM:IJ+I(7V:&79I3CJ1DI=*61TMSR/$Y<.^,7.ER>KLS^%O=&HF-,
MI"G$I2\AWZT8RRE8F<XFSOCN%:6^R3<9FNB6\TKE-:(K2O#/DLSJMT]*VXBQ
MY3Y9GD#&*S.OTZ%9O)Q2114"-Q;,'(<^9)Y7&?(6SX#2)#0@==LP/5TYCEG^
M^,A/L(O+&1,G6R?SKC=Q!9RLU:X;[+675/S%2Y&*A)W+^.RUK$\':I^!2;7&
M8E,64_*B3ALPKE,2K-_ODHO*R#N$G$YJ,SS/9W6_OOXY:+6L+&XN=0>&>FF=
MAX9Q06A8SE8V3?W?(F#;KE_%4#Q)/9_(ETJ=A*\=91D+57L384F8J8G,=K.)
MYE2'K1O%V+VF+S[N'RHZA6=5C9F1=,'H8^C<=MCIPL;=7'GC3+.WJ\>!!OQR
MOW<\HVDVQ_7[J>AJ-+?@3.6-\88L,VC6M\@;Q35,(4"JW'V%/;*Y7V#6PKKY
M)B6>/IJD.YQ]/XUML%,587;=)HBWF81WFVFG+NZNNWSA>U]<^S/]V=^5LNN(
M]KQ+*<L64'=QXAJ>[E\A6O$=_O3^J8TSU%2]5R!3RY7F\9Q5?!Q5)U&_&@[=
M=,*,ZD_:C5'<SCK'"*KJF@:,<N)1IJ>-_CEY6XY1FQ.@X6&8X@:\LK]YC?%8
MX2\F3=-+/L&>#[G:[-BQ%Y5LK7,V2X&X8VR+(T^T.)MC0X9S2V,S 5.SY>M,
MM?9J=?N8J8D6$W+Q%FQ]8 )&=4P;<;7XY]O'6WE<0)SZKYC*V5AX#3@<P8;8
M^#8FYBEUZKNH_%U,95:-N D@8LU$O32W2MM?XJ8OBS4Z^X8*)[75?:30IN*A
MKU7*L.3JC-V'V5C;8_9==BG.,N"OB!RL-+Z#74=<,6=_[^/7S.FAZHZXR"";
M:,2;(@8$6X-T$@.HHJ<$TB@F0#*JG454,!2@!E%#G4..YCG,81$0]L]GRB$-
MC4X0P<J2T'!XWO,K9'$(UA&E7F#/EK(P7E($"J,E4$22T8V8RCF28JN5445V
M#:-D'+PB@MV[)RLH1$X]>D!U:QR98XEAT7-.''^;,:U"1QQB)G1*=49/&E\I
M\RHQNV.Y[A\')DF[D(B(F?9N^YWM\,,V4E+?EF6]1HXJS_6XP2J1%^!%M=.W
M/RMGD-;Q83GF//0W\#\3PT:R&*\-1$79X6BYBQ\["MRUK(M[KU'E(<D7'1^*
MJ>C!S#ZL6'$+G'TEDC&;%S<%JW$GHDJYN-'O;EZNX"<*64;XR.FO9:^7*UCK
MRT,+D9GQOQ'7>W?K;.QM&;K52Q53WV9)2RY/Q'-S5JJ>7,<U&=D2V]P#:S8M
MH-/HJ;>>Q2EBI./API4#%5P)D(27D4SOEDXFLQKU1XFDVSE>YUL1_<#SZLL[
M9G7%\@ ,LB<^?,WXWY".K.#VV/X_&57B,8LNH5&#CT(-DF-2EJ4HLO$H(L7;
MQ>$G(>"D0<O%D1<.7R[ !?KJ*.>G<&.90<BUA;2(F]S?6-LZS&(;5C_,VOWZ
MO\TFK&^/=YPAJ:LA!I"#2$&D(-(1J3/-FLM+PUDFWTU\Q86JL5.4G8 \E#'G
MV;R3BT>N-892+3DX<ZZD^HB$&W5*_3%DYD$GO0N^K]47BHD"XZHR-1?2(BW?
MB/RWCA6[45W+52Y9-J$@T4*V8TV1A ?UA'#\QD%W:C0P3TJ+2O2MZ=57$D+*
MGDSMW=E.[01,=\L9HTK*U#*_?;J)OGSRY?&,V&6MCW\;6TY7,,*I\7V8Y]J#
MFT2-(QG67!,9UAQDBQ4B>D(:O6A2JY#>Y$DWL0C8HXRIK'<:='U['L.ZDV+0
M(^<C9$9&;>R,?%NP6KB1;333A?7GP[H$#A?CRZB/@<^P\,X>N*^(?B-O66:#
M"SM9A*Q29-U&5RRGDZLK%IO;(SPU$9-M32.=O;BI9Z[9 ]L<<YC*I+55\U:-
M(JR1LA8U9.#D"I M6( Z<<LCQ-M3I\!KD;B!:_'MOQ(Y:9:WUA*2XL,K3LKD
MB,H]5? $U.8J9</X.Z$_0?VBO2]RL,'>K-'JW*PT>K7EG(5:O^WBI.F=F@(1
MK%3$<TEY9-VB]%)C4;VT-L.5SU\0,^'#KYK#+OOGII;@2-;::^^*3<3.<*K+
M&BLB%I<5::2>$/:\7MJ?,.K1<Z4YK25SMF5V%AC+=)UZIUZDU]XI&OTVA;A!
MKWFHV>MI69927KP),:L\Q<?D@9Z&Y[CD+$C+,PL.''CPORTS^&1O:,E6[[QD
MRL'BXMH=U&@3V2+Y"5MBA,XUBI1_['+XRL60+;(C&UK,L\P:Q,![4)-G7G4A
M+,9J>4D$"34%6SI(INF)>5N/,=7U;//3(D0LG/4@#@>NW+ZZX;R/%5EAW!3,
MTRL.-'/20D6^EFSZLR=3:X7M2]PB6IL56RUV:UHU25R%(4H+<L!+$[HD1#V^
MNQJ$FHA%VZ!278U6U%[\M-; ]MN^]A"VFO#OYVL.'?\  Q6MQ699=*UM2/=5
M9DRD)RFUU5K*45_'W*;E)FA8QL;Y6%HTM>HX7:;*;R-[&VZK0EKG;M7$8IPY
MA(^QM6$DX!C5]?5M->SMA;7O[-2,S;JL!QYC2.F&KHC!I"#2$/"J?Y_^Y?Z3
MJMSAW^4(ZIGH5J$YA",#83&$/\<8]PB(_HG5.-//X'Y1+ KE\1\XI]H-K_2P
M/]L8_P!ITQIY_ _*&!7+XCYP>T&U_I8'^V,?[3IC3S^!^4,"N7Q'S@]H-K_2
MP/\ ;&/]ITQIY_ _*&!7+XCYP>T&U_I8'^V,?[3IC3S^!^4,"N7Q'S@]H-K_
M $L#_;&/]ITQIY_ _*&!7+XCYP>T&U_I8'^V,?[3IC3S^!^4,"N7Q'SBHM$M
MQ0$I8\2@;X0%?,@ WB[0!UL/8(AVZ8D\_@?E#"KE\1\X]"BV\!$08& 1V$1!
M^R 1V#8-Q!UV[ .P?<[-8Q(ZO=^Z&%7+XCYP>T6W";F&/-S=W-U]ES=^_?UK
M?O[?+VZSB1]#]T,*OHCYP!1;<!1*$>8"CV"4'[("COW[AUK;MTQ)]VF1^4,*
MO?KF/G'@42VAR[1PARCN79\R]Z(^,O\ C78/W0TQ)Y_ _*&%7+XCYP>T.V]W
ML</=M]7,>[?FV^JN[F]]M\?;WZ8D\_@?E#"KE\1\X\&A6L1$1C-Q'M$1>L1$
M1'O$1ZSIB3S^!^4,*N7Q'SAJN\8W91RNH2&YB'4,)1Z_&AN ^/87@#^^&F-/
M/X'Y0P*Y?$?.+?W+KS^DG_>$9_;-,:>?P/RA@5R^(^<<]+EX+"T7V.M49:<D
M6F783%PN%PKT.]@<:N*]77>0<QP&8[DWDXM1 5KNC,NZU&TP$+1(.XYE1U)&
M&;1I3R"SC3$GGWV_=&<*N7QU^/A:,C'^"EKJ4!:V<E&$=6.;H2E"K$]#1U8J
M,+CMO['7!%I-U3'E<D&5&3G8Z:O-BL\=(O(9PZ83CU1ZR7;N57#A;!4D\?>#
MX1FR^OA?/6W?#<)X(F)<U!.I2:I6B+-A,1L2YHE3QQC9.-;VF6HZ]T4]CJJ5
MNQ>/+E6**SH=A?/$E7;ZJR<FQ.M[]'HET<^? \>.FO7&+*_-^(.E[:GAY=L>
M6CP3UDND06*MF2+)9$8VSVRP5J.G:MBZ3K$2CD'+;?-M]CI2N.6YDK>%JOT7
M6WKU>S/9!%JQKC!C',6A7$BH[8DVM<_'Y?N[H *'#JU[N?++]^</ZK>#'1K5
MWQ[?R+/AF\?6!C+-&$*PIE5K$A$1V-*]2V-24K<$9M&L:_'W"L1.5HILR33&
M-M9'"#82L';DJK$CY9:=F4,*N7Q_?RR[(E!BOAMM>*\=U+'T>T=RZ%7B$F"L
MS(/89-_-2"BBCN6FWR;=V5!-Y,RKEY)NB(E!,J[I0I-R@ CG$GG\#\HQA5R^
M(C8'N77G])/^\(S^V:8T\_@?E# KE\1\X;ZV(,AG65.6 W*910Q1]DX@-P,8
M1 =A?@(;@/C[=,:>?P/RC. ]7UW0G[CV1/U/_P#>D/\ V_3&GG\#\H8#U?'Y
M0>X]D3]3_P#WI#_V_3&GG\#\H8#U?'Y0>X]D3]3_ /WI#_V_3&GG\#\H8#U?
M'Y0>X]D3]3__ 'I#_P!OTQIY_ _*& ]7Q^4>AA_(H" A " AV@(2D. AY!]D
M-,:>?P/RA@/5\?E'ON0Y'#N@3!MOM_E6([-^_P#/#Q[!O\>W;IB3S^!^4,!Y
MCX_*//<@R-MM[ #ML(;>RL1ML([B'_6'<(]HAXQTQIY_ _*& ]7Q^4>^Y#D?
M<!]@C;@.X#[*Q&X#L ;A_E#L'8 #R  >+3&GG\#\H8#U?'Y0>Y#D?](3>(?^
MM8CO*&Q1_P"L/K0[ ^(.P-,2>?P/RA@/5\?E![D.1_TB-XQ_ZUB/KNPWYX>,
M.P?C\>F-//X'Y0P'J^/RBGW'LB?J?_[TA_[?IC3S^!^4,!ZOC\H/<>R)^I__
M +TA_P"WZ8T\_@?E# >KX_*#W'LB?J?_ .](?^WZ8T\_@?E# >KX_*#W'LB?
MJ?\ ^](?^WZ8T\_@?E# >KX_*$7&',C*-W"9*]N=1!8A0]E(<-S'2,4H;C(
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MB\CKJXIL;7D23+=!K)H6QX*[MI+HF;I!#R)V^!+TTMJ<]#FB$K6A:07"4%L
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M3]OMI_3 G^Q,?[/K/W13OX/_ /JO_M(?A!5OX2/^A+_LH1]T"U_IB3_86/\
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M3_2)G]K%8VOV@)P^FIU.?HLI?+_DV^$>>ZI>OTY)_%L5_8M9&SM') ]%.?\
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MXFC, _\ L%/_ ++"2N=\H$ -K$GN(_I-!?BW3\#=G?X"K^ESG[>'^,7:[/\
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M&6EMA*$2JU--H5;"2=XZMT V*R0M2KY)L+ 8;]#<P/K>1+N(<!4PF74MLH2
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MAW^44#W!Y/6.D5Q9K?#\P:0A+2$6^N1"#2(K]D]WB(T5E^-2,@LHR>@G(RS
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M=W[-7KFDG0WTTX=Q^,<>7I*FRK>)LH?'LYZ_6D7T("ZXJKF-NF!@ OCW-WB
M=O8 !W]G?L'DO94% +)L!K>VNFND:ZI)#6%EM!+J[Y $V2#K8<[V![XSJJJ:
M(?3#E#N[A ?1YOW]<IMQ)%@03?F/CQX<HTQEWQJTH#F1;GW?']]LX?(()=()
M@$3? +OL(_=^X'W?'XON6%0&NO <X-R[CB[%.$975J->&6>O9&+:*.W*O2"(
M@GN'?W  _=\0#_P\0=VH)5<Z7%[\[==]>(L>7=%[[;+;=C8'WD\NN^?._6=!
MF?\ CJV-4>K2'I4/SQ_<G])UJZE_H?\ F?U<;S9[_6_YO_71T5'O'RCZ==!Q
MZM.I[3XPE]>'[;TFU:-.]/@F(G0]A\(J/\$?-Z0U8-1VCQBD:]Q\#" ]X>7U
M#J^ T/9YB*3]WG]0Z1B+93Q>?U:0A!3N)Y!].K&^/=YQ4O7N\S"6K(A":GB\
M_JTBMSAW^44#W!Y/6.D5Q9K?#\P:0A+2$6^N1"#2(K]D]WB(T5D.7&MR4R_<
M(E.L\B$RP:BQ>=$7!4^K D'-V#U=XH#E9 H@(IJ@81^FZT52"TNE=C8H&$]F
MMN5C>XRR-X])=$,G+UVDTVF,NA'HM8>-8:;4$/[AU:7P]8759^5;,NT\18+9
M4G/=6C4AL614A7%Y)Z*;IVY(9=RNN(*++*J!SJ***&#F,8PB(B(B'C[MM:#>
M$J)SX\[WO_=Q/&T>ED;634G4FI*53Z-+L86F6&4X&FFT>JE"$BR0D 9#7F;Y
MQ\W_ (2[&BM2F8BU4..C2S3Z6]C)8KCD1;.FHH+K(N7)2J(&550% 4>E34*N
M8BJ9!YTT0 G?W0[7)UQR>H;CJG9=#!G94+.(2ZTNH;=0FYNEMW>A92/5"T*4
M "M5_"7^$PZ(>C>;V/V"Z?JI+.4>O/;1L[ [53%$9:9G=J9>?HE4J]"G)HB6
M=8>JM%^X9V33/S:"Y,4Z<:DYAYQ%.IS;/*H[+*SI=-3V8J\:C_Y5!LU7<;;E
M'M*+EJN<^QMO>BLGX_?#X^]#O\0NIL >U9.(]0N<@#ERU-C>/Q[;G>AN5DYM
M'W)MK5)U24B4?FZA(RC+9WB<96B2<:(5NL6!9;>0%X0I@@DB_38Y((JB4T[6
M5D$R'YU5(AX5PX4$!$H+)HN4T0 #"  HW,WY"AN9%8PCJ7XZXLM ' ;LYY9Y
MXP/KB=-?Z?T6*EE@[-[8HFW+>NUM)33+L$+L#+H=HCCI26O6=;F7)A2W#A:?
MET)NJT>NLAEV!2,J@$((_3?9*42%8![ Z!V1) 6:AMNWI2"7WP  GY3",5%[
M/U6\0_WE6(%K6.$6XZA7 7/#DR<KT5;PA56V[4AQ*;+11Z$%2R\RK?2"ZC-)
MGV47%BW-RRU82HI;*DICO)X-##T(XJ,;:)9@D%ELHBZDUE7OLL9NB#A1-HQ:
M/3D(!6B2"22HHH)I)F<J*JJ%.H/-KRWTH5N<G]H)B1<6M$I33N)>7"C@2L(2
MIYW+U5+=<4?7M<-I;1PS_H@^QWT8;'=#GV9MD-I=E&I:H;0=*$@O:VO[6FC(
MI-5J4C,3LTF@T=;97,34O(4>FI83Z$N<?955'JC/-E(FTH;[</Z4QHZ,;9(P
MJ::S$R2BJ10 "NFNY1<-5RAL!DUD]PV,'O#\JI!!4A#!UFVX4J!]XTN#;*V1
M^-\[\([+757-J6YZB3V):)E+B&G%#UI:8*5;B99)N4K:<L3A]M&-M0*%K2=S
M5%PD^<3,BS()8Y<[1%N< $$UED <"X,GXC 3I4DS'#<!, DWYDS 'V5(0I*'
MED$(4I(2.L7O[K@7[M1'BOI=6VTN@4YU:%U*59G7II((4XRQ-&5$JAU0)*2H
MLONH;.80L.:.))>^MQ'34(#WCY1].D(1/W^;UCJU&G?Y"*W.'?Y12/>/E'TZ
MG$5^T>[P$('^$/F] :10/;[SYQ3K(U':/&(0C]?^V]>KXI_+_E><4Z1&+?5W
MY(_D^(A%)_@CYO2&I0A(._S#Z!TA%!_@CYO2&D4#7N/@81TC$:'RQ:<AIJ^U
MS&S=%L_*B1:2L#EFF_,Q%4.=!K'-')5&9W0I\JRZ[Q!T@1)0J1&YE3&41R#U
M_6N>8MPCYRM3=3N96E!#;@2%.S2VPZ6R<PAIM:5-E5K%2G$K2 <(057*8RQN
M7\[XPL#97([P+I3EG":<L1:#BXZ9BV9S@"KZ*<0K*-2<*MRFZ4[)^@Y*Z33%
MN@JR44!P$P4'("Q(OQO>^MB2=>1RZ^'QS=8VGHTRA=5?%2IRE /I5+2[,PP@
MG-V77*M,)44#,MOH<W@&!"VU$KCH$15)P@BX0.11%=--9)4@@)5$E2 <ARF#
MX13E,!BCXP$!T0<R+W%LO>([*Q!2,22"E2<22-""+@CJ(S@U9%7 ]H\#"1^\
M/)\^K&^/=YQ4YP[_ "BC5D5PFIXO/ZM(0@IW$\@^G2$):1!>G?Y&#2*H2/W^
M;UCJU&G?Y"$(G[O/ZAU.*W.'?Y1;*>+S^K5C?'N\XH7IW'Q3">K(@K\G_A$(
M+]Q?*/HTC T/9YB+;2' =I\!!JY'LCO\3&(H/W>?U#J4(04^"7^_C-J:->[S
M$4K]H]W@(2\0>4?0&K.)[!XF,<!VGP$>:@YP[_**G.'?Y0D?O\WK'5<5Q1JQ
MOCW><07IW^1CT>X/)ZQU,:GM\A%9T'9YF$E?@A]\7TZD->X^!B"_9/=XB$]8
MBL^RGO\ &*3_  1\WI#4D>T._P #%:_9/=XB+98P%3YA[BB)A\FWS]FK";$G
MJ'G$4(4LI2 <R?=EG\H8\I8T2$61$=@Y1\NY>WQ=W8'Q]P[A\6JEK !)4,KD
M7M;(?&YR ]YXQN)6145((&I";G4A1MG\#IPM:(<9'RW#QDET1E !43"B',?M
M*8-PW[1#QB'9MOX@[0WUHIF9N5$ 9@WM?+Q&8U/??2.WMGMG'UM(Q)]E0.8R
MPDBXM:]SGGV:WCCQGNZ<,/%!>&U F\DA&7MLX+!QT@K"/300F%PMRLW<DETB
MY3)KK"5-8C R(B<PF5Z,"GU\S,/S!7Z0AHJ;* E7K#$;$^LE/6#H5!1MF 8]
M![/4I^BT\RQPD*<4\$H-RG&E"5)O:Q]F^5\R<R+0YJ/PR81X+4DLKY'M1+&J
MQ=*>P<!#-'B1I&0:""@E</9%HT018I"9,5UFP/%3\Y"))_3!63X+KTS-_BVV
M\ 6,UJ*39-AF DDWTM>T;5,R)HK0T22BP4K"1;%<?E:D83^X6,2$Q1X2;$F1
M+.C6':<Y *NW14&LF60;O42+'-RE.[8G:H=*D [;D;.69B@(F QMN0VP,S4&
M$A5F76TZH"5(.$7L$K*UD6&EPH&UB(^.G-@:8\VHME]#Q!_&+P+!422<2$H2
M3B(-[%/(:1.N\Y=@:1&1RTW8(1@M(=&#%=[)-&B3Q%4I3)+M3.U4!524(<BA
M/>E,!3EYP(/O0V\I/MJ;#A58+ -E$ IP^U<7U&8.9!L<S'5<WL?-.SKLNU+.
MN&7N'-RVM0))LE(*00<0%Q>V1&E[QJ-[Q[80A)9M17>2XXD^J9-/EC62\BP(
MNL.Q07D4SHIF)N(?3V*;Y$Y!YDCJAMO!VMNZ,R[RV$7 5B2W<<5)0HXLSIBP
M$6 -@(V4GT1/J0J:FG9=M]P8MVHJ<*>"4+6D84X0;>IC%[GG$I*E9WLC&>S$
MFN4[)4O2-%R'$47:)NU%= P@!CI+%$IR'Y=S@<H  &YN7=4^:+H2^,6!:04#
M,*.(:6N19/'47RUO'6>T]&;D)ERFI2GTAI:DOA/K!&$W.>F)6&X!L<-BH 6N
M\XN06EURJG**;4HCT9-MA/MWB/8.PB';X@+]WO';H47#KR!XY]IMW=66MH^)
MFY=$HBPL5^'@??&QR]&F@3L*D7L[Q O;L/?OXQ[?3K8I  '7QY_ =>4?*3!6
MM:KW4<1L ";#Z.<5;[]H=H:E'%AZ5#\\?W)_2=:NI?Z'_F?U<;S9[_6_YO\
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M4A""I:)<551TW3<PCLY%31)6Q4%B)II<S58%2I)G(D4J?.B*!R\Y"EYR"3F
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M:I<L 61/LV,JT?.7!$A4,D5T9-FW7.5 #E, F4  /RFY=^43!JC50A5O;X$
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MUT''JTZGM/C"7UX?MO2;5HT[T^"8B=#V'PBH_P $?-Z0U8-1VCQBD:]Q\#"
M]X>7U#J^ T/9YB*3]WG]0Z1B+93Q>?U:0A!3N)Y!].K&^/=YQ4O7N\S$><L9
MQ3H\B2J5B,1L-R503<.$%U%"1<&@N4#MCR8MQ*X<.G)!!9"-04;JBV,5RNY;
M)JM0<[J0IGI+9F9APL2H)2E20"X\1DK=8KI"4GU5.*"ABNE*5E*\/76UNW/W
M)-)H])E$5*MK0EQU#BE)DZ>VX 6U39;LXX\XDA;<JVIM1:(=<=:2MG?::2S=
MFV,.61E8:KRD?S =:.2CI".4!+L$R;1\60=&0.)=P*HZ;O2E[S)GVUSO0:.[
M^+;>F6UZ)<*VW!<\5HW:<0XV0IL\ ;1\:G;/;V54)F<DZ1-RQ(4Y+(E9F57@
M)!PL3'I+N[4?9"W6I@ ZI,2FQ_?X7(T G.0_2H'25,RE(QUR@]BI%,"G5:.
M((E. D4(LW<)B*;A!0BA>0_2))Z6<E'9)[=.64" MMQ/L.()("AQ&8(4DYI(
M(S%B>T-G]H)+:.0$])XVU(66)J4>MOY.90$E;+H&1R4E;;B?5<;4E0LK$A+M
M6^'Y@UQ8WD):0BWUR(0:1%?LGN\1&C<MJF@RC.14D1K,.&I6ZL>=$ZQ7*13]
M"B^$R8"#<S<5>C,+G9%R0A$R&(=$W/J:DAM(WN/"YA(",_7MD#EI:_'6V68C
MO_H27-5=[\'YVFN35$1.;\5!+R&3)NN(#CTH X1Z2'TM;Q*&+NRRUJ=6E:'4
MX=1'Q;%2%;7DWPD=NW)#+N7#@P*KKJG*)CG4.?<YS&$>T1'R=G9KYG>$JOK<
M\\^WZ/'JN?5"-JYJ3J34E*I]'EY<I;9893NVFFFS9*$)2 @!(&0L";&YOG'S
M>>$KQ<K5[)7K;1TH1K)N)5S'33:0.Y;(2Z!F#H[0QA9)G%1RU.B<W,=/F,F"
M8"J5- "&[\Z(*W/.KG:*XYO99I@SLLEU2K,%+K;3R&R,10AW>I7AL4A:2H %
M:B?#O^$KZ)NBZ9V%V/Z>JW3JI2=IIW:&4Z/:]4]F)*G.S59;G:54:U1JG5Y:
M<=DVIR:I*-GYVF)G1-MS;TC4F9286^U)2 E.5"3+*JKY-RM-5EFB7?\ R<5L
MNY1.00$!YA!))8>41 VX+@;F*4.D HF*/>P#Q-\3:0/]TJX6S7B3W6 S,?CB
MJ>Z'Y>1<E44+;6IS*K6J:ZG3:6IL@@@HE!+5)M*E %)2MUU N391 O<A%9(0
M6.Z):H5\J)E-XQ>(ZNQ*C[_HA3.BH+OI1V3[#K$* F.!EE"D*)I87[WWJ%#D
M$$"PU/M%1.@R6!SO%2ZQT5/L-R8V,VBD&T)0HU9O:5$Y5'G_ ,6'&UH<D&*8
MU+B[IQID'W5!+80TT5**4E7V6$B%$(>HN#&V$>@6?!T0;AOSE6?)"([;[]%T
MO=[T#:S=_#HV3GJE0!RT]HD7S&AX9<(-2_0^X^X')S;QB7&$-%2J*XZ<UXU^
MI3 DV& H:46<5U!;S=@J.]_@T\3L'E,B+%8F47[:)\QW4HNT34.DFEUM8K)F
M@HZW< BBU(D90@B!3.CKJ &QB[>6.E"M3L_M#,R+BU)E::H2[$NDJW86EM)>
M=MD"XXXHC'A"MVE"/R;G^AK['/19L'T-_9IV3VKV*EGIJN]*M-.UM?VIJ4K*
MM5V=DWYI]NBT52Y93PE:92I%MHHD&9EYA53>GYY2BY,V1VLF*0WI3%I8(-4K
M1\T(4P"D/*59(0#I&ZY2]ATE2]@E,!MA IR;*%((=9M.%*TGAQZQE?0<<^R]
M^%X[235CM09JCU)OTB7?)2G&D%3#P!W;[2E>RXVH@@BV(%2%70M0C=U(12-&
MJ2!GP/W[Y0O7U 3.B#91$H@1D"*H%5(" *&-SJ% 5Q4Z8@ D=, ^YIS32&<3
M:PLK/KD BQ'Y!!S%M<P";WTM'A+I4J%1F*ZU(35.72Y*G,J^[6%.H?\ 26IA
M=W)_?M%3+AF"TA&!I2DL!D,*)=0Z2]-;&.L(0'O'RCZ=(0B?O\WK'5J-._R$
M5N<._P HI'O'RCZ=3B*_:/=X"$#_  A\WH#2*![?>?.*=9&H[1XQ"$?K_P!M
MZ]7Q3^7_ "O.*=(C%OJ[\D?R?$0BD_P1\WI#4H0D'?YA] Z0B@_P1\WI#2*!
MKW'P,8F4E8V%9*R$J];L&:(!TB[A0"$W'X)" /OE%3C[U-),IE%#;%(0QA -
M5//-,-J=>6EM"=5*/N &I4>"0"3P$72TM,3CR)>6:6\\LV2A N>LDZ)2-5+4
M0E(S40,X9\9D.*E''^*_4VXE3,KMSJ@.Y>?DW$"?&4NXF#L$P@/8'Q\_7WG7
M B4*F6FUI43_ *1W"H*];\UM0!&$&ZA?&;'".R*9L<RPPM<_@F)EUM: @$[F
M7WB"BZ+VWCR;DXU )2JV[&)(<+W*<#E*8IN8I@ Q1^,I@W ?. Z^V0M#K*'4
M#U7$(6D\TJ"5#/CD8ZM>;<9==8=N'&7%M+2>"VU%"AW$&*3]WG]0ZDC7N\Q%
M)T/8?"$M6Q3P/:/ PD?O\WK'5C?'N\XJ<X=_E%&K(KA-3Q>?U:0A!3N)Y!].
MD(2TB"]._P C!I%4)'[_ #>L=6HT[_(0A$_=Y_4.IQ6YP[_*+93Q>?U:L;X]
MWG%"].X^*83U9$%?D_\ "(07[B^4?1I&!H>SS$6VD. [3X"#5R/9'?XF,10?
MN\_J'4H0@I\$O]_&;4T:]WF(I7[1[O 0EX@\H^@-6<3V#Q,8X#M/@(\U!SAW
M^45.<._RA(_?YO6.JXKBC5C?'N\X@O3O\C 80 H"/<!1$?'XQU,:GM\A%>N$
M<Q__ +&,0\Z&01%-!P!5 $0 -]C=F^X"40W]6E[Z6[\OKJCD-W94-XDX";W&
M8^&7=K\8CWDVHW9:&G3TB>+3KFO&.T*];@C$YEO&21TS T=2,,LHBUF6::@%
M%5FX.4%$PV$X;;#K7VW!B4TK=._DJ/LFVM\B+'.YL;7O8VC[2BSU/#K"*DQ]
MY4W&/2)0.8'2C_X+H*5MK3>XS3>V'$B^(0>S5PHU#B8J-5C^)@Z;O)=<AT6C
MG)5#8E@V$RLF8YE3DAGBST6B)U3F5!BLL7D5,J=JJBB8C0FDFVUJ_&*+;4X$
MD+4D$L.B]TXO8(7A_+0D9DA22 D#MS9G: T5U]JB-O36SK[X6Q(3KG_B-/*D
MI2O=+&\2XTH@V0HJ-DI(<"MXI<,\]>#*BYS'=9K]"R"E$15"92;GV%GI%@6?
MLI':Q';I:/16?,>C<E00!*/BSM!%945#$=**.02+H43R&G5[Y:5.*58E""4)
M(N "I(4-3ZQ*LNK#';DG57GU)<5).I;<L0LY%(TNI"@E6N=T\+>K88HU[X-K
M)N.V$WDO&%,I,U3I".@W0A9IJ4<R+N;4CURH^QTDDX(@T9.WRINF028I-4RN
M$2IG3.4A3I\])<0ZE:U)65I(1A3AP* )"0?S%E.!6*^=L\-XUNULFY,R;"RK
M&TW,-[QC(I4VYZBGD@"Y7+CUT@'- 6+8U)C4>2^.O($3-Y#IMGQRI2:FR:SC
M-I(22TZRR I/-DEPA5X]07B).O%DR-#G9DC!@R)B)YALJT354U4MI;Y0Z72I
M9(]0!&[ 5[0-P5&X)2258KBX(R$;>1I,E)M-A@!1LDX@;A60]<CV?6&8XVL+
MF-&8<RQ)2E>L629FFO[7-TR.>/@A6)U6T):"RZC=BZ;6^+;I&3E8Y)19.2,"
M(-G!WK-D==PHBB!"GFP2EM*]VE9L%?E)PW(*"1DJV69-AH 2#&R6D X0; G,
MG74^ZW,:CD;Q)ZD9CF[_ (2D6K*(Q+PW%LDF*+60>EE*V^>O8@Y%&[IBY;-K
M#8'<8"ZX@8#-"13>5CVZA>M.D!&/XBV4MOI4?2)DH3[/J* "M;@X$ VX$XK$
MZ#6LI2%#-2[=XM;N&@TN3K>UC$8,?5#$,%F:,A,WVIM<[7[*%$SVM55\:NR2
MHJB+0RMK&>B7;MHXW2.YD/:JDX(!S'$'6Q5U.4M;JF\32"A&5PI8W@3QLC"1
MBPDV!7:]K$9 2=WA:46 $G"<.(Y!9OA*@$DA(.N9RRC-YGO^5K]<YFS8R?(3
M42VA5JY6(&%DV2$K48Q%TP,DK7HF0;NF*[WJC%1B4T85_(*=>6=M!!T!#ZLN
M@@)<3A R ()3A -DJL0>.)15AQ&Y5J8XTC*-2C6 ^LZXI3LR\H'',/KS6XX1
MF;G)(R"$A*$C"D"-_P#!O?G%13MN1L\R+:BTTG5#2DH\8@V=N9EHR38M2D;-
MVJ3B6L,@#0RD@J#?I73M1X_=@@45#)TN.%I;:9<%:L[MI4+%!N<R20A*5'(\
M!ZH&8O159!%08W "2Y<%M2@2$Y@KY>KAO<9 Y'/47?$%>9#B!C&=DQC#X@S(
MTCW4PXJ=5E8&:<64T+$)Q:DB[7'FK5I=/XYT]*N^1B)QU$"Q=MG(LT01<I-8
M)6H+49E;S*B$@J"DEL$XK!-\: "!9)<&.][DQ.0DF*<R&&@IM%[N*! Q.* !
M5;V4X@!880+#".!.[/![N\\92N#R-RM57#5I%-U58EP6*4B(NO-VG*#>*;MB
ME*DE%MT@*T9)*F4<$$J/2.%CBH*FUD'$^DLRS94Z'"JR1ZZQ9*G"I1&>$X?6
MX D6(S$?#=(C4E(42;JH>:E76U-A:W% !XN.):R"C_G1B"DE-[A*@0<B.^L/
M%EBF96Y3)F,'P^B*4I=]@W$>4 W'L !,(=O9VZ^^DI=$NCU6FVBL J2A*4DG
MFHIUMH+DD<^$>,J]4W:G,8G)F8F@V2$+><=6$I.=FPX3A3D#9-DY YQE-<V-
M!#TJ'YX_N3^DZU=2_P!#_P S^KC>;/?ZW_-_ZZ.BH]X^4?3KH./5IU/:?&$O
MKP_;>DVK1IWI\$Q$Z'L/A%1_@CYO2&K!J.T>,4C7N/@80'O#R^H=7P&A[/,1
M2?N\_J'2,1;*>+S^K2$(*?6>01_XCJ:2 %?.U]8J7KW?.(%UNL3$EDG(5@E8
MIX[)[>;*ES@0IE#M&$NZ9LP1(H<H&129-VZ2 B8"BF0H%'D !#IKI5^U'T>]
M'%88V'$CM7M9M!3J;3YBNR6QM,D)]O9WTZ39G&&ZM.52KT:51.3,N^F<3(R;
M\Y-MRSC+TVU+IF98O?";#=$^T^T]4VAVFF6I.1D']HZNS)S%6?=9746I.H/R
MC9DVF9>8<5+LH82P'GDM,J6@H94YNUX).V:-I3BF(.V"A!<'14(NBJGT*J*R
M6Y%$E$S!SE.F8!*("  (;&*8Q# 8?K>C[;RD=(5'DMJ-F9M<W2)Y3B$J=9<E
MIN5FI=U3,W(3\H\D.RL[*/I4R\TL$&P>96[+NLO.?:;6;.RE&EG)*<:0U.LM
M_C$>HI)2I-T.-K!(<;<20I*D\RDA*@H)T-PZ[H7[(;5F8WL<>+B%W!"[]"5Z
MF]?)-3;=Q5#('=E#L 3E)V[\@;=NU0XI"14O_.!QP)OJ4%""K/77#D=+WXQT
MYT??B]H]HVF"?1ER<DXX ;H#R7YA#)Y!2FE/9@74$@')(M+A;X?F#7S\=OPE
MI"+?7(A!I$5^R>[Q$:/OI8\LO+M)_F293D.5NQ>"'8F4J!D5"MU#!R X:.1Z
MV"?;RF514$-CZT=102]<BZ5( 2>'(Y\+&Y(ZP8]&=%,VZFA2#M)4VJ>HU8<F
M)V6N I9<=0ZTMY"2%J8F9<>C;RV89<;2;MY04MG$&:CEF:J_-(/EX0G*JZBH
MB9D&BR)VQ'**A%6C%<G2*-UDSF;](95(XF3V,)!-K6IISSJDX-U^,L$E;[+8
MN3;1QQ!&:<SI;,G./7LA3MGZD$UA2YF62&U/S4L:?/S3TJ6D-NO-GT*5F ]@
M2XDH4R%%Y-RE 6AU"/F_XT^(QOG&WMXZ'C+^WCJK(NUV[UK".HQ1Y+'068F5
M*E+()\K9LV6<H%*^;H*'.X6$R) *F8?2O1ML<_0)1ZHSQ'IT^VAMMME270Q+
M7#N;J,3*UO+""K=J4VA"$V5B4M*?R,^WI]J6@=+$YL]T2='<ULW-='>QD]-U
M/:*I[4O/TY[:+:U#;E.2TS1%+E:]39+9Z7<FV95R9E9.I3D].SB_1FY25EG)
MJ#R%?E73I)XYA;("R9Q42?+3%88O2CR&('.9@UZT(& P@8IW!]@,/8(AMKM&
MRR1ZJK#B3;/,G*W'0V)'4;B/SE-6HLK3IB58KU!29@!#T@S0MI)Z44@K22$.
MU";,NDHMC0MN22O$+!T8KQZ2'?-G"IV%=L+5RFHN49DDS%F54 YCE4244>H
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M<W.7;'M?::G2VRU/FYBGI<F:I--NM2(##R&V%K3A,V\MU#8.XQ8T-IQ+<<P
MA+:L8EW47"3YQ,R+,G+'+J-4D#AV)K+H OU@Z?9L8"@JDF90-P$Q1)N)DS '
MU5(0M*'5&X2I20D&^HQ7ZLKC3RCP=TNK:970*<XM"ZC*LSKTTD$*<9EYDROH
MC;I!)25EE]U+9L0A87:SB27MK<1TU" ]X^4?3I"$3]_F]8ZM1IW^0BMSAW^4
M4CWCY1].IQ%?M'N\!"!_A#YO0&D4#V^\^<4ZR-1VCQB$(_7_ +;UZOBG\O\
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M(D$6Q: $\[D9 1]E)5RDU)19D)R7F"L72I"T*)3E<)!S) SR%K7-N6#+Q_\
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M[3XPE]>'[;TFU:-.]/@F(G0]A\(J/\$?-Z0U8-1VCQBD:]Q\#" ]X>7U#J^
MT/9YB&M>GTE%TJW24* FF(ZLS[Z)*4@*":2:1+QPP $QW!01=)I !! 0,/O1
M[]<F3;:=FY5IXV9<F6&W3>UFENI2X;\+))SX1QYE3B):86R+NH8=4T+7NXEM
M10+<;J RXZ1\7W@\8N%E56;V54(Y=OGRCIZY<GZ5==PNN8ZRJRB@F.HJJ<3'
M4.<1.8PB<1$PZ]G])+KS.\;926VV6TH;2GU4I2EL!("= D"U@+"V6D><NAMF
M7<D6WG++>???=?<58J4\M]6-2E?G7UOI[[?4(7'V+/<FZZ*[3V3ZK^8<I.TO
M1;\PGW'QAR[;>+?<=>3S4JQ]];L(<W.+VKDYE5K6/5F>1RUCU4).0-.QW3O,
M.ENK09VS.5CV\X^8WC]:,:[*!,UE3JLY#SC&3@W3,-G3>49/47$>LV,0.?IT
MG2:1TN3WW2 7;MVUZJZ/%N3#6XFAC8>EG6IA"SZBF5M*2Z% FP24E6*^@OGP
MCRWTMMML,)F9;U)J7G)1Z44@7<$PW,M*:*+ DJQ6 &IR&>D?6A(6SBE39-U6
M&(X59P=LB=0AJ8D806,D4QRB7V13Y=CB("&Q=N[8-M>%MY);Q8^])G %K"2)
MM9ND*(2;D$G*QOG[H]H)I\@I"2N1E<12"1Z.UD2!<6*.V-4S.1>.E 3>QF"8
M%?\ T=\?$5[0\79-%_?'7(2JFD^M59H?SQ?+_@YY?&)BF4[C)2G]'9Y7_-)Z
MM/E&K97+GA)D1/['\.5>6V^"(XQ*?F__ #"7][7)2*,?:J\R+_\ GE9:Z^KV
M>?*,_=E-_@<I_P!!GD.&#MC7<GF_PK27-U'A@KBO?L XF ^__P"9RA_PWUR$
MHH%[FM30-@/_ &]?_HMVGLM&/NNEYD2,G?/66:O?A;U!YPPY#B \,.GS SX3
MJVI\7_N.E-V>7VUAZ/BUR$M;-\:[-@?_ -06.X (\-!?/2!I=+-[2,GQ.<LU
MYH!O[X9;WB/\-:GS=5X0:VIW[?\ N*<^X;_^EVW_  [NS5R&=EKYU^<'_P"8
MN<N%V^?U:(?=E-_@$GQ_U9G_ -/'2-?3/$!X;9X+H3\$%)?B[3*FYZS@%%QU
ME-/8"$6Z2W""I2@4@%*?F -@V[M85);'.$ERMS"CI=4^I1L--6>N-Q(3T[2T
ML(ILW,2"99Q3LNF3><EDL.+)*W&@RI ;6HDE2DV)N;G.&JYXB/#I)("V:\"5
M%,VY1+T </:(HB  (;=$%S FP]VW+K*:7L*<S6' ?_QIYV/^A[XYQVBKV/>_
M?-4+MR<?I\SCOK?%O+WN!&AKW/\ AAL@@D6Z^"SP'= ;."NVX6;A&KDX"+D@
M& CA'V1LZ_1K$*<P%4((* !C !@YA =K()V2IJUN2&U%0D7%IP+7*5=V76M!
M4%%*E--I)3B2DV.5P";V$:_:2I5';*ER]#VMFIC:>BRLV)^6I-?<<J]-8G4R
M\Q*)FVI&?4_+(F!*S<U+AX-[P,3#S05@=6#K9Q'>%L*)#)>" X8SF1YNB$>"
MRGFY=RB41#_I(':)1$N_?L(AOL.MR*M13:^WM?';M%.?'+/3*_;'5_\ BGZ,
M,*P.C788;RV,?@I1/6LK%;*3%@% *RR) N+@6PRS?PP0*=(EX'KAA,<"F(4P
M\%-/$0((@80_^$X!L(E+OMMN( /DL%5H/';_ &@Z_P#[13G$YV]2U]"21F,N
M$1_Q3=&. M_XM=A<!4%E/X*T6Q4D*2DG_)+G"%* Y8C;4QCE?_#+!^9>!WX8
M!^+_ -Y/3!__ .I#N'4Q5=GKY[?U^W_]PSG_ *(@>B3HQ&G1GL*?_P#%J*/_
M .$AZ5S,'A]Z4@FVIG@M\)UANB&R*$#PEP44DD =H 0C*[H%* #W;!MW^(=:
MF9D>CR=>7,3FTT[-/NJQ.//U1UUQQ1U*EKEU*)/,DQV[3-I-I:+0J;LS2*M4
MZ9L[1I42-(H,A/3,I2*7)I6M:96GT]AU$K)RZ5K6M+++2$)4I1";DW=3KBK_
M ,)!=I]7<^#JQZZ0   $E^&IHJEL'B A\@B4 [M@VVU2FB]&.OW^\#?7T]0_
M_AM8RUM+M.RK>-5FJM+/Y3<],H5^LET$GK[HNDN+S_"44%%%4?!ZT5)18" J
MHGPX(%.H"?-R <P9# 3 3G/R[B.W,.W?KD(I_1PU?=;3SK=]=W4W$7MI?#+"
M]L[1HIT.5%+2)]E,\B7Q[A,TE+Z6=[@WFZ#N(-X]V@+PVQ!"+W"1917C)_PE
ME-,QS>#]I^Q=A'HN' %5.\ ]ZFED%0Y^_M I#;!N/8 ;A9Z+T??[65 =M7>
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MA$W%&RLRQW5L156"J<Q((0KA"*C%CS0MSN"D*J,P[5<R2J_-LJ)57!FYE"E
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M **J)T)?9EV1JU,<EZKM3TDR3NUNTNTS04XN=EIB;FD4"E2CCF)QBFTJCB6
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MU1JK.EM$Q@E6L.%L*"%.KU*R1=1%\D 6O8DWRMQ>B_H_9V<E/O.J)'WU,ES
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MX"3XG<P1>2:?6'K.1:8[K=>>L(BRO(Y9-PQ):Y.9?NE7$&FX2(H]K[.-(65
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M[;Y&.NM/I+2F0<+#UU^*C6'8HLR.4Q$".E""8RRY #M*114YP3 X%,*92B8
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M<B1;6J7-5=J$X5.+?"AVRF*2WI+%I8(-4K1\T3 ^Z0\I5D=@Z1NL!?AHJEV
MQ3 .P@50NRA"&#K)IPI6#IP.>H-M<K7O<\=;B]H[.%6.U!FJ14VP_+OE24[P
M8BR\+[M]HGV'&U9BWM J0JZ%+!W=2$4C1JDB9\60?OSD%\H5-1$&QT2^\8@B
ML!52@WZ0QN=0I17Z7I2 "1DP#[NG--(9*FUAPK/K* M8C\FQ];*YUUU&5H\)
M=*=0J$Q7&J?,TU5*DJ<RL4YA3C;YF6IA8*ZAOV2IA?I.Z0C TI08#(962ZA9
M+TUL(ZQA >\?*/ITA")^_P WK'5J-._R$5N<._RBD>\?*/IU.(K]H]W@(0/\
M(?-Z TB@>WWGSBG61J.T>,0A'Z_]MZ]7Q3^7_*\XITB,6^KOR1_)\1"*3_!'
MS>D-2A"0=_F'T#I"*#_!'S>D-(H&O<? PCI&(H/W>?U#J:->[S$07IW^1A+4
MU^R>[Q$510?N\_J'4$:]WF(P=#V'PA+5L4\#VCP,)'[_ #>L=6-\>[SBISAW
M^44:LBN$U/%Y_5I"$%.XGD'TZ0A+2(+T[_(P:15"1^_S>L=6HT[_ "$(1/W>
M?U#J<5N<._RBV4\7G]6K&^/=YQ0O3N/BF$]61!7Y/_"(YV<?.'):?KT5F.GM
MCKV"AM5V5F:MTQ.L_IAU#NQ=B0NYERUYX==RLB!?>QTA(/#'(5@4#<Z2?W2\
M&+"%'U3>P"]+'_CR':!SO'1?3;L;]]TEFO2TN7IBDM+:J#:$@N.4PE;HF$&Q
M5BI[RE.J _T#\PXHX6;*Y?P5D93292@8K=\4H=*U.;M$0[S(&';I4^\=@]^3
MN.4 V,;?H=QBUR#Q%S\.8^/,<_&$[379-1-L;)/J.@99Z!=O95\#P.=@X]3C
M@0:0@TA#>G[ VA&X]I57J@;-VP#V[B'8JMMVD2+W]NQE!]Z3ZXQ*UN! YJ.@
M\SU>/#B1L)"0<G7!JAE)_&.6X#5*.:C[DZG@#+7@%PS(V.VO,X61LH$3 F>,
M*H=PF(!*V)VD=I(R* &]Z=G",55V9%.44S2+TH-U 7BG!":F:=N,%[J)NKJX
MCXYVX #F(]/=#>RBG9Q6T3[!;D*:ER5I:5I($Q.*2II^8;)]IN4:4ILJL4KF
M'O45CEW .NY^_P WK'7!CTE%&K&^/=YQ!>G?Y&*%B"=,2 (AS%$.SL[Q,&I\
M^T> B*2$E)/ >9AC2=<!QS'6.!4PYA,<P@!"E !'F,8PARAM\?9V;B/?JE:#
M:_ =V>6>MNKOR%HW,O-@6"02K1(&9-^  &?8/C>(VJ7N&=9/G<:0M+N;TU=J
MZ-GF<F2<":+PW'IK* 4T06Z.W")96<:MQZZ[8Q31PU;MP4!Q(HKMW*2&L<=_
M&*3@LTA)*YE?JMH !)O< $6&MSF;82+F/NI:F+32Y:H/STOZ3-S8E92A2J]_
M69HDX$K$L@J+*2N]MX!E97Y385S.XZ^-W!]&I)HJC&@,T3;Y\[@IXD9UMI6H
M-5%$HK=*N5L(2#@PJE!N5JZ.0H *@N%"B #HW76YA9;;2HHM??.)P8L_]&@G
M$!UK2@WRPF\=T;';*UJ6<3-U1S[N%@IF29=2^^$ZX9AT!3(RM=#>/,YJ28YV
M87+EB=KI\HX%CZ^VJ9GSIUEJEW=!*6K74&B!5B2 )K"U==&@U!R"3B)6;S)%
M0*@)G!3HD-P'PUB#;N/&!^+6WDH&]K7 (%[#VAAYY:]E.*;00AU6%1.%HWL2
MHY81Q)/*Y[ !#HNO&LW2*>M\.53Q75LA*/5FCN6D:X_0?'1,DDD7VL.IJPR4
M:T?BX%T8KA\V;K)IBU%H)70" 4ID>,PZ\M&1PXQ;7/%9()Y9'F#!+1S*RK#E
M;/+4\@>%O<=1&D8MAQ-4/)4=56$G*6 ;ZQ:6JV4RP-F%\+7K/.O7S>0 #RK2
M4/$6!RBV:32,M%JQUD292$8#QZL=N@Z7Y'^3NHQ@!.#U$K02WC2D CV,(6D$
MD6-TW!L(D5-8"I6%(1<8\6$!*<[D_FCK)&5K&-WAPBY"PHI,Y3KL*^GW[IY(
M1[B*D99V\CUX.48$1E&ZI8X[1^W=*H/)"*44<](@@J7K")'Q.7?#KHNAE[\7
MB2%() !Q7N!G=((('JG/09&.)+5&4GPL2[R7 RHH58$64%$!0OD0H@X2DVM;
MB(PDWP\7_(X-IV#QDGD""EQ!5GT;IU$VFNO! BCRM2:Z2#Q%VK&*JBD";B)4
M=K)BDY8R"L6JS#5?I+;?J+=W93D01ZJN 6-,E:^UU$ @QRL83E?">7.W'/3N
MOU@:1KJ\NC\-23RF3>%TG<X]!D9VW6<S*!X1P7E<)$]X<I'SELH*)U22;4\>
MLY3 OL69%,X'M1:9&-#XP9Y@)(4!D=0;#_A-['6\2 QV];+X&W#GE?.USKGI
M=&FW#*=6>0LA963[)M/OQ2.3U6\*2+R.@N62:I)/G<:F^(\6/UA5!&,FF;QF
MW(Z.#=40%0K-R6AI5PDAM2#DXV %'(D@$@Y<P0>K2\"$F]K C*XX]0[=<Q>V
MD=+W7#)54;'4^)*%O5OCG]9A4AC<4U5DR:1D H5L9TYAXEVS=(+IHN7"BAE@
M7CY&7='%-%X[>'(18G'2B8]'-D-J"R27%%140%$!2@00;I (.)  (L+:Z)59
MEC.NTMY&&Z@A+R[%MTD))M>Q!"SA&HN+@@Y"'^5;SQ*9_N-\M$GCE2GY!Z2+
M>8\GG%.8,I^86BHM6,EVC2R'CBOVES- QL,\(S!PQF9E@PE7Y$7)F+DY<M"6
M80VT'"MM(4%)QDH0%*QBR K"&L:E: I25)3<7 C<I#;:$)Q70!A(*B1A)RN2
M<\\N5[#4Y[BX!<V\5#:YKTG,4=9+%5BI+E5=3Z3LDE"G;E$Q5V\HH7K IDY.
M0S9RHLW$I_>$(IL([F5G@PZTA!2ZAU24;LV4;*-@I!%R,.I&@3?*X!CK[;G9
M2DSU+FIV7":?.2S:WTO,@(;=P"Y;>:L&U%S,)6D)="RGUE)ND]\8,I'[!%XU
M$RJ9@ =E" 5PG_YIQ+[U3[A^0HCX]?9L-(6-X@%)&H)TOKPS&?4+<!'DVH3+
MDJZIAXI5ZU@J_JJUM[0U.>5U:VO#K9O4TQ!,R(@?X]@#XOB[/'\7Q;B&N<V%
M V.@SL/.]N/#W6,?/S24NI4H97%^?/AGU<1>\;5IP\P2 _'U3^DZX=2_T'_,
M_JXG0A94Y_-_AOQ'18>\?*/IUT''JHZGM/C"7UX?MO2;5HT[T^"8B=#V'PBH
M_P $?-Z0U8-1VCQBD:]Q\#" ]X>7U#J^ T/9YB*3]WG]0Z1B+93Q>?U:0A!3
MN)Y!].K&^/=YQ4O7N\S"6K(A":GB\_JTBMSAW^44#W!Y/6.D5Q9K?#\P:0A+
M2$6^N1"#2(K]D]WB(T??21Y9>8:3X&293D,5LQ=_8RE0,BJ#=0P<A7+1R/6B
MI^^Y3*)*"&RFVM'4D*+MS<I4V G7A<$ WMUZ97OQS]&=%,VZFA2#M(4VJ?HU
M8<F9V6RQ++CR'&5O(!Q*EYF72);>?E!IQL&[=Q!FUY\6I19BK/1?/U88O(J[
MBHR4?-%4CMR.$%2J-FJQ2G.W5(8Z',*B:@F3]]R<VM8BGNN+1AW7XP@)QO,M
M7)-M'%HL+C,J-N)R(,>O*?3Z!4T_?.&H,!MM<S-RJ*/5I]^6W2$//-@4Z0FO
M25!*P6Q+A;CXR0WO$K;1\X?&QQ 2&9KD$7$5R:=UZO.5S].LH>,"2E#E,@H*
M[,SEM((,&B(G3+TS,[I5918Q612 F93TOT:['O;/2KM1GBV9Z?;0AMMIQ#Z6
M)6^\S>0I3:W'E8%*#:EI2E"+**E* _'O[>_VK=C^F.9V?Z).C^J.R6Q71]59
MZK5NK5JAU.FS^T6V"9==,8%.I%5IS4[(RM#DWZA+2RJLU2GYJ:J,^J9;88EI
M-Q^!KE%%-XT*,586)#J@#DE90L)H[97WIA?$739"B"9S L=2,1476!,Y3E5$
MP)Z[0(%P<[Y#\JVHL3PR'_TV&?#\]))Y]VGS:1/;-S264+<EG-HET)%4"T J
M#<BMI4T],I? +269]9E)=Q:7$KE\*G0(2"T(XW+&7=^D==V5%D"DDRCTQ/L=
MH1NBLBWD%EQ0;*K'23*NF!%%USI)E(<K?.F9Q9W%N XWL<^/#,W!MZHOEV19
MJ\L653VQD@ZPS*OJGDIE)N=F,00W,(?FI9R8IS+*'IAM"53!E<#K:6$S"UN)
M,QDF,S)/43.%)29Z0X"8Z%?;,9=K'E\2"HE0DY$%0 =E#.4A6,<IA*BD'TLK
M0$YFX.@4?=;,VRYB^=XU<S2Y-B:1*LT^F(0A02AZO33])?GK'_/$NS,A3T(<
M_)2R\EI"2!OW#^-7U2\']Q;,J<Y:XUG5)1>016,: <HMI>7<OVRRJJXMWI$8
M=LJQ7:',9- IT0;]5!),#D.B4I^@^D[8M]<R]M%(*9+#X09YIYYF74T\E(;W
MK>_6TEQ+R4I*VTJ+H=*S@*571^WGV%/M,4"N]'5#^SMM[)5:4VEV6549786J
MT;9^HU^DU;9Y^;=J"*--+V<57YJ3FZ(].3*)>IS3+5'=HR)5MZ>8FY?_ "WZ
M!ZGD-;(+R,922H,H1 6[J0,NJ0JKMN42J@R11 PG ZXAT2YU ("!!4[UB@B/
M2#<J0J_JD W.%257ZAARSYYY=T>U]J*=+[+4^;?D&WGZI--NLR*?1IAI,NMQ
M.'TM]3S;?^8"MXVV 5..!"2$MJ*Q+NHKI/G$S(LR"6.74:HMSAOT:JS<''6#
MI^(P%!5(AE"[@8P"01$R9@#ZJD(4$/*((0I2</(D8K^ZX%^[41X.Z75-,KH%
M.<6A=2E&9UV: *2XU+S)E?16W;$J25%E]U#:K%*%A=@'$E3VUN(Z9A >\?*/
MITA")^_S>L=6HT[_ "$5N<._RBD>\?*/IU.(K]H]W@(0/\(?-Z TB@>WWGSB
MG61J.T>,0A'Z_P#;>O5\4_E_RO.*=(C%OJ[\D?R?$0BD_P $?-Z0U*$)!W^8
M?0.D(H/\$?-Z0TB@:]Q\#".D8B@_=Y_4.IHU[O,1!>G?Y&$M37[)[O$15%!^
M[S^H=01KW>8C!T/8?"$M6Q3P/:/ PD?O\WK'5C?'N\XJ<X=_E%&K(KA-3Q>?
MU:0A!3N)Y!].D(2TB"]._P C!I%4)'[_ #>L=6HT[_(0A$_=Y_4.IQ6YP[_*
M+93Q>?U:L;X]WG%"].X^*83U9$%?D_\ "(MG)2'3%-0A%$S@<BB:A0.0Y#E$
MIR'(;<IBF*(@8H@(" B @(:1&P(4" 04V((!!!(N"#D0>(.1CD;Q+\"4JWDI
M"^X*: Z9.%%7\ECY Y6[Z-<"(JK+U$YCD2<LCCS*$@A.D[9GV0B.N(J(,&>Q
MEYL6"'3G>P<ZN&/4W&7K<=5<2?-^WG1%,I=?JNRC*7Y5TK=FJ%ZH<:4?7<-.
MQ60ZPHDD29*7&KX);?(4AEGGH-FLU;>N(>Q1KI)\Q5,W>,)9JXC)9FJ01 Z+
ME)=)-9)4@]AB.6_2@(;&'?6T0^;#1:3F#?,CJ4+@]MCG[H\XSU ;0^ZRMM^0
MFFB4O2SK2VU-+&J76'0EQI0(L4G#;\V\9+W0VO+_ -6N.;XNG3Y?X7)O_P#A
MU9OQ^:;]O[O*-;^#[O\ "6[?\"OGYQB7EYDW@@WC6A6QUC FF)>9TZ,<X\I"
M)%Y"DZ0QA "@"1S";;E[=04^HZ )Z]?'+X1RV*'+MJ27G%/J) " ,"5*)R%@
M5+5RL%"]].$2XP'P37O)4@RM.4V\G3:6*B;D[-^51K;;*D \P(M62Y.GAV*P
M!LK)22:3D43$&.9+D5!VWX3CXS"#C5Q5J >W\H_"XUCO+8OHHJ=8+$U6&':-
M1DJ"MPM)9J$ZV/R&6%#%*-+_ "GW@ES"0IAIP+#J.SD%!1%9AHVOP$>VBH6'
M9HL(V.9I@FW:-&Y (FDF7M$>P.8ZAQ,HJH8RJISJ',<>"L'4FZC<D]>4>GI>
M4EI"5EI*38;EI65:2RPPT,*&VT !*4C4Y9E1)4I1*E$J))R)^_S>L=0BV*-6
M-\>[SB"]._R,>CW!Y/6.IC4]OD(K.@[/,QA9:&:RX(D?&7.V2.!S-"+'207,
M [@#@I! 52=G:0P\HZPI"5VQ7('Y/ ]O9P_>8Y,O-NRN(LX4K4+;RUU)'^[>
MX!Z[1%O/];LF0ZQ,8RA4W4)79^,<1#]>**#1<&S@G1FZ-8A! G+\("\HI'VV
M.4X"(#JYQE4PDMJN$:)0G)((((.$>T;ZZ]@SOV)LC5)6B3+-37@?G&U8RX]Z
MY.))2H7-U)38V!20=#?(1S5HW@EL9TVOV2+ND[8+#$SS]O+JKR"C-LI%NT"*
M$%5B0J)S*J+I'!-<IU>10$TC%*F8NY]*_(/^J4+(=O8 H&$C*X(O?CD;BPRM
M8QV\STK(F704R3(;0DA>%Q943^3ZU@/Y.&^=P1:) 5OA_JU+I?N=8OA5H^M)
MKJ*N@="1T[GG)R=$9:3 B9$CH]%NDDT!,4DDCJ<QE%%3&$*:4(475;QQP64K
M#A 3^:C50L<[YDFQ)TMP7MN%SL\W,+"&4,&[+043@S]M2B!C6;<LAE;6_.CB
M1X&\'8806SA9(W([%NVDD%)"O4F)BYQ,CI<%%RJ%7E)N%4CX]15($1.OUP6R
MBR2?.Y.8.;@NM3C(" 6EI6;)4LK2I(_)*L*% Y<1;%D+)N(["V?VKEJXM<JW
MA2^V@J)Q^HY:P5@&9Q"^+#F<()O8&V!X9>-IG>,IP-8DL3,(6)F'C>%JKU-Y
M)KW!K&-C)QL>L^=E%.,DW*:2*?63KQS=!=0%NJHLTA2,3B.2[K* I+I64D*4
MTH# HW)*4V&)-R= HGG?,1O)Z2;=EW@MQ2/565+!("3A422DZI%KD$:<03$O
M>*^F9M9SE%LM!S<EBFHPISFLS9:!!Z207=OUEEEUW METG2"K0$FXQK\4&("
MF"AS"*PB39U!@**0MM#@W24@%6$I4+ZDWO?*Q!OD>_KW8.J2:V9YLLNN3"YA
MQ:%I]9)92E"$H2,0*5)7B.F8(S]6.8/$_#<25KS.K8<>3<E9J:[DTQ@)6J]$
MTB")&$B@I%CXI4S&+4(<QA5;) "!#\YD5%$_?CQ9=EM#9;*,2@/6(!7GUGVN
M\GJL;1V.Q-RH80I\B56H>Q,*"%W!M^7AQ::@Z< <H=M\XQT,8/6E?N$+&7ZW
MM*S7H&P.YUK"S<>VG85P]ZT_:&D(Z5%R]-&+1T"NX0<(M#I0Z2Q".-TW \9N
M4"B5 J0@J64H2I:"4J L#A*2+*!6$VO=7:(NW)6DE*B@7Q73<:VR_- .9TZA
MPC(U:()Q5VBNW^ S/=L>-8^6@$75"=.)&5IC-V3_ !9BI#,(U1K&Q#=TX,9J
MV:K1"3-L[?@D>0YWPBJ5_DP*-RA>*Y#@LE76%%0*E6&=P22$Y#U8BM6X;5B0
M%A"5$D6Q&POQ(!) OKGG>PTVGQ2S>7\>VR+B*5E&BX^J-E@A;VFMW6?@Z4Z>
M,UE%6SF88V"PG;,D7#@@'%JC#RZ4HR<D4*BT,ERJ+<@J4D+:=2M9PI_S2%+!
ML+V*4IQ6)%P2,)2>Z-+2VJ=/M-SH8WJVGU*8>-U[M22<( !U;!PJ"P;+"N.F
MX.!["N#CU>S/<47R3R\XFW:2-S/,NE0<QRZ"QQ2!FQ%NU4-'*+E4<,)@4C&?
M)]$<W4URJLTMK)RJ)L8P2EY+8Q-Y)4W?(D 7Q))U4,@; X21?X?;7::K4B8;
M:G)9J3DBX3(S+=UM3>$'"''5%.[?2@W4Q9)!Q*2IQ%E1MNU8WXV&N:8A.O76
M+KG#]%+QZIB*//9:;E&:7*JZ:RS1ZW7D'[T#BJW;D>N 8(HE3!)<0*(FK^Y'
M$O*<0VELD^H\W^+"!^3A2V00JP!5D,2K\-.*ST@[,3%%W$PEV=J"FE)>DGFL
M:%NV(Q)=62P&;^R4$N(21=&.]^K5,DXEXR3(Q2,V5 H 9$0][N   \H_/OL(
M[ (;=GVL@I6'"L>L,KC\KCF.=M;\M+QY@VG84'%.(5=M1)PJL2D7)R-R3ESN
M>-](>(H(B;G%,O,'CVV]'9K9VCY'>N6PXU$<B;_$YP^JA^>'[D_I.M74O]#_
M ,S^KC<[/DGTLG_R_P#71T5'O'RCZ==!QZL.I[3XPE]>'[;TFU:-.]/@F(G0
M]A\(J/\ !'S>D-6#4=H\8I&O<? P@/>'E]0ZO@-#V>8BD_=Y_4.D8BV4\7G]
M6D(04[B>0?3JQOCW><5+U[O,PEJR(0FIXO/ZM(K<X=_E% ]P>3UCI%<6:WP_
M,&D(2TA%OKD0@TB*_9/=XB-&9:D'+QC+QJ8(%91+%)RN"S9NX.N_<@4&PEZP
MFIT2+<JZ1S&1Z-4XF4*)N4H .GJ,RM!W20+)3B)(!)/"U]!F-+&_&T>@^A;9
MV3,S3*O,*?5-5*?=E& S-3$LAB2EC>9*O1W&RZ\^IIU"4N[QI"4MJ""I1(U
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MBOV3W>(C167XY/J[A9F]3(_EH\[%U%"DLH=XB0#$2?)*-TEA;+-A$"%4<)]
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M>L=6-\>[SBISAW^44:LBN$U/%Y_5I"$%.XGD'TZ0A+2(+T[_ ",&D50D?O\
M-ZQU:C3O\A"$3]WG]0ZG%;G#O\HME/%Y_5JQOCW><4+T[CXIA/5D05^3_P (
MA!?N+Y1]&D8&A[/,1;:0X#M/@(-7(]D=_B8Q%!^[S^H=2A""GP2_W\9M31KW
M>8BE?M'N\!"7B#RCZ U9Q/8/$QC@.T^ CS4'.'?Y14YP[_*$C]_F]8ZKBN*-
M6-\>[SB"]._R,>CW!Y/6.IC4]OD(K.@[/,PDI\$/OB^G4AY'P,05[)[O&+-P
MW(Y)R'[M_B^/LUC77W_7Q^KD.*;PJ&9-]>KASZ_H6229-VZ8E3( !X]P =^W
MQ]G_ //CUD $@'Z\OA&')AP^L3I;*YM]9Q6?8"%  V ##L >0-6@ $@<AYQQ
M5J*[%6N8\(1$?>F^]]8:F-1VB(7C0W$324;UA^^U@72K):PP;J,0>)%YCMG2
MH JW<"4! 5$TETDS*)[E%1/G3 Q!,!@UU48Q2CK:;7<P@$WRLL+%^]%B-#<7
MS$?<[!50T_::F3J_6;DW%NJ1<>NDMJ84E.*]E$.FQM8$ F\?(+9.!?.S;(2S
M9.(5>H>R!A)(M7:*C11,5O>J@H=0ATRF .;98B1R@/ORAMKY0M.I]4MJOE[(
M!![QIJ=3?F,X]E2^U%$?E]\F?:0%)2<#I*'!H2"@C$5"Y'JE0/ F/HEX6,42
M6,\+0-<GWXNI4[PSIVB!Q.BTW00(F@0X[](<.B,98Q/>"82E+S<G.;F4J54A
MR96M.%2]V0,K (QY:V*CBOD3PY&.E^D6OLU&:DT2BKL2J)A.(BV\6XII2EVU
M"+-@)Q 'VB0+@">%6A8UY'D0<(IJ"0NY1$NYM@[/'WAWCW_<';Q[QN50XNZA
M8G*_=E<VUR TCIZ=K,Q*H);4<*57*;G0DA65SS)STAXM8.+C^U%$H#XO> 78
M=NSNW$/7]S7+1(-I-S;+D 3\0!\/*WSTSM),. I23GKF>7;\>X1>@5(HB)2[
M#OOW!_?_ /;7."4IM8:91H%S2UDDYW5?77.^8M]<(15;MUA RJ"1Q#N$2]O[
MX;"/W=Q'3T9I=U%-E7U%NWB#%B*E.M)P(>44C()420!U=0SRSRA0I2D "E "
M@'< =VN0E(0+)T^OKN$<1QUQY94X;J.?'B3EF8\/W>?U#J44KT[_ ",):15#
MTJ'YX_N3^DZU=2_T/_,_JXWFSW^M_P W_KHZ*CWCY1].N@X]6G4]I\82^O#]
MMZ3:M&G>GP3$3H>P^$5'^"/F](:L&H[1XQ2->X^!A >\/+ZAU? :'L\Q%)^[
MS^H=(Q%LIXO/ZM(0@IW$\@^G5C?'N\XJ7KW>9A+5D0A-3Q>?U:16YP[_ "B@
M>X/)ZQTBN+-;X?F#2$):0BWUR(0:1%?LGN\1&B<B2WM>DIE^X1*=P[AT@@U%
MB\Z(K%)U8$PW]Z;J[U3K*R #OT:I3#L"NX:*IA272L^R4#";\K@CEKF1ESXQ
MZ3Z())BN4BF4UEP)#%9>-9::4$3&Z<4'@Z0/6L_*-^CM/$6QLJ0+EHB-3CBV
M(?5M:2>=&Y=N2*+N%UA!15950!,HHH8P;F,<PB(B/;W[;>+0%PJ5KK[\^9X=
M5K<\[6CTHG:R;E*DW)2R=Q+L%+3++2=VTTT@A(0A((2$A*<@ .9SSCYV?"#\
M+$W;KE&RF)X8SBQ\[@+$RC5F4:K*1:)2E;NW*QVQS.%&*QDVH)F53!5)V0%!
M/U9#H^]NB7:/<F=I%1G2U(I9]*E5.XUAAX.(0XTBR5J2AY*PM2;!(4@J%BM6
M+QQ_A%.B:B538W8?ITHVR\M-;;*V@:V%VA7+RR<5:IM0H]4JE*J<\WZ=(LNU
M"B.4:8E6JC^-GW)6?8E7"]+24LW+\ZV/#9Q3Q1RLO<)D7S,AN7KS.0@&#T4^
M4P$W5]ET 4,53E-TQFQ!.F4Q5$S',*H=V&MT9*LJFPM(%[I2Z"#K:Q0+Z\,_
M&/R2_P 5)J\HY./3U5HU34KU*?/2,U49%?K)45),NQ,*83AQ(W:WE#&=XEU"
M1N3<.\-\3<4L#-_B"8,MLN)&Y(Z:E7"R'O1:F-)UV,DJVHX4+SE70;R73)GY
M>D;(%^%-FK4QZRD5"3#=U AU]MM2;&P*D/*;R(-P1<=9.4:ZH=#\A*,*W;VT
MLS.VE"'Y&C-KHZW7&EJFVY=+LT:ZA$L]ND-.3=-9#P#BDJ(LH7DEA/BH:-6S
MLF")A5)P0IC().0?NT^WWY%6C0HN$3  A^;(E-S;E*0^W,.?O>DJ60FIR%D^
MT5/8$<;85+"4.: G=J4.J.+)]$,FI*E3T]M0RHK4& SLJZL. !-G%*3-NK8]
M<J"4S+4N%) 47$%6$=C_  =6%&S. 9R-MK1(.[2*JGL\S>-S%?QPE=+%;QJ@
MN4$7"14&Y4C'0,FF7IU%51)N8HAYEZ3J],56OS$LE_'(2!W$JVTLJ9*@A)>?
M3:R5+=<*AO+7W:4(SL"?W^^R+T.[,] OV<-F*M0Y?TK:SI*DE;5;5;2S,FW+
M56<8>F9A-#HAP.S*Y:FT:FAE*)),TXRJJ/U*H62N<P-]H9&E,*0A'6.,!(B[
M(4U54B[%(Z; )>L-5BAMS)KI;E[>TA^50G*H0A@ZU;=*5 \+_ VR(L+Y_,YB
M.Q357MJ6YZBSUUMS27$-N*!Q2\QA5N)EHFY"VEV-A[2<3:L2%K2=S5)=%ZYF
M7[$G+'+*-44#  @FJN@"_6#)AML;E*JBF=0.\Q>01W3$ ^RI"%I0\HWP*4G#
MK8D7Q$#W7/=PR\5]+BFVET"GNK2NI2S$Z[,I!"G&I>95+>BH<(-TXE-3#B&S
MHE6,"S@)>VMQ'34(#WCY1].D(1/W^;UCJU&G?Y"*W.'?Y12/>/E'TZG$5^T>
M[P$('^$/F] :10/;[SYQ3K(U':/&(0C]?^V]>KXI_+_E><4Z1&+?5WY(_D^(
MA%)_@CYO2&I0A(._S#Z!TA%!_@CYO2&D4#7N/@81TC$4'[O/ZAU-&O=YB(+T
M[_(PEJ:_9/=XB*HH/W>?U#J"->[S$8.A[#X0EJV*>![1X&$C]_F]8ZL;X]WG
M%3G#O\HHU9%<)J>+S^K2$(*=Q/(/ITA"6D07IW^1@TBJ$C]_F]8ZM1IW^0A"
M)^[S^H=3BMSAW^46RGB\_JU8WQ[O.*%Z=Q\4PGJR(*_)_P"$0@OW%\H^C2,#
M0]GF(MM(<!VGP$&KD>R._P 3&(H/W>?U#J4(04^"7^_C-J:->[S$4K]H]W@(
M2\0>4?0&K.)[!XF,<!VGP$>:@YP[_**G.'?Y0D?O\WK'5<5Q1JQOCW><07IW
M^1CT>X/)ZQU,:GM\A%9T'9YF$E?@A]\7TZD->X^!B"_9/=XB$]8BL^RGO\8I
M/\$?-Z0U)'M#O\#%:_9/=XB+=3X ??#Z U;Q/8/$Q5P':? 0B/P3_>CZ0U(:
MCM'C&(Q4DQ1DV2S)<H"FJ @.X;[#MMOM\7B'4G6@ZDCG]?6O9'(E9E<J\EY&
MJ<NXZCX1HAQA*/._.Z!%+M$Q@'8@[]N_?MN'G#<>[?6O5)'AIU@@_P#T^-].
M%X^P:VK6E"05*!%B1IIPU''/RC,!4O8]--JDG[PG:&P!MO\ <V#;L[M@[=2;
ME4MCA<ZV'#.W6?A\^/,UE4XH+4K(7L#GRY]4/FOQYV90$0$._L[A\^^W]]^S
M7*0V+CJMGV<O>--,KQH)R:QXA?+/X\/[^.0AP+?#\P:Y,:!?M'N\!"6D1@U:
MC3O\A"#4XQQ/8/$Q0?N\_J'2(KT[_(PEI%4/2H?GC^Y/Z3K5U+_0_P#,_JXW
MFSW^M_S?^NCHJ/>/E'TZZ#CU:=3VGQA+Z\/VWI-JT:=Z?!,1.A[#X14?X(^;
MTAJP:CM'C%(U[CX&$![P\OJ'5\!H>SS$4G[O/ZATC$6RGB\_JTA""G<3R#Z=
M6-\>[SBI>O=YF$M61"$U/%Y_5I%;G#O\HH'N#R>L=(KBS6^'Y@TA"6D(M]<B
M$&D17[)[O$1A+% 1]FAWT-)(D40>-UDB*F23459K*)F(D]:BH4P).FQC J@J
M78Q3E#MVW#5;K2'FU-K (4DC,7(N+7'(B-MLWM#4MEZS(5NEO+:F9&:8?+8<
M<;:FVFG4..2<T&U)+LK,I26GVC<*;4>-B(6V5IF:JH+U]"H2]C2*!DF4I (]
M>9/4>TB:H@0_2L3B&W2H/2HBD;?E.HERJF^8<I4PARP1O!G9:3D;GB-1V=7'
M6/>NS>WW1'M(RQ69C:FF[/S"DI7.4JMN&4G)-X *=:0I2-S.H2;[IZ44[ODV
M*D-O%32%<.<-LLFZFKUE%LV)9)Y)-E'0!5D'OL!#IJ]85!ZY1,HV5DI)P5!1
M=)LJN@T0:-BE7,LLX31W].9<D4J(OC6 #90%DY$BXYD GE:W$QT?]H[I>V<Z
M0)>A[$[)K<F=E-G)MVIS-3>EGV!6JTMA4HR]+2[R6W6Y"G2KTTU+.OMM/S#L
M[-*4TEEN76YO@<+U( W&-;?(ICZ UM!-3!T*_P#J1Y2-/IHX(_Z2HI]QBHC^
M=S?Y$@>D-2$Q-'3'_P!40]!I@U"1_P E?R@'#-0#OCFWR)/FUG?3?)?_ %1&
M/0:9R1_TE_*(JY%P'<:%>U\@XMBSS\%.=65GZXP,BG)Q,HV12;&D(]HH9$'[
M"02225<H-CJ/4'_6%^A6;N.9KHZE3WYDEY*"5GVTA0)4;6N+&YRUO'O+H/Z;
M]B%[ T_HTVZJC="F=G?26-G:U-M3!IL[2YF9>G4TZ>F&T.>A35/??>;EGGTH
MDW9+<,;QI]@"8V94X;(=Z<,4+3 OZY7&BB2LC[,%!N[D")"4PQ[5B8_6=G @
M":SE5-%!- RADSJ+ 1$W DJ,^M]*WV]VTE0*PJP+@'Y 3K8Z$FX YDY5](G2
MIL!LA2)\;(UZ3VCVFGY=V7IRJ0M;\G35O(4V*E-3P2);%+ EV7EV7'7W9@-)
M<0TP5O)E&B@BV230;HI-T$B@1)%%,B229 [BIII@4A"AXBE  #XM?7@!( 2
MD#0   =@&4>#)B9F)M]R9FGWIF8>45NOON+>><4=5..N%2UJ/%2E$GB85UF*
M80'O'RCZ=(0B?O\ -ZQU:C3O\A%;G#O\HI'O'RCZ=3B*_:/=X"$#_"'S>@-(
MH'M]Y\XIUD:CM'C$(1^O_;>O5\4_E_RO.*=(C%OJ[\D?R?$0BD_P1\WI#4H0
MD'?YA] Z0B@_P1\WI#2*!KW'P,(Z1B*#]WG]0ZFC7N\Q$%Z=_D82U-?LGN\1
M%44'[O/ZAU!&O=YB,'0]A\(2U;%/ ]H\#"1^_P WK'5C?'N\XJ<X=_E%&K(K
MA-3Q>?U:0A!3N)Y!].D(2TB"]._R,&D50D?O\WK'5J-._P A"$3]WG]0ZG%;
MG#O\HME/%Y_5JQOCW><4+T[CXIA/5D05^3_PB$%^XOE'T:1@:'L\Q%MI#@.T
M^ @U<CV1W^)C$4'[O/ZAU*$(*?!+_?QFU-&O=YB*5^T>[P$)>(/*/H#5G$]@
M\3&. [3X"/-0<X=_E%3G#O\ *$C]_F]8ZKBN*-6-\>[SB"]._P C'H]P>3UC
MJ8U/;Y"*SH.SS,)*_!#[XOIU(:]Q\#$%^R>[Q$)ZQ%9]E/?XQ2?X(^;TAJ2/
M:'?X&*U^R>[Q$6ZGP ^^'T!JWB>P>)BK@.T^ A$?@G^]'TAJ0U':/&,1;ZOA
M!I"+,R1##N(=NL%(/"*TNJ&6OUV'X6BHI2E#8 UF(%15K%LM\/S!I%"_:/=X
M"$M(C!JU&G?Y"$&IQCB>P>)B@_=Y_4.D17IW^1A+2*H>E0_/']R?TG6KJ7^A
M_P"9_5QO-GO];_F_]='14>\?*/IUT''JTZGM/C"7UX?MO2;5HT[T^"8B=#V'
MPBH_P1\WI#5@U':/&*1KW'P,(#WAY?4.KX#0]GF(I/W>?U#I&(ME/%Y_5I"$
M%.XGD'TZL;X]WG%2]>[S,):LB$)J>+S^K2*W.'?Y10/<'D]8Z17%FM\/S!I"
M$M(1;ZY$(-(BOV3W>(@'R[?=#Q?=[=P_? =(ICAKD"-\()'1#N1QUE'B0G>D
MG.)"QOT+'#XSA9.OX_Q=DB/Q]BM. :QW#)83VRT7F$EY3*:%"581LK?JM7&[
M6K3D([ I)[@J$P!ZJW3ZSAS#8(2A6%%OQ*L16#CPY%21D4G([1)DC_G&V!9+
M"1A4\0I;J"MS$3,)P);(#97<A"E'$E7Y+\LN2./NPW?(<)6(')U.@;M!56@8
M8NTIC:H*5:$E:SE[$U(N69)2$9N)VWUYU::]:<G7XE?R=&56-"D5JO)UE@_<
MLK!*%F53)4H)2I(4 EM12G#<.(25D9J]8*6K"O",*1;B30EN12AM2E-K4A2U
MO(2XYB(4TZM#04H)0H(4EM&)K$<:E%1 *1&+)FWC86<8_O4Q3LYQ1Y:0R1;K
M'A2(Q@"HP,#&W:X)5N#<VOW,[9"6!%.F4ABS?U-_;<97-TI>XJST*8O$B\8P
M",FW)@*2O"X+[Q1;2@&R05X1BP*Q9) ()0HX@4E1]6,+9D\+B MDV2TE+Q<U
M44("E!.\04^NLD*P.I& I<2A-U&Q8$\('CFG4]AFO)&9I!G<XF0EGTW@:G4;
M-F4X&_052K98"F.EAX>*O6Z73\F6F6L<FY-/TB>CJ$6EL(&8RZ#2V.9!M;><
M0E.]6Z0I))+24.N)6$)PI)W*0A*U%5R4J",("G?6O$#]WN+66&V04* "9A;C
M#2VU+5B6!Z2I2UM("19+B2YC*DLW1:+>.D?"'2MMM=ER'8<G4ZIDQ]D_H8'&
MT#5IL75NQ5AVHP+N&JE7E,'3,E!RN0<QFL]]QC=75^N,#<J_'/*JPI[;K\"\
M?929W$I3A6E.%S) 2JZD-I39*2RH@K<NMM6-04!A",Q?"Q3PA"6PVM6\;]9Q
M2TV2Z\M0*UI?2%);9P-N(W:%(4H*+F2A#-L<[QPT>Z)5DN4.)2WO*1@J"GU$
M4\-KR4-E+,PT&VWRR13>W5#ACE<>(0/M@5K%%C(5_?J7+M!8.8[KDW/O$E5\
M*,TE6'>/J*60K)H%*W<*ED8DL% 3BPH"<:3E;UB<Y)$DM&+=2R0X^4_Y["6F
M=XA"24+FDNWPXEE0;6,[D!(M$]>#&-XDHFN9*BN):V3MEL\+?TX*$+-DAY-(
MD8QJE>=.9RN7:"QAB*/M]7M+Z14DXT"4\'%6=%D:I)2K^7BI!-KRI8/@.!]1
M40NR;X= E/K)4EML*2J^7J^J;I))!MK9]4LI3)ED!"2V5*L5#/$0$J0IQTI4
M@"Q..R[A8 21>9NN5&O@TA" ]X^4?3I"$3]_F]8ZM1IW^0BMSAW^44CWCY1]
M.IQ%?M'N\!"!_A#YO0&D4#V^\^<4ZR-1VCQB$(_7_MO7J^*?R_Y7G%.D1BWU
M=^2/Y/B(12?X(^;TAJ4(2#O\P^@=(10?X(^;TAI% U[CX&$=(Q%!^[S^H=31
MKW>8B"]._P C"6IK]D]WB(JB@_=Y_4.H(U[O,1@Z'L/A$(^-B_<0E9HS*!X:
MZ1>['>9!I8+9+6.GP]6D K-=H[ LFE&)^W=_'04G,W>SKUZLC78P9:Y.:<XN
MDQ4X-]-PS$H\:=<F4H"95MQ2SB6I2 @X$H%[>N0DJ<5A3A&)>#&4I) CG4IF
M36XI<\ZTAH*;;0AQ3B<;CJBG$=VE2@AIO&YC.%L.!I+B@E1C4#^X<0-FG.(!
M^\G>)JG/ZY7LM/ZI2:CAZHEH*%1KS%LOBAU1[I8Z)+3-NR[>Q(26<1D4^O"#
M!=W.U":IU9<L89VKA*YA2IDE4T@I2\4MH9;W>! &ZP.*;4I;SGM627!<K04)
MLDQ8IJ30F22$R#@6N7"W79ES>EQ:[3&];0ZE")=G-&)8:*@$N)<<!4 PV;WC
MCQR\A :6+*&7G7M@HF)7S:X5&J)PYK3=<#6>W3.69%]5Z36>CQE1\O6.F5V6
M?L55$&455I2&4=R$\1X+C -0;( 4Z]ZS;)QH1AQN2RUJ>)0VC\4V^M"5$7 2
MA0N5 @S(I+X65(EY<879D%IQS%NVIQ#29=*5NKN^]+(=6D&Q*W$KPI3AM><.
M%[XDXB3SQ=<HSF?LEMZ-%W=G1L4SV)YZHK611O='<905HET]P/1X.:L$[!0T
M<J\?UK)EKK\62ROI688Q<<DDO')5R:29A;JIAX-AS=LJ94@JLLANQ+"$J4M*
M024NJ2G$2H #*,^U(K3*-RZ).7WRFB[,(?0X&P6@I[$!-NN!"%J-DN,-J44)
M2DJ4?6UVZREX0V"H"+I>DY)E,A4)QFF<NM>?TBH./;O[.PV+(W'5=JDG336&
MJNXFH6+*MKMM<+7;'-3#VNX?=5RT.W\\6;3)#>U)+=RVZIQLOJ6@MH_&8DLI
M:0@HQH(0MU;B<*R<+!2LE6(18)>B+>MOF4L/"50TM+KHW6!<PIYQT.8' IQ$
MNVVX5-I2%S27&PE&$QM4[#BRJ>2Y.0C;OGO)L(AG&"IT53I&&Q;#UF8H4#A%
MGE:XV4DZICNMA$Q-AR0T/B&O3,I;"L4BO'S,SE_-J-7[2^TXATD.3#J=^E 0
M4LI2IM,N'5KQ;I&$*=&Y05+MF<RJQ'$4JG.2Z4K:DY=1E%NJ="GUN(?7-*EV
MF\(>7B6A@B96A+=\@<*4@I(\RSQ0L9W+,ZUJV>I?(;1Q<ZW1L')8OJ7N$,DW
M\W$US#TRAEQZQ@G,]+.VST,@7B;:Y#DZK$QB%JKL^UIRL=7578O304\0W,*<
M&-+;&Z1Z.+J"65!XA)4H@[QPAU2$@+2H(*41$2U.+<LDN226"&G'ILS+OIA(
M07)I!EDE82D$;AE!92X5%MQ&]Q.6UW"9!X\%O:%$+063TD6B-;Q+>G]II%71
ML@3ETX@,D5Y;,SQ]6F,A37?M Q=C6KO+#[3WDG2S-,MMI]FJZCV[!^.&G:B<
M"0EVWJ,N8VD8L3DRZCTBZ$EO\4RRDJP%2"'@H7LE46+8H_XY0<E[DKF60V\Y
M@P-23#@E %D.IW\P^XE&]2EZ\L4&RL289UPR=Q?.*%%/65EXH8"Z6FZ5MIE!
M(W#BJM5<4.TH3(<U/5W$1Z9A;(%\L%5:/XBHU%U;)&H9'KDL69A9F+O!7SJQ
M)1Y;LZ6P0J<0M;B \/1;H9.%Y2DL8&''%H!2VV7%(=0K$E27+E0$DR]+#JPI
M%/6TTVYZ.1/@.3(*I="%S&^FV&$.$*==#:7I=Q.!:%,X0WBW%A,>,1SQ!U-U
M=[;D)7"1T;#&?])(>+!"Q%I&,J=!+A9:X;!],L=-E[ODF4G\A5B[K7)G#RL3
M6Y2GGHL$X?1(/N5*^G^E(+BW?1CC3ZZ4V7NV$)]=/HS:VU./*6ZAPN!*DH4W
MND73&OGA2A(.AEMCTSU%?BUJ_%[V8=7ZCGICK;B69="&'6=T5)6M+P=6 K#T
MXUNX^:5^3_PB$%^XOE'T:1@:'L\Q$7.*".R/)U['K+&EVR=19%]E.J,+',XR
MA*W.O&U&,+N2NKJ8;6*CW@B#=&M14FU@G35DU,6W/Z\@K[)%7)$/>'.!XI:#
M+CS9+R M3*4+(:S+A4%MN6&!)"2!?&4^U?"=C3E2Z5/&89EGDIEWE-HF5N-@
MO62ED(+;[%SO%)*P2K\4EPC#;&F!:UW\(!9XZR5V*JF8JO.6^U4FT4AQ9$<;
MU@\%C%G5<T2+V ]O<)1\L5JO6BR-<?8R:6%K?JDC86.3<@R# ]?J%6DJ^NUU
MX=JJTJ0EN80IQQM;17ND864HF2I&]2V^VEQ8:9"PX@*#SI&!""DC<EBAMJ;<
M+TJXAIMYMX-E]S>3!=DTI7N%O2KCC;9?F5-EAW=JEY=)"W74N U.<J<;$"YJ
M"J[/-=OEJ_2X&85B8[%B,)5+C6RX6B;I/6&XJ*86EUI#)3S(;VPXX+0(Z\XB
ML$/(UF"DV%)E@L3]F,@_4DX#:9=4AM*L(8PH<0)?>*6[>745/*=*V=REV76%
M-H(;.,B EJ.L.@*DVDK><1C7,E;C3GIBFFT-6FT!,L)=*'_2"S-MK2ZM*GD[
MM*AE<4P?%9>J'BHD]G[B0C['8,R^UJ]3)<;1=*/!4B.Q5)VN:DW41E?A@I<A
M&M75IBFM<@I9&*DX \O8$6"4]-O4%&+&Z73/NML!4W-I6N8"'5!E+6!H,*<4
MK#,231 *TA"38IQ+ Q+4+#CSJZ6R_,EN2D%-HD]XP@S"GBX^J:2TA(7*U)T*
M(:67%I*TKP-XMV@>L>LB1!3123,H=8R9"D%57DZ142D*45%.C*0G.<0YC\A"
M$YA'E*4-@#Z("V5R;)2+G4ZYGKCY4Z=Y\HKU%SAW^45.<._RA(_?YO6.JXKB
MC5C?'N\X@O3O\C'H]P>3UCJ8U/;Y"*SH.SS,)*_!#[XOIU(:]Q\#$%^R>[Q$
M)ZQ%9]E/?XQ2?X(^;TAJ2/:'?X&*U^R>[Q$6ZGP ^^'T!JWB>P>)BK@.T^ A
M$?@G^]'TAJ0U':/&,1";.-KS;&9UQ?%X\2R ]IQ6C)>RP5=J298*66<RKUPY
M?R-[D:3:*R=FSBX<\--U>7M>+9IBA.Q]AJ4M:)820J/ G')M,Y+I8WY:L-XA
MML8%745%1=4RXV0 C IM3DNL!>)M2U$)C=R#4@JGS:IDRZ7R5!IQQ[\8@)0D
M!*6$OLNA2EN!QMY#,VVHMJ;?0T@*7$5"63CFRE&XM@Z,[R=5'8T2@P]]L]PK
MK?#8/,CU.CWEWEF7%[<<'Y"7C8F6N]OQHRAA"A^QEL;4BP,Z>^:MAD)T-?O*
MO,)ET,E]M6Y82\XZ@2MWVVGC,JN[*O84J==EPFS5G TM+9 NN-QNJ!**FW'_
M $5X>D3*Y=IESTZTL[,2XDT86)^6"UHEV)LN?Y0%,F8:4^DG"V6P2<XY[!8\
MAPC*^Y5+;?;;%T*O,#8RGJ#CUK'Q-\J]7G<@M;A/<-%BJ;:*L]3@[9;XN8B[
M?D!.)+;(Q8]0=$8J,FL-Y5UJ>0EV8WF]2TV#+K9:"4/MM+>WJY%: EQM#CJ5
M!Q\(WJ;MD)PC.ZV>;;E7%2\H6-RJ8=4)IJ9F5+7+.O-RQ915&GBIIYQEE;:F
M97'N5C?)Q!2LU7[QQBHQT UR+,\0T14PAZW%6^RT7#T':LJQUG=N<R6H\-$L
M/<N7BY@6S=]B3&UAR6TH U)=:LO95-I6T[,O/LI(>J=D!]<ZE&%M+BV9=+DP
MEQ1FG=VD!C HB\NPM\,AO\62$H"RI-3DO0RMTRS=-6]B=6PU,SKC,FMI(D60
MXM7I0<;N4SLTW*&9+P#J4%3I:2VIZ89D>.*;SACN3RP^M%>QZ9,8&TQ/L7 +
M0DC*UC"]=7FT)V!8XT(Z@E[/DF8FY6$R-"Y3]IKAW3)*J,*X5&7KRDQR)156
M7,L*F5.(8]EQ.%&$J;E6\:5H$O=.\?4M27TS&Z):4VEOUD%7!J2=GFY":1)I
M:=F_;97C<"TH=J#H;4VZJ;(<W,HVVAR57)[\)?2\IWU'0CI[K?Q\=!JU&G?Y
M"$&IQCB>P>)B@_=Y_4.D17IW^1A+2*H>E0_/']R?TG6KJ7^A_P"9_5QO-GO]
M;_F_]='14>\?*/IUT);L]X'C'JX@W.1U/"$]AY@'Q=O_ !$?GU8-+7%[IXCA
MA^40.A[# 80Y1[0\7C^[JP:CM$5 &^AT/#J,(;@(AL(=_J'5UQS$+$ W!T\Q
M'APW#L^/Y]9B,6ZA1[.P?'XO)I"$% $>7L[@'?Q>/[NIH(%[]7G%:P2<@=/G
M"/=V#JS$.8BO2$U/%Y_5K-P=#>(+!-K=?E% ^+R>L=(K((UBT5*(G'8/$&D8
MA'N[!TA"/*;XO^(:ON.8]\8OV^X_**=A^+68PK,$#,\AKK!I%5CR/N,<>,D<
M&W$U=LKY,R,PLL7$,+O>%81]!#:WAT)W"60+*VHF4(PR*2/5HR9;8BQGA>V0
M @7I/; QFH BZ NWCI;AJ8<4M2L5@I5K8CFVI6%8MH"$(;4GKN,C<G8(F6$-
M(;PDE*"0< ]5Y"2MLWO<@N./)5PPD&QM8:*D.!7BIF:,B@O2*K675BD:".7J
MA5,PP\B\RO8(23R1>[/E&9>WO&EEQW'NU+I-TJ$@Z\^IUO<.:FQF$)600%O"
M)-(;AXI P@7*<:4K!WANI16<3:DWQ%( PJ]49G(1(3<NE=\3B@@+W*U,D!I)
M"&T-@(=0LC=A9*L:;+*; ^O=W3_@Y,M.*5DZTPTLE$Y F8N)I5*Q_ R=2KIT
MZ*ZQ]0,2VYA.Y(C*NS@Q:O*VROMN85.+Q_$TQ+(4E'V,T()TTV"%OH:[+5<!
M:@$)0"D>K@2A0*PFV8Q*"0C"%65:^E0J#6)I!22VE16M:DK5=8<<>00V3>X4
M6T%6\QEL%.+C&0JO _Q$UI:J3=;")JC1I[F-7ME!>VVJ&;S=*A\NVW+^1'JJ
M^-:#CBD^VJ<>P>)*A&R#*F1JI*@6RL7RKUV*CV0L3+.C"I)";;M*D%20"D.%
MQ9]1+:"HE+: < ]6]\\X@Y.L*"DKQ*/XU2' A8LXIE#+0_&N.+PI"GED%9]?
M"1P U*OP"\43FATZ&/1JU#LB>Y:&1:55LPUV3=7ZY8[IF5XZQ9@LCW).*KEC
MT)G(%GR5&'<0!:9/KHQE(BGC^<&4+$!!1$H^4)&%('XO&E+B58U(0X%.'>-J
M1=:G!EA40$C.]L,S/RV\4K&I1_&[M:V5 (;<<9*64AIU#EFT-$!6-.:U63:X
M5(N)X),PLK1+/)3VNS6-Y&#RI-)8NDYE-6':WVO8VE>'W![%-M'QL5!%KMIP
MW,MSV]JRBHV+@YRKQYVL4!WRAD>0)9S$HD)*"E9W14;8TH4RT,@!A6TKUP
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MVUMGU1<D6MRIBL-ORTXE+B]\^]-%*2V[<2SA0AAI*VWVD)2A 62EUIX#&0D
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MYR:K3RMI14]++8*$A;;)*GT2DNMF4+A2M*T[T3#PF0E04IMI"4J2M>-+ZM?
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MYPP(_-3^J/E!T*7V)/\ @%^;3&O\Y7ZQ^<,"/S4_JCY0="E]B3_@%^;3&O\
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MODR?-IC7^<K]8_.&[;_1H_53\H.@0^PI?)D^;3&O\Y7ZQ^<-VW^C1^JGY0=
MA]A2^3)\VF-?YROUC\X;MO\ 1H_53\H.@0^PI?)D^;3&O\Y7ZQ^<-VW^C1^J
MGY0= A]A2^3)\VF-?YROUC\X;MO]&C]5/RCSJ[?[ C\D3^KIC7^<K]8_.&[;
M_1H_53\H.KM_L"/R1/ZNF-?YROUC\X;MO]&C]5/R@ZNW^P(_)$_JZ8U_G*_6
M/SANV_T:/U4_*#J[?[ C\D3^KIC7^<K]8_.&[;_1H_53\H.KM_L"/R1/ZNF-
M?YROUC\X;MO]&C]5/R@ZNW^P(_)$_JZ8UC1:A_*/SANV_P!&C]5/R@ZNW^P(
M_)$_JZSO'/TB_P!97SANV_T:/U4_*#J[?[ C\D3^KIO'/TB_UE?.&[;_ $:/
MU4_*#J[?[ C\D3^KIO'/TB_UE?.&[;_1H_53\H.KM_L"/R1/ZNF\<_2+_65\
MX;MO]&C]5/R@ZLW'O;HC_P#9)_U=-XY^D7^LKYQC=-'5ML_R$_*/.JMOT.A\
MDG_5TWCGZ1?ZROG#<M?HF_U$_*#JK;]#H?))_P!73>.?I%_K*^<-RU^B;_43
M\H.JMOT.A\DG_5TWCGZ1?ZROG#<M?HF_U$_*#JK;]#H?))_U=-XY^D7^LKYP
MW+7Z)O\ 43\H.JMOT.A\DG_5TWCGZ1?ZROG#<M?HF_U$_*#JK;]#H?))_P!7
M3>.?I%_K*^<-RU^B;_43\H.JMOT.A\DG_5TWCGZ1?ZROG#<M?HF_U$_*/.JM
M1[VS<?\ [%/^KIO'/TB_UE?.&Y:_1-_J)^4'56H=S9O\BG_5TWCGZ1?ZROG#
M<M?HF_U$_*/>JM1[VR'R*?\ 5TWCGZ1?ZROG#<M?HF_U$_*/.J-?T,W^13_J
MZ;QS](O]97SAN6OT3?ZB?E!U1K^AF_R*?]73>.?I%_K*^<-RU^B;_43\H.J-
M?T,W^13_ *NF\<_2+_65\X;EK]$W^HGY0=4:_H9O\BG_ %=-XY^D7^LKYPW+
M7Z)O]1/R@ZHU_0S?Y%/^KIO'/TB_UE?.&Y:_1-_J)^4'5&OZ&;_(I_U=-XY^
MD7^LKYPW+7Z)O]1/R@ZHU_0S?Y%/^KIO'/TB_P!97SAN6OT3?ZB?E!U1K^AF
M_P BG_5TWCGZ1?ZROG#<M?HF_P!1/R@ZHU_0S?Y%/^KIO'/TB_UE?.&Y:_1-
M_J)^4'5&OZ&;_(I_U=-XY^D7^LKYPW+7Z)O]1/R@ZHU_0S?Y%/\ JZSOG?TK
MGZZOG&-PQ^A:_P"FCY0=4:_H9O\ (I_U=-\[^E<_75\X;AC]"U_TT?*#JC7]
M#-_D4_ZNF^=_2N?KJ^<-PQ^A:_Z:/E!U1I^A6_R*?]73?._I7/UU?.&X9_0M
M?]-'R@ZHU_0S?Y%/^KIOG?TKGZZOG#<,?H6O^FCY1YU-I^A6WR"7]73?._I7
M/UU?.,[EG]$W^HGY0=39_H1M\@E_5TWSOZ5S]=7SAN6OT3?ZB?E!U-G^A&WR
M"7]73?._I7/UU?.&Y:_1-_J)^4'4V?Z$;?()?U=-\[^E<_75\X;EK]$W^HGY
M1Z#1J'<V;AY$4P__ -=-ZZ=7'#_+5\X;ED:--C_EI^47&JXL@TA!I"#2$&D(
M-(0:0@TA!I"#2$&D(-(1095,@['4(4>_8QRE';X]A$-(13TZ'V9+Y0GSZ0@Z
M=#[,E\H3Y](0=.A]F2^4)\^D(.G0^S)?*$^?2$'3H?9DOE"?/I"#IT/LR7RA
M/GTA!TZ'V9+Y0GSZ0@Z=#[,E\H3Y](0=.A]F2^4)\^D(.G0^S)?*$^?2$'3H
M?9DOE"?/I"#IT/LR7RA/GTA!TZ'V9+Y0GSZ0@Z=#[,E\H3Y](0=.A]F2^4)\
M^D(.G0^S)?*$^?2$'3H?9DOE"?/I"#IT/LR7RA/GTA!TZ'V9+Y0GSZ0@Z=#[
M,E\H3Y](0=.A]F2^4)\^D(.G0^S)?*$^?2$'3H?9DOE"?/I"#IT/LR7RA/GT
MA!TZ'V9+Y0GSZ0@Z=#[,E\H3Y](0=.A]F2^4)\^D(.G0^S)?*$^?2$'3H?9D
MOE"?/I"#IT/LR7RA/GTA!TZ'V9+Y0GSZ0@Z=#[,E\H3Y](0=.A]F2^4)\^D(
M.G0^S)?*$^?2$'3H?9DOE"?/I"#IT/LR7RA/GTA!TZ'V9+Y0GSZ0@Z=#[,E\
MH3Y](0=.A]F2^4)\^D(.G0^S)?*$^?2$'3H?9DOE"?/I"#IT/LR7RA/GTA!T
MZ'V9+Y0GSZ0@Z=#[,E\H3Y](0=.A]F2^4)\^D(.G0^S)?*$^?2$'3H?9DOE"
M?/I"#IT/LR7RA/GTA!TZ'V9+Y0GSZ0@Z=#[,E\H3Y](0H @8 $H@(#V@(#N
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MA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(1'F@__ !BN(?\
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M1EW*@U,^DR3S[CJ43*%(0DRRVPL-/[I;>-++J%I<#BK-J <OXW^U+-]-6S+
MVFZ/-HZI*[*3E'12-HY"G2LH[,4B89F)MU%8EII4JY.TQ,ZQ-^BO5&3>8<EW
M)1C>3#:E2A1\]]HR0^N,DM9KC=9*W3;LB9%IBP3KVPS3DB8"5!$[N0<O)!4"
M 82(HF.($YA*0H;B&N]9=J4DF!+RC4O*RZ22&)9IIEH$YDAMI*4W)%R;7/&/
MS"JLYM%M'4G*C7)VK5NJO!#;M1J\Y-U"<<2GU6T+G)UUUQ2$!6%M)=*4@V2
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M63MI5O%2F=IA5-XBI#B059-[GB;&0<  G62@8A,Q1Z:0,YR3?Z^N<8MR^OH
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M1;"TMMJAY1K?5<E1QF+&K&9M[4EG7,O$%$J/&+F$6;RD8PNF991DXCG8"$E
M0D<R773=.7[Y="&O!>#?I4%8(2PDR_E*05K:,;["1;XU8) ,'<?,XCL K-(&
M.A&$1%M7,QABM/%F< RAA4&9LZ*[A=N-22J",6R^N_CYQ)GAPX=*WPU4U[3*
MU8[1:&;IW#G+)6Y\21ER,*Y5("E03)9Z"9#N3M8*MQQ%EC F@+@54XQE$Q"4
M?#L$9B0ND(CAPD_^(&E?Z_>__P!1;9I")'Z0@TA!I"#2$&D(-(0:0@TA!I"#
M2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(1'F@_\ QBN(?_T;P=_[
M-OFD(D-I"#2$&D(-(0:0@TA!I"#2$&D(QLM#Q$^P7BIV*C9J+=% KF-EF+61
M8."@.X%79O$EFZQ0'M %$S!OVZ0AO5C'./:2HNM3*'3*BLY*)'*M8J\) *."
MB;F$JYXIBT,J43>^$%!,'-V[;Z7A8<H>>D(-(0:0@TA!I"#2$1#XI^##&/%:
M6GREFF;C0[_CY60&F9*QW(1L;:HEE+BU-+P;HLS$S<1+P$FJQ9.'#!_&J+-G
M+5-S%O(Y=1RHO]GLCMQ5MCS.M2C$C4*=4DMB>I=3:==E'ELXPQ,(+#TN\Q,,
MAQQ*7&W0E:5E#S;J0D)^5VDV2I^TIDWWIB=IU1IQ=]"J=-<:;FV6W\&_EU!]
MF88>EWBVVI;;K*BE2$K:6TNZBR\/^#AX6,7Q,BE9L?0F>[=-RR$W.9&SW6:7
MD*X/7C1$4(]NR5=5EK$P,5&(G4(QCH.+8D$RJKE^J_?*J.S\^M=)VUU6?;5*
MU)_9Z3895+R],V=FIZFR3;;B@IU3@1-+>F'G5!)<=F'G#9*4-AMM(0.%3>CW
M9F20XJ=D&=H)Y]U#S]3V@E9&H3JUM)*64MDRK;,LVRDJ#;<LRT+J4M9<<4I9
MG#%Q49"1[.)A8YC$14>W3:L(R,:(,(]BU1+RI-F;-JFDW;-TB@!4T44R)D+V
M%* :^!===?<6\^XX\\XHK<==6IQQQ9S*EK62I2B=5*))XF/M&VVV6T---H::
M;2$-MMI2AM"4BP2A"0$I2!D   !H(O\ 5<3@TA!I"#2$&D(-(10HF14ATU2%
M434*8ATSE Y#D, E,0Y3 )3%,41*8H@(& 1 0$!'0&V8R(S!'",$!0*5 $$$
M$$7!!R((.1!&1!UC4\9@'!4+8O;?#X8Q5$VOINL!98W'U38SQ7 F PN"2S:)
M2?$7Y@ W3%7!3F[>;?7/75:HXSZ.Y4I];%L.Y7-S"FBG\TMEPI(ZK6CYB7V'
MV+DZA][2FR.S,K5,0<%1EZ%2V9X+%B%B:;E4OA=P#C"\5P#>-MZX$?40:0@T
MA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"(X<)/
M_B!I7^OWO_\ 46V:0B1^D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:
M0@TA!I"#2$&D(-(0:0@TA!I"#2$<!_"16.PU;B5*K69Z9KBDIC*G'DU(*4?1
M!Y$S.6MJ30S\\>NW,[,U3443;BX%04"*'(F)2F, KD:&T+#E$"O=2R;]L6]_
MA=8/QAK-SS/O,8L.0]P@]U+)OVQ;W^%U@_&&ESS/O,+#D/<(/=2R;]L6]_A=
M8/QAI<\S[S"PY#W"#W4LF_;%O?X76#\8:7/,^\PL.0]P@]U+)OVQ;W^%U@_&
M&ESS/O,+#D/<(/=2R;]L6]_A=8/QAI<\S[S"PY#W"#W4LF_;%O?X76#\8:7/
M,^\PL.0]P@]U+)OVQ;W^%U@_&&ESS/O,+#D/<(/=2R;]L6]_A=8/QAI<\S[S
M"PY#W"#W4LF_;%O?X76#\8:7/,^\PL.0]P@]U+)OVQ;W^%U@_&&ESS/O,+#D
M/<(/=2R;]L6]_A=8/QAI<\S[S"PY#W"#W4LF_;%O?X76#\8:7/,^\PL.0]P@
M]U+)OVQ;W^%U@_&&ESS/O,+#D/<(/=2R;]L6]_A=8/QAI<\S[S"PY#W"#W4L
MF_;%O?X76#\8:7/,^\PL.0]P@]U+)OVQ;W^%U@_&&ESS/O,+#D/<(/=2R;]L
M6]_A=8/QAI<\S[S"PY#W"#W4LF_;%O?X76#\8:7/,^\PL.0]P@]U+)OVQ;W^
M%U@_&&ESS/O,+#D/<(/=2R;]L6]_A=8/QAI<\S[S"PY#W"#W4LF_;%O?X76#
M\8:7/,^\PL.0]P@]U+)OVQ;W^%U@_&&ESS/O,+#D/<(/=2R;]L6]_A=8/QAI
M<\S[S"PY#W"#W4LF_;%O?X76#\8:7/,^\PL.0]P@]U+)OVQ;W^%U@_&&ESS/
MO,+#D/<(/=2R;]L6]_A=8/QAI<\S[S"PY#W"#W4LF_;%O?X76#\8:7/,^\PL
M.0]P@]U+)OVQ;W^%U@_&&ESS/O,+#D/<(/=2R;]L6]_A=8/QAI<\S[S"PY#W
M"#W4LF_;%O?X76#\8:7/,^\PL.0]P@]U+)OVQ;W^%U@_&&ESS/O,+#D/<(/=
M2R;]L6]_A=8/QAI<\S[S"PY#W"#W4LF_;%O?X76#\8:7/,^\PL.0]P@]U+)O
MVQ;W^%U@_&&ESS/O,+#D/<(/=2R;]L6]_A=8/QAI<\S[S"PY#W"#W4LF_;%O
M?X76#\8:7/,^\PL.0]P@]U+)OVQ;W^%U@_&&ESS/O,+#D/<(/=2R;]L6]_A=
M8/QAI<\S[S"PY#W"#W4LF_;%O?X76#\8:7/,^\PL.0]P@]U+)OVQ;W^%U@_&
M&ESS/O,+#D/<(/=2R;]L6]_A=8/QAI<\S[S"PY#W"#W4LF_;%O?X76#\8:7/
M,^\PL.0]P@]U+)OVQ;W^%U@_&&ESS/O,+#D/<(/=2R;]L6]_A=8/QAI<\S[S
M"PY#W"#W4LF_;%O?X76#\8:7/,^\PL.0]P@]U+)OVQ;W^%U@_&&ESS/O,+#D
M/<(/=2R;]L6]_A=8/QAI<\S[S"PY#W"#W4LF_;%O?X76#\8:7/,^\PL.0]P@
M]U+)OVQ;W^%U@_&&ESS/OA8<A[H^E[A!110X9,*%1231*I1(IR<J1"IE.X=B
MJZ=KG @ !EG+I99RX5'<ZRZJBRAC*',8<0'F?$Q(_2,P:0@TA!I"#2$&D(-(
..0:0@TA!I"#2$&D(__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g393013g49h81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g49h81.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1G<4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;VP     "W!R:6YT97).86UE5$585    "< 2 !0 "  3 !A ', 90!R $H
M90!T "  -0 P #  ,  @ %, 90!R &D 90!S "  *  P #  ,  Q $4 -@ V
M $0 ,  R #D 10 I       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R
M &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT
M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'6VH]
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M 0 !.$))300F       .             #^    X0DE- _(       H  /__
M_____P  .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          CA"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #-0    8
M ]L   :4          $                          0             &
ME    ]L                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   ]L     4F=H=&QO;F<   :4    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   &E     -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
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MS/8[^Q[$E-E))))2DDSCM:3!= F!R?@A49/K.<!6]FTD$N  D?FZ.<DIE?\
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MSOC5_P">JETO^+[_ )'R/_#3O_/="YKZW?\ BESOC5_YZJ72_P"+[_D?(_\
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M[-_T_P#B_3K9^C]#T?TGJDQ^D75/J>[.NM=7&XN<8>09][=_^B_1;/\ KO\
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M &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '  ( !# %, -@    $ .$))300B      %^34T *@    @ # $   ,
M   !!LP   $!  ,    !! D   $"  ,    $    G@$&  ,    !  4   $2
M  ,    !  $   $5  ,    !  0   $:  4    !    I@$;  4    !
MK@$H  ,    !  (   $Q  (    >    M@$R  (    4    U(=I  0    !
M    Z    2  "  (  @ "  U N8  "<0 #4"Y@  )Q!!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*0 R,#$W.C V.C(R(#$Y.C0V.C(W   $D   !P
M  0P,C(QH $  P    '__P  H ( !     $   :4H , !     $   /;
M      8! P #     0 &   !&@ %     0   6X!&P %     0   78!*  #
M     0 "   " 0 $     0   7X" @ $     0              2     $
M  !(     3A"24T#_0      "           _^$!@$U- "H    (  P!   #
M     0;,   ! 0 #     00)   ! @ #    !    )X!!@ #     0 %   !
M$@ #     0     !%0 #     0 $   !&@ %     0   *8!&P %     0
M *X!*  #     0 "   !,0 "    '@   +8!,@ "    %    -2':0 $
M 0   .@   $@  @ "  (  @   /      0   \     !061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP-CHR,B Q.3HT-CHR-P  !)    <
M   $,#(R,: !  ,    !__\  * "  0    !   &E* #  0    !   #VP
M       & 0,  P    $ !@   1H !0    $   %N 1L !0    $   %V 2@
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M0I/3*#)#1$=3:'&5_\0 ' $!  $% 0$               $" P0&" <%_\0
M31$!  $! P<&"0@(!00" P    $1 B$Q P1!47&!L04R89'!\ 8'$A,V<X*A
MM#,T0G*RL]'A%!<B4I*4TO%58J+"U"-35'0D-163E?_:  P# 0 "$0,1 #\
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MKBF$SC.V>+)O"# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M\VSGZ^;\<JKCF6]MC_<K_,908# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MPZWB?Y&G)'G\._Z,E"_E7%,)G&=LLF\(,!@,!@,!@,!@,!@,!@,!@4 ^_&#
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M)G-N;]&(D!"I24SOWX^Z(X,'/$'CLCJQYDEURJ]72HF&864WQB*HYIXKEO\
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M1,EWE\G/E\9#[ZH?Z'KC\W)IC,TQF--/=^7X5^MZW[KNQI=%T;MJ(\V.%?\
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MU6,49;%CL>A[:ULEM2B936QF\@Q:(F5RFPB@$3-Y<-G*C# *7\HL %@48TQ
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M]^R*J2Z4\12LN?Z]Y7L5IC#Y:K5UE/:ECD&)C2] V&-<&M59%6XBUG8UQ 8
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M/P+_ )ISB_\ N^DOYFSC.5?#STNY;_\ 8R7PN09N3YEG8EB,'[6689L(QZ+
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MR9!CTD<MTFH3K/23Z]74D1=/72L8_LS/NBD[XHG*Z.OAFYVK-TL!XC%FRO8
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M<6P^HV$ME&B<4:8LIQ=]+DRT8T8T8_OQ_%%]S]X9,O/&&27C=5Z1I#$_$,Z
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M-?*F/9C^IA=_@7^W?^?_ "M_I+;?^['*O.='O_)'FX_>G^&/ZC_ O]N_\_\
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K# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g393013g61t74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g61t74.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19J4&AO=&]S:&]P(#,N,  X0DE-! 0
M     ",< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 '1FEG=7)E.  X0DE-
M!"4      !#VLTA36)*^'D+& 8[W2=TH.$))300Z      %_    $     $
M      MP<FEN=$]U='!U=     <     0VQR4V5N=6T     0VQR4P    !2
M1T)#     $YM("!415A4    $0!! &0 ;P!B &4 ( !2 $< 0@ @ "@ ,0 Y
M #D .  I        26YT965N=6T     26YT90    !#;')M     $UP0FQB
M;V]L 0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    G $@ 4  @ $P 80!S &4 <@!* &4 =  @ #4 ,  P #  ( !3 &4
M<@!I &4 <P @ "@ ,  P #  ,0!% #8 -@!$ #  ,@ Y $4 *0      #W!R
M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 \     !  $#P     $  3A"24T$)@      #@
M       _@   .$))300-       $    6CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M    !(<   D;          $                          0
M   )&P  !(<                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P  !(<     4F=H=&QO;F<   D;    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   2'     %)G
M:'1L;VYG   )&P    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M "27[+ZC_P"6=G^8/_))*^B__-WI?[CO\]W]Z7_-WI?[CO\ /=_>F_9?4?\
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M6,PM/KB/<'&- 6_1G;^<K*2FO7?DD$V8SF^ :YCO^_L1:WEX)+',(,;71/\
MT2YJD=1"K873L7!G[.TC< #+B9B?'^LDI__9 #A"24T$(0      50    $!
M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300B
M  %^34T *@    @ # $   ,    !"3H   $!  ,    !!+0   $"  ,    $
M    G@$&  ,    !  4   $2  ,    !  $   $5  ,    !  0   $:  4
M   !    I@$;  4    !    K@$H  ,    !  (   $Q  (    >    M@$R
M  (    4    U(=I  0    !    Z    2  "  (  @ "  X:&0  "<0 #AH
M9   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C V.C(S
M(# X.C T.C0Q   $D   !P    0P,C(QH $  P    '__P  H ( !     $
M  D;H , !     $   2'          8! P #     0 &   !&@ %     0
M 6X!&P %     0   78!*  #     0 "   " 0 $     0   7X" @ $
M 0              2     $   !(     3A"24T#_0      "      !
M_^$!@$U- "H    (  P!   #     0DZ   ! 0 #     02T   ! @ #
M!    )X!!@ #     0 %   !$@ #     0     !%0 #     0 $   !&@ %
M     0   *8!&P %     0   *X!*  #     0 "   !,0 "    '@   +8!
M,@ "    %    -2':0 $     0   .@   $@  @ "  (  @   /      0
M \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP-CHR
M,R P.#HP-#HT,0  !)    <    $,#(R,: !  ,    !__\  * "  0    !
M   )&Z #  0    !   $AP         & 0,  P    $ !@   1H !0    $
M  %N 1L !0    $   %V 2@  P    $  @   @$ !     $   %^ @( !
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M=G=XEYBVUPHQ-#<C46$E)B@R.4%T=;2U_\0 ' $! 0$!  ,! 0
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MV/O.2LT8V2M\F1*V])1ND291AM2[K[$AIR0HR07,5EMYL=/='<+-
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MD]7M")'<Z.%++KK/3%U3U'D75M\YXJUH R\
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M9?+0S5H1F+*5;E;<4UDF_("Y[:77XYM94
M
M !5[;3]P\;_WH=2?XD<9 D^<?/Z2M""@   (9V-_H]9X_L9RA_HA\ 5\5_\
M5^#;_K&J_@VS* O2
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M8459>9?6E*UI;;7]E1)VE%D_M1Y2;LX3DV?[-:YS',T]PY-(G(61LNQRFD:
MU'(CEAC:A7/N0<*39#."& IF=FZ9NL92XH=6=OB;Z<P-JLZ76O-DE:5["CJH
M\2/7W[^>DNZLCQH;F97&WN.*,A8^EQJW)T\R"B?'-*_1HI:^9$PTPX\7SV81
M10W9":9-*F>6M;K+UD7JM0Q"<-LHD42<KX_'G56WFP]^Y;9*?^O[:@
M                               "M>9M3<.YRE;!D&4$SV+9(C3 OB35
MDG$65LE88GM8>Z++'!?#G638OE,6<9#%3G"SY1(89"8Z-S8Z&'.S00@=#C5E
MP_CY1/ZQ./HC-U\''ITZ16#P^S%3C'VK'[#)XLRK8/E#+F/I2Z1J</5TEG4?
MG<V@T[CTQR8SSF2F*)),V_(K[*$THD2Q<^/1:UU7K%9Y;9]Q'Z3[_)SGCP>F
MHCLCO2)L5*(B9;+$$T:W?&>0<G8IDL7>F[%$'P<23"95C291220B/*,4XV@\
M,<XC$W5FBCNVQU <Z,JQ?:8KO%L^^LV_GQXLRC.F.L\,8I?&8GBUNCL?G>#V
M?7&5-+2\R9(C=,/L2[);HAC5UECUY29<:ZY@R0ZNLM27$3)]=)2L<7M_<%I"
M(]*3UM]^G:,EAHU'6>(1U@B<>2>@,$896J.L:'SZE5Z$SLJ$AM;$GI*PY0K4
M>C(DQ!/GU1YZD[R/.'G&&W77W!7C;3]P\;_WH=2?XD<9 D^GS^DK0@JL5NF>
ML=N4G;,OLE9+L@/:V0.S@N-<9&<P5D$M8UD:E4L1P4UYO@C7-9+'W)S9W^;-
M<:1RUX;W1T2N+RH*<EUJ@.P:=1M;65BQC&4.(8K='\-XQF.&<;M#@6O>$,<Q
MCD)L8V:;Q'S#PM76O""4-4<:$+P>_?*C@K3DJ;+UG_M)SJL%O=#=W@SM+J'L
MRU)BR1,[HQ%/9"%\CN;<^1F1&D2*Z.T=R7:1Q[)[8^OY:E/$(BVE6/S@Y6HF
M6*1AB043,T>9T"(.UD^LV"]>\";3KL.8];80JG6(<@&R0Q$O?''SZ9HA\T5L
MK&UEO;HYEQN)L2J0OZIAAL;L:(HQJ'QW/:69&:Y++S@T)_\ $GMKB[>"UTT1
M-2!:YK+\SXBNL2-Z4]8IOM+UXR?<9=:0F+,-NMLMI6Z^M+*TMMI6M?%0?>_R
M:UT4?BSPE5=5-%,>&\;;555%,1;X:NSC,Q'%SVL6[.JSI_U0P'_A)V!]9<>;
MPE/+2[LABJ88,JFJXMRE :92QCRA;>:FM7)[;3O,W&65NKYLRRVZZRAEM:74
MI7Z7^5W:[/:>)^!W>THVEFP\=;N5TU66[3PUEN[,V6L;&)LJ]./T;P8=CS;9
MGR/C&QY69+E$4B$[FQ)KE))JGML<V9VV1R<ZN$JG"N-9)BR5U3J\"/$ OA#"
M?CJ;-*)V9#XFFCN.DEYAYWXZ[?E[GWQ^K:*"@
M
M    *O;:?N'C?^]#J3_$CC($GSCY_25H04   !#.QO\ 1ZSQ_8SE#_1#X KX
MK_ZOP;?]8U7\&V90%Z0
M                                                  5>VT_</&_]
MZ'4G^)'&0)/G'S^DK0@H   "&=C?Z/6>/[&<H?Z(? %?%?\ U?@V_P"L:K^#
M;,H"](
M      #H)1*(_"V)?)I2ZIF1A:[2+W!T65OHF2VJ51"(BXVI=AE_B,5*2";?
M)LK_ #S+?'XJ>.M+$3,V1YDS9QE#7*MUVZV(O]8N^#&KNOEEG?IQTGL<JW7;
MK8B_UB[X,+NOEDWZ<=)[)KCTA996RMTBCKBG=F1V3VJVUQ2UOJG5IKKKK;3B
MJWVV7^36ZRZG\ZVVOCI7]@S,3$V3YM1-O&'<B
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M?8K:O2]N5OS1?%)4I9N7OODZ>MG\<FP0
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MPG$+55S4%65K6Q"6Z/#8@]*,I0FU8XI$]+_.J"[;LHV)@
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M,G((/\X447;;%9X
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MX).
M %4]WMK([I#JYE7:2611ZF\>Q2DBZMQB\=5H4+RZVRB<1F#I[$2MRK1$3<E5
MR9.N.J?7Q7)DQUEG_BW6#VWP/X3M?CGQ7PGPK8[79[#:>+JVM-.UVL554476
MPVNWG>BG]J;8V4TQ9ZS'HS5.[$S@\Y_\K>UM]TK.'&$"^^/T?^J'XI_>_@/^
M%XCLY7\<LYP?RM[6WW2LX<80+[X?U0_%/[W\!_PO$=B_CEG.'I2U)V+8]M];
ML0[(QN.NL28LO1,F6-D;?%*-8[-"8Y8L1T2+E2"M49Q]MZ.Z^MZ>OFZVWVTI
M^VE1^9_%_AVT^$?$O&?#=KM*-KM/![:=C5M=G$Q17,1$[U,5?M1'&SCQX.U,
M[T1.+GNNSF$6/8Z+ZF/$X2-F>YMC)SR[$8.M0NA%TC@[*\JF-U6-#W>BHPK'
M1"J0KE)\=*<JO_R2A7/5C=>U(5BLCUR]73QK;;!,NRBCPVPRQ8KR"NEF9X0F
M9[XU)$Q%\CP 3"#\I(JNBEK*:["V K(L2N3J[U=J1Z^43*,QRZJ%=1.'"G&Y
M&O>.O;&7+9HM1+,%R_'>/9RT(8C+WU_4S[+,=CLHQQ"81'F%C<WS(TJE[7*F
M*C.Q05O?W Y:LO0WD%J$BVQ./?O)S,+[58RS=+)7CIJ;<BP'*$+96:5/V,,P
M8[E&,IO;#9$K7M[%-&AMDB%.DDT3<'%K<&LQZC+@[I6EX2F,S[5J=JEHKQZ1
M/I+'W;>#6]DS(9@U?+I';,$LZC>*W1]38QR>OQ2Q97F38VO$3Q9(<U(8>HQ*
MPY$D+>],E[7$769)'@Y8^L+1<F+>7UG;UHL]^_U=4Q;[ZT2B<NN/8Y))P]/R
M-1DUL85R'#>8+X?DJ28:3NJG)\,PY/KX,7",OS:(6L3X4MB6.9!)'U8H9'TA
MI1.)C"]6H!9Z]O7IYY_6&%T\)?JVB>)>PR\[-N,G.#8YLRM(DV5M:-@L<'$P
MQ7+&R!LJIM3RS&[8K?G>535W0Q.%1AB3N4EFDCN.98LTNSBE4IBBV3TSCNL;
M@_8C%^PK;*5V.ELG)7P6161.<Q&?0"=XKG\,D![,V2-"@D\!R5'8K+FBUUCS
MTTOC*N4L]K:]-2\A:UK%9/EW6$]ZS'T3@                      *OYP_
M[U:8_P!MF1/X7L] +0
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MX[F'LB@K!'L8->.SGF",)"=Z73YN9#G=I1)EM!/IC9C;Z]+8MXS;TL;/P0
M           1!G#*YF&X.GEJ6'N\]<W*:XZ@3)%61Q96A<Z/V2YU'X$RTJYR
M%:WM"%(E<I"F5KU"M59Y"(@_S-AI_FRKPCCVR;#^YY,/\8\)_FP ]LFP_N>3
M#_&/"?YL /;)L/[GDP_QCPG^; #VR;#^YY,/\8\)_FP!C\MV*SG"HK)ID]Z?
M3:QEB4?>9,[WILNX44*+&MA;E+HX7)R+9;2X\^U(E.J432M*FF4MLI6E;O&
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M*G7MSBWJ25B%>A5E6'I5B)6GO,3JDJD@PLY.H(,O).*OL,+ONLNI6H<L
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M[+*5NK7Q>.M1X]555=4UUU55UU3;555,U553C-4VS,]9E78#(
M             J]MI^X>-_[T.I/\2.,@2?./G])6A!5 ]]MT"-.H[C%W3F04
MY;(Y8Y2&8M\U>BV@\C N,&BZ3YMD4/)N=&LQZG#<UJ8\P0]E)N77+I/+&:PU
ML6I;3RZ#W^?E'OIYN#DG+VU[?L%#\=05_P!:[(9F8^6H,8(#XCD#(.08G#(Q
MAY1,3MD,@'M&2X0Q.^.B<JV,N*%D#:V^-WUOGD'=$>6CW5SNC=2\+/7WZ1P_
M.V?E8HM+O"+;>8SB$%EDCLP9-V.8J\TY C\JANOV:TS5*\'XSFV+X##WV5(6
MK->04NN4.RA>_3_(33LQD^3OF)&*!)8/60Q]N>71R2$W#W[]\3AU\N'&+;>-
MOI%OI9$1;/'BL1 ME,T9FP9F,O,:'&*9%E;0]%M1B<C'#-*FI9%H3E6*3TL_
M'4^5223R--*)/$D9,3,K-F)-$FR1JG=Z*)AC,2SISG")/O\ AZ?+57/PJ.6,
M?X4U+T,G^39"7&(BW9*B"-8[FH71RL)4NFK66D2$JJ5G1."Z_P ^I-L*I<6F
MNLL\KRC+K+*5NI[+X3\-\;\5\;L_!_#]A/B/$UT[2NG917LZ)FG9T357.]M:
MZ*/V:;9LFJV;.%L\&:YLIF9Z?K" M>,9S7:S$T=SC@1GI/<72P][31^4%+VU
MA+<#HZ]KXZ\66MDG5LKR1Z&\-:Y'6Y4W$6G5(J<GJ:GO*-O[_$?">)^$^+VO
M@?'[&KP_BMC%$[393517-,;2BG:4?M;.JNB=ZBJFKA5-EMDV3$Q'*(FJ+8XQ
M+9#ICKGF/%675DFGD0N8F0V&O+58MJ]1]PI<O5.#*>01YAL=5JFGG"DBB[SE
M2:%6^;\5U]MUUE+O6[3:4U19'Z=8:IIF*HMA*THU+R&=EK,6567(#)*#<HGZ
M^N)3)-$5S3<U&Z^YA?<MQR,7/+$T.1M\1N)O:X.A2DM]AB!.^2F;.*=^DGI2
M>4\'7C[]_):_#4&7XVQC$(4Z+$"US96\ZCB:TE'$,Q*]Q7JW58@8B%%**"6%
MK4+C&UC*/ML.+:4B.PTLJ^EQ=H2<
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M
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MDK] H   "&=C?Z/6>/[&<H?Z(? %?%?_ %?@V_ZQJOX-LR@+T@
M
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M_P!8U7\&V90%Z0
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M+WZ"/2!2Y>:B"4EM30][?4RU45?/I[Z_6?S,(XZ=O+R_.S%M%$4
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M*J2@8(^?(WRK,T(BT[>VEN1Y"-.21YLNSQ59L
M
M          J_G#_O5IC_ &V9$_A>ST M
M
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MG6=N2+XUOC]_3*WWQZ-JP*
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M8\\8PE; &@   $,[&_T>L\?V,Y0_T0^ *^*_^K\&W_6-5_!MF4!>D
M
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MAUGZ3+8F"@   (9V-_H]9X_L9RA_HA\ 5\5_]7X-O^L:K^#;,H"](
M
M                        *O;:?N'C?^]#J3_$CC($GSCY_25H05@4QR/&
MH*^8QCS]>MM<<MSM3CJ(42)*J23)(DQ_.\EFV.)M+[/047JQCJ27VJJVF4N7
M6(DGD4JJH98%;<B[_P"KV)G&K1D&>F1UUI-\FP:K6:T+E[I13A['KKDW($BJ
MV-5BYQI$&2,M!Y='ZJ6A*Y]5M4=0E*'AT0I#UD^_?0^VO#W'FCZ3^$FQ7%HH
MMEJO"FUJM*POB6,3AH2X,=$\FQY)7BD4.B<?F+ \NS2O2.LY0SB)+H4F:RW?
MU@M?4K<DN^7"EC4F'OS9$X[(QK8K7'9EUAT$RO'HNSX>R-5CF<^AE(S%<B-Z
MR*3-(0]X[<JN:V^1,M]K3Z;1=>F0TN;W-G5V%WV+K:6!4/?18K0X"\'ZH1*E
M"-1;/V&VT]*>:G.MMOU/R];=2TTFZR^E+J5\5U*7>*M/V5\=!TV7[]/Y_I+-
M?[L_E^L*+>M$FZ1/O:[A\0/+LC",H<3UHDW2)][7</B LC",H#UHDW2)][7<
M/B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B
MLC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC"
M,H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#
MUHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHD
MW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)
M][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7
M</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B
M LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC
M",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H
M#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UH
MDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2
M)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][
M7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</
MB LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B LC",H#UHDW2)][7</B L
MC",H#UHDW2)][7</B LC",H&]*)O<T;=(2I#"EU]D^;<%O;M&'!2V.4D.LD:
M&.N*IK45:&YJD+H]*+%A15Y*!(Q/JI:?0L@MG=;KZ(3_  ]I^_5\W:C]V/S_
M %E3"+[';9T8,M/"FDO?W6^.Y@IB2+.L');7*/,;$X(",29 FBAGPL4SS&19
M 1'K#FI/C=VD\97*TU$S/%9(82^D1W#39%KI)99+L11Y\FU[FHD!SK-D)C@[
M%IK%+TTLT[DK-&Y 3<DAF.R%+9((X@:GIE7VP>,U<FA<A7WM95ZFZ\P)N
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MD=GK(_X:A[=MQX;MNX[-+CLO+8')L.HX@HDGD$7L260->13GDE)1FM:[;K7
MUH;;SJJ+3KJ52%^;K92M]+OR/^4SX1\-^"^(^$T_"_";/P=/B-CXNK;1LYKF
M\G9U^'BB9WZZ_P!V*ZHBRSSFUWV7[43O<;)^7Z-P9,QUC<L?Y9F\>U;12)7A
MYN:I9+8JTS!2M?&2$.Z><*";9.D16K'".Y/0'8^>F.0XNN;7!5%I"O8BI)(6
MJ/&/\ECGYAOUQ_\ *??JZ[M.&OW7P2ZHZU+4R=8EQ=&STRL@I2G/)6.AQ)Q!
MY=II)I1Q+J84:687=;>685?>7?;6EUE]UM:5K+ROFDW*<-9[OOR2-<>JF/\
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MC>14RXE&D)IXBR"ZG7F&UMLI7]E;S+KO_.M1F9F9MGS:B+.$.X$
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M@E*E2DE)TR9.582G3IR++2B2""2[;2RB22[;2RBB[;;"[+;;;;:6TI0!]@
M
M                           !5_.'_>K3'^VS(G\+V>@%H
M
M                             5?SA_WJTQ_MLR)_"]GH!:
M
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MN/;*<;:;_JL XX1G/8]OV8?<>V4XVTW_ %6 <<(SGL>W[,/N/;*<;:;_ *K
M..$9SV/;]F'W'ME.-M-_U6 <<(SGLPZ2;=3N)OV/XT^:5[,I7C)\F<HA#4]D
MJU!4V.3\TPF69"7)3CT^TYA#>65%83(E]JE=>0G,-1EHBS+EBM,2:..$9SV9
MC[?LP^X]LIQMIO\ JL XX1G/8]OV8?<>V4XVTW_58!QPC.>Q[?LP^X]LIQMI
MO^JP#CA&<]GP5;$970IE"U;I/L:C1I"#5*I6JG>F:=,F3$67&GJ%!YNUUA1)
M!)=MQAIIE]I9=EMU]]U+:5J!QPC.>R$H7NYD3/J"1^P;7*61AC8RK[E^PN?I
M7BMLUN;D=A"@U>]Q:3XER9DEQS31D*(O4G)H+>W0=2<0H9WO+4-76&&D%X^M
MF=OTA 3A(IS*7!IR;@W%N0?"%Y2;'2RYFV!F!T!Q[JUB%:H2J"CI)K?C2;Y"
MQPPY#N;RCSBFZ28\>WYY?6Y4IC$CVF*.).)*O#Y1G[ZZ0>[+>/UL_/I9%B6X
M,T9(;96UY1RUJ5MCG;+[28:J8I;-ICI:EC&/E:M(<B64P_C)NVM]3\;6F(U*
MMLND"1.[9(<V91<URK(,F)IY58G'",_LLM[?LP^X]LIQMIO^JP#CA&<]CV_9
MA]Q[93C;3?\ 58!QPC.>SH)+M9,H.WI7Z>:@[%1"*WR*(QYSE"^2ZJNS>Q7S
M*5LL.;7)P;XOLL_2)2WIG5^0WKK69D=7"Q)0XU,@5&64*N''",_M'ZKB@H
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M\F,WQA'A\Z))9Q 5$2I+DS0=E=8I1VL%)6ZI3CR<?M;^L1PMU_*QZ!0
M
M
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MUB!/YZZ\WT=(I<S4Z>IM]YE22[*WW5NK6H)/"9C!.@
M
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MI*%M1IDI=;[[KZV%4K====XZU#)
'     !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g393013g62y23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g62y23.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1I,4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %0< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' (% #!"3U(@
M*&)E<W0@3W9E<F%L;"!297-P;VYS92D@5V%T97)F86QL($UA<F-H(#(P,3<X
M0DE-!"4      !!CP+G\>KLII(-WU)JP)ES[.$))300Z      %_    $
M  $       MP<FEN=$]U='!U=     <     0VQR4V5N=6T     0VQR4P
M  !21T)#     $YM("!415A4    $0!! &0 ;P!B &4 ( !2 $< 0@ @ "@
M,0 Y #D .  I        26YT965N=6T     26YT90    !#;')M     $UP
M0FQB;V]L 0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M
M951%6%0    G $@ 4  @ $P 80!S &4 <@!* &4 =  @ #4 ,  P #  ( !3
M &4 <@!I &4 <P @ "@ ,  P #  ,0!% #8 -@!$ #  ,@ Y $4 *0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!V33^         "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 \     !  $#P     $  3A"24T$)@      #@
M           _@   .$))30/R       *  #_______\  #A"24T$#0
M!    %HX0DE-!!D       0    >.$))30/S       )           ! #A"
M24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      S4    &              4Q   (R@         !
M                      $             ",H   4Q
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   4Q     %)G:'1L;VYG
M   (R@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   %,0    !29VAT;&]N9P  ",H    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     @X0DE-! P
M#N(    !    H    %\   '@  "R(   #L8 &  !_]C_[0 ,061O8F5?0TT
M O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( %\ H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M5H>1F8676!E]7>_9+ZZ_1+@':#;ZGZ#?[?S_ $Z_^MJ?A';\/_0%,O\ G/\
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M6L/_ )=P_P#T[X/_ +9,2Z?0J?_3]!Z3<*\3*LL'T,FXN(;MD[OI;#[F[O\
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M1;[\ZO#?A9?JTTV;9O= _05;K*O?_4;:G0-&SXJ?_]DX0DE-!"$      %4
M   ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$
M(@     !?DU- "H    (  P!   #     0DZ   ! 0 #     06)   ! @ #
M    !    )X!!@ #     0 %   !$@ #     0 !   !%0 #     0 $   !
M&@ %     0   *8!&P %     0   *X!*  #     0 "   !,0 "    '@
M +8!,@ "    %    -2':0 $     0   .@   $@  @ "  (  @ -G*8   G
M$  V<I@  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP
M-CHR,R P.#HR-3HT.   !)    <    $,#(R,: !  ,    !__\  * "  0
M   !   (RJ #  0    !   %,0         & 0,  P    $ !@   1H !0
M  $   %N 1L !0    $   %V 2@  P    $  @   @$ !     $   %^ @(
M!     $              $@    !    2     $X0DE- _T       @
M 0   /_A 8!-30 J    "  , 0   P    $).@   0$  P    $%B0   0(
M P    0   "> 08  P    $ !0   1(  P    $      14  P    $ !
M 1H !0    $   "F 1L !0    $   "N 2@  P    $  @   3$  @   !X
M  "V 3(  @   !0   #4AVD !     $   #H   !(  (  @ "  (   #P
M  $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z
M,#8Z,C,@,#@Z,C4Z-#@   20   '    !# R,C&@ 0 #     ?__  "@ @ $
M     0  ",J@ P $     0  !3$         !@$#  ,    !  8   $:  4
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M6RKI31HOMOHLB;%V_&T&1.@>P[07V!U!./;ZV-M6S]HNE&TMY=G:+<-H$KV
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M^";*+^V81_KU?_2'#LXG>A.T?E7_ (?7]37;K^"=1?ZV<?!-E%_;,(_UZO\
MZ0X=G$[T)VC\J_\ #Z_J:[=?P3J+_6SCX)LHO[9A'^O5_P#2'#LXG>A.T?E7
M_A]?U-=NOX)U%_K9Q\$V47]LPC_7J_\ I#AV<3O0G:/RK_P^OZFNW7\$ZB_U
MLX^";*+^V81_KU?_ $AP[.)WH3M'Y5_X?7]37;K^"=1?ZV<?!-E%_;,(_P!>
MK_Z0X=G$[T)VC\J_\/K^IKMU_!.HO];./@FRB_MF$?Z]7_TAP[.)WH3M'Y5_
MX?7]37;K^"=1?ZV<?!-E%_;,(_UZO_I#AV<3O0G:/RK_ ,/K^IKMU_!.HO\
M6SCX)LHO[9A'^O5_](<.SB=Z$[3LJ42WCM@T>FWT.Q,C";O5:];Q<8BVRT0C
MCK*(AF83$YJ,_*CMS&HTUIN4VQ*DLH?2M+3[R,)<5YG/$Z"::!ZHKX99(G*V
MZM5T;U8Y6JJ(ME5%M=$6VM$+DTZ3E7*@. . 8_,:FU78;S7=GG]9Z_.;*J$5
M^#4MAF*97"=YJ\*3ZWQ,.NVV:-?/A(LCXF1Z\<80C-.^N]ZB%>JOS >%0U%J
MC7QZVVJA:PUY2+/?Y^"E[L=0I5;K1ZZDTNOOI(VTP&&PB%DGX>E27L2S,B;(
MP[(?<PYYWG,J R'P"*?1+]"7J%^[+HO\,ZSP2NM>=>LE9P0. . . . . . .
M . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
M . . . . ?'@["0\D>SV\!Z7,-*G[YV7#2[E.58;S*V":8PYE.,IRK",K\V4
MXSC.<8]WOQ_SY]CX:[,PB@?:^9AU*ZW'FTT:V]1H+I<J<OXDZ]O^%\BM3=^U
M+0^\"&_MK=:]E5/6&QM:XT;<M?D#)VY;8@:1#M:Q-O&[:&O$]S8QH&/P&<>!
M$)0@@Z;'(FL#9[+/ 4>5?"IA\N(4#<.I,3I9JJFJ>_X*EK(X*1U:_OJ-K(I(
M&][LD=GV>U'MS'9JN;?-8[7LMU1414M;6MDMI5%T\Q&E'A[=OWK)]%HFH5$9
MV*&1V;DH*OFLBU.31 UQ&:^-V->P1ESET-$0%=C(NL'6563$T(7G1HI6+$4Y
MCG*+E)@J1<*ZMS6]\,I<U]/5,FX>2%U1''WNZ!)U62!CI(UX/->UJJQ5L8YC
MKVMIU[-6K7>QEG;'A>=AM8'?H/%B-7_8&;35J_@?3<AI=)1!.:'C;W.&R&QY
M=DC!*_&I8'!=%AS9XP2!# @Y=VE%8E>?B..Z='E9AM6SAW*M-3I#+(KI\])\
MZ/$%H(XVTK8EDD69^8L?!*]RR2) C'2(ZV2QN3E551$MJTMOKOL_,PCLOIKM
M336H[=LK:4=%2+U;9^IM?LT_*Q9YBQ!]OZWOVRZS?J[=*V9+58[6)(>CY;@S
M <HK *?-4/1R2/@7V%[]+C=)75D-+2+PT<M+65"S_'C6)]'4T]++3R02QLEC
ME1\]W)(C'-S+*Q<Y%(5BM2ZZ-*);CNBK>^K82[JWA;B;@!U2-%=AI[.X=O\
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MYNV2",>L1;Z!<MNM=AZ_&[#UQ.)*#P]EZM+7BL@!NR=?R2>&8J+53I1<8E)
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M(NP1M45 %V4I+O8C=6@ 6_=<Z.*T*^#$6>#8*D6N@VA#]E,Q"529O104#)Q
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M_P#PSK/_ ,^"5UKSKUDK,+2KWX2I*LX_Y^[.,^[W_P#[?_MP0>7 ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M6NPAM$K/9/=UK!=<*9<BUM0_,HE1CHVK- 25;%,P&)'QM:@,2T#LPI!69*B
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M\ ^KB770F,']?_#^)W2N>*FP. . . . . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . . . . . =(;:GLI_8+8.S]CW
MV'VMTX/AW>^W"WQ1\FF79V3!C66PD3+$.0ZT[AIQ^,U-2RZXW_1K<0I2/]G.
M.>XT?=8P^FI*6F=A%8Y:>GA@5R3P6<L4;8U<EVW1%S;VV7-=8%557.37Q' O
MR1_L5_:YTK_!%Y_S>;'PO8=_<];_ +B#L(X!?WD]"C\D?[%?VN=*_P $7G_-
MX^%[#O[GK?\ <0=@X!?WD]"C\D?[%?VN=*_P1>?\WCX7L._N>M_W$'8. 7]Y
M/0H_)'^Q7]KG2O\ !%Y_S>/A>P[^YZW_ '$'8. 7]Y/0H_)'^Q7]KG2O\$7G
M_-X^%[#O[GK?]Q!V#@%_>3T*/R1_L5_:YTK_  1>?\WCX7L._N>M_P!Q!V#@
M%_>3T*/R1_L5_:YTK_!%Y_S>/A>P[^YZW_<0=@X!?WD]"C\D?[%?VN=*_P $
M7G_-X^%[#O[GK?\ <0=@X!?WD]"C\D?[%?VN=*_P1>?\WCX7L._N>M_W$'8.
M 7]Y/0H_)'^Q7]KG2O\ !%Y_S>/A>P[^YZW_ '$'8. 7]Y/0H_)'^Q7]KG2O
M\$7G_-X^%[#O[GK?]Q!V#@%_>3T*/R1_L5_:YTK_  1>?\WCX7L._N>M_P!Q
M!V#@%_>3T*/R1_L5_:YTK_!%Y_S>/A>P[^YZW_<0=@X!?WD]"C\D?[%?VN=*
M_P $7G_-X^%[#O[GK?\ <0=@X!?WD]"C\D?[%?VN=*_P1>?\WCX7L._N>M_W
M$'8. 7]Y/0H_)'^Q7]KG2O\ !%Y_S>/A>P[^YZW_ '$'8. 7]Y/0H_)'^Q7]
MKG2O\$7G_-X^%[#O[GK?]Q!V#@%_>3T*/R1_L5_:YTK_  1>?\WCX7L._N>M
M_P!Q!V#@%_>3T*/R1_L5_:YTK_!%Y_S>/A>P[^YZW_<0=@X!?WD]"C\D?[%?
MVN=*_P $7G_-X^%[#O[GK?\ <0=@X!?WD]"C\D?[%?VN=*_P1>?\WCX7L._N
M>M_W$'8. 7]Y/0H_)'^Q7]KG2O\ !%Y_S>/A>P[^YZW_ '$'8. 7]Y/0H_)'
M^Q7]KG2O\$7G_-X^%[#O[GK?]Q!V#@%_>3T*/R1_L5_:YTK_  1>?\WCX7L.
M_N>M_P!Q!V#@%_>3T*/R1_L5_:YTK_!%Y_S>/A>P[^YZW_<0?^HX!?WD]"G=
MWU/3I.N]6:UU_-F,$9E&H%.ITLA%0XU&G2:S71P5^9':=_I6V)3L)3[3;O\
M2(;6E*_]K&>>&U4R5%34SHBM2>>:9&KI5J2R.>C57:J(ZRKM4V4T(B<16_WR
M/[IUWNS5FQ-0VF]Q4/ZNN5+L]*B='^P?<_6QZ/+M5:.C#9H=I[9-!%TFW I(
MQZ.$F3EN%28LH69<7)@L,-Q*!:^Q%M9;JJ);7J547U>K02OZ5;D/[YT"!V)9
M[,/MAN18[O72),=HZ_=<VX\ZG6PM5B .9J/9MTOUTJY:O$1,L&8:,6)UYXI
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MIJ? +PQY,=+ALB">' ' 'O\ _P#7\W ' .A][0!]6[X,7V.(_!72'/9.X_\
M*L<\WH?:5!34;/K*>Y[,]^CCXNWV+:^^XG9+G)=U#YRR2\ZJ?>,.,(=4G,G4
MXZX?1C]-GIY^]+U^_%FI<]+R@^8L:^RL0]TE*F>&WZS>M"Z;VI_ZRNK?NM:O
M^^^UN=)[E'DU/]JU/N](63^&GU4ZU.Q_[,E]5A3_ +9MQ_WY#YYMW3_*NH\S
MHO9%L/@=*G8,YYZ6C@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@
M#@#@#@#@#@#@#@#@#@#@#@#@%,GBB[Q:UI>]+ K-8]&ZVI,D2B=.M&Z]>T:X
M9VJ(N>Y-1:CVWHNIV'8V?HS31LS3UVLUGV:TS'GV.RU9F"H:S$!UNU3F0]?-
MQ[%U+MM;5Z50E1X;9H$6ZLA(-.':P;UY4=A;>I&M;3I>A#M8ZMV;0JMLFR#
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M2"DZV =DZIV60/ A5A%B614O#+ <(3F2,1DM$BK[CX=%]^0D3J37YC6-)@5
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M+4<U=".15Y%125W.*)' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M?7S]JZ[[-NE9$VOJ/I2Z6,Q:SS&TU&3LYTB14'[$=AZP,S*>]WGS" 5C:8<
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MVGY=Z/I_(_\ :P$^786O"HOO9-F_3M%DY?2O::B:H&2\E]."OJ(FQ""??8;
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M<V/-SDC<JJC470ETS8[^C5SKK:_.2.Z7^T-=3>\'936_5_6FH.Q%9NNSE6I
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M YDD-$YEV61DJ^OX6#@&",JP^E7QJ8;.4/+ Y"JYUC86K#%LHAMJV 3==L;
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MM7DC8]@)L4FL@K&4^/-5\' KQ,;'2!%/J8(K">VO8DN-F0ZX;8/;5!E=6.Z
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MP*5%37!DH<+A7J=GZZM7X]I"[ZM/)IWTD]NU:U(ZV[ORE(A7FUI:VUX/!DV
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M35<K,R9&E7*%JBL=D9#\XF\-6N=6LE]2OE&RSX\B9#PR$/U80&?=ZOE7ZS%
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M?]QI2IX,/UI?2/[;!']UE^=YRV\E,<\R=[2,IC\-O.9H]H3^MV[8_P#<TW^
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M'6X7$ TNVVJAD Y8]>-?.!6\[D!:UAES==L,2VBP<DE*K<H043'/B1.^K?\
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M<V_#V&O,SE<5Y6R2D)^.IMZ%"&,+Q#0">BV^@EQP"O?Q'+B_K_4VO[?]*+:
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M,>,C]:/W=^W>R?\ T('/K#(KR5P/S%GWGFG+XQW1]U"['QB?J(O!S_9W3?\
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MW,G6=8R[?G0MW[>G_O#+YZA!\CA\VC]DA0=JGVMO\_'3G[&;[]\AG/)^X_\
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MP0. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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M(;@#@#@#@#@$4^B7Z$O4+]V71?X9UG@E=:\Z]9*S@@< < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
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M62#ED%F'U$!OE7J"D:]H<@7#AOM1A,L368ZY,!#+TN7/D*7+=#?>]U,M< <
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M?:0OS);>7&CJ=1C"U,-95EM(R76O.I+'@@< < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < ^.IV2_2.WW]MNT
MOOV=Y]D89\U8?]GTGNT9HO\ #=]9W6I]?K7?YOZ+^QU9_N2#SX]J/E$_\:7[
M[C>.8\I X X!Z$P6,(NPGR Z!.>&R<3!STR)'DNP)>$Y1B5"<>;6N+)PA2D8
M?8RV[A*LI\WNSG' # L9%FS2<8= CD26&$D2#$2.U-GIBHRW&3-E-MI?E8C-
MYRAC#[CF&49REORXSG' /?X!%/HE^A+U"_=ET7^&=9X)76O.O62LX(' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M1FS;2>S5UWVR0-6ZPN.S'J!KILD^(SL"^IJ0PBJNUIXC"*1QOJ)?,G/D5D>
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M?C6JX00%:NNP:IJ>M%[Y:*!6+%LZ_@*D@!2 -A*5(P]&*VC(:-$@C#9:;E@
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M(#4NV:5NVD0M@4&82E 99:T5Y]DV",U<\'LE(LY>EW"MGZY88(TV$.5NU #
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MF#@D< < < < < < < < < < < < < < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < < < < < < < < < < < __
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g393013g63b14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g63b14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1QB4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %P< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0! 4$L@9&%T82!'<F%P
M:',@-"!C;VAO<G0@*$AE;'9E=&EC82D@,#4N,#@N,C Q-R H4T5-($524D]2
M($)!4E,I(#A"24T$)0      $)@FSQ8Z@B)2A85]PMA]#:\X0DE-!#H
M 4T    0     0      "W!R:6YT3W5T<'5T    !@    !#;')396YU;0
M  !#;')3     $=R>7,     26YT965N=6T     26YT90    !#;')M
M $UP0FQB;V]L 0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R
M3F%M951%6%0    G $@ 4  @ $P 80!S &4 <@!* &4 =  @ #4 ,  P #
M( !3 &4 <@!I &4 <P @ "@ ,  P #  ,0!% #8 -@!$ #  ,@ Y $4 *0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M    3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT
M<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D
M;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!O
MX            $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L
M=                %)S;'15;G1&(U!X;$!W:7"@        "G9E8W1O<D1A
M=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N
M=$8C4FQT                5&]P(%5N=$8C4FQT                4V-L
M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    %HX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              4<   ).@         !
M                          $             "3H   4<
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   4<     %)G:'1L
M;VYG   ).@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   %'     !29VAT;&]N9P  "3H    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     ,X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M      $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%1
M81,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"
MHW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W
M1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%
M,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55
M-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=W
MAY>GM\?_V@ , P$  A$#$0 _ .6ZOU'KN9U3+R+;LMY?=9MVFW8&A[MC*@WV
MMJ:WZ&U4_5ZQ^_F??<O>>@._R%@DR8H9Y\-4V]3HR6BK$NJ;F. <,>UPWM'M
M<\64L=ZC7-K<I_?K3A&B_BKH^!^KUC]_,^^Y76/:ZMN^_J]5H:T/AIL:Y^V;
M',_28[JJ_6]C&?I?T?Z3_@U[Q0ZZ-E^WU&@$EDANL_O?U45(Y_ZJ.+P? ]]8
M<?UCJ[FEAVG:6EK]S=F_]*_U*O3W[]OIOWJ(L_2.F[JOI[1L^ENW?G[]=NW^
MJO?DDO?_ *OXJXO!^>LB[.+VG%=U ,+?<VUUA(=N?HUS-FYOI>E^;_.>HA>K
MUG]_,^^Y?1227WC^JKC\'YU]7K/[^9]]R]*_Q2Y_4[\?J6'G66V5XSJ7T-OW
M%S1:+18UCK??Z7Z!OL_KKT!9M'_BCSO_  EA_P#GWJ2$\O%$CA 496-GD/\
M&WG]4IIZ;AX5MU=62;WY#:-P<[TO0;4'NJ]_I?IW^SZ&_8O-O6ZQ^_F??<O>
M+_\ Q18/_A/,_P#/O3E;R<NG%V&Z6L<2#9^8V!NW6O\ HL_=2CEX8@<(*A*A
ML_/GJ]9_?S/ON5RE\U,]?(ZLRT[?4V-<Y@]T6>GNMK>_]'[V;OSU[HW+];;?
MBV57XD$.<UVX[PX-]KV;J_;[]RM(_>/ZJN/P? ]U>T?K/5RZ9)],@0"[V#],
M[W/;L_2?X/\ T=J;U&BUS?6ZL^J6;+8+'1#S<#3OM_/]*NG]-_I++/\ 1KWU
M)+W_ .K^*N+P?!FV8OJL#[>M"J'^H6:NW2WT/3W;?9M]3U=ZHWW=2-S_ +.[
M/%,_HQ:ZPOC^66;6;E]#I)#/_5_%7%X/SKZW6?W\S[[E>Z'U'KN'UC"OKMRF
M@7U-LWFW8YCGL;97:'>UU;VKWQ9OUB)'1<J#'L ^]S4O?O3A&J>*^C__T/1/
MJ]_R'@_\0S\BNWB\U.&.YK;?S7/!<W^TUI8[_I*E]7O^0\'_ (AGY$:RK,.5
M:ZEPK8ZJL,L=[@'A]A?%.YO^#=]+_BT3N?-1W24"X/=ZQ:Y^ULE@('+_ -YS
MT= H;:U[A:\6/#6RYK=H.K_S=ST=!2DDEF=8^LG1^BOJ9U&XU.O#G5 5V/D,
MV[_YEC]O\XWZ20!.@U4Q^M/5[^B] R^J8[&VVXS6N:RR=IW/97[MON_/7'?5
M3_&/U3K'U@Q>EWXF/55EFS>^LO+ALJMO&W>[;]*I:?UMZ[TOK7U'ZQ;TZTW,
MI%;+"6/9#B^I\?IF5_FN7 ?XNO\ Q:]+^-__ +;Y"GA >W,D:B_R7 :%]R6;
M1_XH\[_PEA_^?>I+26;1_P"*/._\)8?_ )]ZDH1U\EJK_P#Q1X/_ (2S/_/O
M3EI+-O\ _%'@_P#A+,_\^].6DD>GDII#.KR*6%C+ +6[VDMD !P9M>]FYC7J
MZJ.([=TRHF-Q:)VM# 2#[G!C2Y7D%*220\BYF/19>^2RICGN U,-&XPDI(N-
MZ_\ XR^G]$ZOD=*MPK[K,8LWV,+ T[V,O&W>[=]&U6,/_&-T+,R<?'JJR@_*
MLKJKW5M #K7-K9O/JGV[GKS?_&+_ .+;J?QH_P#;?'4N/'<JD.EK@-=7V+H/
M6*>N=)Q^J4UOIKR0XMKLC<-KG5>[87-_,4?K%_R+E?U1_P!4U9G^+G_Q%],_
MJV?^?K5I_6/_ )%ROZH_ZIJ814Z'0HZ_5__1]$^KW_(>#_Q#/R*]<VQ]3FU/
M].PCVO@.@^.T_25'ZO?\AX/_ !#/R+11.Y\U'=!0VQCW-M?ZCPULO@-G5_YH
M1U3R*+!CWDW.)>#!  ($N+&M]-N_V;MJS\!C_M;2ZVP%NL%]CQ[@]K?4;;C4
M,;_GH*;EO7^BTV/JMS:665DM>TN$M(T<URXK_&=8RW(Z3;6X.K?3>YCAJ""<
M<M<%K9O0,*[.O>\VS=:XN<'O'N<YVX5L&%8QW_;Z-U_ZM8'4:NGMO=>3BU&N
MD,<YGM/I ^HYF+D^[]'^<VM20,8R!U2*#QV#_P#D]^LG_&U?^ZZQ_P#%U_XM
M>E_&_P#]M\A>B8?U3Z8/J]G]-:^_[-G['VPXN?+=FST7NQ:O;^B;_@'JG]7?
MJ/TGIG6<?/QGY OQ]Q8'V%S8LKMI]['=/QOS7^W]-_ZD?[L>&8U]6WV)L47N
MEFT?^*/._P#"6'_Y]ZDM$ @ $R?%9U'_ (H\[_PEA_\ GWJ2A'7R6JO_ /%'
M@_\ A+,_\^].6DLV_P#\4>#_ .$LS_S[TY:21Z>2FJ_$QZJ6AC!^BTK)]Q:'
M.:YVUS]SOS4K^IX5%IJML+7MB1M<>=>6M1;JGV;0VPL:"2X  [O#Z0/T7+&Z
MIC$Y3WR7$@23O:-!#=:L7(:D*ZJ1?6W/M'2L7(P;[*A9>!OK+F$C9=[3]%WT
MFK*Z!FYN13U5N1D6WM;AN+6V/+@#%FHW%;/4^ETY/2L?'>^PLJM+F !S73%H
M]\8]MGY_^A0NC]$Q*&988^T#(J=38"7.]H+FNV.LQ<?])[OW'IPE'AI=8I\S
MZ!_ROTG_ ,-XO_GVI1_QB_\ BVZI\:/_ &WQUVW3OJ5TK'S,:UC\D.Q[*[JM
MSGF34^MXWUNP*_9^]^E4OK+]1ND]2ZQD=1R+,GUKPPV;'EM8+&,H9LVX&7^:
MQF[]*I1ECQWK54KB%NK_ (N?_$7TS^K9_P"?K5I_6/\ Y%ROZH_ZIJ;ZN]+I
MZ3TG'Z?CN>ZC'#VL]75^KWV2\^EC^[W_ .B8G^L7_(N5_5'_ %35"3<[[E'7
MZO\ _]+T3ZO?\AX/_$,_(GM;GY%SL?)Q*'X)?](O+G%C8=6XTFMC6V>JW_2?
MZ/\ L-]7O^0\'_B&?D5FU]EKK<>E_HV-:QPM@.^DYTCTS_)K1.Y\U'=>BJJE
M[JJFAE;6MAK=!R]'0*&6,>YMMGJO#6R^ V=7_FM1T%*223$@"3H DII=:ZMC
M]&Z7?U/*8^RC& <]M0!>07-K]@>ZMGY_[ZP.A?XQ^B=9ZK3TO%QLNN_*+]CK
M6UA@V5NN=N->1:_Z-3OS%:_QA$'ZE]3(_P!&S_SY6O,/\77_ (M>E_&__P!M
M\A2P@#"4CN+7 :$ON2S:/_%'G?\ A+#_ //O4EI+-H_\4>=_X2P__/O4E&.O
MDM5?_P"*/!_\)9G_ )]Z<KN2<EM#SBM8_(C]&VQQ:PN_EO8VQS6_V%2O_P#%
M'@_^$LS_ ,^].6DD>GDISV4W6&S+S,>JK):-E3ZW%Q%<[H-D,]V_^2M!9N,,
MFS%;:ZPMKVO:ZEPWDD/=M?Z[SN^@M)!2DD.Z^BAH?=8VII,!SW!HGP]R$[.Q
MG4VNQKJ[;*V.?M:X.X'YS6'Z*2FRH/L#8&A,Q$@?E7FO3_\ &+]8LC*Q*[*\
M0-R+::[-M=@,6/8Q^W]8/YKUS?\ C)8P_77J)+03%'(_X"I2QPDRHFM+7"+[
M@"")!D+.^L?_ "+E?U1_U35D_P"+, ?4GIP&@F__ -N+UK?6/_D7*_JC_JFI
ME5*NQI'5_]/T3ZO?\AX/_$,_(CV5VU7VY=8-I<QC!0(;):Y_OWO_ .-0/J]_
MR'@_\0S\BT43N?-1W04/>][G65FIQ:V6$@QJ_NPN1U5.9BL=;:;&EK&@.VF3
M+2]KV[6^[<U1JZMA6V"MKG!SN"YCFC0;OI.;M04W%RGUV^M/4^@W8=6"RA[<
MEEKK/7:]Q]AJ#=GIVU?Z5RI=1^LGU@ISLNJA_P"BJM>VJ*-WM:?9[X]RSO\
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M[_OGZ3^;7ERZ#ZB_\OM_XI_\$1PV-U"G_]DX0DE-!"$      %4    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !
M?DU- "H    (  P!   #     0DZ   ! 0 #     04<   ! @ #    !
M )X!!@ #     0 %   !$@ #     0 !   !%0 #     0 $   !&@ %
M 0   *8!&P %     0   *X!*  #     0 "   !,0 "    '@   +8!,@ "
M    %    -2':0 $     0   .@   $@  @ "  (  @ .2AL   G$  Y*&P
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP.3HQ-2 P
M-CHS.3HP,@  !)    <    $,#(R,: !  ,    !__\  * "  0    !   )
M.J #  0    !   %'          & 0,  P    $ !@   1H !0    $   %N
M 1L !0    $   %V 2@  P    $  @   @$ !     $   %^ @( !     $
M             $@    !    2     $X0DE- _T       @          /_A
M 8!-30 J    "  , 0   P    $).@   0$  P    $%'    0(  P    0
M  "> 08  P    $ !0   1(  P    $      14  P    $ !    1H !0
M  $   "F 1L !0    $   "N 2@  P    $  @   3$  @   !X   "V 3(
M @   !0   #4AVD !     $   #H   !(  (  @ "  (   #P     $   /
M     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#DZ,34@
M,#8Z,SDZ,#(   20   '    !# R,C&@ 0 #     ?__  "@ @ $     0
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MY&(B(UC+E14OO55)2+0W,QWWN3A-_"OG\]8H!0%1_7=\DMS-^A,+];>OJV_
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M^%M7C%.5,T\NVWYE_P!7/RZ* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H"@KK%>-YT2_3[#_Q$(K?\#>U&&_Y>D_O%J3+'
MY:<*%^M: 710"@*C^N[Y);F;]"87ZV]?5M^ 7==8OGY^)U!1)I';1.+AUXHO
M%CT<='^K*,5@;8[;6IZ1K>,RE29$VDX"1U8XD4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0% '1"_7#UC?VF^Z_P"<%ZZ!
MAQ]CP-_*]#^E"S%II?.+P(?>F'Y5SKF_6EQB_!VRJ83]R> OX6U>,4Y+-/+M
MM^9?]7/RZ* 4 H!0$&^H3MO=.H^-TX*:&BLX)SPC&IIBA.(3%A4S=:I9@X3(
M)'E,5(V67Q:E"#AX+91P!BY8E1@PL91D9D4:&@UX\:$IE(+S_DSR%QE4P5C.
MR-LQ^0JD91^DO5#G6T4>*\=N.EFNIU@.]0X[+7I@IG-AT=-2"1L+&SLYC\DD
MI::A+QLXEK? %&@]73=X/%KXYQ<=]J[B/:S7)@@Q/D#%\=C[3%0/:LEE,4A1
MB9:Z#S,@RAYM=%E% XHZSR:8N1 24C [%M*H^&%2>ZA50UD9(""5FJYXWVEK
M2 [):#'81M/(A'Y:@'?K-G#T4F?%MB6(]VNSS4:+N&=G'N=59MGF@IFG?-+*
M^&5J []0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0%!76*\;S
MHE^GV'_B(16_X&]J,-_R])_>+4F6/RTX4+]:T NB@% 5']=WR2W,WZ$POUMZ
M^K;\ NZZQ?/S\3J"B32.VB<7#KQ1>+'HXZ/]648K VQVVM3TC6\9E*DR)M)P
M$CJQQ(H!0"@% ?SEW7<Y=QW/=]S?N>Z[?<]UVOZ/==KY>Y[?:[?:^7M?U4!2
MP'Y3\B1^\(M&MD[GUPZ'B]T7UN3UIKLO!M=[!V&O(^3<OU2Q>QS5D_U/M^53
MK7\"C(V/N)0XA^X=<RAD#93B5%#2CEF*'T)U,G3;Q9<>*[6+)6^^2J$W@,*E
MNA]Q0''9,H+PZ-2J2$-&DHWF=$02:[%R;ODX-NJ8RAHB^CD!/Y,G-XRHC9]B
MS:OLF7NGOB8@D)0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@* .B%^N'K&_M-]U_P X+UT##C['@;^5Z']*%F+32^<7@0^],/RKG7-^M+C%
M^#ME4PG[D\!?PMJ\8IR6:>7;;\R_ZN?ET4!!_J&\@9[QLXT$9[K+(&.FDBVC
MHK3P>82L9F9B.M?TW[DA&J'>S).+P?#<2 V$,I:X-MV#A^U8/S#<6R)*V'N'
M5KB42]<>LJ[B*MWKNN.Z\<<]C@I-NC6>R^3T*Y(EH*>A[@=BA&H3$-R:Z%2R
M*-RZ8+<@/7GO3%.Z,N4W)R %&,(B"[^,K*)/<#3AED3R!=J[@]1*NA H!0"@
M(]\3/%@X_?4_K[\,CJ D)0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0%!76*\;SHE^GV'_B(16_X&]J,-_P O2?WBU)EC\M.%"_6M +HH!0%1
M_7=\DMS-^A,+];>OJV_ +NNL7S\_$Z@HDTCMHG%PZ\47BQZ..C_5E&*P-L=M
MK4](UO&92I,B;2<!(ZL<2* B[S;W7,..'$'DIOK7\;2ELVU%I?8$^BX!R@Y=
M,79J.1U\08KE6K+--XY##5D<2AINT51<K"F3Q-!9%7+!7 2F-4375##O%HU,
MP,WQC^Q.>X/DXK,= ZZV\V@,FAVE8K.(WG(2CYF[V3"RFH < :J:.E2F:0B.
M!I=%YE(61-A@M^DXA@LLS<@MVM=N_/5Z7$^+D1]L+9W?L[87<)M+9W=(=Q=T
MMCAFBVMEW?:NX5Q43R31[??,\<\+XXWME;MB#^T7C-SE?!NZ;+YVP[Y?%%=)
M7*R??5$.[OCAEE?N._HK(]UVNY[ZDHGV^[PRM8#^?<#'OR3GW$T]T(9N%$%_
M<Z/?D5'?R.LTE>X[M/-S:UK.,L,K76[7^\OE0$?]V_K+X?>D7)O^DGE'0$BZ
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!0!T0OUP]8W]IO
MNO\ G!>N@8<?8\#?RO0_I0LQ::7SB\"'WIA^5<ZYOUI<8OP=LJF$_<G@+^%M
M7C%.2S3R[;?F7_5S\NB@.M3&&1#8D6/0:?1:/3:%RH8Z"R:)2P,/D,;D A[A
M=-V,-!"S=V-)L'*=^Y6:/&RR"EO^]A?M6H"M[D1TKM![3U=&M3:FB.L-'Q03
M)=OS4Z.$ZT'EFDKFFQ.,NX=!Q>6F\$B(ER3D>O3NQXS/@IDLZ)$4,H )$"G
M=7 85$"47'>N/)JZRHOR, $ND++$9KJDU#]\0*-PS4_($5O<%"[Z%'N"+!PC
M*=(R241J+SI"9M)!#Q^P;:QEK*:HB,;B9%^D4P[/A3+I5XH["_%=XKLNWRXM
M5+L2H34X"\-"?"J [ @I*>@MC^&^P,=@HG!T+=Q!^%]V1.-@58"C9W*I5FOK
MN!J O!_3 /W2AE =7-XY E53*D>R/E 5;_%TR^O*NNMZZI/&A H"/?$SQ8./
MWU/Z^_#(Z@)"4 H!0"@% * 4 H!0"@% * 4 H!0"@/PD28T.S6(ER#(6/;]Q
M[H?$72#)FA913%).ZSIRHD@E;-7/!/"ZF>-LE,\<+=O+*UKRUKG*C6M5SER-
M:BJJZN)$QKB!U*^TM964P1OL:"664P45P2O+X_93--+)+%53##WP[K+!/)9'
M%3.UKXX9*I6RO:ZF/;N]35%U_4\UV2_0I+K]:_.@[2*,ASS3W>#*C3+&ZF:-
MGHI\V(-+K)]KOB5G#159&ZB?=8]WA;/NL>W;MVMV[5;<QS%SKVN8ZZ_.N16K
M<N1;E1%N6X')52!0"@% * 4!05UBO&\Z)?I]A_XB$5O^!O:C#?\ +TG]XM29
M8_+3A0OUK0"Z* 4!4?UW?)+<S?H3"_6WKZMOP"[KK%\_/Q.H*)-([:)Q<.O%
M%XL>CCH_U91BL#;';:U/2-;QF4J3(FTG 2.K'$B@/\ET$'2"S9RBDX;.$E$'
M#==/!9!=!;"Z:J*R2ELDU4E4\LL%$\\<L,\,KXY6OC>]J @M/^G9Q?.PIK ]
M::7T9I8 _P!U:;V_L$;"-'P,>)V=AJ*=,)HE%YB("-(ZS,-C5FKL4F^,6+HA
M\"+ES@)?XYK-%Q-^OCRY?&5MF>@^DOI#'2,9Y+1Z.!W,;U<-+OL^-8<C=W+]
M;Z'(::RV:+NVVJ'/1N;G2;M":O"@>3HJ.L$%HO)\Y8S6;DF(F_'?\]=;[E\6
MX6/<1>$RW%G9_)'9>6Q@DU6Y*2[&=G@P[5K""MX:>3E4\,XB8:]:RL^Z;018
M9+FSU]%"?OBL[VFXV1M?W\2(;2, 18IUO%_CDW+DU">E 1TW;^LOA]Z1<F_Z
M2>4= 2+H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0% '1"_
M7#UC?VF^Z_YP7KH&''V/ W\KT/Z4+,6FE\XO A]Z8?E7.N;]:7&+\';*IA/W
M)X"_A;5XQ3DLT\NVWYE_U<_+HH!0"@% =1G$_@NL8V\F.R)G%8!$AZK)N_D\
MTD F+Q]FX)/$1XY!T8-.V0]!=^_<MV+)%1QBHZ>+HMD,5%E<,,@,>H<FN-[I
MT>8M>0&E'+R+0JVR9,U0VE!UEX]KS(4(.VG9I),YEF+AWO'( !F\F>V1#6%'
M0Q&[VS0HQ6<!==P&1X7.(7LB-#IGKR71F=Q Q=Y83*8>=%R6.DKCG[H60Q8&
M0SIX.=Y,";)Z->XH.,\FC]HZ9KV3<-U4\ ,2<3/%@X_?4_K[\,CJ D)0"@%
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M0&M,GK')A#G;A5HJF[4;)-,5UT0\9,:@% * CWQ,\6#C]]3^OOPR.H"0E *
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M\[\N0L^.G7B3Y9PDZ-EU\%"+D#.] 1TW;^LOA]Z1<F_Z2>4= 2+H!0"@% *
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M/Q.H*)-([:)Q<.O%%XL>CCH_U91BL#;';:U/2-;QF4J3(FTG 2.K'$B@% *
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M0%+_ %\O)RSOZQM5?BE&MPP%[H8/P]5^TH-#>NX 4 H#>K['V\GJ-^N/9O\
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M=IFDX5R=-G"^*"R(=.F,F]0"@% * 4 H"K?DMU3M9\9MQR?34CUE.I&7B[<
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MO[3?=?\ ."]= PX^QX&_E>A_2A9BTTOG%X$/O3#\JYUS?K2XQ?@[95,)^Y/
M7\+:O&*<EFGEVV_,O^KGY=% * 4 H#K$T#DY!%3P4-)CD-)D1RS9G)XRB$7D
M 93*UKY.@Z<C#R )[ONG;-)NH1"DD4<U++6;9JII]H"@>&8<Q[:\AF993FQ?
M<.>O0B/(_P!V?I[N!PT=A!M(^Z5-3)DL? C'DI9@I)[V4U7A^GM78.6Q;'KY
MED!F*)<J]-76U-Q!N+EN_P ZJ>LLSX\9<A$-:+I1-FX>1'#8^T\( IRA*[H9
M[@MK7&9D+0NTEO.Q)+93CM-_=V(1;8ZF$OSB>,;S*]]6SR5R#ITU#,/$'W5?
MBOQUN]LAB]OIC7/NO%KDIFUQ=>"HSW19MDMC@KDA97N[(Y*X8*9)]S?/''*]
M[6 D70"@% * 4 H!0"@% * I?Z^7DY9W]8VJOQ2C6X8"]T,'X>J_:4&AO7<
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M!(2@% * 4 H!0"@% * 4!2_U\O)RSOZQM5?BE&MPP%[H8/P]5^TH-#>NX 4
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M_$2GR7@4UKWG/OF20;*-'?(78*C=7N.^88OF25[]QGBICVE$6*:F/:SPQO\
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MG%X$/O3#\JYUS?K2XQ?@[95,)^Y/ 7\+:O&*<EFGEVV_,O\ JY^710"@% *
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M7>O['1(H+N%B%C;Q[&B9H7DTCS$<.9"S1 0/;-AJON:P&1_]EG6?_F?D;_\
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M..C]!X5Q'V+GP3 :MVWO;86K';"#RSDULD1(M6PTUNV'ZU>;,O((YNTR+)O
MY&4 B<3&AB/OL456<DET!C&(S/,#2_"C".5CXY+<M1\<C7,>QU;4*U['(K7-
M<BO5%:Y%5%1<2HMRXAG&]ZW%JHWQ7ZQL,?[+.L__ #/R-_\ K#Y<?G?6!),J
M0/7@#7 UX*CQ"<D6KY]<@LK/-G[*VF2P7N@BV[VS,;/ELO+CV/>T,,K#&#YL
M-LODLZLTLZ<.%E0.\T H!0"@* .B%^N'K&_M-]U_S@O70,./L>!OY7H?TH68
MM-+YQ>!#[TP_*N=<WZTN,7X.V53"?N3P%_"VKQBG)9IY=MOS+_JY^710"@%
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MW,S4Z"BG"(?6D3DUUQ)]H<F0TT%(C6,D:#![<]$LW7O;+6KJ.LG[(IFNQ;8
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M9BTTOG%X$/O3#\JYUS?K2XQ?@[95,)^Y/ 7\+:O&*<EFGEVV_,O^KGY=% *
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M\_$Z@HDTCMHG%PZ\47BQZ..C_5E&*P-L=MK4](UO&92I,B;2<!(ZL<2* 4!
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M% * 4 H!0"@.B:ZM_P#I\C].]I>LV75?J/K&^8I>+1 [W5@"@% * 4 H!0%
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M;%$0_)43O>#9KK)S4E&VT658N;,U+"R&!;)D7R5:8#5W.3QK9403*H!0"@%
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M!0"@/1#[%9\FQ-?2OV?ZO-.U\Y9JW=/%Z*I?WZLR-/\ 5^O_ $M-E6N:%\4
MH!0"@*"NL5XWG1+]/L/_ !$(K?\  WM1AO\ EZ3^\6I,L?EIPH7ZUH!=% *
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MNK7S[[VLK88^UN#UKI?G[-J7+J9V6%FZBH^_=3:%RZR[BG!#NHKQF71S4?\
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M2V:ZE4.=05Y$A3&)[.FP&*RZ"MVA^8NY5W^'; <B2"T?1LA'!APL]?A=??\
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MV:!-6$8>\V1$-R8D6"4:2EWAQJD$\UD">BY3&01ZY.7+Z_FK(^'_ !PJ;!-
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MBKLF9[VFJ?24W%J0&OU6^ 4!^IC_ &UG_P 4W_U<*A<B[2\ /58;_P!G0_\
M12_Y,:^85RKMKP@T!NRR_'JX_P#HF /7#N"OH',C[16CZ6?Q.D/%594VDX7&
MK-75CR"@%"4RIMIPGL]Q?^[,=_R(1_+V]?%4GUDGEN_4IESG:H H!0"@% 4
M=$+]</6-_:;[K_G!>N@8<?8\#?RO0_I0LQ::7SB\"'WIA^5<ZYOUI<8OP=LJ
MF$_<G@+^%M7C%.2S3R[;?F7_ %<_+HH!0"@% * 4 H# '%CQ>-2_1)I_KN*
MS_0"@% * 4!_DLN@WP[XX6203M>UKJ+*8)8=N_\ 5;NL[XX]N_\ A;M]N_\
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M7FG:^<LU;NGB]%4O[]69&G^K]?\ I:;*M<T+XH!0"@% 4%=8KQO.B7Z?8?\
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MT_[-,5?R?U?(J#K:BD4!R@/_ ,:#_P":#_XM&J7Z1WDNX%!Z!E<)!I.=D?\
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MSP7<%<4,QC/-N_V^U=MGQ#!RVS9L'3=!XXQ<M\DD,L5TKYNR):W@=G>Q4_\
ML@X QT ]$@GDZ&O^H0WS+:TB82<3<*,T6B<.@HS)7L@&QU^H$";9(%GJQTE%
MC@X.+&LWA<D_9X,F;!9R]8).G9$M;P.SO8J?_9!<9T[.+$XXW<;F$*X]\F]:
MS[7!B:S*3(F]A\7MA#)8TD>)!.)RN.&0F7(>%$HZ4BY^)O@)J-R".#9''SS
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MF&R:8%1"J#;D2NZS,CU'[%-X(104)(*/6B:C7')PC;-UZ57@5/[<@Q:R[O\
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MBQXKNUE3#A@BS>9H;+V7K4V(H/>U'*6NI&]\[>U,:ZAWISV*WK5E@Y4>=4"
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MCG)')7,0N-577.,Y&P!"?Z[;86G(76IF$SG7^S(G-Y,.0,Q8)*X'+11X,G*
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MA?7<HW/MV)1_P5U>6GVVT=Q2>0EMCR':<ECLH4&[&2CVR\,\X&;C6OHD#@2
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MO[3?=?\ ."]= PX^QX&_E>A_2A9BTTOG%X$/O3"\JYUS?K2XQ?@[95,)^Y/
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M1[JCY@7S:S-_E'AUV2?\RO3(^T&W/S#IH&9KX;A1[JCY@7S:S-_E'AUV2?\
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#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g393013g68e09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g68e09.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[19H4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "$< 5H  QLE1QP"   "   < @4 #5!+($-M87@@9W)A<&@#.$))300E
M       0\H4;:1J K630!#XO'[<D7CA"24T$.@     !?P   !     !
M   +<')I;G1/=71P=70    '     $-L<E-E;G5M     $-L<E,     4D="
M0P    !.;2 @5$585    !$ 00!D &\ 8@!E "  4@!' $( (  H #$ .0 Y
M #@ *0       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O
M; $    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M    )P!( %  ( !, &$ <P!E '( 2@!E '0 (  U #  ,  P "  4P!E '(
M:0!E ', (  H #  ,  P #$ 10 V #8 1  P #( .0!% "D       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q =W$.4         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 ! \     !  $X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0   !:
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             %=0  "3T          0
M               !              D]   %=0                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   %=0    !29VAT;&]N9P  "3T
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    #.$))300,      LP
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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MT@D$<.AC6?2WJ\-D:1':/!.-O:.=?BDI_]DX0DE-!"$      %4    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !
M?DU- "H    (  P!   #     0F!   ! 0 #     06)   ! @ #    !
M )X!!@ #     0 %   !$@ #     0 !   !%0 #     0 $   !&@ %
M 0   *8!&P %     0   *X!*  #     0 "   !,0 "    '@   +8!,@ "
M    %    -2':0 $     0   .@   $@  @ "  (  @ .3L$   G$  Y.P0
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP.#HP,B Q
M-CHQ,CHP,@  !)    <    $,#(R,: !  ,    !__\  * "  0    !   )
M/: #  0    !   %=0         & 0,  P    $ !@   1H !0    $   %N
M 1L !0    $   %V 2@  P    $  @   @$ !     $   %^ @( !     $
M             $@    !    2     $X0DE- _T       @          /_A
M 8!-30 J    "  , 0   P    $)@0   0$  P    $%B0   0(  P    0
M  "> 08  P    $ !0   1(  P    $      14  P    $ !    1H !0
M  $   "F 1L !0    $   "N 2@  P    $  @   3$  @   !X   "V 3(
M @   !0   #4AVD !     $   #H   !(  (  @ "  (   #P     $   /
M     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#@Z,#(@
M,38Z,3(Z,#(   20   '    !# R,C&@ 0 #     ?__  "@ @ $     0
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MNU44XJG'3E>JKG_BP%VU_C11-Z+EWBT.-KT9;>G+/+9EZZHWZ)-Z]]T9&XG
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MK5FCON+[W?JKIIIGC4UYQ5-VJ891'OG?.NS/.>C3^EG%YJB @(" @(" @("
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M'@#?YD[(_I^G/^0JR6I_]O\ [?<Q3MGKJ_\ R^V6LMB @(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MUNXV,MSJ'CF>_:TS<-6V_-MLV9:<MS?1LYPYSU898D2$@(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M,O?^Z@DCPXO\C767_P"V,7__ *WRL[9ZY^*4[(ZH78440$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M@8]CQ,D)KA@72OF6+91$L79&>4:S\,OCGZ,M-9TK'4'?KL),5V!O\HD".XJ
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MC_MPB.2 @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M,BTCWCS=$NL,V,IBS>X9-^"QMCKCXKX8?P8_Z<?]N$1R0$! 0$! 0$! 0$!
M0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M@TR'YZP84N961!=CR%B03+21&XT69UM764[&$\H2RT:/N!NG77_?SC3T[,F
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M2PW6LM@Y ;:CLN,I]&6>?KTZ]/?#!J#\06\.Q#.0$@!WU G+,F*@JKL"UF8
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MQ_VX1') 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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M]/RA]FU9;$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
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MPV5J23A:.20R_J*!BH68& J1;!_ %95GQHW;I/,\/R(B!*VVPL2U?"<OGO\
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M$!!5'OC_ )'.YO\ 2CV)_P"(3!%C;'7'Q6LP_@Q_TX_[<(CD@(" @(" @("
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M)Q_VUM^(@>=HKZ3C_MK;\1 \[17TG'_;6WXB!YVBOI./^VMOQ$#SM%?2<?\
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MZ&6]N)QLH"QT1N&9\ZGC4=<0>5:QQ=#LO?,QEU?7M[M^2687O-4)#<L94D+
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MJK=AMKUP-+00A86NU.0)QG('V<A".J]B8%XU?YB)C9NV9Q&NW//+/GSW]+$
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4$! 0$! 0$! 0$! 0$! 0$!!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g393013g77v72.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g77v72.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2-*4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "H< 5H  QLE1QP"   "   < @4 %D]V87)I86X@4W!E8W1R=6T@0G5I
M;&0X0DE-!"4      !"^S3Q/(RP,LK089$7H#D^).$))300Z      %_
M$     $       MP<FEN=$]U='!U=     <     0VQR4V5N=6T     0VQR
M4P    !21T)#     $YM("!415A4    $0!! &0 ;P!B &4 ( !2 $< 0@ @
M "@ ,0 Y #D .  I        26YT965N=6T     26YT90    !#;')M
M $UP0FQB;V]L 0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R
M3F%M951%6%0    G $@ 4  @ $P 80!S &4 <@!* &4 =  @ #4 ,  P #
M( !3 &4 <@!I &4 <P @ "@ ,  P #  ,0!% #8 -@!$ #  ,@ Y $4 *0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    6CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M            !B,   BC          $                          0
M           (HP  !B,                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P  !B,     4F=H=&QO;F<   BC    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   8C
M     %)G:'1L;VYG   (HP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !3A"24T$#      8'P    $   "@    <@   >
M -7    8 P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ <@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M^W>DII=-^L.0[(&!EU^K?.UMU(+@>-;:V?0;^_:SV?R&*[=U2VLD"MICS/\
M<K.)T_#PZ?1QZFL8?I=RZ.]CC[GHAQL9WTJF'XM"*G%M^L>2SBAA_M'_ ,BL
MVWZP]1.9]IJ(K&T,=1)?6Z"X[MIV[7^[Z5:ZD]/P'<XU1^+&_P!RIV?5[IUN
M9]H>P"L-#6X[ &5R"XFRP,_G-VY!2V!UO[=CNN92:RPP\.G83_P-T;;?Y7Y[
M$UW6;JYBII^9_N6GZ-.T-V-VM$-$" !V"@</$=]*FL_%H_N14X5OUGRF<45G
M^T?_ "*I=/\ K'F8<,O)R:)X<?TC9/YEA_G/ZEO_ &XNG/3>G'G%I/QK;_Y%
M5NG=!PL&+(];(U_3/[3_ *)GT:O^K_EH*<[)^LN;C6ACJ*G;@' ;GL> >UU#
MV[\>S^0Y6,+ZTX=SA7E,.*XZ!Y.ZOYV>W9_;8M ](Z401]CHUY_1MG7SVK&Z
MQ]6ZZZ79/3P1L!-F/)<"T?2-6[W;_P#@_P ])6CTB2YSZK=3<Z>GVNW-:W?C
M$]FCZ=7]F=U7_F"Z-%"DDDDE/__0ZBS*Q,;K ?F6"IIOLL)=  %;OI$NCVUO
M?4M'+Z_E'.JKZ9BNS\1C2_+NJ .T;MC?2WOJ]7]&S(>WT/M'JOK]-!ZKAMJS
MVW%C7>\7X[GM#MM@^DYFX>U^[]U PL;J%6;E4]#IHPL3*9ZAM=#Q5<0\6?J\
MLNW>IZ;Z&-_4?2]3_"_HT$H<SJ%?7,SIW4<'IS\_"Z>\W.RF.9N:YPK?Z3:_
M6;9:UM7ZR^EK'O\ M=.&Q-;F4_6'JG2^I86"[)P<8DG-#V ->_8_T;F-M]U5
M+ W)^A;^MLHJ]GZ1=!T/$S</IM=&<ZMU[22?2+G-$F?YRP,?9N_G'.V,^FI7
MW51Z5( 8"7.+= 23N/'\KW)*;&.9#OBC(6,PLJ&[0NU(144*22224I))))2D
MDDDE*22224I S,DX]#[&,]:UK=S:08<Z/I;.?=M0[<ES]*C#/WAR?ZO[K/\
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M[99_A_WU[ZN5ZQ]0>G]<^L)ZMU.UUF.*F5-PZY8'%A<=UUS3ZFS])]"KTO\
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M9.>:)J8*MP-ECG7.( &][6MJK8'676/VN^BDI.YM?V)V1Z+*K TG;=[0"/\
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      7Y-30 J    "  , 0   P    $).@   0$  P    $&
MC    0(  P    0   "> 08  P    $ !0   1(  P    $  0   14  P
M  $ !    1H !0    $   "F 1L !0    $   "N 2@  P    $  @   3$
M @   !X   "V 3(  @   !0   #4AVD !     $   #H   !(  (  @ "  (
M #Q%L   )Q  /$6P   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,3<Z,#@Z,S$@,30Z,#4Z,3<   20   '    !# R,C&@ 0 #     ?__
M  "@ @ $     0  "*.@ P $     0  !B,         !@$#  ,    !  8
M  $:  4    !   !;@$;  4    !   !=@$H  ,    !  (   (!  0    !
M   !?@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0& 34T *@    @ # $   ,    !"3H   $!  ,    !
M!HP   $"  ,    $    G@$&  ,    !  4   $2  ,    !      $5  ,
M   !  0   $:  4    !    I@$;  4    !    K@$H  ,    !  (   $Q
M  (    >    M@$R  (    4    U(=I  0    !    Z    2  "  (  @
M"    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$W.C X.C,Q(#$T.C U.C$W   $D   !P    0P,C(QH $  P    '_
M_P  H ( !     $   BCH , !     $   8C          8! P #     0 &
M   !&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $
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M 0$! 0$! 0$! 0$!_\  $0@!?@(9 P$1  (1 0,1 ?_$ !\  0  !P$! 0$
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MF$\20H;$CE\_/JJ!5@D'<5M+Q9F/&N::ZG:,:VR,LT8/=D=IM512DHEPH43
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MG=@\]'[Q(\5 $;[>-222.7NKH./%IV_&L5=LJ59'"-]D&HK/:VC*M+$4S@
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M57$#;#O#EUI:1/BK+Z[B?;)LIQS(M)=N\FF956;I-I+#(KHNI%L1PP8+E0>
MLD1=BT4Z04:HF(XD\MMO#;V8J24J W!SU^_\/N\*FCO;+O8?O8:1?8YS$]D*
MZ#<*^_=NY!R]@@9J$5:!#.EI(Z\8#55))5OZ$=#N%$R'2Z3$*(1XD]WP%2P>
M_P""ORJ%;;5]Y;)2,59XNRPT5A'[J5AE6RCM!2(DWIFYWDC&'2D"&8/W9FC4
MSIXT%)PN9LW,JH<44Q+7C3W<^>P^-.$_(5^53:$V^[Z:PV<LZY3LW5YF\>+2
M+MK"3,O$MG4@X(DFX?.4&$NW27>+IH(D6=*E,NJ1%(ISF*F0 <2#S'O']:84
M.6?9Q?D*DT/MAWD5LD@6 QME6!3E42MI0L.X<Q9))N43"5!^5E(H \1*8YS%
M2< H0HF,(% 1$=.)'A[OTJ/S\^ZOF,VU;QH.4=3<-CS*L/-/RN2O9>,>.H^4
M>E>J=Z\*Z?M9)%VY*[5^V.065."ZGQU>LWCJO$@[9!QT]73?:I84._?J/QQ7
MJUVM[S&IX]PRQCEANI&$DPBEVJSM$\>G.$5),!'J)2!3-"2Z;A<LF#8R82!%
MU2NN]*H<#4*D]V?9^= D^(]A_ 5YEVI;QR2C><)BK*A9IFDT0:3!1<EE&J+!
MDE&L46\@#\':"3*.018-$TEBD;LD4FJ($03(F#C3W'W#\Z<)[_@K\J]&&UC>
M9%!%A%XNRQ&A!O'4C"@P4=LPAY!\F@D]?18-Y!/U>\>)-6R;ITT[E=PFW0(J
M<Y44P+3B3]GX"G">_P""ORKY6VJ[R7#V6D5\6967D)YNLTG'ZQG2CV9:N#HJ
M.&TLZ._,O(MUU&S=19%X=9-4Z")CE,9(@E<2>[X"F#W_  5^53A;;MOH<0 5
M1>D9N7JY6J#$M;6E9=2 *R;&3,V9A#GEC1P-6YDDC(-P;=RD9-,4R%$A>'$G
MN^ JN%<LG'J5^50;K;-O9?/H>3?8ZS$\DJ\5 L!(.GD@X?096IR*-2P[M:2.
MXC"ME$TSH R40!$Y"&3Z3%*(.-/=\!^=4P>_X*_*K$JV7+V*I"<I 6F^T5]&
M2[U*P5N/LLW"%;S903;/Q?LH]^BW._$K=)!PL<IU5"(I$.<Q4R $QPD X!'3
M:J9(VR1X;BJ=F;S=K)'LHBPW"U3T5'=V$=&3-@EI2/8]TD""(,F3YVNV:]T@
M (I]PD3H2 $R\$\-, <@*9)YDUFGMQ[/7,&;_0+#9D%L8X\7%-8)N?8JA/S3
M4P <#5VN*F;N54ETQ(*,K*'CXTZ:@.&1Y+H,@,2L#EO]WZU(()Y["MTF,MO]
M$VXPYXG#..UUIY=N#:6R#/()2=HE>.!/UOCIHBDW.<I% CV*$;#$43*IZM5.
M)E36R2>?Y?/KJX !RJGK-2\CSCI1Z\A)J0<J>:JQ0.;@.1 A $X%33*)AZ$R
M 4A \"% . U2JU:N4Q+DE;K[JG31^>OCI0*/GY?^4TJG7V#X9_.K=R&$<LJ"
M;NZ'8#\B/'2V*/\ _DTH-@!X50$IM^S0OSW6.+*?XG'@U3\_'_SWRZN*4"/8
M>?K!_"J$?^X'X#Y_7:K?R.VK.ZICF3Q?:3 /5QPS3Y\0_P =JA((QG&Y.^>\
M]P/?09&V.[<8[@/7\*H=_M:W"J<]WB6W&Y]S)+__ +ZJ%#X >[-14D_$GWX^
M?ASVJB7^TO<DJ(BGAVYF^9BE[C?_ )CY=1R,(WY'?W@T(/I;'J?>4_E5&/-G
MFYXY3 3"EX,(^7$>E[^?:X#WZD5#A(SOGQ[\U$I/=W#OY#PK'?(^,;]BJ<0@
M,BU66J,R^CDIAI'3")4'*\8NY=,TGJ92G4 45'3%VB4W/(G04#CP\9C!S@YS
MO\!^51QCG5O]5I636 =I.9MQ+Y(U-KQXZJD7!*0O=A(O'5=H!3]*Q&KH4CKS
M3U+@0,PAD'JR)S)^FBS1/WX1*@/7W5())Y5O)P=LBQ3MR0:3;&MN<J9.1(14
MERL;)$6,0\*4![RN0HF6:0W0H'6BZ*9_-E RB8S2:1P1+:*B3X=WZ]>GWU=2
MD#U]Y^3BKCW"$R59EA5?14JZ*4PB@V33 C1OSQX(H ?H*/3\45#=2QP .\4.
M.J56K-RF+<AK=7=5*8/SU<=*!1\_+^'I42,X\% U;>4POE18#=U1IX_QC<<-
MB>/)3>7VSY=5&Q!\:E5 26!<QJE$$\>6,X\>QJ3WB/M5#3ICQ/X?E2J E-N.
M<E@$$L96@_QC#\5HF//(CQQ]N]O^WC4PH#._-1/6H[Y!QW=W<?'QJA'^V'<
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MUQD)4O3G:*8N)F873+T@ZFIER*LE*..1.)!=.#I-RG%)HDW0 J)8$DG)JX
M,"KJ:I5::4II2FE*I.W4.E7^,4AKO4JY;8M0I@%C8H:/EVY!.42BHB1\W7[A
M8H&$4UT.[62-P=-0IP 04QGG6J_<+V6%1G&SZQ[?I,]2G"%5<? 2>>.7]8DC
MAR?T>)F71G$K N%!Z@3+(*RL:<XI(@,2V*=<LPLCGO\ /QJVI'=\^KYZUI#N
M5+M>/;)*5"[0,C6K)#.!;R,3*("@X1.'B15,0$R+IHX)TK,WS51=F];G3<M%
MUFZB:AKH.=Q5OEL:I?2E5YC+)-MQ'>*_D&D22D98:Z](Z;* )A;NT!^(\C)%
M$IB@ZC)-J95F_:F, *MU3@4R:@$4)0C(Q0'!S75]@+-5:S_B^O9)K(E13DT1
M:S4294%7->L3,J99>#=FZ2&,=HL<JK98R:7IL<X8R":9$G:8:LD8.*O@@CYV
MJ\VJ56FE*:4II2FE*:4II2FE*:4II2FE*:4J4STW&UJ$E[%,NB,HF#C'TO)N
MU/N&S".:JO':Q@]H)H(G/TAXF$.D.1$ TI7,IF7(LSE_(UHR!,&4!2:?G-'L
MSGZBQ4*W^T1$4D4!$@%8L2(IJG2 H.'0N'AP%5PJ8UT* V.Q%8BPHJ*A[.\#
MY]]6E41YY P>?EX<?((\^_GQ]_LU.J!7?M[,==SZ\\^FU7BV_P" +%G_ "$R
MJ,0)V$,V[N0M=C%+O$(&$*ITJ*@''0M)O3 +6)9B( Y=&[U44V;9XX0@K W^
M'CWC\>AZ[U=2.(X!]?S]W?ZJZ/<;8UIV)JC&4FC1",1"1B8 !2 4SN0=F*0K
MF4E77251])O3$ [ETK\8P@5-,J:"2**=HDGG5X )&!\^)JO-*K32E-*5\G.5
M,ICG,4A" )C'.(%*4H!R)C&$0   /$1$0  \]*5)9NR0E>K\K:):38LH*&CG
MDI(2B[MNDR;,V**BSA95THH5N0B9$S=1CJ%* AP(AI2N.'#G:)V?=WF$V2<Q
MYGNN/J)-SD@ZKT-3926+$8XKIA=A#L8J B'\221D4&WHK:4FG(GE7ZRCIVH;
MH[MF2G,>OV]*'(./9W;?CGG_ $K?WL2W'2&=\>W1K+38V>3QI;$ZZ%D6%(DA
M,P4C'I2$*[E$TS=8R" @\9.G1BF.X329G<++O5'+A2*L@;;#X[[;>!._Y8Q0
M9]OS\_<!69JSKD?$W2''F///'EX '/Y.3>W5O!/R!RW^'?4\)'UN?/'SS^>E
M2X[SNS<D-TF >2F#D3@/O#@0X$!\>1'GP\/'50DG?'W#QZYYCPZ]U44K.PY5
M>BO2@2T6@Y$?MQ>47(>Y=, ZC>S@%"B54 X   _ >6KH.?G^N/>:C4[U6E-*
M4TI32E?!$TT@$J9"D*)SJ"!"@4!.J<RBAQ  #DZBAC'.8?$QS&,81$1'2E?>
ME*:4II2FE*:4II2FE*:4II2FE*:4KX!-,%#*@0@*G*0AU *4%#D3$YDR&/QU
M&*05%!(41$"BH<2@ F-RI7WI2FE*:4II2FE*:4II2FE*:4II2FE*^#IIJ  *
M$(H!3D4*!R@8 43,!TS@!@$ .F< .0WF4P 8H@( .E*^]*4TI32E-*4TI32E
M-*4TI6)&[/:=4-S5,5;JIM(7(T(U6/3+B"/"K=8.I4(2:,D457E>?JB)5TN%
M%H]<_K%@452KMWDDG!\.M14G/KZ&N7>VU2P4:S3E/M48XA[%7))U$R\:Z* *
MM7K104U"@8HBFLBH  JV<HF.W=-U$G+=11!5-0UX'(S5GEL:I[2E;)^S0SZM
MC/,I,9S+TQ*=EM1O$HIJJ\-XZ[H@8M=?)E./20TOU*5YP5("F=.'<0=8PD8)
M@6"QD9ZC[OG>I(.#CH:Z.=6JO4TI32E-*4TI32E-*4TI32E-*4TI32E8*=H)
M?UJIA1*K,7 HR&0YQO#+ 0_0KZAC"#*S!B"'B)%5THJ/<$\ 4;R"I#<E,)1D
M@9/J^?GU5:=5A/K..[QK1<9,0\?S^?R\?DU=(!Y[_/3K5@+Y9]7<<_=CESQ]
M]0YD .(!TCU#Q[.1,/L^*'GS\G \ZI@C&#D8Y'G]U5(2?7S]?CSP1@?)KHCV
MCX2;84Q'#L'34B=OM"3>R7%P)?MY9!XB!V<.8P\F!&!9'38=T!S(B_"1>)=/
MIIPU:4<G\*R$)X4@=>OSTQW5E#JE3II2FE*:4KEV[:3=Q>:YNRQIM=<R\G7,
M3HXD@<JR$>T<N&#;(,]8[9<*^H6542%(LM%U=K5&Q&<4<ZK5*1DWCQV@HL$<
M=O0YZ>[]>GSZQ7&V?''SGW[=WLK']<L9N6L.%]M.VJ_3D OD%6-]>1U\>/EZ
M5%VAA!R,Q;Y].JUEP=G*-8J.BE7$ H]:H/UEB@T>2$<DL9^@]7W8[_Q]7?UQ
M41GOV/+YSUP.7KQL:NG-_L9J6@K(QF,+[X9>IQTP8'U^A;CA5A9V1K \66=3
M<M0TH'(%1^#\.[<*B,?5)<\\I&]1Q/9WA.A$M,'H>6>G><[;^X>PU/(/-.?;
MW<OZ^W%6IWF8,W!=CI2ZM-XUW!'R!A_.%S)C@T[,0:U/RGCS(DU59&8=S#*5
MK2AH>2AY>-J<FG%*F=PSV'62B(UW'6CT529"O+NP?AX>K[AX<F >0.1TYY^?
M5CER.*]-ONYR"HF.GN16^5[@3+<=*Q:[6'DW;Z:@;;#*HKJS2EGD7THH9RH9
M<B*0-UVZRIRK>DM5TW)2N6K;!]O3._C[.??RZU#?/>/NY\NO/QZ^%=)E8L2=
MEK%=LB;91F2PP,1.$:*CRJT)+1[=^5NKR!?MB +@F?D ^,4>0#R"G&/GJ1XC
M;\/A4PDGX>X]:NWCV4Z9%S''/\1V@*J0<\_;VX\B  '@'4B90QO?W0>[5$JR
M?7CX<_GPH4X&>?L^?Z[5>'4ZC32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E:8^U6V_-EXJ$W#UUB";]@NQJF0O1T@ '4>Z$R-:L#H2@4!58O.BO.%S]
MXLNB_A&X"5%@4-7$'I[O"K:QU]_S\]*T=ZN5;J,CW[R*?L92.<JLY"->-G[!
MV@82+M7C-8CAJY1.'B15!=,BJ9@\2G* AXAI2NP;"^0VV6<48_R,U!,@6ZK1
M,LZ12'E-I**-B)S#$H\CSZ!+)/60^(_&0'6.=B1W5?&X!\*N=I5::4II2FE*
M:4II2FE*:4II2FE*:4K3AVCL^I(9,I57*H8S> IQY04Q'[6F\L,LZ26$"CX=
M9FT&R$1]W2'LU<;Z^S\:QWL$@$XVV[N>_P!W?6N@R'GR'Z.?T:N5:QW%)Y;9
MP?5SQ\]]7LVTT1&_9UQM772 .& V!.8DD3EZDE8^NMU[ Z06Y 0%)TG&^B'
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MGAZ\QX<CCETS78>0$TB$33 I$TRE(FF0 *1,A0 I2$(7@"E*4  I2@ %
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M^-;(=1J5-*4TI32E-*4TI32E-*4TI32E-*5HNWU+*.=Q%B3./Q6<%56R7(^
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M3^3X:YWO(Y5/7605H3(5RI..K;973Q21>E3HE>EF#*/@T%%08(M&:K164:(
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MHE@39F=/FT:UL KIL7S3NQ=#SSX>_KZP-QSYXQBHG8C'7D>1R/Z?=S!!KLR
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M-Y!S^4/HTJH40>?/O^?'I62^$X<Q64C85DQ(9X8&#(3!XBW0,!W2A#?PDU'
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MX*R:Q;%-ML .6_R5:.3-=])N1J:YH<9CJ63Z:WIDGAFR\JRLL%^*,Y++"DD
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M/D[\\ >%<+Q>4M@92G3=Q3]@%U.V^P)7$'J*E'EOUSX3,A+&(H&0MOL;+I&
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MP6>D3\?CK/K9E%2LBMZ%4,G1J?HU(O1P^*DU=F'A&KVE0H *L4Z.DS=+B86
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M54C/KZ'Q'*IFU(JX62;MTSK++J$1012*911510P$(F0I>3',<P@4I2\B)A
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M@MJ4,$[A'I%.<AEYLCAJ,]SB0BS:XB"1'4"(-^C@=JWG8.!U"/2P.%2SP\>
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M&IJ@(#R @J5L"G5SX]75U<^//.E5P.ZJH*4I"@0A2D*4."E* %*4 \@  X
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MM(R[8YN\CS/G#I)-".=I(/4$V)E72"8+(E']$_V0O(I>/)=8[U?=1PG;5/U
MW BP;.\.&5#MT(ON]O-9!*F9,MZ0 F.[B0PAG+R4*>*$?"/[2'E!TMJ:7I_2
M6BI#,^T:81,<DW.,#YG)G2Q';+$-T@!Z+#9B@KD(RR^Z\>Q4M#0<7L=11Z1
M$P$QAX^.'B81_P"('\  ]_W7O$ $2A]AK<SS.!]GDD;[%1QDGEM]7NSS/S0A
MO& C).=U8W./LC/HC.V=E=21RJ9IL?:H;@1\P+QS](CX?@ 0^76.7.@WQRS^
M7Z_=62B/]HX]6Y]I_K7OZ&C[C#_SA_1QJ/&K.=O5@8J[V*.X^^O@[),0^*8Q
M1^7XP?K_ "ZKVAZ@>S;]/A42PD\C[]ZEZS8R8=)R@8GR\B41$/X/B D-[A 0
M'W\AX:NI7DYS@]_\PQU.VX]Y]1K'6V4[*&4]W-)[SGF#OSR"=LU+%P*T(HN8
MQ ;%(85^^$I4BIE 3&!<PB!0(!2F."G)0+TB<!*)3 7)2H+&YX5#=)&V,=1G
MNZ@]#@@@[XJD%&5(W03PJ2?_ &J\#WCUC!V&&S+?-M4>VE[6(O+,3))H.58^
M1ED8Z=/34UD3G(N0;MZK"J'(V4(;IE4)92.*8H*>F 03@%P26W $J<2AYL^@
MX >$*'CRX%IV4"<8)&^ :KYLZ@E26U.,N#"VS@*X3S21D'B01E*@!N <#)37
M-IVR&^ZL7#<#@:A42W.IS!U>C;/(+2R*;AE5+#E4[]HW*JB5T1 TF:(JY$TH
M:3.@#1;UE/\ JA9RW[]P?#ER0^IH\..%!"CC)XR=QGJD8]$]<[>.5 B*CH>!
M.2IT*0-_J8P#PYV4<X5CEC&3BJGP7O1JCN[[;(6FP,77;)%VAE#VF?C9-8[N
MX5^6ERJ3BDFU?.R,$?5]:,_001:B7OSI(*$(9V1J0E(4CS>4R]Q82E:>/&^6
MS@.#ASN"DG'CC;8$UN$82XDACAXEK;7V85Z.'0,MGB(V(6!OG&/"NA"[;LL"
M5B4I$I(Y4K#6\=!$Y"M)K.G=A49MA[M-]*0T>U<R<2B];G7:JK2S5D!S&,FE
M_P![*=WTK$F A$ZW/2&Q"DI[:(YNI+1=YHPD**2TZ$+0E0&.$E7.N1E1+DM=
MMNT>*X;C"7YM-;/"A3R61A+G$HI"TO,J4AQ:2H$*2E)]&KTUV5J\C<%5("4C
MY['^7H)=9B^C'*+N.=*.B.BG!-= YD@63=ED6?=!PHW5=IHJ%(JD)29';.3+
M!&FMJS/L$ILI<!XCV;:V\*SG*D\/8+)R0KL%]Y%87F[4#5,RW/)_[LU3"<"F
MU>BD.NMNDI(Y!7'YPVD8!3YPV.E46:(>3.),AT18QC6'%<TM,PZP"(+$0CW#
MEZ51MS\?J521F2( 40X!RV O@!2ZZ,2FXNI['>4#^PZDAHBRTG'"5OMMLJ0O
MIZ*EQ%+)&26W<[DUQRX3\[16IM.K*C<]'SW)]O< ]-"(SKLA*V@?24I:&YR6
M\='FN'(P*F]@L10LVWC-R!BHHV<4L<VH2\@F8EG04%BBJ)? B$98D'RQC'$"
M@=),#](!X8L*"KZ.USI%>5+M_%?;;G'$#;EI#RTA6"5R("F4@ $X4K'CDW2Z
M)3>/)=Y0&_0;O'!I2]<.R"F\M*5&0X1]5N%=FWUE2CPY0G.!N*FQ<7X'9VSA
MC[Q2C;(%?S!7F_@ ">?2/!7!8@!X=)IV,:GX+QP98W)>1ZC8&HC]*:.T?>_K
M/P//=+3G,Y.(*DS+4DGGD0Y+HWSL@8/=L-&CZ!\I7E'TOG@B7?Z*U]:F<8].
MZ-KME_<3OCA5<H+"L #TEJ)&3E63>O/Z]@II2FE*:4II2FE*:4II2FE*:4II
M2L*]R/:+;(]I*;M//NY#&U*FV95#*TMO+'MF0Q$A.K@N/:<A/W,"G$2D*NI"
M)MN\.4IER\^&ZMNGKW=R/H^VR7T'&'BCLH^YQO(>+;'L[3..E14M*?K* ^>[
MG6C;.O[*JVJTY5TPP)@3+F:';<QTTYBVR4'B&J/.!$"N6+@R-\M*K<0 IP)(
M5.'<& W09-(WQ@[B!Y*KM(P9\^'!!W*&DN3'0.Y0'8- [_RO+&U6524#D"KX
M=W?O[QTK4_EC]E0[Z;2=PWQ=BK;YB>,4$XMG#B$MV0+.W+P/24TI,6B*KJPE
MY 1,:FDZC% >"E$2#UD/R56)O>7,N$M8YA"V8[1S_A2TMSP_OO>=ZM^<J/)(
M&X&^3S\<CIX<ZP3NG;_=K)<#J=6ZAY6&RH'+Z'3L9XB@")E.4@<)/$:*K*D$
M.GJ(IZQ%4HF/TG !XUOV/)_I)D?_  L.D'ZSTJ8X=N\=N$?^G%4[99)'%T[A
MWD'IGI6/TQVP7:?2+@[E??!N 145-R8L=='$0W#XH!PFTBD631$/;PD@0.?$
M Y$1'8M:.TLD<(L=O(&/K,\9]JEE2O>JK?:N8)*CR&!TW./7T[ZE(=KMVG)1
MY#?+N.\/?D:8,'X#*" _3J]^Y^E_^!6W_P#+IJ/;N?:/O/YU]_NO/:=_RY-Q
M?^D*4_G:I^YVEO\ @5N_T$U7MW/M4_=>>T[_ )<FXO\ TA2G\[3]SM+?\"MW
M^@FG;N?:I^Z\]IW_ "Y-Q?\ I"E/YVG[G:6_X%;O]!-.W<^U3]UY[3O^7)N+
M_P!(4I_.T_<[2W_ K=_H)IV[GVJ?NO/:=_RY-Q?^D*4_G:?N=I;_ (%;O]!-
M.W<^U3]UY[3O^7)N+_TA2G\[3]SM+?\  K=_H)IV[GVJ?NO/:=_RY-Q?^D*4
M_G:?N=I;_@5N_P!!-.W<^U3]UY[3O^7)N+_TA2G\[3]SM+?\"MW^@FG;N?:I
M^Z\]IW_+DW%_Z0I3^=I^YVEO^!6[_033MW/M4_=>>T[_ )<FXO\ TA2G\[3]
MSM+?\"MW^@FG;N?:I^Z\]IW_ "Y-Q?\ I"E/YVG[G:6_X%;O]!-.W<^U3]UY
M[3O^7)N+_P!(4I_.T_<[2W_ K=_H)IV[GVJ?NO/:=_RY-Q?^D*4_G:?N=I;_
M (%;O]!-.W<^U3]UY[3O^7)N+_TA2G\[3]SM+?\  K=_H)IV[GVJ?NO/:=_R
MY-Q?^D*4_G:?N=I;_@5N_P!!-.W<^U3]UY[3O^7)N+_TA2G\[3]SM+?\"MW^
M@FG;N?:I^Z\]IW_+DW%_Z0I3^=I^YVEO^!6[_033MW/M4_=>>T[_ )<FXO\
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ME*\7#A!J@LY=+)-VS=)1==PNH1)%!%(@J*K+*G$I$TDR%,=10Y@(0A1,80*
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MNE%5U5EUU5%EEE#K+++',JJLJJ83G445.)CG4.8PF.<PB8YC")A$1$==@
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M'Z+,=8F^<J[-CL/YNT7D%(!Q@I(4%</"0K%?TL=EDEO.E<7;6G&^BNXKKN6
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M*.7F;!C[)-/2@)=U8H67J"[U@E/.Z^@T%PQ7A[ R=P;EL\%M( T>/@%DH\;
MT1TG[+GD-UIY)V+G=M0:@::CZFC,+D:+;AK?,"0THN1)LFYJF(;9N++3CS$B
M)'A/LE#Q2N4M3+91C>77RBZ2UA*9M>GX3LXV:8\8^IE.B.V\P[E+\6+%4RX]
M+AO+2T\W(?=AJ0XT5,M.(<47.A?&66<>9CKA;7C>SL;-# X,S<J-BN&SV-?$
M(112/EXI\BUDXE\1-1-7T21:-ESH*HN4R';K)*G^OZ^>:N'R >8AI2N)SMC]
MSD%6NT/0R%"V$;'C>,QG3L8JVU H+5BNY$J=@NDA9*>E( )VJZ2:4ZQ>C(E'
MT)Q-+SD0DLJYA7!0H?NQ^/+QY>_ET-<9&PWW!Y[YY'U=/#VU46V[M.%76Z2@
M;@K*E%_!-1&P4^6L#:/7JE G9->HHQ#6HMI^'AEZ^C8" ,7/&C0277_W/]8N
MFQ2B1;3(SS QSS\\^[NZ]*H$D)SCNV^\_CGK6^B6[5_%YK3'U6DXRO%T<A'1
MDG87R$E6V,?%IR38KST6)6;OY<9]X@U'T@X"6*9'3.B)7P=X?NGL^?G\:?/S
MRK5YVL_:.&W#X$N&UO;UC^VN;3<W]'7.6314-<;3*52XUZ[#0*;2JV:9>RCJ
M>-!%C2R#EX4C@YSHMHIPU63DBCN-N?0=Y!'X[?'E54D9\-\GN!R,YY<_=6H+
M!>]+*4-6[9MO@Z;?3W6>,Q:VW#Q,>3CS)2$K4Q</"-'%5]1.+?&.HE07*CQ%
M!HU$$2J"[*9 HB%1D[ '/4<SR[AG?\*H1CTB4\/(*V'/EN3R]VX'2M_6$^UA
MQ7CG;WAFO$8N,JWV#@X&C-8N!F&T*Y._K$>W:2PV]";34EJPG%&33CA6;1M@
M!XX[H@),E17;-,IN2$1W&2DDJ!"3D8'%W\]P3MC.?#KA.12N0AX* 2E22H8)
M/HG.W3?ES&!W\JNKD7M1XNF8IE)"4P[882YV1!N$ @[LD<:G-6_=.%"33ZSJ
ML6,F9-$XF[EDSK"YGIT^@CUN7O5D,DW'"F'$M*XV0Z".(;]H@ $*QG8C)'#O
M@;[[80M9*)#)=' ZIDYX-QV;BE$$%1^LDD).>I.,<^3;:GN]FMME_;FNXM4K
MO!S+BQ-W5SC#.8>],5I)X=M<624VD1*PP%A.5P[;R29EDEU#*@#DKM!3N]4D
M[G)).<D[\^??MGO&,^[.[4G..$>C@8  V &,8WY<N1^\CK3[+6<NM[P9GG*E
MFBUH2N9)='GJ4Q49C'(/XY&,60<V2-8="9&\/+O3>BQ8II)HN&L05TU%5BLT
M64Z6U,NMKL[BP4H>NR5,I(QE #*5K ._"K"1G8'ASU%<A>GV'6M0MMD%;%C6
MB01C9Q1D+;;4>7$@$DC)QQ\)P00-@LKU?!S;^(_OGPT: 7W]'K]L'A\Q.GW>
M'Y.JBX\^UN!R^AW>+U^9.<^?7(W&WNSP\W/T;Y./M_3S'#T]'Z0:Y>SA\<>-
M5-!@7[-^<0'][^"-;[WGRY]1-//_ )G5SS\NM?+S^Z&D/M?2=PX._'GCNP]H
MR*V%NQ_V@^4+[/T+:>T[L_1[6,C_ )/AZ\U8E+_Q8MNPF^Z#->-N[]X&#*+\
M"\>W][Y ./S:[/\ _N%KG'+]T=0<6^/_ .G&<]P^MW^VO,<__P H/)25?6'E
M&T9P>O\ ?9T#'7^[SRWQM6PS7A]?4E-*4TI32E-*4TI7/!VM?;CTO9Z6?P'M
MJ<0>1-S94UH^Q3:I22M'PFJJD'(S0$.#:R7Y$% .TJ2:BD=#+AW]N4ZT25N6
M]!TGHAZ\EN?<@Y'MF0IM ]%^:!R[/(RW'S]9['$L;,C?M46UN<.0!D_=\_/(
MUPDY3R?D7-%[L>3LKW.P9 OUL?GDK#:K/(KR<M).# !$P.LL82MVC1 J;2/C
MFB;>/C&"*#".:M63=!!/W6)%C06&HL1AN/':2$-M-)X4)&YXMMR5')6I1*E*
M])2B25'$))W)R?'\*MFJ3@>0#P_('F(^WZ?+655*A%"^WSY\_K^0?E\M3&XQ
MW;I^=OG)[J5!G+YA[O$-5SN%#KL>7M\?NV&:5+U"^8?2'Y_[-7!\_/CSI4"?
MS$..!_3[_K[>=*M+&^>_\,5 *A^80^7Z^/OU<!V_Y2/P S\<^RH@XQZP?=\[
MU+5N./#S]OX0U,9R>[;'XU-(.V>_ ]@5FI"H/)SC[S&_!SX:R1MM45_6/ST%
M?&E1II2FE*O5@7<3F3;#=W.2L$W-3'U]<U>QTXEL90E:EYJ,@K8Q&+GRP#NQ
MPTR>M2SZ-.LP)9*\$99&+1R\;QTLT2>.BK8-PML*ZL"+<&/.8X=;>+*G'4(6
MXTKB;[1+2T=JA*L*[-SB;40"I!(&)H6I!)3C)&-QGW=WKYUXXBW 9?P0GE!'
M%-R6JB.:,5VG">3D0AZ]-I6S&%T5CUK+5W25CB)<C$DBM%,%2R\26/GF*C<#
MQTHS,HJ*B9;H5P\T\[8#OF,IJ;%/&XV693 4&G06EHXN$*4.!?$VH'TD':B7
M%)R >8P<[['I67.(>UN[0W!.(H7!V+]R$] 8]JK"1BJ6W=U+'=DL]"BY8ITY
M"-H=^M%1F;U36"J1Q1;-:]8H]&,2*1.)*P*F3C3S=':<N$QR?*MJ')#RDK?*
M7I+34A:-TJD1VGD,/*SN2XVHJ.2OB-3#[B1P@[#PS\>=8MT/<]GK&C/.+*FY
M)F8W]LI49:BYR?O6L/8)W(E5GY(TO/1DO8['&RT^V-.21C/)F0B9*.E)54P^
MGO7!!$H[:1:K?*5 4]%0KZ+>0_ 2E2VVXSK:0EM2&VEH;/9I "$K2I"1]5(J
M(<4GBP?K<\[[;[=XYU /-Q&97V (G:TYNK@<"0>3G>98_'B4/76S(N3GT K5
MG%N=S+:(1LTF_P#@\NK$H-Y.:=QS1H;I:LT3%*8LDVV"FXKNP8'T@Y%$)4DK
M=)\U2X'0T$%9:2GM %$I;2HGFHY-"XHIX=L9XL8ZCQYUD6GVGF^LD[MULIL_
M2SF8VFU)Y2-O"[^G8VDF^,H!_5F-)=>JXV0ICF,DYP]7C6$0G;+$SF+6W1;)
MK-YI)UU+CK/W5L'9W)KZ.0$7=U+UQ"7Y23*6EY3X"E)?"D-]LI2RRT4,DG!0
M0 !+MW-MQZ/+;ET^[J:QZQ#N2S=@B_6/*.+;_(UV_7"M72H6JR/&$':7=AKN
M1&BS*[1\PA;XN>8R'PB076].>.6JC_OSB[0=(NP*N&RF6N!<([427'2Y'8=8
M>9:2I;(;<C'+"D%E3:D]GMPA)"<>B04[5%+JTDD'<YSG?8\QO7[;MR.:KYBW
M".%;9=E)C%NW)6XKX9IIX&KM8VFKY GVUGN2W>L(1J_L*T].M$'[M6UO)PY#
M%.@V,@U6704HS:X+$J?.98X)5S#(FO=H\5/!ALM,C"G"EH-MDI 9#?><D AV
MBB$@XPGD,>(/MW'R*V$J=O-VL2P\J[LG2A@(1,#GPQMW,<")D!-,H&'$8B!2
M$*4A  >"E*!2@   :Y[]P-(_\('_ .=N7_\ V5/SEWO'^4?E5"43MG.TQQEC
MFL8GH.Z*9JU$ID"G6JO%QF.<-D?PT.D!P!)I9E<=*VD'BAE%%G$LI-'EW+E5
M5TX?*N55%37W]$Z7E279<BU(=?><+KJU29O"M9ZEH20UP] @("  $A( Q5/.
M' , C'J']?;6NJV7FZ7RX360;M;+';;W9)E>PS]RL4S(3%GF9YTOZ2XF)*<?
MN%Y)Y)*N.%3/%W)U^L"B!PZ2\=(U'8891&89::CMH#3;#:$H:0V!@(2VD!(3
MC;A Q5OB)/$=S[>M;)D.VN[3=JC%^A;G9)C*1R42W?6MEC?#S:\6]K!,31L0
MSR+>4L?EMF2&;-D84!:WF8GT'A@(X?INW2::Y>8.AM+$KXK6E2%%92RJ3,,=
MDN*XEF,QYQV,8E6^6$((Y)P-JN><.=X]PZ=_?[:PAQ7N4S;A-+,*6+[TYJGV
M?<<6?$67%T(>N2+VWXYNBR2]JJZDA,P\D^AFDZJ@@=^ZKKB(DE>Y3*#TI"%*
M&]EVN!.,(RXX>^CI+4N&"XZE+,ED8:=X4+2%EL9X0X%IW.4FHAU8XL8]+/%M
MSSM[/94NP'GW+>V#+%5SC@NVFHF4Z2,R-6MB<)6["M#FGX&4K$LHA%VR'GH-
M55U!34FP!9S&+JMBNC.&AT'::*Z<[A;H=UB.P)[/G$1_@[5GM'6@OLW$.HRM
ME;;@"7$(5@+ .,'(R*BA:D'*>?OJ;XIW-YSPBQS'%XSOSNOQFX&A36,LR1KF
M'K=DC[Y2[ J=>3C)5E:H:;;(/#+J++,Y^,28V**57<J14LR,Y<"I;F6JWSU0
MERHX<7;7T28*TK=:5'>; "5(4TM!(P "VOB;6  M"L"I)=6GBP?K<P=Q[C63
MV#NUE[03;EBF+PKB/<3,P&/*YZP^!T7+4_'5UDZ"66!4)%+']GN]0L5GI#=R
M#AP)6M:F(ULT4<.%V"+5PNLJ?5S]'Z=N<Q<Z9;D.2'>'MU(>DL(D\'U3(:8>
M;:?(V])Q"BK "BH "I!]Q(X0=AX9^/.L<<4[L=Q6%,VOMR&.<JV"+SK*!;1D
MLH32,3=K6_<7MB]C;=(O'UYC;(5S,SC*1?HNIQ9(\P47:ZK=\BNH936SF6>V
MSH*;9)B-J@(+)1$;*X[*0PH*92$QU-80A24D-@A!P 4D;5$.+2HJ!](]3O\
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MWMJ" (\%^T&9"8;2E*!PY9*BM0*EK45K6H[UEXL_ ]=VQV,H=16AXR(7, @
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M5QLY'>MH[Y&X'*JC2!-*27;E, -)1/K;''D"]VZX<,S^/L36 B1O<!5/=QK
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M3IT(B/QAX]W(^/S_ %^3PX'5P#VGIMX>_ES^0*53SIT81X Y@#YQY_/]T/Y
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M'X,AL,V.,L,%ZVF)*"CTZC+-9<C%G /$G!%)!:1CP:K!+)NF/4U(@HJAZ.H
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M/RE$!#V#JH)&X.#2K?S]:=))G<1O4X2 !,HW'@5R%\_M7 ?;BAXB)> 4XZ0
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M$I:E*( 2 #DGN-5!Z==MOGITSW[5W;]D9V(-)VBL*[N W*QD-?=S[INWE(&
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MNJ\A2<K%D<:O<88XH$I1)2A-S6.5F,>1<MS=9#)"EH=2#N3MMTMN0,C6Q%Q
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MAR'L'PY^?Z_/QJ5*@E$1#V<A[P]GS_40TI4(9$QC 4A1,8P@4"E 1$PCP %
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MB*V=-*4TI32E-*4TI32E6CR91QF6JLW$I?[K-$^MP@F'C(MDR_& "@'QGB)
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MIXF(H6HH+J@@++0:<K5M79_3=KNWE5U-$6_JC4W86K1VG!Z<IJ/+6$V.QQD
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MU?8HP&K.WA*[7:%IX)* A]]"HI1YWE^4I2%*0A0*4I0*4I0 "E*4. * !X
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M XEOLH3@*XE.H2.%1*4JR5 84H%(/(J! W!%52P\L\*&75')3A+:U'*0"H8
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M-RW$<3)L.@8COG%DLKFY;EWIW^[OEY0D\!*@JWQU=H6$.)<0AC*,
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M=.F7J:"7AU8N-<2\K)(PYN\DWS8S)@@\81S!"/;1S=!K&HE% Q02*CV'D_\
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MY\4R=,;04 Y8MVIU [IBJO(,U9QX)B])'#D))%90W4HV!J!@3)^75P_:N_:
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MZCCUUS28JWH8_)@V1H85NMSDE8742M%V8@.%[(S*FW6:^HHI-!P**R$NJZ1
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M]^:OXM6G_4NF#X>\?G4>U3W*_P II^VMP3]^:OXM6G_4NF#X>\?G3M4]RO\
M*:?MK<$_?FK^+5I_U+I@^'O'YT[5/<K_ "FG[:W!/WYJ_BU:?]2Z8/A[Q^=.
MU3W*_P II^VMP3]^:OXM6G_4NF#X>\?G3M4]RO\ *:?MK<$_?FK^+5I_U+I@
M^'O'YT[5/<K_ "FG[:W!/WYJ_BU:?]2Z8/A[Q^=.U3W*_P II^VMP3]^:OXM
M6G_4NF#X>\?G3M4]RO\ *:?MK<$_?FK^+5I_U+I@^'O'YT[5/<K_ "FG[:W!
M/WYJ_BU:?]2Z8/A[Q^=.U3W*_P II^VMP3]^:OXM6G_4NF#X>\?G3M4]RO\
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MF3(DFDHH3O#]XF=$8[OSM7[=%H^?GXU ^@01R.Q'SWUFR4Q3% Q1 Q3 !BF
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MQU#RD+C!*&EUOHJULK-W@H^ST^=B[+7I5+OH^8AGB+]@Z( B4_=N$#G)UI'
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M>5QY&6ADS=L[0@SN\2\C*W&N"H$@5IB/5>N%BG;I*G3:F57.J^&_AW?/],4
M.-AWG\^\XS\[8J;P.XZ][@Z3EZXY&W460K]RBJS95*.L=CJL-;H&=DSLG$56
M:S!.$8./B6L:F@Y>LI$3+/(\PIO'+]8[I55X^[?.1[/7]W/:J9.WW8SORWQW
M?GZZV2=F1LAVZV?;\VS5DJE4_-MFRPXLD>9/(=-AI^KU.KU.YRE?8UBKUN>1
MEHM%,[VMDF).=[CUC*/5$4@518Q[-N1Z]_7X>_/?FI9QRR._?Y]U;$L^;0,&
M9TP1.8-EL78[;P2-9G(_'"2=4C&#/&EE=Q;MM!V6FIQ#=BO6'T-(+(/4UZ\K
M'KG*D= QCI*J)GK3)_/Q]^:XR\%W7=YM46R]0;=B2Y1%WI"CK$N4&:U<3LRK
MQ6S@U0:.:Z11L^D)Z/N#=5A)5BR5YHN,DQ?M';%V45S%"F>?N_,Y[ORJA Y#
M?.^/7R!\?;M75%V8^UA/#>%F63,D8PA*GN!RL\E;-:G[^&;EOD#6Y)PD2N4V
M5DUP5?QW<1;)I+2D W4:(,Y>2=(/VAI)LX5,]F*J>[/K[L_/SBMB,91Z5"2$
MK+0U0K$1*3HF&<DXR!BV$A,B<1,<95ZU:I.)$3B(B87BBW4(B(\B.JU3-<+G
M:4Q!-JO: 9BR+CBD%CMOEXFH1S&25)KQ$:C2;U$P$5!WNOOV$$U(PKZ,I:8Z
M2L;-XHBU8R[N8D1364?I/"CDO09##3+ZFU=D^@+"DY/ 2<!*^80>#A4,[$$
M9*3B>"H?XASWP2/9OGIOW=#5[\79'L^].W,\IY5K:-CJ5=BVB43+62O-V<;/
MS;)FSB8@\7&F8M6,HVAXYHH=T_!JJV*_!H(JK/B*&;[6R02\^7WF0IAM)X>T
M3E*W#L.%*AA7#N2=P#MSJ@&-SMU\3^7+8GV5E#.8=P_:;&SN%EQ;CJ?M4<5
MC&R3-,KDI.-"->/12(2CR.6>IE;"4H-P*OPAT_:NCI#74KB1W%AQ3+*EC&%*
M:03MRW*2=NF<XZ57!'(G?V'??OV\?$CGFKI$5X  X   . *4 +P >  !> $
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MT! )[DN)2ES(]'&V.)"@/-)25VB]R$/9[.6^Y*CKY)6VZX7.'.0"IE:EMA.
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M.COXO&-NRA0[7,Q[1=:=F:E#U+'S>CP+,SI)NRC'SQ0(Q.RN&*?HRW>$>-6
MR!TBJ.&_W9^?T]W.J'ZPY\B!^9P?O[QW5T[0\O&V")C)V&>MY*(F8]G*1<@U
M4*JV?1S]NFZ9NVZI1$JB+ENJFLD</ Q#E'VZ56K*;E,Q-<*XJGK.59$+"]3&
M#J34XE$[B?D4U2-UP2']\1BD".)9R4W!#HLA;B8JBZ0&SK=$,R4VU@]FDA;Q
M&V&TD$C/3C.$#KZ6>AI7.^9XHX456<*'667.=5954YCJ*JJ&$ZBBJAA,8YU#
MB8QS'$1,81,)A'7H'",8 & , <@.X#'(>'+88Y5+A^R<^'7W=:B$UN/(?9Y^
MT/=]0]OB.@&.7+'/KRVWY'X=.?6.?GX<_5461P/D/'RCSY\>?S^_Q#V^T-4"
MCG!Q[_><<_'D-O#>I9_J/'X>[!V&]1A%P'Q_![!Y^;G@?EX\-2!SO5<\AX;@
M;G'/J,;;XYXY=YJK:777]UME;J46 B_L<U'Q#<W3U@B+YRFB=P<OAPBT3.=R
ML;J I$D3G,8  1"T^XEAEQ]8V:0I?KX02![3L/$T/#[,=V_K[CD[>WIBND&)
MBV<)%1L-'(E0CXF/9QC% OW*+1@W3:MD@\ \$T4B$#P]FO-U*4M2EJW4M14H
M]ZE')^)J%3#4:4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI6*V&O[^^Y+_W
MG3O_ *::U(_53[?OJ(^LKV?=62,U Q=@:@TE&I5R$,)T5 $4UVZG''>-UR\*
M)&]X /0< Z5"G)R4;\67(AN=K'<*"1A2=E(<3D'A<0<I4-MLC(YI(.]8DZWQ
M+BT&9;*7$I/$A7U7&E_;;6/20KOP<*&R@I.15OQQ4T XE2FWQ6H\_$.BDH[*
M CS\1R!TV_)>>""=B< #CO 5'D1W(U$[P^E$9+G>%K2T?6W@KWYG#R=R0"D8
MQSITDT%<*)\@,[^BI"%/ $YV=!2WE(V251U#&.(*.YK> J\/6TCDC6X@LL!0
M</%S J[7Z?N046$"\$+[$DBII /)@)U"8PZJ9/DSE OKRE.>!I X6D9Y\*<G
M<]5**E'EQ8  WUOM4*V(4F*WA:_[QYP\;SF#D!:R!Z(SLA(2@'<)R234.L*M
MC00 0X$.0'S ?$-*4TI32E-*4TI32E?@  >0 'B(^ <>(CR(_.(^(C[1\=*4
M$ '@1 !$!Y#D/(>!#D/</ B'(>P1#R'2E?NE*:4II2OS@.>> Y$  1]H@'/
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M3. &*(:][2L.)2M"DJ;6D*2I!!"DJ&4JSD9!!!!S@@CKM4@G.^<#OJ% GO\
MP?7Z_+IGYZ?F?#/CM5>(#ZH]IY_/SBO<B?E[/D_7]>?IU2H$D\ZBR)>7(!QQ
MX?1Y^_W_ "^_2E112<^ !X>/C\_GR/R_7Y*$@<ZKCV<^?AT]?A71'V0?:6-L
M>##;5<_6 K:CNW!6>(+Y,. *WJ#]VM\2B6!ZL8"H5>0<JF-7)1R<$J\^4-$N
ME"P;ID>"\]U;IPR..ZP$9? S,CI&[B4C^_0D<W@D?Q$#=Q/I@%85QTK:[N[Q
M3OXR/FBN6W;Y>*[3,5T"@9,K$=527^R5N7R!>,GX;R+7&5[LK:*0&ON87&5[
MD,8251C9?TJ9CY*"M5@B^Z._CBCS%HE6"/#<:N##C\J1(C.J>\W:=1'8BS(S
MBH[17EP.2F$RDNK1A!2MIM>0E68D'IRP>_.<>[NY^-8*UC8_VLB2$4VF]U-H
M:RS5G'M"V N=;Q*Q35SBVN8A<XCD7U?<B<TZ6US-%M<'GAL\,HKD1:[6:=DG
M#EO*@@CO';UI3*RBUM*22H]GYA'0LB4Y,$M*7!@(+*'VG(!&T8,-(0 49J.%
M;;].\[8QC/?G?//GFLJ<%;>]^M#R55+MDNZ2%Z-3JJWGY-97<KD-[6;^Y=;<
M6E;DL#GPS(PA:#%JFW-R5FRB;/$T[G;4RK$74JM"&0K[QW6*OJIT^Q/QG6(S
M"8_;.EM'_=L<.1PFY*<3/\\2LR%#Z,2U%\Q0$-*<4\ZYET)==J K()[OM'NY
M8QCZV=^[&.X4+5]K?:1((Q<3E?*OV2$9',F2+O.26/MSF7<*I5L]^@, OJW8
M(9Q'5^?GYJB8GL,+N(95W $B9''<@K;Z060B'T"P,:!OO7/3A*UQ(GFRDPX[
M"$OVR'-[3L')Z7&UA3C;:)$MM=N4Y<$?VA/8O\*DN*_B,*Z[[]Y'=N,=V^W(
MGGM5:[+=N6^ZEYQ#(&X^]3J\(#>R2EB*MN/R%DJLV4UKH6-&<=CJLX:E$BT*
MGQ='R3&Y)N!,C( TMR[.0@:C&ME*R^DTHNS>;A8WH7F]M8;"\MI;Q;8\5UH-
M2))5)=FH_M#RWXRHS/FYRR%)<=40XE!62%9R?_<3T&V-@,'.^,\@-JW#:Y&I
MTTI32E-*4TI4!*Q49.Q<C"3<<QEX:88.XN6B9-J@^C9.,D&ZC1_'R#)R15L\
M8O6JJK9VU<)J(.$%%$5DSIG,45*U?4GL7NSMQ]E!'*=;P>LF\92:<W%4B2O%
MWF<60\LDN#E)TPQY*SSNN^C(+ 4[6#>-G=<8]"16,.V(DD0E,>OU9VZ]/GD*
MJ5$\\>O&];3P     .     #R  \  /FU6J5^\\>(^ :4K2UOJWB(6A20PIB
MV5*M7FZHH7NSL%@,E.N$3#UUJ*<I")58=LJ4/6[Q(QB2;D@,43>KT')I+L+)
M:.SX9LI.'#NPTK_9@_[18/\ M#_(/Y!N?2("+B4]3[!6L!!SQP ^7YODX_1[
M \0'73$9^??CQJJD9W'/X?/WU,B' >! ?F\?S#Y_@\=0W3MC(]7W\_9[.[ C
MQ'DH?/CGW\N8%1B;CCP-Y>_S^;GW?.'TAH4YW'KQR(]GW>'+-5*3S'NY>[^O
MJS4P36^7Z_I#Y_'4*@#C<5-6"3F0=M6#)!5V\>N$&C1J@055G+IRH5%!!%,H
M"<ZRRIRIII@ B8Y@* "(\:H2E*25$!(!*B=@ -R3TQC))JN00<['PZ\ZZ.-O
MN*T<.XJK--$J?K8K?UK9ETQ*8'-DDR)K28@J4 [Y)H8J48T5$ $[)BVZ@YYU
MYY/E&9*=>WX"KA:!SLVG9.QY<6ZR.04HXVJ-7IUATII2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*Q!QQ)>ILM;JYCN^^]5%K\EW//'>^@Q5@==WS[.ONN
MGGY=2/U4^W[ZCR*SW8^ZL+=G_P!C>-4SGNDS).Q"\Q0R2-CDY"3.D[?5MJLQ
MD+)9+06- 5GOICY#EE#JMV_I!BHR+&.!4[@4BR6<8&=AS_7Y]_2VV,DDYS[<
M>.,^OX]V*NON"WC5RT(84J.#=Q>)*)&9O^%C&TY&E':$K9<:02%=0=1UCC8T
MS@L)'S:<FX"%3CK:ZBCB_?MYEHJM%UNP@%H]W7!J_CU_/CTJ=[0<YVS(<UD.
M$L-VH^1F^-LKRN*(>]TDDDW)=8J$9L&OP@GV#L%6+"==O55#/T(9^_B'3MLM
M,0JZE;DX%PYIG!&W/;/,?'J"/OZFGZ?GW?.1W5L77:MG(H&<-T%S-5P=-3+)
M$4,V<E351!P@)RB**X)++) JF)3@FJH0#=)S ,JI5G=R6.668MNV>\1R=I:T
M>-REA?*6.9"ZOFJ3YE4&5VH\[6G=H>,EY&'0>-:^A)J2SAJM+1:3A)H=)219
M$.+E(.8IG&_=O6">4^SKK^6\X.MR.(LX-Z.:0B866:51&H,[[C<^?*/GW;;E
MLV7UFK"W5=VLI9%-J5#QWE.H1LO%#8FL4G-,IZM6Q":?SBF=MNO7U@CQ[\C\
M1M7O2MF.4<4Y(NMIK6[VF063MQ$B[<Y8%?"$4YD)J%8Y(O&4H]/"U>F<JOD:
M1*5L,AY$@$Y:VLLP1:T&[@GDO!/)>MN)";?/]:=VWSM^6>F-\5C>R[$NA1=0
M>4:SYH8/L:252B4;T^6Q_+,[V$[ X"B\+/9JK6:5RQ+8ZJ-:44KT7D(C&6Q/
M:;3#S*4A%M,@$@'+9K&5S[_GY]E5SR/4'.>G/)S[>?R:O9D'85:MPTS(WN][
MC,,9 R\>/Q-'EF8_ TQ&5.OT.C0&7ST&4K+"F[B8C+]$R-)S69[S;$\G4K.-
M::RL8LC54JNK6DW)'-/D[U3N\,_''AX#O^-2-EV7%^JM+S36ZKNQ56D-Q.+G
M^),VW?)N)!R!9[35D4Y]:"L+-^7)]92BL@%?W;(+FXV>23GX^U)VE)1"!@).
M!8RJJE7(V[]G[$8&OK_+=,RQ39B!9UC+RN)9!:C34A+1".7YM"VLYJYW*2R_
M.UJWPE2:%".B28^J&(RV.#53=6B3F'Z*$B53Y-6OMW968AA,>84D*1G.=Q_,
MT)K!Q.4<GW2PW#(==S75;!:J9?K<U5K5JRDA4*!+9,S=3J)DKUQ3^[9C/-UH
MT(>62ET3M5"=NGAT'KSC?;/.IIN%[,Z>W'R&=IVN[FVL-1-RB]PG7-9<TFW6
MRJ087O#>%<6L+?66M/SKCNL6RTL8S%)Y2-F\B0=]JX,[(W;P]4BUXZ2EK.JO
M<<;CKMWD]Q[_ %>'=.X_LS;+$0>7Z5&;@(Q&@[E9"V%W#0[G$2CJ?GJW9-P&
M:,T!%XPLQ,F-2XYE5:_FJ9QK-S4W"Y$;.6T1&6ZN0E4GCO2.JYSS^>7WXJGZ
M8QMC  _#XU";),&[D:9FND.LFP$Q7,0;==J\_MEQ:UM-:QS"3[ID]OV,7]?
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M,]_7OV_3EMCQI\_/X?A4V2/SQ\GX>/:'^WV#JW45)SOU^?D5-&ZO'A\_'O\
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M^J4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5B16WR6/\
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MXBE35,0 ?'WA^35*9^?GX5'HCXE'GW![_$?]@@.H8PH'//8^W)'Y>RE3-,>
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M?_>/BO\ S]Y_6?2F5]P^?;3U_N_^\?%?^?O/ZSZ4RON'S[:>O]W_ -X^*_\
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M/)]OQ'YU.IBCY_2/YM!U]7XBE3,OG]?9X_HXU2J'IZ_NW_#%1R8\ 7_V@'\
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MP74(J17ZC#+4A)W07P+'$1%RJ%/<PS-ZN)A$QC231Z4YN!5(?@ UMHU^NT7
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=32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g393013g80f34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g80f34.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1X64&AO=&]S:&]P(#,N,  X0DE-! 0
M     #D< 5H  QLE1QP"   "   < @4 )4YU0V%N82!3,2!0:7!E;&EN92!2
M1T(@*&YO(#(P,3<@9&%T82D .$))300E       08.NO/[YH=A,I<]#!;,FJ
M#3A"24T$.@     !30   !     !       +<')I;G1/=71P=70    &
M $-L<E-E;G5M     $-L<E,     1W)Y<P    !);G1E96YU;0    !);G1E
M     $-L<FT     37!";&)O;VP!    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M    "W!R:6YT97).86UE5$585    "< 2 !0 "  3 !A ', 90!R $H 90!T
M "  -0 P #  ,  @ %, 90!R &D 90!S "  *  P #  ,  Q $4 -@ V $0
M,  R #D 10 I       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\
M;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N
M=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT
M   0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O
M;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B
M;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M  ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0';^X4
M   *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=0
M0P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M_P  .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          CA"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8             !7
M  D0          $                          0             )$
M!7                       0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!7      4F=H=&QO;F<   D0    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M1;=_._SGI^U$</6TZ.J<G&#0\VL#73M=N$';.^#/YFWW*%V10ZJQK;&%Q;H
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M_=\/ZJ2GFK.MYP (S]LC6:6Z'_,5._ZQ]49NV=1F/H_H6"=/Y5?M6V[KF0T
M_9KCN'M]S-=-WM_1^[VJM=]:KJ(-F)<V>)>P3'_6E*/[@_YJP?WOS>?L^MO7
M6\9T?];J_P#22JV?7/ZPCCJ,?];I_P#2*Z%_UY+?^TMI_P"N,_\ 2*?#^OF)
M;E,IS&68=3_:,ASV/8UQ,,]6*F[&._TB=K_FQ^"1YO*/^O'UE''4O_ J/_2*
M _Z^_6@<=4_\"Q__ $@O7?3?_I7_ /1_\@EZ;_\ 2O\ ^C_Y!-]V/^;'\O\
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M+/\ 1.^]O_DTE,]4M?)0]1_^B=][?_)I>I9_HG?>W_R:2F?N\DWN\E'U+/\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      7Y-30 J    "  , 0
M P    $).@   0$  P    $%D0   0(  P    0   "> 08  P    $ !0
M 1(  P    $  0   14  P    $ !    1H !0    $   "F 1L !0    $
M  "N 2@  P    $  @   3$  @   !X   "V 3(  @   !0   #4AVD !
M  $   #H   !(  (  @ "  ( #@D1   )Q  ."1$   G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#DZ,34@,3 Z-3 Z-#(   20   '
M    !# R,C&@ 0 #     ?__  "@ @ $     0  "1"@ P $     0  !7
M        !@$#  ,    !  8   $:  4    !   !;@$;  4    !   !=@$H
M  ,    !  (   (!  0    !   !?@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0& 34T *@    @ # $
M  ,    !"3H   $!  ,    !!9$   $"  ,    $    G@$&  ,    !  4
M  $2  ,    !      $5  ,    !  0   $:  4    !    I@$;  4    !
M    K@$H  ,    !  (   $Q  (    >    M@$R  (    4    U(=I  0
M   !    Z    2  "  (  @ "    \     !   #P     %!9&]B92!0:&]T
M;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C Y.C$U(#$P.C4P.C0R   $D
M!P    0P,C(QH $  P    '__P  H ( !     $   D0H , !     $   5P
M          8! P #     0 &   !&@ %     0   6X!&P %     0   78!
M*  #     0 "   " 0 $     0   7X" @ $     0             #P
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M8T'TKIW\NMN LX_ZR6]>_P#V29KXOI_^_,U8?@RHOE.H^#^C0_"_QJ!I20_
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M]DZMK;<:6;I*.J=$.G]&N <^5T9$/#/O#.8Q^+1U18V;@FL>\0RM<&"TCA\
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MP>7;WET'E\Y F)$SD)"!-G LXXCK8@\1ZG1MQO\ DINZME/6U=&ZD:_O<UC
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ML<:@7XV:Y*!8OCU6&3\8O2+DI*\GNL,Q*6.@#67*R$9BV69.9.HA&LJDA32
MFB5B-6!]9L]'KN^@]U6A ^5CJF1KH*62JDQ4M4UH;%2BMFA;(8N#=5PTKA-+
M2->9XVGPF AP%> =EQY;-]AMU$Y7U<ZS9/DFMU3&.9<D,OOQ'$K,6813S@T:
MK9JQ3(K<A"K<J)X?)Q.%EXK,3(%[-H_-D#$;/1I<HB7'S!B*@ES%282^*!RV
M![K]$NDHXX>_)N^Z[O$D457&:=QI#6,FF9+ R00208)(Y PM="Y]1?@89GLL
M(#8W(O:XS&^V5B0<\CQV&T+47<+MHRSM<EZ4!S(/BX28\TC80CP*?P::E8\_
M$$%1101*&<.D!Q>-E&;]!5&UJ939]()V5>B5"##_ %5KV-&Z4H]+0FHHG3/@
M\'#+)3SP,D:]H>U\3IHV"5I:0267PGP7AKLEF^,LUG.]K9>@E739S_5:;9/\
M_F)/X]@M<O=+_H[IW_TC2/\ ]251'XPY6_S-63;]?ZM'=!_GLG_W>=ZY^Y#_
M $7T#_Z92_\ +"M+K\[NM3SMAY/V';A\7XBE1O<['\1Y&W$Y[F^W# N.Y#BZ
M8R4--,DQ(/B=XR:2#($9?.D(0/D9K,44CS1^_C1%%FX46>N+KFB:]4,M*]T<
MVC:JMACT5)64^C='P:2TA41U<$3X::9]4'.CIY6@SNBCHY9'-;*TD6:,R%=D
M;7-!O8DEH&>9%N/;?JWJWX5Y++=+F<AB.K-OC**Q?*^68MB*LD/9?QBJ]@9F
M8%Y0&CI*?P09+7D_C Z2OH/+V,+Z5C;-><& M <8L(%"@EN]M7=UFB:)M9B-
M5++24DM8(F4=2&U#(60R2,IZAT0IY71-J(73X)'"!C^$EPL8\@(#<7M8FVS;
M>VHWV&V\Y*+LD; ]SF+<3'<YR.(1MWBP ;?C74DC62\:2MTN":S\IBUCDAG&
M8W+2LH=8ED>0 [Z*Q7*3<0K!)(5M;)!CSU(@.6=]5+W1:*JZR.@BGD%7)&UP
MCEIJF%HD-.RJ=3&66%D0JXZ>1LLM*7B>-ER^,87 5="X NV"^[5JOKU7VVMM
M6F.O<60)&I?THN1;S)+CFS/&$A./%"Q4OC7'5A!V\4O76=O B$ACUQ-PJI6Z
M]9^2;"FJY!Q?=6]PXMJK?6M:Z_DGNMI8:/NCTS3P-#(F5\Y8P  -$N&; T"P
M#6&0M: ,F@#9==\;LL\1NUI&>^^O5_39DOSY_).7A8Q![.MP_P!TL=Z_2?P/
M:^Z#DT9UUZQJ-G\17Y:=?MJY4T1-$31!EFMEY'NRS#*$-OC B5:I!-M45B,3
MQ_&V=YI"./6T*G4ER"'*RD+>:58E3UYJ4D&STFT2%WK"D&+1)-!1O<X5\N/0
M]%$=(N:PE^E)9I:F5V RM,]/'3O;%)@#F1\'$TM:2ZSRXY@V&AE<<.KP18#.
MVN^>>M2Z/Y1C/H\?DMMT7BY\7R#/L^Y)#3 I":D9AB&4;H B<8SHOB0TZ+7W
M 6\[C2#4*ND>0E%X2QHB6C:P>1W.#2_$[N:T<YU*<=6UE-3Z/I7PLGP0UD6B
MG\+0"L8&>^&GE)>#&8L9);('QV8+<,_/Q<R3>QN,7C6SRO\ Y6*VQSMRK8B5
MXR!Q[#N,5 >19,CD9?-\\G0J+6NIB4RGM;(;69@3OO@]0G9%*'\5D4B,I2UT
MRB@QL63#+V0&KM22/#WCZ/[D7PU4DE;5!]+%WL*&GIWS6B;2:5;I:%MJCA."
MB;-'&PPM=*\M,@-1;@FQW=,"VP!OG<D#.[<.=CG?/.PV<:A(/RL6YH'C#&>)
MF0'$%(UBD&&!1Q>L1/(D7"(+!^8-O;%Z3L9S!J&J1OQSFN5ID5A8<4B8DK,3
M+2K=Y(%9$^D'H/[D-%OJJJK,E9PM7(^24<-&6@R5]'I)S6DPF3#WU0PEH>]Y
M9$7PL(B$;8Z<.^P'@Y<1W$;]Q/+M6O.5=Y>6LPXO=8DE;*&(Q=V\VT/E5@X8
MBS+T6VIX%D&W3&=+';@V];VINX%)2#F5VU9UJ5D=K8BPN$,TKQBOHT>A*.BJ
MQ60NG,H;I-MGO:YEM+5\>D:G(1M-VU$31%X7@QW:[&XXQ5TCG"QM;P=7[((&
MWC6INO86::(FB)HBW/Y.W^K?VS?YTP?V#G7S/=E_HOIO_<9/YFJ[-?F](7[(
MI+_MF4_9[O\ ^]?K\KT=_<J'_=:;_E,7Y%7?^)5O^^57_.D4F)[J,IBC <V/
M4!-7 9B?&T;)CW?6)1A(8I#H>^:%T*DJU=(IL8)'B+.B:C>YN:;7OJ776U20
M1YCHBC?'+&X2$/,3KEPQ,=%433M<PAN1+JF5KKWO&<.69/IQ::K62Q2-,33&
MV5E@UV%[9*>GIW-D&/P@&TL+FV(M("[<!A\AW/SU\E=8S!P4 Z<)C$S)4" =
M-#$D6!1=Y%X\\.$ERKMPNO'VKRX@+3:7,F5AA!H^=-'76J25NT.B:<$%TE1(
M,3\#)) 8XA+,)I6QL# T"4MPO+@YQ87-#AB),OTO4N(#8Z>(G")'Q1N:^8Q0
M&*)TCB]Q)B#L3,.$8PUS@[" HGD6=YD9@R4'>CHA=2@0%%G4O3C3-.=$HE%W
M+5W'HL_D5+JWJ"!:@X8FEU!LW(+M!8]@]?N63:QOKM9HVGCJ#4-=/^4EE$!E
M)IV33 B69L6R1^)Q-R6ASG.#0XDK,Z0G?3-IW,@_)Q1&;@AWPZ&(M=%"Z6]^
M#86MM8!Q#6M<YP%E=OER\XBC;PW'S;*-=+9%D6392' I$F0*;')2X$WD1LO'
M7%5J&XVFU$(C&0A92RQNP=$+*K*.'BKG6/L'H]\8CDC=+P=+%2PODP.D@CA;
M)A?"_ #'*7.+G/&MP;E9H"ZFZ:KQ(7L>V+%425,K(PYL<[Y7,#FS-QG''A:&
MM;E8$YW)*P*-;K\I0:%C8(!LCB<?!3)K,@B*X\C>L+5;R<?+;P*%Z1=!-:/N
MS0Q!5RB^1=E+4%GK9J6;)/7-JF\NB*2HJ))Y.%,DD+X)"'-L\<$8!(;L)$@C
M>;%I:RX:2PX6VO#I2I@A9#&(\#)N%8"UW@6D9+P8L\7C+QF'7=8D!P#C?Z0[
M>]F''EK>T$,@"JC-5ZLW=$HVZ=/4ND)S*IZ_0L>IF&[JC1Z3F)I@Y9T5HV4&
MW,+^I4,#6)="E1H&BJ<7"/J1BPX@R4!IPT\5.TX<!%PV&-P-KXPX7X-[F'HI
MM+U4+6AK8#;&071DD8II9R+XP;%TKVVU82/A-#ABYG>QEAXUO:( <:B;70N@
M\ZN&B2C!Y*;V\%6QP()21[:5O=$B8"*.G[$.O15%%%0B]<.F[M12SJ>L6@J,
M'&9*IY#\48?-B;$#4"J>V)I99K9)@USQF2&M +<[W&E:A]Q@IVW;9Y9&6NDM
M%P+3(<5W%D9(;NN2;KK@]\N1FF3V$[DXT,X8JJ"Q\E9QEE8.).HXVS<>SH09
MB%CM\B%-WKR32<P/K<4%$V"L?O0&.&=5J*D5)DT!3.I74T3GAUGNB,KBYC9#
M01T#2\1\&\M;%$QUFO:[A+N!M9HWCTG,9N%D#;6 ?@;9Q8*E]40TNQM!+Y'#
M-I&"PM?,PENJS/$,U3F-DH!#U8/"X7!!,$C@-=$,T6L9,#$A/JK7,8^V;"F*
M='TD=M&R"-7;E1HT;NR9!^4<O72G?H>BFH::5M1,*B>>H?42R R$8G,CCMBD
M<Y[C:(.)-A<D-:U@:T4JZF.I>QT4?!QQQ-B8TAH-@Y[B2&^"/">0+7-@"XEQ
M)5K+?U&XW_X@[_XC$M>8S_3&;_\ 'Q_]Z)=3O_!F?^H'_D.6G3GQ_P#O^UU]
M:-?^,]17E;3R#K*L3CO?2^]=JPU><]96KM7SOYPLN:9=FP/&1G$H<AT9%CTQ
M83<LJP6(,RKTB.CI.-I#G#IL^2;K@U6!AU>Y'KLU>JNK$%>K6V)U2OQ=1025
M,=8]N*:. P,Q!I:UKYFR%P!:2) Y@ <'"S21;-;QS2-@X)ILQS^$=:X)(#FV
M-C8ML3<6S4PPW?+F''[L:Y%!L=$K!<?Q1&TFA^-/B354;AV%3J!12Y2VTXW5
M1(7A<A'7#\FP69OTC"(HJ$<!G3"VJG!-H&BJ X/?4-Q35C[QR-:0ZLF@J9OS
M9!'"4T8:UP+2PO8\/:[+L9731. :(R V%GA-)N(6/8R_A:[2.)(L;AI;AMGW
MBG*,[AGBF12#=.!!Y+DQS$W4CE@B-O6Y>JL0#P@0-O09+'',9<JW=@(,DFY-
M1XN\"$U2BL4<QYL04:6U;W-Z.9WLV]0^*FX811/E:6#AG5#W>$(Q*/[Q(VS)
M&->T,X42.:'*XTC4%TGB-=(&%SFM(-VMC ^$6GQ ;N:2#?"1J6N6Y/<KD7=!
M,6,WR.F :DQHBH=HRC3,@Q%)V*/WI1\\HW)EC+FUX1(/EW#FB;RQBA91NS&L
MF ]JV:)>AHW1E-HN%T%-PA:Y^,NE<US\FM8UMVL8,+6M %P7'-SG.<XDTGJ)
M*AX?)AN!8!H(&LG:3K)WVW *),O9+D.8\C3#)\L2&HR.:EU31A(.V69B['BU
MJ:=]K)JX=/5T4>:E;PL4=+W4KQK6^O'A3KHZ:.CI(:6'%P<#>#9C(<["&GQB
M  3Y@LY)'2R/D=;$\XC86%SN&:B)U]!3U_P:ZQJ9YOY2J*R*>+Z?WM65]C>1
M_45NWOJ_V%M0_P#A.Q=]B4U\EW*:^Z'_ /(](]<:]*JUT_\ NS>IR\]E?'_E
M?AU]@W6WD/6Y<F[^%W_4K6OW[O\ W^:UNSQAY^HJ=W(?Y IZ6W59;I(MO\@Z
M195LVV-<?M\>1Z[IBL664QI*WLPCS^1!.F.MR!)<H_71*O&5PM1TPHFW1ZUO
MMJM=YXT31\'I&/"[^TC*:B3P.% JHFPR-CDP7:T-:"P'%A=<YWLM142$PFX]
MY,0:,[$,)+<0OGQVMSYJ><5<J1N1PLJ 7AX;$BKV,-R+<(2-PEX2*,:%<PRW
M-;^J)&DA;NTTW<GG!X:[8)JV"GP"HNQ^P=' 88ZQX*ON5T;6AXF?689"TO8R
M=K6.P4<-$V[>#();%!&YKCX;9 ["X,>^-W0RMF866##D<RVY%W.DR-[ZWD6U
M6ME< CJ1+E4]S&/&.,PD/&8N"QK&8>3 D(RUC<BM#2EA+08:/F+#EO9AU^#Z
MLUCH5]5/&S^ MECS&R1/6[LVJN^53=RFC*AU5),^J?+5/BD,IECQQ.BD?(S!
M[SADL9'M_&FU!$;N#:0P!HL*V9I8T",-:+6PFQ!!!OX67BCQ<.=R;DJ#<;[W
M)_C7)^;LKO<<88R?*<_,C(J:TR=%Y(68,!$E+U+R(3%;([,HL^"#SMMJ 4LA
M5^[Z^C2%8^XNO%O2C=_WU.@Z>JHZ*D%36TT6CW,?!WM+&QSGQ1AD3YN$AE:]
MT>;V'"W#*>$ QM86HYW-,DF%CG2.L<0-@"1<-LX6&=M>8R-Q>^EI-S1Z[>O+
M6K5E:[=.75&3%.])DTHX545HV9I**+*)-4.?U)NG>JK?8E99;<I?=2MU?=:,
M+0VY=8 8G9N-A:Y.5R=9R&:J#?.P%\[#4.(<2L*_B^E]_5V_"_A*D:CR>D*:
MMK?]4]MU_P ^F)OX] =>7W0_^!:;_P#2=)?_ $WK2'\JS^-G\[5?]]7]6%N1
M_P [\R^ZB^L>Y3_1O0G_ *;2_P#+"TJ?'?\ QGTK453O7>O]_7T"YQJ/)Z0L
M\Q%E&280RSC+,L.2%KRW%$]B>1HPB;:KO0RI^&'6$A$)EF;9VP<.AU[\>A:]
M;H/6BRS>JB:;E"^ZBEM:ZDBKZ2HHIB\0U<,U/*8R&O$<T3XWECBUP#@UQPDM
M< =8.I:PN+'8AK:01?5<76?PO=?E^#*Y-<H%&DF>Y7MQZA)R,SN,R$@DWQEE
MB)YDC+84\7,I+M6]LLA8A!VBO>[34"J/63:UHX63>H<D^AZ*?O4%CHFT8GX)
ML."-I-523T4I> RSB89GD$83PF%QN!A.S9'!I-[EV"][G4<8 SRS',MK9%RN
MVYB3@ L5-0W KF/B,E(986%HX]+,$#,Q;%LEE&I I4?+VJJ;AO=E:5H)E@Z@
MF156H(D"AN^7BV\CUY$?<=HN*1\K)M("1]*:,.-2QQ9"64S'-9BA(L>](B6/
MQQV+X\' O,:Z!.\@ AMA9VK:2X[]E^7COFL<R7RL>[+*>/<V8TEKR#.(WG(F
MH2-WM01M M&$W4)@F.RXZ+E+Y.LX>MC\.QO$A)M_/>S@^]6:$3?324@D,@*E
M-:;N1T123T55"*@2T#6MCO)&62D3U%2QTK!$ TQS5$KF-I^ C <UF LCC:V3
M,\@@VSXN(-UWV@#7=:VK[Q,H5VR7[6$ .+V$,>(C1!F;#\?B6>7)'#0L^(Y3
M!0&0SQ*ZCDK% N0R;N3C;%V73B*_6PI0XK'F#$.V],Z%I/97V5,E4Z9N.1D#
MJA[J2.>2F;325$<!R;-)3L;$XAV B[PP2N>]U.$=AP96.1-L["[@+\1[%J7?
M]#7Z7PTU[9U><=84#7YCU%=2_O\ TOOUU*T9J\_H"],N1^_J_L.?M1E/_P#:
MJ9:^%_"1_HCI#_;:/_\ OTZF/6?X1_(5YI._]E.?V0M_]R[7W#/$;_"WJ"R.
ML\IZUO=MBY2#<KM$5P<KADA%1?:%G>8YW'4"H<B0:RM7.D>QI&YY&,@-43C)
MO(8DHUQ/$'X8:W3%O1)QK<:0)W$&XM8;X.E.YG1FF._^_6S.]D(**"0L>QIA
M%!)4R4\M.3&XQS7JYFR.)>U[#@+,)<':-E<S"!;P;VN/*UWS"RV[E2MQY#%N
M&,/RP'B>>0K"$@B1B.L)C%3I!.2#,?EGYV"PR<CF4N' 9#$8P5>HN$&5H9B2
M-("@XN5%CX=A8/NQ'<GHQM575D,E93SU\<S)70RQM,3ZAC8ZB>G<Z%TD<TS&
MD%V-S&%[W1,C>[$)X=Y !#3;>-VH'/4/\[A8=E'E$\Z9GCN;P>20&)Y*3W%
M,*L,MS1>$*-9A)Y=@1:2)03+-7K$RV%L<HJ@)6:B<E/L@Z Z1 W'5WP2LAJJ
M=5VI>YJ@HI:"2FEK(FZ-DK74< G!ABATAP1GH[.C+W4HDA9+'&7ET;Q82<'[
MV!F>;W#?" !-L\M1UZ]EU79O_F3K;S#-N,IP1MMG,>Q]CX[C.(SN5Q&?JY-#
M1@]+Y9.5K&QX-D\*%M?L)%-#KL6][&^>THLC2ZU51"U2L>UV :2GTG%7Z3@D
MJ:EE5-!%-3BE?+'#% "8WTKWX71PQA[>%\*QV&RCA780VS386!(-P.>W0I_B
M/*RSE_.2,ZS5B7#\V=@MMF;=NN,! C';!C' T$R0P'-H/B*4@7)J@\_@_%]S
M8FVBH19-:9"Q<@,-:2HA<JSO8^=-W'P-IVT]#65M.)-*4.DJM[ZESI7STQ>9
MZR&0,Q1U]5B:99![P]T;"86V-[MG-R7 'P2T6 %@=AXALM8YG/8L0+\KUN\-
M0;,6-W2^-FL+RZG:U:@0T/=Q\=B46EBV)X4:A,2,@1\<R"!&&+H)#XF.&29O
M+VK!,"U,M+$I(L^,N]V=QNAF3T52!5&>CS,CYA(ZL<:J:N+ZQSXW.?(ZKJ)I
MGNB,)<9"PWC#6"IG>;CP;'9;5E;(WOJ Z]=U8G7*D9W(R^/STIC+;(3E[:*S
M^)9%D;C" 5$]GICDO%JN'98XS2?8/V9V0K/X2K>A>QCQ.* %S-U\A?!7AE9P
M\5NWN3T>R&2G95Z5;"9:>:FB%>\QZ/=2U0K(10QN:8X@V< WD;*\,][:\, :
M'#ON#9NV^1\*XL;Y[N3>LA,<K]NZD5V'ZR*N+Y"CB8&3C#T<<ACPJ$RW'#&+
MG^%R@/+D?>R!8";'O\9EBT9>)1D;$;W52CXZX45DJ]QG5&=QNAHN_."[ZB-7
M(V5KHYPQ]'*RJ;6L?1R-C$D;F5+&2M,KIL.$,'O8P(9WFWB\>6O*V?FV9#BN
MHC7Y0C,BFZ?%>[5M#L.B9SAN(1:!0B% X40#XI9Q&&PQ] 0(-6)#Y&@\HS;1
ME^HROL8G&-5+TD5N-M]%>J]@[G*(:)J]#F:M?!6S2U$\[YVOJS--,VHDD$SH
MBW$96XO"C=:Y&JUH,KBX.LVX%A8$#KV+)Q7*69@AN6D,RXEQ?@+"DGMQG)L7
M/Q^,X=+6<=-##Y!D>%R(L/D\_E+I:7P.7"([-X 6;D&K:/RZ, 2]XY[<RO27
MQ?W+T4U&:*KJM(5L1JHJIKJF: RL=&UT;XV.BIH@(:B%\D%0PM)DAED9B;BN
M)X9P-P&MRMD#Z2?,KG#>57W5PK%6!L1,G4&)Q[;M.,>S.!DS((TL>>-\7Y#O
MRC#H9*56$G'"#,383"^QXM6P,RE+QFV8C'$HO8,&2#>)^Y+1,]7I"L<*ADFD
MH*B"H8R1@C::JF[UFGB#HG/9,Z'(7>Z(.+GB+$YQ(3O  LW*ULCL-[:]6]8(
M!Y0K-H/'3S%2D;Q-((60P_E#"ST7*(6Z-VN(YE/.*>XE^:4M<G>H5E47RDV8
M&H<0HA1@P0&LFI84;I8JHMM)W-T$E2VKX6LCG;64M:UT4XCM)24'L:UG@QWX
M*6D+F3-OB<7.+',O81PS]7@_"&HZG.Q;]^KBR6)[J-[.7=W0[%H3(PR#@8]A
MUA)F,( 0<2;8CQU9BY#NY&K:M)I)*RC5D\< 1E["+"2(R#QFB3BR)Q<"F0(6
MNM]$Z"H]#NJY*9]1)+6NB=/).^-SG<"'B+***%A<!([%*]CIY;CAI9,+;0^1
MSP 0 !JL/ZGFU#8 L/V<_P!5IMD_S^8D_CV"U7NE_P!'=._^D:1_^I*HC\8<
MK?YFK)M^O]6CN@_SV3_[O.]<_<A_HOH'_P!,I?\ EA6EU^=W6I V_P#*&Y7V
MXXPBF-H9C3 ,A>XXR=+\R8ER=D3'3R99)Q'DF9AH*&)2J /7TE2B;$DRMQO$
M2858O$#5PPT+1)HUN<(MJM[:1[FZ/2=7-53U6D8VU5+#15E+35+8:6LIH'SO
M;%4-$1E<UW?,S'ADS,3'ENHF\-E<P6 :;$D$BY!.T9VV#8I&C'*U[IHACC$.
M,@HW$* 7#,TP_D./$JP1U8;.S+!\U>SF$'Y>JWD* PP26(E"K*5.T!0]Q+F9
M)T^/JOI):V/-^:7N/T3-55E4]]:7UL%932,[X'!QPUT+8)XX08B]C0UC#$"]
MPA+ V,-CO&;<.\  !HM;8;FV8OGGQ[]JP?+7*4[ALQ;>;ML4@88X!8M2,NG8
MIE#XZ9!/0,64GAO) W&HBE9.[#60:/2<ZX4!IO0SZ4("V8H*\E#X8,:-D^BC
M[F-&T6DO96-U5)5E@#S-*R1LDHIV4SJI_O0?WQ)$P<(6O;$7ESVQ-<XE09G.
M;A-K:LALSX]EUY]Z^B62_HD<B1_4+X=_S>QG[LS/7\I=V_\ I5IO_?7?\F%=
MK-3?X&=15AY03DJ;N4URX83I+3T7[3<WR#?_ $$OCUG7O9T484_U3T]W^M^Q
M+\BZU_NRG5O][UIW*=UU1W*FN-/20U7?PI\?#/>S@^]^'PX<!SQ<.;WU81;:
MK/C,A/$XZB!OW@^NU:"?,IU_IM3W]_QYK[#W7M(_)%%]+/VK/O8[C\X?93YE
M.O\ 3:GO[_CS3W7M(_)%%]+/VIWL=Q^</LI\RG7^FU/?W_'FGNO:1^2*+Z6?
MM3O8[C\X?93YE.O]-J>_O^/-/=>TC\D47TL_:G>QW'YP^RGS*=?Z;4]_?\>:
M>Z]I'Y(HOI9^U.]CN/SA]E/F4Z_TVI[^_P"/-/=>TC\D47TL_:G>QW'YP^RG
MS*=?Z;4]_?\ 'FGNO:1^2*+Z6?M3O8[C\X?93YE.O]-J>_O^/-/=>TC\D47T
ML_:G>QW'YP^RGS*=?Z;4]_?\>:>Z]I'Y(HOI9^U.]CN/SA]E/F4Z_P!-J>_O
M^/-/=>TC\D47TL_:G>QW'YP^RGS*=?Z;4]_?\>:>Z]I'Y(HOI9^U.]CN/SA]
ME/F4Z_TVI[^_X\T]U[2/R11?2S]J=['<?G#[*?,IU_IM3W]_QYI[KVD?DBB^
MEG[4[V.X_.'V5GN+OD<J_:YD*([A*Y*F16F)#+>8]'/E81<S>='TOMZ@XH/I
MU[5._JO=ZV_).]PUYVEOPFUVEM&UFC7Z,I(F5D)A=(R28N8'$'$T$D$Y:BI$
M&&Y-[6\H'T!>M:.QC)TI9-9 T'VU9GFR!AK?21 4N<W)I6/$+NI*V]42XI+6
MUZFI\_9QYMU>=2NOFH.ZFH@AAA;2PN$,<<8+G/N1&T-!-C;,"YM9?+R]Q]/-
M/-4.JIPZ:624M#8K R.+R!<7R+B,UTE>3HRBK2O%G6G'N<*26.>.O'^TX:T]
MMU3G^*09_MR<J@=QM.#?OJH^;$K6MR:F35JUK<W5IQKQ[DDC7F</'975QW85
M3;6HZ?+>^3??>I]IU/>_?51M^#%M &[<%:5N2^R0MW['%O?[TCC%>_Q_O/5U
M?VZ5GQ.F^=+]I6'<?3#+OFHYHNQ6U7DJ\B*\>-[JG'A3N2&,>+N^-/4CNUK!
M^ATWSI=Q'E<9Z,E([D*<9]]3\EH]AOY/$-JMJW),9 5I6E5WU./F2"+>KYJ=
M/-U8=VU6#G14VWX4NVW[7$K^U."W]YF.O*T8U[?%.[4K<IR0\\4[M79"E>%>
M\?BOC_Y*OPZGV[UFRBIOG2_:RZ59O<M +#OB?;KX/;_AXSV*WJ\CQ.5./%^3
MIQI2G"A^)_%<-6'=U6C(45+K\N7[2L.YB!N??$VK='V!6Y7D:)LKQXDBU./F
M'HA\5JP[O*T&_>-+\^;[2N.YN$7]_FS%OS?8NC?R+$R4KW2IFG[NP_U?^)]7
M4CN]KAD*&EMQNF^TK-[G80+&:;_^/L6;.N2/G[G%3?%-SI]:+;S>LXM)VGXK
MTA<^N#KANLJV53ZVZUZBXN6YU+*+=4MI3G\WC37 WNMJAI5VE>](#*ZB[Q,6
M*3@\'#-FQ@WQ8\30-=K7RNNDZ&C-**3A9, FX<.\'%BP%F'5:UC?4#EK45J<
MAW+%.^</4]8Y#/4_XGU->F/P@5U_[A2:R3X<VW+RO7B7-[78=?#37M^[V7XN
M-=-3D+I2IW.GY!3]VX7\3ZNI]T&N^(4EKGX<VTW\I6/<_$1^5EV_J]I!.SUW
M+HJ<A!)E*UK612.E:^8;A7#O4IXT/4\W5A^$.O&7>%);+X<U\B2/A*1H"("P
MEE__ $Z[>A=._D%)(IQXR624K7AWC4)\7_(:GW1*T7_L^EUW'AS;18WS5O8*
M,F_"R7_P;-6SL74NY B0W<>,IDU./#^O,(\7_(>II[HM?E_9]'E^W-NMY2D:
M"C!OPTFJV89Z!Q+J7?(_AZ_C2LLD_=\PS"/'_P VKYNGNBU_R?1_.F^VI]A&
M?K9+?X1Z#Z[5T[_D? W?QXR^4TX_IQ!_-X_H;5O='T@!;V.H]OPYMH(\I3["
M1_K)?_T[%TU/D>4RI3FUF$LI3CWZ&(+Y-][4^Z1I#+^SZ/+]J?=;7C/4H]A(
M_P!9);E8?^D6Z5U+OD=DM7\^<N[GZ<03R:GP:GW2=(?)U'\^?[2M[#1_K)+"
M]O$VZ[Y<VI2[F/D-Y9F5'&J1@^=$TQGC2.XS&U&&H=?4B-CE'%&Y%]UTDI2U
M\XZYNZM8AU-"G-IU.RG=UYFC>[6KT9W\8Z*FD[^KYZ]^-\HP/GPXHV82+L;A
MR)N=ZWDT:V3!=[Q@C$8MAS %KF^TWV*#KOD<8E=^?B94[O'_ &W@7DVO4'X2
MM("Q]CJ/+]Y/Q_M<:S]B6>7)J(^!MOQ<:Z]_R-Z04X\9W,Z<?TV@7F\?T+75
MQ^$W2(-_8VB^?/\ :3V)9Y<G_P"FX#J"ZU_R-F^OX\9]-*=_O%8#X_\ FNI]
MT[2.S1M%LOX<_P '5\+UWI[$,'YQ^L'X.R_[/I75N^1J7E]>-<@36GK%8!Y)
MZFK>Z?I'Y-HK_P <X_ZS?H4^Q3;M\-XME>[3Q:L(ZRNO?\C0.;Z\:Y"F]/6*
MP#U?\$]74>ZAI+Y-H;?QSC_K*DZ*9KQOOEJ+;;=[0=IZ%U+_ )&7<7UXUR%.
MJ=[O%<>^+_FNK#\*.D@+'1E#8WOX=1?5_&K#1K0+!S]8.9;UVXMR^-WR,@M=
M2M*Y%G5*?MICWCWOV)][5O=3TE?_ ,,H;?QU%_YRI&CF@ %S^=O8NO?\C$*7
M]_(\\I^ZF/?5_P #]74C\*FDQ?\ LNAS%ORE1]I3['MS\)^?&WB.[B668Z^1
MM7^.,AP7(@Z>S,B0@<QC4R8CWA6 VLWKR,F&9ELT=W(MDUK6SE9E8BO5&^Q6
MB5]U4[K;N%:<U=^$O2%=1U=&_1U&QE92STSWM?/B8VHB,3G-NX@N:#=MQ:^L
M65FT(80X.<2""!<;"'"^0VC.Q\Z[N8_D<,EF7*4]RF7G,Q$E)_*"LI?C!I:!
M7L&+HLYO<JM6E[ILHXN02NOYJ=RREZE;:?/75KJNC?PDZ0T904>CX]'4<D='
M3QT[)'OG#WMC:&ASL+@W$0,[ !2^C$A))<+F^1:HQK\BYTNX\<EY [OZ9XZ]
M?]!Z[O=6TGMT70_/J#_UA4]CQL+L]Y:-QW%?&[Y%NI=_9,R!X^']$L=>2?@U
M;W6=*?)>C\M7AU')^L4BA#=1=GKN6]B^5WR+/;=W\GY IW>/^V..O(_OZ>ZS
MI2]_8N@^?4'5?]L;U;O(!M@X[,B1?++7:R^5?D6*RO=KE'(/NCCKR/3W6M*_
M)6C_ )]3]M7[TMJ<3D!LV<V]47?(KZ=U.';2R#3O_P!<<=>/_F>I'X6M*:CH
MO1^SX=1LO^\&].]3OY[>BZ^-?D5E*O<KE/(?F\>D<<^1ZD_A;TH3?V+T?J\J
MHW6_6[N-.]3EGJSUY;MU^CSJBOR*LC6G#MI9$[OF$<<??9ZD_A=TK\E:/V?#
MJ1J-_P!85(IB-9WY C:.,+Y5^14F]U>[E/(WF?[8XW\BU/NNZ6V:*T?])4G_
M *PK""V0OSM4L80Y A'8WDH%N6LGLS.705$PQH-+O86LP<=F(9_#JW+)AVJ1
M"M4:':K)51OI;15.RJO%*E]->-I[\(FD-/Z,GT7/H^C@BG="]TD+YC(W@)F3
MBV-Q;F8[&XU'+-1P."YSSL,['9A&H*'[_D52]>^Y?MLSRG5KKE>%%\></R2M
M;^YQ[OC\?=\W7MC\+ND0 /8FBR 'Y6?8.55-,=Q^</LGK*I^93K_ $VI[^_X
M\U/NO:1^2*+Z6?M3O8[C\X?93YE.O]-J>_O^/-/=>TC\D47TL_:G>QW'YP^R
MGS*=?Z;4]_?\>:>Z]I'Y(HOI9^U.]CN/SA]E/F4Z_P!-J>_O^/-/=>TC\D47
MTL_:G>QW'YP^RGS*=?Z;4]_?\>:>Z]I'Y(HOI9^U.]CN/SA]E/F4Z_TVI[^_
MX\T]U[2/R11?2S]J=['<?G#[*?,IU_IM3W]_QYI[KVD?DBB^EG[4[V.X_.'V
M4^93K_3:GO[_ (\T]U[2/R11?2S]J=['<?G#[*?,IU_IM3W]_P >:>Z]I'Y(
MHOI9^U.]CN/SA]E/F4Z_TVI[^_X\T]U[2/R11?2S]J=['<?G#[*?,IU_IM3W
M]_QYI[KVD?DBB^EG[4[V.X_.'V4^93K_ $VI[^_X\T]U[2/R11?2S]J=['<?
MG#[*?,IU_IM3W]_QYI[KVD?DBB^EG[4[V.X_.'V5E4%^1I;L$S6(YLKD^;/Z
M8CDH/)/6+I:"7-7G822;2/K5Q1G_ *JZ@OT=U)7K?\FYEU>I?/\ -UQZ1_"E
M7Z0H*R@?HNCC96TL]*^1LLQ<QL\3HB]H)(+FAUP#D2,U(I\.>>6?C ZB#JL-
MV]=S)'R-W?N2GTPS[3)DT&4R_(">0.CV2T&M:,^R5RH1ZW;T??ZLHBEU;FV4
M<_DW-I3JGSW'6>BOPGU^B]'46CF:,I)645/'3LD?+,'/;&T-#G $ $[0,E+H
M"[.QW^,!K\Q6$_,IU_IM3W]_QYKT/=>TC\D47TL_:J]['<?G#[*?,IU_IM3W
M]_QYI[KVD?DBB^EG[4[V.X_.'V4^93K_ $VI[^_X\T]U[2/R11?2S]J=['<?
MG#[*?,IU_IM3W]_QYI[KVD?DBB^EG[4[V.X_.'V5[;;%MO5=J..E]NM23PO7
M$XR.1CI)_5E<\=\QQ)'W57%1W^HJJ?ZMYO%M^1\+:<.[QU^::8TE)IC2-7I.
M6)L,E9,971,)<QAPL;9I=X1'@[=MU<#"2WR0!S7U\:WVV^>&'<M[,V_W6E.O
M+6[=;N7TE;>Z*Z:(FB)HB:(FB)HB:(FB)HB:(FB)HBB#/W@9R-[&GGV26I&L
M<H5)/$=R+R33W_9MBC-K&Q@G'E["/M4 K&]V"-JN;V@I*QBVN<J)R9%-1>Y%
M"RY:]-%*RY2MUUJ=EM:6T^\I>YC1\U/!*^2JQ2P1RNM)&!B?&'D <#D+FPS)
MMK)7YU4=UVDXJNI@;'1ED,\T328I2XMCD<QN(B< FPSL +Z@-2L[CE+MP25*
M5M#8P[OFQR05\?LMIK?VJZ-M?A*O9^=CVW_<\2HWNOTH38QT?T4OWZL#CE0=
MQ:5>%H7%=?GN'ST:D-?,\R84U=O<GHP@'A*SZ6+[A0>[#2@)'!46S\U+Q?OU
M8'7*J[DT>/,!XF[E*_11B1U_,\?%,J:U'<?HK]96ZS^=BV&WQ=:>V[29SX*C
M%]G!2_?JR+<K-N:3X\T#B'Q]^+2;U?U;>IJWM.T5:_"UNS\[#MO_ *OQ*P[K
M=)$VX*CSVB*;TSE6-QRN^Z)+CS0&'>]7OQ23U[U?4G%-7'<7HD_G:[6?ST.S
M+XNM/;5I*U^#I-?ZJ79;]_MNK,MRP^ZE/N4C^&>]7OQ*4^+_ $ZU([C-$Y'A
M:[DX:'_MPM1W3Z0/YNDV_FY=E_WVVRLZW+*[KT^=S8]A7N4I7NQ"5?S\UHWN
M)T0<S+7:]7#0VU?[O?I5F]TVD";&.DU?JY?OU9U^6EW;)<[FQS"5>''AQA\K
M\7#S)]3S=6'</H<FW"U_TT'_ &RT'='7&_O=+D"?R<FS_P!Y6A;EL]WB?'FQ
MO!W<X]^&RVOF_P",#U-:#N%T-;\MI#.WYZ#+_AE8=T5=AOP=+M_-R;/_ 'E9
MU^7!WA)UKS8U@KN=SNPN75\S_&%ZNI]HNAOUND#RSP^BF"M[8:[R*;Z.3[U6
MQ7ES=Y%E.-L:P/WO'"I?ZO\ C$]36C>X/0I /"Z0^GA_[9/;#7>13?1R?>JU
MK<NSO-LYW-C.!>YW:<81+_-X>F+J?:%H7];I#Z>'_ME<Z?K0T'!3YV^!)N_V
MJM:_+S;TT^/-C& :]SQP>8^96OBR/35AW :$L/?=(9_OX-X'Q;C4MT]6D X*
M?YDGWJMBO+X[V+./",;?^]7OP:9>92OBR135A^#_ $(;^_:1^G@WD?%MP5O9
MVLN!@I\[? ?M _>*WJ<OWO<MK6E(OM\[E*]^"3/Q<?\ &5J/:!H/+WW2.8'Z
M1!O ^*\:N-.5>(C!3ZO(DOL_>\:MBOR0-OALIQI%MO/TX'-/5\S)E/,U;W/M
M!_KM(_3P?]J@TW5Y>!!F+^(_B_><:MROR0COFM[T5V[=SC^<*:U[W_2;JS?P
M>Z#-_?M(ZQ^?@VFWQ53[-U=[8*<<C)-I.^4[E;EODAS?4G;6M(IMSKPK6G=@
M,V]6OBR?3S-6'X/-!&_OVDLB1_>(/^U5CIJJ%O @-P#FR3T2A6V_Y(GWWV]Z
M*;<>_P .[C^;^K_C0IJ?<[T%^NTE]8@_[51[,U=KX(-=O$?NO^L725^2+]^=
MG'A$]MW<\W'TX\WAZ:5-/<[T%^NTE]8@_P"U6K=+U)MX$&=O@R;?_=6P6UGY
M([RDIE86)W>03'=N(S74QSV4XFC<E%22%/%E+:(R!V+*RR3I24"CSJV%A;%%
MD81;5J0&*D'#2@4EY^E/P=4HI'2:)J*COMERV&KDC=%. !>,/9%%P4A^ ]Q+
M+^"["'&1F\.EG8P)VL$9RO&UUVD@&Y!<Z[<\[6(&8N<E^M:$3B'Y*B4?GD D
MH:80R5#&QF.R6/OVY,.8&.[.>@[9/6U]Z2ME>[8I;QHHBM8H@M8FLFHG;^43
M0S4\LD$\;X9HGEDD4C2U['--B"#GQC8001D0O::YKVAS2'-<+@@W!&\%95K)
M631$T1-$31$T1-$31$T1-$31$T1-$31$T1-$6N.[#P&2O]F1K^,HK4C7YCU%
M4D\4\K?Y@MB4/RA']:3^PIJ%=>9&];E+0>R_(+V(FL.FI^#BV"K]P^0)()R)
M (D_!P!M.EH,]:Q:+S-^*=9"EUCI&KQA%01!(D6I>DQ8VWO%4K+RD"^7;Z L
MVQ]REFVJ83',V/I$:-8_F>&99G4*1#'(G-GZ,GCVWU\&;3J2Q,X*BB\?D)1B
MTD0(L^QR!*%\BBA9H.^>QRC0L/<."6/KQ^NO4LTBW*%;2IL3@X**9%D9R19
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MRMZU.T\@ZRK*Y^@K_E5^"[5V_"_B*N[X/\(5C5\?^5^'5D^!_B]"M:_?N_\
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MQW72ZTV+P5M""X#B-\FB5K/<)CC DA,S+:C*9NY=XRJ;C+XC-7\A? [H:?Q
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M/'#5"J:"SIPLX4LN54NOKU.@A>UX?#$\/>U[PZ-C@][6X6N<"#B<&M:T.-R
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MY1N9M!]R2[.QS1NJG>P'L&=]EZ=UMS9DU0NI5-!*VV_>\!<V0PQ%XL0\QMQ
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M29 ACB824/D=+;Z$W "I[F.1TR#M_DX03EK(\FR9#,HO4WD+G=[XRPEH*^;
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MKH4VKMQRXM$OD!4?<3((#^%L22?6T5)2D#&F%C!\SEB@4HN/[(&3N7IMBUJ
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M6+XGQQ/0<KRO9EF^&!!V69+.C<9=P3%KYE5%D=D$?D#$D*I<H_:46<66H*E
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M_%??TSV6Y_Z%%34M)O%$Z5_=YA3_ ,+3.^K+?=/-YO7)4U+RBG>B''_2 ?\
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M@?V71:A^CQ]BL-(U^&_?=1>Q_.NX]E[*PN-\N\>VM:6[F\VTX5\60Y'YM/\
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MM>.NI-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:X[L/
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MEA[4B4W(&6\$^8&W7?S+7[*>P?%2>2I;);MSZ&$9=+LM9QW11],*WAL8ED,
MGMB\9V(EW<07+'+:H@<2)$XWD2R7U#*" TB- XT18L$7S(DY:^@>A+Y6W"W.
MXNSY<QR#+,74%A.2( RK&,MAD5WI.S,T0W&2W(<ES%%8:(?Y*@.02F'<48BG
M<>B\V'9(=Y!QU/!-^,P\F:/%IRY=-WI)(9E",Y(;,F2MQ+ZLO-OSOGZ1S66V
MFV?D^L>87W,Y,W)1K,!3*#:0R3,;T. /WJ'"F/9]ER2QXKFU%.6,Y4L!ZD7D
MT30Z_CS.!1TNQ=(H,Y 8-7 Q*;$E[BWKEJYE&V[? >W5>69V"Y*WJXPV\Y$W
M7Y'V>Y8AXF=&,8#9"&*;2I?#BD8K%HM/9<,[/6<N/PQLP=55%W,V3EPJRZT+
M7)W-U1.H;KV4@G+*X%]^W>L\![&XG*=LSO#$3W&V'\GQ'=P3W/FLV@X]#33$
M+NJ%YT4SP>9F\5#BBL?&Q\=*B-P-_C%T;;&QH!9OUU(;9'P/J%%\_-;HMU*#
M!_([EFI#!ZS[>#D(P$PYF$7G-6'N8$(8Q"3Y#&;R)/N[5-VQH)*!80 Z/.I8
M]Q\><MQY!Q06&C)*,JQAFS.1N1DOU6__ %M_5=BSD@#5&VW8 MN^GSJ![;Y#
MC\]%( M!&2<:)+8NW*5W"1!T1'LIDT8W2%RVN3@$MDJS)X_+C10,J 3B-$38
M>0$OF3;7?I!'IOYEZX0;*N+\GW22S&N2(%D.^&G7$7E]D&F$>EMT5DK3CUW'
M9): (D*@SK7FW=<"2E&K]'A7JC>WA710LL?&!(QP*:DB@X>Z.O[A01L^>MFC
M@P4L8/BMXT4BNJFH0?VBQA(E<S:6K.+6 ]\\JG1NT743(KCHBL,9E,8FH1E)
MH;(P,MC9*KJ@Z01DN//!']6+QP.>T9%13AVP=59D&CMBZH@X4ZW>-7#57F+H
MJ66D5^T11WEWP5Y']@\H^XKS10=1Y#U+H8/\$&-O8<#^T4M$&H<@ZEI!O%Q#
M9D'<QM,DQO>MC/"#.%21,GC;;CD>&P.4)Y@RD@<:**2^+L9;D.+O#4]! 548
MY!EQL9D[O'Q T1E -&R0$6*[$K#4<M=O-8]J@'&NQW;A',+;[\=BMY48ET6D
M6W64[.SLBO)XV5:[0L.".WO($(Y/E@\B10<RN'D<W3,G(S<[?1)=X$CD?9.Q
MH>X65+$BFYN,MM^75UVY[K,1FS3 2'*$XUS:ANQC;G, .%PF5!L'IN<;5RP;
MCL+PI(,+,:1N06E[\EC]MY\,<?Y!D^,!HE]$3N56J$Z4D*:B*K!0HSMQ>G7S
M[.1>O^BA>>C/PTYW_;\!]JE-6/BM\_6N;X;^4*3MOGAAW+>S-O\ =:4ZJMFZ
MW<OI*V]T5TT1-$31$T1-$31$T1-$31$T1-$31%$&?O SD;V-//LDM2-8Y0J2
M>([D7YMY$DK4F2K1-2M.O7E:<++JT_V1?WNYK]>H/[G2?[I!_P EMNE?B5<#
M[(UV7Z75?\]ZCQZBKS:<4E/5XV7>;ZVNK8>4>E9,UGD[%8+B!EBU),63L@T9
M&$T&Y9JV5<(MR39LX3=H(/DDZVV.D$72*;FQ):EZ=JZ2:M+>>G9=;8,8[ YS
M6N<PDL) )83=I+;ZB0;7&=C;:KXY6\(UCGM;(&AX;<!X:0X!UM8#@#8[0#L4
M?OT5OGOR)3O5_,7?VG#S/-[GKZZP1O&L[>,JP!L,M0"Q5RBO3C7J2M/5YE_J
M\.[P];AJ^P\HZC?T="NT$$9$#;KW+&"77CA59POURNNNHJLLNMU559996^JB
MBJJM_.O444ONK????=6Z^ZM;KJUK6M=:MP@6&$ 7L!8"U\LN2UN);G$1<W)+
MB2<R2<LSOSOY[K%72"W&O%%7APN_WN_S:\/%H"+#/.PVYZENT'<?A;.6WHMY
MEC3I!;Y_\A5^AI_O=_X-;,( S(U]BNP&^K9V+&7:"_S_ .0J^/\ WN_U/4UJ
MUPQ#,;=HW%;-V_PE8XZ;K]W\A6[O'A^1W]WZ+^]UJ"+#,:AM6@!P:MA]*QQT
MW7XW?D"W?_N=_J?WNK7&\<X5K=JL#ANOP_*5N]_<[_,K_>^K36K2,(S&W;QE
M38[CS*PN$%_G_P A5[U?][O\VOJ:M<'40KN!PM%C?+8=RL#INX[OY MWO[E?
MYE?[W6H(LW/UQ!6;XH\_6K&X;N.-?R!;O5_WJ_S*?WNI!%SF.?C<>HA:6.)N
M7D]0688IPOD_.V0 >,<40TQ,9I(U^H#Q(UM=P22MNIUR2)/%>ILQ(<>G=UP2
M+$5VS!@WMN6<KIV4I6O+65M+04YJJN9D,,;1B>X[;MLUK1=SWNL0UC07..0!
M6\4,DTV"-A<YVH#5LS).0 VDD +]FW)T<E;C'9@)83V96B\B[BR#'@2F:C:J
MP2#6NT>8\ X[:O$K%&MO4[[F9"5N44CAE*JZ2-@<4[6$7?C/='W556FGN@A+
MZ;1K7>!!>SY['P9*DM)!.UL0)C9E?&\8U];0Z.CI&ASK/G(S?;)@MXK+\Q=X
MSN(&R]9]?)+TDT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1%KCNP\!DK_9D:_C**U(U^8]15)/%/*W^8+8E#\H1_6D_L*:A77D;RB>T[<7
MGO)8B88)6<B+V6T7-V&[),%G_:_E(F99"W&[.9Z-3"F6;\<9&7.(-B'(BUYP
M>Y0HR<M6;&Y:QP3:VWSLMQGT=B#;QX>C%VK2W-W)H[M9[#,VXE&N#TFQ4O#M
M](##T<FFX:6F7%S+(.;=H.5=ND=(24_*2\LN232Q;EIJT>20H0I%DB-1)==(
M4>4;K0I!SN=[>3+%?+SC_.RMN9]D_*0&XTB(Q.!?1A-MN"SAF*&.FN[.?A9E
MCE@1/8/+8KCRRX[(#2%3,72+1+($7NNF >9%FAEXDV0=PX!+)4?>%((SOU#=
M;GU'6-O$K(UY-;?=#<@AF6,R\G@&+F.Z[=9DNBT(W'R0>\;K98W'Q;*F,LX.
MP3N5-!AMNPQ"@3Q5)X'*&,O5L?MY0O2&FK,E'910A//8#4-@M_4'D7H3O Y/
M>5;PMTA8C)9W(\?;<YCLQ)X R0XA37%Q.3S1<SEVLF+0BVF0H9-",49/8Q>H
MX2FL1:B#PYY2VP<9:N[$[K2@&W.#MUC5J6JQC8/O%Q_.<\Y%P8W?6F,J3?E!
M73J,$]RF3HG!9/#\K1: );<*. \-GP12)R)"2"9._I*H==%9Z#)N$W128#$G
M"+YF4W&7%;8+G?T^;B49PS9%RE\7&8)N;W2EX4Q]GW(YQA')GNWDIS&L5Q/*
MLDXRG$<0E8X2;89(*NXV#'3 "((1?*9QZ(LZ5@)*'S*!RER;<DN#?L&NV?)G
MGV+>KD\MLF\;"F:]Q$PW*Y!E$J$S%W(41JSO*96=0O(!-[E&62>+Y  Q$X;+
MN\;/P>/2HF#/ 0@7!@J8YH+CS< 88Q(-(%B@G5V<0Y\[J[;)]LN=<8Y4W=9#
MG.*L<8)#YBAF*(C&(-C*?,#X]*6XS2RF-?R/'!@1" 5<98?(!Y7%%X5"2@$G
M(0,MK.Y.0&MU3-&Q AV;Q?/BRMU=0V+SYA7)S[WB@C %,HQ]T96P?NS;3>.$
M)/N?ETBRLVADCVQ91Q%(\E2N4") QQ_)G\7RF:QG.;;(E#\?R;)@,--5)=#D
M2TL+!S!3<9\;;:MN('F &6O9JLLQB^TCE)BV.*,,E1\U5"-!>3TB$DQ?'-WQ
M\"8SQ%-N$-S#$<]4893BRH4GCTGD.7R+'N2%^JD&#B:!XZT#24_82<D1H\EQ
MNW[!EJMR^B^2QW:/M<W.8?SAL\VQ&BTQ#1(1C<9G/=N#$2R?R>(PZ1X$R]FP
M[A<*(R0LS9160N\]E\O0)6;"FQ2XQ(X]M\(*RJ,V=(/'%Y";Y\@V7U6.5]EM
MUL\L]7Z6=%51WEWP5Y']@\H^XKS10=1Y#U+H8/\ !!C;V' _M%+1!J'(.I>>
M6^_"&9LS9^VZLXAM<B.3L,"2\$DN;\J-IUC6"97<V8ZR]&LE8]Q@/,RH<0E+
M7%\>F<8895G0Z+6(%IF[&A(F'+!$'DF5?%8;<[;LM?3YM1UG4M&8GR5N;2.V
M[>QB;*&-\;D#4CV;,]N>$D6TR:E669LQ0&3;NIU"\_2^R]B*9QQRY,9\AW0K
M:8J$RX.4"SQQ_<G:+CQ1<IOF#GD;]60S\W)93H#V+;E1G*3XRW$UC\/3Q+'U
M,5R P9I-!MXU%.&;/YSM_/HDH'T!=,B6;KY;+$F<5F J8ML4ML16.&QB,.IP
MW;/URBXM;U&8/KN.K6O=+10O/1GX:<[_ +?@/M4IJQ\5OGZUS?#?RA2=M\\,
M.Y;V9M_NM*=56S=;N7TE;>Z*Z:(FB)HB:(FB)HB:(FB)HB:(FB)HBB#/W@9R
M-[&GGV26I&L<H5)/$=R+),;MF]<=P.M4$:UK#8Q6M:I65K6M0K*M:UK6WC6M
M:]^NESO/.K6&X<P69]:-?T,W_>4_Y.ESO/.4L-PY@G6;2O?:MZ_\@E_)TN=Y
MYREAN',%QUFS_0C;]X2_DZ7.\\Y2PW#F"XZQ9?H-K[72_D:8G:L1MRE+#<.8
M)U@QKWV;6O\ S='^1J<3AJ<X><I8;AS!<=8,?T$T]K(_R-,3O*=SE+#<.8+C
MH]A^@6?M9'^1IB=Y3N<I8;AS!.CA_P"@6?M5#^1IB=Y3N<I8;AS+CHT=^@&7
MM5#XO3$[RG<Y2PW#F3HT=^@&7M5#XO3&_P IWSCVI8;AS!<=&#?.]C[4;_%Z
M8G:\3K\I2PU6%DZ,&^=['VHW^+TQO\IWSCVI8;AS!<=%#/.YA[3;_%Z8W^4[
MYQ[5*IZ+'>=@[VJA\1IC?Y3OG'M46&X<RK19-VU];VS)BWOK;S:WHI6)7UMX
MTKS:W)I6UK;QI2O-X\.-*>934%SCK)/*25*['.<?W-/]\N^+U"9^I_HJ*W._
M$DA]-:_XG49WSM;9KNBIK>^\2+:OKN%*?^!74HJ*WD:=YNTK_P Z5I_Y73/U
M/]$5'52GB:,N'[-5I_Y.OPZ)GLZK^D*FJI?Q,V'J<7RWD6F?J?Z(J>JFO$R'
M>Z#C\7UTZO7B]*=?KQ^A4]6.>)B,]TG/XMKHBXJL>\3 7ZG$FY_%>HSXN?\
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M^R>C?E"A^MT_WBOWI5?%JCZ&3[*L2^V3<E6G<V^9PKW/%B>>>K^D&M6Z4T8
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M;^5PM<8AZE/2-B/"/SDU@:PV_6>/9LWK]+VOS1=J:(FB)HB:(FB)HBUQW8>
MR5_LR-?QE%:D:_,>HJDGBGE;_,%L2A^4(_K2?V%-0KKRQW6%-YX;>OMH=82"
M9BF6#R"D#%9$C<>;PN-XL"H.,@DT,CS.29#7E9$RX>BH ^9D",$E^*G# VS
MB6F))V#FYB17-"G*W'G_ )?UOZ%YCX&R1RH&5,72V>8_/;II9#R8IRAD,Z:[
M0:ATG:"WP)Q\U9LGO()HI72EAM*$9'$D[,@)HV6S%I%KFO5)O<W<7E.66K5?
M;M;M\^[CSU*52P;E8B89@?&RO<Q'T89CN62[%X!\UQ,M,IG>VWKQYIB:+[B&
M@D"7CY2?UVHO"JTU# '8RKMFG8ZDKI>6,'U*$-L_-U&_2LB<E>5-;R+=<!9@
M]RQJ%I9'B)8?D*C7#L/R+;B6[<:G6=PG;E!'\KR% #<Y2V\O2]D3GPF2Q84\
M$ @_3$#%YI,)JMB99<G'NXL]>ST$*S.8ERNDCBDGD4?G6?XS(X3M=S.=PA$I
M"IA9H:GLU)[A,H@\+B<YUZ")0I[F\#MB(Q<U<*'E0<=6R&VB;Z<N7[H:;:+$
MRY=5SGQ7YUK[N,@/*DY3VJD<=RP9NUR#%L@8:W)@8I%HM&L,!Y^K-R<YBMN.
MHUNA2D95R7,0%OBND\81P\&J+EI=7K18N-LR%6+.WA!:]\A8@[?/Y[V_J%ZI
M[\2.]$#F?:Z3VSA<R3&')$&[/(,$@C2$@H.1=K3V!56*33)Q25*&(M<,AR<H
ML4%2;%LUQZ: .#-K0K'IVB 74*!;/K]=Z\UW<9Y3#;U@_(,4Q)"MWDND!=KR
MKL7&=9E(/)R O-F0=Q,)R+M(S"->')(P74QZXQ+?.'H\TTH0=(STS+PMT<J]
M*@V-Y6!!.X>]YGB%G"W+;EYRKAG6![ZC6XZ<Y,G4OS9B.[#K+?P6@6?9H5P[
M'-J6)XC((%%5MI[^(GF[EI(F-A=I'D N;.S2MB;@Q?(&A1RC<Z$K5*,LMHRN
M,[Y7[<K<6VZ]EN3VGF4<R[:@&X3*ZQQF5W'2&39QAL*.WHU5QEB";OK5<-05
MO8@DE8E>UQFSC!XW;Q6K=*I!(%;5U4E$ZT*#D;;LNWIU<2W>T4)HB:(H[R[X
M*\C^P>4?<5YHH.H\AZET,'^"#&WL.!_:*6B#4.0=2T8Y3[-^<MO./<29"P-)
MV=LM/Y+>84:XM=UC-5LFR[/,*DF,<)NA2!IJX+.WF.]P9W$\O.(1^JM],>(3
MIR2&D6S9.U K 7OR7YK7Z+ZUI"7FG*S0#+FYX,]=YLR+#,=XLG C&+.)XZQO
M:GD=B.QGC)CC?*&-9FXP6;B[;-#K("\ZDDPC,BD&0TR='!X(/P2T: 86@4)E
MEE;/,Y[]U]5K;MO*I$V0DN4ER-E[#3/<1-\_0C%T&$;JI%++Y/B_&8!SEV\/
MF?'@S;E%\CFG6( *K1-_B.8R<USX8%QK*C*T3LJ;2&E!<E&U(;9VXM^[/IRZ
ME[J:*%YZ,_#3G?\ ;\!]JE-6/BM\_6N;X;^4*^8JR%"X'F#</67R%@!H3FG!
MAU[5:G756A61]<]3ZDDK^4]<(\[G</RRWAQ[O"JU! +K[_25L3\L-A7TQ /U
M3OR716QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6
M&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-
MN_H/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _
M5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6
M&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![%&69<W8HD&+9P%#3@,
M0*$@+ELQ9(7.>K.5[[DZVI)\]O;;SJ\*\.-U*=SOZD:QRA5>X%K@#F0LB@F>
M,0#(1#AK^>A&SX?%H^R>-E+G75&[IJ):(.$+^:VNMYZ2ME]EW"M:<ZVO"M::
MA6QMW]![%E?RPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%
M?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]
M![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIW
MY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%
M?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]
M![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIW
MY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%
M?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]
M![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIW
MY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%
M?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]
M![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIW
MY+HF-N_H/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%
M?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8GRPV%?3$ _5._)=$QMW]
M![$^6&PKZ8@'ZIWY+HF-N_H/8H-W'9BQE+<1R,%')B)+EW;H#>V8-:N*K*VM
MCPYRO=;U1"RS@D@DHK=QNI\[97AQKW-2/0>HJKW ML#G<=#@5-R.X7"UJ25M
M<A@:5M3LI6G.=]RM+:4K3_8OFZA6QMW]![%]/EAL*^F(!^J=^2Z)C;OZ#V+J
MLL[X(&MDV0Z;Q<>S2JK<DT9(K-6R=RRMZZU4T$&2:5E55U5%E:VV4JHJI>I=
MQOONK4F-N_H/8NU\L-A7TQ /U3OR71,;=_0>Q/EAL*^F(!^J=^2Z)C;OZ#V)
M\L-A7TQ /U3OR71,;=_0>Q/EAL*^F(!^J=^2Z)C;OZ#V)\L-A7TQ /U3OR71
M,;=_0>Q/EAL*^F(!^J=^2Z)C;OZ#V+J/\[X'*,W(XG-XL1'O4;V[Q@_05>,W
M;=2G-40<M7#)1!=&^G<O25LOLNIW+K:TT3&W?T'L7:MW"84MMI;;D(!;;;2E
MMMMM7=+;;:4X4I2E&O"E*4[E*4[E*=RFB8V[^@]BY^6&PKZ8@'ZIWY+HF-N_
MH/8GRPV%?3$ _5._)=$QMW]![$^6&PKZ8@'ZIWY+HF-N_H/8L(R7G3$9C'<Y
M$C)V%>$242D+%BT2N==5<NW0ITBW03YS:VWGJJWVV6\:TIQNIQK3107-(.>P
M[]RZ>)<XXF!XR@@<M.0S$F-BXAF_9K7.NJMG2#1.Q9%3FMKK>>G?2MMW-NK3
MC3N5KH@<VPSV#85E9+,NW8R[#$#$HA)5_'7UY./O20ZU\[!$E&RK-0@&<NAR
MJPQ]>S<+M;W;*]!Q<V650N4JDI?;<4XV[^@J\?+#85],0#]4[\ET3&W?T'L3
MY8;"OIB ?JG?DNB8V[^@]B?+#85],0#]4[\ET3&W?T'L6H\9,BY%E7-1L(]1
M(BB)F/N&+YOSNHN4:MRMM%$^?;9=S>=;=;W;:5XTKJQ\4<5_0?2L#X[COL>M
M25A&/@3N8-Q_38009ZVF:?6W2HUD1ZWZJ6DW5>H==HK=2ZIU-/JG4^;S^99S
MN/-MX56S=;N7TE;2]KZ!>@B(>]H-Y%HKIVOH%Z"(A[V@WD6B)VOH%Z"(A[V@
MWD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(
MA[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH
M%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B**,Y0J&C\13]ZPB4
M99/&T==JMW;0"*;.4%*7)\%$5T6EBJ5].->%]E]MU./<KJ1K'*%23Q'<BZ\$
M6P7;!X;0FKB>TC2*Q_K^C^^'T>T>4$M.NNN^N*]7ZYZMS^K]6_)>J\[JGS_'
M6PI:D@.%/.6D7!$4A!&\$-L1QK$UE&TX35TP+3A(,\0((R((Q7!!R(WK**N]
MO5.^ZPS3UUH13X;M3WI5?%JCZ&3[*=^4?QJF^GB^TOG4AMUIWWV%:>NY@U/^
M_IWI5_%:CZ&3[*=^4?QNF^GB^TJ*E=N%O?)82IZ[R"4^%34]YUGQ2I^@E^RG
M?E)\:IOIXOM+YU-;:Z=\M@ZGKOX%3_Q=.\ZSXI4_02_94]]TOQFG^FC^TJ*G
M]L].^:P73UR, I_XVI[QK?BE5]7E^PI[ZIOC$'TT?VE161[9*=\[@BGKE,?T
M_P#'T[QK?BE5]7E^PG?--\8@^EC^TJ*R;;!3OR' M/7+8]I_YC3O&M^)U6_^
M[R_83OFF.JH@^EC^TJ:RK:Y3OR3 =/7,8\I_YC3O&M^)U7U>;["GOBG_ %\/
MTK/M*BLNVLT[\GP!3US6.J?"YU/>%=\3J_J\WV$[XI_U\/TK/M*BLRVJT[\K
MV^T]<[CCRK3O"N^)5?U:;["=\4_Z^'Z5GVE1V;;4:=^7;>J?N_C?RO3O"N^)
M5?U:;["=\4_Z^'Z5GVE36<[3Z=^8;>*>O(,;4_\ -Z=X5WQ*K^K3?83OBG_7
MP_2L^TK['".W28D+A$1?X5E16UNH\N&1QU!3A"UHC>FFJZN9#+W3FC=*]9*Q
M1>J74K+U4[;KJ5OMI7.2EJ86XYJ>>)E[8Y(9(VW-[#$YH%S8Y7V%7;+&\V9(
MQQUV:]KC;?8$K.^U] O01$/>T&\BU@KIVOH%Z"(A[V@WD6B)VOH%Z"(A[V@W
MD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A
M[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%
MZ"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)
MVOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@W
MD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A
M[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B)VOH%Z"(A[V@WD6B+7[=#
M#XD)PM)WPN+QT:]2=QVU)X/"#&;I.BLA&)*43<-VR:ME%$[[D[Z6WTI?9==9
M=QMK6E9'H/4523Q?.W^8*?$<?P*J*5:PB(UK5-.M:UC0:M:UK;3C6M>LM0KK
MZ]KZ!>@B(>]H-Y%HB=KZ!>@B(>]H-Y%HB=KZ!>@B(>]H-Y%HB=KZ!>@B(>]H
M-Y%HB=KZ!>@B(>]H-Y%HB=KZ!>@B(>]H-Y%HB=KZ!>@B(>]H-Y%HB=KZ!>@B
M(>]H-Y%HB=KZ!>@B(>]H-Y%HB=KZ!>@B(>]H-Y%HB=KZ!>@B(>]H-Y%HB=KZ
M!>@B(>]H-Y%HB=KZ!>@B(>]H-Y%HBP'*L&A+/&607;2'Q9JZ;0R2KMW+>/B4
M5T%TA#N])9%9-I:HDJG?;2]-2RZV^RZE+K:TK2E=%#M1Y#U+HX9A$+?8HQZ\
M>Q"+O';F)!5G#IT %.'#A91FG=>JLNJTO554ONK6M]ZEUUUU:\:UK71&C(<@
M4F=KZ!>@B(>]H-Y%HI3M?0+T$1#WM!O(M$3M?0+T$1#WM!O(M$3M?0+T$1#W
MM!O(M$6C0=FS'Y@SBR8-&S%FW. $V[1F@DV;()T;%*\Q%!"RQ)*SC6M>;99;
M3C6M>'&M=6/BMX[^@+G)N]_%8=:E?;YX8=RWLS;_ '6E.JK5NMW+Z2MO=%=-
M$31$T1-$31$T1-$31$T1-$31$T11!G[P,Y&]C3S[)+4C6.4*DGB.Y%^<L@ .
MFR$A4"A2Q=,7>\?$KQ8YX0L',K%E.>\?7-$5;6C6WA7G.'%4TK>%>-].&OUN
MCECCHZ 22,9CIZ9K0][6XW<$SP6AQ&(YZA<K\4JXI9=(Z0,44D@CJJI\AC8Y
MX8P32>$\M!PMXW6'&HUM&$B?7-HT>^(7,V:CYY:Q:+NZM6:-R=BSMS1!-2J#
M9*]1.U1PKS4K+U+*77TK=;2O67-:/"<UN(AK<1 Q.)R OK=8&P&=K\:QC8Y[
MO!:YV$%SL()LT9%QL#87(%SE<C>L=0C,D/.63,#'SAIV6<.VXIJ($OR+@FN.
M;)NB" ]!FW64>JL&JJ3EZDVM4O:H*)K+VV)WVW5OPT4;"9)8XPP O+WM:&![
MB&EQ<0&AQ!#2;7((%R%H(9I7-;%%+(Y[G!@C8]Y>6-87!H:"7%H(+K7L"";7
M6'R^,26)D.BY5'CD9)W(6N[1T@$OPS^YHM>K8BYHT(MVSBK=6])2Q-:B?4[[
MD[[;;JULNI3IAFAGC#X)8YF>+CB>V1N( 7&)A(N+YB]\\U=\,L!#)HI(7X0[
M!(QT;K'4<+@#8YYVSS4;N?S?'S/OU^]K<^*WSWY]JF/;YO2L5=]ZOK_?KK4;
M>7T!:[!RGT+%W7?KZUVI6C/0.MRQIU^:_P FFM(]OF]*V9K\WI"QEU]%?]+X
M=;-U\W\P72T>#_B Z0L=<>+_ "JZV5F>*//UE8X\[_TJ?#3166/N.]]+[UVM
MF^*/7:45A<]Z_P!:OPUU9:G4SE;U*X0O($UQ7,060,=R4M$)E&'R9(%(0CFY
MJ_8.K+;[;N;=2ER:[9PE>HV?,72:[(@S679/F[AHNLC?$U/!5P.IJF)D\$K'
M-DCD%VN%Q;C!:<VN!#FD!S2" 5I#(^(LDC<6/:;M<-8SYB+9$&X(R(LOV!<G
M#RJD)W9LAF*\KK"8+N):-:)(L^?8QC>44VJ//6*1"JZG-:2"B=E[@K#[E+U[
M4[52(*]Z/L?-@WXSW2=RD^B'/JJ0/GT<79NS=)2DD@,FL!>.^3)K6U-DPO+<
M?V.CM*,JP(I;,J -6ILEM99^UM+->LMN ;>PNOCEZR:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+7'=AX#)7^S(U_&45J1K\QZBJ
M2>*>5O\ ,%L2A^4(_K2?V%-0KK6O<1NYPKM=<P1AE=UD-0MDJ^64AP+&>&,P
M9MD11""B6IV7D%(]AR#SHT.$QX.\0)%"Q-BT&M6E5%E'5+$5JV%(%]WG('7;
MF7=Q#NVVZYX+. >*,J1V6DD@4#D[5NAUZ.Z; 9*@0[)\/*1FXPT'VR9L_@Q8
M>>>U!5(* T7-K8[8->VJ-K"$$:_7.W6%)MV6,66!U)#?DN 6 $CU8LJ<NF4=
MM#IR>V_J=T<4)U(T96'K5/R.HBY>A"E_SE6_.[FBA9*A)(ZZ./HPV/A7,E&,
M6A,E'D"C%8X/&O[[TV)!\)37N?M&+R]-2QH[7;IMW%Z=]J*E];;J4(HLA6X[
M"61\P97P+!,A@I9E;!HJ&%\M1<$HN1K!4Y^YE#6,#3I5NA>%;2)W=#CBSV,4
M(WR ,T3'O3(U@U,B%GI+&P.PWMYK7ZQZ@JHCN+PF)RDEAE_D2/(9#N@T[R.\
M#=<W*- <0QH1@HR:DI,=3LO Q=8*YR5#%+QD@)C2CIB8H29,W(]D_<M2>O7V
M%<4W(X#K-4L>6Y>Q_?+U<9JYEL%V289>EVK42O0ETYN*6N*B;(_<2HJ@D]O?
M4M6L:O'*5+VK-RLD2W8I<%%19T:Q,A"0\R()M47HTJ*>-R T@S<6440=L7S1
M19J[:KIW4O17;JJ)*65I=9?=;6E=$5PT1-$31$T1-$4=Y=\%>1_8/*/N*\T4
M'4>0]2Z&#_!!C;V' _M%+1!J'(.I6[(.XC V)IEC_'>3\QXUQ_/,K$+1.-HA
M,)F C\BFY%1\S%HM(V))OFSPHHY+D1H5IULE?:[-DQ@9M<J4(LFBY2K4*W2[
M;3O;EZ%SQB4K3;M<^LSO4?/HT[IB&HRTO4C=D.J)&^D538*1Z0M7BI>K9-L0
MCQ\:M?8_"DVS4GF/,5]$MS^W1?)$)P\EG#%MV5LD1-G.H%CJLV 63.71 B/?
MEAL@ 1V]]:4(CR0D28*C5&[:^X@,"FG[.Q9H')K-26V[%.NB+ST9^&G._P"W
MX#[5*:L?%;Y^M<WPW\H4G;?/##N6]F;?[K2G55LW6[E])6WNBNFB)HB:(FB)
MHB:(FB)HB:(FB)HB:(H@S]X&<C>QIY]DEJ1K'*.M4D\1W(O":(26, J'+) ?
M4'HIRE0VN/;MC:)^CL0V<61LW 382SK=C*1[Q\51<(2ERUCM[-PU6NL>.$ZI
MH?IK89I*6A,4>(FA@C#BZ/@L+V1F5E3'(;NA<UK"# '38FD#"#<_DG#P15FD
M!+-@'LC4RN8&RMFQ1/DX&6CFB&%D['.D#A4.;#A+39QO:_KY P0Q&F&3Q$,2
ML>GJ<$(_"G =!SCL@K<T:19Y51B/6(26)V7VR-<^367>.#*3=-C(2RP]B^K'
M>^D'.8YI>S#%8F6<2%M6T8C.W.0-BF(,0C8 UK"28F!SF+J;5:+:Q[2(W8I1
ME%3&,&D<<+8'7:TOFIQ[Z97ESC(!AFD+&O4"3J70PS+<2,'),&[B<7O:VS)_
M%(FO&0:BK^=%B9MP*C]HH6Y5M2BEP,?:XO%-WQ&X?8H[3O>W+7W=]/#/'!6.
M:R1LLN(T[9IA+( VG8UC7R%[P/?^$=AQEK<1PG#8#CJ)Z>2HH&N?&88".^)(
M8##&2ZH<]Y9&&1G*#@F@X YV&[O"N5\U9QB5L*)RPA6.R*<DXVXHD%*0MP2Y
MDH+LLA/3),VZ)BKA#LDUF,ACKL4NFN115C()BV=NTEJ*!FT][UI<R%O#14[9
M03(R=K?>F.I6L9&UCP]K'012AX+6D32.(!!$CNAM31X'3NX*2H?%?@WP.?[]
M(VI=(Y[GMP.<)Y8BT@N!BC:"X$&,4/,D8/?/WBEK''P1RPEQ]V/*K8A'/AK[
M'MQ..)W!4HZWCES)U,CC8&1+1]T;:-A@)&2E@MAB*648='5;2Z0:P>%4R!T,
M;7L[\<US:C#(<?"F7$((W2,9*(W.D>8HY.#F\,NZ&U- YQ(;3L+9WEKC1M+3
M3XF>!P;8L)FD;&]\9> V,2OCQQ##ACR0Y PL]#Y5;"Q$+"M% XX!C\?;CUHX
MDMUHB,VB6Y9F?=QDI5RM)S;E^7E+XL9ADE"K,PQ4(9/V5(1)7HBIZX24A>^H
M>0]TE2[OEPAN^7&6.C$K+<"P!D+6,GBD!>R2..S)@?443F50:R%@P-93M[W'
M">!%A#L9B=?A9"YTA<^&1A:Q['OSC6BCKOU]:[X=>ZO,9Z/2Y8TZ_-?Y--:1
M[?-Z5LS7YO2%C+KZ.[Z7PZV;KYOY@NEOB_XAUA8ZX\7^576RLSQ1Y^LK''G?
M^E3X::*RQ]QWOI?>NULSQ1Y^LHK"Y[U_K5^&NK+4ZF<K>I8^[[]?6^]76K=3
M>1W6%+/%'GZRI8V]X+S-N$RK'(#@H$6+3J]XV)MB8YPL,:1%!BX04K*S,@3Y
MED=&AUJ(K]*7JV..N^MFHQ-T5<,FB_!I&OH='4LU1I"1C*?"YI:X!QF)+_>6
M1_G'O%QAM:UW.+6!SAU4\$U1*UD#27^";@V#+6\-SO@AIV[\A<D _P! # </
MR5 ,/P&'Y?R)3*^2 (!LPE4]M&6"J'B"=U]U%.M[:]4<U9H7(CZEG5B+\WUI
MTN100?/7"5O\^5\U-45E1-1TW>E-)(70T^/'P;=V+9B\; /!9? TD %?=PL>
MR)C)).$>UH#GVMB/KE<YG6=:E_7(M4T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1:X[L/ 9*_V9&OXRBM2-?F/4523Q3RM_F"V)0_*$
M?UI/["FH5UH]NLV7C=U66=M<ND\NE,?@^%K,V62H/ \AY,Q3,Y2CE.%B(NQ8
MC9QBJ3Q&1L1;90<M=(1:AE-B;'.*L7+=PE6].KUZU(-KZO. >L+4T_R3,?8Y
M@KDC$;C%F-6T:RMM@D>*.9!:FSF.<7;>MN$OP57'3)V^NN5?C2CF1M2]!+@C
M005'LUVD@JY<N.K:;N+M)]*7ZO3?UYUI\"Y$#.03%DLC:>7]O5F1I#,,?RT1
M+ V.\D10%#B,=P82P9)2,>A\4G 6&7IGQE!ADC!#\/.XO-#79*$VQ".,6 L[
M<4W&[+EN==[7]=ZW@VV<F;)\&[TYANED^4X[DA,ZG+## O=&C45R/=(9_"<:
MPV5 C"020609S TKL=-#  34.Z3$4LCPH4.$]C5A4F47R ]>+K*W3AFWEW$=
MW^;MR2!0+9'\L8(P+BAK%6(]5J2'GL39!W$S>02,@YLI:R=)26N;6-B5$[>O
M.OA)-R]O4J[1NT2^0'&3SAH]"\E"?(YYC;2+*I2)92VW,J2.(;B8K&)(;P'>
M<G,X;9YW>XPW4.:[@WYLL="SHD&81.48L"R4>):E(LD3'9  (4.VV"1)3<97
M!V7SW C+KS5GC_(Q9FA,&I'8IE7;HL<<8\G&/R9"5X8)2L6J)*[XRN[8 ,#,
M925D3H*.>QR1&,;DGSIX>DD1>-0LOB9ER;9(NFI+CCY+\5K\NW4O6K8;MK.[
M0]K6/=O4BD@.6DH(:RFZL/1M@6%!G0R<9>GF0PC5F,.$3)5A:(#RQB&5:NS)
M>Y-8>IS"3Q*MB]Y03<\W4MO]%":(FB)HB:(H[R[X*\C^P>4?<5YHH.H\AZET
M,'^"#&WL.!_:*6B#4.0=2T6WMX'W&9KS9@!& 8DP9.-OL?.0N49V<2[*!#%V
M4I@^@&3@>0,>Q"PF-PMDQV;Q7!)1'V&4B$#0.Q#M@3@='!)$^&C3"0LY45A;
M.][[,K\^8MRY\E[+52'\EQE-W#-S\"RX)P9*P)3;AEC!. *J%3$II-I'+\]Y
M\W P?+N50Y^ #F,"DL).9-A[0:V"/,B.1\H82^6CC2-5A""H:PIOF#GE:_,!
MERV5Z$<G;N7&[S=M&;J'\8VXTQ9$MLC>6(HS62M[["6#\#YGQ-*F3G$=N.G$
M;R1,S93*J*^.<TEI_%SN/8HU* D(ZLG8@@9)?*WKLV[-2]S=%5>>C/PTYW_;
M\!]JE-6/BM\_6N;X;^4*3MOGAAW+>S-O]UI3JJV;K=R^DK;W1731$T1-$31$
MT1-$31$T1-$31$T1-$409^\#.1O8T\^R2U(UCE"I)XCN1>'CS:AN%/<XP(QD
M6>C2]*$ASM,B LL=,7U.N6KBRU4NFI;:L@JFI;:I99?2EW"ZVVZE:4_2:/3>
MBXZ:E8^L8UT<$#'C!+<.;&UKAE&;V((RN%^4U?<_IB2MJIF4,CHY*FHD8['#
MX3'RO<T@&2XN"#F =^:Q9ULOW/7T^<Q&;N^=X=PG&N_W/--TUTC3NB<_QV/5
MY$N\?N^)4;W/:9#A^(R?/AW?[18T\V0[J%>=S,/'+N-U*_[:QCO<.'C.ZNW3
M^B  #6Q_,EW_ .S4N[GM,G50R:S^<AW#][Q+&7>Q3=FI6O,PP>NXUN_KM%?'
MQX=\_3S=;CNBT-8?CT>0'P)MW^S5QW/:8L!WB_4/SD'WJQQ?81N\NI=S<)GZ
M\:=S^B\3\VOZH-7/=%H4AH[_ (\K_ FY?U:T9H#2XO>B?L_.0\?[Q8\YY/W>
M+?QYN#9#7N^(Q$O-K^J'6@[H]"9_VA%K\B;</W:T]@M+6'XF_:?'AVV_><2L
M#CD\=YM]?G<$R*O<N_KS$/'WOSQ:>V30GRA']'/]UTJS=!Z5 SHWC(?#AWD_
MK.-6)QR<^]6_G<W DDKQIP_VZAWB]>2:T9W2Z#%[Z0B^9-]TM6:%TH#G2/U>
M7%]XK"XY-S>[?==6W;_):TKWOZ-PSS?9+K1O=-H('/2,6SX$^\']4MVZ(TD!
M8TK_ !@?&CWC]M61?DT]\EW#F[>Y-7YZM?\ ;R%?SFUK[:- ?*47T<_W2LW1
M&D0T7I7_ #H]Y_;5C<\F5OKOKQLV[RBO<I_7R$^IYLGT]M&@?E*+YDXZXE;V
M(TC\5=\^+[:LR_)@[\KJ<+=N<JKW//R$>K^JCU=:M[JNY\-%])1?1S[_ /9)
M[$:1^*N^?%]M6=?DN=_%W.YNV^5UXT[G]'8-YM?U4ZM[:NY_Y3A^CG^Z6GL3
MI"S?Q9V1%_#CV#^-9IB?D=]Z^1Y^%C$SQPMB*)NU>JGY]*BD;(L HQ&MG7-[
M00#/O"1HLK9?S!HM&UJBY<UMH](C65KA\AA5]VF@Z:G=+!4]^3-:1'3Q,E:Y
M[B?!Q/DC:V-F7A/.(@>*UQLTZT^AJU[FLDCX%OPGN<QP OL:UQ+CN&0WD+]9
M>U7:/AO9_CM" 8F T04<4;N)5+R=J#F6S8NBG5/I20E$T4>J6I\]2@X6T3;"
M1**JB3!FC<LY47_(M+:7K=,U)J:R2]KB*%EVPP,.>"-ESKUO>27O(!<XV;;Z
MVFI8:2,1Q-MJQ/.;WD"UW'J L!L 6SNO+70FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HBUQW8> R5_LR-?QE%:D:_,>HJDGBGE;_
M #!;$H?E"/ZTG]A34*Z^NB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*.\N^"O(_L
M'E'W%>:*#J/(>I=#!_@@QM[#@?VBEH@U#D'4I3T4IHB:(FB+ST9^&G._[?@/
MM4GJQ\5OGZUS?#?RA2=M\\,.Y;V9M_NM*=56S=;N7TE;>Z*Z:(FB)HB:(FB)
MHB:(FB)HB:(FB)HBB#/W@9R-[&GGV26I&L<H5)/$=R*(X;NNV] (;$PY?)HA
MD2$QH$-(M%!YZ^]J^8BVK9TWON1$J)W7(KI*)W7)WWIUK;6ME]UO"M?39H72
MDC6/91O<U[6N8X.BLYK@"TB[QK!!"\I_=!H>.1\3ZZ-LD;G,>W!-=KF.+7 V
MCMDX$9$CS65ZOWH[8$^[?EP);ZXR2_>"5U?V!TO\2DR_;A^\5?;#H8_IT?S)
MONUU;][^U:SZ/,(.G[E2C[P+4C0&F"+BBDM_'#]XI]L&A_CT?S)?NUU;]]FT
MQ/Z/,X&W]R957X %=6]KNFOB$GSX?O5/L_H?X]'\R7[M=2[?SM"LX\[-@"G#
MO_T'EOWH]J?:YIK7WA)])#]ZI]G=$?'HOFR?877OY039U9]%G&/T_<67U^".
MUU/M;TW\0D^D@^]4^SNB?CL?S9?L+9N#3R'9+BXN:0*1BY5%C*5RPTT(<4<-
M%Z67U362O[EJK9VV6MO0>,G2:+QFY34;.D$5T[T[?)J*>>EE?!41/AE8;.8\
M6(W'<6D9M<"6N%B"0;KTH9HIXVRPR-DC>+M>PW!["#D0;$&X(!"RW6*T31$T
M1-$5/-XUX\Z[ZJO#_J[VB*GJ?]^I]5__  T14U1I7_?%OI*74_[.]_V:(J>M
MZ?W9Q^_7Z(J>M:?W=U[8OT14U96U_P"$/*>LY4I]_0B_],D5%1]M?^%OZ>L[
M5U %MYY45'1MOZ-)>W5=3ZZ[=2+BHNVO_#B=/6?+4^_J+<O.>O6GKZC4J*B+
M*_\ #RU/6(K_ (>&IML])Z]:>NKT:E3T-9YXF/=)Q^'1%3T)9YY&O=1Q3X*Z
M(J:@DZ_US.?2+.J?][1%3T GYZ'O==U_*U%N,CF](**GL>3K_7:0>[#K^5J4
M3L>3\]I![L.OY6JX>-W.BI['$_/B1>[+K\.IMR\Y]"+CL;2\^)'[MO/Y6EN,
M\Z*FL92K7CTU):>L=>TI_P!EVI14]BZ7GW)_=UY_*XZ(J:Q5&O\ 7R4T]8^^
MI_WM+>OKZ[T5/8FCY_2OWPOOY7#3UU^G6HMQGH[%QV(HU_K_ "SWPOJ?!=J+
M<O.>U2J:Q!&OYX)=3UI&_I_WM2BX[#D?1#+_ 'R/Z?!=HEO6Y5-8:A7\\4QI
MZTE(?RM%%N7G*X[#$?1',O?*_P#AYW'12G86AZ(YE[YB%/@NT1:^[H(PD.PQ
M)GEIJ3.ZI.H]2C<B=>/6E_5)",3XJ-EKJIWULI=SDZW4KS%*6WT[MM-2-?F/
M4523Q?.W^8*>D80A5%*O9+-:<4T^Y24DJ4I\Y3O4Y^H5U5V"M_1/./?62_EZ
M(J>P-O7\],Z]]I.GP7Z*"+[_ #&RI[ 6_HIGGON*4^!31+<O.>U<=@#?T53W
MWW%/Y>B6Y><]JX[7[;T5S[WX%?Y>BE4]KUMZ+,@>_$K\9J+<9Z^NZ6V^D]6I
M<=KQMZ+<@^_(M\9PU*BW+S^C5T*FN.FU:<.R_(=/6F97C_U\_1+96N>7*_5_
M54]KAM7\^&1??H6I\%^B6XST=BX[6[7T89&]^I?X.J<-$MG>Y]'-9<=K9KZ,
M<C^_<Q\9HEN,\Y7%<:-:_GRR1]*;F*?^)HHP\;N=4UQFUK^?/)5/6G)GXS13
M;C/.5@>4,=MF6.)X]I+LA.:M(A(G-&SV9EG3->J EVI1)TV44ZFX04K;2U9&
M_C8HG6ZRZG"M=%!&1S.W:=VI=#$&.VQ'%L!?72W(+2YW%@[BK4=,BS)BA55H
MG=5)HT14HFW0LX\$T4Z4LLMI2E*:(!D,SL.OBXMBD:N+6E?S[Y/IZT]-?&:*
M;<9Y;G_)<=JQIZ-\H>_TU\9HEN,\Y5/:J:>CG*7O_-T^!311A_:=SJGM4LZ_
MGYRI_" <I\"NBFW&3Y^RRTXCP^T3EC-@ZQV0?VM#0!*UX5>*D"*]*-BM>>[>
MKUJLX5[O#JBE:W<VEM/%JQ\5OGZUS_#?RCTJ7MOGAAW+>S-O]UI3JJV;K=R^
MDK;W1731$T1-$31$T1-$31$T1-$31$T1-$409^\#.1O8T\^R2U(UCE'6J2>(
M[D7YXJ0D]*7AIT-M&(-$371G7ADX' -%RCY9Q<S&-7)I\Q1=/E[$E%.HHWW]
M;HV=7=7((76J5_5Z6HBAI*(/QEW>D#\,<<DK@QL4>)Y;&UQ#1<"YM<Y-N00O
MQF>FEGK](.9@#6UM0S%++'"TR/GD+6-=*]@<X@$V!\$9N+005&-\3D3Q(@L@
M)><T:/2)K6J(WI*K-')T?&T+F"2E+5""BA@JT:6HLK5E:UJM?2WJ;9>Y/L,L
M8+;O;X3BP6-P'"-\MG$9-\!CG7=86MM(!PBAE(>1&ZS6M>;BW@F5L(+;V+CP
MDC6V;<Z]@-H_= S2O5.IB"BG4[U[5.8/=W=3N;6N+W%M_-2KS;D+&;NY:EW"
MJ5K5Q6^EM$%.;T,D8 V[VC4<W#47"QU[;BV^XWA#'(3^3>;/\AV5AX6=MF$W
MW83?458;(A)RS$F5' B3H<)%]-OGB;56B"8J\RQC]KQ.^ZVWKI/I@HR8W4:]
M6OL45OOOMM2;N%$MC/"PL8Z5@<]W!M&(7+Q&Z0MRU' QSL[9#C%](X)GL+FQ
MN<UD8>X@9!A>R.X\KPWM;X-]=]0)&&&(T:&B^ER#!5BTN,O(_2UY2C9W0L-:
ML7I!K<Q6YCNRYHW),+W%]Z-MB=7:-EUW/OI36C)6.<6-=B=P8D.'-N!V-K78
MAEX3FNMR*W!/:W&]N$<)P=G9.QMP.<,)SR:X7W7&]1R\X\+O-_\ XUUNW6=U
MW?\ 3;^BOL'*>H=BV7VK;N,J[5I.N=BECJ18]=NFE9W!WE[B@(BFK=1ND]0=
M6I+IQ^1<RR](<733KUQ5*UJ^;$6=E6U/)TQH>DTM$(Y<,52T'O>H '"-(S+2
M+@R1[7,)R\9I:[->OHK251HYY<R[X#AX:(WP.N2 01?!)8 -=Q87 C)?J=P)
MN#QEN0@C.>XS-V$&5_4FY@.ZZFW/Q@M<E158.?&VJJWLWB7&M4E;+UF+]&E'
M8YV[:7V+5_)M(:.JM&3FGJH\+LS&]MS'*R]@^-UA<;QXS3DX Y+]&I*R"NA$
MU._$W4YIR>QVUKV["/.#K:2,U-NN%=2:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBUQW8> R5_LR-?QE%:D:
M_,>HJDGBGE;_ #!;$H?E"/ZTG]A34*Z@G.&Z?;=MH[%_EA,Y8NPO2:U,TB5V
M2YF#B%DB[':"[C]PE0T\:6/+ MIL1<442NJFQL),[W-R=KA.MQ+$ZA=2)$,E
MX\R \D@^#3:+R]Y$' %K*$(V;'FK@3B4Q4+.8TF2J/77L;5/PV1@)0(NONYA
M "9&E&MRK1X@K>19OHB:(HF.9XPK&C,ECQ_*L!$'H83QD$EP=]*!"!*,&,T'
M:1C$@H\SO=47$D<D2&M@>&,GUB+B0/E$D!J;BY9+GD4LZ(L5B,YAT^8E"4)D
MX25#P<HE4(,/0)%L3;#)?!SS^+S&-/5FJBEC<U&9&+(@S8]2MKD<48NF;E--
M=&^RA%<(])([+1:9R*G@\E"JNR@](N!)LRXQ5\#*O09EFF_8+.&M[D2:&D!)
M)"U6JC(DQ=LG%J;ENJG81?0@?!"73%B4-"1KTFI8B-9D"3-FZ(+*NFK%))BW
M<+)JNU%'KUDSLL0L4NO=.VK>VE57"5EY%<[E$[*IVWJ667*W]32MNNMMJJI2
MR]6J:=*UI6^_J::BG-MXW<Q.^_AS;;JT(NL0(#Q+!X4*OF8P8.;+O2!$@Y19
M,&+-LG<LY=O';F]-NU;-TK+U5UUU+$DD[;KU+[;;:UH1=OC3ASN-.;PX\[C3
MAPX<>/'O<.'=X][AHBZ[-XS(LVI >[;/V#YL@\8OF:Z3IF\:.4K5FSIJY0NO
M1<-G"-]BJ"Z-]Z2J5]JB=UUEU*U(L$R[X*\C^P>4?<5YHH.H\AZET,'^"#&W
ML.!_:*6B#4.0=2^&7L]X0V_A@\ASGEW&^'P,@-MXV#,9*F<?A8TN><I*N$A(
MYY('[!!V]ZU;N'BJ*-]]S=DW</7'4FK=9:PIM?4JA>>,)&\H2'"8?+F-RF8(
MG&VDQD^,!\SC[N=@(J^L8*M9"7BR!"\RP#JHE@Z_7[EHFWL;F0SA2^Q$L.4<
MD6'K[N=K36S$][K<3A=M9G<BZ$X6N<Y)B2%,K$F15($Z:0"JI6SLJ52..&H6
MO0W7=MQ=ZQ&677/GS1!8GHU\2V(T1>>C/PTYW_;\!]JE-6/BM\_6N;X;^4*3
MMOGAAW+>S-O]UI3JJV;K=R^DK;W1731$T1-$31$T1-$31$T1-$31$T1-$409
M^\#.1O8T\^R2U(UCE'6J2>([D7Y][Y3&FK%V$DT<(':")8;D89-H;M%,'3LH
MW','@Z0HT'.WCH9?T&-6I<)?""%J-"#--VDH_0?C/U2EAE=3TCXI6Q<)0TL4
MEX\;@&,Q-?$<;6M>.$>/#;(TG XM(86/_':F>$55;#/"Z7@](UD\>&7@VN,D
M@8]DPP.<YAX*,^]NC?;A&!P+P^/*WFXX71@^&)Q^5-D"Y$H^<OD)@A4K'VQN
M.N0;T)"W%P&UN#"#;VT?5$,[FKA;K8:NV7=67WL7 _/V,=B:XRQ$L8QH:8#@
ME,<K9!)4#A+R2.O+C=<#$\. R<'];=+,+7L;#,T/>]Q=WP"^%LL3HW14YX(-
MCB9AAP-L786%I=<M++ VW7NQ9-5VF!)T:-@@P:';U-#'SM%V'D!8XBY*.S4;
M*-B*Y?KT5;(RJ(YB6)O0+)]8NWI=<ULT]AVO8 9&W=(]SS@>T$21LB(8V.9A
M:&89."87N8QLKFV.M79IIS'D\&\-#(XXQPC'.#F2OE#GNDA>'F0.C$S@QKGN
MC#LAX*PA'<H*8NJ+*@YO5%:@95=@WG=B0@:Y%LFC.UG' Z()NR%@1SH2 ,BA
M=U%[G#@"Q%FG1 96ZVWH.BGN;824^7"87&G)>X/<7!TSS(722/:^2.1]Q82.
M?&&NLC-*L!Q<'46<(R6"HLQA:QK<,3!&&LB861O8S.YB8QY<VZB_(>X.R3'V
M)@?$6-&S(:=;7#I/06<L4>R"!Q2 +D.:R#AA]B[<=#Q+M+K88T1JYZYLL0;H
M+=2LZ*;1G!1/8Z9URZ,XX<<9#8ZB>J#?"?(ZQ=,]IN\FQ&9MG6;20FD:]L#;
M-:]N&7!)G)!#3%V3&-N&PQG)@!L19MUCHO/8$'T76^($"#<8@!MN%.2HFX.[
MH-&N1KD2LVK'JK]C2*UZ$@%":NKZVRJQ8\37?O5Z*)W?H^23A )FM+S+X;6/
M#VW<UP>'"3.4CWMS[#WGWM@8T66S*^-@;[TXAN"S"YF X687,(P7X($B1C;G
MWP%[B7&XX#;CTKT!@5Y!BLP(+/P#?HBA!E>UE:+:()PI:/DA]D?(.'J)EZI;
M++6R%JM%)=>JY4:NUWMSE*)-&$.?()V0M#9#CPNQ1$S</PC7&1H:6-' W.J&
MP! %CM%I . :8GR.. 82YMI;1&$L<.#<3C-Y+ 9R&]KN-O:;8?LUG>.I@ON(
MR<:E,6DTABPX QQGTS:JZ=C41+1C>>RPNT31:%Y(^60Z48Q]-.Y*,*W(4?/G
MY9"ZUG\+I_35/4P^QM*R*:*.9TKJHLR#R\N$='<ES(FCP729&47PM:PY_6Z)
MT;-#)W[.^2.1\;6"GQ#-H:&XZD@ /D-L08 !'E<N<,O5_7R2^@31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M6N.[#P&2O]F1K^,HK4C7YCU%4D\4\K?Y@MB4/RA']:3^PIJ%=><6\W9;.MU.
M?-MLG$99FF'L;X^Q7NL@&43^,"$":Y%,,<XM,+#AD6%H9(QAE"/71TVQ@\E1
MDY%D/#2<56P0H ,M57#A2PI!L#E>]M_'N(6G->2]RQB_/1G*FW5:+1AJ!RGC
MX=C*T]E');-K=MV@/)D+;5AL*FPR-K-%GMZ^=0./S1A5BXMD;R-QIA)FDC:G
M XED@2_4><NOU7[%JN/Y+CE!!^(2<=9*0)M*T\PK9(Q]$G>Z4^7Q-"%S>W_&
M^/BJDC &]LYEU,!%N3(@>F*58T]QWE:'I'EB\:RU(YD6DT@+%.5^+;EQG58Y
M=/(O1G:MLTW-XLWPYKW 9>G[B3Q::N<JNA!@#F HZ!R8#/3D$)P.#'\)',7J
M.1%F&!D<(QZ&'T,R/D@XZYW<P$O+IY(T@Y02+#S>G;?;?=U*--S_ ";,^FYO
M>L1PO"L2,A6XN8\GSD$7'74K-8U2F4JVZ[CI1F/.CV<2:(1@J>CI:9"S#= 9
M,!2!R0+$%;U;$VMXYG2XI!U7_:Z199^ELPW*6\G:>V[I%XZRR&2SLOE$=BRS
M,60E82/P8INC9Y@4VDTSK;'DL@61@AAQ!YA]>5MHLF@R1**B6HFZ)MTT[RC;
M_3/5:^LYWSXUHHUY,/?.+9X0&QD5AZ$"\?;D,A9YLMC6XW*3D[CYG-M\33/1
M:$L2AO'+IGDP26P?9V WEU!^-)D_-]*62F4$XB\OB9,IN+D\0&H;&V'3FOK?
MR76].+Q;;WC[&(+"\*"8-RY,9^VF$6S]DD'*'"Y#=P RYT[0$XQT5C;A&882
M&V0!V 'VQ>3CBK-PV+9),PXD[C+\EQF3GEN&O#;H.KDS"] ]R&!-Q60-Y#R5
M8W6>" E\'V5D $P7(%10)@#PYN&SG*MPT)3)L6#YLRD4JCTUQ21:C'-[-68M
M1%$K%+V\0<+,R@=O+F!;I[5JZ\V <H2X!82>WYY(GLDXN&P.0#99-]Q&6Y)6
M)9N/[&,QX,RWDIA0@U)4D80;N%ED"R$Q@9!!".'XFQF8=D.!L94? '27UW&O
M8,MH*O3'9#RC)C%<RC<TW"RQ^=>;8MV$5A0AWN.R02&",^Y''8B!X6*2 TD.
M8%9I%(RF(S&;06GJTQOB[N;,[& Y1 > &Q0IN-V[=F-N6H7R[=^<J;/>4%1R
M&8G#/<5-*)*9(DTR$ EMPN3E8HW&_+Y@9]#PMT*O34C78^TV5*2_')"(7#E8
MXZ//V QZ/?K"8_) A0"+9C/DXK;>.QWZ]ZWUV%PZ7P/:IC..3005C;^U[D8U
M'XD=8K"C4(QQ*LIS:58F@A80YML=!2$'Q<9B$4=@W2+=T#6#WB'+9NNRO1L(
M=?KKV]*GS+O@KR/[!Y1]Q7FBJ=1Y#U+H8/\ !!C;V' _M%+1!J'(.I:7<I5A
MK<)G3&L0@&!,38ER.VD1"5QG,K^>Y(1Q).1V%Y9&%P$X@^),C7XDS$XA)7+8
M]Y6(363L8RH3:0'IT:$N'R,P$E45*PM?.XW6%\^2XZUK_C+D[\AH;J#LDR=$
M,.O-M+T[N%R#<$LD966'Y-\LAA/;EB$E@F1PTI"!@96"P5+#TCO7DCB3$49@
M&K!6?8D)40+),B7R&NXYM9/I6L13DKMUZ4'V.1.+OL3#:8(BCV'3M!"=F8^!
M&ULW@XWW$#71^.,\;FVV=L=-XI *#QV*WQ#'*(B=WCS"1M5O>H[$CK*FX\+C
MOZ>;6OT@Z*J\]&?AISO^WX#[5*:L?%;Y^M<WPW\H4G;?/##N6]F;?[K2G55L
MW6[E])6WNBNO"GED>6<#<F/9BZ#P*&1K+F<\@JWR<G"3I@@-&Q'%3-1X.ODY
MA8/2]\B0D<@0J'BC=2VULYM$R5ZXNK08@V>_=]QG<7)W4&JGGGDHZ&G'!,G8
MQKW35;@'")@?9I;%'X<Q!Q-QQ >.2,Y) RPUD[.+>MR]V'*-89VN[%+-\CY5
M*21>70&'27#<5M()CR&3Y/DR/MSV.XB/=6(O;F]Q-JZH3-OV[-_>$C8TZ;ZR
M>6#+FZGC:)[FZW2NGO8)HX*:*HFBK9<.)M+%2R&.IF<+MO@(PL:7-X25T<>)
MN.XLYX:W%Q9<=]0]>5:98!Y6C.><=S^WK:$SVJ1YEE^38M;9JW<=0R>76!;3
M(8>N;EXI&C:E\#JYDF37L/)1EX:B[FD=1"2F: 8JJ^5592!Z+]C2'<E0T.BM
M(Z8.EI'4<56ZAT/>D8)-+S1W9-*S\9 BI1,V4,E'"E\4+Y,(Q1M=4/)<&X<R
M+NS\4<VOBL,R!?:IHW'<J4,Q1OBQULFQG!HM/BS2&$LN[KLI2O(EL$@6U7#0
MI!F6>2V8$*1\VT<DJ1Q10K8**D(RTZL:@C"\K;67IN!W'HWN6?5Z"J=.5-1)
M3L,[*/1-+%3&HJ-+5KR6"&!O"1D-X3P,;&RFT=0[ >!(=)?9V$9Y7<;V#1OU
M=FQ1-=RK.XK<XZ.__P L#8K+-S..@3Y\)OW*YBFXK;]A(\4&.;VKQ''+>6((
M23)#1)>VK=P[9K1]5@XLOM=,J)5255Z_:IH[18C]M.GH=&5#VM?[&44#](UT
M;7"[>^3"3%2DC,!W"8@18Z[1C+KX&X@/A$V!SMEOU'=;:M^MC65]W.8L2&)-
MO+V\QK;7DT?/9-&!T(CDQ5EZ1:.1]5 >E*U5>IKM6#0N63*V!.LCAUL9"-6,
MA:NDF15I9=\_IVDT11UC(M#:1ETG2NIXI75$D @P2R N,(%\3G,868[QQECR
MZ,@N859I<1X0L;G;?SJU[I=S.>,9RB+XIVT[4)QN"R;+6#@HM+) \?8MVZ8[
M$H6N.<_G>9R  N*<%J=;WK-X7'&SXV\1MI8LX&N'0Y)[X]LKY<^?-K5EJAR>
M7*3YLW0X]W3S7.6W%..-MM\M[%1)C;LYE&91F8"S6AJPY'\<"68A4E)"XA0<
M%<(/A#Y^*)#9>&(.:A&*2KM>2VUAM/1Y]27&L7(Y/1FM>,N\J_OWQCD[;:P)
M<GW%XO"=R\^2B< QE+\RKK;H'X:TJ)9+R*0P0-&ZC<=K*M##=QT29L-VAW22
MS,Z39\*+T!M[G=ZV[4N..^ZPSY,_0MM]\>]C>CM5*365PC9AB^<;<X0$%OG6
M;,E[NH%A]0L3=,K') >*@[J.2,ZK>B]6L!AV5;KCTC+(K)BPRMC@?5U5,MIM
MYOZA11M]Y2W>GDK!)+<;DKDW)O&8660:,L.P3%\LEV5<P9</%;>J"R=(O3%$
M9%X[Q5:UL5>D,H38TS9J-Z->QX)(:D65RLV]?7;Q(;96N?-_4JWX1Y1_>U(N
M4(AVRW.NT/%4)92S'Y#(\B(8PS6ZRA(<*Q_H8T1#]LHDVCS"-K$EB(L6#?#&
MZ 2O5)9'28QX00?,6I!;*^STH;;+D\G/G<ZOZ+UJS]X&<C>QIY]DEH-8Y1UJ
MDGB.Y%Y))[ \W2MDVD8PGCZQA(6R!IC8[.F$G-C0HE:^;6N4TXVLFFO:BO91
M6RQ56RU2EUMJE]M*75^\I>Z;1\-/3Q/958HH88W88XR,3&-:ZQ,PN+@VR"_.
M:CN2TI-5U,[9*,,FGFE9BEE#L,DKGMN! 0#8YV)%]I5G<\FGN#5^A+XR\??D
M9VG?X_J4KK;VU:-_5U?T4?WRJSN1TH+W?1_2R?<+'W/)?[C%>/-,8M[M>/=D
MI^GF?J1KK5G=;HQH%XZS(_JHM]_UZD]R.E"?RE'XP/Y67=_L%87/)6[E%JUY
MAG%'=YU>[)Y#3O\ ']1]?-UJ.[#10 ][K,K#\E%]^I'<CI2P'"4>67Y67[A6
M-?DF]SBG'FF\2=VE._*I%3O5I7T&5U8=V.B@#X%9]#'N(_7\:L.Y/28_.4>S
M\[+O!_4<2LB_)%;HE:5I:=P_3CYLKDE/'7]1-?-U8=V6B02<%;K/YF+;;]_Q
M+7VJZ2M;'2:S^=DXOW/$O3/9;R>,,VWI-)W/+A<YS.HEQ3*II7KQV$VJV\U1
MK$DGJ"*JQ"^RM4G<E=MF[Y1.M[8<W&ME'='WRNG.Z2?29-/3XZ>A!\2]I)^.
M8@D!NT1 ENHN+C;#])HG0<6CVMEEPS55O'M=D6NXBN+WSS>0'; &@F_I-KYA
M>\FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB+7'=AX#)7^S(U_&45J1K\QZBJ2>+YV_P P6Q*'Y0C^M)_8
M4U"NOKHB:(FB)HB:(FB)HB:(FB)HB:(FB)HBCO+O@KR/[!Y1]Q7FB@ZCR'J7
M0P?X'\;>PX']I):(-0Y!U*4]%*:(FB)HB\]&?AISO^WX#[5)ZL?%;Y^M<WPW
M\H4G;?/##N6]F;?[K2G55LW6[E])4F[D\_P/:U@O)N?LE.'*40QE%G\B?M1Z
M=%RYMXE;:W#1D$VK6VCH_)S*[  $;77IIJDR+:U=5!#JJR?;HW1]1I2NI='T
MH!GJI6QM+C9C <WRR'9'$P.DD.=F-.1-@;$AH).H>O3L7YQ=GO)SSS?WMLWO
M;X-XH5/Y9+E&\8S %@J/&K5>ML$XBM:($<*6!4G]$U!UKN0Q^%&6%5*=74A4
M9CCMTZH^E,G25_2-,=T=/W/Z2T'H+0K_ .S.YJJ@DKY(R+Z0K0<-<9"V^*T<
MDS'?OY90!ABB6087ASG#-XR_9&SM]2O'+90SW8;F< -LK9H@!:=;>>18Q#DE
M]B3$;D(5>-\N[GFY0W)H,&F@CF7WR(7B0>I&UYJ-;6J6!X-#0('H^J<\/++?
M9:<.B-&:0-)15+8-(]V]93-K*P2-::/13FQQU#H7_FGUCN$X!QMCFFD>7?B\
M86;;D7(N([V&]WFW97]-RMU>27Y0S N =K63Y'C"-9@WD<K7NMGTXF^3L<1G
M%,])FGLQ<R0\U@:,MR#V/M(:+Q>*1>]F\E?BY ]?LGTK/I*,&UC1ND)\3NN[
MG=(:0TM2Q54M'H;N0T33P04E5+64[8VPB*,U!AI^$,[ZJ0M$$37Q!KA%&<1O
M=]HW --KN>ZY(L=?&=5MM[[5K'RC>R_<GLRVHXPR?N+3EN2)OO7W'D<K\I?/
M,?4N(J  (1_&CV-,")R(?<D.9QJBIJ=G5:)N&D-(9$C\99,'3D5#84ZN]3N;
MTUHS36EZJET:8:6#0>C!2=R]/4^"))7MECJ=(F-UW&6S(&:G3"FEE<X!\TX5
M7@M )SQ&[[<HLWDU\VZR_5/L.Y2/9CNA=Q#!&R"(9%*02 0%&X@288B.X[Q/
MAV,@&;,:#B9(U*4 C1W(7CE9D+#1Z'H299W8D2+K.DQ0L@1M_*=/=S6FM%"6
MOT[+3,J*FH(:UU9%4UE9+(7/?,UD)D(C: YSY)C$&DM8 7O:T[M>TY-N0!KM
M8#<,[>9=+-45W0;5263-Y4QW@YPSYB>#$B\MLV?1/%&&XA&E <@*V!10*DV9
MQ<U/K8QCMJ90D#\DL25*/F4<5=&7ZJ"C^Q;BETEHR31[:*'0-+!5".-CM*&K
MK):@N86F27@3(*8.F <"!'@8'' P$"PW%SB)&QM@-9WVODM,MUVZJ*<IYMMA
MN%=KL3S1)<[S,K'2)R/Q:^;1G'^'>K*6MI-9F*=.!<<B$I!VA5RH9JVLN)A5
MW3_I.SJ;UH/1<^,&X222 !>QW\G]=FPJ"ZX &9-LO1ZVY5.>+-_."]C,G&;#
M,OPPWCEK@O%D2#L<I!(>4<B<OS6R/Q98@ZB^/X/#'+Y"LO*$SY-&1/'"C5^]
M&KW%G=A0E?2R,)=F,[WUV&6?'T<RG$&^"1J_S_R6KFW9N[VT9GS9OPR)A[-9
M.N>#+G&.S3"$Y$%9]N+F!$L\Z96*.#1QJ7+XS&$6J+NZK=X61YX4N:109'VH
MD&H9DY@"X-LR1J'(-OFVH-9=:U\@#D3GZZQYUZ*8WV:9$W"3@!N*Y0EP(ETC
M!.;3.)=K0=?I'"F$:W_DC1X>9W77LLD9(12NZD1-%*/Q#5SU5)E<19H"*":D
M@9,O;:3K/9_EYY )\;F]?7,[U"*/*Y8*RW$LVXCF^+LZ0C*3=8]CN/86@K":
M%,MSZKAJZ&.$H^:B$;'I8_+6N*7L5KWIEF5$\Z]Z/57611I?; 18W%N/BXKY
M[>91CR/%N-^FUO7GESDC=HD]VOX'E!G,@EJ.R[F6;O)V;0?V,BDW!QU4<-9@
MHW,9=U*\L8*)K-B)QR/=DG;40Y,K)6)-BBI>V^'D$Y&X&WLXNE2T'6=9MT>N
MI>@&?O SD;V-//LDM5&1!XU#\V.'$H*B.\O;?'(A%@9G(ES,H%C@042:]B,Y
M<=;/QPULT>(=6:QE=NMU%PDHGU5!55%3F\Y)2^RMMU?7CT#I:5C)&4F)DC&O
M8>'IA=KFAS38S BX(-B 1M 7BO[I="QR21/JR)(GN8]O>]4<+V.+7"XA+39P
M(N"0=8)&:N]^_+:FG]'E*ZG^@^1:_!$JZM[7M,?$_P#B*7[]0.Z;0IU5A^K5
M7W*Z2G* [2$^//RO=3A^H3)-?@A^K#N<TR<Q1_\ $4GWZ>V;0M[=^'ZM5>B
M[PNFIRB.SY+Z/+=]O#]0&3:^+C^9AM?%JWM9TW\2_P")I/\ N%;VR:%^._\
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M\<Z):^M<=K.'?H$G[YY3^.M%%A>]LU3VL(9^@2?OHE7XZT481KMUKCM7PS]
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M5IA#4LS O%,T#A87D>,PG82!B8?!=87%P"/4T?7U%!+PD+LB3PD3KX)0"<G
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M*6=-DA!LS)S,:-MFP<0^>DVB3&KXFU9#UVKI<GKT7ZEE$6G\/F<;$2V/&T7
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M+5LMLNK0BCO"N?L.;BH:YR!A:>AI[$F)HA&R1,;:^9JB#XI!F[?AC8LPS&F
MI)!B1&DJ,RK!FNL*)C"J%BHXBR<KD(LLI=Y,QZQEP&!/)K&6\SE$7DLUCT:5
M,,K2YB(PYZ &RF2,&G5NJ+A03^4QUF2(6TZV;N"[-.Y3G*5I:17*3S*+0R.2
M&72<Z/#QR*"R1F1%7*W.0%#1 Q4R1<.+$**KUN;"T%7U6Z22CE1"VER**E;K
M*7$7,8F,7FD>CLKBYP>9CTM%CC4<)M5N"18:6&HF![ALFM1)QQ<#%TGO4%$4
MW*2%W.613K;=2TBR71%'>7?!7D?V#RC[BO-%!U'D/4NA@_P08V]AP/[12T0:
MAR#J6+9JW1[?MNCV'#\W94C&.7L^<O&\50/K.Z7$$ACL*/*E7-6;1W8'C@=]
M(X^S-2DW<.C8=T<$-R95HJ19VK%*L++>9M8?DLT"D<Z8^2=[=VA(AF>Y^8H+
M901@%(DPIQ^1*$TF@QZR G@I6.'G8=X1;A)*P<QPJHT.)U8:)94M]YNUYW-L
M48Y;YFB:DTSA$(C/,7 N).Q:4Q2?CC1:!D['-X^U@(OFP^-R%>(C3[H45DE0
M)E$,Q>KC'J2!+'/B[;>E;.:(O/1GX:<[_M^ ^U2FK'Q6^?K7-\-_*%)VWSPP
M[EO9FW^ZTIU5;-UNY?25M[HKIHB:(FB)HB:(FB)HB:(FB)HB:(FB*(,_>!G(
MWL:>?9):D:QRCK5)/$=R+\^E9B'&MW@4]%K9(F+E162 J7%U1K-,F^38,GS4
M^SL9.[S8-TF'&7*,&CL&^I<@K:F6L1<JI5_5*6"1]/2213<$7T%/%)[V'N+&
MQXFF-Q<W@Y!C> YPD;G? 2 5^.U%3&RKK898.&$>D:R>+WPL:'OE#'ME:&NX
M6)PBCNUKHG^";2 .(5Q;[B*A;72@^'VV.32<7K(%5I"JHG>XBRP&T==&D4Q2
M'8PV:,0ER Q!-0BN.=/JN:O';5@.'-I?HWA!X4V3'2\&!&!E.)<?"DO/"ESG
M@O/@!P;;""Y[CO%I7!BP0 &00<*3*2+P&(,X$!C> :UL=F-!>6%QLXM:QC<2
M0W$4#W1H8/B%;8I&64N#MA+XN+-DW(V6B18Q>]X_/1(H!>%&][0FOUT0B3X=
M>A(2PUJ'8,5$DT]#HWA!*]TWOTSH7N>UCXV!T#WN&%L4T<C6&[!9L[77B8YS
MW.&9NE>",4;(/>86S,:QTC)'ED\;&'$Z2!\;GC"\XG0N;:5[0QK2 L0/;AT2
M[A0F5A:BIE6-S*(JK,)2X$!DXW)6\RZP&LXZP$)CT>C7,M1O?J.*O+23:/BT
MAB,<?7/"B^[-&%C<#)P&"6"8!\(DD,L+H,3W2NDQ'&("&@6P&1Y>96V8+G2G
M"$/? 2_@IH3AF+(^"E$V%K8FL#1A,WA$WQB-@:(W8G'#LN[@6V0HG?$1,':Q
M%DH<H;56;/0E]RMRRCU8BT6;1Z'1%DXM=JV1NVQZ[;N"E$(L.Z0>E7BJ[ZNE
M)HTTTO#OJ#,X,$=BV3< UUY)YG M'"^""&7F?A:QH#5-3I(5,? LIQ"TOQDA
MS#Y1<"(X86G$>#&(@NM$W$7N)<M0GG>KZU?AU[0U><]97%L'*>H+'[FZ[MRB
MU:H+.73E6QNV;-TKUG#APLI1)%!!%*VY15952ZU---.VZ^^^ZEMM*UK2FHN
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MDM"U^BL!JHVF.3)LL3B^+%GX!=A:6OL+@. N,Q>QMZ-#I2DTAC%.\XV'PHY
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M_NI(?+M,MYYAVI>3R6\Z=+[K/0IA_P!U)#Y=IEO/,.U+R>2WG3I?=9Z%,/\
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MX3%!,W@K<+>)XX.XQ#A+M\"XS&*UQGJ2ZO!631L$[%L#<@!AWQQQUH%9E2S
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MX4&4=IHW6VJJ-K"+MM<O8E=?9:I<E2ZVRZ^VEU:5NIQR16=IE;%S]>UJQR3
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MS?3[^;7J:*,0U^@JGMV0+^Z2O^#V?_S:T0O W\Q6GD<*LS>5\UE6%7%6;XT
M6;U=LG@YS5.K<K;^3,B"#5ZVNXVU_(W#=)3APKS>%:5K8^*W_%UK#X;SOL>/
M;K&Q2_M\\,.Y;V9M_NM*=56S=;N7TE9ENRPG+MQ^WK)V#(7EPK@TGD^/+Q$A
MDH!'D)(?"QLM=8WDS0(R<& :34@<!W/0=I:U[1R*0(+O6%MA!)JX0]'1-;#H
MW2-+7STC*YE+()FTLDABCDD9G$7N#'DMC?A?@M9Y:&NNTD&S@2" ;7VZ^7H6
M";;]CV$=M.S\'LNB@>TIC!#'IV"S-P_;MT">1',T&O&609/)*(T42O*S%<D2
M<NDZ55;CVR[80QI8,',FZ6^D].5VD],2Z:E?AJW5#*B -)+*80N#J>**^89"
M&M#=KB"]WA.<3 : W#LM8\=]?.O*S;+\CU84V][1]V>VYWF:0R^=;KQ2$5-Y
MX8P<=%9##X,$?##D8AX6-K263MW RR1L%"DQX'!])JBNV8+I"K1(M=M]7I3\
M(==I'2^B-)BBBA@T0XRQT#IWRQ35#PYDLSY!'$0XQN#(? =P!!<"_&\&@B :
MX7/A;>K^N]?+$G(791'8=ANUG<;RD.9LT;/()=2P7MPQUBZ*;? T@&4,N)!=
M&9].@<GFL\E\46+.57:H5T:;7(7U3N&/1JK9FJUFL[NJ5];/I71O<U0T.F:C
M-^DJBJFTB^-^ 1\-34\D4%/!,& #&(W7^$'7=<(S8-+R6C4T -'(;9D+8+E!
M.1?PWO.@.W".8LGQ?:/+=I5JS+ TFQI&T"P*(A5EX\]3&UB2)V)NJN112+!B
MX(X*E(8P/)I.WCER14=W<SSNYWNTK="5&DI*JG9IB+2]G:0BJI7,?,^TC2[A
MBR8 /9*]DC'Q2,<T@ -MG+HPX-L<.'5;S<F[>I[V<[*-P>"):XGVYC?QF;>7
M)VL;4C,3%2.-C,5XUBJ3I9.Y^?MQ_&CQUK(YFX:(VBT93)2A)^P&NBJ#.U)0
MHY6UP:9TWH^OB%/HSN?HM"Q&3A9G1ROJZF8B^&/OF6-ACA!./@HF,:YP877P
M- LUI&MQ=E;<.8;>,K;/<)BN7YGQH2Q[#<P2O"+LX^')&9I"6 UW)E(Q1?A(
M (EX0K8J >&A]ZC9M(A:R1,.YHBZ1HY1HX8NOG ;&]K\NKS[U)%Q:]M_)N5>
M!-O.)-L\ 8XWP]$V<8 -K^NB#FE;G9Z3&%+*6NY!*CCCG/SIM[6G%9X\5NM1
M2HFS8I,Q[=LT1$EQN?7B"  >N9Y5"$>V2Q-UN#.;DLTS209[G;,LLIAP;-F(
M]K#<&1VZJ*K89"HD/K4(K($7*?559FZ:6%5ZHLG5B#<ND[+/YQ&UAD-O&=ZC
M#G<F^[B]"O6]_:6VWGX1NQ MD0[B]TVE8:8"Y2#8T+6V$0[,LP39& W282\N
M(7;&72JC-(P-4L?MQ[RUS7K2J*IKL)OK]?785)%Q909CSDYE'4GQO,]V&X.;
M[LRN';6/:NC$@C(#'F+(H\%IMT1QQ7'T<<$$9#(V:;1M;87/EWU7/4;*D6[V
MY)"Y%BUX1AOKX^C+S*,.\XMU_P#/K48M>2ZR-%LY9\RMBO>OD/&(#<@<)%LC
M@@N-HL4GE[,F7*&KQ #*IDRZ>1VP>Y,/6X@D'C+,FS9=:HK.7:K-%>DX[@ @
M'#D-W-M[<U&$W)Q6OGJ]?/L7H/MQVUXFVJXV:8OQ "6$@K'S@R7)$G=Y.1RJ
M1/DT$B$DDY=2Q-0D7>)MFZ5U]J3=HU;-V[(>T9LFZ#9.I))N?\AN"L !ZYGE
M5[S]X&<C>QIY]DEH-8Y0JR>([D7EDWY0S*$1',HTQA<"<M(ZR:A&J[M*0U<+
MMQ2%C%%5QU$ZDG591-"V]6J::=E;[KN99;;PI3[BF[EZ.:""5U15 RPQRD-,
M5@7QAY O$38$V%\U^?5'=A7PU53 *:D+89IHFN+9L1$<CF NM,!<@7-@!?4
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M/ER,9/Q\%BJ/YQCFX4U*,0U!C",E[8LUQ@MAB.L M\A)1"CSLW<FI4NNB$9
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53<WR'3?L6K&M&8&[J':MK=%HO__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g393013g86p18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g393013g86p18.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1K@4&AO=&]S:&]P(#,N,  X0DE-! 0
M     'P< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 P0D]2("AB97-T
M($]V97)A;&P@4F5S<&]N<V4I(%=A=&5R9F%L;"!-87)C:" R,#$W.$))300E
M       0) G D9VPSNM+0!44K3EJ9#A"24T$.@     !?P   !     !
M   +<')I;G1/=71P=70    '     $-L<E-E;G5M     $-L<E,     4D="
M0P    !.;2 @5$585    !$ 00!D &\ 8@!E "  4@!' $( (  H #$ .0 Y
M #@ *0       $EN=&5E;G5M     $EN=&4     0VQR;0    !-<$)L8F]O
M; $    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M    )P!( %  ( !, &$ <P!E '( 2@!E '0 (  U #  ,  P "  4P!E '(
M:0!E ', (  H #  ,  P #$ 10 V #8 1  P #( .0!% "D       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q =:,_@         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 ! \     !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    %HX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  3?   (AP         !                          $
M"(<   3?                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   3?     %)G:'1L;VYG   (AP    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   $WP    !29VAT
M;&]N9P  "(<    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     <X0DE-! P     #V,    !    H    %L   '@  "JH   #T<
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MN&XAKOI-L95^Y8O6EY7]0OV3_P Y,?[-^RO6V6Q]C_:7J1L]VS]H_JG]??\
MF?S:]457.3Q"P1IU2I)))1*4DDDDI22222E))))*?+/\9O2>K9GUEJNP\')R
MJAB5--E--EC0X6Y#G,WUM<W<UKFJITC_ /*N?_3AE_\ GO)7KR\UZ;^RO_'$
M=L_9_P!J^V9/T/VC]IW;;]_\]_DKUO\ 2_X#^<]#_!JS&4N#6.G :(0__]D
M.$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $,
M4P V     0 X0DE-!"(      7Y-30 J    "  , 0   P    $)*    0$
M P    $%3@   0(  P    0   "> 08  P    $ !0   1(  P    $  0
M 14  P    $ !    1H !0    $   "F 1L !0    $   "N 2@  P    $
M @   3$  @   !X   "V 3(  @   !0   #4AVD !     $   #H   !(  (
M  @ "  ( #33C@  )Q  --..   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,3<Z,#8Z,C,@,#@Z,SDZ,34   20   '    !# R,C&@ 0 #
M     ?__  "@ @ $     0  "(>@ P $     0  !-\         !@$#  ,
M   !  8   $:  4    !   !;@$;  4    !   !=@$H  ,    !  (   (!
M  0    !   !?@("  0    !              !(     0   $@    !.$))
M30/]       (      $   #_X0& 34T *@    @ # $   ,    !"2@   $!
M  ,    !!4X   $"  ,    $    G@$&  ,    !  4   $2  ,    !
M  $5  ,    !  0   $:  4    !    I@$;  4    !    K@$H  ,    !
M  (   $Q  (    >    M@$R  (    4    U(=I  0    !    Z    2
M"  (  @ "    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*0 R,#$W.C V.C(S(# X.C,Y.C$U   $D   !P    0P,C(QH $
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# /YF$E':!HTHLW19@#B]& "/0#2]]XLT'>UONF%B_& /78(._C
M#O6\ _F6E2E'GJ2DR<M2IT7I2H+)+ >HT3K82M'FA#HPW101;T7HP0NYK>]!
M[-;W@&L7(GY1.&/M1K?NO<F,JFOH7J4HNKI3K0VERA48 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$,O,Z*2A;RM4/%A49SCO6E7&
MF*[9:T(XQ\IF3C[#HE9B276<KL-&[1K7+?C:Z3*3R5@50-2%^6I7T+:WLA;4
MW:  2L80Z6IRJEUSMJNBIGGQ+Y"3'CLW(VFE:_;F^"VG6B-*T'@3P:[)K_"-
M:<= )S7&>4F4V_A&MOX0N)NQ[6$K/X1I5W&]2C3>?*\#R24/?5;R63HR,TX
MP!@&K7(GY1.&/M1K?NO<F,JFOH7J4HNKI3K0JZ],9TY/.;A!SPLCCQ1ZNI2J
M[B\8K9V:P2RO12![TKE,(9G]UVH=-/J'1Q>W!<?M.#RP/!)[A?>'W>]OLVPS
M8)@6.X!38C7=F=D2S5+';C4)''HQ3OC99JQNLNBU+K?-2"21S762UK)P$77X
M4!TH7_M] _JC'_BG-J^"S8MQ8C^,;_1+-V?R>(GLZ!#I;.6_2+7-?$&Y%J:W
M.8J\K%BED=U"(4*+J].SA*B6=1M:HV[N7F4WDS-]PGPR^Z;V#[^_^;F@;/\
M8AA&QNCP^?#>RDDJ:J2*7=YDE;H,BTTT4W-EEOPW)8GN>JHMLDXBT1G+288
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MV<AVWODW"/MTWHY/!K=S)UE\#."F2, 8 P!@# & , 8 P!@# & , 8 P!@#
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M;WR;A'VZ;T<G@UNYDZR^!G!3)& , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M6*MA,\!R1]X/<KEQ+X_T&?)Y>CA/8E/.M!3>.[1(8],"@I7LF/O!83)2+?\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , @OY[3"/2SEB=35MW
M1;\)KZ(4G6MDP.+T'PH@/,-T*ETGF5I,<M?[+%*.+/*1WKQ0H0Q:*)J^ E:8
M8VOR5%*E!+@\KFQ80VBJ<R+SK;UIT]'3+)QR<B7>D:[<$\XL>R"%#(/1$WMR
MN":CL9_*)<%I!:F4UNGKJI2(DM( 5I$G;2JYB@!($J15IO'YCS:D4_7AOP\Z
M]9FS & >A9I9NA;*, 9H Q%CV6,(] ,!OL&6+N[WW1@W\0@[[!!W\6]:P#5W
MD3\HG#'VHUOW7N3&537T+U*475TIUH=?=UDOULEU?06D_=;&<^F=K3>C1?:*
M[TJ0Q9NWZ$('<WXB+;'5(OSF.6/U%Q3[?ILY#MO?)N$?;IO1R>#6[F3K([NL
M;>MQY&_1ZCO<A ,V/:VWH8=];7^G5!;-V_0A!QF]D1;MZHY\OG,+ZH*[^V;I
MG'=M_P#<L$^U5?Y4)D0?/^[ZR]7G"3(& , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8!HQ;'%R63V_GRVZDYBVMQVF+E6$'@T[AM;
M1?C_ "YND+%&I#.WB%261M-MU;8C@D<B54FEK8T.J,;:6>B*7(0B4@2C+(#H
M1?'TZE3DX,NDVSKN-R.(0N/QN76 _6I)&E&-.ZV#*&F),3_)U E)YP5SFTP1
M@BT10GEDFE)-%,<?:TNRDQ9@B-J!G&F <TP##O(@B=JN/]YIJM$M!9RBG;-(
MKD;:9LIQ!.S84]EQ 2 W6];+6AD F_:4S6]; ?HL6MZ[.W (U^C;;J(36Q82
MGB;%BHM2_P#P8^,[=91+9$9!#V99R,1/EPBD6GI(^-;5M=<K?$CV<FXUYQ)T
MI\91"T\U4F.1"(LD%OUIKYO=.#78RGR5=^7X;7XO ;Z_XVFLY'*5\^ JA9<%
MGIW)T 'CSR.+;-RU&31JI*Q".C8ERQ=IG72/29[*2MJ?:M ><ZIZIZEZL_(4
M7EXTZT(-ND<Z 'FOT@W*V:<GUEL<6JM/E['"V44-3/ELRTI!J'Q=MC05&GPV
MM(^-1M?INTLV7MK)TGV;LG0SM \472MC6V*_8[A,.%IA+:M(9)Y-V6L6%7;M
M*Z6VYI326T=*U]-;VO9"-\6FZ^E;+5:_K-%OP2KF;^DWQB_\M:O^#L][X8)/
MH%G_ +B[_P#$6;A_U_\ Q_4EAZ)SH;^;G1<63:UB()KQ7N8=GP=JA9C4KE]M
MP<+,!L?BWST@!834THVN$=LO2;RPDR71>M^+XP]_Z/-1V7;-G;*J:DIW8<VB
M[%G?-II5+/IZ<>AHV6"+1MKO=;ZK$C(]!56][\EO6IKUTB75]>:_/SEG8G*1
M9;?%NL%$_;X0@'#$SU;,K):]0V$L$.":%\-K5@&K](!8]+Q VUI_+"4[3Z$=
MHKQA^CL;VQG['L(IL*3"6U24[IW;NM8L*NW>>2:VYI326T=TT>W6]KY7L4?%
MINOI6RU6OZS2/\$JYF_I-\8O_+6K_@[/=^&"3Z!9_P"XN_\ Q%FX?]?_ ,?U
M):^B9Z'CFYT6L\MZ;H)EQ6N<5KQ&/14QN5S&VX,%D"PO*IWTM J)J24[7[4[
M4[(V0(A)HK0/$T:9WNYK4-EVS5VRJ"BA=AS:+L.661')4K4;INK&-M98(='1
MT+WNZ]]2$D<>A?.][<%M5^5>,G'].<[_ .B[B1^OFX__ )<,T4D'ISG?_1=Q
M(_7S<?\ \N& /3G._P#HNXD?KYN/_P"7# (#>D'ZPAR,Z/?D>[\;YKPQIVPW
MUHBL5E1LDB/(^=(V8U/*D)BY,D+)=N/12S2A( O8% A T 0]Z\/MUF_['=@-
M7LBPUF)0XC24S'S2Q)%,V17WB5$5UV(J6=?+A(W2M8ME1U^1$]II#^%W6_\
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M2\:XT0CAI34!?Y+'Y=(4\DE7).;KF=.1$610]JDYQ#1Q\-6[-5DIQ$D" 6(
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MW*G&18?A?%K?H U[_:>DG^0&;9\$6)?2U#_IU'\A9N[.)WB3VFWO!'K'-_\
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MZE*+JZ4ZT-I<H5& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M47I#26'M^A3>_K;_ .<;Q'^I.:?;H.>!M0_)V,?;:?\ (4NGUMYEZRH_G7R
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M'\[DAQ9T[M34@ 35,\(:1('Q4Z"7L@9R3M,Y+P'L+5IL<SA;-T<S$#=$Q 0
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MH7J4HNKI3K0VERA48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#5#D%P7XA<K) QROD9Q]KFX)
M'&68<>8'B:,XG):U,ABT]R&VI#-'E>&E$N5*%6P=F_\ 2FC%V_'V9ZN'XYB^
M%1R18;B-511RO221D$BL1[T:C4<ZVM4:B)S%%:BZT1>=$4P#_P 3CT7?Z$%#
M?^ZP_P#XS/0_MCLI^G<1_P!=Q309_"W_ +4]AEFD^CGX-\<9\AM*B^,555?8
M;8A<VQ!+HHQ"0O*1 \I1(71*2IVI-T$E<D&-.H#W/QRQ;#VZ[<Q*W9'CN)4[
MJ6OQ2LJJ=SFN=#-*KV*YBZ3'*B\+5S12J-:F:-1%Y$1#3[I+NA<I/I.;'KNR
MK1MJTZ\<ZXA*N#MC? 2(D:@7H%;ZL?AK%VY"R.BC2L*A:82'1!I1/@A!VE['
MVBW[6QC9K7;%Z:IIJ6CI:EM3.V=SJA9D<US8TCLW<WM2UDOFBK<M?&C[*JKE
MQ6]BD:_X)5Q$_2<Y'_\ E*R_PCFS?"[C'T7AO_=5?UBS<&<;O&GL-SN W5_^
M/?1^\D8WR6KV[KEF\FC3!+(^FC\S3P@MB4)Y<RJ&18>>-CC[>X:.2D*!')M%
MJ0@V:$/BA&#M#OQ-D&V#B.R'#),,J*&BIXI)(9%DA6=9$6%Z/1$W21S;.5++
M=+VU9ES8FM6Z*M^6WL(-NMO_ )QO$?ZDYI]N@YO6U#\G8Q]MI_R%(I];>9>L
MJ/YU\@)U>K>^MLH+Z(7E[FYIFA;9>]&O^OH?3(26'M^A237K=?RK<)OJ]N;[
M20+-8VG_ -UQS[10_EU!?/\ ,^]ZBGKG9#')N.KJ^MYXN_-MZ_=]M'-&VR-Y
M^*=_0?[C2DL/;]"DIG6Z?E>X5_5O;_VGA>:KM0?N>-_::/\ *G+I];>9>LI]
MYV,@)K>KO^M\XH_[B\_N[6QFC;9&\_%._H/]QI22+NC>GS5)9>MV?*9PB^@M
MV_O^NLU+:?\ W?'/KJ'S*@DG^9][U%.W.S&.3.]7O];WQ%_K-T?=YMG-)VQ-
MY^+?Y+T^E)(NZ-Z?-4F2ZWI_*;@9\Q<C?WA2N:;M/=RQ_P"LPWS:XDG^9][U
M%-#.T&.3#= 3ZW+AU](+/]QMGYIFV#O0QCO*7TZF)(NZ-Z?-4FUZWI^5N!GS
M=R-_::5S1]I_5CW/AW56DM1J9SOZF%,3.UF,2^= IZVWAQ]*K!]S5CYINV!O
M0QCZNF]-IB2+NC>GS5.T<SY9,P@YZ1'C'(;+O=1:$MK=RM^!Q>'<=WV!1LJX
M62%)U:*OKCEY?)ZH&.(2.Q( T&SZUZGL-DD\/E"I2F:7-TK)-'7^7P]0W1<;
MN'O[\.OB]:H2"\!H2[USQ&IN%O$:W#1LC;)BV:)*'YEE+Q&H>LG,H<8(Q2N3
MQQU?F.1SMKA2Q@1V _-;Z]I'B;$O[@6\NGF-KU &X. , 8!JUR)^43AC[4:W
M[KW)C*IKZ%ZE*+JZ4ZT-I<H5& , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , HC];
M?_.-XC_4G-/MT'.\[4/R=C'VVG_(4QI];>9>LJ/YU\@)U>K>^MLH+Z(7E[FY
MIFA;9>]&O^OH?3(26'M^A237K=?RK<)OJ]N;[20+-8VG_P!UQS[10_EU!?/\
MS[WJ*>N=D,<FXZNKZWGB[\VWK]WVT<T;;(WGXIW]!_N-*2P]OT*2F=;I^5[A
M7]6]O_:>%YJNU!^YXW]IH_RIRZ?6WF7K*?>=C(":WJ[_ *WSBC_N+S^[M;&:
M-MD;S\4[^@_W&E)(NZ-Z?-4EEZW9\IG"+Z"W;^_ZZS4MI_\ =\<^NH?,J"2?
MYGWO44[<[,8Y,[U>_P!;WQ%_K-T?=YMG-)VQ-Y^+?Y+T^E)(NZ-Z?-4F2ZWI
M_*;@9\Q<C?WA2N:;M/=RQ_ZS#?-KB2?YGWO44T,[08Y,-T!/K<N'7T@L_P!Q
MMGYIFV#O0QCO*7TZF)(NZ-Z?-4FUZWI^5N!GS=R-_::5S1]I_5CW/AW56DM1
MJ9SOZF%,3.UF,2^= IZVWAQ]*K!]S5CYINV!O0QCZNF]-IB2+NC>GS5.T<SY
M9,PKRWK%[0F',&QYA?G"/H[;W?4?&%H?F>K[>Y'RNS)E7E45//9Z>[6?&&%9
MP@F9<;:Y^JG25K=X\V,AKW(Y!#"2V1XD@&5:B;!5%U=LG0G7I<&7'DO&3'\2
M'6*OW&ZH7R#PRG:^B#S$R7:.0Z@) DE-.LC2XK5BQ(3!'Y%":X3KVM26=I<?
ML,'C9B=S5+DBAOTH3FG&BGCZ=?3K,J6+)9-$(<[R&'UU(+7D3?I%MO@,6>8;
M'WU]VI<$J13I"[3^1Q.))-MZ0\]T/]*OZ#1R9$<0CVH7&IDIX$,%L7QR-?\
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MY0J, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8!H+S!Z,;A=SQDL/E_*&J5EAO\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MY0J, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M S1MI0,;4!RD#LM?GUP W-B=,D M>GQR<7EU4A)T<X.J]:X*QFJU1YPP/OX
MP!@&K7(GY1.&/M1K?NO<F,JFOH7J4HNKI3K0VERA48 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MP<7C[]+'^1Q&(KYV(9OPY>(C$W=DC+[- ''$RQY:E\@(..)<0&B%#:[ & ,
MU:Y$_*)PQ]J-;]U[DQE4U]"]2E%U=*=:&TN4*C & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & :D\E."/$7F"YQ5YY+T7$+><X0A<VR*+),-Z :R('
ME0E5.:9)IJ=6X&RUBA$D--\8)HN\0#N"#KMUOUL-QW%\';*S#*^>C9.YCI6P
MJU$>YB.1JKI-<N2.5$SMF6JUKM:(IK-_Q)/14?H4U1__ %IA_B?/3_MMLK^G
M*W_NC_IE-S9_"AE6E.BWZ/\ XYV7';BI'B_7U=6;$M.X8Y,&,V2"=&G3\R.,
M<=])M+WU8DWY]C=W)N.\5,9_H%9G<[AG=&'$KME&R#$J:2CKL5JJFEET%DAD
M5BL>L;VR,O9B+\5[&N3/6B%48U%NC412KGUNSY3.$7T%NW]_UUG5-I_]WQSZ
MZA\RH(9_F?>]13MSLQCDSO5[_6]\1?ZS='W>;9S2=L3>?BW^2]/I22+NC>GS
M5)DNMZ?RFX&?,7(W]X4KFF[3W<L?^LPWS:XDG^9][U%-#.T&.3#= 3ZW+AU]
M(+/]QMGYIFV#O0QCO*7TZF)(NZ-Z?-4FUZWI^5N!GS=R-_::5S1]I_5CW/AW
M56DM1J9SOZF%,3.UF,2^= IZVWAQ]*K!]S5CYINV!O0QCZNF]-IB2+NC>GS5
M.T<SY9,PKP]*B^0JH.5%7VO*7#B/,'M<DH5V88=?7(6MJ8LN$1BG["LYVFZ>
M)([(;G%(JK&Z"9JWM,M=6,29P$]00A"ZM$Q0@;DT=%4S3AX=2*J+JR6W+JOQ
MKRWE8Z/YD9X]P^I1NCTOK>;,0V:0NK.ZTV]CDE1-+:_S62OR.!U:^&%)S'.N
MZP(<@5M"U)B1 9N.1-N"-M;1!VA3BGOGK-QL 8 P#5KD3\HG#'VHUOW7N3&5
M37T+U*475TIUH;2Y0J, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M)%\H5& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M7VLTRZ(3"0Q*<1J<RAN4+&R0/<4F3(_1DQV:UBQK7$-)![8K4H1ISS*%#9/
M/QC;V\Q<2YC0HQN2<@U*G<!IB1+B$IX@#/3$J]@V>40<,LL9I(# EF"+ (8=
M["'>@"5N;T)BLU$A1HS7!1M8O,2I2$YBU6( 2Q*E8R0 $I4;+  &SSMC-V
M0[%W0ZUH#6;D3\HG#'VHUOW7N3&537T+U*475TIUH;2Y0J, 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# *//6[/E,X1?06[?W_76=RVG_W?
M'/KJ'S*@QY_F?>]13MSLQCDSO5[_ %O?$7^LW1]WFV<TG;$WGXM_DO3Z4DB[
MHWI\U29+K>G\IN!GS%R-_>%*YINT]W+'_K,-\VN))_F?>]130SM!CDPW0$^M
MRX=?2"S_ '&V?FF;8.]#&.\I?3J8DB[HWI\U2;7K>GY6X&?-W(W]II7-'VG]
M6/<^'=5:2U&IG._J84Q,[68Q+YT"GK;>''TJL'W-6/FF[8&]#&/JZ;TVF)(N
MZ-Z?-4[1S/EDS"OGR'K+DORUY/2"#K>,-6P^T:6@U66 X674_27WS3BAXBSC
M-K1-I1CDR:,<-U)KO(VAYC-@R*/K@LR_^#\QX=B66>(5$@7(UH(JVU\.K11>
M*]OC+QIQ<I*?P+>6-[XE4Z;'ZU:*>0M#;)8>JK)CFSE9;?#7^"3>30J5-'\(
M[PU,[C/UP)/'W@]VFRE(=N5.QZU]+=7TE>6]N >_%Y. V]P!@# -6N1/RB<,
M?:C6_=>Y,95-?0O4I1=72G6AM+E"IU_?6A;/LN&](C"&J(6'.8JUF<7:Z6&-
ML;EK^QH#%AL^M@HU6-&V."5.)2:60268>(O9HP$E $+82P:U]!;5E+2S[':E
M\U-3S/3%JAJ.EACD<C4IJ-4;I/:JV15542]LU,:951R65>UX^52!Z#:YT6?&
MI+-*U%ROL&'PPHTZ7RN$#MZ51R+E$$!4GF2%[8A+VUF 0F&%2<)P4I]%)A:4
M&=TG\?-^J/V!22Q057[(IIYU1(89THXI955;)N<;]%S[KDFBBW7+61)IKJTE
MMQ74Q+_#W>G]--L_K&F']\YF?L[#_P# T?X:'^0I=>-?&H_A[O3^FFV?UC3#
M^^<?L[#_ / T?X:'^077C7QJ?9CML\E9>^-48B=EWE*)*^KB&QCCT=F4^>GQ
MY<E0]%IF]J:6UR4KW%<I,WH!"1(G./.'O02RQ"WV99)1X7#&^6:EH(HHVJZ2
M22"GCC8U-;GO<U&M:G"JJB($5RY(JJJY(B7S/F$WG?BA04D(N*WSU1YP$Y*8
MFP9F8H.4&#T46042!W$88<88+18"@!V,0]Z $.Q;UK+EH,.1%<M%1(U$NKEI
MH$1$1+JJKH6M;.^JPNO&OC4]UMW\@&Y8K;W"WKB0+T"D]&N0K)_-4JQ&L2FB
M(4I%:8]V <G4IS@#)/(.  TDT RS !&'>M&T&'.:CFT5$YKD1S7-IX%:YJI=
M%149945,T5,E3-!=W&OC4RM6B;GC=")T<J=(Y<6PW,:DA$]+ZT*N2=HF=8I*
M$H3)'15%PNI#>I4$ &<00K,)--* (PL @!WO6'5+L?H7,96K@U(Z1%<QM5V%
M3N>U%LKF)+H*Y$7)51%1%RUE4TUU:2\UU,;O]M\DXH].D:E-FWA&I$R+3VUZ
M8'^:3UG>FAQ2CV4J0.C4XN29<WK4Q@1%GI59!1Y(]; 86$6MZS*CH\+FC9+%
M2T$L4C4<R2."G?&]JZG,>UJM<U>!4544I=R9*JHO2?(_A[O3^FFV?UC3#^^<
MO_9V'_X&C_#0_P @NO&OC4?P]WI_33;/ZQIA_?./V=A_^!H_PT/\@NO&OC4?
MP]WI_33;/ZQIA_?./V=A_P#@:/\ #0_R"Z\:^-1_#W>G]--L_K&F']\X_9V'
M_P"!H_PT/\@NO&OC4?P]WI_33;/ZQIA_?./V=A_^!H_PT/\ (+KQKXU'\/=Z
M?TTVS^L:8?WSC]G8?_@:/\-#_(+KQKXU'\/=Z?TTVS^L:8?WSC]G8?\ X&C_
M  T/\@NO&OC4?P]WI_33;/ZQIA_?./V=A_\ @:/\-#_(+KQKXU'\/=Z?TTVS
M^L:8?WSC]G8?_@:/\-#_ ""Z\:^-1_#W>G]--L_K&F']\X_9V'_X&C_#0_R"
MZ\:^-3[C9:G)E[:Y$]LUCWJ[LL/0(G66N[9,+ 7M<7;')W01]N<9$O2N)J1D
M0+WYU:V1$L<S4R=4[N2!M(,,6K$Y)D;Z3"HWQ1OI</8^9SF0L?#3-?*]K'2.
M;$U6HLCFQL>]S6HJHQKG*FBU51=W&N6O7D<U?EG-R+.@6.3KN4D<>APD^RP-
M+\LM=G<AUTF1J'!1/ H7 U.I%#B$*14K.DNBMLQ9"8\P:S023-A@C3 96;I$
MW"96=D)2Z<;:1[>R5<C4I])J*F[*Y41([Z:JJ(B9H5^.F2Z2+:_#JX^8Q=_#
MW>G]--L_K&F']\YE_L[#_P# T?X:'^0I=>-?&H_A[O3^FFV?UC3#^^<?L[#_
M / T?X:'^077C7QJ?:*M?DL?'ELN)LR\38HW/+;'7"2ES2>#844@>43HY-+&
MJ=PN>T"=W<VYD>5Z!N-4!6*T;2XJ2"3"42@9<:TF%)*V%:6@29T;I6Q+!3[H
ML;'-:^1&:&DK&N>QKG6T4<YJ*MU07=KNMM5\S[#Q-N6L>)D*A_F'(AC(B+DP
MLTK->)%9+8",N\I0N+I&6N0;6K"/0SA(FUH=5[&C<?+*'5&VKU*$L\E(>,%C
M(,&D6)(X<-D6=LCX="*E?NK(G-;*Z+1:NZ-C<YK9%;=&*Y$=950K=W&[R\)G
M?@I=UT.7-WAPW.-NV>X-Z_E5QZ1+T"V?2M4C6HU5N1 A4D5I3W8PA2F4D#&2
M>0< 91Q0QEF $ 6];\_'Z"A9@.-N;1TC7-PC$G-<VGA1S7)1S*CFJC$5%14N
MBIFBYH58JZ3<U[9.'E0[9;/DHS1@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# *//6[/E,X1?06[?W_76=RVG_P!WQSZZA\RH
M,>?YGWO44[<[,8Y,[U>_UO?$7^LW1]WFV<TG;$WGXM_DO3Z4DB[HWI\U29+K
M>G\IN!GS%R-_>%*YINT]W+'_ *S#?-KB2?YGWO44T,[08Y,-T!/K<N'7T@L_
MW&V?FF;8.]#&.\I?3J8DB[HWI\U2;7K>GY6X&?-W(W]II7-'VG]6/<^'=5:2
MU&IG._J84Q,[68Q+YT"GK;>''TJL'W-6/FF[8&]#&/JZ;TVF)(NZ-Z?-4[1S
M/EDS",'DS4M0\Q(51%_U56Z>W'.0V53\*53YCD%H59)1\;GRW6YMN$#@[0F9
MU5+'6/QJ/'2R0-T<E"EW9$CJ%4Y)XPXFK3R%H(MO_%\^;-$SUKY21:%0F(5O
M$8Y 8!&F2&PJ(,Z%@B\6CC<E:6)A96TD*="VM;<C+*3)$J8D 0 +*+#KM[1B
M[PQ"%L#E& , 8!JUR)^43AC[4:W[KW)C*IKZ%ZE*+JZ4ZT-I<H5.O"ZU1ZR"
M"^RI6_O"MS/HG:GWMU7A>H]%HC%G[=.]3K4UBKP$VMRH> ;[QTY;U-QJ9.,D
M<?6NYDLROF&U,_U):O\ #E/9L]WX574EDK ^W&7+Z]D,&3HA0)IFDA=]Q(==
MJVLE*UHB#_3J5IZ*MV0QXG@]7BDF*RL?0K#035<=72=@4\$>']DQ12,HEAJ(
MYU7=WPQLW9*AKE<Y5&:HQ6N1$;K15M9455O;AOS9F1V5IXH+JP1KG9SXJR7C
MZJXW/KD]3YT+J6.\HY+SA46<[::C%<;4.'\/D>871<8RJCHNA0AI1LI0Q0H7
M&;<0.2\>'(_&4JG-8W%HL23$V-CI6+5R85%@*4K-.TJ-[ ED8FFFZN?V<ZML
MC4LK6I7XMOFJU6YN6R.T[WMGGKX+6MXS)[O87#>16&YP]1">#K/!GCFSS^HL
MQT8H+23.>V\4X95K2X<?7QJDA"?1[>2YS)T<E$.NHI5J4R!U0$MK/,CTR,;?
MO&93XU%3MF2HQY\[,#V/8@C7U%<]'XO/5*W$6/B551RMA:W=J*VY1L<KGPHJ
MZ0NW^%G;/;>R=JB9+KU\2\/2M\T5TST11U_4([6@W\.:A@L>#T9\RH-ZB+G2
M\9N,BRI/!J?F%]R:X5;4Y$VBVQ%5$'>P'Z5J[7 WPDAY7UROB78:X[4J\&ID
MQ"OP_$&4KL:K*B7^TT.(LF;6RT2TL4]7#AT5&CVK2NE29E/'$E*KIU:VH;-D
MVR5^*BI=&HEV:-K(M\E6_#9->>6HQ!!7[A'7=7\>9S'HW0!;5$F;AG,D-DOM
MC\=#+&;>0R:SZK6WYMVK]-!G?DD^J&Q3JT"Y"Q6?(4U*-=<DH97#U2%:BA2-
M1F3LQZIJ\0IY9,1TY78U ^FCIL12G=AJTE4E!H5"SLPV-KT[%W*2E8M<ZI5T
M,R.1TZI5-S1J*B)EHY_%O>]U3A6_'=+)P'V;-(X=KX/=[K(8SQBELB?W;F:_
MWQ*VVX.*+ M:K 42><N% JJU UQ*;7 [%.$).JMXKY/QN<@0Z5SU9+F>T0)S
M S!8FCI%QMD] R*7%(HXX\$CH(74>+2-=3)% W$&U&G+#1M1D_93*A<23=HJ
M=L+Z553<6CXEG:2(JW==4MDM\N'2S1$M9.?.Y'3Q4NGCI6O#"0L=]QJ16(V.
MW-BJW9?!ZYN@546:@AR.H[ 1/\W9DZ%"Z+GU W>: UE$K4R!C&]+T"90\H5)
MA(P[/C%#B57CD3\/EBIGQX'5-;/4T*5E*Z9:RG6.![GJUL3G6TU5JND2-KE1
MBI<L:YJ1V7/X^I'66UM>6OA3BY250QYXD6%9]PSZP3N*-VRR:W]&S9=*WFXJ
M0B<4!PE;Z(JMGI5R3.'(-#;-G-;[IN;)DW7>94K@IY-L5G-R!(Y#<URAC+,U
M'0QFEI:*GIDQ>AB@H)=RA91UTLJXXZOJGUS%;ARTM*]FD^%U"E4U,,DI7.5F
MBU'DB:"JY5T555UW;DW1R7XRWU:U3._):_#J#J_B):J+A9'"(OQ91(EEJ\4V
M4$%.74):#W=XWYV$U6$F=7Z.%0WE3$7XM,K5N]X1"\8?**[1K4AJ&MW]L;AP
MA.=-B%7C5(_&Y738LKFTF*R.G1,0I&4.@S2IE;'(LV$S1JJ(R@FH9HJA6KI5
M$;G;NJ41&*C<FYJEM5UX%XG7SNMT5$X,[&'/0E0? (W:ECX!_P#&*E5A*S(S
M&DCAQ;#QLU$MWG"4\=,5$Z=]\6EEX%57J?'-*:6+C) ? #FYT=R%,]*:%(,W
M=*WLA+2[(?[,K51)+,K<4_::3]@3K)HKH?M1*#LO<$>L+4B2HTFL7<--"WXM
MM3%DMDB6T;7Y[71,\UO:QRY[<. C)9-75U#&7B$XUW;EV\IHK?DF5M]=/(XV
MUM/%CCFJ1?P?SA]&<Y5K7(.1;S<YE,2R*KF9(YE-I2>&O:QI1;3CA8W9"^EK
M*FHDQEM314>$S8=$UU4Q)728KB*.6H@8FC4U'[-91]F13->K%5=W8CW*JU^)
M=$^)9VE=<EM\5-2JN27O;/F/KQZ+\#GAKXI.]G%<5X=&6HR"HDT+99+QO?$U
MDRU9Q6L10R/CK:<3*9K;B\(3\@&FNRKMC/-"O'5$RR63;2CESG&&Y\;5=LLV
MR%C\792NQ:>5R3N=,^+$HG4T28K3:;&4DROHY)UP]]0M#)@U0USHH[[BV1S'
M(M'\55T43+++/)>&][(MKZ?#EJN17](^35!=AU297T5KF'2M14Q!MLM%8SRF
M)RS;E?PUF);.J?M<=8E%:-C,Q-AQ; !VC]<:<FWT44P.[V<DE[I(D1.V[%W5
MBTU9V3+4S0I6*E&^J@K8'[CN$*O2-<1EEKI84F5ZLDJ=%VDLC&(L+8U6.31N
MEDMEFF7&O\-TOP^(CJS9B,8 P!@# )S:,M7A^Q]&IRNIF,W0_0JR93QVALOL
MR,2.IHX!PM&^&7E51\CA;1$9:JM@A;+HW"8XR?!MGC#?$$JJ+L4HN&X7(M[+
M*%%B] Q"CQJ391A%;+11STL6(U$%++%62Z-+0/PNMCG?-$E(K89IW/W5\KIE
M262*CHV[GW8F16;FY+YJB*N6M;HJ(F?1ERNY#-L,NBJ.7\0*CG(!Q@E93:]X
MC+9O(VBM;:8:[7&U^OY1,4EF;.OL:[W6?M,+D%C3Z363R'>ZR&6B3:KSCI5L
M=AK<2;9KL>[>?/0U>"SK+AS9ZJGPZ>&"-]32/J&=DIA4D<+FTU"V!\T=-3Q4
MV'LJLU[)Q*JDF<O8S$9<CM/6F:HJV1;?.SS75G=RIQ-2VLKPR9O:VF22%J8W
M<+^RMCX[-[0^@)VF ]-:->H3-[N!.(0Q)PN20LE8$D0Q;*T=H&Q"V'MWTN%S
MWQ1/D9N<CXV.?'>^YO<U%<R_#HN56WX;&.I\/) 2+2*=/=5<1.!L\J@]M1K6
M.T.44@DBY6P1Z4-J:]&]WKU"@6/#+)&UY95CPR5.?6B^,Z>6U1IJ&J-=F8!*
MT:I3FLQT\=9C6R"GK$>YKZ3"HX6I))$Y:!S*A[VQOC<QZ1OK$J&RZ#DT[:#[
MMLBWJJHQBIP*Y5U+\;+G35;6G'8V\M.9QFS^5O2SR]7*6>=5=)N)[W(G>5('
MIO?X\[SM(X4)JK'=&\I52AO6/_\ #.-A;4BI$H-<-^<?D(-[3'NI6_&I():7
M"-A\*0O@JXL89&R%S'12LIW)B'9;5C<B.2/L/3<Y')HV2-VM&*7K972K?+17
M/6E[I;RD<' ?\^KA;[6?'+WPP[-GV0_(&.>!\3]"G(V=NWOF]:';RY\?F<,
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MG,> _P"?5PM]K/CE[X8=D.R'Y QSP/B?H4X9V[>^;UH=O+GQ^9PP!@# & ,
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M40K5;K3UIXTR,4'Q:1)8NUS50S+R8F]OS]%VB0&$""V.,AC#?'760LZ11O\
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MSW@/^?5PM]K/CE[X8=D&R'Y QSP/B?H4X9V[>^;UH=O+GQ^9PP!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , I+=;T_E
M-P,^8N1O[PI7.X;3W<L?^LPWS:XQY_F?>]130SM!CDPW0$^MRX=?2"S_ '&V
M?FF;8.]#&.\I?3J8DB[HWI\U2;7K>GY6X&?-W(W]II7-'VG]6/<^'=5:2U&I
MG._J84Q,[68Q+YT"GK;>''TJL'W-6/FF[8&]#&/JZ;TVF)(NZ-Z?-4[1S/ED
MS"#"LH#!;'64BV4CR7YQ<8ZVYG--]6^UT/6<EHQ77L2,ALC95=FIF*53JJYS
M:=4!F+_.Q/R%GJJ9MK*WN"YY4,!41,TF\05OS>7BLG#;+E122/A$[UJ[\7*I
MU3\$.K.M&!')X-$84I=3WU4T-M=3>30(9JQ[5C-7/"UW61M2]K'1R4*W5>J<
MC53JM6N)JE4<*&UF 8C<* HMVM5LO1TIRL'&Z69$%N:+86P6,JK%;41:8]$4
MF13$YM&_IBR4*I4A(\)>$1")4J2%; G4'%C"_!P'M6]"4?3CK,7RI:?K*LGF
MPG$#O.W6!0>-1)QF#F6<M4EKI(L8FU">\J"U3DY*BQKS#]EJG%P4@[IZU48:
M%S&G(GY1.&/M1K?NO<F,JFOH7J4HNKI3K0VERA4Z\+K5'K((+[*E;^\*W,^B
M=J?>W5>%ZCT6B,6?MT[U.M2+I(MHJ^ZHXM(Y7R98>.+]QMA3]6TPC4F@]L21
M<^M"FY[#MU#9-.'5K$9.S.LQ<T]C#8'>,S9[KC13W$VUS+EIK.Z[%'=I<W$,
M.J\66'"I,3CQ2=E5#+%/21)&]**GHW4M:E3-$]D#%IMT9+ RH^),YNY(]O\
M>6Y.1MW:.BEER5>%5NEDY<[VS2]\\I.)%S%K3D]<D,<8[8JN6PRR(C/8:BX8
M@A<Z=9B==ED<N+7L:OYFZ)$,.,K)S>(<PRR*6(_3U%*SI F$T.T$;$!S0X&
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MWK>MZWK6];UV;R0'K@# & , 8 P!@'VHU'7J7R)@B4;0&NLBE#TU1U@:R!%
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MB7SH%/6V\./I58/N:L?--VP-Z&,?5TWIM,21=T;T^:IVCF?+)F$"T-X2=(Q
M7;B@>VD\!Y0@X=);D;ZS.E;_ 'MMS>-6R22W[?W?2:N#R&21,K42<G3G,1FP
MB](KR?&V09VB#C]_&385J.RC(-'1W G@R2RA(S-RU/6JQ_<(,4X>:4:*#'5D
MH0-C^>CVA\J(P3F@3'Z5;4!"#9(2QB YS@# & :M<B?E$X8^U&M^Z]R8RJ:^
MA>I2BZNE.M#:7*%3KPNM4>L@@OLJ5O[PK<SZ)VI][=5X7J/1:(Q9^W3O4ZU-
M8>-'(3B<AHJFHU>%QQ=X@U8QR8-U@<?;5H!YFEX)G-YD\N?U.^&?)"NHHSN=
M:,TR*>VY6*/SZS8XQ0R<&2.3J$$P1NYC>/T\4PW%W8A6RT-%*RHJI874V(TF
M(,@H%9'%#&W]M8;4RR,J7P[FYNZ4],^2>#<XD6%6(X-<Q$2ZY(BW16K=-?:N
M2RI?GZ[&PU5<\** P5Y*IMR]E14MC],\.X@9!9&JY)MB..(Z0+G:.T6 4GJ^
M$&RY^DRU[/B\JB<)CUE0BGYNC=%:RQI2"2,+$A:?,K-C^(K)40P8-$L,M;C,
MJ5$288]TBUW8ZTLFY54Z0Q1M8DD4L\E-/60.:B4\>YOD<ZY)$M=7+>S$^=P7
MTKJB9W7/6B+E=>+Q<7.+C YL+\*'<DO2=0MD(Z2:$#XE-U<6FUM]BOG).^^2
M,FXXR]$4Y0UMK9"U0MOL*KK-5JG]W:Y+ C8.UMT89UTD5KD3-6DP'%6O8DV%
MJVL?/L:F3&'5-(]U-'AF'X9%B43M&=U2KYWT]53-2-CXZA)GNE>V-K5?17MM
MVV7]Y\6RYZ2KH\%N)=>1S*4=(OQ$=A7,MC,RA34VKKEY>3:3M$LA')=>X<B&
M6X&P*:N%;1"X))(-5\N-5-'@U^]LO(X^.%0)K0:DD<4.ISBL9AP1[&L:;V$V
M2"=SDH<'AA?#/AC6X;)1NO4MDGGCGJH41]ZAC\-259WNW*1&Z*/2[=(\_O7[
M;XUTRU9+Q?&U$4_'QYH2:\+;?X\VCR(B= RUYY.4M<;"MF4"M^9MKY%H36%U
M0V0)D(JJ@4V$F>"7&?LQJ5*]":4RLD"G85@/#[<V[$H\1@QVBQ*DPV;$88\*
MK:*1L-11P.CEGJJ*:-7=ESPW8K:=^DK--6K;XN9$FBK%17:*Z2+J5>!4X$)#
M&?I ^-Z:30E!$K.3QU%5CI#JNB4[M2K[(<!32!5YP1'QK#8DK%5SPCL6M"YU
M*R521I?*\D;Q:E5LSFQO#:QO1S*J2CUJ38YBBQ3OFI'2K5QS54U/25=,W<*B
MHQY,36FB[*:ZFJ=PA5%>R>-E+5O:]CI&::*2)(U%2RZK(BJB\#%2^6:76VK/
MC0R3$.?G#Z.2B8Z8+?1MSR9;M+V1-K1LE-RQF:2R8I$*/AL*?*]KY9 CJZL6
MTV6O98R2-+7<-Y6(X]'9NR23:R7R)C7)E"M?BS;'<:EA@W2A<K.PZVF@I*9<
M)A6FEFKYIXZBH2H[)IJ1]1$^):B;"G220/BT8XWM5$;5)6W5;\*+?//*RI=$
M15MJ^.F=\S@L7YK\0V7CB.)%W040:KI>H6N.5R_P*WY<=7MGQ/DW7-P2U"BI
MA&T13C*5#F9J:96=%7(^936Q;"(, U32Q8T-U<M*LB7 L9?B>[=@*MJZK?+4
MQU%'"E133894T<3G5JNEQ-9I'/B25B0PTU,MW0T\FBVU$>W1M?@2R*BV14=?
MM431R2_#=<LT.</G/CB.HFK^ZG7$QR*V9Q4=F1)IM<]PYH&415ZQ_N2N)^@2
MLCJJ1M?+VM'&QXVUS]!.V^O7>>Q&&GJ(_&(NL=XB_2]-K'9L=QI((VI1/CI(
M*REE?1Z."]GU;8Z.H@5SV(Y^$53:65\#J=U2R":9$DDE:R6.)2NZ-O=79V6R
MW=9,]5]'32_$ET35<@[YMV?#+DY/VC8L 6-+K&'U3&2$K\R1B2P]MDS@Q0R.
MQY^E1#%,Y)+9@6.3OS4Y/JASE;X?)I"I<#I%($C2[NJUI1;]@-)/0X52TU2U
MS)8TE58WRQ3.B;)/))'#ND,<4-HHWMC1L+$BC1J1QJYC4<L#U1SE5-2]' B7
MZ=9JIGL%HP!@# & , 8!F#CW-4-;7Q2]B.;^Y11# [3@,R4REGCC3,76- C,
MH:WK4@;HD^G)V63K&42(+DGC[J>2WO!B8+>K, 2H&+6%B4#JK#ZZF9&V5U12
M5$"1/D?"R7=8GLW-TT:*^)KT=HK(Q%<R^DB70JU;*B\2HOE)9IGR/XK*[KXE
MRRS[7KSD;**2>^0-LV+<L%XZ+ZAB<ZTCB33,^+-$O\,35]!G:5*$%N118URI
MX<(F5&V-GL<;$GDKS%V4]U3:=!A>+-H,8AI*.HPR*OCPZCIZ&;$FUDM.KIGP
M8M7QSNJ9VQ(ZDF1\3&R[I(^F218F2/1JR*YMVW5'6TE54;:_"UO!?-.)$SL:
MN\8.<M@UTMN"0V182&1-BP^>W6EA\FA,8EC[:7(2;N,. 01N6NT;<7Z-15[E
M,;@]@76U(I PLUE0VJ009X+<#79 E%ZV+8!35*44=+3.C>B4]"Z>*>6&.DPZ
M!LZJNXLD;'+,R*6>GH7NC>^FFJUG8K=%RE&O5-)57C6UDS553DU<*IPV.,<^
MY5Q6F<QA\BXU"(4JG8N;NDZ<49,_ 8N0N<L4+Z['.%=B*#W)[N@,;/4"MR0,
M.]1)W?C4BAG&>?IP/'+L<BQ>"":+%$5K6;@RG:Y:?XKF1:-3N"4R(R.AW1&]
MAQO_ +UD=T?9-%"C]&_Q<^-<\^*]_G<:FK5#2F+0>\J9FLY;].T*B%K5W*)@
MU;)THTY1=@ES.ZOZ#:?>MZ/TK:DBM/LC>MZ-\3P]ZWH6>OB,,U1A]=!3NT)Y
MJ.IBA?>VC+)"]D;KIJL]46_!K+6K945=2*B^4WND=EN%*W/TD57VG8[RK063
M$[S0PX"=6_.\0L2P)[:5>RR+SYL2-NEK/W)_ 6O<A9IHJ+)2KH\J;0^E? 6(
MRS=?CI6UU#L8JZ2E8CZ:;#UG548R:FIJ:EJ(IJ=ZOT7_ /#U#MS? EW-D1WQ
M+M6TE]%TB*JV5'V2ZV55U+PWNG"OC.6MLWH5'PNG=!5S;X[>GO(L7'S4+IE/
M2KU$[RAE_1M_C:5_W/[G2-2&/V'3B!L-F$:J>"!F$W+$ODL?>O@7!W]F6/JN
M!U/B"XY3XC54245/AG[16>N[.9+038?)%*L?8]$YZR4U:YVY2UE1N,.44C%F
MFC>UB/BZ*M1=)76LEE1U[IK6UE37;-<E\7ZETEC<KZ:^G'&+.B!_0-_-#BM$
MW*3M1Q:ILF,O@LPJN$SV;-RPH0REZ&:3B/R&4I7$L9@'$AW N"89I1W]T;%+
M#L%KFS,=&YV"8O,R)]T?##40U<]/ Y%S:Z&"2.)6JB*U6Z-DL%6\J6_B;Y+)
MT\_#K.T;SY;,L8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & 4ENMZ?RFX&?,7(W]X4KG<-I[N6/_68;YM<8\_S/O>HI
MH9V@QR8;H"?6Y<.OI!9_N-L_-,VP=Z&,=Y2^G4Q)%W1O3YJDVO6]/RMP,^;N
M1O[32N:/M/ZL>Y\.ZJTEJ-3.=_4PIB9VLQB7SH%/6V\./I58/N:L?--VP-Z&
M,?5TWIM,21=T;T^:IVCF?+)F# & , 8 P#5KD3\HG#'VHUOW7N3&537T+U*4
M75TIUH;2Y0J=>%UJCUD$%]E2M_>%;F?1.U/O;JO"]1Z+1&+/VZ=ZG6IH?5?1
MZ\:G;B_QOY$\A><X^.BKE#*;9B5?QE1QODUEQYO7U/+D$2=%TIF\;L-O.9F@
M\YY95QZXV)BT@3+%.] 6%MYQPO>J]DF*,Q7$\-PW ?VDW"8J26IE3$XJ61S:
MN%TS4B@DIG[H]$8]J-26[E1.UTD0M1C=%JN?HZ5[)HJNI;:[G +CZ,>ZJ:66
MA '!OG4UO*O>5T5XP-$%KNJ9)*85/54U@)]@Q*0QZT$BT*8$AE#(8S.4>K93
M&?A"M8'0Q[4JD/HU6AS)HME-%6I25#5@@H*G"9L4?45-7%%/3I!4=CRQR4JI
M=8XWH]LE2DNYMD:C$1=)JA8U2_&CM%$1->5[WU)DIA"5\!.9T*LJNZ?D?&ZT
MTECVV!T-K*-(X\8]'3DMA",R1F1IP9#'%H<P1<DL:F5C3N @Q=( 2N0;;4VM
MFYGP[(L$GI:FMBQ.E6EH]%*J5S]SW!9%M&DC)$;(U95RA16_WKOBQZ2Y%JL<
MBHELUU<O'GJRX>+A/VH^CSYMKK6=:23<:+3W9C)$T4^=8\<Q:2IT<%<E7D&N
M9F2-4H)BXHHZN/>;&J1%O0VAS="SFU"L4+B34X+7;),";1LKUQ2E[%DF=3LD
M1ZJYT[4TG0I$C5FW5C?C/CW/3:U4<Y$:J*-!U[:*WU]''?5;E/T1+HZ.<TXE
MMB02,\7+>7RZIWI#&K!8SXP<U*HY)'1"%U:(X>-X,0)UL@>FDPIW8V1K.7.C
MTT'IG1J2JT"DA092;9+@,$--42XK2-AJV+)3R))II)$URL?+\1'*V-CT5CY'
MHUC'HK7N1R*@1CUNB-7+7P=9QBO.#?,&UXW/)=77&^W)9'ZS>WN,3=:UPYTV
M:RRB,)3%TGBVF\\HAR<Y1&4)8ULCCC.C<'MA1]U4[(4:<8#!2U./8-22T\%3
MB='#)51LE@:Z9MGQ2K:*722[&12JMHI'N:R1<F.<J*$8Y;KHKEKZ-?\ X/K<
M+.([ER^LF7QM3/&>I:SJ6JIM>MY6X_-#E(6^MZDKU.E,D3^1&6@93K*7HY6X
MMC2Q1IN/3JW9S<""@J$Y(#SB[,=QEF"TL,J4[ZNJK*N"@H*.-[8W5-94*NYQ
MK*^[8HT1KGR2N148UJK95L@:W2779$2ZKQ(<]NOB72PVZH7OA)R+7<LE-LS1
MVK8%-*JQ4U[R3C,T;B&]0V>-4;?)YRNDD2EQ*T0XY+(^M/0^>(/8EI1+JG/+
M#C4.,UR/K(\=PQN#I1P,JEK4JDJ,,EA<JHZU8Z*!L<T2I\>%Z:6BJ/;=MBJM
M3+072NMK:G(O-Q<IP"6\ >:D&GT8J^3<9K=0SV;,DGD<.C::*+7A7*VB$(5#
ME,U,<.9=.*)Z-B*)*>=)T+<J4KV#9?A.J5(<(!8LF'9'@513RU<6*4;J>"2*
M*:5TJ1I$^=R-A21)-%S$F54W)SD1LFMBJF930?=$T5NNI.,SK3?1%\YK7NN/
MT<Z4K,*OD4CJJ9W,WN4ZCSP6UJH-"$'B.!R UG2.>ECRL?U+)"4;+L:=4DF,
MD869]$S#7A-#@5NS' :2ADKV5L-7''5PT3FP2-TVSS+\721ZMM&V-'S+)96N
MBC>Z/3T;%R1N5VBJ66U^@P(Y\!^:+-%D4U=.,=R(8PZR.-Q!D=5$*=@ D4KE
MTB=HE'8U&$W@^=D[ZYR1C=&8#3'TSDN(6IM%JB"-*$PCO09LBP.258&8K1.E
M;'+,]B3M_NXH(V32R2KVL4;(GM>KY%:U47)5LMK58]/FJ; 4ST5/)B5\HZ5X
MUW[#9QQFU=Z2S5,9GDK@XY&U&'5A74KGKVV(2$C\SMCF\)C(V2R/C-J1HW>-
M&NQ"IT0!$ M&J\ZMV787%A5;B>'3P8IV"ZE;+3Q3[D]$JJF*G8YRNC>]K%W1
M7L?N2LD1BHUUETDN2-RN1J_%O?.UTR15MEPY6MP<)CG@=PYA_+U_OX-A7:IH
M>"<>./<NY#3"9(:R5VNN41^'2**,;DUHHJ@ET.5F*1D2<2\H\AP5&"$@\H%"
M/:K1Y&3C^-3X/%ARTU F(5&)8A#A\,#JIM(U))HY7M<LSH9FVO'HK=K41':6
MEE9:,9I7NMD:EU6U_69@NGHQG)%!N-5G\-[0?N94*Y13*QJZ@3<UTG+*ILP$
MUK!*G<9.D'7SV]2<YRCJ=J&N<S9<VO)S.VI6EQ,>1MP$XC,PJ'94U:C$Z7&Z
M2/!)\+@IJFH>^NAJZ7<:I=&-4J(V1HV17Z+4B<Q'O5[48CBJLR16KI(JJB9*
MF:?^#Y53=$!SLM">6=7*JE9;!Y-65"R*_34<A8W-<&:,:$AT(A\:@*R.D.[7
M)I)8TC:'".18"5Q"WF+6I]\=:%0T&HCI*S9G@%+3TE2VMBJ(JK$(\/18WM8L
M#U5BSRU#9=!\4=-$]LLNDS2T7QV:J/1R$B>MTM:R7SX>)$XU7]35U=POY7-E
M(@Y(.% 6<DHX:8MPU8Y\:6 80LY[EMF3R,W6]>?)BJEX#Z)2RLU&"-J7/84!
M#H8J& H7JMQS"'U_[,;B-*ZONK>QDD33TT;IK$B]HLR,^.L*.W5&_&5B(ERW
M0=;2LMN,UCSU2TS'QYI*5<D[UJ.@8.I:T4MN&P8O7K$O>SS$S,VKI.[)FP#F
MZG$%'J0MS8 \:];I(G4K#$R<PM&E4JADD&86)5T6&4%9B$Z.=%1T\M0]K$N]
MZ1,5V@Q%LFDY41J75&HJW<J)=2K4TE1.-;$K9G0Q*YS**<-XY\H8C<E,S^S[
MJJ"Q[E>JNF]7I*4F?'J%*['L[<AB+RJ>7>0,6X.UNSU#'5F5!')#T9;2M1L"
MY45K6H)LW2GBK/VEA4U%6P4E%6TM$RK@JEKH,1F;3TNA.QK&12;L]C)FR-M&
MBJY%>C<Y%BS2SKI=45;6LJ:\N'4MN"YP5MZ+ZLI+=3M"(5R]+EE71RC&RZ)3
M,B./TVC]OQ<UYMF&TTVPA]X[2Z31^1(7A5))]&)&4XF2OT<=7RL^4)1*#2"F
MI3._99514+9Y\&6&KDKWT4,"XA!)1RI'235KYX\2BBDB<Q(X)8E8D6FE0B1+
MK5R4W-%6R.NEKWM9=:)FBJEM?"NK,U/Y#<,WKC-!WI^L><-GPMWR.MVB8%$&
M=J-5IY]&Z'=EL4LVX4C\:XIS&J()YYIMAL43'LJH^4.A4O[JINW#59*[V,-Q
MQF*U$<=+3OW']F4=?43O>B+3RU[&S4M$L:-73F6GTYI51[4B9N.3MV31M<W1
M3-<])41.-$R5?'E_X,4\6^/<JY5<@:MX_P .6I&EXLB2EM:B0N)1AS7$HX@2
M*GN83-W**,*,,:(=$VQZD[F46:6::B:CRBAA-&#>9F+8E%A&'5>(S-5[*:+2
M2-JV=-*Y4CA@8ME^/-,YD3<ELYR*J6*-17*B)P^_D-\*JZ.*GKS@#@N@?.VO
M7Z]E]7W?<M>T0"NY"Y+%-8481)7'PK:L%HDSM'*3GTJAD5.DK'!'LA[*;$2E
MN0N;^F-5)1&:_5[)JV@J&I4;'ZB/#VU5#1U-?V3&Q$JZ]8F_\)3/B9)74\4T
MNYOGC5BN5'.:Q41;7HQ':GI?-42W G&M\LN!=1\Z-='+6TLX^RZS:^YLUK-K
MZJ_C63RWL:AX;#']W:H75R9U:4#TQ*KQ0O8XF"Y(QIY;A.U;J&E J)<E)+82
M\&"[ZLNZ79-518C#2U&!5,&'U>)K@]-7SSQL?/5*UZLD2@=&DW84N@[1J4<Y
M-!%<K/FJ1B6OI)=$TE1$U)SY)?DX\CY-;\<G#B]TI/#2NAR4B=19ZY!\-+0K
M"Q4C4:QH[$JJU)G7$X@4P(9CESH-H/<&1X)3/#/Z4<],S^B=FC3DOTA\V=?5
M8FW%=B>-U*1+3RQX;C=)54RO21::KI(*F">%7HUFFC7LNQ^@S3C<QVBW2LA&
MZ,C4O=+M5%XT54S.U1SY3,P8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & 4ENMZ?RFX&?,7(W]X4KG<-I[N6/\ UF&^
M;7&//\S[WJ*:&=H,<F&Z GUN7#KZ06?[C;/S3-L'>AC'>4OIU,21=T;T^:I-
MKUO3\K<#/F[D;^TTKFC[3^K'N?#NJM):C4SG?U,*8F=K,8E\Z!3UMO#CZ56#
M[FK'S3=L#>AC'U=-Z;3$D7=&]/FJ=HYGRR9@P!@# & , U:Y$_*)PQ]J-;]U
M[DQE4U]"]2E%U=*=:&TN4*G7A=:H]9!!?94K?WA6YGT3M3[VZKPO4>BT1BS]
MNG>IUJ:D12X>C\N+@[PJH7DG=5[5C*N+$WY#264QJL:':K&U8+)<,_89*0S,
MDO>;/A+=%W0#-&BDI;BM:7M(0M=MF*$^BV\0%?K34.R.BQ[',0PRAH*J'%X<
M/BBEJJ]U-V.^CIWQ*]\+*:9TK=.155J.8JM9DOQLK;L5K$5531O>R7O=;Z^#
MRFV$IZ9:H;'E-@6DO%<U02J3])G37)F-E5DT0I[F,1H>J>-KC03>I2JYL!T@
M3Q/!H2&4Y[A[VW*8V_$JWQKVZID2@I:#R8MA-;30T](SL*LBBV,UN&2K5/G9
M!-7U>))7N:K8594,IT57I'.QR21JC'Z"N16E^ZMS7-/CHN5KV1$3ARNMN7UG
M(2NE0X&0>W*P?X]6Q#XO>*BY44Y>MSUIQ>B=(QLAAOZ/M#=#7UAXM*[CFD!E
MDKC+NWK%5EK=/4$0S%E?'9J3I'+1P 9#_9+9!4455'+4[FUE9A5;04-5BLM=
M*LF'OD6:.3%6T4$\,,K'HE,W0J%A>QCE5JI<;HQ%2R<"HJZ-K7_Z;V5>/4<&
M_P",+X*O!KQ!IHZ2>7H:[XZP2M>/EJO_  LI==6T,DJ&U7JQ;09&[B(U65&H
M>]Q5]2*VHJM5-K2R9F1&5[D#J>A1H%I8%4_]F\?9HU$#(H756)5%5B-)'C=8
MVJFB=2,IJ5[\8?32RLF8J/[*2DAA2:)(F(YRM^*TV*BIQ)DNBEKWS^+>W-?4
MMUY\V/?2W<-IWR#Y"2^3RB<*Z9M2?<=;-35=;'$:J[RK]Y%6M$PRM)CI P L
M&N)G4%Z)W2.J$<1LB#SM5#0,?EO&84YZ9,:'"9L/QR##\.ABA@;64M/B-*M3
M28Q54-0SLFOFJH5=)V/50UE K94=-330-G632_O'7L5W1NDJYV546RM14R:B
M+EP.Y<TR,;5CTK'#5BC,)(8F6Q>/9G&CDARGN"BVEKH:IN0LTD,+O&2%RV"-
MC+9]JRP9E2V+%5Z9/'I6\K6:=-KW$B4)6W%T<$)/AY-5L1QM\LZO?38BF*8;
MA5'7O=7U6'0QS4$>Y3NDI:6%.S*:5J[I"QLD#F3756-:Y;T21O*EE<J9(JV7
M/)5U+?R</"1;\%^8<#HFV.0VKRC<G>:3Y>4A;% 7)_!N2Q%3J'L5HKV]\3S:
M!-C@-FC2YZB;^TMZE.PK#FEG6MYBQ,'P.ZF(WMN/8+45]'AO8$L3*[!JZDQ"
MB[*5^X3OI6N8L%0]NG*UDS'*BR(CW(Y&JM\U(V.1JK>^BY%1;6OGQ:D]1M30
MW*GHX^#%S<9)?1,9O6]WJ$2FWUE\\B)5'6ZJ9DK@]J5B[U@QQ2FJK#9,RC"-
MRKLE_634J125T;GIVDZ8;6F>D+&YA$T^1B&$;)L>HL4AQ":@H&3Q4;:##89'
M5<"3TE4RJ?-6U78T,JMJ%C2'<XVN8R-VDYCGLL^Y',8K;7545;NU7145,D55
MX^'BY3./&?I%.'?$!HI"E(%.KRM>#5_*>7MOO]VRZL6V!R)IF5Z\;W>F(' :
M^@[?8<X7H65(Z&H9#/) HDJ,"J1#VXMC:>0D"</S\4V-8UC+ZZNJ*>AI*BHA
MP>BCH8:MT\;X:#$65E14U$[J>!BN<U',IXTB<J1HC7.15LMS7L99+JJ75;JF
MJZ61$S\?*< XJ=(SQRJN!]'%"K$66*5_P?:]Z2*MKD=6.))W\V-IN7:5>@KI
MZC"-9(6;4K3-0U^W&1MQ:YJ/2 ">!()6I$ !F5BVQK$ZJHV2STK:9?VC4[&J
MFB8^98TE7!U:ZI9(K8WI"KM'1C<K7:2Z[)JHU[41B+>Z(]%LG\2GSVSI+:2J
M3D5T4]CPTF=VQ7?!.EE=73]H>(\DB3F[KW27VBB=I;#&)<_O#2GD>X3*HS(F
MP*EY"25)65"SJ7C1#>6[:.V+U]9AFRVFG['HZG'J]M73/9*LS6,9'2O9#/(V
M-CUCW>*6)UH[[D]7HQ5<K!IM1S%3-&I9<K<%KVOTZ\^,RKQ;Z0[A3P[6T!5\
M.G-]W174:Y.7GR@L6UI[5S1"WR,'SOBU8=#0VO8=!T-BSI0]N2YTEZ=[LF6G
M/S*A4JT:,36V.!)9AY.+BNQO',9;B%7/3X?0U4N&8?A=-1T]4Z:.9*;%::OF
MJ)IW4\"1M:R!64L6@]R(YR/<U5SJU[&V2ZJFDKE54XVJEB/WHU.:;3PF<.8,
MT!)99#[&LSA[8U3TA)HBV%."UEMQ\E<%?HNX+3CS0E-3>F!'%IIKF,E8%.<$
M@&TIFC-[#L>R; WXXS!8%BBFIJ7&*:JKXI7Z"/HV131RM2V;W+NB(C45%5+Y
MI8L8Y&Z7&K;)S\!($NZ3KBARBEO#6_N;JBWI%=]/P*TZ5N:)IF=TF%.OQSI"
M7I!5/(MB@2:?0QF\]J1GM&[MJME50]JG^RS' D(DC86SO6N)L5Q?"XL:P[ V
MT<=!6U%+744RO9#6QHV9CJO#GU"T\S[;FC^PJIZ2N@R:JW>KF7:;55JNO=+H
MNNVKMDLJ=*)KZ#F[[TG7"Z1/$&BJN56"W0I1T;7+#@Q+9E#^,4"K9-$Y5;\Y
M*?XG.8U14(L)+$DT)VVEF (C;-+BG<@8$PWU5IR7NCB5CQ[%<<C9/*D-.Z=N
MR;",>AAFQ2>J6:*C@='-!+7STZS+/I*FE))#H+GN::+6L6NFW5?+0<VZ-M:Z
MZ[7U=)C*Q^E%X]27C6>"(.<RB-W+. $6X(.E>(>-=*J4[VF9&5MA;S(7#D8_
M/3]+DU1/T9;]2-+731#D$N8ISY0;7*DB9)Z5'E4VQ/$HL33=F0RT+=D$N/-J
M78G6W8KWNG9&W#8V1Q+61RNW)U2Z989(+Z4+E<K2BR-T>70T+(U/'?/XO_3Q
M\)7>SI1"91I":H*VN:J+"=72>,C5![&A<L<WFK7AOCUEM3?'Y$W.BUQK]\=D
M;BU-,S1)DIJB,KW1 L;4SP6C-7)CDH32Q8E? ZJH:RF8RGD?/33PL95L=)2O
M=)&YK6U#&.8]T*JJ)(C'-<K+Z*HMBJ+947B5%RU]!9\4=//4]>6#0+)'IWR"
MOVOF.V+VLBWK<E%2T[3-E,+/;U5O%60IAK>"P)Q!"7R3UL7(%\YF$K>P1_\
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MC\'*Z7#]'./?KOI/_'N/A*V(?2$WX"M_H#<I/X?*WVC\'*Z7#]'./?KOI/\
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M.=B;GSJ90P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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7@# & , 8 P!@# & , 8 P!@# & ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
